<SEC-DOCUMENT>0000914475-22-000044.txt : 20220804
<SEC-HEADER>0000914475-22-000044.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220804160800
ACCESSION NUMBER:		0000914475-22-000044
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		221136552

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nbix-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:0c42dd0c-c284-4653-91e4-174ef769a678,g:b6b90098-cdc3-4729-a2bb-5ae5dda3bf39,d:a5b26032409f4bcfa80efa90e636a8b2--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nbix="http://www.neurocrine.com/20220630" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80L2ZyYWc6ZDg1N2EyZTBkYTg3NGE5ZGE1ZjJjMDRmYzA3ZDIxYmYvdGFibGU6MmUxNGUwOTY5NzU0NDFkZmE2ZmMwZTFiNWY1ZmJkYzcvdGFibGVyYW5nZToyZTE0ZTA5Njk3NTQ0MWRmYTZmYzBlMWI1ZjVmYmRjN18yLTEtMS0xLTc1MzQx_8e7502ed-58b5-4392-b757-7eac9cc6a181">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80L2ZyYWc6ZDg1N2EyZTBkYTg3NGE5ZGE1ZjJjMDRmYzA3ZDIxYmYvdGFibGU6MmUxNGUwOTY5NzU0NDFkZmE2ZmMwZTFiNWY1ZmJkYzcvdGFibGVyYW5nZToyZTE0ZTA5Njk3NTQ0MWRmYTZmYzBlMWI1ZjVmYmRjN18zLTEtMS0xLTc1MzQx_c4d3808f-e499-4471-aa32-8a3d0171c991">2022</ix:nonNumeric><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80L2ZyYWc6ZDg1N2EyZTBkYTg3NGE5ZGE1ZjJjMDRmYzA3ZDIxYmYvdGFibGU6MmUxNGUwOTY5NzU0NDFkZmE2ZmMwZTFiNWY1ZmJkYzcvdGFibGVyYW5nZToyZTE0ZTA5Njk3NTQ0MWRmYTZmYzBlMWI1ZjVmYmRjN180LTEtMS0xLTc1MzQx_0683a52d-60b8-49c4-8995-eded2f2e4f0d">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80L2ZyYWc6ZDg1N2EyZTBkYTg3NGE5ZGE1ZjJjMDRmYzA3ZDIxYmYvdGFibGU6MmUxNGUwOTY5NzU0NDFkZmE2ZmMwZTFiNWY1ZmJkYzcvdGFibGVyYW5nZToyZTE0ZTA5Njk3NTQ0MWRmYTZmYzBlMWI1ZjVmYmRjN181LTEtMS0xLTc1MzQx_bc667bf7-2b70-494c-a472-f3c34ccfef79">0000914475</ix:nonNumeric><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80L2ZyYWc6ZDg1N2EyZTBkYTg3NGE5ZGE1ZjJjMDRmYzA3ZDIxYmYvdGFibGU6MmUxNGUwOTY5NzU0NDFkZmE2ZmMwZTFiNWY1ZmJkYzcvdGFibGVyYW5nZToyZTE0ZTA5Njk3NTQ0MWRmYTZmYzBlMWI1ZjVmYmRjN182LTEtMS0xLTc1MzQx_4d7777af-4478-4460-80ef-e98caafd782a">12/31</ix:nonNumeric><ix:nonNumeric contextRef="if91a28c2ae1249938c18889676def742_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjEtMC0xLTEtOTE5OTQ_1af9cee6-f810-4eaf-b311-f7383604b8af">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="if91a28c2ae1249938c18889676def742_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjI0MA_27a74808-cedc-4067-91c0-ce68f133d49f">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="if91a28c2ae1249938c18889676def742_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjgwMA_27a74808-cedc-4067-91c0-ce68f133d49f">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="if91a28c2ae1249938c18889676def742_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzA0Mg_27a74808-cedc-4067-91c0-ce68f133d49f">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="if91a28c2ae1249938c18889676def742_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzM2NQ_27a74808-cedc-4067-91c0-ce68f133d49f">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i6c2a25388e8a402297637fc25af2ac23_I20220208" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMTA5OTUxMTYzMDM2OQ_4e49d25c-03ed-44eb-9e93-c4a67b6332d1">P13Y7M</ix:nonNumeric><ix:nonNumeric contextRef="if91a28c2ae1249938c18889676def742_D20211231-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjY2OA_27a74808-cedc-4067-91c0-ce68f133d49f">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81NS9mcmFnOjE0YjE5MmQwNDJjNDRiYmFhZWUyYjU0MmU1Y2YyODAxL3RhYmxlOmExNjliMjU0YWFiNjRkMmFhMGNmMTE5MDczYzdjMGNiL3RhYmxlcmFuZ2U6YTE2OWIyNTRhYWI2NGQyYWEwY2YxMTkwNzNjN2MwY2JfMi0xLTEtMS03NTM0MQ_f64ee74c-7a3a-4141-a6b6-e3b0d5178ab8">0.0131711</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b6bbcbb257d4f17876a212fbc193ac7_I20220728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i19857cd19784459d879fae5b6542a369_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic0112165dc8043d29e138802b05038e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i556d51bdaf9b486095b8ed36cedbe915_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8626a338deed4dddbd32b530cea19a5c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07d1811ee7e34faab1b65618d330ae8a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f2cb608667e43f19507d5f97f5092e1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46565cbc932a4ecc83bc6363809460fd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec8947a06f7f4b8f9ad89f1a53e3024e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3571830b1824c328e93c8aee0d0c12e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9616929076a46a2b8a10b5cadb88003_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea1c6e2bc7341889b0e9bdb1f1db6a9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dcb1e428512458eaf6a0bc1b8414ebc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7db70dedd62742a6831d1f0c2ec694aa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4a6b675fbfc45268b58ff5bf6fb855e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i824b16455d3342c7bf87a435697bab24_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7e2792b074c4cb5b0a136e01c9e0804_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8338e74ebc694742b502151eabd9e41e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d13a78bcd1f4c6882ee9fe8cbf5b711_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6ae0c23a2454cc2abcf61a77e930c6c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf77ed46fbe4d5cb0a4c8117097d74d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0029346e11d24e2489268d48f5de1c60_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7180cf1c41f49b6948e46307ec11e60_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib84184652a2e49aebdf6d92adfcbc04d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1b0a1dff46e4f7a9e47f283288de125_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70110cfad88d4060a5dbaa9f2cedc49f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8b70242d24a48a6a99af94c82b13c0d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied4ed2118815424ab62c252c7749f6de_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f5736e265cf4768afa36a5cd7c9e9a3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6292fa456fa4806a43afc6154943c3d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie39f82d525f6414195ec1a20af940a1d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a894b024126486eab337fda4f4fb0f9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i607fe14f45874407b052191669ff7dcc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644297e85df8490caa1319af010903f3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e390addaf324fa492c8b98404f47c9b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08908942de0f491f8951674a9b93614b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49d6d0041b1b4429b9640e29170494e4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia726c285fe9348d98e1aa42d192576d6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i798f9a1494f44261a5cfc2579e2c5d6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbcf4054dfb74e3793b2c0599d057e19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bb5b491d36940f6b9f1a57707a58f6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9d9884a14e643e0b6e6704e1d74e903_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i787d806f66c443c8ac342b1496f0ee61_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i391c44c0626e492884c04b5900b62430_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if91a28c2ae1249938c18889676def742_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie030c4abde7f4cf784cc031f496e6485_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i465519c475194c1d9739d8c1fca3961d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b516301ebe44a6b87c40ee75c6677c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie20bd8d4ea894bff986d00fbffc83784_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e14680288bd42149b5cdf6969e7f02b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef17498aa9d498c8992b5221561c777_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b42b5fd65e44418a23dcde417525dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72d820c9109a4f90b3f7b8e63c0993ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e67fafca0274dee95d180cc3fb1f41f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1739e70f0194d8fa9900c2c02abbe2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93d94c70d96d4cf8aa28362a0b2141c5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic92e784af6164e40ab1441eb9d508ae1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i570417ef7f454c59b464a0797bfa388a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd39c3aa14042ba9edda98ae8d9cb55_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa023efd07b7418a8139d17baa936118_I20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i8b377cc0ad4940e794a4a0f398f996ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b01af7da7264226a39cc415c4f4de88_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0378ba60bbf54c9c984afe9729769082_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82ea1ca4da564dcb9abb0f23996feb31_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d87729af3eb438a8f50b92d4f11b0ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38ba4b66e35b4a058bd00122f74f68a1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b5f0284f514463fb5639c0b9dc36242_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29dde29babb8447aa6253d6d81080068_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc12b8925fe24715a37c917e89b4a2d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41dedb5b6dd648adafef4d12efc9d560_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3113317a93804d79b80f423ec6d08d4a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i423078e1d1174d878d489e6ef59f9d7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdca041dd4cd4227abc30499d4f8bebf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62a271eec056493ab613a72c7a5b002b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if71d1cf4c4b84dcd8a6b38e623f46644_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53b573b749c34f2dbfe2a3f74272c97c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35309e0240cb45d68c83e6a9539b437e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ec7aad29694aba88b3325431ac3cca_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cea7f1f684e4ceda425fdd38139bd65_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31d5d364edff4ad4b48da1b643c16353_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98646b31fd7d4d0583d03a62061c0725_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bde3727bced42719f1bdb0078bc223e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee097ca4107145a4a7cafe11c7f7c028_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26b03ed42a86426fa271e7a51e9a3975_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:BIALPortelaCaSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08aaa35e1ac4e31a43d685f09135c6e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf5acfc15e784512b7a82dc8e2d2fe95_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic20aa02fac274005a61e03b4bc0375b0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6c1cfc608dd4f8f81032e9e441a7511_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cfb08820e8842e1871b6c2dd2a4c189_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26703103080243799d2bb6d6f1b72bd4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i721def435135454b974f4d03651a3930_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5c1bb3894ae4915b5e4726823772c30_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cfc8c33916a4939a12f81454e0c35ca_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1724975ad3a44d5aafd1acb6e95ee7f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e3fa10d15714457a50f9425cd51126e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia968122986d748ccba38b5b654f41190_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc36e662e8904155b5ef697ff21e9aec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20cfedabe3c94d5bad4df94bc450895e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d2144d7b33a4ad9aadec72dd35693ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd5d17a30ac7439c9cd69e44e7d10155_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic173cd64901047748e412993eb622ad8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8752290fc66f4c8db3353da827e19de9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf0e1c77adff4ec88d625c49c6294e39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d162d0857b48afb064eef3b8599c86_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bcedbc2244f433299e4bcb31bd4bd37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7df34d9c3e404caa9a985cda59b147ed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b67814da34d4da988b4bf57d0e478e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>nbix:security</xbrli:measure></xbrli:unit><xbrli:context id="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4cdb346b995405d841286aaa096490d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i074a75852b8a4e13bae6f329be3373f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ecf9c7bbfe243a89adac1ac817f3336_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie091570b8c7e468aaa662efd674b1a48_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38c4567a749e4031aed667e267ff71cf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67109db4be9c4ba1bdead9f009154aed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2bfb40cca13406fa0b41700ae0ee8fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56225d1fd9af4788a6c4c2c401b49441_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib836ccb73c334b1e92c3bb0032674ed2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56223020056d47c38dbea1cc503a767f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf20361175e48e8a2b61d38d6483435_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d34c798b0c047d18064663be75d6f59_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i578731c40e2a43fd9bd0b849e2773a25_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e334b57cf1645dca4bb9f652d8b8ebd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53bbe7b73503454da09d5f5c6dc24da1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a7d2babfc2941b297b24e9e5e8a7958_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3edac7da69b94cd794ccfbce890c2b19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie155cdd1531a43a589fe6b7ea1553a8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73e9ff90e3d945f48f05c03731be0dea_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00d60ef478c64a6aa6e2b15688f36c19_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie71d87a7ca30406082e35c819e1436ed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8110a30289e34b7b9625883f2787fc8a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id542276cdcda416ab9e520eb0c59e6b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e52574305944b99802e51d55304a886_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93a9c71abed34ec1b434462a578f36c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6fd4b26ceb4e1b95da9a0661d58688_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id80f2f492d604d77ae916ea5296d3824_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfb55cdc59344e51950ad5eb6569c231_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac5f50efda0b428ea5e117442266f762_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a9a8a35647d496daedc583782304e30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9487e38c52d9410798197fe77cd60f57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a9046e38e0432d9b62315b9af06dad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d9e4bf673604e399b7bafea5de77c4a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0d0694197d34f049fae415dfd7cef26_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e3ff765407f4755bfb5dc08e8b68c7f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37fab9ec8504467e986c6cfccf616c70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i123fc2a261774a52826809562d82f303_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84f8c5fe309e43cf85287198b3684b1f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f432d4ebd4d4bcd821e1de57052b96d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36adfd64e3fc494ba2d120614d619968_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied205516acc24818a8843666669b4299_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id43fcc32d6374531b9d90dc9c1ddd0c6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i013f9e5d35d54ee8bb4f7e21d12111c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1f28d0e9745496a9b27303558bbcf74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcbeb7bb580346078bdfa5dea238778a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92d2e80d30204b05a36b4e40d614504c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59e9b7c8721845489d2a7f16466d93aa_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i908c9a1b5d0e454fb77ebdb1a35749ba_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25d1241a853a41268cccdaac0eae9a28_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05b6c8a59df04fb3945d4e66bc2c822d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia631a5398e544dd4908958402f41dc86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e1d5afb5a0c4854bd3eaac9022c5921_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7e2006bc26e4660a1ce0449ce12fef8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i621ed28665cd4c74accdf1592a8116ee_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb7802d7f08044b48c8621fbe04086f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife94fc300dd145afad28237e20171bac_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05896d4787104c06a015bb730c5b5e50_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd7bdc03323d43ba8e38762cd7fca030_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ed7ddd2a42348d1a2f7fec8628844f9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfbdc30b238f4e70816874e44b5711ea_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e101b09704b41349a0ec8f0acd6d9fc_D20220208-20220208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-08</xbrli:startDate><xbrli:endDate>2022-02-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c2a25388e8a402297637fc25af2ac23_I20220208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewaloption"><xbrli:measure>nbix:renewalOption</xbrli:measure></xbrli:unit><xbrli:context id="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id787ce82b3d34435b9e6f64183561da4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24b6741f0df8412ca89fcbb38c28ed03_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a5baeaf4e9c48f8b60039ae0a01b8e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90120fdd18140988db29b2003f29587_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2e9c013eb7a4a48a31e064dfc261340_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i168ae0643eac4fb187856eb9bb504202_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="ibdc8838b1a0d4a7b843404626b18a02c_I20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id38ba1f5324844d0866a8eac585463a2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6357f4608a44780bb374e2677bba023_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i014deb2a111f43c7a8fdebb84cf4af4a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe515815525d40479e6d960e227a7c66_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcac76a70c464f9fa879fb1284e91eda_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife67923fc29b44728cff990336550617_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19b7065611c64ade9f1f759584b9c5f9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef2199eebcc4873a2e393ef3bf1e3d0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b11647fa1d44f21b454d711e8e45279_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97101bf55ded451fb77e7a8e8dabab08_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fb5e17e77a8471e993d6b327c5c67b4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a71ac92a8441239671f089b427fe9f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i142b169cb78e431b902b44d821c15b70_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25c047985ee44b64a2fbeff282b6c067_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDg0_76f24892-4daf-4886-bb7e-3307b04b8c5a">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDg1_6d3639bd-2536-4384-8ef0-6cf29c4336be">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yMjE_7550ed98-b31a-47d8-9f5a-f6cdfd30dabd">June&#160;30, 2022</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDk5_7fc02ce0-4256-4cd9-985e-1f8be996809d">&#9744;</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNTAw_2461ef57-6928-4271-925d-6cdea1421de5">0-22705</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><img src="nbix-20220630_g1.jpg" alt="nbix-20220630_g1.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:420px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDg5_fbbc18be-2728-44aa-887b-0142f5c4a7f5">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDk1_8323d1fd-3993-4bb2-bb16-5bb59c7fe3e8">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(State or other jurisdiction of</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">incorporation or organization)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDkw_2e46503a-17dd-4b29-9339-d9b5578bc4f5">12780 El Camino Real</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDgw_382ce85f-1304-4d23-a42f-4d63fb81ab90">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDk2_3a7b1a8e-b10c-47f5-a2a4-38e6765deca2">CA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive office)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDgx_c4f15692-c440-485b-9b3f-1dae1b85011e">33-0525145</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(IRS Employer</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Identification No.)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDgy_ced37e4d-b690-4d12-9e3d-04c44e24cf22">92130</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Zip Code)</span></div><div style="margin-top:6pt;text-align:center"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDk3_67d15662-0653-4a2d-b465-02bfbb7898e7"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(858</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">)</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDk0_a9168b81-1caa-4e9b-88cf-c90dfcafb829">617-7600</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGFibGU6YzU3NmFhNzY4YjMwNGE3ZWI2NmVmMTdmYWM2NzlkZWYvdGFibGVyYW5nZTpjNTc2YWE3NjhiMzA0YTdlYjY2ZWYxN2ZhYzY3OWRlZl8xLTAtMS0xLTc1MzQx_1991798d-2f3d-4833-a53c-c73c5ac75f99">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGFibGU6YzU3NmFhNzY4YjMwNGE3ZWI2NmVmMTdmYWM2NzlkZWYvdGFibGVyYW5nZTpjNTc2YWE3NjhiMzA0YTdlYjY2ZWYxN2ZhYzY3OWRlZl8xLTItMS0xLTc1MzQx_ec435338-a227-4862-bf99-44db15366e7b">NBIX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGFibGU6YzU3NmFhNzY4YjMwNGE3ZWI2NmVmMTdmYWM2NzlkZWYvdGFibGVyYW5nZTpjNTc2YWE3NjhiMzA0YTdlYjY2ZWYxN2ZhYzY3OWRlZl8xLTQtMS0xLTc1MzQx_550a6e48-3e96-4fec-9e07-ab70c6bf9ad7">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days:&#160;&#160;<ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDkx_283d1bad-c92c-4358-8db2-2c12876afa9b">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDky_337cbbff-7341-4cb8-8cac-5907084143cd">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDg2_93e67756-55ca-4c95-b232-cdcb21419da2">Large accelerated filer</ix:nonNumeric> &#9746;  Accelerated&#160;filer &#9744;  Non-accelerated&#160;filer &#9744;  Smaller&#160;reporting&#160;company <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDk4_80571c4f-70ad-4bbb-ac47-e3aec9b9b51e">&#9744;</ix:nonNumeric>  Emerging&#160;growth&#160;company <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDgz_5db77ca8-12e5-4ce3-b554-c70171498a9d">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDg3_c877f51e-8b6d-4506-9297-e1426b838039">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was <ix:nonFraction unitRef="shares" contextRef="i3b6bbcbb257d4f17876a212fbc193ac7_I20220728" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDY5_c8a8283a-5769-40f7-9c78-91b40b55191d">95,639,321</ix:nonFraction> as of July&#160;28, 2022.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_10">Part I. Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_19">Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_19">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_22">Condensed Consolidated Statements of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_22">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_25">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_28">Notes to the Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_61">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_61">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_64">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_64">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_67">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_67">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_70">Part II. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_70">25</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_73">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_73">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_76">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_76">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_79">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_79">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia5b26032409f4bcfa80efa90e636a8b2_82">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ia5b26032409f4bcfa80efa90e636a8b2_82">51</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Part I. Financial Information</span></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_13"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements</span></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_16"></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMy0xLTEtMS03NTM0MQ_aa52d590-bab8-4f5b-89bd-483e6f9a5fe9">163.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMy0zLTEtMS03NTM0MQ_6a2df597-89ee-411c-b58d-bd19c8154cb7">340.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNC0xLTEtMS03NTM0MQ_d6ceef2d-7bbb-4c3f-bb51-307a7969671e">485.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNC0zLTEtMS03NTM0MQ_c1c7cd1c-74db-40c4-9341-4831e869e302">370.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNS0xLTEtMS03NTM0MQ_6f08b476-0061-45b1-a0e5-58b98197f0e8">279.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNS0zLTEtMS03NTM0MQ_00dd71d2-7ee9-4035-a5e8-0a4e82b6e00f">185.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNi0xLTEtMS03NTM0MQ_9f0a4415-7db9-4806-9e1c-ee914df6157e">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNi0zLTEtMS03NTM0MQ_02820dcf-585a-4739-b187-d72f8bf5c0ba">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNy0xLTEtMS03NTM0MQ_99566c4a-1c91-429d-a260-7dffe6d2f451">62.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNy0zLTEtMS03NTM0MQ_2471c16e-0f7e-4ac0-b9bd-3e79b431bbf9">45.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfOC0xLTEtMS03NTM0MQ_8414e817-3128-48cb-ac42-207b412d52b0">1,019.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfOC0zLTEtMS03NTM0MQ_fc67671b-a42d-4fe6-aacd-e2c62ca8f56c">972.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfOS0xLTEtMS03NTM0MQ_ce77c6f3-a17b-4dc2-a2f8-5397c29c45ec">328.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfOS0zLTEtMS03NTM0MQ_35ebd656-8cf2-4514-9493-1703e6472c0b">315.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTAtMS0xLTEtNzUzNDE_31027b22-00f2-4407-b200-80eea30b1d4b">405.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTAtMy0xLTEtNzUzNDE_a29b703b-20b0-4f51-90a2-5b514b737bad">560.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTEtMS0xLTEtNzUzNDE_4778b679-3b10-47e5-9a83-33390cf72628">92.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTEtMy0xLTEtNzUzNDE_e2a8e683-7102-41e7-b902-bc7ffa526cca">97.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTItMS0xLTEtNzUzNDE_40ba896f-adec-4a4e-baf6-033e51244675">83.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTItMy0xLTEtNzUzNDE_7bff6b65-1d2b-4626-a462-e6611d3556fb">63.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTMtMS0xLTEtNzUzNDE_67112eef-f63d-4154-823d-11bb14c7f860">66.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTMtMy0xLTEtNzUzNDE_7783bb1e-827d-48eb-89cf-be503bc4b0ef">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTQtMS0xLTEtNzUzNDE_8a054dc6-c637-45f7-8db5-829c97151f43">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTQtMy0xLTEtNzUzNDE_0b8fee4d-f3b1-4d93-b7c6-b1f51e8010cb">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTUtMS0xLTEtNzUzNDE_b9b4a0bc-f85c-4d2f-931c-0bb0928bb717">2,005.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTUtMy0xLTEtNzUzNDE_ae70dc25-ddde-4a5c-b269-955ecafb72d8">2,072.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTktMS0xLTEtNzUzNDE_a61c40d4-9d97-4c9b-b975-68d78d265258">265.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTktMy0xLTEtNzUzNDE_473d0ac2-fefa-433a-81a6-25ec5bae4f30">225.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjEtMS0xLTEtNzUzNDE_03ce921c-7095-4b0e-82ab-357324bfa8bb">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjEtMy0xLTEtNzUzNDE_d0515cbd-b611-4221-8fad-b8a3cfbeab52">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjItMS0xLTEtNzUzNDE_de9cd336-e74f-4c0a-910c-56f62fc40824">285.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjItMy0xLTEtNzUzNDE_6e275c41-e87e-4a38-8329-c09bb52e50ea">245.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjMtMS0xLTEtNzUzNDE_297d9798-df4d-45a6-be1d-3bce8ef2f0f8">169.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjMtMy0xLTEtNzUzNDE_764a29ec-e901-436b-a1cf-4ee74d079ebf">335.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjQtMS0xLTEtNzUzNDE_0674d889-b732-4806-aa2f-c77df4db6954">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjQtMy0xLTEtNzUzNDE_d3369e91-e1ee-4182-815d-4b0f6b5953e8">105.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjUtMS0xLTEtNzUzNDE_8afd6446-0c82-4fa4-a809-e566a2849942">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjUtMy0xLTEtNzUzNDE_d633f998-3ded-4be6-adb5-ed31637c24ba">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjYtMS0xLTEtNzUzNDE_7bf42929-26a4-4ca1-a7d3-e2e565e224d3">582.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjYtMy0xLTEtNzUzNDE_6cbc7475-de20-48b7-9103-637b085ca664">698.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV8yMQ_d40153aa-3069-4fd5-8810-816221d16229"><ix:nonFraction unitRef="usdPerShare" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV8yMQ_dc40b07a-12d0-49ad-b679-08b48462e759">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV8zNQ_2bc08a6e-e754-4a3d-a20d-e027bfd4b87d"><ix:nonFraction unitRef="shares" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV8zNQ_b5fab148-db25-4fe2-adfe-7319395e8131">5.0</ix:nonFraction></ix:nonFraction> million shares authorized; <ix:nonFraction unitRef="shares" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV81Nw_0a2d176d-e20f-4a11-b3bd-502483311a6d"><ix:nonFraction unitRef="shares" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV81Nw_22006747-71e1-4c31-b252-43295ae78a20"><ix:nonFraction unitRef="shares" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV81Nw_2a9831a4-4ad6-4f0b-a76e-5bd52220c3bb"><ix:nonFraction unitRef="shares" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV81Nw_8cf27fb2-22a1-4efc-bf92-14709d441c4b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMS0xLTEtNzUzNDE_f17854e3-948d-49b2-9ced-7f08fe264f1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMy0xLTEtNzUzNDE_f6c3e0e3-b978-4a62-8303-1535ad74eca8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF8xOA_0bd4f136-be2c-4292-91ce-dcdadf1be607"><ix:nonFraction unitRef="usdPerShare" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF8xOA_52d3a322-fc9b-4b9c-96bf-c45f29fadf54">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF8zMg_4455336a-ba41-4fc4-b6aa-46cd6497899b"><ix:nonFraction unitRef="shares" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF8zMg_6fb726be-410f-4ce2-84f8-cdafd15ffc5f">220.0</ix:nonFraction></ix:nonFraction> million shares authorized; issued and outstanding shares <ix:nonFraction unitRef="shares" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF84OQ_7950cb44-bda7-4e04-a03f-14cf7aac2596"><ix:nonFraction unitRef="shares" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF84OQ_df9317f7-4303-467e-9494-51bcd2797271">95.6</ix:nonFraction></ix:nonFraction> million at June&#160;30, 2022 and <ix:nonFraction unitRef="shares" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF8xMDI_e6977150-c809-48a4-8f7b-c683c670deda"><ix:nonFraction unitRef="shares" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF8xMDI_f2f8b403-9e58-4cc0-9660-7f4b6f78f9af">94.9</ix:nonFraction></ix:nonFraction> million at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMS0xLTEtNzUzNDE_70bf3a04-fc55-4b72-9ac9-7f57fbaa8e1b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMy0xLTEtNzUzNDE_276af021-3577-4ddb-954c-7cd71f9a217c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzEtMS0xLTEtNzUzNDE_20ef6b6a-6b0e-4c33-9887-50591aa1b403">1,999.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzEtMy0xLTEtNzUzNDE_308d61b2-6044-48bc-a83e-3a2e7fe06d2e">2,011.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzItMS0xLTEtNzUzNDE_570a877d-eb0e-42b0-8a21-338550ebdd52">12.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzItMy0xLTEtNzUzNDE_6a7d1247-666f-4ad3-9705-507265c20c4f">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzMtMS0xLTEtNzUzNDE_54d9f608-4b69-4a74-af8e-cb7453837b14">564.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzMtMy0xLTEtNzUzNDE_d4d8012d-4ec0-4b3e-b4f1-26a4b9bd3afd">635.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzQtMS0xLTEtNzUzNDE_d5f8021b-c697-4cc7-a85e-288417c1cc85">1,423.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzQtMy0xLTEtNzUzNDE_b12a6b3a-7bfe-46dd-a92a-a8dba7cc4321">1,374.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzUtMS0xLTEtNzUzNDE_bea6c4f7-2c75-4a7b-8952-bd6e48c091a4">2,005.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzUtMy0xLTEtNzUzNDE_163d2e81-64c2-4722-bc02-263d25f9edc6">2,072.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND COMPREHENSIVE (LOSS) INCOME</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i556d51bdaf9b486095b8ed36cedbe915_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMy0xLTEtMS03NTM0MQ_80c9331a-ffd5-48a3-8995-cbb29a0d517f">352.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8626a338deed4dddbd32b530cea19a5c_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMy0zLTEtMS03NTM0MQ_5c6e326f-5a8b-4a59-8d7e-cb2d92f95ec5">266.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d1811ee7e34faab1b65618d330ae8a_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMy01LTEtMS03NTM0MQ_7349ad35-7e2a-46c2-83d1-722ab624accf">657.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2cb608667e43f19507d5f97f5092e1_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMy03LTEtMS03NTM0MQ_bef67a90-0125-4d7f-abfb-03992321fff0">497.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46565cbc932a4ecc83bc6363809460fd_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNC0xLTEtMS03NTM0MQ_9acd858a-e489-493b-9ff0-444351e4dfc1">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec8947a06f7f4b8f9ad89f1a53e3024e_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNC0zLTEtMS03NTM0MQ_0182a23e-7ada-48a8-a750-848d9e0709c3">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3571830b1824c328e93c8aee0d0c12e_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNC01LTEtMS03NTM0MQ_067ea060-7f9c-4228-8f27-1b653b6e5d2f">31.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9616929076a46a2b8a10b5cadb88003_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNC03LTEtMS03NTM0MQ_54138892-1a3c-40ca-be56-1c7a1015a3b1">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNS0xLTEtMS03NTM0MQ_4bec69a3-ba2b-421d-a0eb-15e4b7e92c57">378.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNS0zLTEtMS03NTM0MQ_484c6e75-8835-40ac-8a7f-446fbdd0b6b4">288.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNS01LTEtMS03NTM0MQ_523b8dc5-5097-4d40-ae73-1fa0426887f0">688.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNS03LTEtMS03NTM0MQ_ba06f01c-52ec-42e7-bd9c-5a80cbb735d6">525.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNy0xLTEtMS03NTM0MQ_212d8ed3-5a3a-4bcf-872c-d21fd96db3e5">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNy0zLTEtMS03NTM0MQ_276e7eab-c78c-4d06-93e1-d0d78556805f">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNy01LTEtMS03NTM0MQ_93357615-e4b7-4f13-8d89-caae01c53177">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNy03LTEtMS03NTM0MQ_125cc7ab-6cc2-4938-9ac8-a6de5440636f">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOC0xLTEtMS03NTM0MQ_bc286ac0-5ed4-4233-8929-b09b68faeb41">135.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOC0zLTEtMS03NTM0MQ_cbdc828b-bd1b-49c1-86a1-dd7fa9b0f061">74.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOC01LTEtMS03NTM0MQ_8ee46942-8e74-4ef4-9ad6-c8113bbbc4c9">238.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOC03LTEtMS03NTM0MQ_30950c21-f903-4b05-8730-7c038460b1dd">148.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOS0xLTEtMS03NTM0MQ_cd279414-de20-42a8-ab8d-cfccf96e3a7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOS0zLTEtMS03NTM0MQ_f4a79a9d-9219-49c9-8824-9178e62053ec">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOS01LTEtMS03NTM0MQ_265a98d8-d12b-4409-b83e-6a81c8481219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOS03LTEtMS03NTM0MQ_7634118a-2fa0-4efc-bd03-3c53c915b13a">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTAtMS0xLTEtNzUzNDE_3042b334-35ce-46e2-a864-ce193ac0dd31">182.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTAtMy0xLTEtNzUzNDE_c0e572e1-f8c1-4167-9200-ee469613ae26">143.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTAtNS0xLTEtNzUzNDE_e8de32b3-a104-450b-bd51-2fcc4a2d8e20">383.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTAtNy0xLTEtNzUzNDE_4fc8676b-e6e7-4b28-b00e-aad68118ce0f">272.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTEtMS0xLTEtNzUzNDE_c9bedd49-2272-4e40-8704-5b65c8b6c647">323.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTEtMy0xLTEtNzUzNDE_e6b6f107-4f16-479f-aaf7-2c4cf4989386">226.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTEtNS0xLTEtNzUzNDE_f5bf10d3-5b81-45cc-b9e1-eddcfea9cde4">631.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTEtNy0xLTEtNzUzNDE_630a7e91-5129-4939-8b63-6fd3421741ca">431.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTItMS0xLTEtNzUzNDE_66192188-45e7-42a8-b6f1-6f71fb169545">54.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTItMy0xLTEtNzUzNDE_ec1072f1-dcf5-4a85-a94b-e92e4d7e980b">62.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTItNS0xLTEtNzUzNDE_335c68ca-d627-4558-af2b-f4f0d92ce282">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTItNy0xLTEtNzUzNDE_9e11bbaf-b769-4cd4-ab8a-76778cd4a431">94.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTQtMS0xLTEtNzUzNDE_573e7523-a1e5-4114-8ae2-999b1febbbf0">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTQtMy0xLTEtNzUzNDE_8148dc76-7a5e-4499-8d7c-9fb974e2fb72">6.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTQtNS0xLTEtNzUzNDE_09da6cd8-c9aa-4e5d-b676-848d69125d05">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTQtNy0xLTEtNzUzNDE_37fbdff2-4937-45d9-83e2-aa897e413e2c">12.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (loss) gain on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTUtMS0xLTEtNzUzNDE_c08eb35c-d086-4357-b521-057ac4b4495e">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTUtMy0xLTEtNzUzNDE_47d0e1ea-2e5c-4aa1-b22c-0359d953036a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTUtNS0xLTEtNzUzNDE_90904d63-685e-4a51-ac48-4b7955beb552">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTUtNy0xLTEtNzUzNDE_5285c688-b851-4062-b9ba-80225e7f3aea">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtMS0xLTEtOTg1MzM_fe6bbb55-ea94-4453-b7fe-cf4b1b1672b8">70.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtMy0xLTEtOTg1MzU_bda8a225-09fa-40a9-aaf4-a494cd40d0c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtNS0xLTEtOTg1Mjk_8e86a543-6624-4aaf-a1ee-07a9b109751f">70.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtNy0xLTEtOTg1MzE_0ddb218f-4847-4ef3-9fe4-62805e367198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtMS0xLTEtNzUzNDE_a1c7261f-aad6-446b-ac39-3cb1962948ed">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtMy0xLTEtNzUzNDE_fb433a00-685c-40f4-84c0-33a430dd6941">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtNS0xLTEtNzUzNDE_24960742-0a7f-4c5d-9c77-f98f28895c0e">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtNy0xLTEtNzUzNDE_653afaca-b327-4553-a830-49f0823365b5">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTctMS0xLTEtNzUzNDE_f978689b-122f-402e-aa29-998700c44943">78.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTctMy0xLTEtNzUzNDE_b039c7aa-e52f-4587-8870-490adda4e0f0">5.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTctNS0xLTEtNzUzNDE_7a1c5f89-0459-43eb-a7ee-5620a0b19c4b">59.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTctNy0xLTEtNzUzNDE_f63c4c58-4ca9-4911-be63-b7e0b81fae6a">9.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before (benefit from) provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTgtMS0xLTEtNzUzNDE_907603bf-527a-40c2-806f-043fec33cbdb">23.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTgtMy0xLTEtNzUzNDE_d0dd4d68-1fe5-40e5-a5ba-f0e035416ace">57.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTgtNS0xLTEtNzUzNDE_d492c677-0485-4c3e-a529-e7a2d5db900d">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTgtNy0xLTEtNzUzNDE_aa56103d-a38d-4a82-8601-80efb6f9fcd4">84.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTktMS0xLTEtNzUzNDE_d939ef40-7395-45fb-8beb-e08368ac0edc">6.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTktMy0xLTEtNzUzNDE_b241453d-3fb6-4831-89db-ad4c91159c69">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTktNS0xLTEtNzUzNDE_a13c7e3c-e488-4542-b073-ee7689b7c7db">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTktNy0xLTEtNzUzNDE_457797f4-a2a5-4400-9867-d3cd34637949">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjAtMS0xLTEtNzUzNDE_ba708bf8-3dab-4529-b5c0-66dfa4cf3fd1">16.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjAtMy0xLTEtNzUzNDE_1e709037-2027-4794-8760-7da17217e8d6">42.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjAtNS0xLTEtNzUzNDE_79ceed8d-ce8c-4a1a-9718-0b625190c765">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjAtNy0xLTEtNzUzNDE_2036beb2-7889-40f6-9124-3cf05341df17">74.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjEtMS0xLTEtNzUzNDE_08eeb90c-7785-435c-a8b2-a9ccd2e2cbf2">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjEtMy0xLTEtNzUzNDE_6c565926-ef8a-42e8-9f07-e4634e64498f">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjEtNS0xLTEtNzUzNDE_19c31d2c-542a-4ab1-bd79-c1406ad78e3d">10.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjEtNy0xLTEtNzUzNDE_c5305103-c42e-4be4-86ba-c01f9920dc8c">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive (loss) income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjItMS0xLTEtNzUzNDE_f8092fac-bb7a-47c3-9924-e92807c93bf8">19.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjItMy0xLTEtNzUzNDE_14d93d4e-45ec-4ae1-a561-daeaad632aec">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjItNS0xLTEtNzUzNDE_3b9161d4-9c61-4a3e-8f9b-6936638ad52a">13.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjItNy0xLTEtNzUzNDE_627daee1-1ccc-4633-80a8-3ddd1341d324">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) earnings per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjQtMS0xLTEtNzUzNDE_6a392a63-a504-49ea-ab30-a39d100c99de">0.18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjQtMy0xLTEtNzUzNDE_73dd20fb-a8e0-4878-844a-c2448888d457">0.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjQtNS0xLTEtNzUzNDE_a36d9aee-a715-4ff9-bdcb-ef6077e16d0a">0.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjQtNy0xLTEtNzUzNDE_02be3e07-27cf-428c-b841-165d5ddf0ee3">0.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjUtMS0xLTEtNzUzNDE_d80880dd-06a9-4f5e-b938-1b462bcc747d">0.18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjUtMy0xLTEtNzUzNDE_9b0ec50c-183f-483a-ab96-6dcac503781d">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjUtNS0xLTEtNzUzNDE_af97c21f-98db-4f01-bb75-ea0b4e9354d9">0.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjUtNy0xLTEtNzUzNDE_464905a6-5fc6-4417-ac2b-669bae950150">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjctMS0xLTEtNzUzNDE_e9e8ca48-7e4d-4768-bc6e-66e76f59542f">95.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjctMy0xLTEtNzUzNDE_d0756227-ca08-4d5b-b76c-ed78c65f21a7">94.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjctNS0xLTEtNzUzNDE_0316df47-5703-4522-871d-3bd4d8b182ab">95.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjctNy0xLTEtNzUzNDE_6f68e306-8214-4a68-ab67-cdb4e671d4af">94.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjgtMS0xLTEtNzUzNDE_55a36e39-5d81-4ee7-977f-ff8dd8e73413">95.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjgtMy0xLTEtNzUzNDE_8055bdd2-0fda-44f2-ac19-cacf16ae07f1">97.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjgtNS0xLTEtNzUzNDE_750d3d92-d40f-4c82-9afd-b557c4ba13cb">95.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjgtNy0xLTEtNzUzNDE_854f4a9f-96d1-4fa8-8d0e-120606e7d68e">98.0</ix:nonFraction></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.469%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at March&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifea1c6e2bc7341889b0e9bdb1f1db6a9_I20220331" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMy0xLTEtMS03NTM0MQ_c8701e32-6338-4521-b1f6-8a988e6cb2af">95.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea1c6e2bc7341889b0e9bdb1f1db6a9_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMy0zLTEtMS03NTM0MQ_fb7b7776-fbbf-4351-8671-dfcdb52bb07b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcb1e428512458eaf6a0bc1b8414ebc_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMy01LTEtMS03NTM0MQ_6d57abbb-11bb-4ddb-b824-d1c169b4b865">1,947.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7db70dedd62742a6831d1f0c2ec694aa_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMy03LTEtMS03NTM0MQ_7d8ecf80-3de0-42d0-b0be-eb16c332fabf">9.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4a6b675fbfc45268b58ff5bf6fb855e_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMy05LTEtMS03NTM0MQ_43ec0b52-3e16-4dce-af4b-2ce18b523520">547.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824b16455d3342c7bf87a435697bab24_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMy0xMS0xLTEtNzUzNDE_576f9a2a-88ca-4dda-a251-83123f52d6fa">1,391.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7e2792b074c4cb5b0a136e01c9e0804_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfNC05LTEtMS03NTM0MQ_5625aec8-18cc-4522-8c84-f32233a6d06a">16.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfNC0xMS0xLTEtNzUzNDE_4f618c26-7e01-4552-9874-799856d8e5ac">16.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8338e74ebc694742b502151eabd9e41e_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfNS03LTEtMS03NTM0MQ_e99e1218-c389-4ada-9a9b-bd1b89391001">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfNS0xMS0xLTEtNzUzNDE_43bf6891-1651-4c66-bd56-8786fe752446">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d13a78bcd1f4c6882ee9fe8cbf5b711_D20220401-20220630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfNy01LTEtMS03NTM0MQ_4dd57b38-473f-4da1-9260-9cae163f5c85">49.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfNy0xMS0xLTEtNzUzNDE_1e89120b-12ae-400a-9b4a-1d1adf1ce667">49.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6ae0c23a2454cc2abcf61a77e930c6c_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOC0xLTEtMS03NTM0MQ_6433280e-9fc2-430b-a3db-c9abd804402e">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d13a78bcd1f4c6882ee9fe8cbf5b711_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOC01LTEtMS03NTM0MQ_bb28ce60-8c31-4a83-bbea-136768904591">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOC0xMS0xLTEtNzUzNDE_8f596ba0-c266-4164-bbff-595d13200e96">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacf77ed46fbe4d5cb0a4c8117097d74d_I20220630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOS0xLTEtMS03NTM0MQ_2e01b54f-fe1a-4539-9e2b-c2176b9edd0b">95.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf77ed46fbe4d5cb0a4c8117097d74d_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOS0zLTEtMS03NTM0MQ_08ed9ba3-601d-48ba-b6dc-60ae6588b45d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0029346e11d24e2489268d48f5de1c60_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOS01LTEtMS03NTM0MQ_5628fb47-f1ae-4a4b-8a4a-dc83f37ec970">1,999.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7180cf1c41f49b6948e46307ec11e60_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOS03LTEtMS03NTM0MQ_f1dcf8e4-dc5f-494c-93c2-5772f2cf2649">12.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib84184652a2e49aebdf6d92adfcbc04d_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOS05LTEtMS03NTM0MQ_eab979d9-3ae1-47b3-a9a4-d1b6207be457">564.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOS0xMS0xLTEtNzUzNDE_ad06f7c9-47b8-4913-b30f-9588586a31b1">1,423.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1b0a1dff46e4f7a9e47f283288de125_I20210331" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTEtMS0xLTEtNzUzNDE_ca4234e9-1c99-4664-a49d-037a329b4cee">94.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b0a1dff46e4f7a9e47f283288de125_I20210331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTEtMy0xLTEtNzUzNDE_2b63b4eb-a077-441c-b314-60d6abb2776b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70110cfad88d4060a5dbaa9f2cedc49f_I20210331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTEtNS0xLTEtNzUzNDE_1800261f-e58a-4e18-a4d5-093996b6d521">1,897.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b70242d24a48a6a99af94c82b13c0d_I20210331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTEtNy0xLTEtNzUzNDE_4199bde9-9004-4e5e-84ad-2e785b10e1be">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied4ed2118815424ab62c252c7749f6de_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTEtOS0xLTEtNzUzNDE_12c701d9-299d-4d66-9acd-b3735b5fa748">693.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5736e265cf4768afa36a5cd7c9e9a3_I20210331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTEtMTEtMS0xLTc1MzQx_26fc1e39-b143-4e1a-b5d8-1ac4c7c29ca8">1,205.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6292fa456fa4806a43afc6154943c3d_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTItOS0xLTEtNzUzNDE_f2dbbf05-9c62-42f9-aa7a-bedde6ad231d">42.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTItMTEtMS0xLTc1MzQx_514f4497-db98-4dea-98c0-fe812a5ed101">42.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39f82d525f6414195ec1a20af940a1d_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTMtNy0xLTEtNzUzNDE_50bd5fd0-2cd1-4206-850a-49cfa964d61b">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTMtMTEtMS0xLTc1MzQx_bc554810-43b7-4a22-9ea2-be1f4f76fc0f">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a894b024126486eab337fda4f4fb0f9_D20210401-20210630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTQtNS0xLTEtNzUzNDE_4c04c178-7869-43d1-9643-37a340a0227d">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTQtMTEtMS0xLTc1MzQx_ee374560-fb0b-4635-9932-5abda6684365">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i607fe14f45874407b052191669ff7dcc_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTUtMS0xLTEtNzUzNDE_efc63c56-2666-4f4f-938e-ee72cbae43ec">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a894b024126486eab337fda4f4fb0f9_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTUtNS0xLTEtNzUzNDE_643d5648-cc50-4a9d-94fa-16a5fb708b08">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTUtMTEtMS0xLTc1MzQx_17ed8c99-ea21-4315-954d-9a71bd1a635e">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i644297e85df8490caa1319af010903f3_I20210630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTYtMS0xLTEtNzUzNDE_bc8e29dc-dec0-4edf-b4e8-6ebd1bff0c84">94.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644297e85df8490caa1319af010903f3_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTYtMy0xLTEtNzUzNDE_3bba0b40-44ff-4773-80f3-318079fa6076">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e390addaf324fa492c8b98404f47c9b_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTYtNS0xLTEtNzUzNDE_67bd89d4-cce7-473c-8b71-57a9a48854b1">1,929.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08908942de0f491f8951674a9b93614b_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTYtNy0xLTEtNzUzNDE_4992e256-6956-4e63-8263-bb063a0073a6">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49d6d0041b1b4429b9640e29170494e4_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTYtOS0xLTEtNzUzNDE_b91caf03-dbc5-4457-8746-f847b9abbc47">651.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTYtMTEtMS0xLTc1MzQx_f97889a2-3305-456c-81f2-15f210c829cb">1,279.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i798f9a1494f44261a5cfc2579e2c5d6d_I20211231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTgtMS0xLTEtNzUzNDE_d85b14a5-abe0-4631-9d65-203e2e92e5fe">94.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i798f9a1494f44261a5cfc2579e2c5d6d_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTgtMy0xLTEtNzUzNDE_bd7eae04-919a-42af-b741-abe8f5856444">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbcf4054dfb74e3793b2c0599d057e19_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTgtNS0xLTEtNzUzNDE_8207c370-38b2-411c-88fd-5ea2928c2578">2,011.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb5b491d36940f6b9f1a57707a58f6f_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTgtNy0xLTEtNzUzNDE_e34aeb94-d0c8-4dbc-b546-dbd8fb55ef19">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9d9884a14e643e0b6e6704e1d74e903_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTgtOS0xLTEtNzUzNDE_62d7aae6-4189-4b86-ae58-36368dc40a30">635.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTgtMTEtMS0xLTc1MzQx_5fda93ef-ab06-4eca-91ff-7f6cb3d82ea9">1,374.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i787d806f66c443c8ac342b1496f0ee61_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTktOS0xLTEtNzUzNDE_2e5dc5d6-8f19-492d-8ab2-2f3a399e264e">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTktMTEtMS0xLTc1MzQx_d9af7043-021d-419f-a91b-abb297b081b9">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i391c44c0626e492884c04b5900b62430_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjAtNy0xLTEtNzUzNDE_471b1f55-a864-434e-823d-8876883adab6">10.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjAtMTEtMS0xLTc1MzQx_2c96cbea-bf01-40c4-b962-011ff671f4ae">10.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjEtMC0xLTEtOTE5OTQ_1af9cee6-f810-4eaf-b311-f7383604b8af">Cumulative-effect adjustment due to adoption of ASU 2020-06</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie030c4abde7f4cf784cc031f496e6485_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjAtNS0xLTEtOTIwMTk_950f0626-e6cf-4efa-8dd7-51079b3eb61c">106.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i465519c475194c1d9739d8c1fca3961d_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjAtOS0xLTEtOTIwMTM_f3956639-6f59-470c-8d80-0bbcc446730c">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91b516301ebe44a6b87c40ee75c6677c_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjAtMTEtMS0xLTkyMDA3_ebb49526-fd8f-4fd6-a071-be7b1cf77631">32.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bd8d4ea894bff986d00fbffc83784_D20220101-20220630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjEtNS0xLTEtNzUzNDE_5431fe42-ca4a-4720-9156-cdc1ddee4d83">86.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjEtMTEtMS0xLTc1MzQx_9fbb50be-8ed7-4a6e-b8cf-575c1028607d">86.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e14680288bd42149b5cdf6969e7f02b_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjItMS0xLTEtNzUzNDE_69b1c6c0-8d69-4783-ab01-975a83e97469">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20bd8d4ea894bff986d00fbffc83784_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjItNS0xLTEtNzUzNDE_648a4e49-16b3-48d0-a18b-3f8c905c60ae">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjItMTEtMS0xLTc1MzQx_e5296301-2ee7-4201-9cd3-8a7094dfc5ca">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacf77ed46fbe4d5cb0a4c8117097d74d_I20220630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjMtMS0xLTEtNzUzNDE_ec9aab4b-d996-46f9-8bc3-c3085a82a3ea">95.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf77ed46fbe4d5cb0a4c8117097d74d_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjMtMy0xLTEtNzUzNDE_e5f9720e-ccc3-49a1-abc6-3638322d5779">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0029346e11d24e2489268d48f5de1c60_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjMtNS0xLTEtNzUzNDE_96e40438-aaf9-44b0-b62a-2b5952107578">1,999.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7180cf1c41f49b6948e46307ec11e60_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjMtNy0xLTEtNzUzNDE_e219046d-cb0c-4bef-b07f-439a2b563c6c">12.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib84184652a2e49aebdf6d92adfcbc04d_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjMtOS0xLTEtNzUzNDE_43c5d6d8-7384-408f-9889-a5a306462fd1">564.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjMtMTEtMS0xLTc1MzQx_a0797833-4b2d-47be-a988-4a4acbd8e670">1,423.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ef17498aa9d498c8992b5221561c777_I20201231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjUtMS0xLTEtNzUzNDE_22041d72-6ce9-4dff-be7d-e2ce682053d5">93.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef17498aa9d498c8992b5221561c777_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjUtMy0xLTEtNzUzNDE_8d1ff0bf-f329-4492-a23e-9eff12cccdb6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b42b5fd65e44418a23dcde417525dd_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjUtNS0xLTEtNzUzNDE_cea05999-52c4-48d8-8453-b79dc8253d5b">1,849.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d820c9109a4f90b3f7b8e63c0993ee_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjUtNy0xLTEtNzUzNDE_5ffb6c06-19c3-45b1-9bdb-f975fcff719e">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e67fafca0274dee95d180cc3fb1f41f_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjUtOS0xLTEtNzUzNDE_c1b42d51-a296-4655-958f-259ae1dc95d1">725.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1739e70f0194d8fa9900c2c02abbe2b_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjUtMTEtMS0xLTc1MzQx_0d8a93ec-8c9e-40c8-8950-64e49410b1b6">1,126.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93d94c70d96d4cf8aa28362a0b2141c5_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjYtOS0xLTEtNzUzNDE_4744b310-9705-4ae2-9bbf-d7b4762523cb">74.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjYtMTEtMS0xLTc1MzQx_b23c2705-489f-42e3-a51e-d7496173b5c4">74.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic92e784af6164e40ab1441eb9d508ae1_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjctNy0xLTEtNzUzNDE_059277ac-7771-4276-9fa4-41de1c746a92">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjctMTEtMS0xLTc1MzQx_52e38044-c65a-475c-a028-567adc1461d7">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570417ef7f454c59b464a0797bfa388a_D20210101-20210630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjgtNS0xLTEtNzUzNDE_7e69e5fd-1f01-4b62-ba93-15d692aab5bf">61.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjgtMTEtMS0xLTc1MzQx_f66036eb-d5bf-45cc-9584-8874e17a2e14">61.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9dd39c3aa14042ba9edda98ae8d9cb55_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjktMS0xLTEtNzUzNDE_8db22d4d-4d0f-469e-98d2-517b48d9e88f">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570417ef7f454c59b464a0797bfa388a_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjktNS0xLTEtNzUzNDE_d4dfa2a4-78f7-4bc0-8d8c-c958129b7f7e">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjktMTEtMS0xLTc1MzQx_825fa68b-b7b0-48ed-9707-01f83f5b5c71">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i644297e85df8490caa1319af010903f3_I20210630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMzAtMS0xLTEtNzUzNDE_3d7b96b0-5e5f-4648-9fc6-284f34810342">94.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644297e85df8490caa1319af010903f3_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMzAtMy0xLTEtNzUzNDE_dbff8eea-fa4f-4832-8037-3431780666ae">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e390addaf324fa492c8b98404f47c9b_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMzAtNS0xLTEtNzUzNDE_892bc170-a306-47cf-9051-24cb7ee40fba">1,929.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08908942de0f491f8951674a9b93614b_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMzAtNy0xLTEtNzUzNDE_1290f186-5bdd-445a-b4e0-067be9e50155">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49d6d0041b1b4429b9640e29170494e4_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMzAtOS0xLTEtNzUzNDE_3907e40d-a4bd-44aa-9662-8a7d231fa9d4">651.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMzAtMTEtMS0xLTc1MzQx_dea922f6-ab70-4716-939f-53c58fcfac11">1,279.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMy0xLTEtMS03NTM0MQ_3fffa89f-8877-4386-a916-7383194c5c4d">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMy0zLTEtMS03NTM0MQ_f5134777-9bd9-4f19-8ad3-5bf05baf27ba">74.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net (loss) income to net cash from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNS0xLTEtMS03NTM0MQ_ad63f658-d91d-45da-a248-14552acd5aaf">86.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNS0zLTEtMS03NTM0MQ_2871bcb2-1b8c-445d-9d72-753e5aad3f52">61.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNi0xLTEtMS0xMDQ1NTg_1f786860-fc02-4ad4-8dec-f27d52c6d1af">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNi0zLTEtMS0xMDQ1NTg_eabfd3b6-39e1-4d45-a024-962cc5afea69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNi0xLTEtMS03NTM0MQ_7335710a-ac7c-4c1d-988a-fb836459af05">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNi0zLTEtMS03NTM0MQ_1a606b40-8de2-48f8-ba09-4ebd80fe1694">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNy0xLTEtMS03NTM0MQ_ffe26043-9bac-4dfd-b42d-1ced3a3d7525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNy0zLTEtMS03NTM0MQ_224e4d50-4c31-4785-8511-86f70f3b8e37">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfOC0xLTEtMS03NTM0MQ_d22f44b3-4f4d-4394-8098-3e767b82458f">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfOC0zLTEtMS03NTM0MQ_d205ab7e-37e8-490b-8245-55f265dce93c">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity security investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfOS0xLTEtMS03NTM0MQ_142a7a90-c6dc-4492-9a0c-44ba161465f9">12.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfOS0zLTEtMS03NTM0MQ_ece2ffa5-2902-4472-9149-b2bcf3774cf2">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTAtMS0xLTEtNzUzNDE_61c7e3bf-b41f-48e7-91e0-249ac4039d85">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTAtMy0xLTEtNzUzNDE_5c8b795b-c696-4bb7-9cb7-644dbd4435dc">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTEtMS0xLTEtNzUzNDE_52760815-feb4-466b-9e52-659d65c06b05">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTEtMy0xLTEtNzUzNDE_7d624464-4c19-4c3f-9b92-df3855008476">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTMtMS0xLTEtNzUzNDE_50b88c69-53b7-41f8-ba78-e602e7e094f4">93.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTMtMy0xLTEtNzUzNDE_2fc5ce9d-71ab-4780-9915-6d195c2fd9bc">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTQtMS0xLTEtNzUzNDE_0197c211-45ee-4984-83d5-3aba65c9d03a">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTQtMy0xLTEtNzUzNDE_94361334-de88-4006-bf55-d2907c776949">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTUtMS0xLTEtNzUzNDE_eb49f61a-4edb-406f-a6a2-5194d1c072c3">44.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTUtMy0xLTEtNzUzNDE_342a2aaf-0024-4307-84dd-043327bed1ed">29.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTYtMS0xLTEtNzUzNDE_a40e11b2-4c5d-414b-bfbd-b5ea4fc094ce">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTYtMy0xLTEtNzUzNDE_e87e601c-55be-4a66-9bea-9fa67b4e2263">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTctMS0xLTEtNzUzNDE_c1869407-5782-477a-8cd4-d8276ae3c8f0">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTctMy0xLTEtNzUzNDE_5302de94-8116-4a6f-a4c6-354f54c06cf7">190.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjAtMS0xLTEtNzUzNDE_d043b265-1825-4a53-afc1-8210fb61025b">253.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjAtMy0xLTEtNzUzNDE_7ed543f7-0d91-4787-8f7e-0dae653359c9">383.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and maturities of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjEtMS0xLTEtNzUzNDE_f6452634-aa21-46f0-9254-8de0a44df063">277.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjEtMy0xLTEtNzUzNDE_45cdb11d-7b5b-445e-bb3a-4819ddaf1aee">364.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjItMS0xLTEtNzUzNDE_bf858b1e-a0ab-427f-aba2-ad5fbbae824d">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjItMy0xLTEtNzUzNDE_9468f5aa-535f-4528-baa9-88d1c502fcfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjMtMS0xLTEtNzUzNDE_698ca243-f269-400d-b945-6f413e675435">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjMtMy0xLTEtNzUzNDE_ea8bc07f-5b65-49c1-bf38-420ab357a64f">8.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjQtMS0xLTEtNzUzNDE_f2c743b3-b435-4e0c-b6c1-abd9dcf3c2c4">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjQtMy0xLTEtNzUzNDE_bddcc996-a5e6-41d3-b7ae-2c26730db738">27.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances of common stock under benefit plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjctMS0xLTEtNzUzNDE_dade520d-6a93-437e-b88f-2cc570ce99d2">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjctMy0xLTEtNzUzNDE_e3c46585-cffa-4cc9-be55-2bd2a0557ba6">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjgtMS0xLTEtNzUzNDE_181fc01b-6bcb-4a75-8658-4b218b85fa51">279.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjgtMy0xLTEtNzUzNDE_471bc282-cea9-4386-a102-60d65174b46a">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjktMS0xLTEtNzUzNDE_d3494ac6-a2b6-4397-881e-81ef947b0292">270.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjktMy0xLTEtNzUzNDE_3d30edef-8808-4305-b449-ea17c4ec988e">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzAtMS0xLTEtNzUzNDE_21847618-ff5c-45e2-8f86-e0b02b461d46">172.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzAtMy0xLTEtNzUzNDE_ba162d56-ee42-4f70-832f-c9adf882e10c">180.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzEtMS0xLTEtNzUzNDE_658ecf59-616e-4f5f-bbe4-e7e9e57ecb94">344.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1739e70f0194d8fa9900c2c02abbe2b_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzEtMy0xLTEtNzUzNDE_b73f288e-f8c3-4b19-bf79-69e8a852a921">190.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzItMS0xLTEtNzUzNDE_78f694c5-9437-497e-ae0f-63498f572899">171.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzItMy0xLTEtNzUzNDE_6a8d0dfa-950d-4f1a-81e3-f3356b5f14cb">371.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash capital expenditures</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzUtMS0xLTEtNzUzNDE_35e21228-7d22-4447-ae1e-a0a26ac93675">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzUtMy0xLTEtNzUzNDE_fbfdb97e-75f6-4bca-9e72-eefcd31d8226">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets acquired through operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzYtMS0xLTEtNzUzNDE_ca22a9a3-20f4-42ac-8377-5d131b9c0bfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzYtMy0xLTEtNzUzNDE_fe099079-d1ab-444e-9fd3-21b74a317a56">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzctMS0xLTEtNzUzNDE_3504b2df-bd2b-4461-8e41-d39b1f9b5daa">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzctMy0xLTEtNzUzNDE_6ecce6be-664a-4e4f-b2e5-4391f48dfc2d">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzgtMS0xLTEtNzUzNDE_7a44b803-8979-4e8b-823a-dde4aec11c4d">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzgtMy0xLTEtNzUzNDE_b56a36fc-e3dc-47bb-8c78-a4b6689a3e26">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_31"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzgxMQ_b8d153f7-59ab-4d3c-ad1e-c38ad12d7010" continuedAt="iad96ade9338c41aca336d6e99254857a" escape="true">Organization and Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="iad96ade9338c41aca336d6e99254857a"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzgwOA_7f8b0293-4ba7-4131-9f3b-a35b6a3e754f" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K, or the 2021 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2021, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzgxMA_6106a6ff-4bf2-4978-a4ce-82d7ff0829ee" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjI0MA_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjgwMA_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span> removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzA0Mg_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span> prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the <ix:nonFraction unitRef="number" contextRef="ifa023efd07b7418a8139d17baa936118_I20170502" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzI5Ng_49b07f2e-79cb-4242-95e1-120fe697f524">2.25</ix:nonFraction>% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzM2NQ_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span> on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $<ix:nonFraction unitRef="usd" contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzY3OQ_5b64e963-da74-4625-ade7-2825d656559e">42.2</ix:nonFraction> million, reduced deferred tax liabilities by $<ix:nonFraction unitRef="usd" contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzcxOQ_e0a152b1-ce79-4aca-bdab-2230fddb78e0">9.9</ix:nonFraction> million, reduced additional paid-in capital by $<ix:nonFraction unitRef="usd" contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231" decimals="-5" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzc2MQ_c8dc538d-da09-44ab-aab9-bfe81ac74ef8">106.8</ix:nonFraction> million and reduced the accumulated deficit by $<ix:nonFraction unitRef="usd" contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzgwMw_bd015d84-bb81-432d-a353-1f661e1a0e8a">74.5</ix:nonFraction> million.</span></div></ix:nonNumeric></ix:continuation><div id="ia5b26032409f4bcfa80efa90e636a8b2_34"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjAyMTE_e752bcab-44ea-410c-b238-87bf843aa4d8" continuedAt="i7c1ce3d82aac49689c39c83624910606" escape="true">Collaboration and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i7c1ce3d82aac49689c39c83624910606" continuedAt="i6c07900ceaae4597b2e34005992547f8"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Heptares Therapeutics Limited, or Heptares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We entered into a collaboration and license agreement with Heptares, which became effective in December 2021, to develop and commercialize certain compounds containing sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists, which compounds we have the exclusive rights to develop, manufacture and commercialize worldwide, excluding in Japan, where Heptares retains the rights to develop, manufacture, and commercialize all compounds comprised of M1 receptor agonists, subject to certain exceptions. With respect to such rights retained by Heptares, we retain the rights to opt in to profit sharing arrangements, pursuant to which we and Heptares will equally share in the operating profits and losses for such compounds in Japan. Subject to specified conditions, we may elect to exercise such opt-in rights with respect to each such compound either before initiation of the first proof of concept Phase II clinical trial for such compound or following our receipt from Heptares of the top-line data from such clinical trial for such compound. We are responsible for all development, manufacturing and commercialization costs of any collaboration product. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Heptares $<ix:nonFraction unitRef="usd" contextRef="i2b01af7da7264226a39cc415c4f4de88_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTMxMQ_75a06ca2-3ff9-4235-bf3b-eb4c2ea4ded9">100.0</ix:nonFraction> million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;D in 2021. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6c07900ceaae4597b2e34005992547f8" continuedAt="i7987caae3a204e8386823707d6550b44"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, the FDA accepted our submission of an investigational new drug application, or IND, for NBI-1117568 for the treatment of schizophrenia, for which we anticipate initiating a Phase II study during the second half of 2022. Based upon this progress, a milestone of $<ix:nonFraction unitRef="usd" contextRef="i0378ba60bbf54c9c984afe9729769082_D20220401-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjE5OTAyMzI4NjgwOA_a8848962-6d29-41fa-a644-78cdd8132c98">30.0</ix:nonFraction> million was expensed as R&amp;D in the second quarter of 2022, which we expect to pay to Heptares in the third quarter of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Heptares may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i82ea1ca4da564dcb9abb0f23996feb31_I20220630" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTYyOQ_3eeb12c6-3399-44ff-a74c-f8ef177c66e3">2.6</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which the royalty term for such licensed product has expired in such country. On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a licensed product and terminate on the later of (i) the expiration of the last patent covering such licensed product in such country, (ii) a number of years from the first commercial sale of such licensed product in such country and (iii) the expiration of regulatory exclusivity for such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or with respect to one or more targets upon 180 days&#8217; written notice to Heptares during the research collaboration term and upon 90 days&#8217; written notice to Heptares following the expiration of the research collaboration term. Following the expiration of the research collaboration term, Heptares may terminate the agreement on a target-by-target basis in the event that we do not conduct any material development activities outside of Japan with respect to a certain compound or licensed product within the applicable target class for a continuous period of not less than 365 days and do not commence any such activities within 120 days of receiving written notice. Either party may terminate the agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited, or Takeda.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into an exclusive license agreement with Takeda, pursuant to which we acquired the exclusive rights to develop and commercialize certain early to mid-stage psychiatry compounds, including luvadaxistat, NBI-1065845, NBI-1065846 and four non-clinical stage compounds. Luvadaxistat and the 4 non-clinical stage compounds have each been designated as a royalty-bearing product. NBI-1065845 and NBI-1065846 are currently each designated as a profit-share product. We are responsible for all manufacturing, development and commercialization costs of any royalty-bearing product. With respect to NBI-1065845 and NBI-1065846, we and Takeda will equally share in the operating profits and losses. Takeda retains the rights to opt-out of the profit-sharing arrangements, pursuant to which Takeda would be entitled to receive potential future payments upon the achievement of certain event-based milestones with respect to such compounds and receive royalties on the future net sales of such compounds (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out right for such compound immediately following the completion of a second Phase II clinical trial for such compound, or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase III clinical trial for such compound.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Takeda $<ix:nonFraction unitRef="usd" contextRef="i1d87729af3eb438a8f50b92d4f11b0ff_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfNTA4Mw_98594569-7448-491d-85a6-9f890c023682">120.0</ix:nonFraction> million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i38ba4b66e35b4a058bd00122f74f68a1_I20220630" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfNTM5OQ_60531135-e7e8-4f40-a08b-ece9c144b376">1.9</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any royalty-bearing product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any royalty-bearing product, the royalty term has expired in such country; and (ii) for any profit-share product, for so long as we continue to develop, manufacture, or commercialize such licensed product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a royalty-bearing product and terminate on the later of (i) the expiration of the last patent covering such royalty-bearing product in such country, (ii) a number of years from the first commercial sale of such royalty-bearing product in such country and (iii) the expiration of regulatory exclusivity for such royalty-bearing product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or in one or more (but not all) of the United States, Japan, the European Union and the United Kingdom, or, collectively, the major markets, upon six months&#8217; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. We may terminate the agreement in its entirety or in one or more (but not all) of the major markets upon 12 months&#8217; written notice to </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7987caae3a204e8386823707d6550b44" continuedAt="i8d81b5cbdf2d4bc0a6e04e60b47a5b22"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. Takeda may terminate the agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Pharmaceuticals Ltd., or Idorsia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into a collaboration and license agreement with Idorsia, pursuant to which we acquired the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker in clinical development for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. We are responsible for all manufacturing, development and commercialization costs of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Idorsia $<ix:nonFraction unitRef="usd" contextRef="i0b5f0284f514463fb5639c0b9dc36242_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfODc5MQ_a0afd23a-4e96-482d-945c-263e7c89a676">45.0</ix:nonFraction> million upfront, which was expensed as IPR&amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i29dde29babb8447aa6253d6d81080068_I20220630" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfOTA2Mg_3294d20a-e667-4b99-81e1-043866732f35">1.7</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement, in its entirety or with respect to a particular compound or development candidate, upon 90 days&#8217; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon Pharmaceuticals Inc., or Xenon. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Xenon to identify, research and develop sodium channel inhibitors, including NBI-921352 and three preclinical candidates, which compounds we have the exclusive rights to develop and commercialize. We are responsible for all development and manufacturing costs of any collaboration product, subject to certain exceptions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Xenon $<ix:nonFraction unitRef="usd" contextRef="icc12b8925fe24715a37c917e89b4a2d3_I20191231" decimals="-5" name="nbix:UpfrontPaymentsMade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTAxMjI_b37132dd-4220-412e-9abf-24beae0fd548">50.0</ix:nonFraction> million upfront, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="i41dedb5b6dd648adafef4d12efc9d560_D20190101-20191231" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTAxNzI_daf56185-d92a-4651-93f6-002d663e610d">1.4</ix:nonFraction> million shares of Xenon common stock (at $<ix:nonFraction unitRef="usdPerShare" contextRef="icc12b8925fe24715a37c917e89b4a2d3_I20191231" decimals="3" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTAyMDg_7ab4770e-c355-480f-b7d5-9e52fe1f3098">14.196</ix:nonFraction> per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="icc12b8925fe24715a37c917e89b4a2d3_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTAzOTU_b30282b0-35c6-4ed2-9906-23a6739a2bd4">14.1</ix:nonFraction> million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $<ix:nonFraction unitRef="usd" contextRef="i3113317a93804d79b80f423ec6d08d4a_D20190101-20191231" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTA1MzQ_bef44666-1d1f-48c7-95e5-6b2b62c21660">36.2</ix:nonFraction> million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2019.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the European Union&#8217;s approval of our clinical trial application for NBI-921352 for the treatment of focal onset seizures in adults in September 2021, we paid Xenon a regulatory milestone of $<ix:nonFraction unitRef="usd" contextRef="i423078e1d1174d878d489e6ef59f9d7d_I20211231" decimals="-5" name="nbix:MilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTA4NTA_52c5b868-5acb-4ade-adb8-5c16fdd7aaf6">10.0</ix:nonFraction> million, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="icdca041dd4cd4227abc30499d4f8bebf_D20210101-20211231" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTA4OTI_e55cbc75-d058-40ff-8538-44dc7bff4ebf">0.3</ix:nonFraction> million shares of Xenon common stock (at $<ix:nonFraction unitRef="usdPerShare" contextRef="i423078e1d1174d878d489e6ef59f9d7d_I20211231" decimals="4" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTA5Mjg_ca2d466b-3db1-40cc-acd7-e27a71195903">19.9755</ix:nonFraction> per share). The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="i423078e1d1174d878d489e6ef59f9d7d_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTA5OTc_70e3e9dd-81c9-4101-8a36-7e4363978bf7">4.6</ix:nonFraction> million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $<ix:nonFraction unitRef="usd" contextRef="i62a271eec056493ab613a72c7a5b002b_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTExMzY_d76af3fd-e49f-4721-8941-db35a3e3bf56">5.4</ix:nonFraction> million of the milestone payment was expensed as R&amp;D in 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA's acceptance of our amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol in January 2022, we paid Xenon a regulatory milestone of $<ix:nonFraction unitRef="usd" contextRef="if71d1cf4c4b84dcd8a6b38e623f46644_I20220331" decimals="-5" name="nbix:MilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTEzMjg_df6bc807-482c-4b47-98ac-dc9c44b16ec1">15.0</ix:nonFraction> million, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="i53b573b749c34f2dbfe2a3f74272c97c_D20220101-20220331" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTEzNzA_c95c0adf-0ae7-4418-be1d-f30686ba757a">0.3</ix:nonFraction> million shares of Xenon common stock (at $<ix:nonFraction unitRef="usdPerShare" contextRef="if71d1cf4c4b84dcd8a6b38e623f46644_I20220331" decimals="3" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTE0MDY_185f456f-02a3-4994-b36f-49984c1a7479">31.855</ix:nonFraction> per share). The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="if71d1cf4c4b84dcd8a6b38e623f46644_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTE0NzU_3ebc9f39-216c-4cc3-be77-d919e9f1515a">7.7</ix:nonFraction> million after considering Xenon&#8217;s stock price on the measurement date. The remaining $<ix:nonFraction unitRef="usd" contextRef="i35309e0240cb45d68c83e6a9539b437e_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTE1NTU_441e733d-ff06-420d-85e3-00411b1ae414">7.3</ix:nonFraction> million of the milestone payment was expensed as R&amp;D in the first quarter of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i05ec7aad29694aba88b3325431ac3cca_I20220630" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTE3MzU_a19a02d5-a15c-4868-b3fb-b6791e8d2abc">1.7</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product. Xenon retains the right to elect to co-develop one product in a major indication, pursuant to which Xenon would receive a mid-single digit percentage increase in royalties earned on the future net sales of such product in the United States and we and Xenon would equally share in the development costs of such product in the applicable indication, except where such development costs relate solely to the regulatory approval of such product outside the United States.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular licensed product and country, the license obtained by us with respect to such product and country will become fully paid, royalty free, perpetual and irrevocable. We may terminate the agreement upon 90 days&#8217; written notice to Xenon, </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8d81b5cbdf2d4bc0a6e04e60b47a5b22" continuedAt="ia4a3da47f112449cbbef0a05b6b554a8"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager Therapeutics, Inc., or Voyager.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Voyager, pursuant to which we acquired certain rights to develop and commercialize the NBIb-1817 for Parkinson&#8217;s disease program, Friedreich&#8217;s ataxia program and two undisclosed programs. We are responsible for all development costs of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager. In February 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#8217;s disease program, which became effective August 2, 2021. The termination did not apply to any program other than the NBIb-1817 for Parkinson&#8217;s disease program.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Voyager $<ix:nonFraction unitRef="usd" contextRef="i2cea7f1f684e4ceda425fdd38139bd65_I20191231" decimals="-5" name="nbix:UpfrontPaymentsMade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTM5MTk_17632eb7-8f0c-40cd-a933-b427f8169adf">165.0</ix:nonFraction> million upfront, including a purchase of approximately <ix:nonFraction unitRef="shares" contextRef="i31d5d364edff4ad4b48da1b643c16353_D20190101-20191231" decimals="-5" name="nbix:SaleOfStockNumberOfSharesSoldInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTM5Njk_31630462-2650-41c9-97b4-44741a613cc4">4.2</ix:nonFraction> million shares of Voyager common stock (at $<ix:nonFraction unitRef="usdPerShare" contextRef="i2cea7f1f684e4ceda425fdd38139bd65_I20191231" decimals="4" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTQwMDc_44a31d5c-310d-45a2-adbb-47b56e17710f">11.9625</ix:nonFraction> per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $<ix:nonFraction unitRef="usd" contextRef="i2cea7f1f684e4ceda425fdd38139bd65_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTQxOTQ_aa9c97f0-2b31-41d9-91a3-e74d5a348ba3">54.7</ix:nonFraction> million after considering Voyager&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $<ix:nonFraction unitRef="usd" contextRef="i98646b31fd7d4d0583d03a62061c0725_D20190101-20190331" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTQzMzU_3ae57c2f-67e9-4cca-bdf1-f7156599ea79">113.1</ix:nonFraction> million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2019. In addition, we paid Voyager $<ix:nonFraction unitRef="usd" contextRef="i6bde3727bced42719f1bdb0078bc223e_D20190401-20190630" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTQ0NzE_0e9cba27-a70c-4d06-8830-c28a8768423e">5.0</ix:nonFraction> million upfront, which was expensed as IPR&amp;D in 2019, to acquire the rights outside the United States to the Friedreich&#8217;s ataxia program.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Voyager may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="iee097ca4107145a4a7cafe11c7f7c028_I20220630" decimals="-8" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTQ3MDg_5a1fc73b-0838-4966-a45d-3123eae8dd0f">1.3</ix:nonFraction> billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement. We may terminate the agreement upon 180 days&#8217; written notice to Voyager prior to the first commercial sale of any collaboration product or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A., or BIAL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We acquired the United States and Canada rights to ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(opicapone) from BIAL in 2017, and launched ONGENTYS in the United States in September 2020 as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations. We are responsible for all commercialization costs of ONGENTYS in the United States and Canada and rely on BIAL for the commercial supply of ONGENTYS.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, BIAL may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="i26b03ed42a86426fa271e7a51e9a3975_I20220630" decimals="-5" name="nbix:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTYwMTc_ee8ca2a4-e0ee-411a-ac62-716983c5468e">75.0</ix:nonFraction> million upon the achievement of certain event-based milestones. In addition, with respect to ONGENTYS, in the event we fail to meet certain minimum sales requirements for a particular year in comparison to our annual sales forecast for such year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year. Further, upon our written request to BIAL 12 months prior to the estimated expiration of the term of a licensed product, we will negotiate the continuation of BIAL&#8217;s supply of such licensed product after the term. After the term, and if BIAL is no longer supplying such licensed product, BIAL would be entitled to receive a low double-digit royalty on our future quarterly net sales of such licensed product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until a generic product with respect to such licensed product is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement upon nine months&#8217; written notice to BIAL. BIAL may terminate the agreement in the event we fail to meet the minimum sales requirements for any two years, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party&#8217;s insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation, or MTPC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We out-licensed the rights to valbenazine in Japan and other select Asian markets to MTPC in 2015. In December 2020, we entered into a commercial supply agreement with MTPC, pursuant to which we agreed to supply MTPC with valbenazine drug product for commercial use in Japan and other select Asian markets. MTPC is responsible for all development, manufacturing and commercialization costs of valbenazine in such markets.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia4a3da47f112449cbbef0a05b6b554a8"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, MTPC launched DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in Japan for the treatment of tardive dyskinesia. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="id08aaa35e1ac4e31a43d685f09135c6e_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjE5OTAyMzI4MjM1Nw_89e22f71-1bc9-42df-b248-9c627cd8555a">20.0</ix:nonFraction> million in the second quarter of 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC&#8217;s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in the second quarter of 2022. In addition, we will receive royalties at tiered percentage rates on MTPC net sales of DYSVAL. DYSVAL royalty revenue was not significant for the three and six months ended June&#160;30, 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with MTPC, we may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="idf5acfc15e784512b7a82dc8e2d2fe95_I20220630" decimals="-5" name="nbix:PotentialMilestonePaymentReceipts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTg3NDE_20d64390-87b8-42f1-8048-674b5c4af6dc">30.0</ix:nonFraction> million upon the achievement of certain sales-based milestones and are entitled to receive royalties at tiered percentage rates on future MTPC net sales of valbenazine for the longer of <ix:nonNumeric contextRef="ic20aa02fac274005a61e03b4bc0375b0_D20220101-20220630" name="nbix:PatentTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTg5MjY_757119b9-8572-4ac9-a271-d7ed573dded1">10</ix:nonNumeric> years or the life of the related patent rights. MTPC may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Inc., or AbbVie.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix tablets) in the United States for the treatment of moderate to severe pain associated with endometriosis. In June 2020, AbbVie launched ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States for the treatment of heavy menstrual bleeding related to uterine fibroids in premenopausal women. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $<ix:nonFraction unitRef="usd" contextRef="id6c1cfc608dd4f8f81032e9e441a7511_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjE5OTAyMzI3OTAzNg_b637f174-55eb-44c7-87cf-07f20fa0ff2a">5.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7cfb08820e8842e1871b6c2dd2a4c189_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjE5OTAyMzI3OTA3MA_459529e2-b7c9-42f4-a343-3edf1f19cd80">9.4</ix:nonFraction>&#160;million, respectively, for the three and six months ended June&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i26703103080243799d2bb6d6f1b72bd4_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjE5OTAyMzI3OTA3Ng_06e62a24-862e-4b2b-81ac-3bd28b79f5fc">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i721def435135454b974f4d03651a3930_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjE5OTAyMzI3OTA1NQ_738f725f-0e68-4b6b-9e02-34e2819d7890">10.4</ix:nonFraction> million, respectively, for the three and six months ended June&#160;30, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with AbbVie, we may be entitled to receive potential future payments of up to $<ix:nonFraction unitRef="usd" contextRef="ib5c1bb3894ae4915b5e4726823772c30_I20220630" decimals="-5" name="nbix:PotentialMilestonePaymentReceipts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTk4NDM_daad9dcf-afa4-458a-bf7f-0a3e21879304">366.0</ix:nonFraction> million upon the achievement of certain event-based milestones and are entitled to receive royalties at tiered percentage rates on future AbbVie net sales of elagolix for the longer of <ix:nonNumeric contextRef="i3cfc8c33916a4939a12f81454e0c35ca_D20220101-20220630" name="nbix:PatentTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjAwMjQ_1d7c5cea-dcd0-4fc1-ad2c-87221e26d618">10</ix:nonNumeric> years or the life of the related patent rights. AbbVie may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div></ix:continuation><div id="ia5b26032409f4bcfa80efa90e636a8b2_37"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTc5NQ_38a65841-17ff-4c7a-82d1-b64daf593daf" continuedAt="iaa7d39c163b04cfb8da248e6dd9ad518" escape="true">Debt Securities</ix:nonNumeric></span></div><ix:continuation id="iaa7d39c163b04cfb8da248e6dd9ad518" continuedAt="i02001587058f4c7ca49cf75d46538472"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTc5Ng_3a9c254e-06a8-4c3b-917a-e8d379769a06" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1724975ad3a44d5aafd1acb6e95ee7f_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi0zLTEtMS03NTM0MQ_f59e749c-5e1e-4d1d-8db3-4cda978c1cdf">78.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1724975ad3a44d5aafd1acb6e95ee7f_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi01LTEtMS03NTM0MQ_69b715f4-06a8-4cf1-8ef5-91e9bf65477d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1724975ad3a44d5aafd1acb6e95ee7f_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi03LTEtMS03NTM0MQ_a78cf5fb-1efe-4811-9ae8-eb0ee0dcb587">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1724975ad3a44d5aafd1acb6e95ee7f_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi05LTEtMS03NTM0MQ_08d298fd-3286-419a-a3a4-dbfe15786526">77.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3fa10d15714457a50f9425cd51126e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi0xMS0xLTEtNzUzNDE_33987c00-a0be-42bc-9685-f9c60c78ca93">204.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3fa10d15714457a50f9425cd51126e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi0xMy0xLTEtNzUzNDE_d7775508-bb1c-4362-a5e8-780e342b5795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3fa10d15714457a50f9425cd51126e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi0xNS0xLTEtNzUzNDE_bc2b57ee-3313-4a60-a990-e3cd53993bb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3fa10d15714457a50f9425cd51126e_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi0xNy0xLTEtNzUzNDE_68c00316-386f-4590-ac1b-f27b21a8c2fc">204.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia968122986d748ccba38b5b654f41190_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy0zLTEtMS03NTM0MQ_d89093d5-ae5e-4f17-96bd-8dca96ee62cf">213.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia968122986d748ccba38b5b654f41190_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy01LTEtMS03NTM0MQ_b8c79b5e-a5bb-4a20-b520-7656150be63e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia968122986d748ccba38b5b654f41190_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy03LTEtMS03NTM0MQ_5a79a771-217e-47b6-83db-6fb8436cd527">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia968122986d748ccba38b5b654f41190_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy05LTEtMS03NTM0MQ_00ce52ea-2bc7-4048-b037-89c159254fca">210.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc36e662e8904155b5ef697ff21e9aec_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy0xMS0xLTEtNzUzNDE_de28c5cf-d563-4398-88e0-799cbb4dcf98">128.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc36e662e8904155b5ef697ff21e9aec_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy0xMy0xLTEtNzUzNDE_4fd4e455-a1be-40ab-9fda-941980eaf9ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc36e662e8904155b5ef697ff21e9aec_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy0xNS0xLTEtNzUzNDE_fcff4a07-61c2-4c2c-929c-0f7bfd383496">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc36e662e8904155b5ef697ff21e9aec_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy0xNy0xLTEtNzUzNDE_21c977bc-8db5-4de9-a9d4-c7975f71743f">128.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20cfedabe3c94d5bad4df94bc450895e_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC0zLTEtMS03NTM0MQ_fe7f8d3b-6093-4ba1-b087-42393006a4c8">199.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20cfedabe3c94d5bad4df94bc450895e_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC01LTEtMS03NTM0MQ_1947c669-1efd-401e-a16f-176a81548976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20cfedabe3c94d5bad4df94bc450895e_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC03LTEtMS03NTM0MQ_7cbe383f-77f1-450a-bb4d-0de07ef33137">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20cfedabe3c94d5bad4df94bc450895e_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC05LTEtMS03NTM0MQ_aa2248aa-3200-4901-b487-e07dbba5bf28">196.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2144d7b33a4ad9aadec72dd35693ef_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC0xMS0xLTEtNzUzNDE_26581310-5b2d-4d13-aa8e-6ef3e3b6d9f7">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2144d7b33a4ad9aadec72dd35693ef_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC0xMy0xLTEtNzUzNDE_422cb335-984b-44f1-a6fa-0ac05235003d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2144d7b33a4ad9aadec72dd35693ef_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC0xNS0xLTEtNzUzNDE_124a0d6f-d2ca-4b67-9eb6-f654fc2d2559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2144d7b33a4ad9aadec72dd35693ef_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC0xNy0xLTEtNzUzNDE_032f2eae-be41-4c94-b85e-28592628b86a">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd5d17a30ac7439c9cd69e44e7d10155_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS0zLTEtMS03NTM0MQ_76df2971-d5bb-4dc3-85a0-fdbda38ab63a">491.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd5d17a30ac7439c9cd69e44e7d10155_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS01LTEtMS03NTM0MQ_945861ef-65d9-4860-883b-b2e2262f7bf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd5d17a30ac7439c9cd69e44e7d10155_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS03LTEtMS03NTM0MQ_c17ddd38-43be-402d-a82e-b44e65391a25">6.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd5d17a30ac7439c9cd69e44e7d10155_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS05LTEtMS03NTM0MQ_5fbc6f41-b1a1-46e3-822d-3032f206071c">485.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic173cd64901047748e412993eb622ad8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS0xMS0xLTEtNzUzNDE_2eb4a347-0f57-488e-8bca-9dd03f9f169d">370.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic173cd64901047748e412993eb622ad8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS0xMy0xLTEtNzUzNDE_3ed8ed00-f115-47ec-a1a6-60f459bbcfe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic173cd64901047748e412993eb622ad8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS0xNS0xLTEtNzUzNDE_dc076b56-cc4f-4e1f-833f-f9e1ab769887">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic173cd64901047748e412993eb622ad8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS0xNy0xLTEtNzUzNDE_64d47e16-e95a-4c93-ab09-84db309460eb">370.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8752290fc66f4c8db3353da827e19de9_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy0zLTEtMS03NTM0MQ_86182ef0-ece6-41e5-951b-904ee29b9226">266.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8752290fc66f4c8db3353da827e19de9_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy01LTEtMS03NTM0MQ_fd76b88a-aff1-4d08-8e94-67884e6b6b8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8752290fc66f4c8db3353da827e19de9_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy03LTEtMS03NTM0MQ_95543c29-9dfc-41fd-ab4d-e69b5e2238f0">5.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8752290fc66f4c8db3353da827e19de9_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy05LTEtMS03NTM0MQ_7e255f62-8646-4886-91e4-2bd0a99ae030">261.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf0e1c77adff4ec88d625c49c6294e39_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy0xMS0xLTEtNzUzNDE_8e7c8138-78f1-4fa5-bf95-5d12514a248f">358.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf0e1c77adff4ec88d625c49c6294e39_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy0xMy0xLTEtNzUzNDE_05d39dd2-4c57-4211-a215-405ec340fc6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf0e1c77adff4ec88d625c49c6294e39_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy0xNS0xLTEtNzUzNDE_e7b88e33-cc1e-4f0b-baff-afc2a20a4a1a">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf0e1c77adff4ec88d625c49c6294e39_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy0xNy0xLTEtNzUzNDE_7862a7e1-1186-4668-9cc9-16f4ff53503a">357.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d162d0857b48afb064eef3b8599c86_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC0zLTEtMS03NTM0MQ_dd48b0d8-1871-48bd-98b3-3e338afc186d">148.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d162d0857b48afb064eef3b8599c86_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC01LTEtMS03NTM0MQ_5437333d-ebc1-411e-93f9-b4a8a4e56674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7d162d0857b48afb064eef3b8599c86_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC03LTEtMS03NTM0MQ_ba50d622-0661-48c3-97cb-dc0c888c5093">4.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d162d0857b48afb064eef3b8599c86_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC05LTEtMS03NTM0MQ_284f05a2-78cc-4bad-b8e1-4f26f808fcb6">144.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bcedbc2244f433299e4bcb31bd4bd37_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC0xMS0xLTEtNzUzNDE_25428597-349b-44c0-894c-659066e3cbaf">204.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bcedbc2244f433299e4bcb31bd4bd37_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC0xMy0xLTEtNzUzNDE_dc747cfc-ab5b-486d-b474-57fe554067de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bcedbc2244f433299e4bcb31bd4bd37_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC0xNS0xLTEtNzUzNDE_1db57b03-0f2b-45d0-858d-2cf6594a4249">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bcedbc2244f433299e4bcb31bd4bd37_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC0xNy0xLTEtNzUzNDE_2a688d35-fa49-4db9-af6a-12b3e001a75b">203.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df34d9c3e404caa9a985cda59b147ed_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS0zLTEtMS03NTM0MQ_1c7352c0-0172-4441-952c-a18364f6264d">415.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df34d9c3e404caa9a985cda59b147ed_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS01LTEtMS03NTM0MQ_feb38e9e-c1dd-4547-b47d-94d0f2f56cfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df34d9c3e404caa9a985cda59b147ed_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS03LTEtMS03NTM0MQ_2b9c99a5-eb50-423a-9faf-35195114a930">10.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df34d9c3e404caa9a985cda59b147ed_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS05LTEtMS03NTM0MQ_db95220b-6da3-4639-8fe1-3b16fac6265b">405.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b67814da34d4da988b4bf57d0e478e6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS0xMS0xLTEtNzUzNDE_d0fd0536-bd11-4eef-8eb3-502c0403aa5c">563.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b67814da34d4da988b4bf57d0e478e6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS0xMy0xLTEtNzUzNDE_3df0d800-f502-4882-a8ad-36bed979eafc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b67814da34d4da988b4bf57d0e478e6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS0xNS0xLTEtNzUzNDE_1b67a646-dff7-4683-b274-74c2d277ebd6">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b67814da34d4da988b4bf57d0e478e6_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS0xNy0xLTEtNzUzNDE_8af42e20-cddd-4ba8-a214-6355d152bb2c">560.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our security portfolio consisted of <ix:nonFraction unitRef="security" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="INF" name="nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMzIw_836bcec0-c7ea-461f-9940-0f45fc395773">166</ix:nonFraction> debt securities available-for-sale, including <ix:nonFraction unitRef="security" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMzY5_35abdd10-5ecf-43e8-ba33-35d4da1ff858">164</ix:nonFraction> such securities that were in an unrealized loss position but of high credit quality. Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recognized as of June&#160;30, 2022 or December&#160;31, 2021.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i02001587058f4c7ca49cf75d46538472"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTc5Mg_4c58f46a-93e5-4272-8905-49d7b45ecd79" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of June&#160;30, 2022, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMi0xLTEtMS03NTM0MQ_e7bdd20c-4bb3-4de7-886e-50dc9fff1f28">61.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMi0zLTEtMS03NTM0MQ_2c5125ec-0bca-421b-920f-c58e48250918">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMi01LTEtMS03NTM0MQ_fea69c13-46d3-4c99-b1f0-7d662ce9cfdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMi03LTEtMS03NTM0MQ_d031c557-4c40-4406-8d87-ff0297e73ead">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMi05LTEtMS03NTM0MQ_b49d9949-66cf-4914-8699-4a9317991186">61.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMi0xMS0xLTEtNzUzNDE_87eb26b0-9274-4547-9173-d5e83ea1e279">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4cdb346b995405d841286aaa096490d_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMy0xLTEtMS03NTM0MQ_c14dac74-a594-459e-96aa-0de79f1613af">403.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4cdb346b995405d841286aaa096490d_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMy0zLTEtMS03NTM0MQ_fd8c69e5-83e2-46fc-b915-36331d99362e">7.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4cdb346b995405d841286aaa096490d_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMy01LTEtMS03NTM0MQ_2ae40d4f-7e1b-46c0-a021-5f9609750700">60.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4cdb346b995405d841286aaa096490d_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMy03LTEtMS03NTM0MQ_20acce1f-567c-49c1-9a49-26ce280372f0">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4cdb346b995405d841286aaa096490d_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMy05LTEtMS03NTM0MQ_c60e3abf-9854-4ecb-9a9f-944f2c03d1d4">464.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4cdb346b995405d841286aaa096490d_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMy0xMS0xLTEtNzUzNDE_44a26858-fd7c-4ace-8b3a-eef2e1014885">8.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfNC0xLTEtMS03NTM0MQ_e95801ae-c19d-405e-ae71-69ab926e8cef">329.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfNC0zLTEtMS03NTM0MQ_a6108789-13f8-4761-ac5b-01e53590c8d2">7.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfNC01LTEtMS03NTM0MQ_eb2f2aef-4925-4c78-b5d6-a146a9bfbd06">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfNC03LTEtMS03NTM0MQ_9b59a1ac-eca5-4ae0-9f3c-171f6011dff3">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfNC05LTEtMS03NTM0MQ_1eec3c96-06a2-42bd-a9b1-2bf1d3464b28">340.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfNC0xMS0xLTEtNzUzNDE_06cf6cfc-a150-475b-b4ec-7ad71320fc74">7.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMi0xLTEtMS03NTM0MQ_516a50d4-29f4-4f86-aee4-855307436820">428.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMi0zLTEtMS03NTM0MQ_d38bd67e-6d10-4fa6-8f61-bb9e98fd0770">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMi01LTEtMS03NTM0MQ_3b052b89-5c30-4143-a74a-57c5ad1ab5f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMi03LTEtMS03NTM0MQ_d15abf91-ea47-4626-8b5f-b1a18921f06b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMi05LTEtMS03NTM0MQ_80c07f80-8fac-478e-b31a-aee4164c6f77">428.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMi0xMS0xLTEtNzUzNDE_e4359b47-561f-484c-aa9a-4fc8469a3e3d">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMy0xLTEtMS03NTM0MQ_9ce9730c-66e7-4400-bfda-7b51c45ed1a2">230.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMy0zLTEtMS03NTM0MQ_6b590329-81ce-45bd-9968-a1fe4ca0ff29">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMy01LTEtMS03NTM0MQ_7d334113-2ffb-47b0-8f00-d3b29cffd8ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMy03LTEtMS03NTM0MQ_84ffe46c-32f2-4b56-a2b8-f54f7c878f82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMy05LTEtMS03NTM0MQ_3858ca98-47a5-4e51-812f-d2dd1e433275">230.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMy0xMS0xLTEtNzUzNDE_848b54f6-378b-4547-b60e-49f962017943">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale totaled $<ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTI2MA_6e1fd68f-015d-41ba-a033-fbb2b179d59b">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTI2Nw_16cc8dec-10ce-4b99-9a42-9a05a64442fb">2.2</ix:nonFraction> million, respectively, as of June&#160;30, 2022 and December&#160;31, 2021. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. <ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTcwOA_1f07f627-7b35-4859-9989-5e834278ecae"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTcwOA_fd897c09-cefd-486b-b90b-9ca8b5b62666">No</ix:nonFraction></ix:nonFraction> accrued interest receivables were written off during the six months ended June&#160;30, 2022 or 2021.</span></div></ix:continuation><div id="ia5b26032409f4bcfa80efa90e636a8b2_40"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RleHRyZWdpb246YzFiYTIxZTBiOTdmNDM0NzhhY2Q3MGYwZDY0NDgyY2JfMzA1OA_79f3a821-5f22-4250-956f-39825dedc2c5" continuedAt="i4c0d952043f646b6a7955aa2e757dbe3" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i4c0d952043f646b6a7955aa2e757dbe3" continuedAt="i03ecd9662906493b8c7b810e1a6e1fec"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RleHRyZWdpb246YzFiYTIxZTBiOTdmNDM0NzhhY2Q3MGYwZDY0NDgyY2JfMzA1OQ_270ff8b9-620e-4d71-90bf-5ceeb098b2b7" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RleHRyZWdpb246YzFiYTIxZTBiOTdmNDM0NzhhY2Q3MGYwZDY0NDgyY2JfMzA1NQ_3a830e1a-5228-425b-9376-716b89148e9d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of investments, which were measured at fair value on a recurring basis.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ecf9c7bbfe243a89adac1ac817f3336_I20220630" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC0xLTEtMS03NTM0MQ_66ed7db0-1d18-49d0-903d-f8a918dcf936">163.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie091570b8c7e468aaa662efd674b1a48_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC0zLTEtMS03NTM0MQ_246bb5ba-eec7-42df-b884-6f257326d652">163.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c4567a749e4031aed667e267ff71cf_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC01LTEtMS03NTM0MQ_5dee0094-5860-4a17-85ed-cda18f893166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67109db4be9c4ba1bdead9f009154aed_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC03LTEtMS03NTM0MQ_268109b6-dcdd-4c56-a3a2-bee7ccbd12ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2bfb40cca13406fa0b41700ae0ee8fe_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC05LTEtMS03NTM0MQ_9ec2aeaa-7a09-48b8-8704-a51a4f00197b">340.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56225d1fd9af4788a6c4c2c401b49441_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC0xMS0xLTEtNzUzNDE_552f3f9f-7f59-446c-a37d-e8cd424e41b5">340.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib836ccb73c334b1e92c3bb0032674ed2_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC0xMy0xLTEtNzUzNDE_d339c9a6-1769-445e-967d-66f3ca1543f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56223020056d47c38dbea1cc503a767f_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC0xNS0xLTEtNzUzNDE_0784bf18-52ab-47d4-88de-a83f1e95c7c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bf20361175e48e8a2b61d38d6483435_I20220630" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi0xLTEtMS03NTM0MQ_ffa4a497-7a51-4bf2-9018-4e972a0caaff">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d34c798b0c047d18064663be75d6f59_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi0zLTEtMS03NTM0MQ_1d51238a-2bbc-4d96-baa2-3b31e1dd4fed">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i578731c40e2a43fd9bd0b849e2773a25_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi01LTEtMS03NTM0MQ_5b2e2862-57b6-4e8f-9e43-5ea6aa44f35d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e334b57cf1645dca4bb9f652d8b8ebd_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi03LTEtMS03NTM0MQ_a113385d-ff61-44a7-b6d8-14200c95a9b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53bbe7b73503454da09d5f5c6dc24da1_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi05LTEtMS03NTM0MQ_bd19b22a-210b-42e5-a0b2-2484efc4da7b">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7d2babfc2941b297b24e9e5e8a7958_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi0xMS0xLTEtNzUzNDE_f8ce8e71-7c8f-4f77-b661-52c7b42bcb77">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3edac7da69b94cd794ccfbce890c2b19_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi0xMy0xLTEtNzUzNDE_20df762d-0f93-405a-b993-ed912499d6ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie155cdd1531a43a589fe6b7ea1553a8d_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi0xNS0xLTEtNzUzNDE_2ea65b42-981c-4428-a505-ad9954b7a9cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e9ff90e3d945f48f05c03731be0dea_I20220630" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC0xLTEtMS03NTM0MQ_3b209379-b264-4ac6-ac1e-017da9b6e542">77.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d60ef478c64a6aa6e2b15688f36c19_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC0zLTEtMS03NTM0MQ_30ad2a27-2275-4f1b-ab34-d423ee2a2b04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie71d87a7ca30406082e35c819e1436ed_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC01LTEtMS03NTM0MQ_d7bad3f9-ceb6-4e4c-8a09-f9321228a88e">77.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8110a30289e34b7b9625883f2787fc8a_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC03LTEtMS03NTM0MQ_cf4501bf-e837-4615-8b30-1325550d4c85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id542276cdcda416ab9e520eb0c59e6b9_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC05LTEtMS03NTM0MQ_0fb89af2-1a0a-4646-9c39-ac2116e1c417">204.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e52574305944b99802e51d55304a886_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC0xMS0xLTEtNzUzNDE_bb524b47-ba30-4995-bb47-f79a6f5af44d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a9c71abed34ec1b434462a578f36c8_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC0xMy0xLTEtNzUzNDE_5e03f842-7e81-4282-94ac-e3e6f89364a2">204.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6fd4b26ceb4e1b95da9a0661d58688_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC0xNS0xLTEtNzUzNDE_d312f198-025a-4ef2-bb88-05903af5cc8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4cdb346b995405d841286aaa096490d_I20220630" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS0xLTEtMS03NTM0MQ_00837eed-bbfb-4e11-9359-84440530f64a">471.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80f2f492d604d77ae916ea5296d3824_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS0zLTEtMS03NTM0MQ_2a48c8b5-ae71-426b-ac14-9c0264bfc6c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb55cdc59344e51950ad5eb6569c231_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS01LTEtMS03NTM0MQ_e0365fd2-0583-4b91-b609-afdbdb71f8a9">471.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5f50efda0b428ea5e117442266f762_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS03LTEtMS03NTM0MQ_f4a1c70d-7362-4839-b0db-24597718631a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS05LTEtMS03NTM0MQ_2b34324c-99fb-4b87-9b25-337d5b0307c2">485.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a9a8a35647d496daedc583782304e30_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS0xMS0xLTEtNzUzNDE_842bacea-0af1-4228-b856-b218a72140cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9487e38c52d9410798197fe77cd60f57_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS0xMy0xLTEtNzUzNDE_8ac62db3-76df-470a-b1c7-764e8481617a">485.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a9046e38e0432d9b62315b9af06dad_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS0xNS0xLTEtNzUzNDE_c06bfbff-a0f5-406b-80fc-32a9e31799e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtMS0xLTEtNzUzNDE_36bc928d-ad01-42b1-aba4-f9b4a3ff4ad2">340.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9e4bf673604e399b7bafea5de77c4a_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtMy0xLTEtNzUzNDE_4e84b370-7336-4391-8b60-a1853a07376d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d0694197d34f049fae415dfd7cef26_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtNS0xLTEtNzUzNDE_4172c6cf-fe7a-43d7-bf93-5b4054512b2d">340.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e3ff765407f4755bfb5dc08e8b68c7f_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtNy0xLTEtNzUzNDE_70b498a8-2d66-4971-b91a-1c22493116a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtOS0xLTEtNzUzNDE_5d44b210-02ae-497f-bab0-3aab830a8e6d">240.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37fab9ec8504467e986c6cfccf616c70_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtMTEtMS0xLTc1MzQx_8108ff14-bac2-433f-867b-319e21e93a66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i123fc2a261774a52826809562d82f303_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtMTMtMS0xLTc1MzQx_4c951eda-e6fb-4542-9bad-78b305644db5">240.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f8c5fe309e43cf85287198b3684b1f_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtMTUtMS0xLTc1MzQx_891d3c13-f7ee-44fe-9f4b-5fd0bb6060d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f432d4ebd4d4bcd821e1de57052b96d_I20220630" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItMS0xLTEtNzUzNDE_ea27e64d-f99c-4811-8e75-e8bc2ee31b9c">83.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36adfd64e3fc494ba2d120614d619968_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItMy0xLTEtNzUzNDE_251aa21c-9693-42b8-84e0-132681c94fdf">83.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied205516acc24818a8843666669b4299_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItNS0xLTEtNzUzNDE_9aeb8775-96e1-42ae-80fa-4fd83d04e3b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id43fcc32d6374531b9d90dc9c1ddd0c6_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItNy0xLTEtNzUzNDE_9190b4ab-1808-4f94-82d1-ef78f43e4120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i013f9e5d35d54ee8bb4f7e21d12111c7_I20211231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItOS0xLTEtNzUzNDE_0dc48d1c-7f95-4366-9da2-7c887b4e6874">63.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f28d0e9745496a9b27303558bbcf74_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItMTEtMS0xLTc1MzQx_a332cdef-08ad-4129-bcaa-6959f5bc98ea">52.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcbeb7bb580346078bdfa5dea238778a_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItMTMtMS0xLTc1MzQx_3bea0510-0a09-4add-8aab-457705e850b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d2e80d30204b05a36b4e40d614504c_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItMTUtMS0xLTc1MzQx_d1976267-05b0-4f83-b6e8-5e3e1cbd70e5">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtMS0xLTEtNzUzNDE_2b623c05-4915-4a74-97b3-834e6afd7742">1,145.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59e9b7c8721845489d2a7f16466d93aa_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtMy0xLTEtNzUzNDE_428661c2-46e3-4060-9d81-a792549820a6">254.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908c9a1b5d0e454fb77ebdb1a35749ba_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtNS0xLTEtNzUzNDE_46477c69-4b15-4374-a83b-6c17802ba290">890.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d1241a853a41268cccdaac0eae9a28_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtNy0xLTEtNzUzNDE_9a748e0f-a941-4698-be08-40011e6a92d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtOS0xLTEtNzUzNDE_11c44f8f-2bac-4d51-9891-582b12db426d">1,338.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b6c8a59df04fb3945d4e66bc2c822d_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtMTEtMS0xLTc1MzQx_c3b00ebb-6a40-4272-8a85-de63cac67dab">396.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia631a5398e544dd4908958402f41dc86_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtMTMtMS0xLTc1MzQx_330618b5-42f0-4797-ba6a-0b9bbe8a9b24">931.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1d5afb5a0c4854bd3eaac9022c5921_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtMTUtMS0xLTc1MzQx_80c23124-7dc7-4d8b-8e21-89fbf132377d">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i03ecd9662906493b8c7b810e1a6e1fec"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RleHRyZWdpb246YzFiYTIxZTBiOTdmNDM0NzhhY2Q3MGYwZDY0NDgyY2JfMzA1Ng_be7e3869-8f35-424b-b791-267c07048a46" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e2006bc26e4660a1ce0449ce12fef8_I20220331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfMi0xLTEtMS03NTM0MQ_b93ec4ae-49ce-4560-a508-01f2f37ee027">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i621ed28665cd4c74accdf1592a8116ee_I20210331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfMi0zLTEtMS03NTM0MQ_660eea09-64be-4139-a9d1-25cab9ea2e85">38.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d2e80d30204b05a36b4e40d614504c_I20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfMi01LTEtMS03NTM0MQ_c47ac9f9-c04c-4a7d-9433-c5bae9a584a8">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7802d7f08044b48c8621fbe04086f8_I20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfMi03LTEtMS03NTM0MQ_b347f9b8-9185-4ebf-9ecc-bc1450e5bd10">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain included in earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife94fc300dd145afad28237e20171bac_D20220401-20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNC0xLTEtMS03NTM0MQ_cedf3ce1-93d5-40b8-9a8f-67f5de3090c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05896d4787104c06a015bb730c5b5e50_D20210401-20210630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNC0zLTEtMS03NTM0MQ_36609465-9612-4efc-9fd2-003df9472a5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7bdc03323d43ba8e38762cd7fca030_D20220101-20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNC01LTEtMS03NTM0MQ_88c60dcb-fc85-4a14-bd1f-ac562f370973">20.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ed7ddd2a42348d1a2f7fec8628844f9_D20210101-20210630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNC03LTEtMS03NTM0MQ_4e9b160b-1f75-4155-b842-1e63049d0099">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife94fc300dd145afad28237e20171bac_D20220401-20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNS0xLTEtMS03NTM0MQ_8dc19c0a-2dbf-41bc-b63c-9f716a75258a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05896d4787104c06a015bb730c5b5e50_D20210401-20210630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNS0zLTEtMS03NTM0MQ_7f977e3d-8b28-480e-820c-c8a5645748cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7bdc03323d43ba8e38762cd7fca030_D20220101-20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNS01LTEtMS03NTM0MQ_26b2d824-02fc-46d4-a33b-2a9c292d58e2">31.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ed7ddd2a42348d1a2f7fec8628844f9_D20210101-20210630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNS03LTEtMS03NTM0MQ_6323e91a-d107-4bd1-ac86-4f75eafed5df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id43fcc32d6374531b9d90dc9c1ddd0c6_I20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNi0xLTEtMS03NTM0MQ_1aee6414-f37e-4863-9241-875a11a3775d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbdc30b238f4e70816874e44b5711ea_I20210630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNi0zLTEtMS03NTM0MQ_647dac38-cc20-442f-8935-6c7619371e0c">38.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id43fcc32d6374531b9d90dc9c1ddd0c6_I20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNi01LTEtMS03NTM0MQ_db465987-15b5-49f9-afb4-98e2d1fb52b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbdc30b238f4e70816874e44b5711ea_I20210630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNi03LTEtMS03NTM0MQ_ba58a3ad-18a7-456c-b4e9-bc553a3b1983">38.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Unrealized gains and losses on restricted equity security investments were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) In the first quarter of 2022, our equity security investment in Voyager was transferred from Level 3 to Level 1 as the associated holding period restriction expired.</span></div></ix:nonNumeric></ix:continuation><div id="ia5b26032409f4bcfa80efa90e636a8b2_43"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RleHRyZWdpb246ODAwZTY1YjI2YTljNDkzM2EzOWRjZDNiYmQ3YTY0MjZfNjI_ecf01704-c1a6-4c72-a40e-f892a1aec2ac" continuedAt="i3640c36be2084f79b17f4b739f60f213" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i3640c36be2084f79b17f4b739f60f213"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RleHRyZWdpb246ODAwZTY1YjI2YTljNDkzM2EzOWRjZDNiYmQ3YTY0MjZfNjA_b60773bb-ed63-4888-8455-b6887501732b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfMS0xLTEtMS03NTM0MQ_310c8e22-b37d-4c7c-890f-18a617684a82">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfMS0zLTEtMS03NTM0MQ_4c2a781d-7de6-4bcf-a1d8-ec209128a39c">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfMi0xLTEtMS03NTM0MQ_a824f259-256b-4f6d-a846-beabfa7bb2f4">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfMi0zLTEtMS03NTM0MQ_36718f77-5201-4beb-94a6-553e5fe15461">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfMy0xLTEtMS03NTM0MQ_de380db6-d6bd-4a79-bfcb-7dfe20fbfb36">17.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfMy0zLTEtMS03NTM0MQ_997e9a2a-850a-427b-a63d-4c0e8acdf65b">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfNC0xLTEtMS03NTM0MQ_8f535f5e-f8ce-4eef-9224-d014af9dc086">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0112165dc8043d29e138802b05038e8_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfNC0zLTEtMS03NTM0MQ_46f583ed-7dbc-4e3b-815c-62cb399409c7">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia5b26032409f4bcfa80efa90e636a8b2_46"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="nbix:RestrictedCashTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RleHRyZWdpb246OWMyMjE3NWUyMzFjNDQ1YWFmM2I1OGRkZTJkMzkwOWJfMjE3_35ef6dec-d969-4718-959c-2730729b64f7" continuedAt="i15ba7ec148a448f58d57fc06ac2cc0d0" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="i15ba7ec148a448f58d57fc06ac2cc0d0"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RleHRyZWdpb246OWMyMjE3NWUyMzFjNDQ1YWFmM2I1OGRkZTJkMzkwOWJfMjE4_e025ca32-d579-47e3-90e5-da26133459b0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RhYmxlOmUyZmFjNDY0ZGRiYzRlNTNiZTY3NjFiMGVlZjdiZmQ4L3RhYmxlcmFuZ2U6ZTJmYWM0NjRkZGJjNGU1M2JlNjc2MWIwZWVmN2JmZDhfMS0xLTEtMS03NTM0MQ_f3070120-cad2-4e84-9648-75de62af347c">163.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RhYmxlOmUyZmFjNDY0ZGRiYzRlNTNiZTY3NjFiMGVlZjdiZmQ4L3RhYmxlcmFuZ2U6ZTJmYWM0NjRkZGJjNGU1M2JlNjc2MWIwZWVmN2JmZDhfMS0zLTEtMS03NTM0MQ_55d4690f-3b71-4dcd-9dab-d7370e678766">368.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RhYmxlOmUyZmFjNDY0ZGRiYzRlNTNiZTY3NjFiMGVlZjdiZmQ4L3RhYmxlcmFuZ2U6ZTJmYWM0NjRkZGJjNGU1M2JlNjc2MWIwZWVmN2JmZDhfMi0xLTEtMS03NTM0MQ_00edca9c-29b0-4518-b2ac-53e511eed6a8">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RhYmxlOmUyZmFjNDY0ZGRiYzRlNTNiZTY3NjFiMGVlZjdiZmQ4L3RhYmxlcmFuZ2U6ZTJmYWM0NjRkZGJjNGU1M2JlNjc2MWIwZWVmN2JmZDhfMi0zLTEtMS03NTM0MQ_17d3c80a-4655-479c-80ee-ea892950bbb4">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RhYmxlOmUyZmFjNDY0ZGRiYzRlNTNiZTY3NjFiMGVlZjdiZmQ4L3RhYmxlcmFuZ2U6ZTJmYWM0NjRkZGJjNGU1M2JlNjc2MWIwZWVmN2JmZDhfMy0xLTEtMS03NTM0MQ_e593b560-3a93-41d4-a46f-cc9329f58b85">171.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RhYmxlOmUyZmFjNDY0ZGRiYzRlNTNiZTY3NjFiMGVlZjdiZmQ4L3RhYmxlcmFuZ2U6ZTJmYWM0NjRkZGJjNGU1M2JlNjc2MWIwZWVmN2JmZDhfMy0zLTEtMS03NTM0MQ_99ca9166-d2ef-48b5-90f8-2045f86fbad2">371.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia5b26032409f4bcfa80efa90e636a8b2_49"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjQ2MA_e2569e01-1321-4045-afe3-e0666690bfe3" continuedAt="i00f8c0f2cb074c838bd4ed83a53ac50b" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i00f8c0f2cb074c838bd4ed83a53ac50b" continuedAt="ic54a84b7d6bf4dbeba2d554dd0d333e3"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases that have commenced have terms that expire beginning 2024 through 2031 and consist of office space and research and development laboratories, including our corporate headquarters. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our operating lease right-of-use, or ROU, assets or operating lease liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, pursuant to which we also secured a <ix:nonNumeric contextRef="i7e101b09704b41349a0ec8f0acd6d9fc_D20220208-20220208" name="nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjQ3MQ_8a6c0871-723d-4546-b1e1-4175e5b91e02">six-year</ix:nonNumeric> option for the construction of a fifth building and an option to purchase the entire campus facility, which will consist of office space and research and development laboratories, in the future. Upon completion of construction, we expect to utilize the campus facility as our new corporate headquarters. This lease has not commenced for accounting purposes. Under the terms of the lease, on a building-by-building basis, base rent will be subject to a <ix:nonNumeric contextRef="i7e101b09704b41349a0ec8f0acd6d9fc_D20220208-20220208" name="nbix:RentAbatementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjQ3Mg_14d38738-32ea-499c-9a6c-cd6a0deedf57">10-month</ix:nonNumeric> rent abatement period following the respective lease commencement date, which dates will be determined in the future based upon achievement of substantial completion of construction with respect to each such building in the condition suitable for the installation of our furniture, fixtures, and equipment, and on which date we will record a lease liability, corresponding right-of-use asset, and begin lease expense recognition with respect to each such building. After the rent abatement period, monthly base rent will be $<ix:nonFraction unitRef="usd" contextRef="i6c2a25388e8a402297637fc25af2ac23_I20220208" decimals="0" name="nbix:LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMTYyNg_44924e2c-9096-4e02-b2db-a67e472d08b3">6</ix:nonFraction> per square foot, subject to annual escalations of <ix:nonFraction unitRef="number" contextRef="i6c2a25388e8a402297637fc25af2ac23_I20220208" decimals="INF" name="nbix:AnnualRentEscalationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMTY3OQ_f933c3e5-f623-43a0-9d1b-33fdccc897aa">3</ix:nonFraction>% during the initial <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMTA5OTUxMTYzMDM2OQ_4e49d25c-03ed-44eb-9e93-c4a67b6332d1">13.6-year</span> lease term, which term we have the option to renew for <ix:nonFraction unitRef="renewaloption" contextRef="i6c2a25388e8a402297637fc25af2ac23_I20220208" decimals="INF" name="nbix:NumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjQ2NQ_a5d6f8f0-1c95-485d-9883-9352cb7e598c">two</ix:nonFraction> additional terms of <ix:nonNumeric contextRef="i6c2a25388e8a402297637fc25af2ac23_I20220208" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMTc4Nw_2e8fda68-f677-4f70-ad05-1a3811214001">five years</ix:nonNumeric> each.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our operating leases, in lieu of a cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $<ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMTk3Nw_74643fd7-495a-42ec-a68a-99e2fd5cf8ac">7.8</ix:nonFraction> million.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic54a84b7d6bf4dbeba2d554dd0d333e3"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjQ2Mw_abe3d14a-626e-446f-af65-c644eaaa2ec0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental operating lease information for operating leases that have commenced.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfMi0xLTEtMS03NTM0MQ_eb85acb2-8463-46e2-a055-881210dc2e63">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfMi0zLTEtMS03NTM0MQ_040de5a6-6c09-41d1-a38c-64ba7f6ca632">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfMy0xLTEtMS03NTM0MQ_f5554e88-c4b8-4297-99ff-83e197d049ae">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfMy0zLTEtMS03NTM0MQ_ae1d1c09-e1b0-4676-acec-09364c06e83b">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i19857cd19784459d879fae5b6542a369_I20220630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfNi0xLTEtMS03NTM0MQ_f98febb8-0a00-42df-be46-ed3468d61da3">8.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfNi0zLTEtMS03NTM0MQ_99beedd9-ae76-41fe-b79e-75572c3f0273">9.2</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfNy0xLTEtMS03NTM0MQ_4d91a6c4-2241-4d6c-8f4d-cddbadc0b7a9">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfNy0zLTEtMS03NTM0MQ_1a602a5c-bdd4-4bef-b442-44a44ebe8c61">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjQ2Ng_4ab8d0ee-df79-472c-bda6-94949cdfde0d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate non-cancelable future minimum lease payments under operating leases as of June&#160;30, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 (6 months remaining)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfMS0xLTEtMS03NTM0MQ_74e03082-ab35-47ba-b29c-27461de0285c">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfMi0xLTEtMS03NTM0MQ_a8e8f694-f1ea-47d0-b811-02127bc17b2e">17.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfMy0xLTEtMS03NTM0MQ_909f78cf-93bc-4f05-8163-62575f6a7a2a">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfNC0xLTEtMS03NTM0MQ_0486affc-155f-4227-b610-b4184259a553">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfNS0xLTEtMS03NTM0MQ_b36d910b-0cf8-4246-8b87-9fa83ddb6e14">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="nbix:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfNi0xLTEtMS03NTM0MQ_24708a90-64e7-4c11-9858-4c97ec7bc03d">70.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfNy0xLTEtMS03NTM0MQ_e668b092-2d86-409e-beec-ad6841c2fc76">146.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfOC0xLTEtMS03NTM0MQ_26e45bb3-27a4-4c6f-8ee2-b73cd5b13192">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfOS0xLTEtMS03NTM0MQ_e1fa2c08-e8f3-4fc3-a6c1-38c51e0a76b7">116.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less current operating lease liabilities included in other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfMTAtMS0xLTEtNzUzNDE_e3b0da59-d1e4-4abe-8f86-aba19e7b2ceb">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfMTEtMS0xLTEtNzUzNDE_1f02d5eb-575c-4966-884b-20ae132d3bd8">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts presented in the table above exclude $<ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjI5MQ_1279d6bd-391e-48ad-ab33-c17498bc95d6">17.2</ix:nonFraction> million for 2024, $<ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjMwNA_301af7f2-1d80-4a67-97b7-13c0991b457d">33.3</ix:nonFraction> million for 2025, $<ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjMxNw_92d1ea37-08d0-49eb-909c-eb8e7fe52902">41.9</ix:nonFraction> million for 2026, and $<ix:nonFraction unitRef="usd" contextRef="i19857cd19784459d879fae5b6542a369_I20220630" decimals="-5" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjMzNA_2a941cda-8114-4cf9-93ce-cd3e020e571f">479.7</ix:nonFraction> million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.</span></div></ix:nonNumeric></ix:continuation><div id="ia5b26032409f4bcfa80efa90e636a8b2_52"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNzY3MA_3908bcf3-1c5c-4690-9065-d084758f383c" continuedAt="i14591bf64f6d48349fbb91a5847400fd" escape="true">Convertible Senior Notes</ix:nonNumeric></span></div><ix:continuation id="i14591bf64f6d48349fbb91a5847400fd" continuedAt="i2d7a0fedf2dc4aca8bea7f5cb79cdffc"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="ifa023efd07b7418a8139d17baa936118_I20170502" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNzY3MQ_3c757e7a-e0d9-4aac-8292-6c6d7b55f46a">517.5</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ifa023efd07b7418a8139d17baa936118_I20170502" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMTEy_49b07f2e-79cb-4242-95e1-120fe697f524">2.25</ix:nonFraction>% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance in effect at the time of issuance, we were required to separately account for the liability and equity components of the 2024 Notes. The initial carrying value of the liability component of $<ix:nonFraction unitRef="usd" contextRef="ifa023efd07b7418a8139d17baa936118_I20170502" decimals="-5" name="nbix:CarryingAmountOfLiabilityComponentUponIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTAy_35e78912-f48c-46e5-98ca-39c1bf3e73a9">368.3</ix:nonFraction> million was calculated using a <ix:nonFraction unitRef="number" contextRef="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTI4_b8ecbd25-9aaf-4cb3-9e16-673e06d104f2">7.50</ix:nonFraction>% assumed borrowing rate, which reflected the market interest rate for a similar non-convertible instrument at the date of issuance. The equity component of $<ix:nonFraction unitRef="usd" contextRef="ifa023efd07b7418a8139d17baa936118_I20170502" decimals="-5" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNjg2_7bc88231-2a44-41b7-b55d-3003322c5612">149.2</ix:nonFraction> million, which was treated as a discount on the liability component and amortized over the <ix:nonNumeric contextRef="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNzY3Mg_2463b5a0-37a0-4e2c-b5a7-dd2d5f8c746f">seven-year</ix:nonNumeric> term of the 2024 Notes using the effective interest rate method, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and recorded as an increase to additional paid-in capital on the issuance date. In addition, we allocated transaction costs of $<ix:nonFraction unitRef="usd" contextRef="ifa023efd07b7418a8139d17baa936118_I20170502" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMTA2Mw_92c1c59c-d10f-408e-afd3-ac094e5bd869">14.7</ix:nonFraction> million related to the issuance of the 2024 Notes to the liability and equity components based on their relative values on the issuance date. Transaction costs attributable to the liability component were being amortized over the <ix:nonNumeric contextRef="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNzY3Mw_33cae26f-ce05-4f60-8941-df58249ca858">seven-year</ix:nonNumeric> term of the 2024 Notes using the effective interest rate method, while transaction costs attributable to the equity component were recorded as a reduction to additional paid-in capital on the issuance date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $<ix:nonFraction unitRef="usd" contextRef="id787ce82b3d34435b9e6f64183561da4_I20201231" decimals="-5" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMTYxMA_2c2d8041-ded8-4925-9618-75c29ef54e88">136.2</ix:nonFraction> million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $<ix:nonFraction unitRef="usd" contextRef="i24b6741f0df8412ca89fcbb38c28ed03_D20201001-20201231" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMTY4Nw_29b5aa64-2e86-4892-a1a6-99deb3a7d29b">186.9</ix:nonFraction> million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $<ix:nonFraction unitRef="usd" contextRef="i24b6741f0df8412ca89fcbb38c28ed03_D20201001-20201231" decimals="-5" name="nbix:FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMTgwMg_3d49c0e7-2317-4733-ba5b-54a15bad91ef">130.7</ix:nonFraction> million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of <ix:nonFraction unitRef="number" contextRef="i5a5baeaf4e9c48f8b60039ae0a01b8e3_I20201231" decimals="4" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjA4NQ_9aacf96a-0d63-4fa6-a322-a7560e1d2401">3.37</ix:nonFraction>%, which was the market rate for similar notes that have no conversion rights. The difference of $<ix:nonFraction unitRef="usd" contextRef="i24b6741f0df8412ca89fcbb38c28ed03_D20201001-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjE4Mw_e154100b-0f99-4e7e-8f72-1b169228a1cf">56.3</ix:nonFraction> million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2d7a0fedf2dc4aca8bea7f5cb79cdffc" continuedAt="i99924a2fb3ba439ea53819c0aa821cb0"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component and recorded as a reduction to additional paid-in capital. The carrying amount of the liability of $<ix:nonFraction unitRef="usd" contextRef="i24b6741f0df8412ca89fcbb38c28ed03_D20201001-20201231" decimals="-5" name="nbix:CarryingAmountOfLiabilityComponentAtSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjQ4Mw_7ca8ae60-7ed1-420c-92e7-6c8dc8667fba">112.4</ix:nonFraction> million at settlement was recognized as a reduction to the 2024 Notes and resulted in an $<ix:nonFraction unitRef="usd" contextRef="i24b6741f0df8412ca89fcbb38c28ed03_D20201001-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjU1OQ_03a6bd55-672e-407f-87af-1407a3334a04">18.4</ix:nonFraction> million loss on extinguishment, which we recognized in the fourth quarter of 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjY2OA_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span> using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $<ix:nonFraction unitRef="usd" contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjk3NQ_5b64e963-da74-4625-ade7-2825d656559e">42.2</ix:nonFraction> million, reduced deferred tax liabilities by $<ix:nonFraction unitRef="usd" contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMzAxNQ_e0a152b1-ce79-4aca-bdab-2230fddb78e0">9.9</ix:nonFraction> million, reduced additional paid-in capital by $<ix:nonFraction unitRef="usd" contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231" decimals="-5" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMzA1Nw_c8dc538d-da09-44ab-aab9-bfe81ac74ef8">106.8</ix:nonFraction> million, and reduced the accumulated deficit by $<ix:nonFraction unitRef="usd" contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMzEwMA_bd015d84-bb81-432d-a353-1f661e1a0e8a">74.5</ix:nonFraction> million.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $<ix:nonFraction unitRef="usd" contextRef="ia90120fdd18140988db29b2003f29587_I20220630" decimals="-5" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjE5OTAyMzI2NTc1NA_c438646b-7888-4f0a-a8a0-1d1ecf4ad33c">210.8</ix:nonFraction> million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $<ix:nonFraction unitRef="usd" contextRef="id2e9c013eb7a4a48a31e064dfc261340_D20220401-20220630" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjE5OTAyMzI2NTc3Ng_02a54324-112b-4bc6-9699-905118be95d7">279.0</ix:nonFraction> million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment, which resulted in the recognition of a $<ix:nonFraction unitRef="usd" contextRef="id2e9c013eb7a4a48a31e064dfc261340_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjE5OTAyMzI2NTc5Ng_732b3a3d-cb9d-45d2-a340-cfecd2089360">70.0</ix:nonFraction> million loss on extinguishment in the second quarter of 2022.</span></div><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNzY3NA_d177d57f-6b71-4b42-9c88-1801f48cef2d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of June&#160;30, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90120fdd18140988db29b2003f29587_I20220630" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmE2ZjA0NmJhN2MwNzRkOWE5Yzk0OGZiZjE1OWIxNTBmL3RhYmxlcmFuZ2U6YTZmMDQ2YmE3YzA3NGQ5YTljOTQ4ZmJmMTU5YjE1MGZfMi0xLTEtMS03NTM0MQ_d52f68cb-7b33-4202-964f-9c6e37199949">170.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90120fdd18140988db29b2003f29587_I20220630" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmE2ZjA0NmJhN2MwNzRkOWE5Yzk0OGZiZjE1OWIxNTBmL3RhYmxlcmFuZ2U6YTZmMDQ2YmE3YzA3NGQ5YTljOTQ4ZmJmMTU5YjE1MGZfMi0zLTEtMS03NTM0MQ_cbfcce85-cc37-4630-ac03-0f6895606b35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia90120fdd18140988db29b2003f29587_I20220630" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmE2ZjA0NmJhN2MwNzRkOWE5Yzk0OGZiZjE1OWIxNTBmL3RhYmxlcmFuZ2U6YTZmMDQ2YmE3YzA3NGQ5YTljOTQ4ZmJmMTU5YjE1MGZfMi01LTEtMS03NTM0MQ_0a701312-d4bb-464b-8b62-0c85f9be7a2c">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90120fdd18140988db29b2003f29587_I20220630" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmE2ZjA0NmJhN2MwNzRkOWE5Yzk0OGZiZjE1OWIxNTBmL3RhYmxlcmFuZ2U6YTZmMDQ2YmE3YzA3NGQ5YTljOTQ4ZmJmMTU5YjE1MGZfMi03LTEtMS03NTM0MQ_fbfef37c-f5a7-4f47-b982-0e6afaf2e583">169.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90120fdd18140988db29b2003f29587_I20220630" decimals="-5" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmE2ZjA0NmJhN2MwNzRkOWE5Yzk0OGZiZjE1OWIxNTBmL3RhYmxlcmFuZ2U6YTZmMDQ2YmE3YzA3NGQ5YTljOTQ4ZmJmMTU5YjE1MGZfMi05LTEtMS03NTM0MQ_89aeccdb-991e-4c0e-936e-59e252cc196a">224.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) While the 2024 Notes were classified as a long-term liability as of June&#160;30, 2022, the future convertibility and associated balance sheet classification will be monitored at each quarterly reporting date and determined based on the market prices of our common stock during the prescribed measurement period. In the event that we have the election to redeem the 2024 Notes or the holders of the 2024 Notes have the election to convert the 2024 Notes at any time during the prescribed measurement period, the 2024 Notes would be classified as a current obligation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168ae0643eac4fb187856eb9bb504202_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmJjZWM0NjM2YWJhOTRmN2JhNjg0NmNkZDUxZjkzZmY2L3RhYmxlcmFuZ2U6YmNlYzQ2MzZhYmE5NGY3YmE2ODQ2Y2RkNTFmOTNmZjZfMi0xLTEtMS03NTM0MQ_47196eba-334a-4a5d-8130-184b0e8d3d7a">381.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i168ae0643eac4fb187856eb9bb504202_I20211231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmJjZWM0NjM2YWJhOTRmN2JhNjg0NmNkZDUxZjkzZmY2L3RhYmxlcmFuZ2U6YmNlYzQ2MzZhYmE5NGY3YmE2ODQ2Y2RkNTFmOTNmZjZfMi0zLTEtMS03NTM0MQ_96760441-90fe-4dfb-ba15-1c7be9ba6fd3">43.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i168ae0643eac4fb187856eb9bb504202_I20211231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmJjZWM0NjM2YWJhOTRmN2JhNjg0NmNkZDUxZjkzZmY2L3RhYmxlcmFuZ2U6YmNlYzQ2MzZhYmE5NGY3YmE2ODQ2Y2RkNTFmOTNmZjZfMi01LTEtMS03NTM0MQ_e47122fb-b750-4577-b9f0-396d532dc160">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168ae0643eac4fb187856eb9bb504202_I20211231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmJjZWM0NjM2YWJhOTRmN2JhNjg0NmNkZDUxZjkzZmY2L3RhYmxlcmFuZ2U6YmNlYzQ2MzZhYmE5NGY3YmE2ODQ2Y2RkNTFmOTNmZjZfMi03LTEtMS03NTM0MQ_7ec45956-ba21-408f-800b-0018105e2512">335.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168ae0643eac4fb187856eb9bb504202_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmJjZWM0NjM2YWJhOTRmN2JhNjg0NmNkZDUxZjkzZmY2L3RhYmxlcmFuZ2U6YmNlYzQ2MzZhYmE5NGY3YmE2ODQ2Y2RkNTFmOTNmZjZfMi05LTEtMS03NTM0MQ_cb349808-4b0a-4ec7-af50-3bc37093c302">464.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the interest expense of the 2024 Notes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMi0xLTEtMS03NTM0MQ_d254b29c-260c-4f20-bb6b-70f52b5e3cbb">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMi0zLTEtMS03NTM0MQ_57ed719e-1a6f-4c07-9dfb-b8b1841dcd34">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMi01LTEtMS03NTM0MQ_6779bb7d-a666-4c1e-8b00-38952719a73a">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="nbix:DebtInstrumentCouponInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMi03LTEtMS03NTM0MQ_f7f7bb46-2476-48ed-aec7-c056d564314f">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMy0xLTEtMS03NTM0MQ_1cb6fb41-901f-4a60-85fe-2be5ab773f3d">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMy0zLTEtMS03NTM0MQ_2808555a-163a-46cf-a382-5b90b3110863">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMy01LTEtMS03NTM0MQ_9219777f-4bc7-43f4-bc5c-1aaf887211c3">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMy03LTEtMS03NTM0MQ_8a14177b-ffcc-4e07-86cf-d44c77913428">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfNC0xLTEtMS03NTM0MQ_ef529daa-6e1e-4771-8ba2-753f4e2c0609">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfNC0zLTEtMS03NTM0MQ_3c7f3a28-578e-4afc-802d-033ead7c28d5">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfNC01LTEtMS03NTM0MQ_b5f087e3-742c-4df1-a780-a7b5aee263f7">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfNC03LTEtMS03NTM0MQ_5462b0a7-03c8-4b1a-b46c-e56908970b84">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2024 Notes in cash upon conversion and to settle any conversion premium, calculated based on the per share volume-weighted average price for each of the <ix:nonFraction unitRef="d" contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDE0Ng_42ce3d9f-af74-41c7-ba0b-9de9e6b46388">30</ix:nonFraction> consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $<ix:nonFraction unitRef="usd" contextRef="ibdc8838b1a0d4a7b843404626b18a02c_I20170502" decimals="INF" name="nbix:PrincipalAmountOnConversionRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDQ0MA_1400a132-63f9-46ea-ab2d-5124e908a874">1,000</ix:nonFraction> principal amount and equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ifa023efd07b7418a8139d17baa936118_I20170502" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDUyMw_80cac108-8c57-45b7-ad73-734dd749db92">75.92</ix:nonFraction> per share, reflecting a conversion premium of approximately <ix:nonFraction unitRef="number" contextRef="ifa023efd07b7418a8139d17baa936118_I20170502" decimals="3" name="nbix:DebtInstrumentConvertibleConversionPremium" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDU4Ng_1ea7e9f8-fe9c-4d8d-8377-63846eeed4c2">42.5</ix:nonFraction>% above the closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifa023efd07b7418a8139d17baa936118_I20170502" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDYxNg_c0d11bb2-690d-4b0c-a803-af5748c3fcb9">53.28</ix:nonFraction> per share of our common stock on April&#160;26, 2017.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDc5NA_407bd8c4-cf67-49bf-952f-6d98efdd7354">130</ix:nonFraction>% of the conversion price then in effect (equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="id38ba1f5324844d0866a8eac585463a2_D20220101-20220630" decimals="2" name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDg0Ng_736b149c-e988-4088-859d-f1d232da1e25">98.70</ix:nonFraction> as of June&#160;30, 2022) for at least <ix:nonFraction unitRef="d" contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDg3Mg_38bdcb06-72d4-4582-845f-daa2f6f7986b">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="d" contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDkyOA_42ce3d9f-af74-41c7-ba0b-9de9e6b46388">30</ix:nonFraction> consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;<ix:nonFraction unitRef="d" contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTM3Mg_38bdcb06-72d4-4582-845f-daa2f6f7986b">20</ix:nonFraction>&#160;trading days (whether or not consecutive) during a period of&#160;<ix:nonFraction unitRef="d" contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTQzNg_42ce3d9f-af74-41c7-ba0b-9de9e6b46388">30</ix:nonFraction>&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;<ix:nonFraction unitRef="number" contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTU1Nw_407bd8c4-cf67-49bf-952f-6d98efdd7354">130</ix:nonFraction>%&#160;of the conversion price (equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="id38ba1f5324844d0866a8eac585463a2_D20220101-20220630" decimals="2" name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTU5NA_736b149c-e988-4088-859d-f1d232da1e25">98.70</ix:nonFraction> as of June&#160;30, 2022) on each applicable trading day;</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i99924a2fb3ba439ea53819c0aa821cb0"><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">during the&#160;<ix:nonFraction unitRef="d" contextRef="if6357f4608a44780bb374e2677bba023_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTY1MA_a2cbda75-5604-4b9e-b6d6-2c993f5a9ee0">five</ix:nonFraction> business-day period immediately after any&#160;<ix:nonFraction unitRef="d" contextRef="if6357f4608a44780bb374e2677bba023_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTY5NQ_a2cbda75-5604-4b9e-b6d6-2c993f5a9ee0">five</ix:nonFraction>&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2017 Indenture) per&#160;$<ix:nonFraction unitRef="usd" contextRef="ibdc8838b1a0d4a7b843404626b18a02c_I20170502" decimals="INF" name="nbix:PrincipalAmountOnConversionRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTgwOA_1400a132-63f9-46ea-ab2d-5124e908a874">1,000</ix:nonFraction>&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;<ix:nonFraction unitRef="number" contextRef="if6357f4608a44780bb374e2677bba023_D20170502-20170502" decimals="INF" name="nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTg5OQ_ce4fea78-8e1e-4333-9fd0-f9369f26ab0e">98</ix:nonFraction>% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNjYyMA_4c1e12d4-5345-42c0-a9cc-738b68418552">100</ix:nonFraction>% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change (as defined in the 2017 Indenture) occurs prior to January&#160;15, 2024, we would, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2017 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, <ix:nonFraction unitRef="number" contextRef="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNzU2Ng_4c1e12d4-5345-42c0-a9cc-738b68418552">100</ix:nonFraction>% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div></ix:continuation><div id="ia5b26032409f4bcfa80efa90e636a8b2_58"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RleHRyZWdpb246ZmYwNTQ2MDVjZWMyNGNkNjk5NmEwOGM2ZTI0OTcwNTdfNzQ_e39ba332-8fed-4b27-9e27-46d95ec4dd51" continuedAt="i98c33aad25814ae78f49c97d9157c8e7" escape="true">(Loss) Earnings per Share</ix:nonNumeric></span></div><ix:continuation id="i98c33aad25814ae78f49c97d9157c8e7"><ix:nonNumeric contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RleHRyZWdpb246ZmYwNTQ2MDVjZWMyNGNkNjk5NmEwOGM2ZTI0OTcwNTdfNzU_78cce948-c88b-4eac-b024-e94f826499b7" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Loss) earnings per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi0xLTEtMS03NTM0MQ_325a0431-a79d-4848-9e4a-55308f1ed966"><ix:nonFraction unitRef="usd" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi0xLTEtMS03NTM0MQ_afaf9ae8-cc8d-4df2-b3f6-7c81d911e711">16.9</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi0zLTEtMS03NTM0MQ_14991c04-bfc9-404d-9e6e-9e5e5b285bf7"><ix:nonFraction unitRef="usd" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi0zLTEtMS03NTM0MQ_d34085f6-c375-4274-bba1-4ea40d3cc143">42.3</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi01LTEtMS03NTM0MQ_b1a626ba-a87d-43ed-9e49-4bc86af505b2"><ix:nonFraction unitRef="usd" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi01LTEtMS03NTM0MQ_ff6fabaf-2aa6-4d50-a450-015f9675901a">3.0</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi03LTEtMS03NTM0MQ_195ba536-ca55-4d1f-af81-861a039b16d4"><ix:nonFraction unitRef="usd" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi03LTEtMS03NTM0MQ_3e21993b-2373-4675-9849-f371cc8972c0">74.4</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNC0xLTEtMS03NTM0MQ_66fc8131-6625-43c9-8f79-75d9260b50af">95.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNC0zLTEtMS03NTM0MQ_a2e3ae7a-f9e3-440d-8eac-e7c042b9caef">94.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNC01LTEtMS03NTM0MQ_01a177a7-7302-452b-86c3-672c53dd0963">95.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNC03LTEtMS03NTM0MQ_39fe30b8-c54f-4027-bb0e-4bcfb49a687c">94.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i014deb2a111f43c7a8fdebb84cf4af4a_D20220401-20220630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNi0xLTEtMS03NTM0MQ_2381849a-45e5-4aa8-a138-a1ed64651302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe515815525d40479e6d960e227a7c66_D20210401-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNi0zLTEtMS03NTM0MQ_08e6e9d4-8ccf-463e-a537-09c18d1a5285">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcac76a70c464f9fa879fb1284e91eda_D20220101-20220630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNi01LTEtMS03NTM0MQ_bd30a19d-8c61-431b-9136-ff2d36fb29d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife67923fc29b44728cff990336550617_D20210101-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNi03LTEtMS03NTM0MQ_d37542a2-0853-440e-b9c7-5707026722cb">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19b7065611c64ade9f1f759584b9c5f9_D20220401-20220630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNy0xLTEtMS03NTM0MQ_8cc75ef4-ddfa-470b-9056-8ade853f85d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icef2199eebcc4873a2e393ef3bf1e3d0_D20210401-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNy0zLTEtMS03NTM0MQ_0b116be1-cda9-487a-9e0c-5439fdf513ee">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b11647fa1d44f21b454d711e8e45279_D20220101-20220630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNy01LTEtMS03NTM0MQ_4ae18eb1-25ff-4d8a-9990-4a0b9524d5ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97101bf55ded451fb77e7a8e8dabab08_D20210101-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNy03LTEtMS03NTM0MQ_0b389eca-3cce-4be8-8e97-4099e35690a5">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fb5e17e77a8471e993d6b327c5c67b4_D20220401-20220630" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOC0xLTEtMS03NTM0MQ_fd8882a0-8e07-4fdc-9ace-69048c4d2e04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13a71ac92a8441239671f089b427fe9f_D20210401-20210630" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOC0zLTEtMS03NTM0MQ_e2985c9f-eb22-49e5-90e5-48df50ba7f8e">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i142b169cb78e431b902b44d821c15b70_D20220101-20220630" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOC01LTEtMS03NTM0MQ_78ca160c-7f5e-45db-a7f3-854f546cffd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25c047985ee44b64a2fbeff282b6c067_D20210101-20210630" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOC03LTEtMS03NTM0MQ_9b8c4caf-242a-4854-bd59-779e090807f5">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOS0xLTEtMS03NTM0MQ_31dbd372-b35c-43cf-b9a8-5341381d37c3">95.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOS0zLTEtMS03NTM0MQ_6d25a6d9-6955-4acb-add3-80e1a59f680a">97.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOS01LTEtMS03NTM0MQ_c2d048d9-9833-4d60-b9b1-e6358a308af8">95.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOS03LTEtMS03NTM0MQ_1036de02-1b72-40c7-97af-3b6419178fd0">98.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) earnings per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTAtMS0xLTEtNzUzNDE_88ffe2b6-4707-48be-94f4-555712c34c99">0.18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTAtMy0xLTEtNzUzNDE_aeedb4d4-008d-404b-9c57-78faf37645a1">0.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTAtNS0xLTEtNzUzNDE_e86e8ee0-abd3-46dd-af9d-4db371fdd9b8">0.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTAtNy0xLTEtNzUzNDE_5cafb1ba-beaf-4a20-ac24-07b1a314c4ea">0.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTEtMS0xLTEtNzUzNDE_ca993863-9769-4ccd-9ae6-6c9869a6cdc6">0.18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTEtMy0xLTEtNzUzNDE_dc0d217c-6f4d-4871-ab6c-535c03e0acf1">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTEtNS0xLTEtNzUzNDE_1528b57e-a976-4055-9462-91ab59e951d1">0.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTEtNy0xLTEtNzUzNDE_55db97db-5706-4e2c-a3e8-dabf1dfeddd5">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTMtMS0xLTEtNzUzNDE_fd53e1b4-51f2-4b3c-a6ad-cdfdab9945a9">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTMtMy0xLTEtNzUzNDE_1ce7d154-f373-402a-a1d4-3a8647395238">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTMtNS0xLTEtNzUzNDE_668e1a35-d779-4dc6-b390-d9f39cef5222">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTMtNy0xLTEtNzUzNDE_35ecb69c-b6dd-4360-951c-cac8860b8a3a">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section contains forward-looking statements, which involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Part II, Item&#160;1A under the caption &#8220;Risk Factors.&#8221; The interim financial statements and this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December&#160;31, 2021 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, which are contained in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 and our Quarterly Report on Form 10-Q for the three months ended March&#160;31, 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Neurocrine Biosciences, our purpose is simple: to relieve suffering for people with great needs, but few options. For three decades, we have applied our unique insight into neuroscience to advance medicines for neurological, endocrine and psychiatric disorders. Our efforts have resulted in United States Food and Drug Administration, or FDA, approved treatments for tardive dyskinesia, Parkinson&#8217;s disease, endometriosis* and uterine fibroids* and a diversified portfolio of investigational therapies with the potential to address unmet clinical needs of patients worldwide living with neurological, endocrine and psychiatric disorders. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(*in collaboration with AbbVie Inc., or AbbVie)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in the United States in May 2017 as the first FDA-approved drug for the treatment of tardive dyskinesia and launched ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (opicapone) in the United States in September 2020 as an FDA-approved add-on treatment for levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations. INGREZZA net product sales represent the significant majority of our total net product sales.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix tablets) in the United States in August 2018 for the treatment of moderate to severe pain associated with endometriosis and launched ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States in June 2020 for the treatment of heavy menstrual bleeding related to uterine fibroids in premenopausal women. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner Mitsubishi Tanabe Pharma Corporation, or MTPC, launched DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in Japan in June 2022 for the treatment of tardive dyskinesia. We receive royalties at tiered percentage rates on MTPC net sales of DYSVAL.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Highlights </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In connection with MTPC's first commercial sale of DYSVAL in Japan in June 2022, we received a milestone payment of $20.0 million, which was recognized as revenue in the second quarter of 2022.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the second quarter of 2022, the FDA accepted our submission of an investigational new drug application, or IND, for NBI-1117568 for the treatment of schizophrenia, for which we anticipate initiating a Phase II study during the second half of 2022. Based upon this progress, a milestone of $30.0 million was expensed as R&amp;D in the second quarter of 2022, which we expect to pay to Heptares in the third quarter of 2022.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total debt outstanding decreased by $210.8 million to $170.4 million following our repurchase of approximately 55% of total debt outstanding in the second quarter of 2022. The total aggregate repurchase price of $279.0 million was paid in cash and resulted in the recognition of a $70.0 million loss on extinguishment in the second quarter of 2022.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2022, the Phase IIa study of NBI-827104 in essential tremor did not meet specified endpoints. Based on the totality of data from the Phase IIa study, at this time, we do not plan to proceed further with the clinical development of NBI-827104 in essential tremor.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Impacts of Macro-Economic Factors on Our Business</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Global Pandemic.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the impact of the COVID-19 pandemic on our business, including our clinical trials, third-party manufacturers, suppliers and service providers. The extent to which COVID-19 may impact our financial condition and results of operations remains uncertain and is dependent on numerous evolving factors, including the measures being taken by authorities to mitigate against the spread of COVID-19, the emergence of new variants and the availability and successful administration of effective vaccines. For more information on the risks and uncertainties associated with the evolving effects of COVID-19 on our business, our ability to generate sales of and revenues from our approved products and our clinical development and regulatory efforts, refer to Part II Item 1A. Risk Factors.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Russia/Ukraine Conflict.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia commenced a military invasion of Ukraine. The ongoing geopolitical turmoil and continuing military action in the region, together with widening sanctions imposed on Russia, have caused us to suspend all planned clinical trial activities for valbenazine and luvadaxistat in Russia and Ukraine.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration and impact of the conflict between Russia and Ukraine is highly unpredictable and the extent to which the conflict may impact certain of our clinical development and regulatory efforts remains uncertain. For more information on the risks and uncertainties associated with the evolving effects of the conflict between Russia and Ukraine on our business and certain of our clinical development and regulatory efforts, refer to Part II Item 1A. Risk Factors.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations for the Three and Six Months Ended June&#160;30, 2022 and 2021</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Net Product Sales by Sales Product. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">INGREZZA net product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ONGENTYS net product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">497.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, the increase in INGREZZA net product sales was driven by increased new patient starts and record total prescriptions, reflecting higher customer demand and increased commercial activities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues by Category.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of royalties earned at tiered percentage rates on AbbVie net sales of elagolix and, beginning in June 2022, MTPC net sales of DYSVAL.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of license fees earned under the terms of our license agreements with AbbVie and MTPC.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenue for the six months ended June&#160;30, 2022 reflected the achievement of a $20.0 million milestone in connection with MTPC's first commercial sale of DYSVAL in Japan in June 2022. For the comparable period last year, milestone revenue reflected the achievement of a $15.0 million milestone in connection with MTPC's submission of a marketing authorization application for valbenazine for the treatment of tardive dyskinesia with the Ministry of Health and Welfare in Japan in April 2021.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenues. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, the increase in cost of revenues primarily reflected increased INGREZZA net product sales driven by increased new patient starts and record total prescriptions reflecting higher customer demand and increased commercial activities.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Research and Development by Category. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs, and business development opportunities. Costs are reflected in the applicable development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same reporting period. For several of our programs, the research and development activities are part of our collaborative arrangements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Late stage</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Early stage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Late Stage.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of expenses incurred for product candidates in Phase II registrational studies and all subsequent activities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, late-stage expenses primarily reflected increased investment in our Phase III programs for valbenazine in schizophrenia and dyskinetic cerebral palsy, partially offset by lower spend related to the completion of the Phase III KINECT-HD study in the first quarter of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Stage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of expenses incurred for product candidates after the approval of an investigational new drug application by the applicable regulatory agency through Phase II non-registrational studies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, early-stage expenses primarily reflected increased investment in support of our advancing Phase II epilepsy and neuropsychiatry programs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Discovery.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of expenses incurred prior to the approval of an investigational new drug application by the applicable regulatory agency.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, research and discovery expenses primarily reflected increased investment in our preclinical development programs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consists of development and regulatory milestone expenses incurred in connection with our collaborative arrangements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone expenses for the six months ended June&#160;30, 2022 primarily reflected $30.0 million of expense recognized in connection with the FDA's acceptance of our IND for NBI-1117568 for the treatment of schizophrenia in June 2022 and $7.3 million of expense recognized in connection with the FDA's acceptance of our amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol in January 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payroll and Benefits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consists of costs incurred for salaries and wages, payroll taxes, benefits and stock-based compensation associated with employees involved in research and development activities. Stock-based compensation may fluctuate from period to period based on factors that are not within our control, such as our stock price on the dates stock-based grants are issued.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, the increase in payroll and benefits expenses was primarily due to higher headcount and increases of $7.0 million and $4.5 million, respectively, in non-cash stock-based compensation expense for the three and six months ended June&#160;30, 2022 primarily related to unvested performance-based restricted stock units, or PRSUs, to our executive officers, for which attainment of the performance-based criteria was determined to be probable and an equity grant in August 2021 of approximately 0.5 million restricted stock units, or RSUs, to our full-time employees other than our executive officers, which are vesting over a 2-year period. The six months ended June 30, 2021 included a non-cash stock-based compensation charge of $6.4 million related to the modification of certain stock-based awards.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, the increase in sales, general and administrative expense was primarily due to increased investment in ongoing commercial initiatives, including our TD Spotlight-branded direct-to-consumer INGREZZA advertising campaign which launched in May 2021 and deployment of our expanded salesforce, and increased personnel expenses driven by higher headcount and increases of $13.9 million and $20.5 million, respectively, in non-cash stock-based compensation expense for the three and six months ended June&#160;30, 2022 primarily related to unvested PRSUs to our executive officers, for which attainment of the performance-based criteria was determined to be probable and an equity grant in August 2021 of approximately 0.5 million RSUs to our full-time employees other than our executive officers, which are vesting over a 2-year period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (loss) gain on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared to the comparable periods last year, other expense, net, for the three and six months ended June&#160;30, 2022 primarily reflected a $70.0 million loss on extinguishment recognized in connection with the repurchase of $210.8 million aggregate principal amount of our convertible senior notes for an aggregate repurchase price of $279.0 million in cash in the second quarter of 2022 and periodic fluctuations in the fair values of our equity security investments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(Benefit from) Provision for Income Taxes. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The benefit from and provision for income taxes for the three and six months ended June 30, 2022, respectively, reflected an effective tax rate that differs from the federal and state statutory rates primarily due to credits generated for research activities and certain nondeductible expenses, including the premium paid on the repurchase of our convertible senior notes. The provision for income taxes for the three and six months ended June 30, 2021, reflected an effective tax rate that was lower than the federal and statutory rates primarily due to excess tax benefits related to stock-based compensation. Based upon available Federal net operating losses and tax credits, we expect to begin making cash payments for Federal income tax beginning in 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Net (Loss) Income.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable periods last year, the change in net (loss) income primarily reflected a $70.0 million loss on extinguishment recognized in connection with the repurchase of our convertible senior notes in the second quarter of 2022, increased milestone expenses incurred in connection with certain of our collaborative arrangements, and increased investments in ongoing commercial initiatives and our expanded clinical portfolio, partially offset by increased INGREZZA net product sales driven by increased new patient starts and record total prescriptions, reflecting higher customer demand and increased commercial activities.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources and anticipated revenues will be sufficient to satisfy our current and projected funding requirements for at least the next 12&#160;months. However, we cannot guarantee that our existing capital resources and anticipated revenues will be sufficient to conduct and complete all of our research and development programs or commercialization activities as planned. We may seek to access the public or private equity markets whenever conditions are favorable or pursue opportunities to obtain additional debt financing in the future. We may also seek additional funding through strategic alliances or other financing mechanisms. However, we cannot provide assurance that adequate funding will be available on terms acceptable to us, if at all. In addition, the disruption of global financial markets caused by the COVID-19 pandemic, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Information Regarding Our Financial Condition.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,053.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,272.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Working Capital:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,019.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">972.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total working capital</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Information Regarding Our Cash Flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(270.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable period last year, cash flows from operating activities primarily reflected increased INGREZZA net product sales driven by increased new patient starts and record total prescriptions, reflecting higher customer demand and increased commercial activities, partially offset by increased investments in ongoing commercial initiatives and our expanded clinical portfolio. In addition, we experienced an increase in accounts receivable due to extended customer payment terms attributed to the expansion of our distribution network at the end of fiscal 2021 and an increase in accounts payable driven by $30.0 million of milestone expense recognized in the second quarter of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic fluctuations in cash flows from investing activities primarily reflect timing differences related to purchases, sales and maturities of debt security investments and changes in our portfolio-mix. Compared with the comparable period last year, cash flows from investing activities also reflected an increase of $7.6 million in capital expenditures driven by increased investment in our new campus facilities and scientific equipment and a $7.7 million equity investment in Xenon in connection with the FDA's acceptance of our amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol in January 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with the comparable period last year, cash flows from financing activities primarily reflected the repurchase of $210.8 million aggregate principal amount of our convertible senior notes for an aggregate repurchase price of $279.0 million in cash in the second quarter of 2022.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the pharmaceutical industry, it can take a significant amount of time and capital resources to successfully complete all stages of research and development and commercialize a product candidate, which ultimate length of time and spend required cannot be accurately estimated as it varies substantially according to the type, complexity, novelty and intended use of a product candidate. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The funding necessary to execute our business strategies is subject to numerous uncertainties and we may be required to make substantial expenditures if unforeseen difficulties arise in certain areas of our business. In particular, our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success of INGREZZA, ONGENTYS, ORILISSA, ORIAHNN and/or DYSVAL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued scientific progress in our research and clinical development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the magnitude and complexity of our research and development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress with preclinical testing and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities and arrangements, including our advertising campaigns;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing of our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to any future litigation; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing factors, we have significant future capital requirements, including:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">External Business Developments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our independent efforts to develop and market products, we may enter into collaboration and license agreements or acquire businesses from time-to-time to enhance our drug development and commercial capabilities. With respect to our existing collaboration and license agreements, we may be required to make potential future payments of up to $10.8 billion upon the achievement of certain event-based milestones.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2 to the condensed consolidated financial statements for more information on our significant collaboration and license agreements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% fixed-rated convertible senior notes due May&#160;15, 2024, or the 2024 Notes. At our election, we may redeem all or any portion of the 2024 Notes under certain circumstances. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. There are customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the notes would become due and payable. In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. As of June&#160;30, 2022, $170.4 million aggregate principal amount of the 2024 Notes remained outstanding. With respect to the 2024 Notes, unless earlier converted, redeemed, or repurchased, we would be required to pay interest of $1.9 million in 2022, $3.8 million in 2023, and $1.9 million in 2024 and pay the aggregate principal amount outstanding of $170.4 million upon maturity of the 2024 Notes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 8 to the condensed consolidated financial statements for more information on the 2024 Notes.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases that have commenced have terms that expire beginning 2024 through 2031 and consist of office space and research and development laboratories, including our corporate headquarters. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, pursuant to which we also secured a six-year option for the construction of a fifth building and an option to purchase the entire campus facility, which will consist of office space and research and development laboratories, in the future. Upon completion of construction, we expect to utilize the campus facility as our new corporate headquarters and expect to begin subleasing our existing leased facilities.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 7 to the condensed consolidated financial statements for more information on our leases, including a presentation of our approximate future minimum lease payments under non-cancelable operating leases.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to our critical accounting policies as disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a diversified investment portfolio consisting of low-risk, investment-grade debt securities with maturities of up to three years, including investments in commercial paper, securities of government-sponsored entities and corporate bonds that are subject to interest rate risk. The primary objective of our investment activities is to preserve principal and maintain liquidity. If a 1% unfavorable change in interest rates were to have occurred on June&#160;30, 2022, it would not have had a material effect on the fair value of our investment portfolio as of that date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;hopes,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;proforma,&#8221; or &#8220;anticipates,&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as the development of new products, technology enhancements, possible changes in legislation and other statements that are not historical. These statements include but are not limited to statements under the captions &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; as well as other sections in this report. You should be aware that the occurrence of any of the events discussed under the heading in Part II titled &#8220;Item 1A. Risk Factors&#8221; and elsewhere in this report could substantially harm our business, results of operations and financial condition and that if any of these events occurs, the trading price of our common stock could decline and you could lose all or a part of the value of your shares of our common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future.</span></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_64"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion of our exposure to, and management of, market risk appears in Part I, Item&#160;2 of this Quarterly Report on Form&#160;10-Q&#160;under the heading &#8220;Interest Rate Risk.&#8221;</span></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_67"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports required by the Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the timelines specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the quarter covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any changes to our internal control over financial reporting that occurred during our last fiscal quarter and that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Our evaluation did not identify significant changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that occurred during the quarter ended June&#160;30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_73"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second, third and fourth quarters of 2021 and the first and second quarters of 2022, we received notices from (i) Teva Pharmaceuticals Development, Inc., (ii) Lupin Limited, (iii) Crystal Pharmaceutical (Suzhou) Co. Ltd., and (iv) Zydus Pharmaceuticals (USA) Inc. (each an &#8220;ANDA Filer&#8221;) that each company had filed an abbreviated new drug application, or ANDA, with the FDA seeking approval of a generic version of INGREZZA. These companies represented that their respective ANDAs each contained a Paragraph IV Patent Certification alleging that certain of our patents covering INGREZZA are invalid and/or will not be infringed by each ANDA Filer&#8217;s manufacture, use or sale of the medicine for which the ANDA was submitted. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed suit in the United States District Court for the District of Delaware in July, August and October 2021 and January, May and July 2022, against (i) Teva Pharmaceuticals, Inc. and its affiliates Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (entity dismissed), (ii) Lupin Limited, and its affiliates Lupin Pharmaceuticals, Inc., and Lupin Atlantis Holdings S.A., (iii) Crystal Pharmaceutical (Suzhou) Co., Ltd., and its affiliate Crystal Pharmatech Co., Ltd., and (iv) Zydus Pharmaceuticals (USA) Inc. and its affiliates Zydus Worldwide DMCC, Cadila Healthcare Limited d/b/a Zydus Cadila and Zydus Healthcare (USA) LLC (entity dismissed). The cases filed in July, August and October 2021 and January 2022 have been consolidated in the United States District Court for the District of Delaware, and the trial is currently scheduled for January 2, 2024.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also filed suit in the United States District Court for the District of New Jersey in July and October 2021 against Zydus Pharmaceuticals (USA) Inc., and its affiliates Zydus Worldwide DMCC, Cadila Healthcare Limited d/b/a Zydus Cadila and Zydus Healthcare (USA) LLC seeking to prevent any ANDA Filer from selling a generic version of INGREZZA and these cases were dismissed in favor of continued prosecution of the Delaware proceedings against the same entities. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we filed suit in the United States District Court for the District of Delaware and in the United States District Court for the District of New Jersey in April 2022, against Zydus Pharmaceuticals (USA) Inc. and its affiliates Zydus Worldwide DMCC, Zydus Lifesciences Limited (f/k/a Cadila Healthcare Limited) and Zydus Healthcare (USA) LLC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_76"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Quarterly Report on Form 10-Q and those we may make from time to time. If any of the following risks actually occur, our business, operating results, prospects or financial condition could be harmed. Additional risks not presently known to us, or that we currently deem immaterial, may also affect our business operations. The risk factors set forth below with an asterisk (*) contain changes to the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks and uncertainties related to our business, many of which are beyond our control.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, risks associated with our business include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to continue to successfully commercialize INGREZZA, ONGENTYS, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS, or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products that could limit our product revenues and delay sustained profitability.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, which could also cause significant disruption in the operations of third-party manufacturers, contract research organizations, or CROs, or other third parties upon whom we rely.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may be delayed for safety or other reasons, or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Several of our planned clinical trial sites have been impacted and could be delayed or suspended as a result of the conflict between Russia and Ukraine.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use of our approved products or those of our collaborators could be associated with side effects or adverse events.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to retain and recruit qualified scientists and other employees or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or ONGENTYS, could materially and adversely affect our ability to successfully commercialize INGREZZA or ONGENTYS.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health care reform measures and other recent legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Company</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We may not be able to continue to successfully commercialize INGREZZA, ONGENTYS, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to produce INGREZZA revenues consistent with expectations ultimately depends on our ability to continue to successfully commercialize INGREZZA and secure adequate third-party reimbursement. Our experience in marketing and selling pharmaceutical products began with INGREZZA&#8217;s approval in 2017, when we hired our salesforce and established our distribution and reimbursement capabilities, all of which are necessary to successfully commercialize our current and future products. We have continued to invest in our commercial infrastructure and distribution capabilities in the past four years, including the expansion of our specialty salesforce, which we announced in the third quarter of 2021 and completed in April 2022. While our team members and consultants have experience marketing and selling pharmaceutical products, we may face difficulties related to managing the rapid growth of our personnel and infrastructure, and there can be no guarantee that we will be able to maintain the personnel, systems, arrangements and capabilities necessary to continue to successfully </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize INGREZZA, or to successfully commercialize ONGENTYS or any product candidate approved by the FDA in the future. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business has been and may continue to be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic. In parts of the country where the pandemic is having a greater impact, some hospitals, community mental health facilities and other healthcare facilities continue to have policies that limit access of our sales representatives, medical affairs personnel and patients to such facilities. These policies are likely to change from time to time as communities or regions grapple with outbreaks. These facilities also may be facing staffing shortages that impact their ability to see patients and conduct necessary screenings. In addition, many health care practitioners have adopted telehealth for patient interactions, which may impact the ability of the health care practitioner to screen for and diagnose tardive dyskinesia. Further, during the COVID-19 pandemic, the use of physician telehealth services increased significantly, fueled by an expansion of coverage and reimbursement from government and other payors. The limitations that telehealth places on the ability to conduct a thorough visual and physical examination may impact the ability of providers to screen for movement disorders, leading to potentially fewer patients to be diagnosed and referred for treatment. The ultimate impact of the COVID-19 pandemic, including any lasting effects on the way we conduct our business, is highly uncertain and subject to continued change. If we fail to maintain successful marketing, sales and reimbursement capabilities, our product revenues may suffer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of INGREZZA or ONGENTYS will depend upon the acceptance of those products as safe and effective by the medical community and patients.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market acceptance of INGREZZA or ONGENTYS could be affected by a number of factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of receipt of marketing approvals for additional indications;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of the products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing of our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of healthcare payor coverage and adequate reimbursement for the products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public perception regarding any products we may develop;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of existing competitor products addressing our target markets or the emergence of equivalent or superior products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost-effectiveness of the products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the medical community, patients and payors do not continue to accept our products as being safe, effective, superior and/or cost-effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products or impose policies that could limit our product revenues and delay sustained profitability.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to commercialize INGREZZA successfully or to successfully commercialize ONGENTYS, will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available. The continuing efforts of government and third-party payors to contain or reduce the costs of health care and the price of prescription drugs through various means may impact our revenues. These payors&#8217; efforts could decrease the price that we receive for any products we may develop and sell in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the out-of-pocket cost of our products. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available regardless of whether they are approved by the FDA for that particular use. Coverage decisions by payors for our competitors' products may also impact coverage for our products.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. In addition, communications from government officials regarding health care costs and pharmaceutical pricing could have a negative impact on our stock price, even if such communications do not ultimately impact coverage or reimbursement decisions for our products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may also be significant delays in obtaining coverage and reimbursement for newly approved drugs or indications, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize INGREZZA, ONGENTYS or any other product candidate for which we obtain marketing approval. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. Further, a majority of our current revenue is derived from federal healthcare program payors, including Medicare and Medicaid. Thus, changes in government reimbursement policies, reductions in payments and/or our suspension or exclusion from participation in federal healthcare programs could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, during the COVID-19 pandemic, the use of physician telehealth services has rapidly increased, fueled by an unprecedented expansion of coverage and reimbursement across insurers. The limitations that telehealth places on the ability to conduct a thorough physical examination may impact the ability of providers to screen for movement disorders, leading to fewer patients being diagnosed and/or treated.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, which could also cause significant disruption in the operations of third-party manufacturers CROs, or other third parties upon whom we rely.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health pandemics or epidemics, which could also cause significant disruption in the operations of third-party manufacturers, CROs and other third parties upon whom we rely. As a result of the ongoing COVID-19 pandemic, we may experience disruptions that could severely impact our supply chain, ongoing and future clinical trials and commercialization of INGREZZA and ONGENTYS. For example, the COVID-19 pandemic has resulted in travel restrictions and the shutdown or delay of business activities in various regions. In response to the COVID-19 pandemic, we implemented a remote work model for all employees except certain key essential members involved in business-critical activities.&#160;Most of our field-based employees have resumed in-person interactions in accordance with location-specific guidance. Our office-based employees have returned to the office under flexible work guidelines to help balance business needs, employee health, well-being and safety and the evolving work environment. However, as the effects of the pandemic continue to rapidly evolve with the emergence of new COVID-19 variants and spikes or surges in infection and hospitalization rates, a remote work model may nevertheless need to be reinstated at some point in the future. The effects of a remote and flexible work model may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In addition, we may face several challenges or disruptions upon a return back to the workplace, including re-integration challenges by our employees and distractions to management related to such transition. These and similar, and perhaps more severe, disruptions in our operations due to the COVID-19 pandemic could negatively impact our business, operating results and financial condition. We continue to evaluate the impact of the COVID-19 pandemic on our business and will update our plans and policies as needed going forward.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarantines, stay at home orders, travel restrictions and other state and local restrictions, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, clinical site initiation and patient enrollment may be delayed due to concerns for patient safety and prioritization of healthcare resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient travel or interrupt healthcare services. Similarly, our ability to recruit and retain patients, principal investigators and site staff may be hindered, which would adversely impact our clinical trial operations. Increases in COVID-19 cases or hospitalizations in the future could cause us or any of our clinical sites to again limit or suspend our patient enrollment and screening activities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic has caused disruption in the global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the COVID-19 pandemic could materially affect our business and the value of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the COVID-19 pandemic continue to evolve. The ultimate impact of the COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to continued change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations, or the operations of third parties on whom we rely.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may also arise from, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other drug development technologies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">methods of preventing or reducing the incidence of disease, including vaccines; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new small molecule or other classes of therapeutic agents.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments by others (including the development of generic equivalents) may render our product candidates or technologies obsolete or noncompetitive.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are commercializing and performing research on or developing products for the treatment of several disorders including endometriosis, tardive dyskinesia, uterine fibroids, essential tremor, classic congenital adrenal hyperplasia, pain, Parkinson&#8217;s disease and other neurology, neuroendocrinology and neuropsychiatry-related diseases and disorders, and there are a number of competitors to our products and product candidates. If one or more of our competitors&#8217; products or programs are successful (including the development of generic equivalents), the market for our products may be reduced or eliminated.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">INGREZZA competes with AUSTEDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (deutetrabenazine), which was approved by the FDA for the treatment of tardive dyskinesia in adults in August 2017 and is marketed by Teva Pharmaceutical Industries, and several clinical development-stage programs targeting tardive dyskinesia and related movement disorders. Additionally, there are a number of commercially available medicines used to treat tardive dyskinesia off-label, such as XENAZINE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tetrabenazine) and generic equivalents, and various antipsychotic medications (e.g., clozapine), anticholinergics, benzodiazepines (off-label), and botulinum toxin.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ONGENTYS competes with two other FDA-approved COMT inhibitors and their generic equivalents. Additionally, there are a number of alternative adjunctive treatment options (FDA-approved and in clinical development) for Parkinson&#8217;s patients which compete with ONGENTYS, including various L-dopa preparations, dopamine agonists, MAO-B inhibitors and others. In terms of potential future competition, there are several programs in late-stage clinical development.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ORILISSA and ORIAHNN each compete with several FDA-approved products for the treatment of endometriosis, uterine fibroids, infertility and central precocious puberty. Additionally, there is also competition from surgical intervention, including hysterectomies and ablations. Separate from these options, there are many programs in clinical development which serve as potential future competition. Lastly, there are numerous medicines used to treat the symptoms of disease (vs. endometriosis or uterine fibroids directly) which may also serve as competition: oral contraceptives, NSAIDs and other pain medications, including opioids.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For CAH, high doses of corticosteroids are the current standard of care to both correct the endogenous cortisol deficiency as well as reduce the excessive ACTH levels. In the United States alone, there are more than two dozen companies manufacturing steroid-based products. In addition, there are several programs in clinical development targeting CAH and several companies developing medicinal treatments for CAH.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in epilepsy may in the future compete with numerous approved anti-seizure medications and development-stage programs being pursued by several other companies. Commonly used anti-seizure medications include phenytoin, levetiracetam, brivaracetam, cenobamate, carbamazepine, clobazam, lamotrigine, valproate, oxcarbazepine, topiramate, lacosamide, perampanel and cannabidiol, among others. There are currently no FDA-approved treatments specifically indicated for the early infantile epileptic encephalopathies SCN8A-DEE and EE-CSWS; however, a number of different anti-seizure medications are currently used in these patient populations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in schizophrenia and depression may in the future compete with several development-stage programs being pursued by other companies. Currently, there are no FDA-approved treatments specifically indicated for cognitive impairment associated with schizophrenia, or CIAS; however, there are a number of different anti-psychotic medications currently used in these patient populations.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational treatments for potential use in neurology, neuroendocrinology and neuropsychiatry may in the future compete with numerous approved products and development-stage programs being pursued by several other companies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared to us, many of our competitors and potential competitors have substantially greater:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital resources;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales and marketing experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">research and development resources, including personnel and technology;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical study and clinical testing experience;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing, marketing and distribution experience; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production facilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increased competition in certain disorders or therapies may make it more difficult for us to recruit or enroll patients in our clinical trials for similar disorders or therapies.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only a small number of research and development programs ultimately result in commercially successful drugs. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential products that appear to be promising at early stages of development may not reach the market for a number of reasons. These reasons include the possibilities that the potential products may:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be found ineffective or cause harmful side effects during preclinical studies or clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fail to receive necessary regulatory approvals on a timely basis or at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be precluded from commercialization by proprietary rights of third parties;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be difficult to manufacture on a large scale; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be uneconomical to commercialize or fail to achieve market acceptance.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates encounters any of these potential problems, we may never successfully market that product candidate.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our clinical trials may be delayed for safety or other reasons or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval for the sale of any of our potential products, we must subject these product candidates to extensive preclinical and clinical testing to demonstrate their safety and efficacy for humans. Clinical trials are expensive, time-consuming and may take years to complete and the outcomes are uncertain.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the clinical trials of our product candidates, we face the risks that:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authority may not allow an IND or foreign equivalent filings required to initiate human clinical studies for our drug candidates or the FDA may require additional preclinical studies as a condition of the initiation of Phase I clinical studies, or additional clinical studies for progression from Phase&#160;I to Phase&#160;II, or Phase&#160;II to Phase&#160;III, or for NDA approval;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidate may not prove to be effective or as effective as other competing product candidates;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may discover that a product candidate may cause harmful side effects or results of required toxicology or other studies may not be acceptable to the FDA;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial results may not replicate the results of previous trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authorities may require use of new or experimental endpoints that may prove insensitive to treatment effects;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the FDA or similar foreign regulatory authorities may suspend the trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not be statistically significant;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical site initiation or patient recruitment and enrollment may be slower or more difficult than expected;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may not accept the data from any trial or trial site outside of the United States;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients may drop out of the trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen disruptions or delays may occur, caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic and the conflict between Russia and Ukraine; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory requirements may change.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks and uncertainties impact all of our clinical programs and any of the clinical, regulatory or operational events described above could change our planned clinical and regulatory activities. In addition, due to the impact of the COVID-19 pandemic, clinical site initiation and new patient enrollment has been negatively impacted. Additionally, any of these events described above could result in suspension of a program and/or obviate any filings for necessary regulatory approvals.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, late-stage clinical trials are often conducted with patients having the most advanced stages of disease. During the course of treatment, these patients can die or suffer other adverse medical effects for reasons that may not be related to the pharmaceutical agent being tested but which can nevertheless adversely affect clinical trial conduct, completion and results. Any failure or substantial delay in completing clinical trials for our product candidates may severely harm our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Several of our planned clinical trial sites have been impacted and could be delayed or suspended as a result of the conflict between Russia and Ukraine.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia commenced a military invasion of Ukraine. We have planned clinical trial sites in both Russia and Ukraine, but no patients yet enrolled. Ongoing geopolitical turmoil and continuing military action in the region, together with widening sanctions imposed on Russia, have caused us to suspend all planned clinical trial activities in Russia and Ukraine. Alternative clinical trial sites that would fully and timely compensate for our planned clinical trial activities in Ukraine and Russia may not be available and we may need to find other countries in which to conduct such activities. Our planned clinical development timelines for valbenazine and luvadaxistat could be significantly delayed, which would increase our development costs and delay the development and/or regulatory approval process of such product candidates and jeopardize our ability to commence product sales and generate revenues.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates. For example, we depend on AbbVie for the manufacture and commercialization of ORILISSA and ORIAHNN and for the continued development of elagolix. We collaborate with MTPC for the commercialization of DYSVAL in Japan and for the continued development and commercialization of valbenazine for movement disorders in other select Asian markets. We also rely on BIAL for the commercial supply of ONGENTYS. In addition, we collaborate with Xenon Pharmaceuticals, Inc. for the development of NBI-921352, Idorsia Pharmaceuticals Ltd for the development of NBI-827104, Takeda Pharmaceutical Company Limited for the development of luvadaxistat, NBI-1065845 and NBI-1065846 and Heptares Therapeutics Limited for the development of NBI-1117568.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future collaborations and licenses could subject us to a number of risks, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may sell, transfer or divest assets or programs related to our partnered product or product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to undertake the expenditure of substantial operational, financial and management resources; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to assume substantial actual or contingent liabilities; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our products or product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to influence our strategic collaborator&#8217;s decisions regarding the development and collaboration of our partnered product and product candidates, and as a result, our collaboration partners may not pursue or prioritize the development and commercialization of those partnered products and product candidates in a manner that is in our best interest;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may select indications or design clinical trials in a way that may be less successful than if we were doing so; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not conduct collaborative activities in a timely manner, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements or disputes may arise between us and our strategic collaborators that result in delays or in costly litigation or arbitration that diverts management&#8217;s attention and consumes resources; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may experience financial difficulties; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and commercialization and may increase the cost of developing and commercializing our products or product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators could develop, either alone or with others, products or product candidates that may compete with ours. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these issues arise, it may delay and/or negatively impact the development and commercialization of drug candidates and, ultimately, our generation of product revenues.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to successfully commercialize ONGENTYS.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we received FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson&#8217;s disease patients, and in September 2020, we launched the commercial sale of ONGENTYS with our existing commercial infrastructure. The successful commercialization of ONGENTYS is subject to many risks, and there are numerous examples of unsuccessful product launches and failures, including by pharmaceutical companies with more experience and resources than us. If we are unable to effectively train our employees and equip them with effective materials, including medical and sales literature to help them inform and educate health care practitioners about the benefits of ONGENTYS and its proper administration, our commercialization of ONGENTYS may not be successful. Even if we are successful in effectively training and equipping our salesforce, there are many factors that could cause the commercialization of ONGENTYS to be unsuccessful, including a number of factors that are outside our control. Health care practitioners may not prescribe ONGENTYS and patients may be unwilling to use ONGENTYS if insurance coverage is not provided or reimbursement is inadequate. In addition, our ability to train our employees and effectively communicate with potential prescribers could be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of our approved products or those of our collaborators could be associated with side effects or adverse events.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with most pharmaceutical products, use of our approved products or those of our collaborators could be associated with side effects or adverse events which can vary in severity (from minor adverse reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our products or those of our collaborators may be observed at any time, including after a product is commercialized, and reports of any such side effects or adverse events may negatively impact demand for our or our collaborators&#8217; products or affect our or our collaborators&#8217; ability to maintain regulatory approval for such products. Side effects or other safety issues associated with the use of our approved products or those of our collaborators could require us or our collaborators to modify or halt commercialization of these products or expose us to product liability lawsuits which will harm our business. We or our collaborators may be required by regulatory agencies to conduct additional studies regarding the safety and efficacy of our products which we have not planned or anticipated. Furthermore, there can be no assurance that we or our collaborators will resolve any issues related to any product related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had more than 1,100 full-time employees. Although we have substantially increased the size of our organization, we may need to add additional qualified personnel and resources, especially with the recent increase in the size of our salesforce. Our current infrastructure may be inadequate to support our development and commercialization efforts and expected growth. Future growth will impose significant added responsibilities on our organization, including the need to identify, recruit, maintain and integrate additional employees, and may take time away from running other aspects of our business, including development and commercialization of our product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize INGREZZA, ONGENTYS and any other product candidates that receive regulatory approval will depend, in part, on our ability to manage any future growth effectively. In particular, as we commercialize INGREZZA and ONGENTYS, we will need to support the training and ongoing activities of our salesforce and will likely need to continue to expand the size of our employee base for managerial, operational, financial and other resources. To that end, we must be able to successfully:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our development efforts effectively;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integrate additional management, administrative and manufacturing personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further develop our marketing and sales organization; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compensate our employees on adequate terms in an increasingly competitive, inflationary market;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain personnel; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain sufficient administrative, accounting and management information systems and controls.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to accomplish these tasks or successfully manage our operations and, accordingly, may not achieve our research, development and commercialization goals. Our failure to accomplish any of these goals could harm our financial results and prospects.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to retain and recruit qualified scientists and other employees or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the principal members of our management, commercial and scientific staff. The loss of any of these people could impede the achievement of our objectives, including the successful commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA. Furthermore, recruiting and retaining qualified scientific personnel to perform research and development work in the future, along with personnel with experience marketing and selling pharmaceutical products, is critical to our success. We may be unable to attract and retain personnel on acceptable terms given effects of the COVID-19 pandemic, as well as the competition among biotechnology, pharmaceutical and health care companies, universities and non-profit research institutions for experienced scientists and individuals with experience marketing and selling pharmaceutical products. We may face particular retention challenges in light of the recent rapid growth in our personnel and infrastructure and the perceived impact of those changes upon our corporate culture. In addition, we rely on a significant number of consultants to assist us in formulating our research and development strategy and our commercialization strategy. Our consultants may have commitments to, or advisory or consulting agreements with, other entities that may limit their availability to us.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past utilized, and intend to continue to utilize, third-party manufacturers to produce the drug compounds we use in our clinical trials and for the commercialization of our products. We have limited experience in manufacturing products for commercial purposes and do not currently have any manufacturing facilities. Establishing internal commercial manufacturing capabilities would require significant time and resources, and we may not be able to timely or successfully establish such capabilities. Consequently, we depend on, and will continue to depend on, several contract manufacturers for all production of products for development and commercial purposes, including INGREZZA and ONGENTYS. If we are unable to obtain or retain third-party manufacturers, we will not be able to develop or commercialize our products, including INGREZZA and ONGENTYS. The manufacture of our products for clinical trials and commercial purposes is subject to specific FDA regulations, including current Good Manufacturing Practice regulations. Our third-party manufacturers, including BIAL and its suppliers, might not comply with FDA regulations relating to manufacturing our products for clinical trials and commercial purposes or other regulatory requirements now or in the future. Our reliance on contract manufacturers also exposes us to the following risks:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturers may encounter difficulties in achieving volume production, quality control or quality assurance, and also may experience shortages in qualified personnel. As a result, our contract manufacturers might not be able to meet our clinical schedules or adequately manufacture our products in commercial quantities when required;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly on acceptable terms, or at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store or distribute our products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the United States Drug Enforcement Administration, and other agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current dependence upon third parties for the manufacture of our products may reduce our profit margin, if any, on the sale of INGREZZA, ONGENTYS, or our future products and our ability to develop and deliver products on a timely and competitive basis.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or ONGENTYS, could materially and adversely affect our ability to successfully commercialize INGREZZA or ONGENTYS.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of process controls required to consistently produce the active pharmaceutical ingredients, or API, the finished drug product and packaging in sufficient quantities while meeting detailed product specifications on a repeated basis. Manufacturers of pharmaceutical products may encounter difficulties in production, such as difficulties with production costs and yields, process controls, quality control and quality assurance, including testing of stability, impurities and impurity levels and other product specifications by validated test methods, compliance with strictly enforced United States, state and non-United States regulations, and disruptions or delays caused by man-made or natural disasters, pandemics or epidemics, or other business interruptions, including, for example, the COVID-19 pandemic and the conflict between Russia and Ukraine. We depend on a limited number of suppliers for the production and packaging of INGREZZA and its API. If our third-party suppliers for INGREZZA encounter these or any other manufacturing, quality or compliance difficulties, we may be unable to meet commercial demand for INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA. In addition, under the terms of our agreement with BIAL, although we are responsible for the management of all ONGENTYS commercialization activities, we rely on BIAL and its suppliers to supply all drug product for the commercialization of ONGENTYS. BIAL relies on third-party contract manufacturers to produce ONGENTYS. These contract manufacturers may encounter difficulties in achieving volume production, quality control, or quality assurance. As a result, these contract manufacturers may not be able to adequately produce ONGENTYS in commercial quantities when required, which may impact our ability to deliver ONGENTYS on a timely basis.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our suppliers fail or refuse to supply us with INGREZZA or its API for any reason, it would take a significant amount of time and expense to qualify a new supplier. The FDA and similar international regulatory bodies must approve manufacturers of the active and inactive pharmaceutical ingredients and certain packaging materials used in pharmaceutical products. The loss of a supplier could require us to obtain regulatory clearance and to incur validation and other costs associated with the transfer of the API or product manufacturing processes. If there are delays in qualifying new suppliers or facilities or if a new supplier is unable to meet FDA or a similar international regulatory body&#8217;s requirements for approval, there could be a shortage of INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA. If BIAL is unable or refuses to supply us with ONGENTYS drug product for any reason, or does not meet FDA or international regulators&#8217; requirements for approval, we have limited opportunity to qualify a new supplier. This could materially and adversely affect our ability to successfully commercialize ONGENTYS.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The independent clinical investigators and contract research organizations that we rely upon to conduct our clinical trials may not be diligent, careful or timely, and may make mistakes, in the conduct of our trials.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators and CROs to conduct our clinical trials under their agreements with us. The investigators are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. If our independent investigators fail to devote sufficient time and resources to our drug development programs, or if their performance is substandard, or not in compliance with Good Clinical Practices, it may delay or prevent the approval of our regulatory applications and our introduction of new treatments. The CROs we contract with for execution of our clinical trials play a significant role in the conduct of the trials and the subsequent collection and analysis of data. Failure of the CROs to meet their obligations could adversely affect clinical development of our products. Moreover, these independent investigators and CROs may also have relationships with other commercial entities, some of which may compete with us. If independent investigators and CROs assist our competitors at our expense, it could harm our competitive position.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not and will not have access to all information regarding the products and product candidates we licensed to AbbVie.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not and will not have access to all information regarding elagolix, including potentially material information about commercialization plans, medical information strategies, clinical trial design and execution, safety reports from clinical trials, safety reports, regulatory affairs, process development, manufacturing and other areas known by AbbVie. In addition, we have confidentiality obligations under our agreement with AbbVie. Thus, our ability to keep our shareholders informed about the status of elagolix will be limited by the degree to which AbbVie keeps us informed and allows us to disclose such information to the public. If AbbVie fails to keep us informed about commercialization efforts related to elagolix, or the status of the clinical development or regulatory approval pathway of other product candidates licensed to it, we may make operational and/or investment decisions that we would not have made had we been fully informed, which may materially and adversely affect our business and operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing obligations and continued regulatory review for INGREZZA. Additionally, our other product candidates, if approved, could be subject to labeling and other post-marketing requirements and restrictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approvals for any of our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. For example, with respect to the FDA&#8217;s approval of INGREZZA for tardive dyskinesia in April 2017, we are subject to certain post-marketing requirements and commitments. In addition, with respect to INGREZZA, and any product candidate that the FDA or a comparable foreign regulatory authority approves, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current Good Clinical Practices for any clinical trials that we conduct post-approval. Failure to comply with these ongoing regulatory requirements, or later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, may result in, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, changes in the product&#8217;s label, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning or untitled letters or holds on clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse inspection findings or other activities that temporarily delay manufacture and distribution of our products;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events may adversely affect our business, prospects and ability to achieve or sustain profitability on a sustained basis.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our products and product candidates are smaller than we believe they are, our expected revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the diseases that INGREZZA, ONGENTYS and our other product candidates are being developed to address are in underserved and underdiagnosed populations. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who will seek treatment utilizing our products or product candidates, may not be accurate. If our estimates of the prevalence or number of patients potentially on therapy prove to be inaccurate, the market opportunities for INGREZZA, ONGENTYS and our other product candidates may be smaller than we believe they are, our prospects for generating expected revenue may be adversely affected and our business may suffer.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on licenses from third parties for some of our key technologies. These licenses typically subject us to various commercialization, reporting and other obligations. If we fail to comply with these obligations, we could lose important rights. If we were to default on our obligations under any of our licenses, we could lose some or all of our rights to develop, market and sell products covered by these licenses. For example, BIAL may terminate our license agreement, pursuant to which we have rights to commercialize ONGENTYS, if we fail to use commercially reasonable efforts to comply with specified obligations under the license agreement, or if we otherwise breach the license agreement. In addition, several of our collaboration and license agreements allow our licensors to terminate such agreements if we challenge the validity or enforceability of certain intellectual property rights or if we commit a material breach in whole or in part of the agreement and do not cure such breach within the agreed upon cure period. In addition, if we were to violate any of the terms of our licenses, we could become subject to damages. Likewise, if we were to lose our rights under a license to use proprietary research tools, it could adversely affect our existing collaborations or adversely affect our ability to form new collaborations. We also face the risk that our licensors could, for a number of reasons, lose patent protection or lose their rights to the technologies we have licensed, thereby impairing or extinguishing our rights under our licenses with them.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The conditional conversion feature of the 2024 Notes, if triggered, may adversely affect our financial condition, operating results, or liquidity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the conditional conversion feature of the 2.25% convertible senior notes due May 15, 2024, or the 2024 Notes, is triggered, holders of 2024 Notes will be entitled to convert their 2024 Notes at any time during specified periods at their option. If one or more of the holders of the 2024 Notes elects to convert their notes, unless we satisfy our conversion obligation by delivering only shares of our common stock with respect to any conversion premium, we would be required to settle all or a portion of our conversion obligation through the payment of cash, which could adversely affect our liquidity. The conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods. In the event that we have the election to redeem the 2024 Notes or the holders of the 2024 Notes have the election to convert the 2024 Notes at any time during the prescribed measurement period, the 2024 Notes would then be considered a current obligation and classified as such. We are not aware of any events or market conditions that would allow us to redeem the 2024 Notes or the holders of the 2024 Notes to convert the 2024 Notes for the quarterly period ended June&#160;30, 2022, or as of the date of this report.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we sold $517.5&#160;million aggregate principal amount of the 2024 Notes. In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. As of June&#160;30, 2022, $170.4 million aggregate principal amount of the 2024 Notes remained outstanding. We may also incur </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing our vulnerability to adverse economic and industry conditions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our ability to obtain additional financing;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our flexibility to plan for, or react to, changes in our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of the 2024 Notes; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under the 2024 Notes and any additional indebtedness that we may incur. In addition, our cash needs may increase in the future. In addition, any future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant net losses and negative cash flow from operations. As of June&#160;30, 2022, we had an accumulated deficit of $564.3 million as a result of historical operating losses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received FDA approval for INGREZZA for tardive dyskinesia in April 2017 and for ONGENTYS for Parkinson&#8217;s disease in April 2020. Our partner AbbVie received FDA approval for ORILISSA for endometriosis in July 2018 and for ORIAHNN for uterine fibroids in May 2020. Additionally, our partner MTPC received Japanese Ministry of Health, Labour and Welfare approval for DYSVAL for the treatment of tardive dyskinesia in March 2022. However, we have not yet obtained regulatory approvals for any other product candidates. Even if we continue to succeed in commercializing INGREZZA, or if we successfully commercialize ONGENTYS or are successful in developing and commercializing any of our other product candidates, we may not be able to sustain profitability. We also expect to continue to incur significant operating and capital expenditures as we:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize INGREZZA for tardive dyskinesia;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize ONGENTYS for Parkinson&#8217;s disease;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for our product candidates or for additional indications for our current products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop, formulate, manufacture and commercialize our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire new product development opportunities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implement additional internal systems and infrastructure; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, scientific, sales and marketing personnel.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to increase our expenses and other investments in the coming years as we fund our operations and capital expenditures. Thus, our future operating results and profitability may fluctuate from period to period due to the factors described above, and we will need to generate significant revenues to achieve and maintain profitability and positive cash flow on a sustained basis. We may not be able to generate these revenues, and we may never achieve profitability on a sustained basis in the future. Our failure to maintain or increase profitability on a sustained basis could negatively impact the market price of our common stock.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is commonplace in the biotechnology industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Because our operating results may vary significantly in future periods, our stock price may decline.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenues, expenses and operating results have fluctuated in the past and are likely to fluctuate significantly in the future. Our financial results are unpredictable and may fluctuate, for among other reasons, due to seasonality and timing of customer purchases and commercial sales of INGREZZA, impact of the commercial launch of ONGENTYS and ORIAHNN, royalties from out-licensed products, the impact of Medicare Part D coverage, our achievement of product development objectives and milestones, clinical trial enrollment and expenses, research and development expenses and the timing and nature of contract manufacturing, contract research payments, fluctuations in our effective tax rate, and disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic and the conflict between Russia and Ukraine. Because a majority of our costs are predetermined on an annual basis, due in part to our significant research and development costs, small declines in revenue could disproportionately affect financial results in a quarter. Thus, our future operating results and profitability may fluctuate from period to period, and even if we become profitable on a quarterly or annual basis, we may not be able to sustain or increase our profitability. Moreover, as our company and our market capitalization have grown, our financial performance has become increasingly subject to quarterly and annual comparisons with the expectations of securities analysts or investors. The failure of our financial results to meet these expectations, either in a single quarterly or annual period over a sustained period time, could cause our stock price to decline.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenses for tax purposes in the year incurred and requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. Unless the United States Department of the Treasury issues regulations that narrow the application of this provision to a smaller subset of our research and development expenses or the provision is deferred, modified, or repealed by Congress, we expect a material decrease in our cash flows from operations and an offsetting similarly sized increase in our net deferred tax assets over these amortization periods. The actual impact of this provision will depend on multiple factors, including the amount of research and development expenses we will incur and whether we conduct our research and development activities inside or outside the United States.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, new income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Biden administration and Congress have proposed various United States federal tax law changes which, if enacted, could have a material impact on our business, cash flows, financial condition, or results of operations. In addition, it is uncertain if and to what extent various states will conform to federal tax laws. Future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future United States tax expense.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net operating loss, or NOL, carryforwards generated in tax years beginning on or prior to December 31, 2017, are only permitted to be carried forward for 20 years under applicable United States tax law. Under current law, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax laws. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We do not believe we have experienced any previous ownership changes, but the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determination is complex and there can be no assurance we are correct. Furthermore, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, our pre-2018 NOL carryforwards may expire prior to being used and our NOL carryforwards generated in tax years beginning after December 31, 2017, will be subject to a percentage limitation and, if we undergo an ownership change (or if we previously underwent such an ownership change), our ability to use all of our pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset our post-change income or taxes may be limited. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each such place. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including the impact of stock-based compensation, changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on December 31, 2020, we determined, based on our facts and circumstances, that it was more likely than not that a substantial portion of our deferred tax assets would be realized and, as a result, substantially all of our valuation allowance against our deferred tax assets was released. Therefore, beginning in 2021, we commenced recording income tax expense at an estimated tax rate that will likely approximate statutory tax rates, which could result in a significant reduction in our net income and net income per share.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*The price of our common stock is volatile.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology and pharmaceutical companies historically have been highly volatile, and the market for these securities has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. The COVID-19 pandemic, for example, has negatively affected the stock market and investor sentiment and has resulted in significant volatility. Furthermore, especially as we and our market capitalization have grown, the price of our common stock has been increasingly affected by quarterly and annual comparisons with the valuations and recommendations of the analysts who cover our business. If our results do not meet these analysts&#8217; forecasts, the expectations of our investors or the financial guidance we provide to investors in any period, which is based on assumptions that may be incorrect or that may change from quarter to quarter, the market price of our common stock could decline. Over the course of the last twelve months, the price of our common stock has ranged from approximately $72 per share to approximately $108 per share. The market price of our common stock may fluctuate in response to many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of INGREZZA and our other products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the status and cost of our post-marketing commitments for INGREZZA;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reports of safety issues related to INGREZZA, ONGENTYS, ORILISSA, ORIAHNN, or DYSVAL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning new and existing collaboration agreements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new therapeutic products by us or others;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and market conditions, including economic and market conditions affecting the biotechnology industry;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to the FDA and foreign regulatory agencies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future sales of our common stock by us or our stockholders;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comments by securities analysts;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential litigation matters and developments in existing litigation matters, such as the ANDA litigation matters;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government regulation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government and third-party payor coverage and reimbursement;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our product candidates, if approved, to achieve commercial success;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions caused by man-made or natural disasters, pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic and the conflict between Russia and Ukraine; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of our drugs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are a member of the S&amp;P MidCap 400 index. If we cease to be represented in the S&amp;P MidCap 400 index, or other indexes or indexed products, as a result of our market capitalization falling below the threshold for inclusion in the index, certain institutional shareholders may, due to their internal policies and investment guidelines, be required to sell their shareholdings. Such sales may result in further negative pressure on our stock price and, when combined with reduced trading volume and liquidity, could adversely affect the value of your investment and your ability to sell your shares.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors, and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 89% of our total product revenue for the six months ended June&#160;30, 2022 and approximately 94% of our accounts receivable balance as of June&#160;30, 2022. If any of these significant customers becomes subject to bankruptcy, is unable to pay us for our products or is acquired by a company that wants to terminate the relationship with us, or if we otherwise lose any of these significant customers, our revenue, results of operations and cash flows would be adversely affected. Even if we replace the loss of a significant customer, we cannot predict with certainty that such transition would not result in a decline in our revenue, results of operations and cash flows.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional funding to continue our research and development programs, to conduct preclinical studies and clinical trials, for operating expenses, to pursue regulatory approvals for our product candidates, for the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims, if any, and the cost of product in-licensing and any possible acquisitions. In addition, we may require additional funding to establish manufacturing and marketing capabilities in the future. We believe that our existing capital resources and anticipated revenues will be sufficient to satisfy our current and projected funding requirements for at least the next 12&#160;months. However, these resources might be insufficient to conduct research and development programs, the cost of product in-taking and possible acquisitions, fully commercialize products and operate the company to the full extent currently planned. If we cannot obtain adequate funds, we may be required to significantly curtail our commercial plans or one or more of our research and development programs or obtain funds through additional arrangements with corporate collaborators or others that may require us to relinquish rights to some of our technologies or product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success of INGREZZA, ONGENTYS, ORILISSA, ORIAHNN and/or DYSVAL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt services obligations on the 2024 Notes;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued scientific progress in our R&amp;D and clinical development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the magnitude and complexity of our research and development programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress with preclinical testing and clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to any future litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities and arrangements, including advertising campaigns;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our product candidates; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of any strategic alliances, collaborations, product in-licensing, or acquisitions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek additional funding through strategic alliances and may seek additional funding through public or private sales of our securities, including equity securities. In addition, during the second quarter of 2017, we issued the 2024 Notes and we have previously financed capital purchases and may continue to pursue opportunities to obtain additional debt financing in the future. In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2&#160;million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9&#160;million in cash. In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. As of June&#160;30, 2022, $170.4 million aggregate principal amount of the 2024 Notes remained outstanding. Additional equity or debt financing might not be available on reasonable terms, if at all. In addition, disruptions due to the COVID-19 pandemic could make it more difficult for us to access capital. Any additional equity financings will be dilutive to our stockholders and any additional debt financings may involve operating covenants that restrict our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act, new SEC regulations and Nasdaq rules, are creating uncertainty for companies such as ours. These laws, regulations and standards are subject to varying interpretations in some cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We are committed to maintaining high standards of corporate governance and public disclosure. As a result, our efforts to comply with evolving laws, regulations and standards have resulted in, and are likely to continue to result in, increased selling, general and administrative expenses and management time related to compliance activities. If we fail to comply with these laws, regulations and standards, our reputation may be harmed and we might be subject to sanctions or investigation by regulatory authorities, such as the SEC. Any such action could adversely affect our financial results and the market price of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing use of social media could give rise to liability and result in harm to our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees are increasingly utilizing social media tools and our website as a means of communication. Despite our efforts to monitor social media communications, there is risk that the unauthorized use of social media by our employees to communicate about our products or business, or any inadvertent disclosure of material, nonpublic information through these means, may result in violations of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a material adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend on our ability to, among other things:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patent protection for our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve our trade secrets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent third parties from infringing upon our proprietary rights; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing upon the proprietary rights of others, both in the United States and internationally.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the substantial length of time and expense associated with bringing new products through the development and regulatory approval processes in order to reach the marketplace, the pharmaceutical industry places considerable importance on obtaining patent and trade secret protection for new technologies, products and processes. Accordingly, we intend to seek patent protection for our proprietary technology and compounds. However, we face the risk that we may not obtain any of these patents and that the breadth of claims we obtain, if any, may not provide adequate protection of our proprietary technology or compounds.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, through confidentiality </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements with our commercial collaborators, employees and consultants. We also have invention or patent assignment agreements with our employees and some, but not all, of our commercial collaborators and consultants. However, if our employees, commercial collaborators or consultants breach these agreements, we may not have adequate remedies for any such breach, and our trade secrets may otherwise become known or independently discovered by our competitors.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we own a number of patents, the issuance of a patent is not conclusive as to its validity or enforceability, and third parties may challenge the validity or enforceability of our patents. We cannot assure you how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court or in other proceedings. It is possible that a competitor may successfully challenge our patents or that challenges will result in limitations of their coverage. Moreover, competitors may infringe our patents or successfully avoid them through design innovation. In addition, potential competitors have in the past and may in the future file an ANDA with the FDA seeking approval to market a generic version of our products, or our competitors&#8217; products, before the expiration of the patents covering our products or our competitors&#8217; products, as applicable. To prevent infringement or unauthorized use, we have in the past and may in the future need to file infringement claims, which are expensive and time-consuming. For example, we are currently engaged in various intellectual property litigation matters against potential competitors related to INGREZZA. Refer to Item 1. Legal Proceedings f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or a more detailed description of these matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, in an infringement proceeding a court may decide that a patent of ours or a patent of a competitor is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. Derivation proceedings declared by the United States Patent and Trademark Office may be necessary to determine the priority of inventions with respect to our patent applications (or those of our licensors) or a patent of a competitor. Litigation or derivation proceedings may fail and, even if successful, may result in substantial costs and be a distraction to management. Litigation or derivation proceedings, including proceedings of a competitor, may also result in a competitor entering the marketplace faster than expected. We cannot assure you that we will be able to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Health care reform measures and other recent legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third-party payors to contain or reduce the costs of health care and to lower drug prices. In the United States, comprehensive health care reform legislation has been enacted by the Federal government and we expect that there will continue to be a number of federal and state proposals to implement government control over the pricing of prescription pharmaceuticals. In addition, increasing emphasis on reducing the cost of health care in the United States will continue to put pressure on the pricing and reimbursement of prescription pharmaceuticals. Moreover, in some foreign jurisdictions, pricing of prescription pharmaceuticals is already subject to government control. Additionally, other federal and state legislation impose obligations on manufacturers of pharmaceutical products, among others, related to disclosure of new drug products introduced to the market and increases in drug prices above a specified threshold.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was signed into law, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our drug products and potential drug candidates are:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures, or imports, specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a Medicare Part&#160;D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been executive legal and political challenges to certain aspects of the ACA. For example, on June 17, 2021 the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, prior to the United States Supreme Court ruling, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments to the statute, including the Infrastructure Investment and Jobs Act, will remain in effect through 2030, except for a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic, unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequestration. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, which ended the use of the statutory formula, also referred to as the Sustainable Growth Rate, for clinician payment and established a quality payment incentive program, also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, the Centers for Medicare &amp; Medicaid Services, or CMS, issued a final rule finalizing the changes to the Quality Payment Program. At this time, it remains unclear how the introduction of the Quality Payment Program will impact overall physician reimbursement.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempted to implement several of the administration&#8217;s proposals. As a result, the FDA concurrently released a final rule and guidance in September 2020 providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the United States Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The implementation of which has been delayed until January 1, 2027. In addition, In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering additional health reform measures, including proposed legislation that, among other issues, would direct the Secretary of Health and Human Services to negotiate drug </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prices covered under Medicare Part D, require drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation, and cap out-of-pocket costs to patients. It is unclear whether or when these or similar policy initiatives will be implemented. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. In particular, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain sustained profitability or commercialize our drugs, particularly since the majority of our current revenue is derived from federal healthcare programs, including Medicare and Medicaid.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently unable to predict what additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency or approval of such proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital or to enter into collaboration agreements for the further development and commercialization of our programs and products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could&#160;face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and activities may be directly, or indirectly, subject to various federal and state healthcare laws, including without limitation, fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as current and future sales, marketing, patient co-payment assistance and education programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such laws include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the federal civil False Claims Act, and Civil Monetary Penalties Laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Health Insurance Portability and Accountability Act, or HIPAA, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, which also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans and healthcare clearinghouses, as well as their business associates and their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state, local and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures or drug pricing; state laws that require disclosure of price increases above certain identified thresholds as well as of new commercial launches in the state; state and local laws that require the registration of pharmaceutical sales representatives; state and local &#8220;drug take back&#8221; laws and regulations; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While our interactions with healthcare professionals, including our speaker programs and other arrangements have been structured to comply with these laws and related guidance, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. For example, we maintain a patient assistance program to help eligible patients afford our products. These types of programs have become the subject of governmental scrutiny, and numerous organizations, including pharmaceutical manufacturers, have been subject to litigation, enforcement actions and settlements related to their patient assistance programs. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any sales of our product once commercialized outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could face liability if a regulatory authority determines that we are promoting INGREZZA, ONGENTYS or any of our product candidates that receives regulatory approval, for &#8220;off-label&#8221; uses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company may not promote &#8220;off-label&#8221; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#8217;s FDA-approved label in the United States or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their salesforce with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. A company that is found to have promoted off-label use of its product may be subject to significant liability, including civil and criminal sanctions. We intend to comply with the requirements and restrictions of the FDA and other regulatory agencies with respect to our promotion of our products, including INGREZZA and ONGENTYS, but we cannot be sure that the FDA or other regulatory agencies will agree that we have not violated their restrictions. As a result, we may be subject to criminal and civil liability. In addition, our management&#8217;s attention could be diverted to handle any such alleged violations. If the FDA or any other governmental agency initiates an enforcement action against us, or if we are the subject of a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suit brought by a private plaintiff on behalf of the government, and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*If our information technology systems or data is or were compromised, we could experience adverse impacts resulting from such compromise, including, but not limited to, interruptions to our operations such as our clinical trials, claims that we breached our data protection obligations, harm to our reputation, and a loss of customers or sales.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, use, safeguard, share, transfer and otherwise process confidential and sensitive electronic information on our networks and in our data centers. This information includes, among other things, our intellectual property and proprietary information, the confidential information of our collaborators and licensees, and the personal data of our employees. It is important to our operations and business strategy that this electronic information remains secure and is perceived to be secure. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, and the volume of data we retain, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches, ransomware attacks, social engineering attacks, supply-chain attacks, and other cyber-attacks. Ransomware attacks are becoming increasingly prevalent and severe. To alleviate the financial, operational and reputational impact of a ransomware attack, it may be preferable to make extortion payments, but we may be unwilling or unable to do so (including, for example, if applicable laws or regulations prohibit such payments). Similarly, supply chain attacks have increased in frequency and severity, and we cannot guarantee that third parties in our supply chain have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems and infrastructure or the information technology systems and infrastructure of third parties that support our operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if the COVID-19 pandemic requires us to reinstate a remote workforce model, our information technology systems and data will be at increased risk as more of our employees work from home, utilizing network connections outside our premises.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, natural disasters, public health pandemics or epidemics (including, for example, the COVID-19 pandemic), terrorism, war and geopolitical conflicts (including, for example, the conflict between Russia and Ukraine) and telecommunication and electrical failures may result in damage to or the interruption or impairment of key business processes, or the loss or corruption of confidential information, including intellectual property, proprietary business information and personal data. Information security risks have significantly increased in recent years in part due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign private parties and state actors.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities. Our efforts to identify and remediate such vulnerabilities may not be successful and we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Further, we may be unable to detect such vulnerabilities in the future because such threats and techniques change frequently, are often sophisticated in nature and may not be detected until after a security breach has occurred.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although to our knowledge we have not experienced any material incident or disruption to date, we and our vendors have been the target of cybersecurity incidents of this nature and expect them to continue. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we (or a third party upon whom we rely) experience a security breach or are perceived to have experienced a security breach, we may experience adverse consequences. Such consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Similarly, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position would be harmed.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to any patent protection, we rely on forms of regulatory exclusivity to protect our products such as orphan drug designation. A product candidate that receives orphan drug designation can benefit from a streamlined regulatory process as well as potential commercial benefits following approval. Currently, this designation provides market exclusivity in the United States for seven years and the European Union for 10 years if a product is the first such product approved for such orphan indication. This market exclusivity does not, however, pertain to indications other than those for which the drug was specifically designated in the approval, nor does it prevent other types of drugs from receiving orphan designations or approvals in these same indications. Further, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the new drug is clinically superior to the orphan product or a market shortage occurs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, orphan exclusivity may be reduced to 6 years if the drug no longer satisfies the original designation criteria or can be lost altogether if the marketing authorization holder consents to a second orphan drug application or cannot supply enough drug, or when a second applicant demonstrates its drug is &#8220;clinically superior&#8221; to the original orphan drug. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not have adequate patent protection for our products, then the relative importance of obtaining regulatory exclusivity is even greater. We may not be successful obtaining orphan drug designations for any indications and, even if we succeed, such product candidates with such orphan drug designations may fail to achieve FDA approval. Even if a product candidate with orphan drug designation may receive marketing approval from the FDA, it may fail to result in or maintain orphan drug exclusivity upon approval, which would harm our competitive position.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The technologies we use in our research as well as the drug targets we select may infringe the patents or violate the proprietary rights of third&#160;parties.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that third parties will not assert patent or other intellectual property infringement claims against us or our collaborators with respect to technologies used in potential products. If a patent infringement suit were brought against us or our collaborators, we or our collaborators could be forced to stop or delay developing, manufacturing or selling potential products that are claimed to infringe a third party&#8217;s intellectual property unless that party grants us or our collaborators rights to use its intellectual property. In such cases, we could be required to obtain licenses to patents or proprietary rights of others in order to continue to commercialize our products. However, we may not be able to obtain any licenses required under any patents or proprietary rights of third parties on acceptable terms, or at all. Even if our collaborators or we were able to obtain rights to the third party&#8217;s intellectual property, these rights may be non-exclusive, thereby giving our competitors access to the same intellectual property. Ultimately, we may be unable to commercialize some of our potential products or may have to cease some of our business operations as a result of patent infringement claims, which could severely harm our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations may subject us to disputes, claims and lawsuits, which may be costly and time-consuming and could materially and adversely impact our financial position and results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in disputes, claims and lawsuits relating to our business operations. In particular, we may face claims related to the safety of our products, intellectual property matters, employment matters, tax matters, commercial disputes, competition, sales and marketing practices, environmental matters, personal injury, insurance coverage and acquisition or divestiture-related matters. Any dispute, claim or lawsuit may divert management&#8217;s attention away from our business, we may incur significant expenses in addressing or defending any dispute, claim or lawsuit, and we may be required to pay damage awards or settlements or become subject to equitable remedies that could adversely affect our operations and financial results. For example, we are currently engaged in various intellectual property litigation matters against potential competitors related to INGREZZA. Refer to Item 1. Legal Proceedings f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or a more detailed description of these matters.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation related to these disputes may be costly and time-consuming and could materially and adversely impact our financial position and results of operations if resolved against us. In addition, the uncertainty associated with litigation could lead to increased volatility in our stock price.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees and independent contractors, such as principal investigators, consultants, commercial partners and vendors, or by employees of our commercial partners could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws, to report financial information or data accurately, to maintain the confidentiality of our trade secrets or the trade secrets of our commercial partners, or to disclose unauthorized activities to us. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. Employee and independent contractor misconduct could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any action against our employees, independent contractors, principal investigators, consultants, commercial partners or vendors for violations of these laws could result in significant civil, criminal and administrative penalties, fines and imprisonment.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our insurance coverage.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of any of our potential products in clinical trials, and the sale of any approved products, including INGREZZA and ONGENTYS, may expose us to liability claims. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling our products. We have product liability insurance coverage for our clinical trials in the amount of $45.0 million per occurrence and $45.0 million in the aggregate. In addition, we have product liability insurance related to the sale of INGREZZA and ONGENTYS in the amount of $45.0 million per occurrence and $45.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability from any current or future clinical trials or approved products. A successful product liability claim, or series of claims, brought against us would decrease our cash reserves and could cause our stock price to fall. Furthermore, regardless of the eventual outcome of a product liability claim, any product liability claim against us may decrease demand for our approved products, including INGREZZA and ONGENTYS, damage our reputation, result in regulatory investigations that could require costly recalls or product modifications, cause clinical trial participants to withdrawal, result in costs to defend the related litigation, decrease our revenue, and divert management&#8217;s attention from managing our business.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our activities involve hazardous materials, and we may be liable for any resulting contamination or injuries.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research activities involve the controlled use of hazardous materials. We cannot eliminate the risk of accidental contamination or injury from these materials. If an accident occurs, a court may hold us liable for any resulting damages, which may harm our results of operations and cause us to use a substantial portion of our cash reserves, which would force us to seek additional financing.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We are subject to stringent and changing obligations related to data privacy and information security. Our actual or perceived failure to comply with such obligations could have a material adverse effect on our reputation, business, financial condition or results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we process confidential and sensitive information, including personal data, proprietary and confidential business data, trade secrets, intellectual property, data we collect about clinical trial participants in connection with clinical trials, and sensitive third-party data, on our networks and in our data centers. We are subject to numerous federal, state, local and foreign laws, orders, codes, regulations and regulatory guidance regarding privacy, data protection, information security and the processing of personal information, the number and scope of which are expanding, changing, subject to differing applications and interpretations, and may be inconsistent among countries. Our data processing activities may also subject us to other data privacy and security obligations, such as industry standards, external and internal privacy and security policies, contracts and other obligations that govern the processing of data by us and by third parties on our behalf.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws in Europe regarding privacy, data protection, information security and the processing of personal data have been significantly reformed and continue to undergo reform. For example, the European Union&#8217;s General Data Protection Regulation, or the EU GDPR, and the United Kingdom&#8217;s GDPR, or the UK GDPR, impose strict requirements for processing the personal data of individuals located, respectively, within the European Economic Area, or EEA, and the United Kingdom, or the UK. The EU GDPR and the UK GDPR enhance data protection obligations for processors and controllers of personal data, including, for example, obligations relating to: processing health and other sensitive data; obtaining consent of individuals; providing notice to individuals regarding data processing activities; responding to data subject requests; taking certain measures when engaging third-party processors; notifying data subjects and regulators of data breaches; and implementing safeguards to protect the security and confidentiality of personal data. The EU GDPR and the UK GDPR impose substantial fines for breaches of data protection requirements. For example, under the EU GDPR, such fines can be up to four percent of global revenue or 20 million euros, whichever is greater, and also confer a private right of action on data subjects for breaches of data protection requirements. The EU GDPR, the UK GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as EU regulations governing clinical trial data and other healthcare data, could require us to change our business practices or lead to government enforcement actions, private litigation or significant penalties against us and could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain jurisdictions have enacted data localization laws and cross-border personal data transfers laws. For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the EEA, such as the United States, which the European Commission does not consider to provide an adequate level of personal data protection. If we cannot implement a valid compliance mechanism for cross-border personal data transfers, we may face increased exposure to regulatory actions, substantial fines and injunctions against processing or transferring personal data from Europe or elsewhere. The inability to import personal data to the United States may significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere; limiting our ability to collaborate with parties subject to European and other data protection laws or requiring us to increase our personal data processing capabilities in Europe and/or elsewhere at significant expense.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws regarding privacy, data protection, information security and the processing of personal data are also becoming increasingly common in the United States at both the federal and state level. For example, the California Consumer Privacy Act, or CCPA, which went into effect in 2020, imposes obligations on businesses to which it applies. These obligations include, without limitation, providing specific disclosures in privacy notices, affording California residents certain rights related to their personal data, and requiring businesses subject to the CCPA to implement certain measures to effectuate California residents&#8217; personal data rights. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). In addition, it is anticipated that the California Privacy Rights Act of 2020, or the CPRA, effective January 1, 2023, will expand the CCPA. For example, the CPRA establishes a new California Privacy Protection Agency to implement and enforce the CCPA (as amended), which could increase the risk of an enforcement action. Other states have also enacted data privacy laws. For example, Virginia passed its Consumer Data Protection Act, Colorado passed the Colorado Privacy Act, and Utah passed the Utah Consumer Privacy Act, all of which become effective in 2023.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion. These obligations may be subject to differing applications and interpretations, which may be inconsistent among jurisdictions or in conflict. Preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources). These obligations may necessitate changes to our information technologies, systems and practices and those of any third parties that process personal data on our behalf. In addition, these obligations may even require us to change to our business model.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third-parties upon whom we rely may fail to comply such obligations that impacts our compliance posture. If we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions, litigation, additional reporting requirements and/or oversight, bans on processing personal data and orders to destroy or not use personal data. Any of these events could have a material adverse effect on our reputation, business, financial condition or results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following exhibits are filed as part of, or incorporated by reference into, this report:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459018026844/nbix-ex31_91.htm">Certificate of Incorporation, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 5, 2018</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447521000036/nbix-20210331exhibit3_2.htm">Bylaws, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.2 of the Company's Quarterly Report on Form 10-Q filed on May 5, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/0000898430-96-002108.txt">Form of Common Stock Certificate</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-03172)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex41.htm">Indenture, dated as of May&#160;2, 2017, by and between the Company and U.S. Bank National Association, as Trustee</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447522000013/nbix-20211231exhibit43.htm">First Supplemental Indenture, dated as of December 22, 2021, by and between the Company and U.S. Bank National Association, as Trustee</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Incorporated by reference to Exhibit 4.3 of the Company&#8217;s Annual Report on Form 10-K filed on February 11, 2022</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex991.htm">Form of Note representing the Company&#8217;s 2.25% Convertible Notes due 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q2-2022xexhibit101.htm">Employment Agreement dated November 29, 2021 between the Company and Jude Onyia</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="q2-2022xexhibit102.htm">Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="q2-2022xexhibit102.htm"> and restated</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="q2-2022xexhibit103.htm">Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan, as amended</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="q2-2022xexhibit103.htm"> and restated</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q2-2022xexhibit311.htm">Certification of Chief Executive Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q2-2022xexhibit312.htm">Certification of Chief Financial Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q2-2022xexhibit32.htm">Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document. &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">+ Management contract or compensatory plan or arrangement.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Neurocrine Biosciences, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except as specifically noted above, the Company&#8217;s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K have a Commission File Number of 000-22705. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="ia5b26032409f4bcfa80efa90e636a8b2_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: August&#160;4, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br/>(Duly authorized officer and Principal Financial Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>q2-2022xexhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i283f1fe7d6e14423974bf70622a40d45_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THIS EMPLOYMENT AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (hereinafter &#8220;Agreement&#8221;) is entered into effective November 29, 2021 by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Neurocrine Biosciences, Inc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., 12780 El Camino Real, San Diego, California 92130 (hereinafter the &#8220;Company&#8221;), and Jude Onyia, Ph.D. (hereinafter &#8220;Executive&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">R  E  C  I  T  A  L  S</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company and Executive wish to set forth in this Agreement the terms and conditions under which Executive is to be employed by the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company and Executive, in consideration of the mutual promises set forth herein, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.73pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">NATURE OF EMPLOYMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Executive&#8217;s full-time employment with the Company will commence on November 29, 2021 (&#8220;Commencement Date&#8221;).  This Agreement shall govern the terms of Executive&#8217;s employment on and after the Commencement Date until it is terminated by either the Company or Executive pursuant to the terms set forth in Article 6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Executive shall be employed at-will by the Company and therefore either Executive or the Company may terminate the employment relationship and this Agreement at any time, with or without Cause (as defined herein) and with or without advance notice, subject to the provisions of Article 6.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.73pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EMPLOYMENT DUTIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Title&#47;Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Executive hereby accepts employment with the Company pursuant to the terms and conditions hereof.  Executive agrees to serve the Company in the position of Chief Scientific Officer.  Executive shall have the powers and duties commensurate with such position, including but not limited to hiring personnel necessary to carry out the responsibilities for such position as set forth in the annual business plan approved by the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Full Time Attention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except upon the prior written consent of the CEO, Executive shall devote his best efforts and his full business time and attention to the performance of the services customarily incident to such office and to such other services as the Chief Executive Officer (hereinafter &#8220;CEO&#8221;) or Board of Directors may reasonably request. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Other Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except upon the prior written consent of the CEO, Executive shall not during the period of employment engage, directly or indirectly, in any other business activity (whether or not pursued for pecuniary advantage) that is or may be competitive with, or that might place him in a competing position to that of the Company or any other corporation or entity that directly or indirectly controls, is controlled by, or is under common control with the Company (an &#8220;Affiliated Company&#8221;), provided that Executive may own less than two percent (2%) of the outstanding securities of any such publicly traded competing corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.73pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">COMPENSATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Executive shall receive a Base Salary at an annual rate of $575,000, payable semi-monthly in equal installments in accordance with the Company&#8217;s normal payroll practices. The CEO shall provide Executive with annual performance reviews, and, thereafter, Executive shall be entitled to such increase in Base Salary as the CEO and the Compensation Committee of the Board of Directors (hereinafter the &#8220;Compensation Committee&#8221;) may from time to time establish in their sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Incentive Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In addition to any other bonus Executive shall be awarded by the Compensation Committee, Executive shall be eligible to receive an annual incentive bonus as determined by the Company&#8217;s Compensation Committee and CEO based upon the achievement by the Company of annual corporate goals established by the Board of Directors and the achievement of Executive in meeting annual personal goals established by the CEO and the Compensation Committee.   Executive&#8217;s annual incentive bonus at target will be as set forth in the Company&#8217;s Executive Officer Bonus Plan (the &#8220;Target Annual Bonus&#8221;)&#59; for fiscal year 2021, this target is set at 50% of base pay earned.  The Company&#8217;s annual corporate goals, and if applicable, the Executive&#8217;s annual personal goals, will be set forth in writing by the CEO and the Compensation Committee within ninety (90) days after the start of the Company&#8217;s fiscal year. The Compensation Committee in consultation the CEO shall, in their sole discretion, determine whether Executive&#8217;s annual personal goals have been attained.  The Compensation Committee in consultation with the independent members of the Board of Directors shall, in its sole discretion, determine whether the annual corporate goals have been attained.  Any annual incentive bonus shall be considered earned only if Executive is employed by the Company both on the date that the determination is made as to whether annual personal goals have been met, and on the date that the determination is made as to whether annual corporate goals have been met.  These determinations generally will be made within the first quarter following the end of the Company&#8217;s fiscal year.  Except as provided in Article 6 herein, no pro-rata bonus will be considered earned if Executive leaves the Company for any reason prior to the foregoing determination dates.  Any annual incentive bonus that is earned shall be paid no later than the fifteenth day of the third month following the end of the Company&#8217;s fiscal year for which such bonus was earned.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Equity.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">New Hire Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will receive (i) a new hire grant with a Black-Scholes value of $4,500,000 of stock options that would enable Executive to purchase up to shares of common stock of the Company (the &#8220;New Hire Option&#8221;) (ii) a new hire grant of restricted stock units with a value of $1,500,000 (the &#8220;New Hire RSU Grant&#8221;) and (iii) new hire grants of performance restricted stock units with a target value of $1,500,000 (the &#8220;New Hire PRSU Grants&#8221; and, together with the New Hire Option and the New Hire RSU Grant, the &#8220;New Hire Equity Grants&#8221;).  The grant of the New Hire Equity Grants is subject to Executive&#8217;s timely execution of this Agreement and Executive&#8217;s actual commencement of employment with the Company. The New Hire Equity Grants will (i) automatically be granted to Executive on the Commencement Date (the &#8220;Grant Date&#8221;), (ii) the New Hire Option will have an exercise price per share equal to the closing price per share of the Company&#8217;s common stock on the Grant Date, (iii) be subject to terms and conditions consistent with the Company&#8217;s 2020 Equity Incentive Plan and applicable form of stock option agreement, restricted stock agreement, or performance restricted stock agreement, respectively, as previously approved by the Compensation Committee,  (iv) the New Hire Option shall vest 25% on the first anniversary of the Grant Date, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject in each case to Executive&#8217;s continued service with the Company, (vi) the New Hire RSU </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant will vest 25% each year on the anniversary of the Grant Date, vesting in full on the fourth anniversary of the Grant Date, subject to Executive&#8217;s continued service with the Company, and (vii) the New Hire PRSU Grants will vest as follows&#58; (a) a grant having a target value of $500,000 will vest in accordance with the metrics set forth in 2020 PRSU grants made to the Company&#8217;s executive officers, and (b) a grant having a target value of $1,000,000 will vest in accordance with the metrics set forth in 2021 PRSU grants made to the Company&#8217;s executive officer.  As soon as administratively practicable following the Grant Date, Executive will separately receive a stock option agreement, a restricted stock unit agreement, and two performance restricted stock unit agreements, along with associated documentation related to the New Hire Equity Grants, including the applicable exercise price of the New Hire Option.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">Additional Stock Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to approval by the Company&#8217;s Compensation Committee, Executive will be eligible to receive additional Stock Awards on terms to be determined by the Compensation Committee at the time of any such grant.  The determination whether to grant any additional Stock Award to Executive is in the sole discretion of the Compensation Committee, in consultation with the independent members of the Board of Directors.  For all purposes of this Agreement, &#8220;Stock Awards&#8221; shall mean any rights granted by the Company to Executive with respect to the common stock of the Company, including, without limitation, stock options, stock appreciation rights, restricted stock, stock bonuses and restricted stock units.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Inducement Advance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Executive shall receive a one-time cash inducement advance (the &#8220;Inducement Advance&#8221;) in the total amount of $175,000.00, subject to applicable withholding, which shall be deemed earned when Executive successfully completes two full years of employment from the Commencement Date. The Inducement Advance shall be paid on the second payroll date following the Commencement Date.  Should Executive&#8217;s employment terminate within 24 months after the Commencement Date either pursuant to a Voluntary Resignation (as set forth in Section 6.7 herein) or pursuant to a Termination by the Company With Cause (as set forth in Section 6.4 herein), Executive shall be required to repay to the Company any amounts previously paid to him for the Inducement Advance, and hereby authorizes the Company to withhold any such amount from Executive&#8217;s final paycheck or other earned compensation.  Should Executive&#8217;s employment terminate at any time pursuant to Sections 6.2, 6.3, 6.5, and 6.6 as set forth herein, Executive shall not be required to repay any portion of the Inducement Advance previously paid to him.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  All compensation and benefits payable to Executive under this Agreement shall be subject to all federal, state, local taxes and other withholdings and similar taxes and payments required by applicable law.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.73pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXPENSE ALLOWANCES AND FRINGE BENEFITS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Vacation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Executive shall be entitled to participate in the Company&#8217;s vacation plan pursuant to the terms of that plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  During Executive&#8217;s employment hereunder, the Company shall also provide Executive with the health insurance benefits it generally provides to its other senior management employees.  As Executive becomes eligible in accordance with criteria to be adopted by the Company, the Company shall provide Executive with the right to participate in and to receive benefit from life, accident, disability, medical, and savings plans and similar benefits made available generally to employees of the Company as such plans and benefits may be adopted by the Company.  With respect to long-term disability insurance coverage, the Executive will pay all premiums for such coverage with after-tax dollars, and the Company will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reimburse the Executive for the premium costs so paid by the Executive, which reimbursement benefit shall be taxable income, subject to withholding.  The amount and extent of benefits to which Executive is entitled shall be governed by the specific benefit plan as it may be amended from time to time.  With respect to personal financial and tax planning expenses incurred by Executive (the &#8220;Financial Planning Expenses&#8221;), the Company will reimburse the Executive for Financial Planning Expenses incurred by the Executive during the 2021 calendar year and each calendar year thereafter, up to a maximum reimbursement benefit of $3,000 each calendar year, which reimbursement benefit shall be taxable income, subject to withholding.  Such Financial Planning Expenses shall be reimbursed and accounted for under the expense reimbursement policies and procedures established by the Company (the &#8220;Expense Reimbursement Policy&#8221;), subject to Executive&#8217;s timely provision of adequate records and other documentary evidence of having incurred such Financial Planning Expenses in accordance with the terms of the Expense Reimbursement Policy&#59; such reimbursement shall be made promptly, but in no event later than December 31 of the calendar year following the year in which such Financial Planning Expenses were incurred by Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Business Expense Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  During the term of this Agreement, Executive shall be entitled to receive proper reimbursement for all reasonable out-of-pocket expenses incurred by him (in accordance with the Expense Reimbursement Policy) in performing services hereunder.  Executive agrees to furnish to the Company adequate records and other documentary evidence of such expense for which Executive seeks reimbursement under the terms of the Expense Reimbursement Policy.  Such expenses shall be reimbursed and accounted for under the Expense Reimbursement Policy, and such reimbursement shall be made promptly, but in no event later than December 31 of the calendar year following the year in which such expenses were incurred by Executive.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.73pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Proprietary Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Executive represents and warrants that he has previously executed and delivered to the Company the Company&#8217;s standard Proprietary Information and Inventions Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Return of Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  All documents, records, apparatus, equipment and other physical property which is furnished to or obtained by Executive in the course of his employment with the Company shall be and remain the sole property of the Company.  Executive agrees that, upon the termination of his employment, he shall return all such property (whether or not it pertains to Proprietary Information as defined in the Proprietary Information and Inventions Agreement), and agrees not to make or retain copies, reproductions or summaries of any such property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">No Use of Prior Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Executive will not intentionally disclose to the Company or use on its behalf any confidential information belonging to any of his former employers or any other third party.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.73pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As set forth in Section 1.2 herein, Executive shall be employed on an at-will basis by the Company.  Notwithstanding the foregoing, Executive&#8217;s employment and this Agreement may be terminated in one of six ways as set forth in this Article 6&#58; (a) Executive&#8217;s Death (Section 6.2)&#59; (b) Executive&#8217;s Disability (Section 6.3)&#59; (c) Termination by the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for Cause (Section 6.4)&#59; (d) Termination by the Company without Cause (Section 6.5)&#59; (e) Termination by Executive due to a Constructive Termination (Section 6.6)&#59; or (f) Voluntary Resignation (Section 6.7).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">By Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive&#8217;s employment and this Agreement shall terminate automatically upon the death of Executive.  In such event&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Stock Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The vesting of all outstanding Stock Awards held by Executive shall be accelerated so that the amount of shares vested under such Stock Awards shall equal that number of shares that would have been vested if Executive had continued to render services to the Company for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> continuous months after the date of Executive&#8217;s termination of employment.  All Stock Awards held by Executive that are vested at the time of termination (including any accelerated Stock Awards) will be exercisable in accordance with their terms until the earlier of (x) one year after the termination date, or (y) the expiration of the maximum term of the option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company shall pay to Executive&#8217;s beneficiaries or his estate, as the case may be, a lump sum amount equal to Executive&#8217;s Target Annual Bonus (as defined in Section 3.2) for the Company&#8217;s fiscal year in which Executive&#8217;s death occurs multiplied by a fraction, the numerator of which is the number of full months of employment by Executive in such fiscal year and the denominator of which is 12.  Such amount shall be paid as soon as administratively practicable, but in no event later than March 15 following the year in which Executive&#8217;s death occurred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt;text-decoration:underline">Accrued Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company shall pay to Executive&#8217;s beneficiaries or his estate, as the case may be, any accrued Base Salary, any vested deferred compensation (other than pension plan or profit-sharing plan benefits that will be paid in accordance with the applicable plan), any benefits under any plans of the Company (other than pension and profit-sharing plans) in which Executive is a participant to the full extent of Executive&#8217;s rights under such plans, any accrued vacation pay and any appropriate business expenses incurred by Executive in connection with his duties hereunder, all to the date of termination (collectively &#8220;Accrued Compensation&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">No Severance Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The compensation and benefits set forth in Sections 6.2(a) through (c) herein shall be the only compensation and benefits provided by the Company in the event of Executive&#8217;s death and no other severance compensation or benefits shall be provided.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">By Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If Executive is prevented from performing his duties hereunder by reason of any physical or mental incapacity that results in Executive&#8217;s satisfaction of all requirements necessary to receive benefits under the Company&#8217;s long-term disability plan due to a total disability, then, to the extent permitted by law, the Company may terminate the employment of Executive and this Agreement at or after such time.  In such event, and if Executive signs the General Release set forth as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or such other form of release as the Company may require (the &#8220;Release&#8221;) on or within the time period set forth therein, but in no event later than forty-five (45) days after the termination date and allows such Release to become effective (the &#8220;Release Effective Date&#8221;), then&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt;text-decoration:underline">Accrued Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company shall pay to Executive all Accrued Compensation (as defined in Section 6.2(c) herein).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt;text-decoration:underline">Base Salary Continuation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall continue to pay Executive&#8217;s Base Salary, less required withholdings, for a period of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> months (the &#8220;Disability Base Salary Payments&#8221;) following Executive&#8217;s separation from service&#59; provided that the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Disability Base Salary Payments shall be reduced by any insurance or other payments to Executive under policies and plans sponsored by the Company, even if premiums are paid by Executive.  Subject to the provisions of Section 6.11, the Disability Base Salary Payments shall be paid in accordance with the Company&#8217;s standard payroll practices&#59; provided, however, that any amounts that would otherwise be scheduled to be paid prior to the Release Effective Date shall instead accrue and be paid during the first payroll period following the Release Effective Date, and all other payments shall be made as originally scheduled. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company shall pay a lump sum amount equal to Executive&#8217;s Target Annual Bonus (as defined in Section 3.2) for the Company&#8217;s then-current fiscal year multiplied by a fraction, the numerator of which is the number of full months of employment by Executive in the current fiscal year and the denominator of which is 12.  Such payment shall be made within ten (10) days following the Release Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">Stock Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The vesting of all outstanding Stock Awards held by Executive shall be accelerated so that the amount of shares vested under such Stock Awards shall equal that number of shares which would have been vested if Executive had continued to render services to the Company for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> continuous months after the date of Executive&#8217;s termination of employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt;text-decoration:underline">Health Insurance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company&#8217;s current group health insurance policies, Executive will be eligible to continue Executive&#8217;s group health insurance benefits at Executive&#8217;s own expense.  If Executive timely elects continued coverage under COBRA, the Company shall pay Executive&#8217;s COBRA premiums, and any applicable Company COBRA premiums, necessary to continue Executive&#8217;s then-current coverage for a period of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> months after the date of Executive&#8217;s termination of employment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that any such payments will cease if Executive voluntarily enrolls in a health insurance plan offered by another employer or entity during the period in which the Company is paying such premiums.  Executive agrees to immediately notify the Company in writing of any such enrollment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot provide the foregoing benefit without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof provide to Executive a taxable monthly amount to continue his group health insurance coverage in effect on the date of separation from service (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made regardless of whether Executive elects COBRA continuation coverage and shall commence in the month following the month in which Executive incurs a separation from service and shall end on the earlier of (x) the date on which Executive voluntarily enrolls in a health insurance plan offered by another employer or entity during the period in which the Company is paying such amounts and (y) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> months after the date of Executive&#8217;s separation from service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt;text-decoration:underline">Disability Plans.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothing in this Section 6.3 shall affect Executive&#8217;s rights under any disability plan in which Executive is a participant. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Termination by the Company for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">No Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company may terminate Executive&#8217;s employment and this Agreement for Cause (as defined below) without liability at any time.  In such event, the Company shall pay Executive all Accrued Compensation (as defined in Section 6.2(c) herein), but no other compensation or reimbursement of any kind, including without limitation, any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">severance compensation or benefits shall be paid, and thereafter the Company&#8217;s obligations hereunder shall terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt;text-decoration:underline">Definition of &#8220;Cause.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  For purposes of this Agreement, &#8220;Cause&#8221; shall mean one or more of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Executive&#8217;s intentional commission of an act, or intentional failure to act, that materially injures the business of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that in no event shall any business judgment made in good faith by Executive and within Executive&#8217;s defined scope of authority constitute a basis for termination for Cause under this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Executive&#8217;s intentional refusal or intentional failure to act in accordance with any lawful and proper direction or order of the Board of Directors, the Chief Executive Officer, or the individual to whom Executive reports&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Executive&#8217;s material breach of Executive&#8217;s fiduciary, statutory, contractual, or common law duties to the Company (including any material breach of this Agreement, the Proprietary Information and Inventions Agreement, or the Company&#8217;s written policies)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Executive&#8217;s indictment for or conviction of any felony or any crime involving dishonesty&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Executive&#8217;s participation in any fraud or other act of willful misconduct against the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that in the event that any of the foregoing events is reasonably capable of being cured, the Company shall provide written notice to Executive describing the nature of such event and Executive shall thereafter have ten (10) business days to cure such event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Termination by the Company without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.03pt;text-decoration:underline">The Company&#8217;s Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company may terminate Executive&#8217;s employment and this Agreement without Cause (as defined in Section 6.4(b) herein) at any time by giving thirty (30) days advance written notice to Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   If the Company terminates Executive&#8217;s employment without Cause, and if Executive signs the Release on or within the time period set forth therein (but in no event later than forty-five (45) days after the termination date) and allows such Release to become effective (the &#8220;Release Effective Date&#8221;), then&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.69pt;text-decoration:underline">Accrued Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company shall pay to Executive all Accrued Compensation (as defined in Section 6.2(c) herein).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15.36pt;text-decoration:underline">Cash Compensation Amount Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall pay Executive an amount calculated as follows&#58; &#91;Executive&#8217;s annualized Base Salary + Executive&#8217;s Target Annual Bonus (as defined in Section 3.2 herein)&#93; multiplied by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.0</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;Cash Compensation Amount&#8221;).  Subject to the provisions of Section 6.11, the Cash Compensation Amount will be paid in equal installments on the Company&#8217;s standard payroll dates over a period of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> months following Executive&#8217;s separation from service&#59; provided, however, that any amounts that would otherwise be scheduled to be paid prior to the Release Effective Date shall instead accrue and be paid during the first payroll period following the Release Effective Date, and all other payments shall be made as originally scheduled.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12.03pt;text-decoration:underline">Stock Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The vesting of all outstanding Stock Awards held by Executive shall be accelerated so that the amount of shares vested under such Stock Awards shall equal that number of shares which would have been vested if Executive had continued to render services to the Company for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> continuous months after the date of Executive&#8217;s termination of employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.69pt;text-decoration:underline">Health Insurance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company&#8217;s current group health insurance policies, Executive will be eligible to continue Executive&#8217;s group health insurance benefits at Executive&#8217;s own expense.  If Executive timely elects continued coverage under COBRA, the Company shall pay Executive&#8217;s COBRA premiums, and any applicable Company COBRA premiums, necessary to continue Executive&#8217;s then-current coverage for a period of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> months after the date of Executive&#8217;s termination of employment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that any such payments will cease if Executive voluntarily enrolls in a health insurance plan offered by another employer or entity during the period in which the Company is paying such premiums.  Executive agrees to immediately notify the Company in writing of any such enrollment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot provide the foregoing benefit without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof provide to Executive a taxable monthly amount to continue his group health insurance coverage in effect on the date of separation from service (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made regardless of whether Executive elects COBRA continuation coverage and shall commence in the month following the month in which Executive incurs a separation from service and shall end on the earlier of (x) the date on which Executive voluntarily enrolls in a health insurance plan offered by another employer or entity during the period in which the Company is paying such amounts and (y) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> months after the date of Executive&#8217;s separation from service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Termination by Executive due to a Constructive Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Executive&#8217;s Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive may resign his employment and terminate this Agreement at any time as a result of a Constructive Termination (as defined in Section 6.6(c) herein).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If Executive resigns his employment and terminates this Agreement as a result of a Constructive Termination, and if Executive signs the Release on or within the time period set forth therein (but in no event later than forty-five (45) days after the termination date) and allows such Release to become effective, then Executive shall receive all of the severance benefits set forth in Section 6.5(b) herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">Definition of &#8220;Constructive Termination.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> For purposes of this Agreement, &#8220;Constructive Termination&#8221; shall mean a resignation of employment and termination of this Agreement by Executive for one or more of the following reasons&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Assignment to, or withdrawal from, Executive of any duties or responsibilities that results in a material diminution in such Executive&#8217;s authority, duties or responsibilities as in effect immediately prior to such change&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">A material diminution in the position, authority, duties or responsibilities of the supervisor to whom Executive is required to report, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">A material reduction by the Company of Executive&#8217;s annual Base Salary&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">A relocation of Executive or the Company&#8217;s principal executive offices if Executive&#8217;s principal office is at such offices, to a location more than forty (40) miles from the location at which Executive is then performing his duties, except for an opportunity to relocate which is accepted by Executive in writing&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xiv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.69pt">A material breach by the Company of any provision of this Agreement or any other enforceable written agreement between Executive and the Company&#59; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Executive must first provide the Company with written notice specifying the condition giving rise to a Constructive Termination within ninety (90) days following the initial existence of such condition&#59; and Executive&#8217;s notice must specify that Executive intends to terminate his employment no earlier than thirty (30) days after providing such notice, and the Company must be given an opportunity to cure such condition within thirty (30) days following its receipt of such notice and avoid paying benefits.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Voluntary Resignation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Executive may resign his or her employment and terminate this Agreement at any time for any reason other than due to a Constructive Termination (as defined in Section 6.6(c) herein).  In such event, the Company shall pay Executive all Accrued Compensation (as defined in Section 6.2(c) herein), but no other compensation or reimbursement of any kind, including without limitation, any severance compensation or benefits shall be paid, and thereafter the Company&#8217;s obligations hereunder shall terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Change In Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If (i) within six months after the consummation of a Change in Control (as defined in Section 6.8(b) herein), (1) the Company terminates Executive&#8217;s employment and this Agreement without Cause pursuant to Section 6.5 herein or (2) Executive resigns his employment and terminates this Agreement as a result of a Constructive Termination pursuant to Section 6.6 herein, and (ii) in either event (1) or (2), Executive signs the Release on or within the time period set forth therein, but in no event later than forty-five (45) days after the termination date and allows such Release to become effective (the &#8220;Release Effective Date&#8221;), then Executive shall receive the following severance benefits in lieu of any severance benefits set forth in Section 6.5(b) or Section 6.6(b) herein&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.02pt;text-decoration:underline">Accrued Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company shall pay to Executive all Accrued Compensation (as defined in Section 6.2(c) herein).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xvi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:12.69pt;text-decoration:underline">CIC Cash Compensation Amount Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall pay Executive an amount calculated as follows&#58; &#91;Executive&#8217;s annual Base Salary + Executive&#8217;s Target Annual Bonus (as defined in Section 3.2 herein)&#93; multiplied by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (collectively, the &#8220;CIC Cash Compensation Amount&#8221;).  The CIC Cash Compensation Amount will be paid in one lump sum within ten (10) days following the Release Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xvii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9.36pt;text-decoration:underline">Cash Payment for Stock Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Within ten (10) days following the Release Effective Date, the Company shall pay Executive a cash amount equal to the value, as of the date of the consummation of the Change in Control, of (1) all Stock Awards that are unvested at the time of termination of employment, and (2) all Stock Awards that are vested at the time of termination of employment and for which the shares subject to such Stock Awards have not yet been issued, including, without limitation, any unexercised stock options, unexercised stock appreciation rights, and unissued shares subject to a restricted stock unit </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">award, provided, in either case, that such Stock Awards were held by Executive as of the date of consummation of the Change in Control, and all rights of Executive in such Stock Awards and any unvested shares of stock that previously may have been issued thereunder shall be extinguished as a result of such payment, with the result that such Stock Awards shall automatically terminate unexercised and unvested shares of stock previously issued shall automatically be reacquired by the Company or its successor.  For purposes of the foregoing cash payment, (1) stock options and stock appreciation rights shall be valued on the basis of the difference between the value of the subject stock for purposes of the transaction constituting the Change of Control and the exercise or base price of the award, and (2) restricted stock, restricted stock units or other full value awards and shares of stock acquired under Stock Awards shall be valued on the basis of the value of the subject stock for purposes of the transaction constituting the Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xviii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:6.03pt;text-decoration:underline">Health Insurance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company&#8217;s current group health insurance policies, Executive will be eligible to continue Executive&#8217;s group health insurance benefits at Executive&#8217;s own expense.  If Executive timely elects continued coverage under COBRA, the Company shall pay Executive&#8217;s COBRA premiums, and any applicable Company COBRA premiums, necessary to continue Executive&#8217;s then-current coverage for a period of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> months after the date of Executive&#8217;s termination of employment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that any such payments will cease if Executive voluntarily enrolls in a health insurance plan offered by another employer or entity during the period in which the Company is paying such premiums.  Executive agrees to immediately notify the Company in writing of any such enrollment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot provide the foregoing benefit without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof provide to Executive a taxable monthly amount to continue his group health insurance coverage in effect on the date of separation from service (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made regardless of whether Executive elects COBRA continuation coverage and shall commence in the month following the month in which Executive incurs a separation from service and shall end on the earlier of (x) the date on which Executive voluntarily enrolls in a health insurance plan offered by another employer or entity during the period in which the Company is paying such amounts and (y) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> months after the date of Executive&#8217;s separation from service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.36pt;text-decoration:underline">Definition of &#8220;Change in Control.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  For purposes of this Agreement, a &#8220;Change in Control&#8221; shall have occurred if at any time during Executive&#8217;s employment hereunder, any of the following events shall occur&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The Company is merged, or consolidated. or reorganized into or with another corporation or other legal person, and as a result of such merger, consolidation or reorganization less than 50% of the combined voting power of the then-outstanding securities of such corporation or person immediately after such transaction are held in the aggregate by the holders of voting securities of the Company immediately prior to such transaction&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">The Company sells all or substantially all of its assets or any other corporation or other legal person and thereafter, less than 50% of the combined voting power of the then-outstanding voting securities of the acquiring or consolidated entity are held in the aggregate by the holders of voting securities of the Company immediately prior to such sale&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">There is a report filed after the date of this Agreement on Schedule 13 D or schedule 14 D-1 (or any successor schedule, form or report), each as promulgated </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to the Securities Exchange Act of l934 (the &#8220;Exchange Act&#8221;) disclosing that any person (as the term &#8220;person&#8221; is used in Section 13(d)(3) or Section 14(d)(2) of the Exchange Act) has become the beneficial owner (as the term beneficial owner is defined under Rule 13d-3 or any successor rule or regulation promulgated under the Exchange Act) representing 50% or more of the combined voting power of the then-outstanding voting securities of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">The Company shall file a report or proxy statement with the Securities and Exchange Commission pursuant to the Exchange Act disclosing in response to item 1 of Form 8-X thereunder or Item 5(f) of Schedule 14 A thereunder (or any successor schedule, form or report or item therein) that the change in control of the Company has or may have occurred or will or may occur in the future pursuant to any then-existing contract or transaction&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">During any period of two (2) consecutive years, individuals who at the beginning of any such period constitute the directors of the Company cease for any reason to constitute at least a majority thereof unless the election to the nomination for election by the Company&#8217;s shareholders of each director of the Company first elected during such period was approved by a vote of at least two-thirds of the directors of the Company then still in office who were directors of the Company at the beginning of such period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt;text-decoration:underline">Parachute Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.69pt">If any payment or benefit (including payments or benefits pursuant to this Agreement) that Executive would receive in connection with a Change in Control or otherwise (&#8220;Payment&#8221;) would (1) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and (2) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;Excise Tax&#8221;), then such Payment shall be equal to the Reduced Amount.  The &#34;Reduced Amount&#34; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive's receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#34;parachute payments&#34; is necessary so that the Payment equals the Reduced Amount, Executive shall have no rights to any additional payments and&#47;or benefits, and reduction shall occur in the manner that results in the greatest economic benefit for Executive.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xx)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">In the event it is subsequently determined by the Internal Revenue Service that some portion of the Reduced Amount as determined pursuant to clause (x) in the preceding paragraph is subject to the Excise Tax, Executive agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax.  For the avoidance of doubt, if the Reduced Amount is determined pursuant to clause (y) in the preceding paragraph, Executive will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xxi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.69pt">The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the event described in Section 280G(b)(2)(A)(i) of the Code will perform the foregoing calculations.  If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting such Change in Control or similar transaction, the Company will appoint a nationally recognized independent registered </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">public accounting firm to make the determinations required hereunder.  The Company will bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.  Any good faith determinations of the independent registered public accounting firm made hereunder will be final, binding and conclusive upon the Company and you.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Mitigation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise specifically provided herein, Executive shall not be required to mitigate the amount of any payment provided under this Agreement by seeking other employment or self-employment, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by another employer or through self-employment or by retirement benefits after the date of Executive&#8217;s termination of employment from the Company, except as provided herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Coordination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If upon termination of employment, Executive becomes entitled to rights under other plans, contracts or arrangements entered into by the Company, this Agreement shall be coordinated with such other arrangements so that Executive&#8217;s rights under this Agreement are not reduced, and that any payments under this Agreement offset the same types of payments otherwise provided under such other arrangements, but do not otherwise reduce any payments or benefits under such other arrangements to which Executive becomes entitled.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Application of Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything to the contrary herein, the following provisions apply to the extent severance benefits provided herein are subject to Section 409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (collectively &#8220;Section 409A&#8221;).  Severance benefits shall not commence until Executive has a &#8220;separation from service&#8221; for purposes of Section 409A. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Executive is a &#8220;specified employee&#8221; within the meaning of 409A(a)(2)(B)(i) of the Code, any installment payments of Disability Base Salary Payments pursuant to Section 6.3(b) or Cash Compensation Amounts pursuant to Section 6.5(b) or 6.6(b) that are triggered by a separation from service shall be accelerated to the minimum extent necessary so that (a) the lesser of (y) the total cash severance payment amount, or (z) six (6) months of such installment payments are paid no later than March 15 of the calendar year following such termination, and (b) all amounts paid pursuant to the foregoing clause (a) will constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations and thus will be payable pursuant to the &#8220;short-term deferral&#8221; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations.  It is intended that if Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code at the time of such separation from service the foregoing provision shall result in compliance with the requirements of Section 409A(a)(2)(B)(i) of the Code because payments to Executive will either be payable pursuant to the &#8220;short-term deferral&#8221; rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations or will not be paid until at least 6 months after separation from service.  The severance benefits are intended to qualify for an exemption from application of Section 409A or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.73pt"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">GENERAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The validity, interpretation, construction and performance of this Agreement and the rights of the parties thereunder shall be interpreted and enforced under California law without reference to principles of conflicts of laws.  The parties expressly agree that inasmuch as the Company&#8217;s headquarters and principal place of business are located in California, it is appropriate that California law govern this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Assignment&#59; Successors Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive may not assign, pledge or encumber his interest in this Agreement or any part thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">Assumption by Successo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">r</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and&#47;or assets of the Company, by operation of law or by agreement in form and substance reasonably satisfactory to Executive, to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">This Agreement shall inure to the benefit of and be enforceable by Executive&#8217;s personal or legal representatives, executors, administrators, successors, heirs, distributee, devisees and legatees.  If Executive should die while any amount is at such time payable to Executive hereunder, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to Executive&#8217;s devisee, legates or other designee or, if there be no such designee, to his estate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> For the purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by certified or registered mail, return receipt requested, postage prepaid, addressed to the respective addresses set forth below or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon receipt.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the Company&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Neurocrine Biosciences, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12780 El Camino Real</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;San Diego, CA 92130</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Attn.&#58; Chief Executive Officer</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To Executive&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Jude Onyia</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Address on file with the Company</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Modification&#59; Waiver&#59; Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Agreement constitutes the complete, final and exclusive embodiment of the entire agreement between Executive and the Company with regard to this subject matter.  It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations, including, without limitation, the Prior Employment Agreement which shall have no further force or effect.  No provisions of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing signed by Executive and such officer as may be specifically designated by the Board of Directors of the Company.  No waiver by either party hereto at any time of any breach by the other party of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or any prior or subsequent time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Validity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Controlling Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Except to the extent described in Section 6.10, in case of conflict between any of the terms and condition of this Agreement and any document herein referred to, the terms and conditions of this Agreement shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Executive Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Executive acknowledges (a) that he has consulted with or has had the opportunity to consult with independent counsel of his own choice concerning this Agreement, and has been advised to do so by the Company, and (b) that he has read and understands the Agreement, is fully aware of its legal effect, and has entered into it freely based on his own judgment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To ensure the rapid and economical resolution of disputes that may arise in connection with Executive&#8217;s employment, Executive and the Company agree that any and all disputes, claims, or causes of action, in law or equity, arising from or relating to the enforcement, breach, performance, execution, or interpretation of this Agreement, Executive&#8217;s  employment, or the termination of that employment, shall be resolved, to the fullest extent permitted by law pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, by final, binding and confidential arbitration in San Diego, California conducted before a single arbitrator by Judicial Arbitration and Mediation Services, Inc. (&#8220;JAMS&#8221;) or its successor, under the then applicable JAMS rules&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in no event shall the Arbitrator be empowered to hear or determine any class or collective claim of any type.  The JAMS rules can be found online at www.jamsadr.com.  By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or by administrative proceeding.  The arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (b) issue a written arbitration decision including the arbitrator&#8217;s essential findings and conclusions and a statement of the award.  The Company shall pay all of JAMS&#8217; arbitration fees.  Nothing in this letter agreement shall prevent either Executive or the Company from obtaining injunctive relief in court if necessary to prevent irreparable harm pending the conclusion of any arbitration.  The parties agree that the arbitrator shall award reasonable attorneys&#8217; fees, costs, and all other related expenses to the prevailing party in any action brought hereunder, and the arbitrator shall have discretion to determine the prevailing party in an arbitration where multiple claims may be at issue.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt;text-decoration:underline">Injunctive Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The parties agree that the services to be rendered by Executive hereunder are of a unique nature and that in the event of any breach or threatened breach of any of the covenants contained herein, the damage or imminent damage to the value and the goodwill of the Company&#8217;s business will be irreparable and extremely difficult to estimate, making any remedy at law or in damages inadequate. Accordingly, the parties agree that the Company shall be entitled to injunctive relief against Executive in the event of any breach or threatened breach of any such provisions by Executive, in addition to any other relief (including damage) available to the Company under this Agreement or under law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt;text-decoration:underline">Exclusive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Both parties agree that the remedy specified in Section 7.9(a) above is not exclusive of any other remedy for the breach by Executive of the terms hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> This Agreement may be executed in one or more counterparts, all of which taken together shall constitute one and the same Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executed by the parties as follows&#58;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXECUTIVE&#160;&#160;&#160;&#160;NEUROCRINE BIOSCIENCES, INC.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-indent:22.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i283f1fe7d6e14423974bf70622a40d45_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GENERAL RELEASE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pursuant to the terms of the Employment Agreement between Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;) and --- (&#8220;Executive&#8221;) dated --- (the &#8220;Agreement&#8221;), the parties hereby enter into the following General Release (the &#8220;Release&#8221;)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Accrued Salary and Vacation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Executive understands that, on the last date of Executive&#8217;s employment with the Company, the Company will pay Executive any accrued salary and accrued and unused vacation to which Executive is entitled by law, regardless of whether Executive signs this Release.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">General Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive hereby generally and completely releases the Company and its directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively the &#8220;Released Parties&#8221;) of and from any and all claims, liabilities and obligations, both known and unknown, arising out of or in any way related to events, acts, conduct, or omissions occurring at any time prior to or at the time that Executive signs this Release.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Scope of Release.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This general release includes, but is not limited to&#58; (1) all claims arising out of or in any way related to Executive&#8217;s employment with the Company or the termination of that employment&#59; (2) all claims related to Executive&#8217;s compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership or equity interests in the Company&#59; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing (including claims based on or arising under the Agreement)&#59; (4) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy&#59; and (5) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#8217; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act (as amended) (&#8220;ADEA&#8221;), the federal Family and Medical Leave Act, the California Labor Code (as amended), the California Family Rights Act, and the California Fair Employment and Housing Act (as amended).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">ADEA Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges that Executive is knowingly and voluntarily waiving and releasing any rights Executive may have under the ADEA, and that the consideration given for the waiver and release in the preceding paragraph is in addition to anything of value to which Executive is already entitled.  Executive further acknowledges that Executive has been advised by this writing that&#58;  (1) Executive&#8217;s waiver and release do not apply to any rights or claims that may arise after the date Executive signs this Release&#59; (2) Executive should consult with an attorney prior to signing this Release (although Executive may choose voluntarily not to do so)&#59; (3) Executive has twenty-one (21) days to consider this Release (although Executive may choose voluntarily to sign it earlier)&#59; (4) Executive has seven (7) days following the date Executive signs this Release to revoke it by providing written notice of revocation to the Company&#8217;s Chief Executive Officer&#59; and (5) this Release will not be effective until the date upon which the revocation period has expired, which will be the eighth calendar day after the date Executive signs it provided that Executive does not revoke it (the &#8220;Effective Date&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Section 1542 Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  EXECUTIVE UNDERSTANDS THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.  Executive acknowledges that Executive has read and understands Section 1542 of the California </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Civil Code which reads as follows&#58; &#8220;A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.&#8221;  Executive hereby expressly waives and relinquishes all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to Executive&#8217;s respective release of claims herein, including but not limited to Executive&#8217;s release of unknown and unsuspected claims.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Excluded Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Executive understands that notwithstanding the foregoing, the following are not included in the Released Claims (the &#8220;Excluded Claims&#8221;)&#58; (i) any rights or claims for indemnification Executive may have pursuant to any written indemnification agreement to which he is a party, the charter, bylaws, or operating agreements of any of the Released Parties, or under applicable law&#59; or (ii) any rights which are not waivable as a matter of law.  In addition, Executive understands that nothing in this release prevents Executive from filing, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or the California Department of Fair Employment and Housing, except that Executive acknowledges and agrees that Executive shall not recover any monetary benefits in connection with any such claim, charge or proceeding with regard to any claim released herein.  Executive hereby represents and warrants that, other than the Excluded Claims, Executive is not aware of any claims he has or might have against any of the Released Parties that are not included in the Released Claims.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Executive Representations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive hereby represents that Executive has been paid all compensation owed and for all hours worked&#59; Executive has received all the leave and leave benefits and protections for which Executive is eligible, pursuant to the Family and Medical Leave Act, the California Family Rights Act, or otherwise&#59; and Executive has not suffered any on-the-job injury for which Executive has not already filed a workers&#8217; compensation claim.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Nondisparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive agrees not to disparage the Company, its parent, or its or their officers, directors, employees, shareholders, affiliates and agents, in any manner likely to be harmful to its or their business, business reputation, or personal reputation (although Executive may respond accurately and fully to any question, inquiry or request for information as required by legal process).  The Company agrees that it shall instruct its directors and officers not to disparage Executive in any manner likely to be harmful to his business reputation or personal reputation (although such individuals may respond accurately and fully to any question, inquiry or request for information as required by legal process).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive agrees not to voluntarily (except in response to legal compulsion) assist any third party in bringing or pursuing any proposed or pending litigation, arbitration, administrative claim or other formal proceeding against the other party, or against the Company&#8217;s parent or subsidiary entities, affiliates, officers, directors, employees or agents.  Executive further agrees to reasonably cooperate with the other party, by voluntarily (without legal compulsion) providing accurate and complete information, in connection with such other party&#8217;s actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters, arising from events, acts, or failures to act that occurred during the period of Executive&#8217;s employment by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt;text-decoration:underline">No Admission of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The parties agree that this Release, and performance of the acts required by it, does not constitute an admission of liability, culpability, negligence or wrongdoing on the part of anyone, and will not be construed for any purpose as an admission of liability, culpability, negligence or wrongdoing by any party and&#47;or by any party&#8217;s current, former or future parents, subsidiaries, related entities, predecessors, successors, officers, directors, shareholders, agents, employees and assigns.  The parties specifically acknowledge and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agree that this Release is a compromise of disputed claims and that the Company denies any liability for any matter released herein.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Neurocrine Biosciences, Inc.&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Executive&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>q2-2022xexhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i520e08774cae4beea0b7017241622e42_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">Neurocrine Biosciences, Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">2020 Equity Incentive Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adopted by the Compensation Committee&#58; March 16, 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Approved by the Stockholders&#58; May 19, 2020</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended and Restated by the Compensation Committee&#58; March 14, 2022</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Approved by the Stockholders&#58; May 18, 2022</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Termination Date&#58; March 15, 2030</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><div id="i520e08774cae4beea0b7017241622e42_4"></div><hr style="page-break-after:always"><div style="min-height:120.24pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Table of Contents</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Page</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;General.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;Shares Subject to the Plan.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;Eligibility and Limitations.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;Options and Stock Appreciation Rights.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;Awards Other Than Options and Stock Appreciation Rights.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;Adjustments upon Changes in Common Stock&#59; Other Corporate Events.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;Administration.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;Tax Withholding.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;Miscellaneous.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;Covenants of the Company.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;Additional Rules for Awards Subject to Section 409A.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;Severability.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">20</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;Termination of the Plan.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">20</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;Definitions.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">21</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><div id="i520e08774cae4beea0b7017241622e42_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">General.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Successor to and Continuation of Prior Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Plan is the successor to and continuation of the Prior Plan.  As of the day immediately following the Effective Date&#58; (i) no additional awards may be granted under the Prior Plan&#59; (ii) the Prior Plan&#8217;s Available Reserve, plus any Prior Plan&#8217;s Returning Shares (as such shares become available from time to time), will become available for issuance pursuant to Awards granted under this Plan&#59; and (iii) all Prior Plan Awards will remain subject to the terms of the Prior Plan (except that any Prior Plan&#8217;s Returning Shares will become available for issuance pursuant to Awards granted under this Plan).  All Awards granted under this Plan will be subject to the terms of this Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Plan Purpose.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate, and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Available Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Plan provides for the grant of the following Awards&#58; (i) Incentive Stock Options&#59; (ii) Nonstatutory Stock Options&#59; (iii) SARs&#59; (iv) Restricted Stock Awards&#59; (v) RSU Awards&#59; (vi) Performance Awards&#59; and (vii) Other Awards.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Adoption Date.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Plan will come into existence on the Adoption Date.  No Award may be granted under the Plan prior to the Adoption Date.  Any Award granted prior to the Effective Date is contingent upon timely receipt of stockholder approval to the extent required under applicable tax, securities and regulatory rules, and satisfaction of any other compliance requirements.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Shares Subject to the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Share Reserve.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Subject to Section 2(a)(iii), any adjustment in accordance with Section 2(b), and any adjustment as necessary to implement any Capitalization Adjustment, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed the sum of&#58; (i) the Prior Plan&#8217;s Available Reserve&#59; (ii) an additional 3,300,000 shares that were approved at the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Annual Meeting in 2020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; (iii) an additional 5,900,000 shares that were approved at the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Annual Meeting in 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; and (iv) the number of Prior Plan&#8217;s Returning Shares, if any, as such shares become available from time to time.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Subject to Section 2(b), the number of shares of Common Stock available for issuance under the Plan will be reduced by&#58; (A) one share for each share of Common Stock issued pursuant to an Appreciation Award granted under the Plan&#59; (B) one share for each share of Common Stock issued pursuant to a Full Value Award granted under the Plan prior to May 18, 2022&#59; and (C) 2.13 shares for each share of Common Stock issued pursuant to a Full Value Award granted under the Plan on or after May 18, 2022.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Subject to Section 2(b), the number of shares of Common Stock available for issuance under the Plan will be increased by&#58; (A) one share for each Prior Plan&#8217;s Returning Share or 2020 Plan Returning Share (as defined in Section 2(b)(iii)(1)) subject to an Appreciation Award&#59; (B) one share for each Prior Plan&#8217;s Returning Share or 2020 Plan Returning Share subject to a Full Value Award that returns to the Plan prior to May 18, 2022&#59; and (C) 2.13 shares for each Prior Plan&#8217;s Returning Share or 2020 Plan Returning Share subject to a Full Value Award that returns to the Plan on or after May 18, 2022.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Share Reserve Operation.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt">Limit Applies to Shares Issued Pursuant to Awards.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For clarity, the Share Reserve is a limit on the number of shares of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue shares pursuant to such Awards.  Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section 303A.08, NYSE American Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.36pt">Actions that Will Not Constitute Issuance of Shares and Will Not Reduce Share Reserve.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The following actions will not result in an issuance of shares of Common Stock under the Plan and accordingly will not reduce the number of shares of Common Stock subject to the Share Reserve and available for issuance under the Plan&#58; (1) the expiration or termination of any portion of an Award without the shares covered by such portion of the Award having been issued&#59; and (2) the settlement of any portion of an Award in cash (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Participant receives cash rather than shares of Common Stock).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.03pt">Reversion of Shares to the Share Reserve.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Shares Available for Subsequent Issuance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If any shares of Common Stock issued pursuant to an Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares, then such shares will revert to the Share Reserve and become available again for issuance under the Plan (such shares, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">2020 Plan Returning Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Shares Not Available for Subsequent Issuance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The following shares of Common Stock will not become available again for issuance under the Plan&#58; (i) any shares that are reacquired or withheld (or not issued) by the Company to satisfy the exercise, strike or purchase price of an Award or a Prior Plan Award (including any shares subject to such award that are not delivered because such award is exercised through a reduction of shares subject to such award (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#8220;net exercised&#8221;))&#59; (ii) any shares that are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with an Award or a Prior Plan Award&#59; (iii) any shares repurchased by the Company on the open market with the proceeds of the exercise, strike or purchase price of an Award or a Prior Plan Award&#59; and (iv) in the event that a Stock Appreciation Right granted under the Plan or a stock appreciation right granted under the Prior Plan is settled in shares of Common Stock, the gross number of shares of Common Stock subject to such award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Eligibility and Limitations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Eligible Award Recipients.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive Awards.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Specific Award Limitations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt">Limitations on Incentive Stock Option Recipients.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Incentive Stock Options may be granted only to Employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections 424(e) and (f) of the Code).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.36pt">Incentive Stock Option $100,000 Limitation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To the extent that the aggregate Fair Market Value (determined at the time of grant) with respect to which Incentive Stock Options are exercisable for the first time by any Participant during any calendar year (under all plans of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.03pt">Limitations on Incentive Stock Options Granted to Ten Percent Stockholders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A Ten Percent Stockholder may not be granted an Incentive Stock Option unless (1) the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant of such Option and (2) such Option is not exercisable after the expiration of five years from the date of grant of such Option.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.69pt">Limitations on Nonstatutory Stock Options and SARs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#8220;parent&#8221; of the Company (as such term is defined in Rule&#160;405) unless the stock underlying such Awards is treated as &#8220;service recipient stock&#8221; under Section&#160;409A because such Awards are granted pursuant to a corporate transaction (such as a spin off transaction) or unless such Awards otherwise comply with the distribution requirements of Section&#160;409A.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Aggregate Incentive Stock Option Limit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding anything to the contrary in Section 2(a) and subject to any adjustment as necessary to implement any Capitalization Adjustment, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is 23,900,000 shares.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Non-Employee Director Compensation Limit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The aggregate value of all compensation granted or paid, as applicable, by the Company to any individual for service as a Non-Employee Director with respect to any period commencing on the date of the Annual Meeting for a particular year and ending on the date of the Annual Meeting for the next subsequent year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Annual Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), including Awards granted and cash fees paid by the Company to such Non-Employee Director, will not exceed $1,250,000 in total value.  In addition, the aggregate value of any equity award(s) granted under the Plan or otherwise by the Company to any individual for service as a Non-Employee Director upon or in connection with his or her initial election or appointment to the Board will not exceed $2,000,000 in total value&#59; for the avoidance of doubt, the aggregate compensation granted or paid, as applicable, by the Company to any individual for service as a Non-Employee Director with respect to an Annual Period </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in which such individual is first appointed or elected to the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">will not exceed the sum of the two preceding limitations in this Section&#160;3(d).  The value of any equity awards, for purposes of the limitations described in this Section&#160;3(d), will be calculated based on the grant date fair value of such equity awards for financial reporting purposes.&#160; The limitations in this Section&#160;3(d) will apply beginning with the Annual Period in which the Annual Meeting in 2020 occurs.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Options and Stock Appreciation Rights.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Option and SAR will have such terms and conditions as determined by the Board.  Each Option will be designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if an Option is not so designated, then such Option will be a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted for.  Each SAR will be denominated in shares of Common Stock equivalents.  The terms and conditions of separate Options and SARs need not be identical&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that each Option Agreement and SAR Agreement will conform (through incorporation of the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Term.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to Section 3(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Exercise or Strike Price.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Subject to Section 3(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award.  Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Transaction and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Exercise Procedure and Payment of Exercise Price for Options.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In order to exercise an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company.  The Board has the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment.  The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">by cash or check, bank draft or money order payable to the Company&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">pursuant to a &#8220;cashless exercise&#8221; program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1) the Common Stock is publicly traded at the time of exercise, (2) any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3) such delivery would not violate any Applicable Law or agreement restricting the redemption of the Common Stock, (4) any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5) such shares have been held by the Participant for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery&#59; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">if the Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1) such shares used to pay the exercise price will not be exercisable thereafter and (2) any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in cash or other permitted form of payment&#59; or</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">in any other form of consideration that may be acceptable to the Board and permissible under Applicable Law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Exercise Procedure and Payment of Appreciation Distribution for SARs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In order to exercise a SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the SAR Agreement or otherwise provided by the Company.  The appreciation distribution payable to a Participant upon the exercise of a SAR will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be greater than an amount equal to the excess of (i) the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under such SAR, over (ii) the strike price of such SAR.  Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the Board and specified in the SAR Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Options and SARs may not be transferred to third party financial institutions for value.  The Board may impose such additional limitations on the transferability of an Option or SAR as it determines.  In the absence of any such determination by the Board, the following restrictions on the transferability of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt">Restrictions on Transfer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  An Option or SAR will not be transferable, except by will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Board may permit transfer of an Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant&#8217;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section 671 of the Code and applicable state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.36pt">Domestic Relations Orders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding the foregoing, subject to the execution of transfer documentation in a format acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">Vesting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Board may impose such restrictions on or conditions to the vesting and&#47;or exercisability of an Option or SAR as determined by the Board.  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the Participant&#8217;s Continuous Service.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Termination of Continuous Service for Cause.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as explicitly otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Options and SARs will terminate and be forfeited immediately upon such termination of Continuous Service, the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous Service, and the Participant will have no further right, title or interest in the forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than for Cause.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, subject to Section 4(i), if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if applicable, such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a))&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">three months following the date of such termination if such termination is a termination without Cause (other than any termination due to the Participant&#8217;s Disability or death)&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">12 months following the date of such termination if such termination is due to the Participant&#8217;s Disability&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">18 months following the date of such termination if such termination is due to the Participant&#8217;s death&#59; or</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">18 months following the date of the Participant&#8217;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i) or (ii) above).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Following the date of such termination or death, as applicable, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or, if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in the terminated Award, the shares of Common Stock subject to the terminated Award, or any consideration in respect of the terminated Award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt">Restrictions on Exercise&#59; Extension of Exercisability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Participant may not exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law.  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause and, at any time during the applicable Post-Termination Exercise Period&#58; (i) the exercise of the Participant&#8217;s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law&#59; or (ii) the immediate sale of any shares of Common Stock issued upon such exercise would violate the Company&#8217;s Trading Policy, then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">Non-Exempt Employees.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  No Option or SAR, whether or not vested, granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the date of grant of such Award.  Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the event of (i) such Participant&#8217;s death or Disability, (ii) a Transaction in which such Award is not assumed, continued or substituted, (iii) a Change in Control, or (iv) such Participant&#8217;s retirement (as such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#8217;s then current employment policies and guidelines).  This Section 4(j) is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Whole Shares. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Awards Other Than Options and Stock Appreciation Rights.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Restricted Stock Awards and RSU Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board.  The terms and conditions of separate Restricted Stock Awards and RSU Awards need not be identical&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions&#58; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt">Form of Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Restricted Stock Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To the extent consistent with the Company&#8217;s Bylaws, at the Board&#8217;s election, shares of Common Stock subject to a Restricted Stock Award may be (i) held in book entry form subject to the Company&#8217;s instructions until such shares become vested or any other restrictions lapse, or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.  Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a Restricted Stock Award.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">RSU Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A RSU Award represents a Participant&#8217;s right to be issued on a future date the number of shares of Common Stock that is equal to the number of restricted stock units subject to the RSU Award.  As a holder of a RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company&#8217;s unfunded obligation, if any, to issue shares of Common Stock in settlement of such Award and nothing contained in the Plan or any RSU Award Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person.  A Participant will not have voting or any other rights as a stockholder of the Company with respect to a RSU Award (unless and until shares are actually issued in settlement of a vested RSU Award).  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.36pt">Consideration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Restricted Stock Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A Restricted Stock Award may be granted in consideration for (A) cash or check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of consideration (including future services)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as the Board may determine and permissible under Applicable Law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">RSU Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Unless otherwise determined by the Board at the time of grant, a RSU Award will be granted in consideration for the Participant&#8217;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any shares of Common Stock pursuant to the RSU Award.  If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant&#8217;s services to the Company or an Affiliate) upon the issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.03pt">Vesting.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as determined by the Board.  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the Participant&#8217;s Continuous Service. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.69pt">Termination of Continuous Service.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason, (1) the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement, and (2) any portion of the Participant&#8217;s RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Settlement of RSU Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  A RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement.  At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the vesting of the RSU Award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Performance Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  With respect to any Performance Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by the Board.  In addition, to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards.  Performance Awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Other Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Other forms of Awards valued in whole or in part by reference to, or otherwise based on, Common Stock may be granted either alone or in addition to Awards provided for under Section 4 and the preceding provisions of this Section 5.  Subject to the provisions of the Plan, the Board will have sole and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards, and all other terms and conditions of such Other Awards.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Adjustments upon Changes in Common Stock&#59; Other Corporate Events.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Capitalization Adjustments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust&#58; (i) the class(es) and maximum number of shares of Common Stock subject to the Plan pursuant to Section 2(a)&#59; (ii) the class(es) and maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c)&#59; and (iii) the class(es) and number of shares of Common Stock and the exercise, strike or purchase price of Common Stock subject to outstanding Awards.  The Board will make such adjustments, and its determination will be final, binding and conclusive.  Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock will be created in order to implement any Capitalization Adjustment.  The Board will determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that may be created by the adjustments referred to in the preceding provisions of this Section 6(a).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Dissolution or Liquidation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">dissolution or liquidation, and the shares of Common Stock subject to a forfeiture condition or the Company&#8217;s right of repurchase may be reacquired or repurchased by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Transaction.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event of a Transaction, the provisions of this Section 6(c) will apply to each outstanding Award unless otherwise provided in the instrument evidencing the Award, in any other written agreement between a Participant and the Company or an Affiliate, or in any director compensation policy of the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt">Awards May Be Assumed.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event of a Transaction, the Acquiring Entity may assume or continue any or all outstanding Awards or may substitute similar awards for any or all outstanding Awards (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to outstanding Awards may be assigned by the Company to the Acquiring Entity.  For clarity, in the event of a Transaction, the Acquiring Entity may choose to assume or continue only a portion of an outstanding Award, to substitute a similar award for only a portion of an outstanding Award, or to assume or continue, or substitute similar awards for, the outstanding Awards held by some, but not all, Participants.  The terms of any assumption, continuation or substitution will be set by the Board.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.36pt">Awards Held by Current Employee and Director Participants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event of a Transaction in which the Acquiring Entity does not assume or continue outstanding Awards or substitute similar awards for outstanding Awards, then with respect to any such Awards that have not been assumed, continued or substituted and that are held by Participants who are Employees or Directors and, in each case, whose Continuous Service has not terminated prior to the effective time of the Transaction (referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Current Employee and Director Participants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the vesting (and exercisability, if applicable) of such Awards will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be accelerated in full (and with respect to any such Awards that are subject to performance-based vesting conditions or requirements, vesting will be deemed to be satisfied at the greater of (x) the target level of performance or (y) the actual level of performance measured in accordance with the applicable performance goals as of the date of the Transaction) to a date prior to the effective time of such Transaction (contingent upon the effectiveness of the Transaction) as the Board determines (or, if the Board does not determine such a date, to the date that is 15 days prior to the effective time of the Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Transaction).  With respect to the vesting of Awards that will accelerate upon the occurrence of a Transaction pursuant to this Section 6(c)(ii) and are settled in the form of a cash payment, such cash payment will be made no later than 30 days following the occurrence of the Transaction.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.03pt">Awards Held by Persons other than Current Participants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event of a Transaction in which the Acquiring Entity does not assume or continue outstanding Awards or substitute similar awards for outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Employee and Director Participants, such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Transaction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Transaction.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.69pt">Payment for Awards in Lieu of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding the foregoing, in the event an Award will terminate if not exercised at or prior to the effective time of a Transaction, the Board may provide that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in value, at the effective time, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the excess, if any, of (1) the value of the property the Participant would have received upon the exercise of the Award, over (2) any exercise price payable by such holder in connection with such exercise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Involuntary Termination Upon or Following a Transaction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as otherwise provided in the Award Agreement, in any other written agreement between a Participant and the Company or an Affiliate, or in any director compensation policy of the Company, in the event that an Employee or Director&#8217;s Continuous Service is involuntarily terminated without Cause (including any such termination due to such Employee or Director&#8217;s death or Disability) upon or within 12 months following the effective time of a Transaction, the vesting (and exercisability, if applicable) of any Assumed Awards (as defined in this Section 6(d)) held by such Employee or Director as of the date of such termination will be accelerated in full (and with respect to any such Awards that are subject to performance-based vesting conditions or requirements, vesting will be deemed to be satisfied at the greater of (x)&#160;the target level of performance or (y)&#160;the actual level of performance measured in accordance with the applicable performance goals as of the date of such termination), effective as of the date of such termination.  For purposes of this Section 6(d), an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Assumed Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any outstanding Award that was assumed or continued, or any outstanding similar award that was granted in substitution for an Award, in each case by the Acquiring Entity in connection with the applicable Transaction.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Appointment of Stockholder Representative.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  As a condition to the receipt of an Award, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant&#8217;s behalf with respect to any escrow, indemnities and any contingent consideration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">No Restriction on Right to Undertake Transactions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The grant of any Award and the issuance of shares of Common Stock pursuant to any Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company&#8217;s capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Administration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Administration by Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in Section 7(c).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Powers of Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">To determine from time to time&#58; (1) which of the persons eligible under the Plan will be granted Awards&#59; (2) when and how each Award will be granted&#59; (3) what type or combination of types of Award will be granted&#59; (4) the provisions of each Award (which need not be identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award&#59; (5) the number of shares of Common Stock or cash equivalent with respect to which an Award will be granted to each such person&#59; and (6) the Fair Market Value applicable to an Award.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration.  The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it deems necessary or expedient to make the Plan or Awards fully effective.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">To settle all controversies regarding the Plan and Awards granted under it.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock, including any Transaction, for reasons of administrative convenience.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">To suspend or terminate the Plan at any time.  Suspension or termination of the Plan will not Materially Impair a Participant&#8217;s rights under any Award granted while the Plan is in effect unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">To amend the Plan in any respect the Board deems necessary or advisable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that stockholder approval will be required for any such amendment to the extent required by Applicable Law.  Except as provided above, a Participant&#8217;s rights under any Award granted before any amendment of the Plan will not be Materially Impaired by any such amendment unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">To submit any amendment to the Plan for stockholder approval.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that a Participant&#8217;s rights under any Award will not be Materially Impaired by any such amendment unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">To adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant foreign jurisdiction).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Delegation to Committee.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt">General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board.  Each Committee may retain the authority to concurrently administer the Plan with any Committee or subcommittee to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated.  The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.36pt">Rule 16b-3 Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To the extent an Award is intended to qualify for the exemption from Section 16(b) of the Exchange Act that is available under Rule 16b-3 of the Exchange Act, the Award will be granted by the Board or a Committee that consists solely of two or more Non-Employee Directors, as determined under Rule 16b-3(b)(3) of the Exchange Act, and thereafter any action establishing or modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Effect of Board&#8217;s Decision.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  All determinations, interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Cancellation and Re-Grant of Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except in connection with a Transaction, as provided in Section 6(a) relating to Capitalization Adjustments, or unless the stockholders of the Company have approved such an action within 12 months prior to such an event, neither the Board nor any Committee will have the authority to&#58; (i) reduce the exercise or strike price of any outstanding Option or SAR&#59; or (ii) cancel any outstanding Option or SAR that has an exercise or strike price greater than the then-current Fair Market Value in exchange for cash or other Awards under the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">Delegation to an Officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Board or any Committee may delegate to one or more Officers the authority to do one or both of the following&#58; (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by Applicable Law, other types of Awards) and, to the extent permitted by Applicable Law, the terms thereof&#59; and (ii) determine the number of shares of Common Stock to be subject to such Awards granted to such Employees&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the resolutions or charter adopted by the Board or any Committee evidencing such delegation will specify the total number of shares of Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself.  Any such Awards will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving the delegation authority.  Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the Fair Market Value.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Tax Withholding.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Withholding Authorization.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  As a condition to acceptance of any Award, a Participant authorizes withholding from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for, any sums required to satisfy any U.S. federal, state, local and&#47;or foreign tax or social insurance contribution withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable.  Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company will have no obligation to issue shares of Common Stock subject to an Award, unless and until such withholding obligations are satisfied.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Satisfaction of Withholding Obligations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any U.S. federal, state, local and&#47;or foreign tax or social insurance contribution withholding obligations relating to an Award by any of the following means or by a combination of such means&#58; (i) causing the Participant to tender a cash payment&#59; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award&#59; (iii) withholding cash from an Award settled in cash&#59; (iv) withholding payment from any amounts otherwise payable to the Participant&#59; (v) by allowing a Participant to effectuate a &#8220;cashless exercise&#8221; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board&#59; or (vi) by such other method as may be set forth in the Award Agreement.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">No Obligation to Notify or Minimize Taxes&#59; No Liability to Claims.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as required by Applicable Law, the Company has no duty or obligation to any Participant to advise such Participant as to the time or manner of exercising an Award.  Furthermore, the Company has no duty or obligation to warn or otherwise advise such Participant of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised.  The Company has no duty or obligation to minimize the tax consequences of an Award to any Participant and will not be liable to any Participant for any adverse tax consequences to such Participant in connection with an Award.  As a condition to accepting an Award, each Participant (i) agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii) acknowledges that such Participant was advised to consult with his or her own personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so.  Additionally, each Participant acknowledges that any Option or SAR is exempt from Section 409A only if the exercise or strike price of such Option or SAR is at least equal to the &#8220;fair market value&#8221; of the Common Stock on the date of grant of such Option or SAR as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award.  Additionally, as a condition to accepting an Option or SAR, each Participant agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that the exercise or strike price of such Option or SAR is less than the &#8220;fair market value&#8221; of the Common Stock on the date of grant of such Option or SAR as subsequently determined by the Internal Revenue Service.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Withholding Indemnification. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> As a condition to accepting an Award, in the event that the amount of the Company&#8217;s and&#47;or its Affiliate&#8217;s withholding obligations in connection with such Award was greater than the amount actually withheld by the Company and&#47;or its Affiliates, each Participant agrees to indemnify and hold the Company and&#47;or its Affiliates harmless from any failure by the Company and&#47;or its Affiliates to withhold the proper amount.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Miscellaneous.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Dividends and Dividend Equivalents.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dividends or dividend equivalents may not be paid or credited to any Awards.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Source of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Use of Proceeds from Sales of Common Stock.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Corporate Action Constituting Grant of Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant.  In the event that the corporate records (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Stockholder Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and (ii) the issuance of the Common Stock subject to such Award is reflected in the records of the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">No Employment or Other Service Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to any Award (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state or foreign jurisdiction in which the Company or the Affiliate is incorporated, as the case may be.  Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and&#47;or Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Change in Time Commitment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee and has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (i) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payable after the date of such change in time commitment, and (ii) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award.  In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Execution of Additional Documents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  As a condition to accepting an Award, the Participant agrees to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#8217;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and&#47;or other regulatory requirements, in each case at the Plan Administrator&#8217;s request</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt">Electronic Delivery and Participation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Any reference herein or in an Award Agreement to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).  By accepting any Award, the Participant consents to receive documents by electronic delivery and to participate in the Plan through any on-line electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator.  The form of delivery of any Common Stock (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a stock certificate or electronic entry evidencing such shares) will be determined by the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">Clawback&#47;Recovery.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law, and any other clawback policy that the Company adopts.  In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause.  No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&#8217;s right to voluntary terminate employment upon a &#8220;resignation for good reason,&#8221; or for a &#8220;constructive termination&#8221; or any similar term under any plan of or agreement with the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Securities Law Compliance.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Participant will not be issued any shares in respect of an Award unless either (i) the shares are registered under the Securities Act or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act.  Each Award also must comply with other Applicable Law governing the Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt">Transfer or Assignment of Awards&#59; Issued Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Except as expressly provided in the Plan or an Award Agreement, Awards may not be transferred or assigned by the Participant.  After the vested shares subject to an Award have been issued, or in the case of Restricted Stock and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and Applicable Law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.03pt">Effect on Other Employee Benefit Plans. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The value of any Award, as determined upon grant, vesting or settlement, will not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#8217;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Deferrals.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants.  Deferrals by will be made in accordance with the requirements of Section 409A.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Section 409A.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless otherwise expressly provided for in an Award Agreement, the Plan and each Award Agreement will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A, and, to the extent not so exempt, in compliance with the requirements of Section 409A.  If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement.  Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section 409A is a &#8220;specified employee&#8221; for purposes of Section 409A, no distribution or payment of any amount that is due because of a &#8220;separation from service&#8221; (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant&#8217;s &#8220;separation from service&#8221; or, if earlier, the date of the Participant&#8217;s death, unless such distribution or payment may be made in a manner that complies with Section 409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Choice of Law.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Plan and any controversy arising out of or relating to this Plan will be governed by, and construed in accordance with, the internal laws of the State of California, without regard to conflict of law principles that would result in any application of any law other than the law of the State of California.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Covenants of the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Compliance with Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company will seek to obtain from each regulatory commission or agency, as may be deemed to be necessary, having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that this undertaking will not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award.  If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting of such Awards unless and until such authority is obtained.  A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of any Applicable Law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Additional Rules for Awards Subject to Section 409A.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Application. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Unless the provisions of this Section 11 are expressly superseded by the provisions in an Award Agreement, the provisions of this Section 11 will apply and will supersede anything to the contrary set forth in the Award Agreement for a Non-Exempt Award. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Non-Exempt Awards Subject to Non-Exempt Severance Arrangements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To the extent a Non-Exempt Award is subject to Section 409A due to application of a Non-Exempt Severance Arrangement, the following provisions of this Section 11(b) will apply.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">If the Non-Exempt Award vests in the ordinary course during the Participant&#8217;s Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a Non-Exempt Severance Arrangement, in no event will the shares be issued in respect of such Non-Exempt Award any later than the later of&#58; (i) December 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the calendar year that includes the applicable vesting date&#59; or (ii) the 60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day that follows the applicable vesting date. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">If vesting of the Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with the Participant&#8217;s Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the Non-Exempt Award and, therefore, are part of the terms of such Non-Exempt Award as of the date of grant, then the shares will be earlier issued in settlement of such Non-Exempt Award upon the Participant&#8217;s Separation from Service in accordance with the terms of the Non-Exempt Severance Arrangement, but in no event later than the 60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day that follows the date of the Participant&#8217;s Separation from Service.  However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained in Section 409A applicable to &#8220;specified employees,&#8221; as defined in Section 409A(a)(2)(B)(i) of the Code, such shares will not be issued before the date that is six months following the date of such Participant&#8217;s Separation from Service, or, if earlier, the date of the Participant&#8217;s death that occurs within such six month period.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">If vesting of a Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with a Participant&#8217;s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the Non-Exempt Award and, therefore, are not a part of the terms of such Non-Exempt Award on the date of grant, then such acceleration of vesting of the Non-Exempt Award will not accelerate the issuance date of the shares, but the shares will instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course during the Participant&#8217;s Continuous Service, notwithstanding the vesting acceleration of the Non-Exempt Award.  Such issuance schedule is intended to satisfy the requirements of payment on a specified date or pursuant to a fixed schedule, as provided under Treasury Regulations Section 1.409A-3(a)(4).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Treatment of Non-Exempt Awards Upon a Transaction for Employees and Consultants.</font><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The provisions of this Section 11(c) will apply and will supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any Non-Exempt Award in connection with a Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the Non-Exempt Award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt">Vested Non-Exempt Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The following provisions will apply to any Vested Non-Exempt Award in connection with a Transaction&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If the Transaction is also a Section 409A Change in Control, then the Acquiring Entity may not assume, continue or substitute the Vested Non-Exempt Award.  Upon the Section 409A Change in Control, the settlement of the Vested Non-Exempt Award will automatically be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accelerated and the shares will be immediately issued in respect of the Vested Non-Exempt Award.  Alternatively, the Company may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section 409A Change in Control.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If the Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or substitute each Vested Non-Exempt Award.  The shares to be issued in respect of the Vested Non-Exempt Award will be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Transaction had not occurred.  In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Transaction.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.36pt">Unvested Non-Exempt Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The following provisions will apply to any Unvested Non-Exempt Award unless otherwise determined by the Board pursuant to Section 11(e).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In the event of a Transaction, the Acquiring Entity will assume, continue or substitute any Unvested Non-Exempt Award.  Unless otherwise determined by the Board, any Unvested Non-Exempt Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Transaction.  The shares to be issued in respect of any Unvested Non-Exempt Award will be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Transaction had not occurred.  In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Transaction.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If the Acquiring Entity will not assume, substitute or continue any Unvested Non-Exempt Award in connection with a Transaction, then such Award will automatically terminate and be forfeited upon the Transaction with no consideration payable to any Participant in respect of such forfeited Unvested Non-Exempt Award.  Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section 409A, the Board may in its discretion determine to elect to accelerate the vesting and settlement of the Unvested Non-Exempt Award upon the Transaction, or instead substitute a cash payment equal to the Fair Market Value of such shares that would otherwise be issued to the Participant, as further provided in Section 11(e)(ii).  In the absence of such discretionary election by the Board, any Unvested Non-Exempt Award will be forfeited without payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested Non-Exempt Awards in connection with the Transaction.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The foregoing treatment will apply with respect to all Unvested Non-Exempt Awards upon any Transaction, and regardless of whether or not such Transaction is also a Section 409A Change in Control.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Treatment of Non-Exempt Awards Upon a Transaction for Non-Employee Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The following provisions of this Section 11(d) will apply and will supersede anything to the contrary that may be set forth in the Plan with respect to the permitted treatment of a Non-Exempt Director Award in connection with a Transaction. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">If the Transaction is also a Section 409A Change in Control, then the Acquiring Entity may not assume, continue or substitute the Non-Exempt Director Award.  Upon the Section </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">409A Change in Control, the vesting and settlement of any Non-Exempt Director Award will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the Non-Exempt Director Award.  Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section 409A Change in Control pursuant to the preceding provision.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">If the Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or substitute the Non-Exempt Director Award.  Unless otherwise determined by the Board, the Non-Exempt Director Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Transaction.  The shares to be issued in respect of the Non-Exempt Director Award will be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Transaction had not occurred.  In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value made on the date of the Transaction.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If the RSU Award is a Non-Exempt Award, then the provisions in this Section 11(e) will apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such Non-Exempt Award&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Any exercise by the Board of discretion to accelerate the vesting of a Non-Exempt Award will not result in any acceleration of the scheduled issuance dates for the shares in respect of the Non-Exempt Award unless earlier issuance of the shares upon the applicable vesting dates would be in compliance with the requirements of Section 409A.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">The Company explicitly reserves the right to earlier settle any Non-Exempt Award to the extent permitted and in compliance with the requirements of Section 409A, including pursuant to any of the exemptions available in Treasury Regulations Section 1.409A-3(j)(4)(ix).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">To the extent the terms of any Non-Exempt Award provide that it will be settled upon a Transaction, to the extent it is required for compliance with the requirements of Section 409A, the Transaction event triggering settlement must also constitute a Section 409A Change in Control.  To the extent the terms of a Non-Exempt Award provide that it will be settled upon a termination of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section 409A, the termination event triggering settlement must also constitute a Separation from Service.  However, if at the time the shares would otherwise be issued to a Participant in connection with a &#8220;separation from service&#8221; such Participant is subject to the distribution limitations contained in Section 409A applicable to &#8220;specified employees,&#8221; as defined in Section 409A(a)(2)(B)(i) of the Code, such shares will not be issued before the date that is six months following the date of the Participant&#8217;s Separation from Service, or, if earlier, the date of the Participant&#8217;s death that occurs within such six month period.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">The provisions in this Section 11(e) for delivery of the shares in respect of the settlement of a RSU Award that is a Non-Exempt Award are intended to comply with the requirements of Section 409A so that the delivery of the shares to the Participant in respect of such Non-Exempt Award will not trigger the additional tax imposed under Section 409A, and any ambiguities herein will be so interpreted.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Severability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid.  Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Termination of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Board may suspend or terminate the Plan at any time.  Unless terminated sooner by the Board, the Plan will automatically terminate on the day before the tenth anniversary of the earlier of&#58; (i) the Adoption Date&#59; or (ii) the Effective Date.  No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Definitions.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As used in the Plan, the following definitions apply to the capitalized terms indicated below&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Acquiring Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the surviving or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) in connection with a Transaction.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Adoption Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date the Plan is first approved by the Compensation Committee.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act.  The Board may determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the first meeting of the Company&#8217;s stockholders held each calendar year at which Directors are selected.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial Industry Regulatory Authority).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Appreciation Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) a stock option or stock appreciation right granted under the Prior Plan or (ii) an Option or SAR, in each case with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the stock option or stock appreciation right, or Option or SAR, as applicable, on the date of grant.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any right to receive Common Stock, cash or other property granted under the Plan (including an Incentive Stock Option, a Nonstatutory Stock Option, a SAR, a Restricted Stock Award, a RSU Award, a Performance Award or any Other Award).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.  The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided to a Participant along with the Grant Notice. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Board of Directors of the Company (or its designee).  Any decision or determination made by the Board will be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination will be final and binding on all Participants.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Capitalization Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Adoption Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events&#58; (i)&#160;such Participant&#8217;s commission of any crime involving fraud, dishonesty or moral turpitude&#59; (ii)&#160;such Participant&#8217;s attempted commission of, or participation in, a fraud or act of dishonesty against the Company or an Affiliate that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate&#59; (iii) such Participant&#8217;s intentional, material violation of any contract or agreement between such Participant and the Company or an Affiliate, or of any statutory duty such Participant owes to the Company or an Affiliate&#59; or (iv) such Participant&#8217;s conduct that constitutes gross insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the action or conduct described in clauses (iii) and (iv) above will constitute &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; only if such action or conduct continues after the Company has provided such Participant with written notice thereof and not less than five business days to cure the same.  The determination that a termination of the Participant&#8217;s Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are Officers and by the Chief Executive Officer of the Company with respect to Participants who are not Officers.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the extent necessary to avoid adverse personal income tax consequences to the Participant in connection with an Award, such transaction also constitutes a Section 409A Change in Control&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction.  Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#8217;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C) solely because the level of Ownership held by any Exchange Act Person (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Subject Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will be deemed to occur&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">the stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur, except for a liquidation into a parent corporation&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition&#59; or</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">individuals who, on the date the Plan is adopted by the Compensation Committee, are members of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Incumbent Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) cease for any reason to constitute at least a majority of the members of the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member will, for purposes of this Plan, be considered as a member of the Incumbent Board.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing or any other provision of this Plan, (A) the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B) the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant will supersede the foregoing definition with respect to Awards subject to such agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (1) if no definition of Change in Control (or any analogous term) is set forth in such an individual written agreement, the foregoing definition will apply&#59; and (2) no Change in Control (or any analogous term) will be deemed to occur with respect to Awards subject to such an individual written agreement without a requirement that the Change in Control (or any analogous term) actually occur.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Compensation Committee and any other committee of Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the common stock of the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Neurocrine Biosciences, Inc., a Delaware corporation.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Compensation Committee of the Board.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services.  However, service solely as a Director, or payment of a fee for such service, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan.  Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service.  To the extent permitted by law, the Board or the Chief Executive Officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or Chief Executive Officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.  In addition, to the extent required for exemption from or compliance with Section 409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of &#8220;separation from service&#8221; as defined under Treasury Regulation Section 1.409A-1(h) (without regard to any alternative definition thereunder).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Corporate Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">a sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or other disposition of all or substantially all, as determined by the Board, of the consolidated assets of the Company and its Subsidiaries&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">a sale or other disposition of at least 90% of the outstanding securities of the Company&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">a merger, consolidation or similar transaction following which the Company is not the surviving corporation&#59; or</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">determine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">determined</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means as determined by the Board or the Committee (or its designee) in its sole discretion.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a member of the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Section 22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date of the Annual Meeting in 2020, provided this Plan is approved by the Company&#8217;s stockholders at such meeting.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Company or the Affiliate of the Company that employs the Participant.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(aa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a corporation, partnership, limited liability company or other entity.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(bb)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(cc)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i) the Company or any Subsidiary, (ii) any employee benefit plan of the Company or any Subsidiary or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary, (iii) an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company, or (v) any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(dd)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, as of any date, unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing sales price on the last preceding date for which such quotation exists.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">In the absence of such exchange or market for the Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ee)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Full Value Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) a stock award granted under the Prior Plan or (ii) an Award, in each case that is not an Appreciation Award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ff)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.04pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Governmental</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Body</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any&#58; (i) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature&#59; (ii) federal, state, local, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">municipal, foreign or other government&#59; (iii) governmental or regulatory body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any tax authority) or other body exercising similar powers or authority&#59; or (iv) self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(gg)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the notice provided to a Participant that he or she has been granted an Award and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(hh)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Incentive Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an option granted pursuant to Section 4 that is intended to be, and qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Materially Impair</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that a Participant&#8217;s rights under an Award will be materially adversely affected by a suspension or termination of the Plan, an amendment of the Plan, or an amendment to the terms of the Award, as applicable.  For purposes of the Plan, a Participant&#8217;s rights under an Award will not be deemed to have been Materially Impaired by any of the foregoing actions if the Board, in its sole discretion, determines that such action, taken as a whole, does not materially impair the Participant&#8217;s rights under the Award.  For example, an amendment to the terms of an Award in order to do any of the following, or that results in any of the following, will not be deemed to Materially Impair the Participant&#8217;s rights under the Award&#58; (i) an imposition of reasonable restrictions on the minimum number of shares subject to an Option that may be exercised&#59; (ii) to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code&#59; (iii) a change in the terms of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code&#59; (iv) to clarify the manner of exemption from, or to bring the Award into compliance with or qualify it for an exemption from, Section 409A&#59; or (v) to comply with other Applicable Laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(jj)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.04pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Regulation S-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation S-K, or (ii) is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(kk)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Non-Exempt Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any Award that is subject to, and not exempt from, Section 409A, including as the result of (i) a deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company, or (ii) the terms of any Non-Exempt Severance Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ll)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Non-Exempt Director Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Non-Exempt Award granted to a Participant who was a Director but not an Employee on the applicable grant date. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(mm)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.04pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Non-Exempt Severance Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a severance arrangement or other agreement between the Participant and the Company or an Affiliate that provides for acceleration </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&#8217;s termination of employment or separation from service (as such term is defined in Section 409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and such severance benefit does not satisfy the requirements for an exemption from application of Section 409A provided under Treasury Regulations Section 1.409A-1(b)(4), 1.409A-1(b)(9) or otherwise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(nn)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Nonstatutory Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any option granted pursuant to Section 4 that does not qualify as an Incentive Stock Option.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(oo)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(pp)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock which is granted pursuant to the terms and conditions of Section 4.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(qq)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Option grant.  The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of the general terms and conditions applicable to the Option and which is provided to a Participant along with the Grant Notice.  Each Option Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(rr)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Other Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 5(c).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ss)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Other Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a written agreement between the Company and a Participant evidencing the terms and conditions of an Other Award grant.  Each Other Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(tt)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.04pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Own</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Owned</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Owner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means that a person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(uu)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Performance Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Award that may vest or may be exercised, or that may become earned and paid, contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted pursuant to the terms and conditions of Section 5(b) and such terms as approved by the Board.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ww)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Performance Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the one or more criteria that the Board will select for purposes of establishing the Performance Goals for a Performance Period.  The Performance Criteria that will be used to establish such Performance Goals may be based on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any one of, or combination of, the following, as determined by the Board&#58; (1)&#160;earnings (including earnings per share and net earnings, in either case before or after any or all of&#58; interest, taxes, depreciation and amortization, legal settlements or other income (expense), or stock-based compensation, other non-cash expenses and changes in deferred revenue)&#59; (2)&#160;total stockholder return&#59; (3)&#160;return on equity or average stockholder&#8217;s equity&#59; (4)&#160;return on assets, investment, or capital employed&#59; (5)&#160;stock price&#59; (6)&#160;margin (including gross margin)&#59; (7)&#160;income (before or after taxes)&#59; (8)&#160;operating income&#59; (9)&#160;operating income after taxes&#59; (10)&#160;pre-tax profit&#59; (11)&#160;operating cash </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">flow&#59; (12)&#160;sales, prescriptions, or revenue targets&#59; (13)&#160;increases in revenue or product revenue&#59; (14)&#160;expenses and cost reduction goals&#59; (15)&#160;improvement in or attainment of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">working capital levels&#59; (16)&#160;economic value added (or an equivalent metric)&#59; (17)&#160;market share&#59; (18)&#160;cash flow&#59; (19)&#160;cash flow per share&#59; (20)&#160;cash burn&#59; (21)&#160;share price performance&#59; (22)&#160;debt reduction&#59; (23)&#160;implementation or completion of projects or processes (including, without limitation, discovery of a pre-clinical drug candidate, recommendation of a drug candidate to enter a clinical trial, clinical trial initiation, clinical trial enrollment and dates, clinical trial results, regulatory filing submissions, regulatory filing acceptances, regulatory or advisory committee interactions, regulatory approvals, presentation of studies and launch of commercial plans, compliance programs or education campaigns)&#59; (24)&#160;customer satisfaction&#59; (25)&#160;stockholders&#8217; equity&#59; (26)&#160;capital expenditures&#59; (27)&#160;debt levels&#59; (28)&#160;financings&#59; (29)&#160;operating profit or net operating profit&#59; (30)&#160;workforce diversity&#59; (31)&#160;growth of net income or operating income&#59; (32)&#160;billings&#59; (33)&#160;employee hiring&#59; (34)&#160;funds from operations&#59; (35)&#160;budget management&#59; (36)&#160;strategic partnerships or transactions (including acquisitions, joint ventures or licensing transactions)&#59; (37)&#160;engagement of thought leaders and patient advocacy groups&#59; (38)&#160;enhancement of intellectual property portfolio, filing of patent applications and granting of patents&#59; (39)&#160;litigation preparation and management&#59; and (40)&#160;any other measure of performance selected by the Board.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xx)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria.  Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices.  Unless specified otherwise by the Board (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of the Performance Goals for a Performance Period as follows&#58; (1) to exclude restructuring and&#47;or other nonrecurring charges&#59; (2) to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated Performance Goals&#59; (3) to exclude the effects of changes to generally accepted accounting principles&#59; (4) to exclude the effects of any statutory adjustments to corporate tax rates&#59; (5) to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles&#59; (6) to exclude the dilutive effects of acquisitions or joint ventures&#59; (7) to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture&#59; (8) to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends&#59; (9) to exclude the effects of stock based compensation and the award of bonuses under the Company&#8217;s bonus plans&#59; (10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles&#59; (11) to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles&#59; and (12) to exclude the effects of the timing of acceptance for review and&#47;or approval of submissions to the U.S. Food and Drug Administration or any other regulatory body.  In addition, the Board retains the discretion to define the manner of calculating the Performance Criteria it selects to use for a Performance Period and to reduce or eliminate the compensation or economic benefit due upon the attainment of any Performance Goal.  Partial attainment of any Performance Goal may result in payment or vesting corresponding to the degree of attainment as specified in the applicable Award Agreement or the written terms of a Performance Award. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(yy)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant&#8217;s right to vesting or exercise of, or any payment under, an Award.  Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(zz)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means this Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(aaa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the person, persons, and&#47;or third-party administrator designated by the Company to administer the day to day operations of the Plan and the Company&#8217;s other equity incentive programs.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(bbb)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Post-Termination Exercise Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period following termination of a Participant&#8217;s Continuous Service within which an Option or SAR is exercisable, as specified in Section 4(h).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ccc)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.06pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Prior Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ddd)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Prior Plan Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an award granted under the Prior Plan that is outstanding as of the Effective Date. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(eee)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.06pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Prior Plan&#8217;s Available Reserve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the number of shares available for the grant of new awards under the Prior Plan as of immediately following the Effective Date.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(fff)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Prior Plan&#8217;s Returning Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means shares of Common Stock subject to a Prior Plan Award that following the Effective Date&#58; (i)&#160;are not issued because such Prior Plan Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Prior Plan Award having been issued&#59; (ii)&#160;are not issued because such Prior Plan Award or any portion thereof is settled in cash&#59; or (iii)&#160;are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ggg)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the document containing the Plan information specified in Section 10(a) of the Securities Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(hhh)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Restricted Stock Award grant.  The Restricted Stock Award Agreement includes the Grant Notice for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award and which is provided to a Participant along with the Grant Notice.  Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(jjj)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means an Award of restricted stock units representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(kkk)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">RSU Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a written agreement between the Company and a Participant evidencing the terms and conditions of a RSU Award grant.  The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and conditions applicable to the RSU Award and which is provided to a Participant along with the Grant Notice.  Each RSU Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(lll)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Rule 16b-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(mmm)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:34.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Rule 405</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Rule 405 promulgated under the Securities Act.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(nnn)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Section 409A of the Code and the regulations and other guidance thereunder.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ooo)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Section 409A Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#8217;s assets, as provided in Section 409A(a)(2)(A)(v) of the Code and Treasury Regulations Section 1.409A-3(i)(5) (without regard to any alternative definition thereunder).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ppp)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(qqq)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Share Reserve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the number of shares of Common Stock available for issuance under the Plan as set forth in Section 2(a)(i).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(rrr)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.06pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">SAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Stock Appreciation Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a right to receive the appreciation on Common Stock which is granted pursuant to the terms and conditions of Section 4.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(sss)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.04pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">SAR Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a SAR grant.  The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided to a Participant along with the Grant Notice.  Each SAR Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ttt)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(uuu)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Ten Percent Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vvv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Trading Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Company&#8217;s policy permitting certain individuals to sell Company shares only during certain &#8220;window&#8221; periods and&#47;or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(www)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.04pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Corporate Transaction or a Change in Control.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(xxx)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Unvested Non-Exempt Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the portion of any Non-Exempt Award that had not vested in accordance with its terms upon or prior to the date of any Transaction.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(yyy)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Vested Non-Exempt Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the portion of any Non-Exempt Award that had vested in accordance with its terms upon or prior to the date of a Transaction.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>q2-2022xexhibit103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7bd613f117c5496ea004e705c20acfcb_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Neurocrine Biosciences, Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:100%">2018 Employee Stock Purchase Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adopted by the Board of Directors&#58; February 6, 2018</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Approved by the Stockholders&#58; May 24, 2018</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended and Restated by the Compensation Committee&#58; March 14, 2022</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Approved by the Stockholders&#58; May 18, 2022</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">General&#59; Purpose.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock.  The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Administration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Board will administer the Plan.  The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">To determine when and how Purchase Rights will be granted and the provisions of each Offering (which need not be identical).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">To designate from time to time which Related Corporations will be eligible to participate in the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for the administration of the Plan.  The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make the Plan fully effective.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">To settle all controversies regarding the Plan and Purchase Rights.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To amend the Plan at any time as provided in Section 12.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">To suspend or terminate the Plan at any time as provided in Section 12.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:7pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references to the Board in this Plan and in any applicable Offering Document will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board.  The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.  Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Shares of Common Stock Subject to the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Subject to Section 11(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued under the Plan will not exceed nine hundred thousand (900,000) shares, which number is the sum of (i) three hundred thousand (300,000) shares that were approved at the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Annual Meeting in 2018 and (ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">six hundred thousand (600,000) shares that were approved at the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Annual Meeting in 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">If any Purchase Right terminates without having been exercised in full, the shares of Common Stock not purchased under such Purchase Right will again become available for issuance under the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Grant of Purchase Rights&#59; Offering.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Board may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board.  Each Offering will be in such form and will contain such terms and conditions as the Board will deem appropriate and will comply with the requirement of Section 423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges.  The terms and conditions of an Offering will be incorporated by reference into the Plan and treated as part of the Plan.  The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed twenty-seven (27) months beginning with the Offering Date, and the substance of the provisions contained in Sections 5 through 8, inclusive.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">If a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise indicates in forms delivered to the Company&#58; (i) each form will apply to all of his or her Purchase Rights under the Plan, and (ii) a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:7pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i) that Offering will terminate immediately as of that first Trading Day, and (ii) the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Eligibility.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section 2(b), to Employees of a Related Corporation.  Except as provided in Section 5(b), an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company or the Related Corporation, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or greater than two (2) years.  In addition, the Board may provide that no Employee will be eligible to be granted Purchase Rights unless, on the Offering Date, such Employee&#8217;s customary employment with the Company or the Related Corporation is more than twenty (20) hours per week and more than five (5) months per calendar year or such other criteria as the Board may determine consistent with Section 423 of the Code.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering.  Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">the date on which such Purchase Right is granted will be the &#8220;Offering Date&#8221; of such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">the period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of the Offering, he or she will not receive any Purchase Right under that Offering.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">No Employee will be eligible for the grant of any Purchase Rights if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or of any Related Corporation.  For purposes of this Section 5(c), the rules of Section 424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights and options will be treated as stock owned by such Employee.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">As specified by Section 423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee&#8217;s rights to purchase stock of the Company or any Related Corporation to accrue at a rate which exceeds twenty-five thousand dollars ($25,000) of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:7pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">will be determined as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Officers of the Company and any designated Related Corporation, if they are otherwise Eligible Employees, will be eligible to participate in Offerings under the Plan.  Notwithstanding the foregoing, the Board may provide in an Offering that Employees who are highly compensated Employees within the meaning of Section 423(b)(4)(D) of the Code will not be eligible to participate.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Purchase Rights&#59; Purchase Price.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding fifteen percent (15%) of such Employee&#8217;s earnings (as defined by the Board in each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The Board will establish one (1) or more Purchase Dates during an Offering on which Purchase Rights granted pursuant to that Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">In connection with each Offering made under the Plan, the Board may specify (i) a maximum number of shares of Common Stock that may be purchased by any Participant pursuant to such Offering, (ii) a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date pursuant to such Offering, (iii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants pursuant to such Offering, and&#47;or (iv) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date pursuant to such Offering.  If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under such Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant&#8217;s accumulated Contributions) allocation of the shares of Common Stock available will be made in as nearly a uniform manner as will be practicable and equitable.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be not less than the lesser of&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">an amount equal to eighty-five percent (85%) of the Fair Market Value of the shares of Common Stock on the Offering Date&#59; or</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">an amount equal to eighty-five percent (85%) of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Participation&#59; Withdrawal&#59; Termination.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">An Eligible Employee may elect to authorize payroll deductions as the means of making Contributions by completing and delivering to the Company, within the time specified in the Offering, an enrollment form provided by the Company.  The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board.  Each Participant&#8217;s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where applicable law requires that Contributions be deposited with a third party.  To the extent provided in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:7pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Offering, a Participant may begin such Contributions on or after the Offering Date.  To the extent provided in the Offering, a Participant may thereafter decrease (including to zero) or increase his or her Contributions.  To the extent specifically provided in the Offering, in addition to or instead of making Contributions by payroll deductions, a Participant may make Contributions through payment by cash or check prior to a Purchase Date.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company a withdrawal form provided by the Company.  The Company may impose a deadline before a Purchase Date for withdrawing.  Upon such withdrawal, such Participant&#8217;s Purchase Right in that Offering will immediately terminate and the Company will distribute to such Participant all of his or her accumulated but unused Contributions without interest.  A Participant&#8217;s withdrawal from an Offering will have no effect upon his or her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Purchase Rights granted pursuant to any Offering under the Plan will terminate immediately if the Participant either (i) is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by law) or (ii) is otherwise no longer eligible to participate.  The Company will distribute to such individual all of his or her accumulated but unused Contributions without interest.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Purchase Rights will not be transferable by a Participant except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section 10.  During a Participant&#8217;s lifetime, Purchase Rights will be exercisable only by such Participant.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Unless otherwise specified in an Offering, the Company will have no obligation to pay interest on Contributions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Exercise of Purchase Rights.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">On each Purchase Date, each Participant&#8217;s accumulated Contributions will be applied to the purchase of shares of Common Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering.  No fractional shares will be issued upon the exercise of Purchase Rights unless specifically provided for in the Offering.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Unless otherwise provided in the Offering, if any amount of accumulated Contributions remains in a Participant&#8217;s account after the purchase of shares of Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be held in such Participant&#8217;s account for the purchase of shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in such next Offering, in which case such amount will be distributed to such Participant after the final Purchase Date without interest.  If the amount of Contributions remaining in a Participant&#8217;s account after the purchase of shares of Common Stock is at least equal to the amount required to purchase one (1) whole share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be distributed in full to such Participant after the final Purchase Date of such Offering without interest.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable federal, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:7pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">state, foreign and other securities and other laws applicable to the Plan.  If, on a Purchase Date, the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase Date will be delayed until the shares of Common Stock are subject to such an effective registration statement and the Plan is in such compliance, except that the Purchase Date will not be delayed more than twelve (12) months and the Purchase Date will in no event be more than twenty-seven (27) months from the Offering Date.  If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Covenants of the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will seek to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder.  If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and&#47;or to issue and sell Common Stock upon exercise of such Purchase Rights.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Designation of Beneficiary.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any shares of Common Stock and&#47;or Contributions from the Participant&#8217;s account under the Plan if the Participant dies before such shares and&#47;or Contributions are delivered to the Participant.  The Company may, but is not obligated to, permit the Participant to change such designation of beneficiary.  Any such designation and&#47;or change must be on a form approved by the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">If a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock and&#47;or Contributions to the executor or administrator of the estate of the Participant.  If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common Stock and&#47;or Contributions to the Participant&#8217;s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Adjustments upon Changes in Common Stock&#59; Corporate Transactions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust&#58; (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a)&#59; (ii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights&#59; and (iii) the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering.  The Board will make these adjustments, and its determination will be final, binding and conclusive.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">In the event of a Corporate Transaction, (i) any surviving or acquiring corporation (or its parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for outstanding Purchase Rights, or (ii) if any surviving or acquiring corporation (or its parent company)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">does not assume or continue outstanding Purchase Rights or does not substitute similar rights for outstanding Purchase Rights, then the Participants&#8217; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:7pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accumulated Contributions will be used to purchase shares of Common Stock within ten (10) business days prior to the Corporate Transaction under such Purchase Rights, and such Purchase Rights will terminate immediately after such purchase.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Amendment, Suspension or Termination of the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Board may amend the Plan at any time in any respect the Board deems necessary or advisable.  However, except as provided in Section 11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by applicable law or listing requirements.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The Board may suspend or terminate the Plan at any time.  No Purchase Rights may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Any benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i) with the consent of the person to whom such Purchase Rights were granted, (ii) as necessary to comply with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section 423 of the Code and the regulations and other interpretive guidance issued thereunder relating to Employee Stock Purchase Plans) including, without limitation, any such regulations or other guidance that may be issued or amended after the Adoption Date, or (iii) as necessary to obtain or maintain favorable tax, listing, or regulatory treatment.  To be clear, the Board may amend outstanding Purchase Rights without a Participant&#8217;s consent if such amendment is necessary to ensure that the Purchase Right and&#47;or the Plan complies with the requirements of Section 423 of the Code.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Notwithstanding anything in the Plan or any Offering Document to the contrary, the Board will be entitled to&#58; (i) establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars&#59; (ii) permit Contributions in excess of the amount designated by a Participant in order to adjust for mistakes in the Company&#8217;s processing of properly completed Contribution elections&#59; (iii) establish reasonable waiting and adjustment periods and&#47;or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts withheld from the Participant&#8217;s Contributions&#59; (iv) amend any outstanding Purchase Rights or clarify any ambiguities regarding the terms of any Offering to enable the Purchase Rights to qualify under and&#47;or comply with Section&#160;423 of the Code&#59; and (v) establish other limitations or procedures as the Board determines in its sole discretion advisable that are consistent with the Plan.  The actions of the Board pursuant to this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the initial terms of each Offering and the Purchase Rights granted under each Offering.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Effective Date of Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Plan will become effective on the Effective Date.  No Purchase Rights will be exercised unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section 12(a), materially amended) by the Board. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Miscellaneous Provisions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:7pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common Stock subject to Purchase Rights unless and until the Participant&#8217;s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Plan and Offering do not constitute an employment contract.  Nothing in the Plan or in the Offering will in any way alter the at will nature of a Participant&#8217;s employment or  be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation, or on the part of the Company or a Related Corporation to continue the employment of a Participant.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">The provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state&#8217;s conflicts of laws rules.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Definitions.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As used in the Plan, the following definitions will apply to the capitalized terms indicated below&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Adoption Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means February 6, 2018, which is the date the Plan was adopted by the Board.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the first meeting of the Company&#8217;s stockholders held each calendar year at which Directors are selected.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Capitalization Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the Adoption Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a committee of one (1) or more members of the Board to whom authority has been delegated by the Board in accordance with Section 2(c).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the common stock of the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Neurocrine Biosciences, Inc., a Delaware corporation.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Contributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the payroll deductions and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right.  A Participant may make additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:7pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Corporate Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">a sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">a sale or other disposition of at least ninety percent (90%) of the outstanding securities of the Company&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">a merger, consolidation or similar transaction following which the Company is not the surviving corporation&#59; or</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a member of the Board.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the effective date of this Plan document, which is the date of the Annual Meeting in 2018, provided that this Plan is approved by the Company&#8217;s stockholders at such meeting.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Eligible Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Employee who meets the requirements set forth in the document(s) governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any person, including an Officer or Director, who is &#8220;employed&#8221; for purposes of Section 423(b)(4) of the Code by the Company or a Related Corporation.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Employee Stock Purchase Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a plan that grants Purchase Rights intended to be options issued under an &#8220;employee stock purchase plan,&#8221; as that term is defined in Section 423(b) of the Code.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, as of any date, the value of the Common Stock determined as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing sales price on the last preceding date for which such quotation exists.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:7pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith in compliance with applicable laws and in a manner that complies with Section 409A of the Code.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the grant to Eligible Employees of Purchase Rights, with the exercise of those Purchase Rights automatically occurring at the end of one or more Purchase Periods.  The terms and conditions of an Offering will generally be set forth in the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Offering Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; approved by the Board for that Offering.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Offering Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a date selected by the Board for an Offering to commence.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a person who is an officer of the Company or a Related Corporation within the meaning of Section 16 of the Exchange Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Eligible Employee who holds an outstanding Purchase Right. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means this Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Purchase Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means one or more dates during an Offering selected by the Board on which Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Purchase Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a period of time specified within an Offering, generally beginning on the Offering Date or on the first Trading Day following a Purchase Date and ending on a Purchase Date.  An Offering may consist of one or more Purchase Periods.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Purchase Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an option to purchase shares of Common Stock granted pursuant to the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Related Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(aa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Act of 1933, as amended.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(bb)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.68pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to the Company, (i) any corporation of which more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%).  For purposes of the foregoing clause (i), the Company will be deemed to &#8220;Own&#8221; or have &#8220;Owned&#8221; such securities if the Company, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(cc)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any day on which the exchange(s) or market(s) on which shares of Common Stock are listed (including, but not limited to, the NYSE, the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto) is open for trading.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>q2-2022xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i93a0c492ba4e4f13a05083eebde39314_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; August&#160;4, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kevin C. Gorman&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>q2-2022xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icff880412adb4f14aa4501988fffa0d7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Matthew C. Abernethy, Chief Financial Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; August&#160;4, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew C. Abernethy&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>q2-2022xexhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3028c73420864983af00044b9a1026c0_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Neurocrine Biosciences, Inc. (Company) on Form 10-Q for the period ended June&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (Report), I, Kevin C. Gorman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Neurocrine Biosciences, Inc. (Company) on Form 10-Q for the period ended June&#160;30, 2022 as filed with the Securities and Exchange Commission on the date hereof (Report), I, Matthew C. Abernethy, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew C. Abernethy&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>nbix-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0c42dd0c-c284-4653-91e4-174ef769a678,g:b6b90098-cdc3-4729-a2bb-5ae5dda3bf39-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.neurocrine.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2403401 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreements">
        <link:definition>2104102 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails">
        <link:definition>2405402 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecurities" roleURI="http://www.neurocrine.com/role/DebtSecurities">
        <link:definition>2106103 - Disclosure - Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesTables" roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables">
        <link:definition>2307301 - Disclosure - Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails">
        <link:definition>2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails">
        <link:definition>2409404 - Disclosure - Debt Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails">
        <link:definition>2410405 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.neurocrine.com/role/FairValueMeasurements">
        <link:definition>2111104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables">
        <link:definition>2312302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail">
        <link:definition>2413406 - Disclosure - Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail">
        <link:definition>2414407 - Disclosure - Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.neurocrine.com/role/Inventories">
        <link:definition>2115105 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.neurocrine.com/role/InventoriesTables">
        <link:definition>2316303 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesSummaryofInventoriesDetails" roleURI="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails">
        <link:definition>2417408 - Disclosure - Inventories - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCash" roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash">
        <link:definition>2118106 - Disclosure - Cash, Cash Equivalents and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashTables" roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables">
        <link:definition>2319304 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2420409 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.neurocrine.com/role/Leases">
        <link:definition>2121107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.neurocrine.com/role/LeasesTables">
        <link:definition>2322305 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeInformationDetails" roleURI="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails">
        <link:definition>2423410 - Disclosure - Leases - Narrative Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalInformationDetails" roleURI="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails">
        <link:definition>2424411 - Disclosure - Leases - Supplemental Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLiabilityPaymentDueDetails" roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails">
        <link:definition>2425412 - Disclosure - Leases - Liability, Payment, Due (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLiabilityPaymentDueDetails_1" roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1">
        <link:definition>2425412 - Disclosure - Leases - Liability, Payment, Due (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes">
        <link:definition>2126108 - Disclosure - Convertible Senior Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesTables" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables">
        <link:definition>2327306 - Disclosure - Convertible Senior Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesAdditionalInformationDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails">
        <link:definition>2428413 - Disclosure - Convertible Senior Notes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes2024NotesDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails">
        <link:definition>2429414 - Disclosure - Convertible Senior Notes - 2024 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesInterestExpenseDetails" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails">
        <link:definition>2430415 - Disclosure - Convertible Senior Notes - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossEarningsperShare" roleURI="http://www.neurocrine.com/role/LossEarningsperShare">
        <link:definition>2131109 - Disclosure - (Loss) Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossEarningsperShareTables" roleURI="http://www.neurocrine.com/role/LossEarningsperShareTables">
        <link:definition>2332307 - Disclosure - (Loss) Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossEarningsperShareScheduleofNetIncomePerShareDetails" roleURI="http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails">
        <link:definition>2433416 - Disclosure - (Loss) Earnings per Share - Schedule of Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nbix_RestrictedCashTextBlock" abstract="false" name="RestrictedCashTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PrincipalAmountOnConversionRate" abstract="false" name="PrincipalAmountOnConversionRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AnnualRentEscalationPercentage" abstract="false" name="AnnualRentEscalationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" abstract="true" name="SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" abstract="false" name="IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_DebtInstrumentConversionDomain" abstract="true" name="DebtInstrumentConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_DebtInstrumentConvertibleConversionPremium" abstract="false" name="DebtInstrumentConvertibleConversionPremium" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nbix_RentAbatementPeriod" abstract="false" name="RentAbatementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_AbbVieIncMember" abstract="true" name="AbbVieIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_BIALPortelaCaSAMember" abstract="true" name="BIALPortelaCaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" abstract="false" name="MinimumPercentageOfTradingPriceToLastReportedSalePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nbix_InvestmentIncomeAndOtherNet" abstract="false" name="InvestmentIncomeAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PatentTerm" abstract="false" name="PatentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_ConversionPeriodOneMember" abstract="true" name="ConversionPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" abstract="false" name="SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nbix_ConversionPeriodTwoMember" abstract="true" name="ConversionPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_DebtInstrumentCouponInterest" abstract="false" name="DebtInstrumentCouponInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_CarryingAmountOfLiabilityComponentUponIssuance" abstract="false" name="CarryingAmountOfLiabilityComponentUponIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_LongTermInvestmentsMember" abstract="true" name="LongTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" abstract="false" name="LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DebtInstrumentConversionAxis" abstract="true" name="DebtInstrumentConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_SaleOfStockNumberOfSharesSoldInTransaction" abstract="false" name="SaleOfStockNumberOfSharesSoldInTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" abstract="false" name="LesseeOperatingLeaseOptionTermToConstructFifthBuilding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_IdorsiaPharmaceuticalsLtdMember" abstract="true" name="IdorsiaPharmaceuticalsLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" abstract="false" name="FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_CashAndMoneyMarketFundMember" abstract="true" name="CashAndMoneyMarketFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_MitsubishiTanabePharmaCorporationMember" abstract="true" name="MitsubishiTanabePharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_A225ConvertibleSeniorNotesMember" abstract="true" name="A225ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_UpfrontPaymentsMade" abstract="false" name="UpfrontPaymentsMade" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_PotentialMilestonePaymentReceipts" abstract="false" name="PotentialMilestonePaymentReceipts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_HeptaresTherapeuticsLimitedMember" abstract="true" name="HeptaresTherapeuticsLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_XenonPharmaceuticalsIncMember" abstract="true" name="XenonPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" abstract="false" name="DebtSecuritiesAvailableForSalePositionNumberOfPositions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_TakedaPharmaceuticalCompanyLimitedMember" abstract="true" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_CarryingAmountOfLiabilityComponentAtSettlement" abstract="false" name="CarryingAmountOfLiabilityComponentAtSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_NumberOfRenewalOptions" abstract="false" name="NumberOfRenewalOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_MilestonePayment" abstract="false" name="MilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_VoyagerTherapeuticsMember" abstract="true" name="VoyagerTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbix_PotentialMilestonePayments" abstract="false" name="PotentialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>nbix-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0c42dd0c-c284-4653-91e4-174ef769a678,g:b6b90098-cdc3-4729-a2bb-5ae5dda3bf39-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_56c151b3-af65-4b81-9f46-80ea5af2bac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fa84877e-976c-47b3-b469-ac5d2f9b55f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_56c151b3-af65-4b81-9f46-80ea5af2bac3" xlink:to="loc_us-gaap_LiabilitiesCurrent_fa84877e-976c-47b3-b469-ac5d2f9b55f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_cfc9cd1c-38ba-4b5f-bfef-8661a33b7e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_56c151b3-af65-4b81-9f46-80ea5af2bac3" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_cfc9cd1c-38ba-4b5f-bfef-8661a33b7e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_286772d1-aed3-44c2-9bf9-929a17f82d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_56c151b3-af65-4b81-9f46-80ea5af2bac3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_286772d1-aed3-44c2-9bf9-929a17f82d1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_71a4fd80-c789-4ec1-8b9e-ebcd084f9ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_56c151b3-af65-4b81-9f46-80ea5af2bac3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_71a4fd80-c789-4ec1-8b9e-ebcd084f9ab4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3d96284b-3c2b-4e03-b53a-fec25eb0ab2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a3cf7524-5fb7-46f5-bde8-cd7524d1f67e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3d96284b-3c2b-4e03-b53a-fec25eb0ab2b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a3cf7524-5fb7-46f5-bde8-cd7524d1f67e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_19ef05c4-e588-4470-a5a3-cc35d38f960d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3d96284b-3c2b-4e03-b53a-fec25eb0ab2b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_19ef05c4-e588-4470-a5a3-cc35d38f960d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_51df8fbb-7cf9-4c30-a805-1eba3bbf6669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2a146921-3868-4c85-964a-3125df0e2863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_51df8fbb-7cf9-4c30-a805-1eba3bbf6669" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2a146921-3868-4c85-964a-3125df0e2863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_77e48e43-cf1e-4c09-9602-74f269e35805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_51df8fbb-7cf9-4c30-a805-1eba3bbf6669" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_77e48e43-cf1e-4c09-9602-74f269e35805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_71f3f95f-46e4-4415-9283-014931ba4d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_51df8fbb-7cf9-4c30-a805-1eba3bbf6669" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_71f3f95f-46e4-4415-9283-014931ba4d69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2ea5d8d5-355f-49de-bddf-1e1434020944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_51df8fbb-7cf9-4c30-a805-1eba3bbf6669" xlink:to="loc_us-gaap_InventoryNet_2ea5d8d5-355f-49de-bddf-1e1434020944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_412c9968-fc36-48c0-9dcb-f4522196394f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_51df8fbb-7cf9-4c30-a805-1eba3bbf6669" xlink:to="loc_us-gaap_OtherAssetsCurrent_412c9968-fc36-48c0-9dcb-f4522196394f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ff2db616-24ee-4fd4-8678-7c06fa350c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0937bbd1-8d58-4f84-84c1-72fa91fffe35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff2db616-24ee-4fd4-8678-7c06fa350c68" xlink:to="loc_us-gaap_AssetsCurrent_0937bbd1-8d58-4f84-84c1-72fa91fffe35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_64c5ab5c-546a-460d-8656-a4885164e7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff2db616-24ee-4fd4-8678-7c06fa350c68" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_64c5ab5c-546a-460d-8656-a4885164e7e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f88ac96b-b5bc-4737-902e-13c4f0f64517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff2db616-24ee-4fd4-8678-7c06fa350c68" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f88ac96b-b5bc-4737-902e-13c4f0f64517" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fdc8a5df-c2ec-498a-a794-743a74ad48b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff2db616-24ee-4fd4-8678-7c06fa350c68" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fdc8a5df-c2ec-498a-a794-743a74ad48b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6d10a158-54ea-4eed-b76b-7314d8351505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff2db616-24ee-4fd4-8678-7c06fa350c68" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6d10a158-54ea-4eed-b76b-7314d8351505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cfeae66a-15a7-4f49-8552-b944d7e401c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff2db616-24ee-4fd4-8678-7c06fa350c68" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cfeae66a-15a7-4f49-8552-b944d7e401c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_db011fd0-49f0-4099-a1c7-6de8a0ae43cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff2db616-24ee-4fd4-8678-7c06fa350c68" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_db011fd0-49f0-4099-a1c7-6de8a0ae43cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b06402d6-d4ef-4daa-8ac1-b92d5429cbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bda3757f-03ef-4f6e-884a-a4a93d5b096a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b06402d6-d4ef-4daa-8ac1-b92d5429cbc7" xlink:to="loc_us-gaap_Liabilities_bda3757f-03ef-4f6e-884a-a4a93d5b096a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8873357c-e315-4728-a599-85ff481415f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b06402d6-d4ef-4daa-8ac1-b92d5429cbc7" xlink:to="loc_us-gaap_StockholdersEquity_8873357c-e315-4728-a599-85ff481415f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eca3bb28-6776-4410-a7cf-3b0b74e529b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_aff5085e-f357-45cf-ac32-4be3d8898732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eca3bb28-6776-4410-a7cf-3b0b74e529b0" xlink:to="loc_us-gaap_PreferredStockValue_aff5085e-f357-45cf-ac32-4be3d8898732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_756ffb59-1b6b-457a-9c8c-65614f0fb445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eca3bb28-6776-4410-a7cf-3b0b74e529b0" xlink:to="loc_us-gaap_CommonStockValue_756ffb59-1b6b-457a-9c8c-65614f0fb445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2799b643-f394-431c-abb3-4f93661b3c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eca3bb28-6776-4410-a7cf-3b0b74e529b0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2799b643-f394-431c-abb3-4f93661b3c23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_953da228-dc13-4731-af23-f3f4de2cfdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eca3bb28-6776-4410-a7cf-3b0b74e529b0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_953da228-dc13-4731-af23-f3f4de2cfdfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59c1c20d-e1c1-4dba-890d-3becaecebed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_eca3bb28-6776-4410-a7cf-3b0b74e529b0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59c1c20d-e1c1-4dba-890d-3becaecebed5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="simple" xlink:href="nbix-20220630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d14833bc-0105-44ac-ad94-735dbeca8f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ce1cab58-3ec1-4425-92cf-42882ae1c9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d14833bc-0105-44ac-ad94-735dbeca8f7f" xlink:to="loc_us-gaap_OperatingIncomeLoss_ce1cab58-3ec1-4425-92cf-42882ae1c9ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_25ec9a41-d060-465a-83c1-cc08b341e4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d14833bc-0105-44ac-ad94-735dbeca8f7f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_25ec9a41-d060-465a-83c1-cc08b341e4de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_30481ded-0868-44dd-aac1-e10a83249b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_37f24fb2-db2b-46c8-922d-c9265abc33e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_30481ded-0868-44dd-aac1-e10a83249b49" xlink:to="loc_us-gaap_InterestExpense_37f24fb2-db2b-46c8-922d-c9265abc33e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_618bfbd7-90e5-431e-a850-127173c23e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_30481ded-0868-44dd-aac1-e10a83249b49" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_618bfbd7-90e5-431e-a850-127173c23e8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d45dc4ab-fee7-48e3-ab3a-a984b4de2ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_30481ded-0868-44dd-aac1-e10a83249b49" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d45dc4ab-fee7-48e3-ab3a-a984b4de2ceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_a0cba128-f471-4385-8610-54755184b858" xlink:href="nbix-20220630.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_30481ded-0868-44dd-aac1-e10a83249b49" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_a0cba128-f471-4385-8610-54755184b858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_108c5e15-0100-4a98-85cf-c33ca93cdc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7439e781-5989-42df-8bd9-554ecb2fb50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_108c5e15-0100-4a98-85cf-c33ca93cdc49" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7439e781-5989-42df-8bd9-554ecb2fb50f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_67921bd7-d8a3-4749-a416-064dba816dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_108c5e15-0100-4a98-85cf-c33ca93cdc49" xlink:to="loc_us-gaap_CostsAndExpenses_67921bd7-d8a3-4749-a416-064dba816dbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_867a660b-4422-4073-be47-ed30e766de91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b1950691-a111-4787-a126-1b25699746bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_867a660b-4422-4073-be47-ed30e766de91" xlink:to="loc_us-gaap_NetIncomeLoss_b1950691-a111-4787-a126-1b25699746bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_014adcc5-ba56-4b8f-a759-379ea58954a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_867a660b-4422-4073-be47-ed30e766de91" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_014adcc5-ba56-4b8f-a759-379ea58954a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_281accf6-5e5b-4fce-9375-a038018efe36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_54cfff1a-1bb7-45fa-808c-d3f9add39427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_281accf6-5e5b-4fce-9375-a038018efe36" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_54cfff1a-1bb7-45fa-808c-d3f9add39427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_733455d2-f66b-405d-b0ef-720afde0e424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_281accf6-5e5b-4fce-9375-a038018efe36" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_733455d2-f66b-405d-b0ef-720afde0e424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_94da81e6-d11d-4dcd-8222-e79d5e4c0296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_09e9a2af-b6ee-4d7d-a1a6-d507b0a6c528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_94da81e6-d11d-4dcd-8222-e79d5e4c0296" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_09e9a2af-b6ee-4d7d-a1a6-d507b0a6c528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_21e5be88-0c81-4eea-87aa-6b6e1cadefb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_94da81e6-d11d-4dcd-8222-e79d5e4c0296" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_21e5be88-0c81-4eea-87aa-6b6e1cadefb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_3ba51339-49d3-4b19-9b7f-34f549759c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_94da81e6-d11d-4dcd-8222-e79d5e4c0296" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_3ba51339-49d3-4b19-9b7f-34f549759c82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1a88471b-cf6d-45e2-914c-96a501a93553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_94da81e6-d11d-4dcd-8222-e79d5e4c0296" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1a88471b-cf6d-45e2-914c-96a501a93553" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c29ea105-b88f-4a9d-8315-a3d8bd5ecd62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a8c9c1bf-f4e8-4a71-9a04-837fbd5de0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c29ea105-b88f-4a9d-8315-a3d8bd5ecd62" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a8c9c1bf-f4e8-4a71-9a04-837fbd5de0b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eeb7256c-01fc-40a8-89a4-c86506c73d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c29ea105-b88f-4a9d-8315-a3d8bd5ecd62" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eeb7256c-01fc-40a8-89a4-c86506c73d0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_abea1a59-188d-4da8-9d64-c0917f4e22f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c29ea105-b88f-4a9d-8315-a3d8bd5ecd62" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_abea1a59-188d-4da8-9d64-c0917f4e22f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f3fe067b-81ea-4fd6-8499-e9066c0639cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e61cd1c0-4e58-4e2c-9351-6de1a63e1aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f3fe067b-81ea-4fd6-8499-e9066c0639cd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e61cd1c0-4e58-4e2c-9351-6de1a63e1aa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_558c71de-0ee7-4725-b677-0bf4ce3bcd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f3fe067b-81ea-4fd6-8499-e9066c0639cd" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_558c71de-0ee7-4725-b677-0bf4ce3bcd8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e25d33f-d63a-4e0e-b102-463118ef13ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5b6ae83d-6ae3-4d80-98ae-b5afab1dad6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e25d33f-d63a-4e0e-b102-463118ef13ae" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5b6ae83d-6ae3-4d80-98ae-b5afab1dad6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_a44d9d0b-7b98-429a-92af-76cec3ca0035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e25d33f-d63a-4e0e-b102-463118ef13ae" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_a44d9d0b-7b98-429a-92af-76cec3ca0035" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_29a8cc5a-5dd3-462c-b75b-5389455c9395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e25d33f-d63a-4e0e-b102-463118ef13ae" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_29a8cc5a-5dd3-462c-b75b-5389455c9395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca7e3a13-790a-4d40-a7f0-6a645fa2c0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e25d33f-d63a-4e0e-b102-463118ef13ae" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca7e3a13-790a-4d40-a7f0-6a645fa2c0a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_643f4cb4-4a24-4711-93b3-7c66c18b9fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:to="loc_us-gaap_NetIncomeLoss_643f4cb4-4a24-4711-93b3-7c66c18b9fa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6c4afe36-2b3e-4616-b098-5e9b017c35ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:to="loc_us-gaap_ShareBasedCompensation_6c4afe36-2b3e-4616-b098-5e9b017c35ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a1717605-6a39-4141-a498-b1f0ddf3d56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:to="loc_us-gaap_Depreciation_a1717605-6a39-4141-a498-b1f0ddf3d56a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_e3c7ee30-ae5a-4cf9-aadc-45f67f997bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_e3c7ee30-ae5a-4cf9-aadc-45f67f997bb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_d662fe93-7dd4-4994-bb5e-67584e528cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_d662fe93-7dd4-4994-bb5e-67584e528cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_87fc3681-706b-41d9-8c5d-f83ac573b86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_87fc3681-706b-41d9-8c5d-f83ac573b86a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_01b84f0d-c56a-477c-8487-77c77e479c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_01b84f0d-c56a-477c-8487-77c77e479c18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f192718f-a620-4055-bbec-833e6ba79cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f192718f-a620-4055-bbec-833e6ba79cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_918fb4f4-6108-40fe-b3bd-169fb37e4e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_918fb4f4-6108-40fe-b3bd-169fb37e4e58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_13daf758-0c47-42cb-bd4b-2e8b48492801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_13daf758-0c47-42cb-bd4b-2e8b48492801" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_301c37dc-7b0b-4494-8386-e7ffd049b6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_301c37dc-7b0b-4494-8386-e7ffd049b6c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2a58c3a1-c5a1-416d-8758-8730381cd5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2a58c3a1-c5a1-416d-8758-8730381cd5c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_91225249-4db9-4dd7-897b-422283410d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_89435f6e-0cf0-4a79-9245-d2ce00b2a27a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_91225249-4db9-4dd7-897b-422283410d3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c1b246f5-7e2a-4472-b190-e491cb3f3cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3b22c9be-806c-4900-a923-bd96b20707b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c1b246f5-7e2a-4472-b190-e491cb3f3cf0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3b22c9be-806c-4900-a923-bd96b20707b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_33bcc5ec-2a1e-4ca1-b08b-37e552c64441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c1b246f5-7e2a-4472-b190-e491cb3f3cf0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_33bcc5ec-2a1e-4ca1-b08b-37e552c64441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f6adb377-f551-409d-947b-9d19f94e99cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c1b246f5-7e2a-4472-b190-e491cb3f3cf0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f6adb377-f551-409d-947b-9d19f94e99cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_e9d69a6c-a1f7-4740-8ffa-f209c3f8352e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_abf92152-c850-4723-8445-ababd0b6926d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_e9d69a6c-a1f7-4740-8ffa-f209c3f8352e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_abf92152-c850-4723-8445-ababd0b6926d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_16b7a95b-d174-4b25-a83f-e25e433869bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_e9d69a6c-a1f7-4740-8ffa-f209c3f8352e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_16b7a95b-d174-4b25-a83f-e25e433869bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_ba6afaf0-80b3-427b-9f73-d8323edeac00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0cd710df-d4da-42c9-84c5-1a849a4e58ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_ba6afaf0-80b3-427b-9f73-d8323edeac00" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0cd710df-d4da-42c9-84c5-1a849a4e58ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_24e5f164-646f-4ac7-ba01-debfc1ab3182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_ba6afaf0-80b3-427b-9f73-d8323edeac00" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_24e5f164-646f-4ac7-ba01-debfc1ab3182" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#InventoriesSummaryofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_314e806f-61e5-45ff-830e-fd37933948f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e1783a9c-42ec-44a0-b1ce-73afe85fe2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_314e806f-61e5-45ff-830e-fd37933948f3" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e1783a9c-42ec-44a0-b1ce-73afe85fe2ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3b593a8-e2d2-4f11-9246-acfa6d413010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_314e806f-61e5-45ff-830e-fd37933948f3" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3b593a8-e2d2-4f11-9246-acfa6d413010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5afe6f3e-acb1-41c9-91de-5c4da84f0318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_314e806f-61e5-45ff-830e-fd37933948f3" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5afe6f3e-acb1-41c9-91de-5c4da84f0318" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_4329562e-b258-4f3f-91da-2982f492e78a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a518b31-bf96-4f06-b992-ca1d6a71e88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_4329562e-b258-4f3f-91da-2982f492e78a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a518b31-bf96-4f06-b992-ca1d6a71e88a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_728ea161-5383-4660-830b-6ece6a16be47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_4329562e-b258-4f3f-91da-2982f492e78a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_728ea161-5383-4660-830b-6ece6a16be47" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#LeasesLiabilityPaymentDueDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d4ec8465-51aa-4352-b8c7-17b1f2f37871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2c260442-2c29-462d-ab13-afa73c15b2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d4ec8465-51aa-4352-b8c7-17b1f2f37871" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2c260442-2c29-462d-ab13-afa73c15b2c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e6fd5449-045f-47dc-8763-55a3242944f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d4ec8465-51aa-4352-b8c7-17b1f2f37871" xlink:to="loc_us-gaap_OperatingLeaseLiability_e6fd5449-045f-47dc-8763-55a3242944f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_eca8e1f3-3f76-49f0-8c1a-99bc713cceb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_089965a5-76d2-48c3-9698-24929c5b0671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_eca8e1f3-3f76-49f0-8c1a-99bc713cceb8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_089965a5-76d2-48c3-9698-24929c5b0671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cb981372-73cc-479c-99a4-d135e3bc79a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_eca8e1f3-3f76-49f0-8c1a-99bc713cceb8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cb981372-73cc-479c-99a4-d135e3bc79a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1" xlink:type="simple" xlink:href="nbix-20220630.xsd#LeasesLiabilityPaymentDueDetails_1"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b84e1030-aae7-44f1-8f6c-2e6ced48ff7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d6dec6d3-f618-4774-b2a9-42074b969a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b84e1030-aae7-44f1-8f6c-2e6ced48ff7e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d6dec6d3-f618-4774-b2a9-42074b969a45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8db61a29-83ae-4625-b8af-c0c8e0744b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b84e1030-aae7-44f1-8f6c-2e6ced48ff7e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8db61a29-83ae-4625-b8af-c0c8e0744b6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3fed9a40-f345-416c-98a0-4f9d31e1cc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b84e1030-aae7-44f1-8f6c-2e6ced48ff7e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3fed9a40-f345-416c-98a0-4f9d31e1cc6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5c39cf9b-e9e6-49ea-b09a-84291735ea6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b84e1030-aae7-44f1-8f6c-2e6ced48ff7e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5c39cf9b-e9e6-49ea-b09a-84291735ea6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f70839d4-3061-4d2c-a1bc-da85faa0af33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b84e1030-aae7-44f1-8f6c-2e6ced48ff7e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f70839d4-3061-4d2c-a1bc-da85faa0af33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_e575b7ce-4215-4e59-bc39-c093de76cc3a" xlink:href="nbix-20220630.xsd#nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b84e1030-aae7-44f1-8f6c-2e6ced48ff7e" xlink:to="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_e575b7ce-4215-4e59-bc39-c093de76cc3a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#ConvertibleSeniorNotesInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_17d6d3a4-db74-4470-bd5a-64e24a1a8958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentCouponInterest_1689f549-1544-4e70-a3e2-72dea9489857" xlink:href="nbix-20220630.xsd#nbix_DebtInstrumentCouponInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_17d6d3a4-db74-4470-bd5a-64e24a1a8958" xlink:to="loc_nbix_DebtInstrumentCouponInterest_1689f549-1544-4e70-a3e2-72dea9489857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_21d9760f-d8f7-4380-a132-d817ebc9d82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_17d6d3a4-db74-4470-bd5a-64e24a1a8958" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_21d9760f-d8f7-4380-a132-d817ebc9d82b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#LossEarningsperShareScheduleofNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8dfa052c-f34e-4409-b264-95b72163feca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_acf32782-cb28-441a-bcab-a34164e9196d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8dfa052c-f34e-4409-b264-95b72163feca" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_acf32782-cb28-441a-bcab-a34164e9196d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9e256e0d-94f2-4f8b-b602-4bdbf70f8f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8dfa052c-f34e-4409-b264-95b72163feca" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9e256e0d-94f2-4f8b-b602-4bdbf70f8f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_e8a8e6d6-c767-47fe-87d9-8d7e2c5015c8" xlink:href="nbix-20220630.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8dfa052c-f34e-4409-b264-95b72163feca" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_e8a8e6d6-c767-47fe-87d9-8d7e2c5015c8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>nbix-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0c42dd0c-c284-4653-91e4-174ef769a678,g:b6b90098-cdc3-4729-a2bb-5ae5dda3bf39-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="simple" xlink:href="nbix-20220630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="extended" id="ic953639b015649138b8558de93387ffb_CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_de661414-01cf-463d-a937-76a22616dc42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_RevenuesAbstract_de661414-01cf-463d-a937-76a22616dc42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_58fbc88b-4977-4526-b84d-28914c04bb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_de661414-01cf-463d-a937-76a22616dc42" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_58fbc88b-4977-4526-b84d-28914c04bb89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8abbab7a-2c9c-48bf-9d6a-4ca8f5510602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8abbab7a-2c9c-48bf-9d6a-4ca8f5510602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4906781c-7081-4334-9bad-b42a41289be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4906781c-7081-4334-9bad-b42a41289be7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5e9367cc-81c2-4985-b468-ce38ccb5fa54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5e9367cc-81c2-4985-b468-ce38ccb5fa54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a8c0e6c4-de00-4b32-a386-d5c422aeb3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a8c0e6c4-de00-4b32-a386-d5c422aeb3df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b078ead0-ab7e-46a2-b3a8-f19b3d3f243f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:to="loc_us-gaap_CostsAndExpenses_b078ead0-ab7e-46a2-b3a8-f19b3d3f243f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9f753cea-ed8a-4128-ae86-5006e2c7dff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_OperatingIncomeLoss_9f753cea-ed8a-4128-ae86-5006e2c7dff0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_113a7892-7cac-443d-95a7-1f595ee61853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:to="loc_us-gaap_InterestExpense_113a7892-7cac-443d-95a7-1f595ee61853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6cec25dc-0258-4cc6-8e83-c2d4a32f7e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6cec25dc-0258-4cc6-8e83-c2d4a32f7e36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_66f5c053-783d-49df-8df1-9e4e293010a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_66f5c053-783d-49df-8df1-9e4e293010a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_8775cee4-55b4-4662-9b0d-1dcdac404727" xlink:href="nbix-20220630.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_8775cee4-55b4-4662-9b0d-1dcdac404727" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f0eea723-188c-45de-90a2-fd76a446cfa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_f0eea723-188c-45de-90a2-fd76a446cfa3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7716df4d-903b-45dd-b0a9-3e7ee7e4da35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7716df4d-903b-45dd-b0a9-3e7ee7e4da35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cc2b209c-dd36-489d-901d-5d52efe81356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cc2b209c-dd36-489d-901d-5d52efe81356" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e7de6f50-2bfe-4af3-8190-e281a10527b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_NetIncomeLoss_e7de6f50-2bfe-4af3-8190-e281a10527b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3ed4362b-ce78-4051-85ae-bf4c33061aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3ed4362b-ce78-4051-85ae-bf4c33061aa1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c1f8d2fa-ee2f-4824-8e87-db2f57c8b89e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c1f8d2fa-ee2f-4824-8e87-db2f57c8b89e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_222523b6-515b-4d6d-8f23-aa119a972753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_222523b6-515b-4d6d-8f23-aa119a972753" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6659b7f0-15cd-4e5c-9af5-6647ef6dbb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_222523b6-515b-4d6d-8f23-aa119a972753" xlink:to="loc_us-gaap_EarningsPerShareBasic_6659b7f0-15cd-4e5c-9af5-6647ef6dbb5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9f59cfde-239b-47f3-960d-457bd81db9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_222523b6-515b-4d6d-8f23-aa119a972753" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9f59cfde-239b-47f3-960d-457bd81db9d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5c109f15-f0ff-485d-8f95-0edc4d00f81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5c109f15-f0ff-485d-8f95-0edc4d00f81e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b5b0e658-5529-48be-9a42-a470c24dbb60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5c109f15-f0ff-485d-8f95-0edc4d00f81e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b5b0e658-5529-48be-9a42-a470c24dbb60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8ed18bad-396f-45ec-b68e-5e2f93e31bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5c109f15-f0ff-485d-8f95-0edc4d00f81e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8ed18bad-396f-45ec-b68e-5e2f93e31bf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3907596b-e00a-4277-84c2-85b0be5a804e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_StatementTable_3907596b-e00a-4277-84c2-85b0be5a804e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_403b11dc-ab09-4221-a3df-77f53ab19f7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3907596b-e00a-4277-84c2-85b0be5a804e" xlink:to="loc_srt_ProductOrServiceAxis_403b11dc-ab09-4221-a3df-77f53ab19f7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_403b11dc-ab09-4221-a3df-77f53ab19f7f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_403b11dc-ab09-4221-a3df-77f53ab19f7f" xlink:to="loc_srt_ProductsAndServicesDomain_403b11dc-ab09-4221-a3df-77f53ab19f7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6e7e0b97-8e46-4a3f-9311-4553b9a0edf5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_403b11dc-ab09-4221-a3df-77f53ab19f7f" xlink:to="loc_srt_ProductsAndServicesDomain_6e7e0b97-8e46-4a3f-9311-4553b9a0edf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f83907ef-ff2e-4a2e-a2e5-ddd6f300e293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6e7e0b97-8e46-4a3f-9311-4553b9a0edf5" xlink:to="loc_us-gaap_ProductMember_f83907ef-ff2e-4a2e-a2e5-ddd6f300e293" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_3c58b080-8d35-40f8-b252-c48bdac410ae" xlink:href="nbix-20220630.xsd#nbix_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6e7e0b97-8e46-4a3f-9311-4553b9a0edf5" xlink:to="loc_nbix_CollaborationRevenueMember_3c58b080-8d35-40f8-b252-c48bdac410ae" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i46c67abdebdf4c14a1322f1cc2340717_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5c80272a-bf6a-4803-a006-fdd53ed10cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5c80272a-bf6a-4803-a006-fdd53ed10cab" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_893e8a41-e6d8-4394-8a2f-e1337c25dce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_SharesOutstanding_893e8a41-e6d8-4394-8a2f-e1337c25dce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_13f88140-b791-4e8f-8325-601ef53f049e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_StockholdersEquity_13f88140-b791-4e8f-8325-601ef53f049e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d38afc69-27f5-438b-a9f8-7cbadeba014e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_NetIncomeLoss_d38afc69-27f5-438b-a9f8-7cbadeba014e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6e3424f7-53de-48a3-848e-5302caabeb62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6e3424f7-53de-48a3-848e-5302caabeb62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_710b0417-668b-4ac4-a85a-2f9f8cd9bfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_710b0417-668b-4ac4-a85a-2f9f8cd9bfc6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f5d9ce81-6467-44c7-a286-51144ec2405f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f5d9ce81-6467-44c7-a286-51144ec2405f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a8014bab-9b32-4d3d-98da-be31ba22c057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a8014bab-9b32-4d3d-98da-be31ba22c057" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9322566f-edf3-48d2-9557-73a776d339c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9322566f-edf3-48d2-9557-73a776d339c4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9b5322fa-1faf-4ceb-a59a-56bc2226815e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36ea5108-fc68-4473-8bf5-ad368e0596b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1b70569d-994e-4604-bc62-8998c4858925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5c80272a-bf6a-4803-a006-fdd53ed10cab" xlink:to="loc_us-gaap_StatementTable_1b70569d-994e-4604-bc62-8998c4858925" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ee4a0590-6a51-4ec6-a354-9cfce9f44270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1b70569d-994e-4604-bc62-8998c4858925" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ee4a0590-6a51-4ec6-a354-9cfce9f44270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ee4a0590-6a51-4ec6-a354-9cfce9f44270_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ee4a0590-6a51-4ec6-a354-9cfce9f44270" xlink:to="loc_us-gaap_EquityComponentDomain_ee4a0590-6a51-4ec6-a354-9cfce9f44270_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3486e7c5-8e89-4807-a260-df76d1301124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ee4a0590-6a51-4ec6-a354-9cfce9f44270" xlink:to="loc_us-gaap_EquityComponentDomain_3486e7c5-8e89-4807-a260-df76d1301124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a5a76b39-ba25-438d-aedd-b8edd866ea97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3486e7c5-8e89-4807-a260-df76d1301124" xlink:to="loc_us-gaap_CommonStockMember_a5a76b39-ba25-438d-aedd-b8edd866ea97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_042e9237-0983-4b94-8c08-23906c82b197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3486e7c5-8e89-4807-a260-df76d1301124" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_042e9237-0983-4b94-8c08-23906c82b197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec0c5192-efb9-463a-b2c9-76d79bd9aeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3486e7c5-8e89-4807-a260-df76d1301124" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec0c5192-efb9-463a-b2c9-76d79bd9aeb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_36779209-2ab4-4cdf-8191-db5ddf2f644a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3486e7c5-8e89-4807-a260-df76d1301124" xlink:to="loc_us-gaap_RetainedEarningsMember_36779209-2ab4-4cdf-8191-db5ddf2f644a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e48a984f-ef8d-45dd-b514-0166e9ac0490" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1b70569d-994e-4604-bc62-8998c4858925" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e48a984f-ef8d-45dd-b514-0166e9ac0490" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e48a984f-ef8d-45dd-b514-0166e9ac0490_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e48a984f-ef8d-45dd-b514-0166e9ac0490" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e48a984f-ef8d-45dd-b514-0166e9ac0490_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d8cdd286-9c2b-4533-9e1d-8a5b81eba8e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e48a984f-ef8d-45dd-b514-0166e9ac0490" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d8cdd286-9c2b-4533-9e1d-8a5b81eba8e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1f668dfc-fc78-4289-bb1f-a1530b836ad0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d8cdd286-9c2b-4533-9e1d-8a5b81eba8e6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1f668dfc-fc78-4289-bb1f-a1530b836ad0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="ibbac044463df4e2c9b412fbf48e2c472_OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_5d853f28-a6f2-443f-89c0-e5a6f8931063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_5d853f28-a6f2-443f-89c0-e5a6f8931063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4a9f44eb-d621-4a7a-8eaf-54c6e2597d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4a9f44eb-d621-4a7a-8eaf-54c6e2597d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_39f8b906-962e-4484-bb0e-4a7bd7cfa0db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_39f8b906-962e-4484-bb0e-4a7bd7cfa0db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9ce45e88-141c-498b-b987-dee04083e690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9ce45e88-141c-498b-b987-dee04083e690" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b49a2174-4ab4-4cc2-918c-6c0921e18cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b49a2174-4ab4-4cc2-918c-6c0921e18cf0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5ce19022-cb70-4976-9cc1-60391c850797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5ce19022-cb70-4976-9cc1-60391c850797" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_591f03c3-a052-45b1-9e24-5241d42739eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_591f03c3-a052-45b1-9e24-5241d42739eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7e76db3c-3810-45fe-ae0d-3ef0f39722de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_591f03c3-a052-45b1-9e24-5241d42739eb" xlink:to="loc_us-gaap_DebtInstrumentAxis_7e76db3c-3810-45fe-ae0d-3ef0f39722de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7e76db3c-3810-45fe-ae0d-3ef0f39722de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7e76db3c-3810-45fe-ae0d-3ef0f39722de" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7e76db3c-3810-45fe-ae0d-3ef0f39722de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9961347d-8ca5-4c9a-8c59-69b75d37e162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7e76db3c-3810-45fe-ae0d-3ef0f39722de" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9961347d-8ca5-4c9a-8c59-69b75d37e162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_f895f1ff-3037-44fe-9208-39395dedbd8a" xlink:href="nbix-20220630.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9961347d-8ca5-4c9a-8c59-69b75d37e162" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_f895f1ff-3037-44fe-9208-39395dedbd8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1f1da57-4ecd-4ea3-bd38-0569010d58b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_591f03c3-a052-45b1-9e24-5241d42739eb" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1f1da57-4ecd-4ea3-bd38-0569010d58b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a1f1da57-4ecd-4ea3-bd38-0569010d58b3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1f1da57-4ecd-4ea3-bd38-0569010d58b3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a1f1da57-4ecd-4ea3-bd38-0569010d58b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d09214a0-b65c-4a04-8509-df9eabf32cba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1f1da57-4ecd-4ea3-bd38-0569010d58b3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d09214a0-b65c-4a04-8509-df9eabf32cba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_40177365-46dd-48a9-a6c6-5d15f576e4f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d09214a0-b65c-4a04-8509-df9eabf32cba" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_40177365-46dd-48a9-a6c6-5d15f576e4f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3d8d4a30-9402-4e1e-aafa-aedcb1e6d2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_591f03c3-a052-45b1-9e24-5241d42739eb" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3d8d4a30-9402-4e1e-aafa-aedcb1e6d2ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_3d8d4a30-9402-4e1e-aafa-aedcb1e6d2ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3d8d4a30-9402-4e1e-aafa-aedcb1e6d2ea" xlink:to="loc_us-gaap_TypeOfAdoptionMember_3d8d4a30-9402-4e1e-aafa-aedcb1e6d2ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_32a3d689-efed-40d7-8666-79f8a121ea64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3d8d4a30-9402-4e1e-aafa-aedcb1e6d2ea" xlink:to="loc_us-gaap_TypeOfAdoptionMember_32a3d689-efed-40d7-8666-79f8a121ea64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_51471ff1-9db9-4720-b390-2f94a8fbf056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_32a3d689-efed-40d7-8666-79f8a121ea64" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_51471ff1-9db9-4720-b390-2f94a8fbf056" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended" id="i1abd0a7483e340d190b37d8ae8125994_CollaborationandLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5f4a538b-aa5d-4139-b178-091260807700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5f4a538b-aa5d-4139-b178-091260807700" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ec46f2a0-5c24-4762-965e-3b7844debc04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ec46f2a0-5c24-4762-965e-3b7844debc04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_1fad87a5-f989-41de-986a-5b75d4c3e206" xlink:href="nbix-20220630.xsd#nbix_PotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_nbix_PotentialMilestonePayments_1fad87a5-f989-41de-986a-5b75d4c3e206" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_30adbec0-0f6a-478f-921a-a7e7babd26d9" xlink:href="nbix-20220630.xsd#nbix_UpfrontPaymentsMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_nbix_UpfrontPaymentsMade_30adbec0-0f6a-478f-921a-a7e7babd26d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_39bb346b-be4c-4bb3-97a7-8f1e020cd1b9" xlink:href="nbix-20220630.xsd#nbix_SaleOfStockNumberOfSharesSoldInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_39bb346b-be4c-4bb3-97a7-8f1e020cd1b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_8f1b7ffe-8f85-4557-abe4-0cda234d7ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_us-gaap_SharePrice_8f1b7ffe-8f85-4557-abe4-0cda234d7ff4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_4c85cb01-6641-4a65-8252-e591044f39dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_4c85cb01-6641-4a65-8252-e591044f39dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_3cd15ea8-930c-4701-92a4-a636293a3992" xlink:href="nbix-20220630.xsd#nbix_MilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_nbix_MilestonePayment_3cd15ea8-930c-4701-92a4-a636293a3992" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_1cb3876a-f98b-45ac-b35f-6bb243a95318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_1cb3876a-f98b-45ac-b35f-6bb243a95318" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_4dca30fb-a187-4d27-8a60-b706c062573c" xlink:href="nbix-20220630.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_4dca30fb-a187-4d27-8a60-b706c062573c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm_ac497df4-36d1-459d-a513-4abe7297426b" xlink:href="nbix-20220630.xsd#nbix_PatentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_nbix_PatentTerm_ac497df4-36d1-459d-a513-4abe7297426b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6a00b4c5-bbda-4313-acdb-1a570d83ec98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6a00b4c5-bbda-4313-acdb-1a570d83ec98" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1f17253a-db8a-44b4-9eaf-2689f6fa038a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1f17253a-db8a-44b4-9eaf-2689f6fa038a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f17253a-db8a-44b4-9eaf-2689f6fa038a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1f17253a-db8a-44b4-9eaf-2689f6fa038a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f17253a-db8a-44b4-9eaf-2689f6fa038a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67586398-bbf8-4f21-9b02-269ccb66faee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1f17253a-db8a-44b4-9eaf-2689f6fa038a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67586398-bbf8-4f21-9b02-269ccb66faee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_cdb15f01-ee2a-46e8-ba28-e311c748305e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67586398-bbf8-4f21-9b02-269ccb66faee" xlink:to="loc_us-gaap_CollaborativeArrangementMember_cdb15f01-ee2a-46e8-ba28-e311c748305e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ed554f13-d41e-4844-a492-ceeb3cae6fb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:to="loc_srt_ProductOrServiceAxis_ed554f13-d41e-4844-a492-ceeb3cae6fb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ed554f13-d41e-4844-a492-ceeb3cae6fb3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ed554f13-d41e-4844-a492-ceeb3cae6fb3" xlink:to="loc_srt_ProductsAndServicesDomain_ed554f13-d41e-4844-a492-ceeb3cae6fb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c9dc91c8-35ff-4a77-a3c9-0c4f3ead25fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ed554f13-d41e-4844-a492-ceeb3cae6fb3" xlink:to="loc_srt_ProductsAndServicesDomain_c9dc91c8-35ff-4a77-a3c9-0c4f3ead25fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_51610487-9196-40ec-8363-2573e9e85518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c9dc91c8-35ff-4a77-a3c9-0c4f3ead25fc" xlink:to="loc_us-gaap_RoyaltyMember_51610487-9196-40ec-8363-2573e9e85518" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aad3930c-71c8-4145-bbb7-015f2f9c506a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:to="loc_srt_CounterpartyNameAxis_aad3930c-71c8-4145-bbb7-015f2f9c506a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aad3930c-71c8-4145-bbb7-015f2f9c506a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_aad3930c-71c8-4145-bbb7-015f2f9c506a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aad3930c-71c8-4145-bbb7-015f2f9c506a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_aad3930c-71c8-4145-bbb7-015f2f9c506a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_HeptaresTherapeuticsLimitedMember_c6ad404e-fdc9-4836-8619-5c1a0b890efa" xlink:href="nbix-20220630.xsd#nbix_HeptaresTherapeuticsLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_HeptaresTherapeuticsLimitedMember_c6ad404e-fdc9-4836-8619-5c1a0b890efa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_c4d0b5ec-08db-4022-a47c-99a0f8bd3dfb" xlink:href="nbix-20220630.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_c4d0b5ec-08db-4022-a47c-99a0f8bd3dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_f56e32e4-41b0-449e-828d-4c28c930f859" xlink:href="nbix-20220630.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_f56e32e4-41b0-449e-828d-4c28c930f859" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_7e62e89a-7570-44b1-b1e2-b50b3795c6f5" xlink:href="nbix-20220630.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_7e62e89a-7570-44b1-b1e2-b50b3795c6f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_4234d351-c85f-4d1a-8650-e17406e06911" xlink:href="nbix-20220630.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_VoyagerTherapeuticsMember_4234d351-c85f-4d1a-8650-e17406e06911" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember_b9e13937-7919-4cea-9670-f80f3f0d99b3" xlink:href="nbix-20220630.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_BIALPortelaCaSAMember_b9e13937-7919-4cea-9670-f80f3f0d99b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_5fcc73a4-ffd6-4765-86ba-5a9c9e0523aa" xlink:href="nbix-20220630.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_5fcc73a4-ffd6-4765-86ba-5a9c9e0523aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember_692cad51-375a-42b3-85a2-79555a03ed34" xlink:href="nbix-20220630.xsd#nbix_AbbVieIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_AbbVieIncMember_692cad51-375a-42b3-85a2-79555a03ed34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_675a9692-c5ba-42b8-a05d-6afb00a698fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:to="loc_srt_RangeAxis_675a9692-c5ba-42b8-a05d-6afb00a698fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_675a9692-c5ba-42b8-a05d-6afb00a698fd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_675a9692-c5ba-42b8-a05d-6afb00a698fd" xlink:to="loc_srt_RangeMember_675a9692-c5ba-42b8-a05d-6afb00a698fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6aae9bdd-2193-460d-8f5e-d28934d3c3a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_675a9692-c5ba-42b8-a05d-6afb00a698fd" xlink:to="loc_srt_RangeMember_6aae9bdd-2193-460d-8f5e-d28934d3c3a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7779cb95-04b6-4535-9dfc-9c4bb52ab6d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6aae9bdd-2193-460d-8f5e-d28934d3c3a4" xlink:to="loc_srt_MinimumMember_7779cb95-04b6-4535-9dfc-9c4bb52ab6d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f25533d2-d40a-48fd-821a-5a1dae427652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f25533d2-d40a-48fd-821a-5a1dae427652" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f25533d2-d40a-48fd-821a-5a1dae427652_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f25533d2-d40a-48fd-821a-5a1dae427652" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f25533d2-d40a-48fd-821a-5a1dae427652_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5d333bf-2e09-4084-a864-460ea8794213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f25533d2-d40a-48fd-821a-5a1dae427652" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5d333bf-2e09-4084-a864-460ea8794213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_a4d3c5ea-e213-42a9-bb3d-2cc15b38403a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5d333bf-2e09-4084-a864-460ea8794213" xlink:to="loc_us-gaap_PatentsMember_a4d3c5ea-e213-42a9-bb3d-2cc15b38403a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5d3940cb-f471-420a-8085-d4b385ee82ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5d3940cb-f471-420a-8085-d4b385ee82ee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5d3940cb-f471-420a-8085-d4b385ee82ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5d3940cb-f471-420a-8085-d4b385ee82ee" xlink:to="loc_us-gaap_EquityComponentDomain_5d3940cb-f471-420a-8085-d4b385ee82ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_60e8be5d-d9fc-4b16-841e-8d6b2bd4d0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5d3940cb-f471-420a-8085-d4b385ee82ee" xlink:to="loc_us-gaap_EquityComponentDomain_60e8be5d-d9fc-4b16-841e-8d6b2bd4d0cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f224e442-c041-47d3-8f54-a14b6e55f191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_60e8be5d-d9fc-4b16-841e-8d6b2bd4d0cd" xlink:to="loc_us-gaap_CommonStockMember_f224e442-c041-47d3-8f54-a14b6e55f191" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="extended" id="ieb2d1627fc7e4914a1757878505928a7_DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f89e0581-d6fb-401d-a0ab-57594e241a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9c7ff0e0-0b63-42f6-9d82-881eadf8229b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f89e0581-d6fb-401d-a0ab-57594e241a22" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9c7ff0e0-0b63-42f6-9d82-881eadf8229b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cc6bd975-9b86-4de6-8b6c-8275026ffe35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f89e0581-d6fb-401d-a0ab-57594e241a22" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cc6bd975-9b86-4de6-8b6c-8275026ffe35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6f815853-b2f9-41ec-acb6-ca8d1a6278b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f89e0581-d6fb-401d-a0ab-57594e241a22" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6f815853-b2f9-41ec-acb6-ca8d1a6278b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b3a037ab-7089-43b1-9d66-64cd34c65085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f89e0581-d6fb-401d-a0ab-57594e241a22" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b3a037ab-7089-43b1-9d66-64cd34c65085" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_25c82eb0-4f5f-4b03-ad3d-a2db9ecc2fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f89e0581-d6fb-401d-a0ab-57594e241a22" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_25c82eb0-4f5f-4b03-ad3d-a2db9ecc2fc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_cf0bba79-fa90-4158-808c-f41391f35049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_25c82eb0-4f5f-4b03-ad3d-a2db9ecc2fc4" xlink:to="loc_us-gaap_InvestmentTypeAxis_cf0bba79-fa90-4158-808c-f41391f35049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_cf0bba79-fa90-4158-808c-f41391f35049_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_cf0bba79-fa90-4158-808c-f41391f35049" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_cf0bba79-fa90-4158-808c-f41391f35049_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0b187985-9c0b-42df-983b-3a0c0ab68203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_cf0bba79-fa90-4158-808c-f41391f35049" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0b187985-9c0b-42df-983b-3a0c0ab68203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_23c685d2-048f-4a55-baed-14a8bcda35e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0b187985-9c0b-42df-983b-3a0c0ab68203" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_23c685d2-048f-4a55-baed-14a8bcda35e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember_73603d2c-182b-4fcb-9005-2879d57674ed" xlink:href="nbix-20220630.xsd#nbix_LongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0b187985-9c0b-42df-983b-3a0c0ab68203" xlink:to="loc_nbix_LongTermInvestmentsMember_73603d2c-182b-4fcb-9005-2879d57674ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_1e36008a-1d75-496b-a373-2f9915e45cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_25c82eb0-4f5f-4b03-ad3d-a2db9ecc2fc4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_1e36008a-1d75-496b-a373-2f9915e45cc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1e36008a-1d75-496b-a373-2f9915e45cc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_1e36008a-1d75-496b-a373-2f9915e45cc5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1e36008a-1d75-496b-a373-2f9915e45cc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c12f50f5-fec8-4e0f-ae52-0565f0658d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_1e36008a-1d75-496b-a373-2f9915e45cc5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c12f50f5-fec8-4e0f-ae52-0565f0658d84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_017008ff-8e61-4c55-8f3a-48d1c3a2fc19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c12f50f5-fec8-4e0f-ae52-0565f0658d84" xlink:to="loc_us-gaap_CommercialPaperMember_017008ff-8e61-4c55-8f3a-48d1c3a2fc19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_22c6e9c3-1304-4058-a94b-ce374ebc7869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_25c82eb0-4f5f-4b03-ad3d-a2db9ecc2fc4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_22c6e9c3-1304-4058-a94b-ce374ebc7869" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22c6e9c3-1304-4058-a94b-ce374ebc7869_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_22c6e9c3-1304-4058-a94b-ce374ebc7869" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_22c6e9c3-1304-4058-a94b-ce374ebc7869_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c0a1137-c437-4e8e-b312-282b6dc6613b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_22c6e9c3-1304-4058-a94b-ce374ebc7869" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c0a1137-c437-4e8e-b312-282b6dc6613b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e5ac71ee-1022-49f6-9cbe-e07b3a567edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c0a1137-c437-4e8e-b312-282b6dc6613b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e5ac71ee-1022-49f6-9cbe-e07b3a567edd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_3f1bd96d-37f9-4a16-8078-50a35c108e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c0a1137-c437-4e8e-b312-282b6dc6613b" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_3f1bd96d-37f9-4a16-8078-50a35c108e09" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="extended" id="ieed0802a90264924be2960ab71060f3c_DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d2700cb5-d2ab-484e-ab42-97247c768d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d2700cb5-d2ab-484e-ab42-97247c768d74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b8a4b632-cda7-4ebd-bc93-84224fc495f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b8a4b632-cda7-4ebd-bc93-84224fc495f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_22e95109-4f37-4e6a-8105-f47ea9d9ebd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_22e95109-4f37-4e6a-8105-f47ea9d9ebd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ad09eee8-6545-4d17-977d-eeb6dcbf0963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ad09eee8-6545-4d17-977d-eeb6dcbf0963" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_930426cb-cd26-40f8-970e-4905fb105f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_930426cb-cd26-40f8-970e-4905fb105f0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_217e7dcb-1c59-4795-8660-60928eef7939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_217e7dcb-1c59-4795-8660-60928eef7939" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_8772fa3b-2b49-4515-82d3-02204c0a14e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_8772fa3b-2b49-4515-82d3-02204c0a14e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_50b0f78a-7677-4436-afd7-c2345e056036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_8772fa3b-2b49-4515-82d3-02204c0a14e6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_50b0f78a-7677-4436-afd7-c2345e056036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_50b0f78a-7677-4436-afd7-c2345e056036_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_50b0f78a-7677-4436-afd7-c2345e056036" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_50b0f78a-7677-4436-afd7-c2345e056036_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d4c3ede-58e3-4a65-b487-a512a051a3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_50b0f78a-7677-4436-afd7-c2345e056036" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d4c3ede-58e3-4a65-b487-a512a051a3b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5cfdc44b-6e2c-4165-98ce-dc6e09f05bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d4c3ede-58e3-4a65-b487-a512a051a3b9" xlink:to="loc_us-gaap_CommercialPaperMember_5cfdc44b-6e2c-4165-98ce-dc6e09f05bff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4f17c2ce-3da0-40c6-a0a0-f3e22d2dd8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d4c3ede-58e3-4a65-b487-a512a051a3b9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4f17c2ce-3da0-40c6-a0a0-f3e22d2dd8b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8953a26e-0e16-4ab9-b3f0-ef1e1984e983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d4c3ede-58e3-4a65-b487-a512a051a3b9" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8953a26e-0e16-4ab9-b3f0-ef1e1984e983" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="nbix-20220630.xsd#FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended" id="ie63d47ff6e56473381b2f7a0129d7697_FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ce79a6fe-a913-4919-addd-51527cd82841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_cccc2cf8-cf05-453d-97a7-37eb2727b3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ce79a6fe-a913-4919-addd-51527cd82841" xlink:to="loc_us-gaap_Investments_cccc2cf8-cf05-453d-97a7-37eb2727b3ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7f76fe0d-beed-49f5-bfe4-e4acc44f6f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ce79a6fe-a913-4919-addd-51527cd82841" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7f76fe0d-beed-49f5-bfe4-e4acc44f6f6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f741ef43-2db4-4df4-89e7-3f97d0fba864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ce79a6fe-a913-4919-addd-51527cd82841" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f741ef43-2db4-4df4-89e7-3f97d0fba864" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_9f31c540-6490-4de3-a751-f22778023df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f741ef43-2db4-4df4-89e7-3f97d0fba864" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_9f31c540-6490-4de3-a751-f22778023df1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9f31c540-6490-4de3-a751-f22778023df1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_9f31c540-6490-4de3-a751-f22778023df1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9f31c540-6490-4de3-a751-f22778023df1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3901cdfa-7003-4532-a38e-1df3078bde9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_9f31c540-6490-4de3-a751-f22778023df1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3901cdfa-7003-4532-a38e-1df3078bde9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_dfe44def-17a4-4bd8-90ff-8dcf2318e797" xlink:href="nbix-20220630.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3901cdfa-7003-4532-a38e-1df3078bde9f" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_dfe44def-17a4-4bd8-90ff-8dcf2318e797" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d695bebc-3ca9-4abf-9fa9-6c9be4a83e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3901cdfa-7003-4532-a38e-1df3078bde9f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d695bebc-3ca9-4abf-9fa9-6c9be4a83e33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d0502ae0-0b0b-4ebf-87ae-a13563daa956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3901cdfa-7003-4532-a38e-1df3078bde9f" xlink:to="loc_us-gaap_CommercialPaperMember_d0502ae0-0b0b-4ebf-87ae-a13563daa956" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d3896575-61d5-4a4c-b085-6f1ac5460429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f741ef43-2db4-4df4-89e7-3f97d0fba864" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d3896575-61d5-4a4c-b085-6f1ac5460429" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d3896575-61d5-4a4c-b085-6f1ac5460429_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d3896575-61d5-4a4c-b085-6f1ac5460429" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d3896575-61d5-4a4c-b085-6f1ac5460429_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6854d821-ea5d-4776-9a1a-6a3d83840ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d3896575-61d5-4a4c-b085-6f1ac5460429" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6854d821-ea5d-4776-9a1a-6a3d83840ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b667e155-b4c2-4993-875b-09f9b89aaf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6854d821-ea5d-4776-9a1a-6a3d83840ca6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b667e155-b4c2-4993-875b-09f9b89aaf7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5ec868e1-b1f0-4581-8cc2-c73560440152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6854d821-ea5d-4776-9a1a-6a3d83840ca6" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5ec868e1-b1f0-4581-8cc2-c73560440152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_c14c26f7-4e18-48b5-8661-20df56da61e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6854d821-ea5d-4776-9a1a-6a3d83840ca6" xlink:to="loc_us-gaap_EquitySecuritiesMember_c14c26f7-4e18-48b5-8661-20df56da61e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7860fb4c-16ae-4ddc-9672-db91370070e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f741ef43-2db4-4df4-89e7-3f97d0fba864" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7860fb4c-16ae-4ddc-9672-db91370070e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7860fb4c-16ae-4ddc-9672-db91370070e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7860fb4c-16ae-4ddc-9672-db91370070e4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7860fb4c-16ae-4ddc-9672-db91370070e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9df3692-563d-4e7b-a62a-76a48dee0ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7860fb4c-16ae-4ddc-9672-db91370070e4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9df3692-563d-4e7b-a62a-76a48dee0ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1cb63a15-eccc-4c06-a74a-e5168936b6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9df3692-563d-4e7b-a62a-76a48dee0ff4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1cb63a15-eccc-4c06-a74a-e5168936b6f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d864bf09-6846-4310-9443-01c28dd048b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9df3692-563d-4e7b-a62a-76a48dee0ff4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d864bf09-6846-4310-9443-01c28dd048b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_07140425-057d-4950-9a6d-e73fa3041d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9df3692-563d-4e7b-a62a-76a48dee0ff4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_07140425-057d-4950-9a6d-e73fa3041d0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e6b3bbe-0f31-4769-a49c-f45b20cbfff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f741ef43-2db4-4df4-89e7-3f97d0fba864" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e6b3bbe-0f31-4769-a49c-f45b20cbfff8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4e6b3bbe-0f31-4769-a49c-f45b20cbfff8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e6b3bbe-0f31-4769-a49c-f45b20cbfff8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4e6b3bbe-0f31-4769-a49c-f45b20cbfff8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_70557603-23ee-4386-ae25-a24ef13bd81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e6b3bbe-0f31-4769-a49c-f45b20cbfff8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_70557603-23ee-4386-ae25-a24ef13bd81b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_85c95152-55a2-4646-b169-156ddcdd9d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_70557603-23ee-4386-ae25-a24ef13bd81b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_85c95152-55a2-4646-b169-156ddcdd9d5f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="simple" xlink:href="nbix-20220630.xsd#FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="extended" id="id179e83004d34b4cb1d8d86bfc1020a6_FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ec1a8ac-6ec9-44d7-91b1-fc1c795568b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_891f0afc-ebda-4309-b996-7f2e32d47894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ec1a8ac-6ec9-44d7-91b1-fc1c795568b7" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_891f0afc-ebda-4309-b996-7f2e32d47894" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_0e5ed575-4ee3-4df4-b25b-d8fca6c98b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_891f0afc-ebda-4309-b996-7f2e32d47894" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_0e5ed575-4ee3-4df4-b25b-d8fca6c98b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_6c51b2ad-3c03-4216-8b6b-92d182cb7a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_891f0afc-ebda-4309-b996-7f2e32d47894" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_6c51b2ad-3c03-4216-8b6b-92d182cb7a36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_56e42e87-aaee-4b21-9ac0-15bdb10822e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_891f0afc-ebda-4309-b996-7f2e32d47894" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_56e42e87-aaee-4b21-9ac0-15bdb10822e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_ff7695c6-34f2-4955-a14c-53f6bad09928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172497a9-3c64-4735-bb30-3b149c18275b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ec1a8ac-6ec9-44d7-91b1-fc1c795568b7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172497a9-3c64-4735-bb30-3b149c18275b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f6fe32b-7eee-4dda-9103-a2373d4319a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172497a9-3c64-4735-bb30-3b149c18275b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f6fe32b-7eee-4dda-9103-a2373d4319a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6f6fe32b-7eee-4dda-9103-a2373d4319a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f6fe32b-7eee-4dda-9103-a2373d4319a8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6f6fe32b-7eee-4dda-9103-a2373d4319a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71919397-f010-43ba-902e-4c89969b29be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f6fe32b-7eee-4dda-9103-a2373d4319a8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71919397-f010-43ba-902e-4c89969b29be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a7b1cddd-0e9b-4041-8126-b5ad0afbad98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71919397-f010-43ba-902e-4c89969b29be" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a7b1cddd-0e9b-4041-8126-b5ad0afbad98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_778d6dc0-0955-43d2-9312-90962a0f3cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172497a9-3c64-4735-bb30-3b149c18275b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_778d6dc0-0955-43d2-9312-90962a0f3cda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_778d6dc0-0955-43d2-9312-90962a0f3cda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_778d6dc0-0955-43d2-9312-90962a0f3cda" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_778d6dc0-0955-43d2-9312-90962a0f3cda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_258f7654-ba5c-4096-8c89-7ad6e16ee7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_778d6dc0-0955-43d2-9312-90962a0f3cda" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_258f7654-ba5c-4096-8c89-7ad6e16ee7e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3ba8e550-3156-4434-9c7b-0da9538b5730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_258f7654-ba5c-4096-8c89-7ad6e16ee7e2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3ba8e550-3156-4434-9c7b-0da9538b5730" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0bfbd201-6e87-4098-bd03-de62bdea2b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172497a9-3c64-4735-bb30-3b149c18275b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0bfbd201-6e87-4098-bd03-de62bdea2b02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bfbd201-6e87-4098-bd03-de62bdea2b02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0bfbd201-6e87-4098-bd03-de62bdea2b02" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bfbd201-6e87-4098-bd03-de62bdea2b02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b0bd7a02-4ce7-4d77-b0f2-e0a78b0a6718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0bfbd201-6e87-4098-bd03-de62bdea2b02" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b0bd7a02-4ce7-4d77-b0f2-e0a78b0a6718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_be6afcb4-e72c-4fb0-9c76-c78d9369d2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b0bd7a02-4ce7-4d77-b0f2-e0a78b0a6718" xlink:to="loc_us-gaap_EquitySecuritiesMember_be6afcb4-e72c-4fb0-9c76-c78d9369d2d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#ConvertibleSeniorNotesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="extended" id="i7061cd1fdfab49d68c81499a515b7cbe_ConvertibleSeniorNotesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c6533769-9280-408f-b36a-9391a0a781ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c6533769-9280-408f-b36a-9391a0a781ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7daba78c-390b-4d44-be60-b4a6974e6e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7daba78c-390b-4d44-be60-b4a6974e6e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_bf008f27-9f5c-489c-8fcb-497de74005cd" xlink:href="nbix-20220630.xsd#nbix_CarryingAmountOfLiabilityComponentUponIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_bf008f27-9f5c-489c-8fcb-497de74005cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1ae53073-9818-4737-ac3c-f8aea65b95b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1ae53073-9818-4737-ac3c-f8aea65b95b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8a63fcbe-c904-4f82-9e1e-b63bfe54ce56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8a63fcbe-c904-4f82-9e1e-b63bfe54ce56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_bbabf951-259b-4921-8da1-3851bae602a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentTerm_bbabf951-259b-4921-8da1-3851bae602a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_49be04b9-ef9d-4c09-a702-db000ba239b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_49be04b9-ef9d-4c09-a702-db000ba239b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4cd569c0-0e9d-4faa-9216-9ee93bdb5d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4cd569c0-0e9d-4faa-9216-9ee93bdb5d76" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_da5ca27d-5979-44bc-8c90-37fd682f34c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_RepaymentsOfDebt_da5ca27d-5979-44bc-8c90-37fd682f34c1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_f3e433da-b0ba-4d71-b701-0d4fb2543687" xlink:href="nbix-20220630.xsd#nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_f3e433da-b0ba-4d71-b701-0d4fb2543687" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_be550a4f-48d1-4b3a-8836-cdc0337e4382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_be550a4f-48d1-4b3a-8836-cdc0337e4382" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_36e6f755-f98d-4e36-ba92-c499edb15ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_36e6f755-f98d-4e36-ba92-c499edb15ec9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_232c358a-3eaa-47cd-b3c1-cbe93b89d3dc" xlink:href="nbix-20220630.xsd#nbix_CarryingAmountOfLiabilityComponentAtSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_232c358a-3eaa-47cd-b3c1-cbe93b89d3dc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fe6fff79-e237-4829-8b00-56845c1e61f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fe6fff79-e237-4829-8b00-56845c1e61f4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_48b92b77-bf3d-4a78-98d3-340e33690368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_48b92b77-bf3d-4a78-98d3-340e33690368" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_7a1aeabc-1bc4-48a0-86d0-23127466968d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_7a1aeabc-1bc4-48a0-86d0-23127466968d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b5e3d141-a127-4d18-aad8-4399c7224083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b5e3d141-a127-4d18-aad8-4399c7224083" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_12510ae8-39d6-4e84-a3f2-21ba69a14cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_12510ae8-39d6-4e84-a3f2-21ba69a14cc0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a7006426-a7d9-4977-8808-5e2eddf0b9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a7006426-a7d9-4977-8808-5e2eddf0b9a8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_b56cb8bd-3571-46ac-89b5-a7a2377db480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_b56cb8bd-3571-46ac-89b5-a7a2377db480" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_57313cec-4c1d-4cd4-b111-f07f6d848f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_57313cec-4c1d-4cd4-b111-f07f6d848f8b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_c72f7665-4e25-4acc-9dda-8a0d5a63691a" xlink:href="nbix-20220630.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_c72f7665-4e25-4acc-9dda-8a0d5a63691a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_fde97c31-57ba-40e5-84ef-e3e00aa809d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_fde97c31-57ba-40e5-84ef-e3e00aa809d6" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_8c7f11aa-3450-4ca9-b681-7d3571d06b5e" xlink:href="nbix-20220630.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_8c7f11aa-3450-4ca9-b681-7d3571d06b5e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_efe00c71-c84f-4f51-9010-767f54fc1d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_SharePrice_efe00c71-c84f-4f51-9010-767f54fc1d43" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_edd787dd-2a60-4ee2-9a64-086b4a7b25ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_edd787dd-2a60-4ee2-9a64-086b4a7b25ec" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_ab2faa2b-f6d8-4aae-b187-7a1b51028ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_ab2faa2b-f6d8-4aae-b187-7a1b51028ded" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_9d1aaa25-1300-42e9-9736-fccd12dfaaac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_9d1aaa25-1300-42e9-9736-fccd12dfaaac" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_dbb5a8fa-c239-41b8-8c5d-61f466e96c80" xlink:href="nbix-20220630.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_dbb5a8fa-c239-41b8-8c5d-61f466e96c80" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_5957565a-2fe0-4ecf-9ae2-2c18cd35c5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_5957565a-2fe0-4ecf-9ae2-2c18cd35c5c9" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_954bc100-6a5a-43f9-b345-1becff8d8b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:to="loc_us-gaap_DebtInstrumentAxis_954bc100-6a5a-43f9-b345-1becff8d8b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_954bc100-6a5a-43f9-b345-1becff8d8b07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_954bc100-6a5a-43f9-b345-1becff8d8b07" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_954bc100-6a5a-43f9-b345-1becff8d8b07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aeb24792-36aa-4e94-81ea-781042b608f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_954bc100-6a5a-43f9-b345-1becff8d8b07" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aeb24792-36aa-4e94-81ea-781042b608f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_db5d8237-7688-4aa1-ac40-014bdf0f4607" xlink:href="nbix-20220630.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aeb24792-36aa-4e94-81ea-781042b608f9" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_db5d8237-7688-4aa1-ac40-014bdf0f4607" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_97d7530a-21e8-4c13-9e4a-f9d44a897b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_97d7530a-21e8-4c13-9e4a-f9d44a897b7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_97d7530a-21e8-4c13-9e4a-f9d44a897b7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_97d7530a-21e8-4c13-9e4a-f9d44a897b7b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_97d7530a-21e8-4c13-9e4a-f9d44a897b7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c231caac-7cf8-405d-8ac7-eccee87157b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_97d7530a-21e8-4c13-9e4a-f9d44a897b7b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c231caac-7cf8-405d-8ac7-eccee87157b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_8c8dd9b9-a24a-4bab-83e3-71dce1b5bdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c231caac-7cf8-405d-8ac7-eccee87157b4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_8c8dd9b9-a24a-4bab-83e3-71dce1b5bdbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_771cffba-c627-4ff4-924c-9d5f29b93242" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_771cffba-c627-4ff4-924c-9d5f29b93242" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_771cffba-c627-4ff4-924c-9d5f29b93242_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_771cffba-c627-4ff4-924c-9d5f29b93242" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_771cffba-c627-4ff4-924c-9d5f29b93242_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_02f7bc41-1db1-40ca-b905-059168fee609" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_771cffba-c627-4ff4-924c-9d5f29b93242" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_02f7bc41-1db1-40ca-b905-059168fee609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9da6b944-a86e-4a75-99ef-bbb322b0b47a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_02f7bc41-1db1-40ca-b905-059168fee609" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9da6b944-a86e-4a75-99ef-bbb322b0b47a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_89c79a5e-bd00-4c1e-95eb-26c3db4f438f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_89c79a5e-bd00-4c1e-95eb-26c3db4f438f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_89c79a5e-bd00-4c1e-95eb-26c3db4f438f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_89c79a5e-bd00-4c1e-95eb-26c3db4f438f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_89c79a5e-bd00-4c1e-95eb-26c3db4f438f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_6300536b-148c-46e2-b7a4-6dac386fb057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_89c79a5e-bd00-4c1e-95eb-26c3db4f438f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_6300536b-148c-46e2-b7a4-6dac386fb057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_d5ed6b18-fb06-416b-9c7b-a7f5be4f9378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_6300536b-148c-46e2-b7a4-6dac386fb057" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_d5ed6b18-fb06-416b-9c7b-a7f5be4f9378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis_e79c1ed1-d21e-4651-bce4-56c222a4dedb" xlink:href="nbix-20220630.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:to="loc_nbix_DebtInstrumentConversionAxis_e79c1ed1-d21e-4651-bce4-56c222a4dedb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_e79c1ed1-d21e-4651-bce4-56c222a4dedb_default" xlink:href="nbix-20220630.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbix_DebtInstrumentConversionAxis_e79c1ed1-d21e-4651-bce4-56c222a4dedb" xlink:to="loc_nbix_DebtInstrumentConversionDomain_e79c1ed1-d21e-4651-bce4-56c222a4dedb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_49c03596-1351-4d5c-8003-3022093070ca" xlink:href="nbix-20220630.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbix_DebtInstrumentConversionAxis_e79c1ed1-d21e-4651-bce4-56c222a4dedb" xlink:to="loc_nbix_DebtInstrumentConversionDomain_49c03596-1351-4d5c-8003-3022093070ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember_aa552d55-68bc-4e0f-9145-9c855e787490" xlink:href="nbix-20220630.xsd#nbix_ConversionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_DebtInstrumentConversionDomain_49c03596-1351-4d5c-8003-3022093070ca" xlink:to="loc_nbix_ConversionPeriodOneMember_aa552d55-68bc-4e0f-9145-9c855e787490" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember_a2f2931e-743d-4dc4-8315-82cbfacbb962" xlink:href="nbix-20220630.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbix_DebtInstrumentConversionDomain_49c03596-1351-4d5c-8003-3022093070ca" xlink:to="loc_nbix_ConversionPeriodTwoMember_a2f2931e-743d-4dc4-8315-82cbfacbb962" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#ConvertibleSeniorNotes2024NotesDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="extended" id="i9946e24ba015463284041ceee9f486ec_ConvertibleSeniorNotes2024NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bac0eb2f-1e33-4d0a-b19f-e3b4dd823bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bac0eb2f-1e33-4d0a-b19f-e3b4dd823bd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_8aafb649-5aa5-49d9-a322-1677d8a8aa9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_8aafb649-5aa5-49d9-a322-1677d8a8aa9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_78ddd0fe-5fac-44e0-9a68-a7be73aac83f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_78ddd0fe-5fac-44e0-9a68-a7be73aac83f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_9604efef-661a-485f-a3b0-30f0a5e33274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_9604efef-661a-485f-a3b0-30f0a5e33274" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_5ae6cc82-f33d-4aac-b74a-119ba39e0d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:to="loc_us-gaap_DebtInstrumentFairValue_5ae6cc82-f33d-4aac-b74a-119ba39e0d04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_da41fc7e-54ca-4a3d-818d-7bcb50b594b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:to="loc_us-gaap_DebtInstrumentTable_da41fc7e-54ca-4a3d-818d-7bcb50b594b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_56623a3c-56af-4c4d-9369-3adc17eb0d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_da41fc7e-54ca-4a3d-818d-7bcb50b594b8" xlink:to="loc_us-gaap_DebtInstrumentAxis_56623a3c-56af-4c4d-9369-3adc17eb0d59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_56623a3c-56af-4c4d-9369-3adc17eb0d59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_56623a3c-56af-4c4d-9369-3adc17eb0d59" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_56623a3c-56af-4c4d-9369-3adc17eb0d59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_990c5ce6-703d-4f25-a8a8-3221a5eded63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_56623a3c-56af-4c4d-9369-3adc17eb0d59" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_990c5ce6-703d-4f25-a8a8-3221a5eded63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_872b64f0-133a-4a6e-a33a-bb70cef2356d" xlink:href="nbix-20220630.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_990c5ce6-703d-4f25-a8a8-3221a5eded63" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_872b64f0-133a-4a6e-a33a-bb70cef2356d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#LossEarningsperShareScheduleofNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails" xlink:type="extended" id="i03c3d071c8a64380be86fe02bfcca2e9_LossEarningsperShareScheduleofNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fbed4d55-7848-4e95-8ecc-85b76d12e531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fbed4d55-7848-4e95-8ecc-85b76d12e531" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_43c0151f-0b2f-429e-bf59-126d77e1f7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_43c0151f-0b2f-429e-bf59-126d77e1f7a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b21bb400-1b9e-4c4c-8f26-33a3184bb77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b21bb400-1b9e-4c4c-8f26-33a3184bb77b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6213a09-a72d-467b-8be7-e7192c1e1ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b21bb400-1b9e-4c4c-8f26-33a3184bb77b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6213a09-a72d-467b-8be7-e7192c1e1ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_058963d4-7cca-4b5f-a3e7-85944dfa8d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_058963d4-7cca-4b5f-a3e7-85944dfa8d77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4e50c4ed-aec0-4909-bb9f-ab98ee8e2360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_058963d4-7cca-4b5f-a3e7-85944dfa8d77" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4e50c4ed-aec0-4909-bb9f-ab98ee8e2360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_94fc3d45-da62-4246-aa60-9f2f3e431331" xlink:href="nbix-20220630.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_058963d4-7cca-4b5f-a3e7-85944dfa8d77" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_94fc3d45-da62-4246-aa60-9f2f3e431331" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f3caf8f2-955e-41de-b025-a0ce1a15a432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_058963d4-7cca-4b5f-a3e7-85944dfa8d77" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f3caf8f2-955e-41de-b025-a0ce1a15a432" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f2628e28-41c6-4476-b956-d635d51e6c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_EarningsPerShareBasic_f2628e28-41c6-4476-b956-d635d51e6c68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0badb6eb-8e12-413c-949f-e14320902539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0badb6eb-8e12-413c-949f-e14320902539" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_496db5e3-b30e-444e-99b5-b9a04d4a1761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_496db5e3-b30e-444e-99b5-b9a04d4a1761" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce8d52d9-ceb2-4093-9ad1-d75d03db48a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce8d52d9-ceb2-4093-9ad1-d75d03db48a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_703f0767-28dc-4fbe-8c4a-556a62bf1d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce8d52d9-ceb2-4093-9ad1-d75d03db48a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_703f0767-28dc-4fbe-8c4a-556a62bf1d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_703f0767-28dc-4fbe-8c4a-556a62bf1d31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_703f0767-28dc-4fbe-8c4a-556a62bf1d31" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_703f0767-28dc-4fbe-8c4a-556a62bf1d31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6d76a428-f684-41d0-a3ac-ba10842dd09c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_703f0767-28dc-4fbe-8c4a-556a62bf1d31" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6d76a428-f684-41d0-a3ac-ba10842dd09c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29261944-8786-48ba-be30-aabb36c5c5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6d76a428-f684-41d0-a3ac-ba10842dd09c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29261944-8786-48ba-be30-aabb36c5c5c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_66af5f49-be01-480e-b516-918e3d61faaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6d76a428-f684-41d0-a3ac-ba10842dd09c" xlink:to="loc_us-gaap_RestrictedStockMember_66af5f49-be01-480e-b516-918e3d61faaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d69d9df1-0578-4074-b4fe-92d1301f0756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce8d52d9-ceb2-4093-9ad1-d75d03db48a9" xlink:to="loc_us-gaap_DebtInstrumentAxis_d69d9df1-0578-4074-b4fe-92d1301f0756" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d69d9df1-0578-4074-b4fe-92d1301f0756_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d69d9df1-0578-4074-b4fe-92d1301f0756" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d69d9df1-0578-4074-b4fe-92d1301f0756_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d8be7ca0-a4d8-4bc9-affb-a5025f727478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d69d9df1-0578-4074-b4fe-92d1301f0756" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d8be7ca0-a4d8-4bc9-affb-a5025f727478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_a46be431-ea04-4740-baaa-41875baba286" xlink:href="nbix-20220630.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8be7ca0-a4d8-4bc9-affb-a5025f727478" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_a46be431-ea04-4740-baaa-41875baba286" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>nbix-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0c42dd0c-c284-4653-91e4-174ef769a678,g:b6b90098-cdc3-4729-a2bb-5ae5dda3bf39-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_d33348f8-4b2b-4499-988f-d11a21208a81_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_label_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Domain]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionDomain_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain" xlink:href="nbix-20220630.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConversionDomain" xlink:to="lab_nbix_DebtInstrumentConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_579486f0-4d8d-464a-a2db-4d4d7f18b635_terseLabel_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_label_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_documentation_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of reconciliation of cash cash equivalents and restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:href="nbix-20220630.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_236b1c2c-4dee-46c7-bf5c-0e3b4325c9af_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fc1cacc-3513-4d87-aa4c-ad78173d192c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a8db0dc1-d62b-4984-88e3-081e63b4dd78_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4e35f03b-6156-4a29-b7a7-28359e5595af_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Benefit from) provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4f14885e-6abf-45bc-b70d-5986fec30c82_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1ead305d-158b-4ea4-83d9-b86bae0cfb82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_236109ff-b492-4276-8463-4878837cf948_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_a8ab1c62-6c68-44fe-a1ea-80aee84cd89a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_905dd6e7-19de-4761-b48b-78e1e2ef276a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ca2ca014-2b1a-4033-8de2-02e2c7818258_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2f6d8de4-d5f4-47f4-8db3-3ac34db29e8b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_6bcdf38b-b044-4f9d-a8d6-7a0d24fc9fdf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1c15cd6f-722a-43a9-b945-a03ef4586d77_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d4b13a01-a146-4d33-a72d-4f158c82d3c1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_49d52fb3-223d-4cb3-a04e-3fa27a36e6bd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_110f2bf2-27f2-4374-ae93-4edf08055199_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f169a8fd-a3ba-4a21-a09f-fa1b04b72d3d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bbb17c34-917a-4e05-931a-f3cf2b023429_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_411aafa8-9cc7-4313-a65a-c7bfb6068858_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b33e9b04-912e-44c1-b776-b56647aab115_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_81cc8916-ecb5-4bec-a9ec-fe0acd52cac2_terseLabel_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of common stock price trigger</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_label_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percentage Of Trading Price To Last Reported Sale Price</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_documentation_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:href="nbix-20220630.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:to="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_51be8436-92bd-49a4-8549-befffb9d62fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_5b3b6cf6-7ae0-47ba-8a46-fc23c40385a4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_HeptaresTherapeuticsLimitedMember_bcce97bf-37cc-44ac-9740-b53a9e316ccf_terseLabel_en-US" xlink:label="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heptares</link:label>
    <link:label id="lab_nbix_HeptaresTherapeuticsLimitedMember_label_en-US" xlink:label="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heptares Therapeutics Limited [Member]</link:label>
    <link:label id="lab_nbix_HeptaresTherapeuticsLimitedMember_documentation_en-US" xlink:label="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heptares Therapeutics Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_HeptaresTherapeuticsLimitedMember" xlink:href="nbix-20220630.xsd#nbix_HeptaresTherapeuticsLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_HeptaresTherapeuticsLimitedMember" xlink:to="lab_nbix_HeptaresTherapeuticsLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_UpfrontPaymentsMade_512a3870-5ad9-416e-9f3b-e491b6e67292_terseLabel_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsMade_label_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments Made</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsMade_documentation_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments made under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade" xlink:href="nbix-20220630.xsd#nbix_UpfrontPaymentsMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_UpfrontPaymentsMade" xlink:to="lab_nbix_UpfrontPaymentsMade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_159d30a3-b070-4e9d-aa6b-02973060a077_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_f1f2eebf-fb8a-4cbc-9267-1191c2b04c4f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_eb3143f0-03a8-49c1-a662-b0530d8c388b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_d0dc4329-adbf-4659-a7bb-5deecf1f13ff_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_0324cb42-f986-4c66-bfeb-c6af5fd2f246_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_8baf1248-a912-46e5-bb86-5263a6c5bc85_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f71b99ad-53b6-41d1-b4f8-13f6ba7e6603_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_15cc527f-5cc7-44b0-90b8-af99fd91f4ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_0808a31b-ca2e-4178-a596-418c2c936c55_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction cost related to issuance of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_fed8097e-b3c2-4813-bf3f-b2fda3c6ee41_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_e0554e46-c31f-4e39-8807-f44abcc36c8a_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_e153bada-2adc-490f-b5c7-88cc35a1e49c_terseLabel_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other, net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_label_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income And Other Net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_documentation_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet" xlink:href="nbix-20220630.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_InvestmentIncomeAndOtherNet" xlink:to="lab_nbix_InvestmentIncomeAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_fadc8a44-6a61-452f-a367-a8067539f3dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_de2bf39a-874a-4ca1-899f-851da4890457_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 220.0 million shares authorized; issued and outstanding shares 95.6 million at June&#160;30, 2022 and 94.9 million at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d382e79b-0b5c-4a3f-930f-9a65b5bfd91d_negatedLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_85da62be-ca12-4ce1-85a0-e46e0a7dffd3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2d5f7bcd-0604-44c0-9fac-34c47b2ddec5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cce3246-2d81-4c96-9885-68cf1fb44b18_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8a8cdcf0-38ac-406b-806a-f6417e612ec4_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_b80d24d6-e75e-4f73-b70c-93c7dd1a8bd2_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_ec4c1944-2ca3-48cc-880c-5782ce60024b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes conversion price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_289f1afc-a4b6-4c4b-9c51-8812dd27c179_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_77c22a0d-3ef6-4530-8071-51c72afa52fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_62c31441-90fc-4e55-9f48-7180c48db724_terseLabel_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes (in shares)</link:label>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_label_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable To Dilutive Effect Of Conversion Of Debt Securities</link:label>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_documentation_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:href="nbix-20220630.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:to="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b8c87317-cafd-4c4a-bf3e-ecd14480e8f0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_fd21a876-62d5-4a4d-8c93-0db92185de03_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ee42adc-8d76-4618-829c-848d3c6d8f6c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf347603-7e55-4e8f-8623-955e246c6207_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_21102579-7ce0-42ae-b871-fbe74b7a750e_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate repurchase price paid in cash</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CollaborationRevenueMember_69042eae-722e-4d14-baed-b5673f1765f7_terseLabel_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenues</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_label_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember" xlink:href="nbix-20220630.xsd#nbix_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CollaborationRevenueMember" xlink:to="lab_nbix_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_fb8dc4a9-77d1-44c9-a501-c707e408c5f1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e64a6a2a-c0d7-4ccf-9a92-594a385fa2c5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_deda6285-1986-40c4-a5e4-a8e0b3fe13b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ec8dcd19-6677-43a6-9a4d-78e0208e4b97_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_54c03a1e-7bc3-4a0a-b73d-28d6617d58f3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_22cf1535-8201-4a64-8c71-0ef11d128e8a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_334dc4d0-dd75-4285-a6e2-ed306ba0b83e_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2933eb63-eb2e-4e3b-b915-82d5e8b40df4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_b4bedb2a-90d2-4930-9499-71f253164db9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3de46a1c-e63e-4202-8240-b72547c1bccf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b6b6c790-0f01-4d43-a458-457ac0ed8533_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_28e8e535-94d5-47a1-bf5a-e1c526f8deb7_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9b7f3f94-13a0-421a-bdb2-d2b7815a9065_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_c722d0e5-aeac-40f1-8c27-83d9ce6c750c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities available for sale in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_c76f5fac-c5ea-4d3b-b689-0ef934c7ea99_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0cc2c5aa-7311-46ba-be5c-803f9c8839c0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4296dbcb-0596-4c7a-a836-45dd11293224_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2f615123-fbe5-4378-9817-2b9c1121d151_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_baad1ab2-0cbc-404d-a17d-fa37696aa706_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_990c7a82-f4f7-4478-8db2-b8435781e9a2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_75117a48-923e-47b9-9d09-9aaf72e03643_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_23842633-4e62-49a7-8351-89537c34d142_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ddb51327-fc19-4b8e-9241-c15cfc89f511_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets on recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4049dcab-bd31-41ac-9319-64083c482693_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_6aeec608-a934-4af1-8fa6-97e2b5c94556_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_13b8d79c-2fd5-4589-a049-c4259c6d686c_terseLabel_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and money market funds</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_label_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Money Market Fund [Member]</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_documentation_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember" xlink:href="nbix-20220630.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CashAndMoneyMarketFundMember" xlink:to="lab_nbix_CashAndMoneyMarketFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_90f44870-f307-46cf-bbb3-19ea362e14b9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_fd21a22f-c15f-4848-8e90-e12fdfea7b7b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4c3a4329-9485-4dcb-9d39-88ae1de0fdc6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_82178962-c4aa-4eff-b93b-8e2c25a6b78d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f6a2f840-f063-4cae-a117-bc37cd433c4b_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_fdc87e37-318e-49c5-9407-5ef17f32fd78_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock price trigger (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_eb20f0ba-6a94-4ca6-bae3-51805844cdb2_terseLabel_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_label_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount On Conversion Rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_documentation_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate" xlink:href="nbix-20220630.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PrincipalAmountOnConversionRate" xlink:to="lab_nbix_PrincipalAmountOnConversionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_5c8c361f-2e8b-4d8c-8e0c-aadf3db37aff_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d8e950d0-45d1-4d2a-82e5-2ff17bfd84e6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (6 months remaining)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_87ef4b17-2508-496c-b63b-e5e7af6aa1c2_terseLabel_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus lease lessee option term for construction of fifth building</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_label_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Option Term To Construct Fifth Building</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_documentation_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of term of lessee's option for the construction of a fifth building under operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:href="nbix-20220630.xsd#nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:to="lab_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5798f130-1acf-406b-948b-29e67d3f4755_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_af7c984d-e82e-40eb-99fa-c7a9034be46b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_b8d3d78d-2b9e-476e-a1ee-994bf7b07fbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers out of Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9e8761be-821f-4511-98d9-13ca6a59b07b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_8ce8f701-95df-4c01-aa94-010d27c3fbf2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_5e622fcb-c6f0-4525-a048-42b46280ff5d_terseLabel_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL</link:label>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_label_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL &#8211; Portela &amp; Ca, S.A. [Member]</link:label>
    <link:label id="lab_nbix_BIALPortelaCaSAMember_documentation_en-US" xlink:label="lab_nbix_BIALPortelaCaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIAL &#8211; Portela &amp; Ca, S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember" xlink:href="nbix-20220630.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BIALPortelaCaSAMember" xlink:to="lab_nbix_BIALPortelaCaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_895989a3-f669-475b-8940-b060222a809f_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_RentAbatementPeriod_49fb5ead-ffcf-4d39-9aad-7b9735f7f158_terseLabel_en-US" xlink:label="lab_nbix_RentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus rent abatement period</link:label>
    <link:label id="lab_nbix_RentAbatementPeriod_label_en-US" xlink:label="lab_nbix_RentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Abatement Period</link:label>
    <link:label id="lab_nbix_RentAbatementPeriod_documentation_en-US" xlink:label="lab_nbix_RentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Abatement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RentAbatementPeriod" xlink:href="nbix-20220630.xsd#nbix_RentAbatementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_RentAbatementPeriod" xlink:to="lab_nbix_RentAbatementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_6c1da26f-0bfa-40a3-9aec-840eccfb2047_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2024</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:href="nbix-20220630.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfRenewalOptions_4090c0fa-e5ac-48f0-89ab-51fe6f0209c3_terseLabel_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus lease number of renewal options</link:label>
    <link:label id="lab_nbix_NumberOfRenewalOptions_label_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Renewal Options</link:label>
    <link:label id="lab_nbix_NumberOfRenewalOptions_documentation_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of renewal options under the terms of the lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfRenewalOptions" xlink:href="nbix-20220630.xsd#nbix_NumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfRenewalOptions" xlink:to="lab_nbix_NumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_a35114c4-316d-42bb-8001-d0b751417989_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance_0ec2ab6b-d264-448a-a7e7-5b265a59defc_terseLabel_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the liability component upon issuance</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance_label_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount Of Liability Component Upon Issuance</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance_documentation_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying amount of the liability component upon issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:href="nbix-20220630.xsd#nbix_CarryingAmountOfLiabilityComponentUponIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:to="lab_nbix_CarryingAmountOfLiabilityComponentUponIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_06de7904-23e8-44c6-848e-b2017288b11f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6900b3d9-946b-49b1-bda1-1a7f3ff269e3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b44ce156-4a35-43f0-a663-8dc2bd170992_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_258e8b5f-ad8c-441f-9793-59cecad59b65_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current operating lease liabilities included in other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7583c266-f9cd-46fe-92d7-1877c1ec8c6c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_744326a8-12b5-4f37-ad56-7b0b645c0f18_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d89422d3-eae8-4b65-b910-531cec8903b9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_c0f5dcde-65f3-445d-b343-c832ea4bef74_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_354cbe91-9944-404a-8216-4c4ae0fb0a8d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_f36e3d17-54b2-44e7-8eb6-0c34eb5013d2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables write-off</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_71294ca8-4c7e-4886-b9e9-7256c87ccb7a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on debt securities available-for-sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_601e72f7-8451-4f18-b218-bb6c0b6128d1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_2f921af8-886a-4fd4-9965-8a3c05eeeac4_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d789e7e8-491c-4ff1-b7e0-56cee69f46f9_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_df0992a1-8ad4-4c6f-b1fd-23163bb7ee75_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_60343188-bf7c-4dae-a992-7e213cbfc926_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8bc376de-bb64-4bc0-91f9-1821abcf086f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_9cf7fde7-c8af-43fb-a043-925eb48e04ed_verboseLabel_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes</link:label>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember" xlink:href="nbix-20220630.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A225ConvertibleSeniorNotesMember" xlink:to="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b0c843bf-3baa-4199-b25b-117c4087efa5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c4f53d0-a589-40b0-a7cc-a4e6e77d7787_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c0103daa-68fc-4929-998f-261700f40094_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a850e111-6d4d-417d-a812-e68a05fb1f49_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash in connection with operating leases</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_36521872-ffd0-414c-8995-c20bf5392264_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a6845b38-2d98-45a2-8138-2250301f5984_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_16cac77f-328e-440a-a26d-22432a19f1b1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_34a2d8f6-1496-4527-9722-bfe26a09795f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_ce55437a-c517-4663-ac43-9b8ce8f16106_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9ec531ce-a606-41f5-92f7-af8261a5c3f0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8753eb0a-a618-4486-af94-d0af21e6eb23_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_56e2c854-251d-4060-8671-2397e913f4df_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_33225679-b5a3-4193-a019-03caff424166_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f813162c-daa6-4028-80af-bee4d03b38ff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_f7f34346-1a7c-45ac-958f-210ea39386cf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a96b77b-0446-48ca-a66e-f1fcf6ab1ef8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MilestonePayment_38cd05d1-5446-4328-93df-e4b25dde1dab_terseLabel_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_nbix_MilestonePayment_label_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_nbix_MilestonePayment_documentation_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment" xlink:href="nbix-20220630.xsd#nbix_MilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MilestonePayment" xlink:to="lab_nbix_MilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f14f6bbf-9b8f-459c-aa04-45d47a19a8ee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2e7de894-70b5-47da-b7bd-81765798cbd1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ea12ecd2-568f-47e3-b87d-da0829af041c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6831db36-b479-4fd6-8e9e-24c48592ab33_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_444a4ac0-2f7e-41d2-a135-d08ff73e5875_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a2c5b980-9907-4405-82a4-9611d752bab1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_85aa2451-c1d8-404b-9250-9ceb194a17d8_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a7cef33d-6dd9-4aa1-bd3e-83a8f52d85c7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_245d0d38-97cd-4766-a5a3-303aac4e3210_terseLabel_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTPC</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_label_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_documentation_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:href="nbix-20220630.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:to="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4b1b4533-363c-47d0-b8d9-8700b24ceabc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9babf0d0-fd52-4820-a894-32d170fbb4ff_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0e979c4c-a99c-4829-9d4c-77c542d21524_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_aa23f46c-8b4b-4216-bb3a-48435bf6ebab_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain included in earnings</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3c8aa6ea-9951-43a7-8e10-dbe4c811d90d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePayments_4e8903c3-4c2f-4f93-9841-b2b384587d50_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_label_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of potential milestone payments under a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments" xlink:href="nbix-20220630.xsd#nbix_PotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePayments" xlink:to="lab_nbix_PotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PatentTerm_cc65bdc0-022a-44eb-ac8d-9e99707357ac_terseLabel_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent term</link:label>
    <link:label id="lab_nbix_PatentTerm_label_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent term</link:label>
    <link:label id="lab_nbix_PatentTerm_documentation_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm" xlink:href="nbix-20220630.xsd#nbix_PatentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PatentTerm" xlink:to="lab_nbix_PatentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_1b7c0c4c-1d3e-4a66-ac4b-57beb42a8bdd_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_23fde16c-a5ed-4747-91d4-cb238cf7b8f8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_e00b6158-b5a0-425a-938b-779d5a6f89a7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_e005e9d6-0152-4a81-8f0a-7a5c16d9f63e_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_b5cfdb1a-ee0e-462d-a95c-9660060ec34b_terseLabel_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities available for sale</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_label_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Available For Sale Position Number Of Positions</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_documentation_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available for sale position number of positions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:href="nbix-20220630.xsd#nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:to="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2c515c36-822e-4df4-9c10-ca9671826a56_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under stock plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_d7458e49-3f3b-4ea7-9f6e-519b134a5808_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3c9aef20-0e92-4147-ac62-6f28cd6b0292_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b3a4acb1-d6e9-43fd-9869-4890923b5fde_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_8f526cf7-0317-461f-a591-5f739db2b2c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5d1e909d-c455-4e9c-aee3-8d018f2c3cec_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) earnings per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bbd76505-3593-4b49-87b5-1b3fb24539ea_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f254755e-e6b3-4b9b-b4fb-83fc7740d847_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer, Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0cdbb4d7-905c-46bd-b2f2-7e79c90d3ce9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_198e14a0-1e65-4893-b22c-de10e967a856_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement_71f9de25-f42d-4485-9610-56a1fb15d16b_terseLabel_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the liability component at settlement</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement_label_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount Of Liability Component At Settlement</link:label>
    <link:label id="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement_documentation_en-US" xlink:label="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of the liability component at settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:href="nbix-20220630.xsd#nbix_CarryingAmountOfLiabilityComponentAtSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:to="lab_nbix_CarryingAmountOfLiabilityComponentAtSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4bf4394a-377e-47d3-b824-e1fdae1fe009_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_efd8ed82-c072-4157-ade1-2aec01497da8_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4cf952d3-3eb0-415d-8321-07eb24a7e4ff_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ff3eb3ed-5877-4b77-bc86-b6c1d7952588_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_bf55bb1e-8971-4212-92b0-8c36127cad48_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_ff7f92ac-5c2e-4ad2-bb05-a740f31e02d4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_5923860e-4ede-4817-8990-b2ff91e64cc7_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_877d05e8-f5bf-426c-86b8-2cf55219613c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income before (benefit from) provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4e1ba8dd-fb7b-4888-8032-2808bdd9e072_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_ee40878f-3040-45c5-87e0-04e75e4e4772_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_2104cad5-ae7a-40f3-8c72-8a08bc1cf0e3_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0034afcf-d171-418b-bb98-66e8c7bfae96_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_a3331d97-0a06-45ee-8071-2a600fc987ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of common stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6f93ca21-ee9b-4222-81a4-fc0c51803928_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_9f12932f-b497-474e-8c73-68999d2df370_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, stock price</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AnnualRentEscalationPercentage_d2249fb7-3bda-4fef-b5c6-fe6a229e6250_terseLabel_en-US" xlink:label="lab_nbix_AnnualRentEscalationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus lease annual rent escalation percentage</link:label>
    <link:label id="lab_nbix_AnnualRentEscalationPercentage_label_en-US" xlink:label="lab_nbix_AnnualRentEscalationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Rent Escalation Percentage</link:label>
    <link:label id="lab_nbix_AnnualRentEscalationPercentage_documentation_en-US" xlink:label="lab_nbix_AnnualRentEscalationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Rent Escalation Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AnnualRentEscalationPercentage" xlink:href="nbix-20220630.xsd#nbix_AnnualRentEscalationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AnnualRentEscalationPercentage" xlink:to="lab_nbix_AnnualRentEscalationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0ca20b4d-5993-4bf1-b34f-7ffd15d469c1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_f57dc4ce-fe09-410f-9cc3-b783052b390c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_651ef2f9-bffd-4daf-8de2-4db79974fc44_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under benefit plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_94efb9f9-df2e-40ae-bf1b-f9164d8e7b18_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9873c205-9d3d-4a4f-aafe-347875eda215_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_c3b941f5-e051-4e80-abda-597a63de73b3_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_e15682ac-f20b-4b3c-8720-e08892198b91_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_46cf5181-f706-4aad-b136-fde1be087256_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_10fdf315-0980-4b98-a850-d7b9bcaae0f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8cce3bba-605c-41cb-bcc4-eea0da72623d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior note carrying value of the equity component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LongTermInvestmentsMember_28c048e0-524d-4c1d-b7ac-6144bfabc9c7_terseLabel_en-US" xlink:label="lab_nbix_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_nbix_LongTermInvestmentsMember_label_en-US" xlink:label="lab_nbix_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments [Member]</link:label>
    <link:label id="lab_nbix_LongTermInvestmentsMember_documentation_en-US" xlink:label="lab_nbix_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember" xlink:href="nbix-20220630.xsd#nbix_LongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LongTermInvestmentsMember" xlink:to="lab_nbix_LongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_041fb65a-c7c1-4bad-a382-9b8845c1f89e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_bf8ca23c-be7b-4906-a42d-16977a4070d3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_7302ec2a-599d-4829-991f-291957609c65_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount repurchased</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_20624d0a-7f1e-403a-ab80-38a1af853812_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_3b3b715d-8d13-4504-b297-9e11920d03cb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_272587da-6165-41f0-a944-bff3d10a266e_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_858cfecb-d730-4263-8f4c-fa97c6f158a1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b0f09c6e-99f0-49ca-867e-3f12d12a23f2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_1052b4c0-d245-4d6c-bf55-ae4c7fcd788d_terseLabel_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus lease monthly base rent per square foot</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_label_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Monthly Base Rent Per Square Foot</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_documentation_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Monthly Base Rent Per Square Foot</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:href="nbix-20220630.xsd#nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:to="lab_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_a8c0769a-7856-490f-bef5-0fcac8375eff_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8df381ed-5ce2-4f75-955b-0fa89576fd49_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_8474ea6f-39c1-422a-867e-ca915207adb6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ff5e11d7-d0b5-4855-a2a4-6325dd4771f3_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_d83115fd-a612-4de4-8c2e-425d0f99ff02_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f241aa65-6768-4c54-a049-ada930734c74_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c42efcf1-c101-4b8a-8492-207bf613217a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_941179eb-e64a-47a6-9c44-3ccad3d7e8c5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_52fee701-90f3-405a-a901-ce6ce9c9f2d2_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_2e62da53-989f-4ce1-978c-f8ececf0126c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_6fc4b0bf-dc4f-40f3-8787-9a16d1f8c22d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes convertible in to shares</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_RestrictedCashTextBlock_b92348fc-3dbf-4c05-baac-68b61ba3a78d_terseLabel_en-US" xlink:label="lab_nbix_RestrictedCashTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_nbix_RestrictedCashTextBlock_label_en-US" xlink:label="lab_nbix_RestrictedCashTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashTextBlock" xlink:href="nbix-20220630.xsd#nbix_RestrictedCashTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_RestrictedCashTextBlock" xlink:to="lab_nbix_RestrictedCashTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5b3d3b52-2106-4f8c-88a5-b3e906209b1f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_06683ddc-bb60-46c5-bb91-1ba8d7824732_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_528d7376-f26c-44fb-9bc3-ab671ef5fd6b_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e6c0e7d7-4196-4970-9eef-4c1f00f3c12d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_48a51c11-0d20-4be9-ab0d-9bc2df2c9988_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_c56ef5f0-0c72-47ff-8dec-99621c0803b7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_d134c987-ad85-4dd9-8c2e-d38d3f65a992_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt, Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_129725e4-c8a3-4bea-99d0-ee6e2abe0f60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_38099cdf-cc4b-497f-a759-89a42874c3b0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_c16956c4-908d-46c2-94af-6ded5e2e4476_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_6ea2416c-685b-4b16-b7eb-ca783a2c2648_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market price of common stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ff825d8e-8344-4c8c-b97a-e979f947487c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f91eae27-2ad5-4b09-a20e-d62508359da9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fef9b623-b9ff-47b3-b9ec-28b94a229c4f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_9e3fb52d-747d-4df1-a491-ce1e72c18421_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_4f69e7b8-5a7c-4a66-9e22-7a4c98d7b05e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_d2942c63-04e7-4267-b6a4-47aa242023a7_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for thereafter</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:href="nbix-20220630.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_4b8d473e-b878-4c13-9ac8-a7208208f765_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_29a5bd7f-b928-4ceb-8178-14227b5a8c56_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2025</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:href="nbix-20220630.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7c81fdc7-2a89-47ee-9394-262ea8cca488_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_378d1694-746c-43e1-aa2a-1903bcc3ac5a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_81e33e33-46b6-4cf2-a4e1-6d7a353a632d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of repurchased convertible senior notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_294562b4-bbe0-4318-8683-21ad098d2dae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_995d1c7f-69a3-4b03-a77b-0afc6536b77f_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_77f258aa-23ca-4119-8b37-5c3529948243_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_a0d422a7-2ac5-460a-846d-d5488ee70134_terseLabel_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible senior notes due 2024</link:label>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Two Point Two Five Percent Due In May Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the 2.25% Convertible Senior Notes Due in May 2024.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:href="nbix-20220630.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:to="lab_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_72124161-ceba-48e9-8c31-4689d273ad46_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accreted interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_fee23041-97e0-4474-8914-7d66f6997760_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_57718eb7-1034-4e5d-b844-7a53600f5ffe_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_261f893c-7bbe-4b00-b019-160c3395daab_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8e4ba368-b5cf-4598-8e4a-48699eea025c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) earnings per share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e55aab7d-bf48-44ec-bf4a-ea57aa8c2a8b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_589b34b6-097d-476d-b992-b29f9e229be2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_bf25897c-007b-4748-8651-30e33ff97fe6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_a892d0dc-b0f7-419a-b937-a60800bd8250_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3793c769-7d1a-4e3a-9deb-83d35fd3cd56_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_3a9fb198-114f-4fd9-abb0-e52b386fd4a1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8938e0cc-697e-4954-833f-c7fadfaa4b0c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_67cd8277-bfee-45e2-b6f0-6a9d8eb167af_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_f1128555-1fe9-4c2b-86eb-47c84a9429ed_terseLabel_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:href="nbix-20220630.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_cc141269-3e0e-4d64-8aca-da16042cedf4_terseLabel_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_label_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager Therapeutics [Member]</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_documentation_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager therapeutics.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember" xlink:href="nbix-20220630.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_VoyagerTherapeuticsMember" xlink:to="lab_nbix_VoyagerTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2640568b-fef1-401a-8918-2c00441e0b3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_02bd6601-ed7e-476e-af91-ff5c9c0dc05b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ee4cfca4-62e5-4b7f-98a8-a7fc573c379a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_11e2fc08-73d5-4bbb-920e-44cc773cd5dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_1146abe4-9d1b-4712-9379-5f0701e7b768_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities&#8211;biotechnology industry</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b25fbbc4-3747-4550-a49e-b8e5f5fa3b52_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6f082764-908d-45f0-931b-047e36977e5d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_74d5bb71-e283-42b7-88f8-168ded805180_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) earnings per share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ConversionPeriodOneMember_bb557d51-f41b-47e5-9635-72825ccb8980_terseLabel_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:label id="lab_nbix_ConversionPeriodOneMember_label_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One [Member]</link:label>
    <link:label id="lab_nbix_ConversionPeriodOneMember_documentation_en-US" xlink:label="lab_nbix_ConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember" xlink:href="nbix-20220630.xsd#nbix_ConversionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ConversionPeriodOneMember" xlink:to="lab_nbix_ConversionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction_42488843-fe67-4892-bd0d-d822f38602b6_terseLabel_en-US" xlink:label="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction_label_en-US" xlink:label="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Sold in Transaction</link:label>
    <link:label id="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction_documentation_en-US" xlink:label="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares sold by the collaboration partner per stock transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:href="nbix-20220630.xsd#nbix_SaleOfStockNumberOfSharesSoldInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:to="lab_nbix_SaleOfStockNumberOfSharesSoldInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cd7c3cd9-4868-4dd7-88f2-79e7b320a0a9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_3c6e48ab-423c-4cf6-aa1a-f0bbf6801684_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d532edbf-0593-4cc3-b423-fb0f09d8cc26_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0c5e2fcf-0ff6-4148-a50c-e824ccf73272_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_baa4445d-247d-4226-9bda-f83ddca4ed59_terseLabel_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Four</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="nbix-20220630.xsd#nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5a5b52a6-e33a-4fff-9a9a-ff03276757dc_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7edc10bf-c290-47de-a68b-3312237150c0_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity security investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_721a0920-e22f-43ec-9067-fbd2a1c051ef_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_887c05a9-c0b4-4249-bd08-e99abe08b317_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_87fc8689-63e3-42ec-bc44-c4b9b4561dbf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_5c8d935f-2a92-45f6-acd6-48a726ea2844_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d4e5eb9f-8764-4353-abaf-056cfadbd857_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f6f7a86b-d566-427c-9d47-866dff77c570_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_25f2b3f0-7ab2-4020-8137-850e4c487166_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_617b2ada-7d18-448c-8aa8-73a603079673_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3e426089-94a6-45b0-ba2d-c79c1fbea351_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_3cad9db9-2be0-4858-8242-065447ed069b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_54042a65-6c26-4e0f-bc95-8d215c01090d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_d385cbf2-d7c6-40f3-bcb1-5c78169bbdfd_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_f8e0a2b6-7fa1-469a-bf2e-e3bf0875908f_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_833a37ae-8e5c-4692-8a38-c11c57ceecc7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentCouponInterest_b2d3b99e-2de9-4c2c-9740-2026ade0aae1_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentCouponInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coupon interest</link:label>
    <link:label id="lab_nbix_DebtInstrumentCouponInterest_label_en-US" xlink:label="lab_nbix_DebtInstrumentCouponInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Coupon Interest</link:label>
    <link:label id="lab_nbix_DebtInstrumentCouponInterest_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentCouponInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Coupon Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentCouponInterest" xlink:href="nbix-20220630.xsd#nbix_DebtInstrumentCouponInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentCouponInterest" xlink:to="lab_nbix_DebtInstrumentCouponInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_055a5313-fdf1-4530-961e-b6827e4aab24_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on debt securities available-for-sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0d097e39-4378-4c2b-9070-858d257fc39a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_926c29c1-116b-4f85-9fc1-e13ee6d24f05_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities of government-sponsored entities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9bb95ffa-4176-4f2c-8228-f46de7e0d9c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_a0af4bda-5861-42b7-a56a-6c8aec23c62e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_233c87e6-7ee6-49a9-919c-e148946d5fb5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f20636a6-81a5-4508-a346-93fd24e3e54f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Notes Net of Discount and Deferred Financing Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7c993aad-95b1-4706-bb6f-dfd9371e604a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_a2ffe7b2-eab6-4240-b01d-ec136806c5ab_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a9b942f8-4b62-46fd-950c-5f14a949cf60_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_35a96d90-f006-4752-a775-1eec2c0f8202_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4e1701bf-46c2-4569-a625-f2c6c8a777a9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances of common stock under stock plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_0f8de95f-2d81-476e-ab7b-64492bfda26b_terseLabel_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_label_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd. [Member]</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_documentation_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:href="nbix-20220630.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:to="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_7264b642-d354-4123-b76f-739cd908f55b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Description of Operating Lease</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3f199862-def2-4112-bc8b-688b03f6e313_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_4c58fa41-c648-49a3-9df1-16301690be2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_1501fb25-6151-46e6-a196-4697fd971a71_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes redemption rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_a5bc377c-1549-4270-b572-5879f7d40a24_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New campus lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_19b9e0b1-8d57-47e1-afd7-10368d082fe1_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6583a4b5-152e-4653-94ee-08a7bd1c7499_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4da122bc-84a3-48ff-88ba-01819395ec97_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b93c9685-1fd0-490f-8d30-e3edb2d31a58_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2369ea50-3132-41d8-af00-376682eae589_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_d2bacafd-d604-4a1b-8910-a43a1cd68218_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior note assumed borrowing rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ce86beb6-8ee9-41a6-b454-ee611013a30e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_d776f080-8bc5-448f-b761-1c1b5c9c3b3a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9289ca77-5b19-439f-8792-7f6da19c66cf_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_d1377e0b-a559-429d-b73d-466b8f6406b3_terseLabel_en-US" xlink:label="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the liability component immediately before extinguishment</link:label>
    <link:label id="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_label_en-US" xlink:label="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Liability Component Immediately Before Extinguishment</link:label>
    <link:label id="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_documentation_en-US" xlink:label="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the liability component immediately before extinguishment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:href="nbix-20220630.xsd#nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:to="lab_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_63a54c16-1761-47c1-bb09-fa5d4a44e141_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_f33cbff4-4b76-4ca6-9876-ce4ad0a7009f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_48714e48-3775-48ff-8039-29a142ea4756_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c4b44560-a3fb-400e-ae4d-37d874c42482_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a80811b1-d8d0-4392-ae0f-ad96badfb377_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_7c8cdd16-525e-4ae5-a8f9-4f0d0edbd8d6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_dd4c4d86-1eac-4a16-a4cb-03679ffc0b4f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a0356cd4-0969-48ad-a385-9f79e71b1b41_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_9207613f-6ec6-41c7-9eb1-50903ff7b5a4_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_label_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment Receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of potential milestone payment receipts under a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts" xlink:href="nbix-20220630.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePaymentReceipts" xlink:to="lab_nbix_PotentialMilestonePaymentReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_e79b696d-d383-427c-b97d-ae7ba360371f_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2026</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:href="nbix-20220630.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_55da2ab3-8d58-4905-a800-8502afa1aa86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fd27ac51-95e4-4cb4-9dc8-10596cfd860f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_41130522-ddd8-44a6-b01d-11b9b3e9e2ac_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_72087236-db60-4f15-bde4-565ef9bcba61_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d3d284e1-e3b8-463b-add5-f13e881a86ee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7da24db0-d7f6-4ae8-8fb3-05156535f745_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_b48bf918-8a6a-43d6-9d87-4f0e802a0979_terseLabel_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_label_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember" xlink:href="nbix-20220630.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_XenonPharmaceuticalsIncMember" xlink:to="lab_nbix_XenonPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_236d4bca-60d5-4e68-8814-d7d22b9cd37b_terseLabel_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_label_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two [Member]</link:label>
    <link:label id="lab_nbix_ConversionPeriodTwoMember_documentation_en-US" xlink:label="lab_nbix_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember" xlink:href="nbix-20220630.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ConversionPeriodTwoMember" xlink:to="lab_nbix_ConversionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_a7659827-76be-468b-81e2-efade188d2f1_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4439c7bf-c93e-484f-8df9-4db736de9321_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_51869031-8ac4-4f2f-a7a6-115514fea2f1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_45204295-1da9-43cf-a076-13e3f7a40001_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_3a55f939-0909-432e-9e1d-ef7843c72892_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_79b7e179-13e2-4a5b-bff6-90fbf3b3f1bc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_4e33c259-ebba-4f97-b89d-deb47dfa0271_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9933fb09-9daf-40d6-85a6-bc77fd31c86f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e2f4df3a-4b40-47f2-9590-fd3f5e052936_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_878d0bee-1c3a-4aed-a1e5-2adda28d7be0_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_5331f4d5-8c96-4f4a-a5d0-bb72d89182fd_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_759d605a-81ad-4673-9699-ca60f63b596b_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391256d4-dfa9-4322-94fe-9fd41e3cef74_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3d89b114-cffe-4636-afc0-b88265d4fd20_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_7d586900-9210-427a-8e75-b75cf4e95e01_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9bf7da8d-4a27-46d3-b3a8-24c82456444d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8e9c689a-7a47-4539-ab8d-de0613101168_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AbbVieIncMember_e0e54063-6824-41ee-96f6-a6582d87f578_terseLabel_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_nbix_AbbVieIncMember_label_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Inc. [Member]</link:label>
    <link:label id="lab_nbix_AbbVieIncMember_documentation_en-US" xlink:label="lab_nbix_AbbVieIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember" xlink:href="nbix-20220630.xsd#nbix_AbbVieIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AbbVieIncMember" xlink:to="lab_nbix_AbbVieIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_4dc53b39-fe24-4a84-97cf-ae79089358f3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d55fffa7-4c04-42b4-9525-ac194519c345_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_437dbcbe-1516-46b0-b802-714d434ca72d_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_label_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Conversion Premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:href="nbix-20220630.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:to="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9096b15f-8943-4997-9ced-bc6e68ce13d3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_31da76df-f94f-4a45-98a6-9e5d2c92baaa_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fbd07fb0-a423-42e8-9788-0631dcfdd24a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1b1d6a24-a311-4f66-896f-c90645c2125c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ee0dbb77-9c34-441b-a899-07c35ee4a802_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9f1aeb69-0f76-4083-be8d-2c3886496b31_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_599c3c54-93fe-4a8c-85a6-15f41d223268_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_c65dca03-544c-491a-92fb-d18dc4a5c5d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt, Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b25612fa-f859-4ac5-a1c4-7fedca8a1737_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7c0bd000-29a4-4565-a08b-d3a6ddbb1398_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets acquired through operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_7a2838e3-13fd-4f0c-934e-fa4b8db693ce_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_a29f6594-cbc3-45b7-b6eb-ba172434ad08_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_label_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion [Axis]</link:label>
    <link:label id="lab_nbix_DebtInstrumentConversionAxis_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis" xlink:href="nbix-20220630.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConversionAxis" xlink:to="lab_nbix_DebtInstrumentConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_52bab76e-13c0-46c5-b0e4-e61e19a4c306_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_31e5d6f4-df56-48cf-905b-f4293b09589f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_f0c2da08-f009-4706-8a79-1cfd10fb093d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>nbix-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0c42dd0c-c284-4653-91e4-174ef769a678,g:b6b90098-cdc3-4729-a2bb-5ae5dda3bf39-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/CoverPage" xlink:type="simple" xlink:href="nbix-20220630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_da0af2f8-bd4b-4274-a7a3-8628114882c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_DocumentType_da0af2f8-bd4b-4274-a7a3-8628114882c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1af13eb4-4299-4267-95fb-d4b1166397a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_DocumentQuarterlyReport_1af13eb4-4299-4267-95fb-d4b1166397a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_28b08147-197b-4f35-ad72-a4933c113dca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_DocumentPeriodEndDate_28b08147-197b-4f35-ad72-a4933c113dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_cae35de6-0517-4167-9b29-7781770f8baf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_DocumentTransitionReport_cae35de6-0517-4167-9b29-7781770f8baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_de574e22-ef17-4ddc-ba8f-a38f99593a33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityFileNumber_de574e22-ef17-4ddc-ba8f-a38f99593a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e7207e2c-ef75-4a63-9776-10f5e5c2e6d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityRegistrantName_e7207e2c-ef75-4a63-9776-10f5e5c2e6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_96715eb3-4480-408f-bfcb-0a5c42886be7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_96715eb3-4480-408f-bfcb-0a5c42886be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fd0aba3d-9b20-4e8f-b7aa-d88db1754980" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityTaxIdentificationNumber_fd0aba3d-9b20-4e8f-b7aa-d88db1754980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2a19e317-c39d-4a5e-a197-c6187a11bdc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityAddressAddressLine1_2a19e317-c39d-4a5e-a197-c6187a11bdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7b1c7375-2c00-4c6b-bc33-49639a401ff1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityAddressCityOrTown_7b1c7375-2c00-4c6b-bc33-49639a401ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1fd68f39-0d9f-45b4-babf-17c602030f5d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityAddressStateOrProvince_1fd68f39-0d9f-45b4-babf-17c602030f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ab1e18bd-743d-4f0d-8f0a-69a109ba797e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityAddressPostalZipCode_ab1e18bd-743d-4f0d-8f0a-69a109ba797e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_31f6e2dc-f5c7-4cb1-be63-ef78f03a1b38" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_CityAreaCode_31f6e2dc-f5c7-4cb1-be63-ef78f03a1b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b82577c0-8cce-4232-b763-38260cf8bf7d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_LocalPhoneNumber_b82577c0-8cce-4232-b763-38260cf8bf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_86d95f33-6ee9-4461-8724-267cbe27bacd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_Security12bTitle_86d95f33-6ee9-4461-8724-267cbe27bacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_446847b6-cd66-4607-b3f0-1da9b3413844" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_TradingSymbol_446847b6-cd66-4607-b3f0-1da9b3413844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4b6c1daa-0692-4778-977e-4ffe8c3e3d67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_SecurityExchangeName_4b6c1daa-0692-4778-977e-4ffe8c3e3d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3f7cbdd4-5e87-429f-8fc1-ed9e069b3617" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityCurrentReportingStatus_3f7cbdd4-5e87-429f-8fc1-ed9e069b3617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_980ae675-202f-446d-a559-4a2e8748d86e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityInteractiveDataCurrent_980ae675-202f-446d-a559-4a2e8748d86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e7a93af9-7c9c-494e-8baa-82fb0a2dd05f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityFilerCategory_e7a93af9-7c9c-494e-8baa-82fb0a2dd05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a5395aa6-a4bc-429b-961a-b1ea784b50cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntitySmallBusiness_a5395aa6-a4bc-429b-961a-b1ea784b50cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0d32a438-d3a7-46ca-a14b-7c1ee9d889a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityEmergingGrowthCompany_0d32a438-d3a7-46ca-a14b-7c1ee9d889a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b5247d99-d8cf-4859-ad02-023a510d5fcf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityShellCompany_b5247d99-d8cf-4859-ad02-023a510d5fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d1881e75-8878-4541-9fbc-55f7fdfb18b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d1881e75-8878-4541-9fbc-55f7fdfb18b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c33c7709-0af6-4ed5-b58f-7d67e0f1981b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_AmendmentFlag_c33c7709-0af6-4ed5-b58f-7d67e0f1981b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_acb9e7ca-06b3-4a82-8ec7-7ae4437427a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_DocumentFiscalYearFocus_acb9e7ca-06b3-4a82-8ec7-7ae4437427a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e56d6fdb-26d6-41d9-a8b8-d28f554a5c57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e56d6fdb-26d6-41d9-a8b8-d28f554a5c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_97743f8b-f9bb-4320-b8ac-d5f6cc8b3f72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_EntityCentralIndexKey_97743f8b-f9bb-4320-b8ac-d5f6cc8b3f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_21a2b9f1-48ad-4df3-9915-7c638d91f90a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_77824f0e-81c7-45a2-90b5-dac1cd2a90b3" xlink:to="loc_dei_CurrentFiscalYearEndDate_21a2b9f1-48ad-4df3-9915-7c638d91f90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_85a91a7e-a744-439c-87c9-675ebb185ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7237c2d5-161e-4e1e-a0da-afed3acdfd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_85a91a7e-a744-439c-87c9-675ebb185ff6" xlink:to="loc_us-gaap_AssetsAbstract_7237c2d5-161e-4e1e-a0da-afed3acdfd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_64f82db7-c265-487b-9936-6ead3a30205a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7237c2d5-161e-4e1e-a0da-afed3acdfd1d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_64f82db7-c265-487b-9936-6ead3a30205a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3985d77b-0503-4ad6-8341-e031675c8833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_64f82db7-c265-487b-9936-6ead3a30205a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3985d77b-0503-4ad6-8341-e031675c8833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3c576019-d8b7-4096-97a6-3f8b2466800d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_64f82db7-c265-487b-9936-6ead3a30205a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3c576019-d8b7-4096-97a6-3f8b2466800d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_456e10d0-bdeb-471e-91f1-4e3f4fedfd42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_64f82db7-c265-487b-9936-6ead3a30205a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_456e10d0-bdeb-471e-91f1-4e3f4fedfd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7feae6ea-15a9-48ea-984d-6b4aa85b7f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_64f82db7-c265-487b-9936-6ead3a30205a" xlink:to="loc_us-gaap_InventoryNet_7feae6ea-15a9-48ea-984d-6b4aa85b7f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e71101a3-94cd-4fe8-98a8-49ca70a03b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_64f82db7-c265-487b-9936-6ead3a30205a" xlink:to="loc_us-gaap_OtherAssetsCurrent_e71101a3-94cd-4fe8-98a8-49ca70a03b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9879c59c-ca90-4e22-b0f5-3334115b9225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_64f82db7-c265-487b-9936-6ead3a30205a" xlink:to="loc_us-gaap_AssetsCurrent_9879c59c-ca90-4e22-b0f5-3334115b9225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_9cabb661-c788-4859-b03f-1f16872f1f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7237c2d5-161e-4e1e-a0da-afed3acdfd1d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_9cabb661-c788-4859-b03f-1f16872f1f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_163104cc-8f3c-4bd7-8a13-c501aaa3f817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7237c2d5-161e-4e1e-a0da-afed3acdfd1d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_163104cc-8f3c-4bd7-8a13-c501aaa3f817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_91146b28-9d4e-413d-bc29-eb4ffbfd8524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7237c2d5-161e-4e1e-a0da-afed3acdfd1d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_91146b28-9d4e-413d-bc29-eb4ffbfd8524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_5581353e-f048-41db-976a-363300701027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7237c2d5-161e-4e1e-a0da-afed3acdfd1d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_5581353e-f048-41db-976a-363300701027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e97f76ae-3b3b-4cef-a1f4-fd91ad432dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7237c2d5-161e-4e1e-a0da-afed3acdfd1d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e97f76ae-3b3b-4cef-a1f4-fd91ad432dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7ae1376c-1826-405b-bd8d-4228c2d0a923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7237c2d5-161e-4e1e-a0da-afed3acdfd1d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7ae1376c-1826-405b-bd8d-4228c2d0a923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_437c5898-7dab-4508-8f71-cf8b124bee3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7237c2d5-161e-4e1e-a0da-afed3acdfd1d" xlink:to="loc_us-gaap_Assets_437c5898-7dab-4508-8f71-cf8b124bee3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34bb88db-0e2c-4655-910b-6ba80290ffdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_85a91a7e-a744-439c-87c9-675ebb185ff6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34bb88db-0e2c-4655-910b-6ba80290ffdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_44b07647-e756-4e45-8d24-398828114446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34bb88db-0e2c-4655-910b-6ba80290ffdd" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_44b07647-e756-4e45-8d24-398828114446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_59dc41b2-5ecd-4d47-a2b5-79ab32741fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44b07647-e756-4e45-8d24-398828114446" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_59dc41b2-5ecd-4d47-a2b5-79ab32741fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_17a714c6-7c0f-4385-8177-ed5674585c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44b07647-e756-4e45-8d24-398828114446" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_17a714c6-7c0f-4385-8177-ed5674585c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ef25e67d-fc95-4bc1-b07f-5aa8fc0e9857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44b07647-e756-4e45-8d24-398828114446" xlink:to="loc_us-gaap_LiabilitiesCurrent_ef25e67d-fc95-4bc1-b07f-5aa8fc0e9857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_ed39d51a-0d75-4c10-8641-a7a9bc0ed07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34bb88db-0e2c-4655-910b-6ba80290ffdd" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_ed39d51a-0d75-4c10-8641-a7a9bc0ed07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cbf6c132-0387-4bf4-b708-098be187c1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34bb88db-0e2c-4655-910b-6ba80290ffdd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cbf6c132-0387-4bf4-b708-098be187c1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c761df1f-796f-46ea-ba99-ced0d119220c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34bb88db-0e2c-4655-910b-6ba80290ffdd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c761df1f-796f-46ea-ba99-ced0d119220c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4d6cc8f8-1093-45c0-b1dc-0ee9445eda28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34bb88db-0e2c-4655-910b-6ba80290ffdd" xlink:to="loc_us-gaap_Liabilities_4d6cc8f8-1093-45c0-b1dc-0ee9445eda28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e1ba38fc-7f6d-45b0-8771-59ed1262b790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34bb88db-0e2c-4655-910b-6ba80290ffdd" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e1ba38fc-7f6d-45b0-8771-59ed1262b790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9b177ea4-33a0-4bb2-a052-73ddbd73b31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e1ba38fc-7f6d-45b0-8771-59ed1262b790" xlink:to="loc_us-gaap_PreferredStockValue_9b177ea4-33a0-4bb2-a052-73ddbd73b31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d7de9737-0f14-47ff-a984-b2af83f781f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e1ba38fc-7f6d-45b0-8771-59ed1262b790" xlink:to="loc_us-gaap_CommonStockValue_d7de9737-0f14-47ff-a984-b2af83f781f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c7ac2836-ea6b-43cf-836a-a444976dbffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e1ba38fc-7f6d-45b0-8771-59ed1262b790" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c7ac2836-ea6b-43cf-836a-a444976dbffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b664725d-8cdf-4771-a44c-49f5f5293eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e1ba38fc-7f6d-45b0-8771-59ed1262b790" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b664725d-8cdf-4771-a44c-49f5f5293eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fbd750ad-ecd4-4a47-8dad-9e95fb4bcc70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e1ba38fc-7f6d-45b0-8771-59ed1262b790" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fbd750ad-ecd4-4a47-8dad-9e95fb4bcc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6a4c3428-4474-4b21-bdb1-d8220001b17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e1ba38fc-7f6d-45b0-8771-59ed1262b790" xlink:to="loc_us-gaap_StockholdersEquity_6a4c3428-4474-4b21-bdb1-d8220001b17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f86ad58-27fa-4a81-9899-e446b388b6be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34bb88db-0e2c-4655-910b-6ba80290ffdd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f86ad58-27fa-4a81-9899-e446b388b6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nbix-20220630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ea6abb95-b1ec-49a0-b142-9435854c9d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c8dce398-842e-4089-ace7-0ed563502688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ea6abb95-b1ec-49a0-b142-9435854c9d7a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c8dce398-842e-4089-ace7-0ed563502688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c8b26ee3-1d95-4003-8080-a7ca60c400ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ea6abb95-b1ec-49a0-b142-9435854c9d7a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c8b26ee3-1d95-4003-8080-a7ca60c400ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ac85fd9b-9c42-47dc-aba3-14d11216562b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ea6abb95-b1ec-49a0-b142-9435854c9d7a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ac85fd9b-9c42-47dc-aba3-14d11216562b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_fa000a74-2c05-445d-b42b-f56778d9c845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ea6abb95-b1ec-49a0-b142-9435854c9d7a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_fa000a74-2c05-445d-b42b-f56778d9c845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_abc282e5-afe6-47e1-840f-db603714c308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ea6abb95-b1ec-49a0-b142-9435854c9d7a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_abc282e5-afe6-47e1-840f-db603714c308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b7c21f9e-1255-4478-b310-efd96d8ec616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ea6abb95-b1ec-49a0-b142-9435854c9d7a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b7c21f9e-1255-4478-b310-efd96d8ec616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b639226d-e926-477d-a08a-60f067c229c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ea6abb95-b1ec-49a0-b142-9435854c9d7a" xlink:to="loc_us-gaap_CommonStockSharesIssued_b639226d-e926-477d-a08a-60f067c229c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6b56f72d-ed4a-4157-98e6-6277d4f4d35c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ea6abb95-b1ec-49a0-b142-9435854c9d7a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6b56f72d-ed4a-4157-98e6-6277d4f4d35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="simple" xlink:href="nbix-20220630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2f06f88a-d0d3-49fc-9ba4-78c73cb7cd33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3907596b-e00a-4277-84c2-85b0be5a804e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f06f88a-d0d3-49fc-9ba4-78c73cb7cd33" xlink:to="loc_us-gaap_StatementTable_3907596b-e00a-4277-84c2-85b0be5a804e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_403b11dc-ab09-4221-a3df-77f53ab19f7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3907596b-e00a-4277-84c2-85b0be5a804e" xlink:to="loc_srt_ProductOrServiceAxis_403b11dc-ab09-4221-a3df-77f53ab19f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6e7e0b97-8e46-4a3f-9311-4553b9a0edf5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_403b11dc-ab09-4221-a3df-77f53ab19f7f" xlink:to="loc_srt_ProductsAndServicesDomain_6e7e0b97-8e46-4a3f-9311-4553b9a0edf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f83907ef-ff2e-4a2e-a2e5-ddd6f300e293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6e7e0b97-8e46-4a3f-9311-4553b9a0edf5" xlink:to="loc_us-gaap_ProductMember_f83907ef-ff2e-4a2e-a2e5-ddd6f300e293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_3c58b080-8d35-40f8-b252-c48bdac410ae" xlink:href="nbix-20220630.xsd#nbix_CollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6e7e0b97-8e46-4a3f-9311-4553b9a0edf5" xlink:to="loc_nbix_CollaborationRevenueMember_3c58b080-8d35-40f8-b252-c48bdac410ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3907596b-e00a-4277-84c2-85b0be5a804e" xlink:to="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_de661414-01cf-463d-a937-76a22616dc42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_RevenuesAbstract_de661414-01cf-463d-a937-76a22616dc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_58fbc88b-4977-4526-b84d-28914c04bb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_de661414-01cf-463d-a937-76a22616dc42" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_58fbc88b-4977-4526-b84d-28914c04bb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8abbab7a-2c9c-48bf-9d6a-4ca8f5510602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8abbab7a-2c9c-48bf-9d6a-4ca8f5510602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4906781c-7081-4334-9bad-b42a41289be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4906781c-7081-4334-9bad-b42a41289be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5e9367cc-81c2-4985-b468-ce38ccb5fa54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5e9367cc-81c2-4985-b468-ce38ccb5fa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a8c0e6c4-de00-4b32-a386-d5c422aeb3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a8c0e6c4-de00-4b32-a386-d5c422aeb3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b078ead0-ab7e-46a2-b3a8-f19b3d3f243f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f244420e-5553-46d4-a0e9-32d9bb74dbd3" xlink:to="loc_us-gaap_CostsAndExpenses_b078ead0-ab7e-46a2-b3a8-f19b3d3f243f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9f753cea-ed8a-4128-ae86-5006e2c7dff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_OperatingIncomeLoss_9f753cea-ed8a-4128-ae86-5006e2c7dff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_113a7892-7cac-443d-95a7-1f595ee61853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:to="loc_us-gaap_InterestExpense_113a7892-7cac-443d-95a7-1f595ee61853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6cec25dc-0258-4cc6-8e83-c2d4a32f7e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6cec25dc-0258-4cc6-8e83-c2d4a32f7e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_66f5c053-783d-49df-8df1-9e4e293010a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_66f5c053-783d-49df-8df1-9e4e293010a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_8775cee4-55b4-4662-9b0d-1dcdac404727" xlink:href="nbix-20220630.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_8775cee4-55b4-4662-9b0d-1dcdac404727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f0eea723-188c-45de-90a2-fd76a446cfa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_49e3157c-de3e-4639-88e4-0115402e543e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_f0eea723-188c-45de-90a2-fd76a446cfa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7716df4d-903b-45dd-b0a9-3e7ee7e4da35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7716df4d-903b-45dd-b0a9-3e7ee7e4da35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cc2b209c-dd36-489d-901d-5d52efe81356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cc2b209c-dd36-489d-901d-5d52efe81356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e7de6f50-2bfe-4af3-8190-e281a10527b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_NetIncomeLoss_e7de6f50-2bfe-4af3-8190-e281a10527b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3ed4362b-ce78-4051-85ae-bf4c33061aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3ed4362b-ce78-4051-85ae-bf4c33061aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c1f8d2fa-ee2f-4824-8e87-db2f57c8b89e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c1f8d2fa-ee2f-4824-8e87-db2f57c8b89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_222523b6-515b-4d6d-8f23-aa119a972753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_222523b6-515b-4d6d-8f23-aa119a972753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6659b7f0-15cd-4e5c-9af5-6647ef6dbb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_222523b6-515b-4d6d-8f23-aa119a972753" xlink:to="loc_us-gaap_EarningsPerShareBasic_6659b7f0-15cd-4e5c-9af5-6647ef6dbb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9f59cfde-239b-47f3-960d-457bd81db9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_222523b6-515b-4d6d-8f23-aa119a972753" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9f59cfde-239b-47f3-960d-457bd81db9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5c109f15-f0ff-485d-8f95-0edc4d00f81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bde2ec7-7245-4875-ba35-ac7d50f4f16c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5c109f15-f0ff-485d-8f95-0edc4d00f81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b5b0e658-5529-48be-9a42-a470c24dbb60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5c109f15-f0ff-485d-8f95-0edc4d00f81e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b5b0e658-5529-48be-9a42-a470c24dbb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8ed18bad-396f-45ec-b68e-5e2f93e31bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5c109f15-f0ff-485d-8f95-0edc4d00f81e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8ed18bad-396f-45ec-b68e-5e2f93e31bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f5a92d34-a999-4632-971b-e1d0a28e3f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1b70569d-994e-4604-bc62-8998c4858925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f5a92d34-a999-4632-971b-e1d0a28e3f67" xlink:to="loc_us-gaap_StatementTable_1b70569d-994e-4604-bc62-8998c4858925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ee4a0590-6a51-4ec6-a354-9cfce9f44270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1b70569d-994e-4604-bc62-8998c4858925" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ee4a0590-6a51-4ec6-a354-9cfce9f44270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3486e7c5-8e89-4807-a260-df76d1301124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ee4a0590-6a51-4ec6-a354-9cfce9f44270" xlink:to="loc_us-gaap_EquityComponentDomain_3486e7c5-8e89-4807-a260-df76d1301124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a5a76b39-ba25-438d-aedd-b8edd866ea97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3486e7c5-8e89-4807-a260-df76d1301124" xlink:to="loc_us-gaap_CommonStockMember_a5a76b39-ba25-438d-aedd-b8edd866ea97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_042e9237-0983-4b94-8c08-23906c82b197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3486e7c5-8e89-4807-a260-df76d1301124" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_042e9237-0983-4b94-8c08-23906c82b197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec0c5192-efb9-463a-b2c9-76d79bd9aeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3486e7c5-8e89-4807-a260-df76d1301124" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec0c5192-efb9-463a-b2c9-76d79bd9aeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_36779209-2ab4-4cdf-8191-db5ddf2f644a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3486e7c5-8e89-4807-a260-df76d1301124" xlink:to="loc_us-gaap_RetainedEarningsMember_36779209-2ab4-4cdf-8191-db5ddf2f644a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e48a984f-ef8d-45dd-b514-0166e9ac0490" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1b70569d-994e-4604-bc62-8998c4858925" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e48a984f-ef8d-45dd-b514-0166e9ac0490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d8cdd286-9c2b-4533-9e1d-8a5b81eba8e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e48a984f-ef8d-45dd-b514-0166e9ac0490" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d8cdd286-9c2b-4533-9e1d-8a5b81eba8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1f668dfc-fc78-4289-bb1f-a1530b836ad0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d8cdd286-9c2b-4533-9e1d-8a5b81eba8e6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1f668dfc-fc78-4289-bb1f-a1530b836ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5c80272a-bf6a-4803-a006-fdd53ed10cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1b70569d-994e-4604-bc62-8998c4858925" xlink:to="loc_us-gaap_StatementLineItems_5c80272a-bf6a-4803-a006-fdd53ed10cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5c80272a-bf6a-4803-a006-fdd53ed10cab" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_893e8a41-e6d8-4394-8a2f-e1337c25dce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_SharesOutstanding_893e8a41-e6d8-4394-8a2f-e1337c25dce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_13f88140-b791-4e8f-8325-601ef53f049e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_StockholdersEquity_13f88140-b791-4e8f-8325-601ef53f049e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d38afc69-27f5-438b-a9f8-7cbadeba014e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_NetIncomeLoss_d38afc69-27f5-438b-a9f8-7cbadeba014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6e3424f7-53de-48a3-848e-5302caabeb62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6e3424f7-53de-48a3-848e-5302caabeb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_710b0417-668b-4ac4-a85a-2f9f8cd9bfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_710b0417-668b-4ac4-a85a-2f9f8cd9bfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f5d9ce81-6467-44c7-a286-51144ec2405f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f5d9ce81-6467-44c7-a286-51144ec2405f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a8014bab-9b32-4d3d-98da-be31ba22c057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a8014bab-9b32-4d3d-98da-be31ba22c057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9322566f-edf3-48d2-9557-73a776d339c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9322566f-edf3-48d2-9557-73a776d339c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9b5322fa-1faf-4ceb-a59a-56bc2226815e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_SharesOutstanding_9b5322fa-1faf-4ceb-a59a-56bc2226815e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36ea5108-fc68-4473-8bf5-ad368e0596b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6c71b352-4d8a-4269-bf11-37b382f1d1fd" xlink:to="loc_us-gaap_StockholdersEquity_36ea5108-fc68-4473-8bf5-ad368e0596b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c3fa6cde-d5c1-41b4-b918-e795e27824c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_383d91f2-fffd-4857-94f2-e549ad3c6caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c3fa6cde-d5c1-41b4-b918-e795e27824c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_383d91f2-fffd-4857-94f2-e549ad3c6caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aea8feed-f8fd-4a6d-b81e-1d3c24ec5366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_383d91f2-fffd-4857-94f2-e549ad3c6caa" xlink:to="loc_us-gaap_NetIncomeLoss_aea8feed-f8fd-4a6d-b81e-1d3c24ec5366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31d0fc08-ad8f-4b1a-b1fc-2c1590205d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_383d91f2-fffd-4857-94f2-e549ad3c6caa" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31d0fc08-ad8f-4b1a-b1fc-2c1590205d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4aba894a-f06b-4762-b2c0-0c06e4cecd46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31d0fc08-ad8f-4b1a-b1fc-2c1590205d0f" xlink:to="loc_us-gaap_ShareBasedCompensation_4aba894a-f06b-4762-b2c0-0c06e4cecd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5aa2d60d-b3e6-4bc0-b23c-747a95b10613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31d0fc08-ad8f-4b1a-b1fc-2c1590205d0f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5aa2d60d-b3e6-4bc0-b23c-747a95b10613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f0b77b15-eed0-4219-b30b-c639872b3e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31d0fc08-ad8f-4b1a-b1fc-2c1590205d0f" xlink:to="loc_us-gaap_Depreciation_f0b77b15-eed0-4219-b30b-c639872b3e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_2d6438ad-b815-4333-a329-08668e58b762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31d0fc08-ad8f-4b1a-b1fc-2c1590205d0f" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_2d6438ad-b815-4333-a329-08668e58b762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_9a423769-0dd5-4f15-8d7f-30909beb4d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31d0fc08-ad8f-4b1a-b1fc-2c1590205d0f" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_9a423769-0dd5-4f15-8d7f-30909beb4d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_78354aa8-5800-404f-9b6a-7aa5d5cebca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31d0fc08-ad8f-4b1a-b1fc-2c1590205d0f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_78354aa8-5800-404f-9b6a-7aa5d5cebca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_3d955baa-8288-4561-92c6-0892c826e39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31d0fc08-ad8f-4b1a-b1fc-2c1590205d0f" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_3d955baa-8288-4561-92c6-0892c826e39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_a9770c9f-1359-4c74-a8a9-fcd61d4c6e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31d0fc08-ad8f-4b1a-b1fc-2c1590205d0f" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_a9770c9f-1359-4c74-a8a9-fcd61d4c6e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e99c9cdb-293d-4554-ab96-942711f7c248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31d0fc08-ad8f-4b1a-b1fc-2c1590205d0f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e99c9cdb-293d-4554-ab96-942711f7c248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_97e3159c-2a35-4a70-aceb-1047893fd307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e99c9cdb-293d-4554-ab96-942711f7c248" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_97e3159c-2a35-4a70-aceb-1047893fd307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ec75da4d-2f86-4ad1-a05a-28a1e551db6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e99c9cdb-293d-4554-ab96-942711f7c248" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ec75da4d-2f86-4ad1-a05a-28a1e551db6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b464aed9-93c1-47ab-92b8-5a50109765c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e99c9cdb-293d-4554-ab96-942711f7c248" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b464aed9-93c1-47ab-92b8-5a50109765c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_dd69dae5-cbfb-4f70-bca2-67311bc5b56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e99c9cdb-293d-4554-ab96-942711f7c248" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_dd69dae5-cbfb-4f70-bca2-67311bc5b56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a65c5d78-4b60-45e9-95db-7ba4b4741aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_383d91f2-fffd-4857-94f2-e549ad3c6caa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a65c5d78-4b60-45e9-95db-7ba4b4741aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a20a134d-6899-463d-8d12-8bffd8246809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c3fa6cde-d5c1-41b4-b918-e795e27824c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a20a134d-6899-463d-8d12-8bffd8246809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_09307e14-341f-47cd-87a4-d0b1f90b64c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a20a134d-6899-463d-8d12-8bffd8246809" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_09307e14-341f-47cd-87a4-d0b1f90b64c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5cc2872e-18f4-4db5-8cc6-2f5b1069377b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a20a134d-6899-463d-8d12-8bffd8246809" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5cc2872e-18f4-4db5-8cc6-2f5b1069377b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_1e8fca71-5d50-44a0-8ad1-483c3a0e69cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a20a134d-6899-463d-8d12-8bffd8246809" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_1e8fca71-5d50-44a0-8ad1-483c3a0e69cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_01b4671b-d972-4dd2-939d-ff73fdd36ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a20a134d-6899-463d-8d12-8bffd8246809" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_01b4671b-d972-4dd2-939d-ff73fdd36ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6e9048f5-32ed-418a-8eab-77ea5724cfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a20a134d-6899-463d-8d12-8bffd8246809" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6e9048f5-32ed-418a-8eab-77ea5724cfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3595651f-85aa-4671-8e77-637febf9673e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c3fa6cde-d5c1-41b4-b918-e795e27824c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3595651f-85aa-4671-8e77-637febf9673e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_651af17d-a21e-4bd6-a75a-326103030435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3595651f-85aa-4671-8e77-637febf9673e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_651af17d-a21e-4bd6-a75a-326103030435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_6875aa85-09c9-49d2-9837-17d196824adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3595651f-85aa-4671-8e77-637febf9673e" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_6875aa85-09c9-49d2-9837-17d196824adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cf388a3b-4a02-45bf-a99d-151165f348c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3595651f-85aa-4671-8e77-637febf9673e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cf388a3b-4a02-45bf-a99d-151165f348c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a3a27d3-1f71-4454-b3e4-d8dc99104f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c3fa6cde-d5c1-41b4-b918-e795e27824c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a3a27d3-1f71-4454-b3e4-d8dc99104f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e1e1cb04-5275-449e-aebd-f5151bb441e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c3fa6cde-d5c1-41b4-b918-e795e27824c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e1e1cb04-5275-449e-aebd-f5151bb441e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9646624d-f60b-4728-809b-5a97e04bddea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c3fa6cde-d5c1-41b4-b918-e795e27824c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9646624d-f60b-4728-809b-5a97e04bddea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e98666b3-5085-4bb3-b6d5-a62054b5bd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c3fa6cde-d5c1-41b4-b918-e795e27824c5" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e98666b3-5085-4bb3-b6d5-a62054b5bd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_764da7b8-dbc7-4f28-8c33-5bb2a726267c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e98666b3-5085-4bb3-b6d5-a62054b5bd0d" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_764da7b8-dbc7-4f28-8c33-5bb2a726267c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b3a3389b-5020-4584-92dc-5e5393332637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e98666b3-5085-4bb3-b6d5-a62054b5bd0d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b3a3389b-5020-4584-92dc-5e5393332637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_1141f595-900f-490f-864a-686466bae9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e98666b3-5085-4bb3-b6d5-a62054b5bd0d" xlink:to="loc_us-gaap_InterestPaidNet_1141f595-900f-490f-864a-686466bae9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_8b476c19-fd02-4a55-8a16-38771e43983e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e98666b3-5085-4bb3-b6d5-a62054b5bd0d" xlink:to="loc_us-gaap_IncomeTaxesPaid_8b476c19-fd02-4a55-8a16-38771e43983e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="nbix-20220630.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6172ff4e-c36a-4ee5-b877-f3ab91e35afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_a647a2c4-43b6-4279-99e6-00751adc2375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6172ff4e-c36a-4ee5-b877-f3ab91e35afd" xlink:to="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_a647a2c4-43b6-4279-99e6-00751adc2375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nbix-20220630.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_33251bad-2e1d-4a3d-b459-ee6824e55e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bac5992c-3f6c-45df-af36-71fc480c39e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_33251bad-2e1d-4a3d-b459-ee6824e55e0e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bac5992c-3f6c-45df-af36-71fc480c39e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8200e202-e754-43f3-8c0a-7237159ce20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_33251bad-2e1d-4a3d-b459-ee6824e55e0e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8200e202-e754-43f3-8c0a-7237159ce20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_b81532ae-9aab-49b4-9988-bf262c8b84b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_33251bad-2e1d-4a3d-b459-ee6824e55e0e" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_b81532ae-9aab-49b4-9988-bf262c8b84b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5f0b8067-4ed5-4c62-8914-0b4fd78b40d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_591f03c3-a052-45b1-9e24-5241d42739eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f0b8067-4ed5-4c62-8914-0b4fd78b40d0" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_591f03c3-a052-45b1-9e24-5241d42739eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7e76db3c-3810-45fe-ae0d-3ef0f39722de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_591f03c3-a052-45b1-9e24-5241d42739eb" xlink:to="loc_us-gaap_DebtInstrumentAxis_7e76db3c-3810-45fe-ae0d-3ef0f39722de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9961347d-8ca5-4c9a-8c59-69b75d37e162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7e76db3c-3810-45fe-ae0d-3ef0f39722de" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9961347d-8ca5-4c9a-8c59-69b75d37e162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_f895f1ff-3037-44fe-9208-39395dedbd8a" xlink:href="nbix-20220630.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9961347d-8ca5-4c9a-8c59-69b75d37e162" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_f895f1ff-3037-44fe-9208-39395dedbd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1f1da57-4ecd-4ea3-bd38-0569010d58b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_591f03c3-a052-45b1-9e24-5241d42739eb" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1f1da57-4ecd-4ea3-bd38-0569010d58b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d09214a0-b65c-4a04-8509-df9eabf32cba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1f1da57-4ecd-4ea3-bd38-0569010d58b3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d09214a0-b65c-4a04-8509-df9eabf32cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_40177365-46dd-48a9-a6c6-5d15f576e4f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d09214a0-b65c-4a04-8509-df9eabf32cba" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_40177365-46dd-48a9-a6c6-5d15f576e4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3d8d4a30-9402-4e1e-aafa-aedcb1e6d2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_591f03c3-a052-45b1-9e24-5241d42739eb" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3d8d4a30-9402-4e1e-aafa-aedcb1e6d2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_32a3d689-efed-40d7-8666-79f8a121ea64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_3d8d4a30-9402-4e1e-aafa-aedcb1e6d2ea" xlink:to="loc_us-gaap_TypeOfAdoptionMember_32a3d689-efed-40d7-8666-79f8a121ea64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_51471ff1-9db9-4720-b390-2f94a8fbf056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_32a3d689-efed-40d7-8666-79f8a121ea64" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_51471ff1-9db9-4720-b390-2f94a8fbf056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_591f03c3-a052-45b1-9e24-5241d42739eb" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_5d853f28-a6f2-443f-89c0-e5a6f8931063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_5d853f28-a6f2-443f-89c0-e5a6f8931063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4a9f44eb-d621-4a7a-8eaf-54c6e2597d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4a9f44eb-d621-4a7a-8eaf-54c6e2597d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_39f8b906-962e-4484-bb0e-4a7bd7cfa0db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_39f8b906-962e-4484-bb0e-4a7bd7cfa0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9ce45e88-141c-498b-b987-dee04083e690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9ce45e88-141c-498b-b987-dee04083e690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b49a2174-4ab4-4cc2-918c-6c0921e18cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b49a2174-4ab4-4cc2-918c-6c0921e18cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5ce19022-cb70-4976-9cc1-60391c850797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_32d2b959-c05e-4b08-9809-8d582167f0ef" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5ce19022-cb70-4976-9cc1-60391c850797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="nbix-20220630.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_105a7977-47ed-4174-9cdd-e112eda3f26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d55f6950-ed3b-49b4-bcbe-ef99f7d083af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_105a7977-47ed-4174-9cdd-e112eda3f26d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d55f6950-ed3b-49b4-bcbe-ef99f7d083af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4c7d81bd-9dfc-442a-b44a-c7ddd8a6a64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4c7d81bd-9dfc-442a-b44a-c7ddd8a6a64a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1f17253a-db8a-44b4-9eaf-2689f6fa038a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1f17253a-db8a-44b4-9eaf-2689f6fa038a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67586398-bbf8-4f21-9b02-269ccb66faee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1f17253a-db8a-44b4-9eaf-2689f6fa038a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67586398-bbf8-4f21-9b02-269ccb66faee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_cdb15f01-ee2a-46e8-ba28-e311c748305e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67586398-bbf8-4f21-9b02-269ccb66faee" xlink:to="loc_us-gaap_CollaborativeArrangementMember_cdb15f01-ee2a-46e8-ba28-e311c748305e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ed554f13-d41e-4844-a492-ceeb3cae6fb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:to="loc_srt_ProductOrServiceAxis_ed554f13-d41e-4844-a492-ceeb3cae6fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c9dc91c8-35ff-4a77-a3c9-0c4f3ead25fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ed554f13-d41e-4844-a492-ceeb3cae6fb3" xlink:to="loc_srt_ProductsAndServicesDomain_c9dc91c8-35ff-4a77-a3c9-0c4f3ead25fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_51610487-9196-40ec-8363-2573e9e85518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c9dc91c8-35ff-4a77-a3c9-0c4f3ead25fc" xlink:to="loc_us-gaap_RoyaltyMember_51610487-9196-40ec-8363-2573e9e85518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aad3930c-71c8-4145-bbb7-015f2f9c506a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:to="loc_srt_CounterpartyNameAxis_aad3930c-71c8-4145-bbb7-015f2f9c506a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_aad3930c-71c8-4145-bbb7-015f2f9c506a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_HeptaresTherapeuticsLimitedMember_c6ad404e-fdc9-4836-8619-5c1a0b890efa" xlink:href="nbix-20220630.xsd#nbix_HeptaresTherapeuticsLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_HeptaresTherapeuticsLimitedMember_c6ad404e-fdc9-4836-8619-5c1a0b890efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_c4d0b5ec-08db-4022-a47c-99a0f8bd3dfb" xlink:href="nbix-20220630.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_c4d0b5ec-08db-4022-a47c-99a0f8bd3dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_f56e32e4-41b0-449e-828d-4c28c930f859" xlink:href="nbix-20220630.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_f56e32e4-41b0-449e-828d-4c28c930f859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_7e62e89a-7570-44b1-b1e2-b50b3795c6f5" xlink:href="nbix-20220630.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_7e62e89a-7570-44b1-b1e2-b50b3795c6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_4234d351-c85f-4d1a-8650-e17406e06911" xlink:href="nbix-20220630.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_VoyagerTherapeuticsMember_4234d351-c85f-4d1a-8650-e17406e06911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALPortelaCaSAMember_b9e13937-7919-4cea-9670-f80f3f0d99b3" xlink:href="nbix-20220630.xsd#nbix_BIALPortelaCaSAMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_BIALPortelaCaSAMember_b9e13937-7919-4cea-9670-f80f3f0d99b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_5fcc73a4-ffd6-4765-86ba-5a9c9e0523aa" xlink:href="nbix-20220630.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_5fcc73a4-ffd6-4765-86ba-5a9c9e0523aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbVieIncMember_692cad51-375a-42b3-85a2-79555a03ed34" xlink:href="nbix-20220630.xsd#nbix_AbbVieIncMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_042a9fd4-77f3-430d-b1f7-398449a32d1c" xlink:to="loc_nbix_AbbVieIncMember_692cad51-375a-42b3-85a2-79555a03ed34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_675a9692-c5ba-42b8-a05d-6afb00a698fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:to="loc_srt_RangeAxis_675a9692-c5ba-42b8-a05d-6afb00a698fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6aae9bdd-2193-460d-8f5e-d28934d3c3a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_675a9692-c5ba-42b8-a05d-6afb00a698fd" xlink:to="loc_srt_RangeMember_6aae9bdd-2193-460d-8f5e-d28934d3c3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7779cb95-04b6-4535-9dfc-9c4bb52ab6d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6aae9bdd-2193-460d-8f5e-d28934d3c3a4" xlink:to="loc_srt_MinimumMember_7779cb95-04b6-4535-9dfc-9c4bb52ab6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f25533d2-d40a-48fd-821a-5a1dae427652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f25533d2-d40a-48fd-821a-5a1dae427652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5d333bf-2e09-4084-a864-460ea8794213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f25533d2-d40a-48fd-821a-5a1dae427652" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5d333bf-2e09-4084-a864-460ea8794213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_a4d3c5ea-e213-42a9-bb3d-2cc15b38403a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5d333bf-2e09-4084-a864-460ea8794213" xlink:to="loc_us-gaap_PatentsMember_a4d3c5ea-e213-42a9-bb3d-2cc15b38403a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5d3940cb-f471-420a-8085-d4b385ee82ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5d3940cb-f471-420a-8085-d4b385ee82ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_60e8be5d-d9fc-4b16-841e-8d6b2bd4d0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5d3940cb-f471-420a-8085-d4b385ee82ee" xlink:to="loc_us-gaap_EquityComponentDomain_60e8be5d-d9fc-4b16-841e-8d6b2bd4d0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f224e442-c041-47d3-8f54-a14b6e55f191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_60e8be5d-d9fc-4b16-841e-8d6b2bd4d0cd" xlink:to="loc_us-gaap_CommonStockMember_f224e442-c041-47d3-8f54-a14b6e55f191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46febe0e-e893-48a7-a708-50aae76abdf3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5f4a538b-aa5d-4139-b178-091260807700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5f4a538b-aa5d-4139-b178-091260807700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ec46f2a0-5c24-4762-965e-3b7844debc04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ec46f2a0-5c24-4762-965e-3b7844debc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_1fad87a5-f989-41de-986a-5b75d4c3e206" xlink:href="nbix-20220630.xsd#nbix_PotentialMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_nbix_PotentialMilestonePayments_1fad87a5-f989-41de-986a-5b75d4c3e206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_30adbec0-0f6a-478f-921a-a7e7babd26d9" xlink:href="nbix-20220630.xsd#nbix_UpfrontPaymentsMade"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_nbix_UpfrontPaymentsMade_30adbec0-0f6a-478f-921a-a7e7babd26d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_39bb346b-be4c-4bb3-97a7-8f1e020cd1b9" xlink:href="nbix-20220630.xsd#nbix_SaleOfStockNumberOfSharesSoldInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_nbix_SaleOfStockNumberOfSharesSoldInTransaction_39bb346b-be4c-4bb3-97a7-8f1e020cd1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_8f1b7ffe-8f85-4557-abe4-0cda234d7ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_us-gaap_SharePrice_8f1b7ffe-8f85-4557-abe4-0cda234d7ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_4c85cb01-6641-4a65-8252-e591044f39dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_4c85cb01-6641-4a65-8252-e591044f39dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_3cd15ea8-930c-4701-92a4-a636293a3992" xlink:href="nbix-20220630.xsd#nbix_MilestonePayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_nbix_MilestonePayment_3cd15ea8-930c-4701-92a4-a636293a3992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_1cb3876a-f98b-45ac-b35f-6bb243a95318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_1cb3876a-f98b-45ac-b35f-6bb243a95318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_4dca30fb-a187-4d27-8a60-b706c062573c" xlink:href="nbix-20220630.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_4dca30fb-a187-4d27-8a60-b706c062573c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm_ac497df4-36d1-459d-a513-4abe7297426b" xlink:href="nbix-20220630.xsd#nbix_PatentTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_nbix_PatentTerm_ac497df4-36d1-459d-a513-4abe7297426b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6a00b4c5-bbda-4313-acdb-1a570d83ec98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8fe2b392-3ac3-47f4-bbd2-b8cfe1d9815e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6a00b4c5-bbda-4313-acdb-1a570d83ec98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecurities" xlink:type="simple" xlink:href="nbix-20220630.xsd#DebtSecurities"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3fed0f98-c7cf-47a7-9d86-ac0863df29ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_a48f8b1a-b4e7-4dc9-bfe6-f15e21f9e473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3fed0f98-c7cf-47a7-9d86-ac0863df29ae" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_a48f8b1a-b4e7-4dc9-bfe6-f15e21f9e473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="simple" xlink:href="nbix-20220630.xsd#DebtSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ea164e95-e819-4573-90de-b2b5688a771c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_e7d9f7f4-b9b4-4a17-a48f-f46382a480dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ea164e95-e819-4573-90de-b2b5688a771c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_e7d9f7f4-b9b4-4a17-a48f-f46382a480dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_1752a991-5f32-4839-99b2-69ec1a061e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ea164e95-e819-4573-90de-b2b5688a771c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_1752a991-5f32-4839-99b2-69ec1a061e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_431f0fbf-6060-4df1-b081-13f0439b4aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_25c82eb0-4f5f-4b03-ad3d-a2db9ecc2fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_431f0fbf-6060-4df1-b081-13f0439b4aba" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_25c82eb0-4f5f-4b03-ad3d-a2db9ecc2fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_cf0bba79-fa90-4158-808c-f41391f35049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_25c82eb0-4f5f-4b03-ad3d-a2db9ecc2fc4" xlink:to="loc_us-gaap_InvestmentTypeAxis_cf0bba79-fa90-4158-808c-f41391f35049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0b187985-9c0b-42df-983b-3a0c0ab68203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_cf0bba79-fa90-4158-808c-f41391f35049" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0b187985-9c0b-42df-983b-3a0c0ab68203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_23c685d2-048f-4a55-baed-14a8bcda35e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0b187985-9c0b-42df-983b-3a0c0ab68203" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_23c685d2-048f-4a55-baed-14a8bcda35e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember_73603d2c-182b-4fcb-9005-2879d57674ed" xlink:href="nbix-20220630.xsd#nbix_LongTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_0b187985-9c0b-42df-983b-3a0c0ab68203" xlink:to="loc_nbix_LongTermInvestmentsMember_73603d2c-182b-4fcb-9005-2879d57674ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_1e36008a-1d75-496b-a373-2f9915e45cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_25c82eb0-4f5f-4b03-ad3d-a2db9ecc2fc4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_1e36008a-1d75-496b-a373-2f9915e45cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c12f50f5-fec8-4e0f-ae52-0565f0658d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_1e36008a-1d75-496b-a373-2f9915e45cc5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c12f50f5-fec8-4e0f-ae52-0565f0658d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_017008ff-8e61-4c55-8f3a-48d1c3a2fc19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c12f50f5-fec8-4e0f-ae52-0565f0658d84" xlink:to="loc_us-gaap_CommercialPaperMember_017008ff-8e61-4c55-8f3a-48d1c3a2fc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_22c6e9c3-1304-4058-a94b-ce374ebc7869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_25c82eb0-4f5f-4b03-ad3d-a2db9ecc2fc4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_22c6e9c3-1304-4058-a94b-ce374ebc7869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c0a1137-c437-4e8e-b312-282b6dc6613b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_22c6e9c3-1304-4058-a94b-ce374ebc7869" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c0a1137-c437-4e8e-b312-282b6dc6613b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e5ac71ee-1022-49f6-9cbe-e07b3a567edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c0a1137-c437-4e8e-b312-282b6dc6613b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e5ac71ee-1022-49f6-9cbe-e07b3a567edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_3f1bd96d-37f9-4a16-8078-50a35c108e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7c0a1137-c437-4e8e-b312-282b6dc6613b" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_3f1bd96d-37f9-4a16-8078-50a35c108e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f89e0581-d6fb-401d-a0ab-57594e241a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_25c82eb0-4f5f-4b03-ad3d-a2db9ecc2fc4" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f89e0581-d6fb-401d-a0ab-57594e241a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9c7ff0e0-0b63-42f6-9d82-881eadf8229b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f89e0581-d6fb-401d-a0ab-57594e241a22" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9c7ff0e0-0b63-42f6-9d82-881eadf8229b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cc6bd975-9b86-4de6-8b6c-8275026ffe35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f89e0581-d6fb-401d-a0ab-57594e241a22" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cc6bd975-9b86-4de6-8b6c-8275026ffe35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6f815853-b2f9-41ec-acb6-ca8d1a6278b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f89e0581-d6fb-401d-a0ab-57594e241a22" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6f815853-b2f9-41ec-acb6-ca8d1a6278b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b3a037ab-7089-43b1-9d66-64cd34c65085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f89e0581-d6fb-401d-a0ab-57594e241a22" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b3a037ab-7089-43b1-9d66-64cd34c65085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#DebtSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e53ce3b0-1f6d-4a8c-abe4-07db30c59ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_51bfa16f-5cb6-4a20-9233-588679f54b79" xlink:href="nbix-20220630.xsd#nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e53ce3b0-1f6d-4a8c-abe4-07db30c59ef8" xlink:to="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_51bfa16f-5cb6-4a20-9233-588679f54b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_4f7c8473-6b98-4209-a048-6eb37733354d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e53ce3b0-1f6d-4a8c-abe4-07db30c59ef8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_4f7c8473-6b98-4209-a048-6eb37733354d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_253bd792-a16f-457f-b94f-581b7f565196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e53ce3b0-1f6d-4a8c-abe4-07db30c59ef8" xlink:to="loc_us-gaap_InterestReceivableCurrent_253bd792-a16f-457f-b94f-581b7f565196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_060b16d3-093b-44ef-afa2-0f7925abf0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e53ce3b0-1f6d-4a8c-abe4-07db30c59ef8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_060b16d3-093b-44ef-afa2-0f7925abf0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6152e7d3-437f-46ae-99d7-1f20ea523ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_8772fa3b-2b49-4515-82d3-02204c0a14e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6152e7d3-437f-46ae-99d7-1f20ea523ddb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_8772fa3b-2b49-4515-82d3-02204c0a14e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_50b0f78a-7677-4436-afd7-c2345e056036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_8772fa3b-2b49-4515-82d3-02204c0a14e6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_50b0f78a-7677-4436-afd7-c2345e056036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d4c3ede-58e3-4a65-b487-a512a051a3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_50b0f78a-7677-4436-afd7-c2345e056036" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d4c3ede-58e3-4a65-b487-a512a051a3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5cfdc44b-6e2c-4165-98ce-dc6e09f05bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d4c3ede-58e3-4a65-b487-a512a051a3b9" xlink:to="loc_us-gaap_CommercialPaperMember_5cfdc44b-6e2c-4165-98ce-dc6e09f05bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4f17c2ce-3da0-40c6-a0a0-f3e22d2dd8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d4c3ede-58e3-4a65-b487-a512a051a3b9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4f17c2ce-3da0-40c6-a0a0-f3e22d2dd8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8953a26e-0e16-4ab9-b3f0-ef1e1984e983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2d4c3ede-58e3-4a65-b487-a512a051a3b9" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_8953a26e-0e16-4ab9-b3f0-ef1e1984e983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_8772fa3b-2b49-4515-82d3-02204c0a14e6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d2700cb5-d2ab-484e-ab42-97247c768d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d2700cb5-d2ab-484e-ab42-97247c768d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b8a4b632-cda7-4ebd-bc93-84224fc495f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b8a4b632-cda7-4ebd-bc93-84224fc495f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_22e95109-4f37-4e6a-8105-f47ea9d9ebd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_22e95109-4f37-4e6a-8105-f47ea9d9ebd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ad09eee8-6545-4d17-977d-eeb6dcbf0963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_ad09eee8-6545-4d17-977d-eeb6dcbf0963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_930426cb-cd26-40f8-970e-4905fb105f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_930426cb-cd26-40f8-970e-4905fb105f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_217e7dcb-1c59-4795-8660-60928eef7939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f0e2a1c9-fde1-45d7-b1f0-f3984f342971" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_217e7dcb-1c59-4795-8660-60928eef7939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nbix-20220630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2647025a-48ab-416b-b13b-e301e1a7e87e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a4cf8dc8-ca8e-4b33-b730-5001f2ecd0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2647025a-48ab-416b-b13b-e301e1a7e87e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a4cf8dc8-ca8e-4b33-b730-5001f2ecd0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nbix-20220630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_14d84a5b-8876-4bf1-a53c-c2ee3f1dd5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_5f4d6bf9-b1d3-4d89-8639-a8c06057610f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_14d84a5b-8876-4bf1-a53c-c2ee3f1dd5bc" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_5f4d6bf9-b1d3-4d89-8639-a8c06057610f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3f514606-d96d-4440-abd3-3f9eef190e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_14d84a5b-8876-4bf1-a53c-c2ee3f1dd5bc" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3f514606-d96d-4440-abd3-3f9eef190e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="nbix-20220630.xsd#FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_34f910f7-c5c6-4f96-8476-038df438af93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f741ef43-2db4-4df4-89e7-3f97d0fba864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_34f910f7-c5c6-4f96-8476-038df438af93" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f741ef43-2db4-4df4-89e7-3f97d0fba864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_9f31c540-6490-4de3-a751-f22778023df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f741ef43-2db4-4df4-89e7-3f97d0fba864" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_9f31c540-6490-4de3-a751-f22778023df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3901cdfa-7003-4532-a38e-1df3078bde9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_9f31c540-6490-4de3-a751-f22778023df1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3901cdfa-7003-4532-a38e-1df3078bde9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_dfe44def-17a4-4bd8-90ff-8dcf2318e797" xlink:href="nbix-20220630.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3901cdfa-7003-4532-a38e-1df3078bde9f" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_dfe44def-17a4-4bd8-90ff-8dcf2318e797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d695bebc-3ca9-4abf-9fa9-6c9be4a83e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3901cdfa-7003-4532-a38e-1df3078bde9f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d695bebc-3ca9-4abf-9fa9-6c9be4a83e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d0502ae0-0b0b-4ebf-87ae-a13563daa956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3901cdfa-7003-4532-a38e-1df3078bde9f" xlink:to="loc_us-gaap_CommercialPaperMember_d0502ae0-0b0b-4ebf-87ae-a13563daa956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d3896575-61d5-4a4c-b085-6f1ac5460429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f741ef43-2db4-4df4-89e7-3f97d0fba864" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d3896575-61d5-4a4c-b085-6f1ac5460429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6854d821-ea5d-4776-9a1a-6a3d83840ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d3896575-61d5-4a4c-b085-6f1ac5460429" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6854d821-ea5d-4776-9a1a-6a3d83840ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b667e155-b4c2-4993-875b-09f9b89aaf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6854d821-ea5d-4776-9a1a-6a3d83840ca6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b667e155-b4c2-4993-875b-09f9b89aaf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5ec868e1-b1f0-4581-8cc2-c73560440152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6854d821-ea5d-4776-9a1a-6a3d83840ca6" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5ec868e1-b1f0-4581-8cc2-c73560440152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_c14c26f7-4e18-48b5-8661-20df56da61e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6854d821-ea5d-4776-9a1a-6a3d83840ca6" xlink:to="loc_us-gaap_EquitySecuritiesMember_c14c26f7-4e18-48b5-8661-20df56da61e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7860fb4c-16ae-4ddc-9672-db91370070e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f741ef43-2db4-4df4-89e7-3f97d0fba864" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7860fb4c-16ae-4ddc-9672-db91370070e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9df3692-563d-4e7b-a62a-76a48dee0ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7860fb4c-16ae-4ddc-9672-db91370070e4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9df3692-563d-4e7b-a62a-76a48dee0ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1cb63a15-eccc-4c06-a74a-e5168936b6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9df3692-563d-4e7b-a62a-76a48dee0ff4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1cb63a15-eccc-4c06-a74a-e5168936b6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d864bf09-6846-4310-9443-01c28dd048b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9df3692-563d-4e7b-a62a-76a48dee0ff4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d864bf09-6846-4310-9443-01c28dd048b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_07140425-057d-4950-9a6d-e73fa3041d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9df3692-563d-4e7b-a62a-76a48dee0ff4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_07140425-057d-4950-9a6d-e73fa3041d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e6b3bbe-0f31-4769-a49c-f45b20cbfff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f741ef43-2db4-4df4-89e7-3f97d0fba864" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e6b3bbe-0f31-4769-a49c-f45b20cbfff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_70557603-23ee-4386-ae25-a24ef13bd81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4e6b3bbe-0f31-4769-a49c-f45b20cbfff8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_70557603-23ee-4386-ae25-a24ef13bd81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_85c95152-55a2-4646-b169-156ddcdd9d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_70557603-23ee-4386-ae25-a24ef13bd81b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_85c95152-55a2-4646-b169-156ddcdd9d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ce79a6fe-a913-4919-addd-51527cd82841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f741ef43-2db4-4df4-89e7-3f97d0fba864" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ce79a6fe-a913-4919-addd-51527cd82841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_cccc2cf8-cf05-453d-97a7-37eb2727b3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ce79a6fe-a913-4919-addd-51527cd82841" xlink:to="loc_us-gaap_Investments_cccc2cf8-cf05-453d-97a7-37eb2727b3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7f76fe0d-beed-49f5-bfe4-e4acc44f6f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ce79a6fe-a913-4919-addd-51527cd82841" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7f76fe0d-beed-49f5-bfe4-e4acc44f6f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="simple" xlink:href="nbix-20220630.xsd#FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_22036471-f1c9-4f82-aa99-76f0d13097ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172497a9-3c64-4735-bb30-3b149c18275b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_22036471-f1c9-4f82-aa99-76f0d13097ca" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172497a9-3c64-4735-bb30-3b149c18275b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f6fe32b-7eee-4dda-9103-a2373d4319a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172497a9-3c64-4735-bb30-3b149c18275b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f6fe32b-7eee-4dda-9103-a2373d4319a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71919397-f010-43ba-902e-4c89969b29be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f6fe32b-7eee-4dda-9103-a2373d4319a8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71919397-f010-43ba-902e-4c89969b29be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a7b1cddd-0e9b-4041-8126-b5ad0afbad98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71919397-f010-43ba-902e-4c89969b29be" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a7b1cddd-0e9b-4041-8126-b5ad0afbad98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_778d6dc0-0955-43d2-9312-90962a0f3cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172497a9-3c64-4735-bb30-3b149c18275b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_778d6dc0-0955-43d2-9312-90962a0f3cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_258f7654-ba5c-4096-8c89-7ad6e16ee7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_778d6dc0-0955-43d2-9312-90962a0f3cda" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_258f7654-ba5c-4096-8c89-7ad6e16ee7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3ba8e550-3156-4434-9c7b-0da9538b5730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_258f7654-ba5c-4096-8c89-7ad6e16ee7e2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3ba8e550-3156-4434-9c7b-0da9538b5730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0bfbd201-6e87-4098-bd03-de62bdea2b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172497a9-3c64-4735-bb30-3b149c18275b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0bfbd201-6e87-4098-bd03-de62bdea2b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b0bd7a02-4ce7-4d77-b0f2-e0a78b0a6718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0bfbd201-6e87-4098-bd03-de62bdea2b02" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b0bd7a02-4ce7-4d77-b0f2-e0a78b0a6718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_be6afcb4-e72c-4fb0-9c76-c78d9369d2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b0bd7a02-4ce7-4d77-b0f2-e0a78b0a6718" xlink:to="loc_us-gaap_EquitySecuritiesMember_be6afcb4-e72c-4fb0-9c76-c78d9369d2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ec1a8ac-6ec9-44d7-91b1-fc1c795568b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_172497a9-3c64-4735-bb30-3b149c18275b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ec1a8ac-6ec9-44d7-91b1-fc1c795568b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_891f0afc-ebda-4309-b996-7f2e32d47894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0ec1a8ac-6ec9-44d7-91b1-fc1c795568b7" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_891f0afc-ebda-4309-b996-7f2e32d47894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_0e5ed575-4ee3-4df4-b25b-d8fca6c98b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_891f0afc-ebda-4309-b996-7f2e32d47894" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_0e5ed575-4ee3-4df4-b25b-d8fca6c98b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_6c51b2ad-3c03-4216-8b6b-92d182cb7a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_891f0afc-ebda-4309-b996-7f2e32d47894" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_6c51b2ad-3c03-4216-8b6b-92d182cb7a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_56e42e87-aaee-4b21-9ac0-15bdb10822e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_891f0afc-ebda-4309-b996-7f2e32d47894" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_56e42e87-aaee-4b21-9ac0-15bdb10822e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_ff7695c6-34f2-4955-a14c-53f6bad09928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_891f0afc-ebda-4309-b996-7f2e32d47894" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_ff7695c6-34f2-4955-a14c-53f6bad09928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Inventories" xlink:type="simple" xlink:href="nbix-20220630.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f0f7faf7-3329-41d1-a5f2-353f90ae4e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_111564a2-df18-4c6b-8995-0392e635cdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f0f7faf7-3329-41d1-a5f2-353f90ae4e07" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_111564a2-df18-4c6b-8995-0392e635cdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesTables" xlink:type="simple" xlink:href="nbix-20220630.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_10339ab9-fc75-42f2-9ada-4b875b1d8836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7c911815-6eb4-4551-aeb6-58979366639f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_10339ab9-fc75-42f2-9ada-4b875b1d8836" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7c911815-6eb4-4551-aeb6-58979366639f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#InventoriesSummaryofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c6c2ae6e-9c8a-4f54-b9f6-94c4525a70cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_90d6e265-9e1b-4a19-928f-1357a4efa3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c6c2ae6e-9c8a-4f54-b9f6-94c4525a70cd" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_90d6e265-9e1b-4a19-928f-1357a4efa3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c9418b28-44e3-4b73-a9fb-1206e092c270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c6c2ae6e-9c8a-4f54-b9f6-94c4525a70cd" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c9418b28-44e3-4b73-a9fb-1206e092c270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_714a4713-1710-42c0-a91c-a4e7f5274de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c6c2ae6e-9c8a-4f54-b9f6-94c4525a70cd" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_714a4713-1710-42c0-a91c-a4e7f5274de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_78dc778c-608c-41d1-8204-56169662ffcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c6c2ae6e-9c8a-4f54-b9f6-94c4525a70cd" xlink:to="loc_us-gaap_InventoryNet_78dc778c-608c-41d1-8204-56169662ffcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="simple" xlink:href="nbix-20220630.xsd#CashCashEquivalentsandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_2b49d2f3-0f61-4937-b681-63334fd249b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashTextBlock_d81248a2-bb12-4439-8e9e-e0174d7ffdc7" xlink:href="nbix-20220630.xsd#nbix_RestrictedCashTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_2b49d2f3-0f61-4937-b681-63334fd249b8" xlink:to="loc_nbix_RestrictedCashTextBlock_d81248a2-bb12-4439-8e9e-e0174d7ffdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="simple" xlink:href="nbix-20220630.xsd#CashCashEquivalentsandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_0ff0f3e6-071a-4e0b-997f-a4e2163786e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_c626cbf5-f6d2-49d4-9d4c-b15cbf895681" xlink:href="nbix-20220630.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_0ff0f3e6-071a-4e0b-997f-a4e2163786e8" xlink:to="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_c626cbf5-f6d2-49d4-9d4c-b15cbf895681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_3d584f12-5b7b-4253-81e3-229e4361e68e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0fe4ad10-cfbc-46fa-a5e2-b0785281bdda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_3d584f12-5b7b-4253-81e3-229e4361e68e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0fe4ad10-cfbc-46fa-a5e2-b0785281bdda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9e6b64a4-aec6-4da1-9d66-a7d9e2968790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_3d584f12-5b7b-4253-81e3-229e4361e68e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9e6b64a4-aec6-4da1-9d66-a7d9e2968790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_7406b743-90c5-4757-a539-86ca91c04018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_3d584f12-5b7b-4253-81e3-229e4361e68e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_7406b743-90c5-4757-a539-86ca91c04018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Leases" xlink:type="simple" xlink:href="nbix-20220630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5fd6adc0-91ab-4f2a-9fd4-f14dcb5478b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_c5492d5c-dd64-46f1-8497-16311e690f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5fd6adc0-91ab-4f2a-9fd4-f14dcb5478b9" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_c5492d5c-dd64-46f1-8497-16311e690f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesTables" xlink:type="simple" xlink:href="nbix-20220630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_827778cb-dd89-406f-b32c-ac200045abac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_bc25e4ea-d985-41af-82cf-4745706ed008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_827778cb-dd89-406f-b32c-ac200045abac" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_bc25e4ea-d985-41af-82cf-4745706ed008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3420ec50-10f6-4e09-b948-20dd78c94c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_827778cb-dd89-406f-b32c-ac200045abac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3420ec50-10f6-4e09-b948-20dd78c94c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#LeasesNarrativeInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesNarrativeInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9c9f3d7e-fb2a-46b3-a78f-fc279a5761f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_e85fb46d-8eca-4e43-82cb-e1af8b0da623" xlink:href="nbix-20220630.xsd#nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c9f3d7e-fb2a-46b3-a78f-fc279a5761f8" xlink:to="loc_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding_e85fb46d-8eca-4e43-82cb-e1af8b0da623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RentAbatementPeriod_2d9f4786-3928-46a8-b248-3751c35c8b31" xlink:href="nbix-20220630.xsd#nbix_RentAbatementPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c9f3d7e-fb2a-46b3-a78f-fc279a5761f8" xlink:to="loc_nbix_RentAbatementPeriod_2d9f4786-3928-46a8-b248-3751c35c8b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_f5d3d27d-cc59-4567-98f6-0d640a4dcb9e" xlink:href="nbix-20220630.xsd#nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c9f3d7e-fb2a-46b3-a78f-fc279a5761f8" xlink:to="loc_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_f5d3d27d-cc59-4567-98f6-0d640a4dcb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AnnualRentEscalationPercentage_9e75aa52-f600-488a-95ba-346973162044" xlink:href="nbix-20220630.xsd#nbix_AnnualRentEscalationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c9f3d7e-fb2a-46b3-a78f-fc279a5761f8" xlink:to="loc_nbix_AnnualRentEscalationPercentage_9e75aa52-f600-488a-95ba-346973162044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_35174bbe-b5e1-453f-91ed-95e90b93fedd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c9f3d7e-fb2a-46b3-a78f-fc279a5761f8" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_35174bbe-b5e1-453f-91ed-95e90b93fedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfRenewalOptions_7e7aab3c-bd62-49e9-ae88-5df742b03b5e" xlink:href="nbix-20220630.xsd#nbix_NumberOfRenewalOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c9f3d7e-fb2a-46b3-a78f-fc279a5761f8" xlink:to="loc_nbix_NumberOfRenewalOptions_7e7aab3c-bd62-49e9-ae88-5df742b03b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_37bf38e8-cdf9-4288-b51a-aaaa9edbb02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c9f3d7e-fb2a-46b3-a78f-fc279a5761f8" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_37bf38e8-cdf9-4288-b51a-aaaa9edbb02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_61534b13-daca-4d74-a6d8-13a74a1d8939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c9f3d7e-fb2a-46b3-a78f-fc279a5761f8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_61534b13-daca-4d74-a6d8-13a74a1d8939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#LeasesSupplementalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesSupplementalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7624ebb4-c06c-4850-8b2a-6cdf543aab2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_8ec96e74-10d8-4c70-b724-42a7d8a206ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7624ebb4-c06c-4850-8b2a-6cdf543aab2c" xlink:to="loc_us-gaap_OperatingLeaseCost_8ec96e74-10d8-4c70-b724-42a7d8a206ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_bcfaff5d-8376-40f5-a409-c8aed11e170b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7624ebb4-c06c-4850-8b2a-6cdf543aab2c" xlink:to="loc_us-gaap_OperatingLeasePayments_bcfaff5d-8376-40f5-a409-c8aed11e170b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_840dc50c-d2b1-4a37-a966-40bf254bffaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7624ebb4-c06c-4850-8b2a-6cdf543aab2c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_840dc50c-d2b1-4a37-a966-40bf254bffaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_633e7932-2f65-4a2d-9cd0-c165bca46083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7624ebb4-c06c-4850-8b2a-6cdf543aab2c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_633e7932-2f65-4a2d-9cd0-c165bca46083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#LeasesLiabilityPaymentDueDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_67ad3055-ff26-4af0-9a69-f46dd39dd1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_67ad3055-ff26-4af0-9a69-f46dd39dd1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cf97bbf7-457e-46b7-9498-3783236d7656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cf97bbf7-457e-46b7-9498-3783236d7656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fdda5c98-7a13-405d-97ee-e9f9a7dd10e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fdda5c98-7a13-405d-97ee-e9f9a7dd10e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cee21a90-0752-41f1-9436-64369e58cd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cee21a90-0752-41f1-9436-64369e58cd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ee3aca98-31c4-4be1-a7a4-c3bdac49c9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ee3aca98-31c4-4be1-a7a4-c3bdac49c9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_03988eb8-a063-4a66-81fe-10b9a761d7a5" xlink:href="nbix-20220630.xsd#nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_03988eb8-a063-4a66-81fe-10b9a761d7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c48ace3-f9dd-466b-845f-07f7edb23d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c48ace3-f9dd-466b-845f-07f7edb23d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f80dc138-c093-4fca-bc50-1f4a678d3f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f80dc138-c093-4fca-bc50-1f4a678d3f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_94474022-5a67-40d7-9772-5c980ba7a7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_us-gaap_OperatingLeaseLiability_94474022-5a67-40d7-9772-5c980ba7a7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b17b796e-16c9-4b92-836d-6c0640b423aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b17b796e-16c9-4b92-836d-6c0640b423aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3c45ce19-fe47-4d8e-9eb6-9e2d40e6509b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3c45ce19-fe47-4d8e-9eb6-9e2d40e6509b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_b8b40997-1b02-49e9-883f-cedd3b388099" xlink:href="nbix-20220630.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo_b8b40997-1b02-49e9-883f-cedd3b388099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_78ee2f86-95bc-4274-8a99-0722df1c5c12" xlink:href="nbix-20220630.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree_78ee2f86-95bc-4274-8a99-0722df1c5c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_23415be2-cd61-45d5-89bf-47cd5f6d6957" xlink:href="nbix-20220630.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour_23415be2-cd61-45d5-89bf-47cd5f6d6957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_6f67f48d-42fe-450a-825a-6dda14cf1d67" xlink:href="nbix-20220630.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac820857-57bf-4160-a3df-227f0b2b3479" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive_6f67f48d-42fe-450a-825a-6dda14cf1d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1" xlink:type="simple" xlink:href="nbix-20220630.xsd#LeasesLiabilityPaymentDueDetails_1"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="nbix-20220630.xsd#ConvertibleSeniorNotes"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_883700c3-bac8-4d25-b431-7826fccc9d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2fd2f569-043b-4043-ba19-dc89adf184f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_883700c3-bac8-4d25-b431-7826fccc9d0d" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_2fd2f569-043b-4043-ba19-dc89adf184f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="nbix-20220630.xsd#ConvertibleSeniorNotesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4b3178b9-5f8d-4d43-8cd9-967fa6328446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_35cd9083-392f-4dcf-bb8a-a7604cc0b3da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4b3178b9-5f8d-4d43-8cd9-967fa6328446" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_35cd9083-392f-4dcf-bb8a-a7604cc0b3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#ConvertibleSeniorNotesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f0a0b220-48ef-4aa1-93ce-65e992958fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f0a0b220-48ef-4aa1-93ce-65e992958fd6" xlink:to="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_954bc100-6a5a-43f9-b345-1becff8d8b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:to="loc_us-gaap_DebtInstrumentAxis_954bc100-6a5a-43f9-b345-1becff8d8b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aeb24792-36aa-4e94-81ea-781042b608f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_954bc100-6a5a-43f9-b345-1becff8d8b07" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aeb24792-36aa-4e94-81ea-781042b608f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_db5d8237-7688-4aa1-ac40-014bdf0f4607" xlink:href="nbix-20220630.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aeb24792-36aa-4e94-81ea-781042b608f9" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_db5d8237-7688-4aa1-ac40-014bdf0f4607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_97d7530a-21e8-4c13-9e4a-f9d44a897b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_97d7530a-21e8-4c13-9e4a-f9d44a897b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c231caac-7cf8-405d-8ac7-eccee87157b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_97d7530a-21e8-4c13-9e4a-f9d44a897b7b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c231caac-7cf8-405d-8ac7-eccee87157b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_8c8dd9b9-a24a-4bab-83e3-71dce1b5bdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c231caac-7cf8-405d-8ac7-eccee87157b4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_8c8dd9b9-a24a-4bab-83e3-71dce1b5bdbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_771cffba-c627-4ff4-924c-9d5f29b93242" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_771cffba-c627-4ff4-924c-9d5f29b93242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_02f7bc41-1db1-40ca-b905-059168fee609" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_771cffba-c627-4ff4-924c-9d5f29b93242" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_02f7bc41-1db1-40ca-b905-059168fee609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9da6b944-a86e-4a75-99ef-bbb322b0b47a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_02f7bc41-1db1-40ca-b905-059168fee609" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9da6b944-a86e-4a75-99ef-bbb322b0b47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_89c79a5e-bd00-4c1e-95eb-26c3db4f438f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_89c79a5e-bd00-4c1e-95eb-26c3db4f438f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_6300536b-148c-46e2-b7a4-6dac386fb057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_89c79a5e-bd00-4c1e-95eb-26c3db4f438f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_6300536b-148c-46e2-b7a4-6dac386fb057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_d5ed6b18-fb06-416b-9c7b-a7f5be4f9378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_6300536b-148c-46e2-b7a4-6dac386fb057" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_d5ed6b18-fb06-416b-9c7b-a7f5be4f9378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionAxis_e79c1ed1-d21e-4651-bce4-56c222a4dedb" xlink:href="nbix-20220630.xsd#nbix_DebtInstrumentConversionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:to="loc_nbix_DebtInstrumentConversionAxis_e79c1ed1-d21e-4651-bce4-56c222a4dedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConversionDomain_49c03596-1351-4d5c-8003-3022093070ca" xlink:href="nbix-20220630.xsd#nbix_DebtInstrumentConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionAxis_e79c1ed1-d21e-4651-bce4-56c222a4dedb" xlink:to="loc_nbix_DebtInstrumentConversionDomain_49c03596-1351-4d5c-8003-3022093070ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodOneMember_aa552d55-68bc-4e0f-9145-9c855e787490" xlink:href="nbix-20220630.xsd#nbix_ConversionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionDomain_49c03596-1351-4d5c-8003-3022093070ca" xlink:to="loc_nbix_ConversionPeriodOneMember_aa552d55-68bc-4e0f-9145-9c855e787490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ConversionPeriodTwoMember_a2f2931e-743d-4dc4-8315-82cbfacbb962" xlink:href="nbix-20220630.xsd#nbix_ConversionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbix_DebtInstrumentConversionDomain_49c03596-1351-4d5c-8003-3022093070ca" xlink:to="loc_nbix_ConversionPeriodTwoMember_a2f2931e-743d-4dc4-8315-82cbfacbb962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d7e0c9f-d801-407c-a052-3a6f6e1467f2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c6533769-9280-408f-b36a-9391a0a781ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c6533769-9280-408f-b36a-9391a0a781ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7daba78c-390b-4d44-be60-b4a6974e6e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7daba78c-390b-4d44-be60-b4a6974e6e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_bf008f27-9f5c-489c-8fcb-497de74005cd" xlink:href="nbix-20220630.xsd#nbix_CarryingAmountOfLiabilityComponentUponIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentUponIssuance_bf008f27-9f5c-489c-8fcb-497de74005cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1ae53073-9818-4737-ac3c-f8aea65b95b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1ae53073-9818-4737-ac3c-f8aea65b95b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8a63fcbe-c904-4f82-9e1e-b63bfe54ce56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8a63fcbe-c904-4f82-9e1e-b63bfe54ce56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_bbabf951-259b-4921-8da1-3851bae602a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentTerm_bbabf951-259b-4921-8da1-3851bae602a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_49be04b9-ef9d-4c09-a702-db000ba239b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_49be04b9-ef9d-4c09-a702-db000ba239b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4cd569c0-0e9d-4faa-9216-9ee93bdb5d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4cd569c0-0e9d-4faa-9216-9ee93bdb5d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_da5ca27d-5979-44bc-8c90-37fd682f34c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_RepaymentsOfDebt_da5ca27d-5979-44bc-8c90-37fd682f34c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_f3e433da-b0ba-4d71-b701-0d4fb2543687" xlink:href="nbix-20220630.xsd#nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment_f3e433da-b0ba-4d71-b701-0d4fb2543687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_be550a4f-48d1-4b3a-8836-cdc0337e4382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_be550a4f-48d1-4b3a-8836-cdc0337e4382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_36e6f755-f98d-4e36-ba92-c499edb15ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_36e6f755-f98d-4e36-ba92-c499edb15ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_232c358a-3eaa-47cd-b3c1-cbe93b89d3dc" xlink:href="nbix-20220630.xsd#nbix_CarryingAmountOfLiabilityComponentAtSettlement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_nbix_CarryingAmountOfLiabilityComponentAtSettlement_232c358a-3eaa-47cd-b3c1-cbe93b89d3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fe6fff79-e237-4829-8b00-56845c1e61f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fe6fff79-e237-4829-8b00-56845c1e61f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_48b92b77-bf3d-4a78-98d3-340e33690368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_48b92b77-bf3d-4a78-98d3-340e33690368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_7a1aeabc-1bc4-48a0-86d0-23127466968d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_7a1aeabc-1bc4-48a0-86d0-23127466968d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b5e3d141-a127-4d18-aad8-4399c7224083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b5e3d141-a127-4d18-aad8-4399c7224083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_12510ae8-39d6-4e84-a3f2-21ba69a14cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_12510ae8-39d6-4e84-a3f2-21ba69a14cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a7006426-a7d9-4977-8808-5e2eddf0b9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a7006426-a7d9-4977-8808-5e2eddf0b9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_b56cb8bd-3571-46ac-89b5-a7a2377db480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_b56cb8bd-3571-46ac-89b5-a7a2377db480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_57313cec-4c1d-4cd4-b111-f07f6d848f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_57313cec-4c1d-4cd4-b111-f07f6d848f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_c72f7665-4e25-4acc-9dda-8a0d5a63691a" xlink:href="nbix-20220630.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_c72f7665-4e25-4acc-9dda-8a0d5a63691a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_fde97c31-57ba-40e5-84ef-e3e00aa809d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_fde97c31-57ba-40e5-84ef-e3e00aa809d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_8c7f11aa-3450-4ca9-b681-7d3571d06b5e" xlink:href="nbix-20220630.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_8c7f11aa-3450-4ca9-b681-7d3571d06b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_efe00c71-c84f-4f51-9010-767f54fc1d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_SharePrice_efe00c71-c84f-4f51-9010-767f54fc1d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_edd787dd-2a60-4ee2-9a64-086b4a7b25ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_edd787dd-2a60-4ee2-9a64-086b4a7b25ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_ab2faa2b-f6d8-4aae-b187-7a1b51028ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleStockPriceTrigger_ab2faa2b-f6d8-4aae-b187-7a1b51028ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_9d1aaa25-1300-42e9-9736-fccd12dfaaac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_9d1aaa25-1300-42e9-9736-fccd12dfaaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_dbb5a8fa-c239-41b8-8c5d-61f466e96c80" xlink:href="nbix-20220630.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_dbb5a8fa-c239-41b8-8c5d-61f466e96c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_5957565a-2fe0-4ecf-9ae2-2c18cd35c5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc338d36-18eb-4fc8-8c1f-a6ca7f21dc9b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_5957565a-2fe0-4ecf-9ae2-2c18cd35c5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#ConvertibleSeniorNotes2024NotesDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_61dbb42e-c38c-4d6d-8d59-e972145b4fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_da41fc7e-54ca-4a3d-818d-7bcb50b594b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_61dbb42e-c38c-4d6d-8d59-e972145b4fb4" xlink:to="loc_us-gaap_DebtInstrumentTable_da41fc7e-54ca-4a3d-818d-7bcb50b594b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_56623a3c-56af-4c4d-9369-3adc17eb0d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_da41fc7e-54ca-4a3d-818d-7bcb50b594b8" xlink:to="loc_us-gaap_DebtInstrumentAxis_56623a3c-56af-4c4d-9369-3adc17eb0d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_990c5ce6-703d-4f25-a8a8-3221a5eded63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_56623a3c-56af-4c4d-9369-3adc17eb0d59" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_990c5ce6-703d-4f25-a8a8-3221a5eded63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_872b64f0-133a-4a6e-a33a-bb70cef2356d" xlink:href="nbix-20220630.xsd#nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_990c5ce6-703d-4f25-a8a8-3221a5eded63" xlink:to="loc_nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember_872b64f0-133a-4a6e-a33a-bb70cef2356d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_da41fc7e-54ca-4a3d-818d-7bcb50b594b8" xlink:to="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bac0eb2f-1e33-4d0a-b19f-e3b4dd823bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bac0eb2f-1e33-4d0a-b19f-e3b4dd823bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_8aafb649-5aa5-49d9-a322-1677d8a8aa9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_8aafb649-5aa5-49d9-a322-1677d8a8aa9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_78ddd0fe-5fac-44e0-9a68-a7be73aac83f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_78ddd0fe-5fac-44e0-9a68-a7be73aac83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_9604efef-661a-485f-a3b0-30f0a5e33274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_9604efef-661a-485f-a3b0-30f0a5e33274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_5ae6cc82-f33d-4aac-b74a-119ba39e0d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904ba9f2-6131-4bba-a7b6-078af99b9904" xlink:to="loc_us-gaap_DebtInstrumentFairValue_5ae6cc82-f33d-4aac-b74a-119ba39e0d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#ConvertibleSeniorNotesInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ed168aeb-65e8-4c03-8a25-fef73ca48371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentCouponInterest_e413a0d2-125c-446d-9bcf-5b746b1cb71a" xlink:href="nbix-20220630.xsd#nbix_DebtInstrumentCouponInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ed168aeb-65e8-4c03-8a25-fef73ca48371" xlink:to="loc_nbix_DebtInstrumentCouponInterest_e413a0d2-125c-446d-9bcf-5b746b1cb71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2bfa9dae-d5c3-4d70-97ca-edba15b81e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ed168aeb-65e8-4c03-8a25-fef73ca48371" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2bfa9dae-d5c3-4d70-97ca-edba15b81e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_187d4ad5-2898-4a0d-99c9-6b1084f2d0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ed168aeb-65e8-4c03-8a25-fef73ca48371" xlink:to="loc_us-gaap_InterestExpense_187d4ad5-2898-4a0d-99c9-6b1084f2d0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LossEarningsperShare" xlink:type="simple" xlink:href="nbix-20220630.xsd#LossEarningsperShare"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LossEarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_48b1ff91-51ca-438b-89a2-8af4e7181e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_81a79e42-ff4e-4943-b4c8-af25f71a05b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_48b1ff91-51ca-438b-89a2-8af4e7181e13" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_81a79e42-ff4e-4943-b4c8-af25f71a05b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LossEarningsperShareTables" xlink:type="simple" xlink:href="nbix-20220630.xsd#LossEarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LossEarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_49bef037-cb36-4916-8098-e234974cbe56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b490a6e0-836d-46a9-b8c7-cae2a96dec75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_49bef037-cb36-4916-8098-e234974cbe56" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b490a6e0-836d-46a9-b8c7-cae2a96dec75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails" xlink:type="simple" xlink:href="nbix-20220630.xsd#LossEarningsperShareScheduleofNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a83fa9ec-581e-4af9-a37a-1026218df43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce8d52d9-ceb2-4093-9ad1-d75d03db48a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a83fa9ec-581e-4af9-a37a-1026218df43e" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce8d52d9-ceb2-4093-9ad1-d75d03db48a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_703f0767-28dc-4fbe-8c4a-556a62bf1d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce8d52d9-ceb2-4093-9ad1-d75d03db48a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_703f0767-28dc-4fbe-8c4a-556a62bf1d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6d76a428-f684-41d0-a3ac-ba10842dd09c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_703f0767-28dc-4fbe-8c4a-556a62bf1d31" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6d76a428-f684-41d0-a3ac-ba10842dd09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29261944-8786-48ba-be30-aabb36c5c5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6d76a428-f684-41d0-a3ac-ba10842dd09c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29261944-8786-48ba-be30-aabb36c5c5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_66af5f49-be01-480e-b516-918e3d61faaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6d76a428-f684-41d0-a3ac-ba10842dd09c" xlink:to="loc_us-gaap_RestrictedStockMember_66af5f49-be01-480e-b516-918e3d61faaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d69d9df1-0578-4074-b4fe-92d1301f0756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce8d52d9-ceb2-4093-9ad1-d75d03db48a9" xlink:to="loc_us-gaap_DebtInstrumentAxis_d69d9df1-0578-4074-b4fe-92d1301f0756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d8be7ca0-a4d8-4bc9-affb-a5025f727478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d69d9df1-0578-4074-b4fe-92d1301f0756" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d8be7ca0-a4d8-4bc9-affb-a5025f727478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_a46be431-ea04-4740-baaa-41875baba286" xlink:href="nbix-20220630.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d8be7ca0-a4d8-4bc9-affb-a5025f727478" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_a46be431-ea04-4740-baaa-41875baba286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ce8d52d9-ceb2-4093-9ad1-d75d03db48a9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fbed4d55-7848-4e95-8ecc-85b76d12e531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fbed4d55-7848-4e95-8ecc-85b76d12e531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_43c0151f-0b2f-429e-bf59-126d77e1f7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_43c0151f-0b2f-429e-bf59-126d77e1f7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b21bb400-1b9e-4c4c-8f26-33a3184bb77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b21bb400-1b9e-4c4c-8f26-33a3184bb77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6213a09-a72d-467b-8be7-e7192c1e1ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b21bb400-1b9e-4c4c-8f26-33a3184bb77b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6213a09-a72d-467b-8be7-e7192c1e1ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_058963d4-7cca-4b5f-a3e7-85944dfa8d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_058963d4-7cca-4b5f-a3e7-85944dfa8d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4e50c4ed-aec0-4909-bb9f-ab98ee8e2360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_058963d4-7cca-4b5f-a3e7-85944dfa8d77" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4e50c4ed-aec0-4909-bb9f-ab98ee8e2360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_94fc3d45-da62-4246-aa60-9f2f3e431331" xlink:href="nbix-20220630.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_058963d4-7cca-4b5f-a3e7-85944dfa8d77" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_94fc3d45-da62-4246-aa60-9f2f3e431331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f3caf8f2-955e-41de-b025-a0ce1a15a432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_058963d4-7cca-4b5f-a3e7-85944dfa8d77" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f3caf8f2-955e-41de-b025-a0ce1a15a432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f2628e28-41c6-4476-b956-d635d51e6c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_EarningsPerShareBasic_f2628e28-41c6-4476-b956-d635d51e6c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0badb6eb-8e12-413c-949f-e14320902539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0badb6eb-8e12-413c-949f-e14320902539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_496db5e3-b30e-444e-99b5-b9a04d4a1761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_cfcc96ab-c29b-4802-84d3-88097cc7a224" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_496db5e3-b30e-444e-99b5-b9a04d4a1761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>nbix-20220630_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20220630_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MR:G++?KO,[ZZ=-["QGBEC:/'2X35&/LW**Y[OF]ZFI[;;NWH?=GBS]I;X>^
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M0+.< Y>UE3?-Z+\[GXK+PHXSIT7EN'QT?J[TM[2HE9[KEY7OU2=F?G)^Q?\
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MCO-6\(Z3<:??:A;?9)GDOIK@-'N#XP[$#D#D<UZ^,XCHXC!.C)/G:\K7^_\
M0_-N&_ W,\EXKI9G0JPEA:<W)7E+VG*TTDURVNKVOS:VOI>Q^;O_  4L_P"3
MVO&W^]:?^DD-7OV9O^"B_BK]ESX9_P#"+Z/H/A_4;/[7+>>=>&;S=TF,CY6
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MU+6MTNN37EI(XZ+-$YRRD\'!Z=CTKZ]M[>.TMXXHD6..-0B(HPJ@<  >@I]
M'S-^P!^UOXJ^*^K^*OAK\4-/33?BA\/91%?2PQ%+;6;<G"W4? 7NN0O!#HP
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M9SRTLC=7D8\LQZGVP*ZJBBOGI2<G=[GXQ6K5*U256JW*4G=MZMM[ML*^??\
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M*/C9_P $]O@_^T5X]F\3^,O!\.M:Y<0QV\ERU]<Q%DC!"#;'(J\ GM7*V_\
MP2*_9XM+F.:/X=6JR0NLB'^T[WAE((/^N]10!Q7_  49_P"3TOV3_P#L:[O^
M5M7UAX^\":3\4/!.J^'==LH=0T?6K62SO+:4966-P01['G((Y! (Y%8OQ%^
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MY('-4?CO^PK\)?VEM3&H>,_ ^CZKJB@+]O0-;79 Z9EB*NV.VXG%<_\ "O\
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979354145184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,639,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979352310368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 163.3<span></span>
</td>
<td class="nump">$ 340.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities available-for-sale</a></td>
<td class="nump">485.0<span></span>
</td>
<td class="nump">370.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">279.0<span></span>
</td>
<td class="nump">185.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">29.3<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">62.7<span></span>
</td>
<td class="nump">45.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,019.3<span></span>
</td>
<td class="nump">972.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">328.4<span></span>
</td>
<td class="nump">315.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Debt securities available-for-sale</a></td>
<td class="nump">405.2<span></span>
</td>
<td class="nump">560.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">92.2<span></span>
</td>
<td class="nump">97.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">83.8<span></span>
</td>
<td class="nump">63.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">66.8<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,005.7<span></span>
</td>
<td class="nump">2,072.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">265.7<span></span>
</td>
<td class="nump">225.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">285.7<span></span>
</td>
<td class="nump">245.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">169.0<span></span>
</td>
<td class="nump">335.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">99.6<span></span>
</td>
<td class="nump">105.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">28.0<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">582.3<span></span>
</td>
<td class="nump">698.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 220.0 million shares authorized; issued and outstanding shares 95.6 million at June&#160;30, 2022 and 94.9 million at December&#160;31, 2021</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,999.8<span></span>
</td>
<td class="nump">2,011.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(12.2)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(564.3)<span></span>
</td>
<td class="num">(635.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,423.4<span></span>
</td>
<td class="nump">1,374.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,005.7<span></span>
</td>
<td class="nump">$ 2,072.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979354090032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">220.0<span></span>
</td>
<td class="nump">220.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">95.6<span></span>
</td>
<td class="nump">94.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">95.6<span></span>
</td>
<td class="nump">94.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979351622528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 378.2<span></span>
</td>
<td class="nump">$ 288.9<span></span>
</td>
<td class="nump">$ 688.8<span></span>
</td>
<td class="nump">$ 525.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">135.9<span></span>
</td>
<td class="nump">74.8<span></span>
</td>
<td class="nump">238.1<span></span>
</td>
<td class="nump">148.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">182.8<span></span>
</td>
<td class="nump">143.2<span></span>
</td>
<td class="nump">383.5<span></span>
</td>
<td class="nump">272.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">323.5<span></span>
</td>
<td class="nump">226.1<span></span>
</td>
<td class="nump">631.0<span></span>
</td>
<td class="nump">431.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">54.7<span></span>
</td>
<td class="nump">62.8<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">94.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="num">(4.8)<span></span>
</td>
<td class="num">(12.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized (loss) gain on equity securities</a></td>
<td class="num">(7.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="num">(70.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(70.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_InvestmentIncomeAndOtherNet', window );">Investment income and other, net</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(78.0)<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
<td class="num">(59.7)<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before (benefit from) provision for income taxes</a></td>
<td class="num">(23.3)<span></span>
</td>
<td class="nump">57.5<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="nump">84.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit from) provision for income taxes</a></td>
<td class="num">(6.4)<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(16.9)<span></span>
</td>
<td class="nump">42.3<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="nump">74.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on debt securities available-for-sale, net of tax</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (19.8)<span></span>
</td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="num">$ (13.5)<span></span>
</td>
<td class="nump">$ 73.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>(Loss) earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">95.6<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
<td class="nump">94.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">95.6<span></span>
</td>
<td class="nump">97.7<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
<td class="nump">98.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 352.0<span></span>
</td>
<td class="nump">$ 266.8<span></span>
</td>
<td class="nump">$ 657.0<span></span>
</td>
<td class="nump">$ 497.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="nump">$ 22.1<span></span>
</td>
<td class="nump">$ 31.8<span></span>
</td>
<td class="nump">$ 27.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_InvestmentIncomeAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment income and other net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_InvestmentIncomeAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979348827648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,126.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1,849.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="num">$ (725.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">74.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on debt securities available-for-sale, net of tax</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">61.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">18.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2021</a></td>
<td class="nump">1,279.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,929.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(651.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2021</a></td>
<td class="nump">1,205.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,897.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="num">(693.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">42.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on debt securities available-for-sale, net of tax</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">28.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2021</a></td>
<td class="nump">1,279.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,929.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(651.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">1,374.0<span></span>
</td>
<td class="num">$ (32.3)<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">2,011.4<span></span>
</td>
<td class="num">$ (106.8)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(635.8)<span></span>
</td>
<td class="nump">$ 74.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on debt securities available-for-sale, net of tax</a></td>
<td class="num">(10.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">86.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2022</a></td>
<td class="nump">1,423.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,999.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="num">(564.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2022</a></td>
<td class="nump">1,391.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,947.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.3)<span></span>
</td>
<td class="num">(547.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(16.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on debt securities available-for-sale, net of tax</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under stock plans</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 1,423.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1,999.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12.2)<span></span>
</td>
<td class="num">$ (564.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979348746032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (3.0)<span></span>
</td>
<td class="nump">$ 74.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">86.5<span></span>
</td>
<td class="nump">61.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Change in fair value of equity security investments</a></td>
<td class="num">(12.5)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(93.5)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">44.2<span></span>
</td>
<td class="nump">29.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="nump">97.6<span></span>
</td>
<td class="nump">190.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of debt securities available-for-sale</a></td>
<td class="num">(253.7)<span></span>
</td>
<td class="num">(383.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of debt securities available-for-sale</a></td>
<td class="nump">277.6<span></span>
</td>
<td class="nump">364.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Purchases of equity securities</a></td>
<td class="num">(7.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(16.4)<span></span>
</td>
<td class="num">(8.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash flows from investing activities</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(27.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuances of common stock under benefit plans</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">18.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repurchase of convertible senior notes</a></td>
<td class="num">(279.0)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash flows from financing activities</a></td>
<td class="num">(270.3)<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(172.9)<span></span>
</td>
<td class="nump">180.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">344.0<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">171.1<span></span>
</td>
<td class="nump">371.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Non-cash capital expenditures</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets acquired through operating leases</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979353665072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">Organization and Significant Accounting Policies<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K, or the 2021 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2021, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjI0MA_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjgwMA_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span> removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzA0Mg_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span> prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzM2NQ_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span> on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million and reduced the accumulated deficit by $74.5 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979434924368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">Collaboration and License Agreements<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Heptares Therapeutics Limited, or Heptares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We entered into a collaboration and license agreement with Heptares, which became effective in December 2021, to develop and commercialize certain compounds containing sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists, which compounds we have the exclusive rights to develop, manufacture and commercialize worldwide, excluding in Japan, where Heptares retains the rights to develop, manufacture, and commercialize all compounds comprised of M1 receptor agonists, subject to certain exceptions. With respect to such rights retained by Heptares, we retain the rights to opt in to profit sharing arrangements, pursuant to which we and Heptares will equally share in the operating profits and losses for such compounds in Japan. Subject to specified conditions, we may elect to exercise such opt-in rights with respect to each such compound either before initiation of the first proof of concept Phase II clinical trial for such compound or following our receipt from Heptares of the top-line data from such clinical trial for such compound. We are responsible for all development, manufacturing and commercialization costs of any collaboration product. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Heptares $100.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;D in 2021. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, the FDA accepted our submission of an investigational new drug application, or IND, for NBI-1117568 for the treatment of schizophrenia, for which we anticipate initiating a Phase II study during the second half of 2022. Based upon this progress, a milestone of $30.0 million was expensed as R&amp;D in the second quarter of 2022, which we expect to pay to Heptares in the third quarter of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Heptares may be entitled to receive potential future payments of up to $2.6 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which the royalty term for such licensed product has expired in such country. On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a licensed product and terminate on the later of (i) the expiration of the last patent covering such licensed product in such country, (ii) a number of years from the first commercial sale of such licensed product in such country and (iii) the expiration of regulatory exclusivity for such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or with respect to one or more targets upon 180 days&#8217; written notice to Heptares during the research collaboration term and upon 90 days&#8217; written notice to Heptares following the expiration of the research collaboration term. Following the expiration of the research collaboration term, Heptares may terminate the agreement on a target-by-target basis in the event that we do not conduct any material development activities outside of Japan with respect to a certain compound or licensed product within the applicable target class for a continuous period of not less than 365 days and do not commence any such activities within 120 days of receiving written notice. Either party may terminate the agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited, or Takeda.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into an exclusive license agreement with Takeda, pursuant to which we acquired the exclusive rights to develop and commercialize certain early to mid-stage psychiatry compounds, including luvadaxistat, NBI-1065845, NBI-1065846 and four non-clinical stage compounds. Luvadaxistat and the 4 non-clinical stage compounds have each been designated as a royalty-bearing product. NBI-1065845 and NBI-1065846 are currently each designated as a profit-share product. We are responsible for all manufacturing, development and commercialization costs of any royalty-bearing product. With respect to NBI-1065845 and NBI-1065846, we and Takeda will equally share in the operating profits and losses. Takeda retains the rights to opt-out of the profit-sharing arrangements, pursuant to which Takeda would be entitled to receive potential future payments upon the achievement of certain event-based milestones with respect to such compounds and receive royalties on the future net sales of such compounds (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out right for such compound immediately following the completion of a second Phase II clinical trial for such compound, or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase III clinical trial for such compound.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Takeda $120.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $1.9 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any royalty-bearing product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any royalty-bearing product, the royalty term has expired in such country; and (ii) for any profit-share product, for so long as we continue to develop, manufacture, or commercialize such licensed product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a royalty-bearing product and terminate on the later of (i) the expiration of the last patent covering such royalty-bearing product in such country, (ii) a number of years from the first commercial sale of such royalty-bearing product in such country and (iii) the expiration of regulatory exclusivity for such royalty-bearing product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement in its entirety or in one or more (but not all) of the United States, Japan, the European Union and the United Kingdom, or, collectively, the major markets, upon six months&#8217; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. We may terminate the agreement in its entirety or in one or more (but not all) of the major markets upon 12 months&#8217; written notice to </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. Takeda may terminate the agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Pharmaceuticals Ltd., or Idorsia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, we entered into a collaboration and license agreement with Idorsia, pursuant to which we acquired the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker in clinical development for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. We are responsible for all manufacturing, development and commercialization costs of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Idorsia $45.0 million upfront, which was expensed as IPR&amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement, in its entirety or with respect to a particular compound or development candidate, upon 90 days&#8217; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon Pharmaceuticals Inc., or Xenon. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Xenon to identify, research and develop sodium channel inhibitors, including NBI-921352 and three preclinical candidates, which compounds we have the exclusive rights to develop and commercialize. We are responsible for all development and manufacturing costs of any collaboration product, subject to certain exceptions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Xenon $50.0 million upfront, including a purchase of approximately 1.4 million shares of Xenon common stock (at $14.196 per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $14.1 million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $36.2 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2019.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the European Union&#8217;s approval of our clinical trial application for NBI-921352 for the treatment of focal onset seizures in adults in September 2021, we paid Xenon a regulatory milestone of $10.0 million, including a purchase of approximately 0.3 million shares of Xenon common stock (at $19.9755 per share). The purchased shares were recorded at a fair value of $4.6 million after considering Xenon&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $5.4 million of the milestone payment was expensed as R&amp;D in 2021.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA's acceptance of our amended KAYAK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study protocol in January 2022, we paid Xenon a regulatory milestone of $15.0 million, including a purchase of approximately 0.3 million shares of Xenon common stock (at $31.855 per share). The purchased shares were recorded at a fair value of $7.7 million after considering Xenon&#8217;s stock price on the measurement date. The remaining $7.3 million of the milestone payment was expensed as R&amp;D in the first quarter of 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product. Xenon retains the right to elect to co-develop one product in a major indication, pursuant to which Xenon would receive a mid-single digit percentage increase in royalties earned on the future net sales of such product in the United States and we and Xenon would equally share in the development costs of such product in the applicable indication, except where such development costs relate solely to the regulatory approval of such product outside the United States.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular licensed product and country, the license obtained by us with respect to such product and country will become fully paid, royalty free, perpetual and irrevocable. We may terminate the agreement upon 90 days&#8217; written notice to Xenon, </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager Therapeutics, Inc., or Voyager.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a collaboration and license agreement with Voyager, pursuant to which we acquired certain rights to develop and commercialize the NBIb-1817 for Parkinson&#8217;s disease program, Friedreich&#8217;s ataxia program and two undisclosed programs. We are responsible for all development costs of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager. In February 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#8217;s disease program, which became effective August 2, 2021. The termination did not apply to any program other than the NBIb-1817 for Parkinson&#8217;s disease program.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Voyager $165.0 million upfront, including a purchase of approximately 4.2 million shares of Voyager common stock (at $11.9625 per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $54.7 million after considering Voyager&#8217;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $113.1 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;D in 2019. In addition, we paid Voyager $5.0 million upfront, which was expensed as IPR&amp;D in 2019, to acquire the rights outside the United States to the Friedreich&#8217;s ataxia program.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Voyager may be entitled to receive potential future payments of up to $1.3 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement. We may terminate the agreement upon 180 days&#8217; written notice to Voyager prior to the first commercial sale of any collaboration product or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A., or BIAL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We acquired the United States and Canada rights to ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(opicapone) from BIAL in 2017, and launched ONGENTYS in the United States in September 2020 as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations. We are responsible for all commercialization costs of ONGENTYS in the United States and Canada and rely on BIAL for the commercial supply of ONGENTYS.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, BIAL may be entitled to receive potential future payments of up to $75.0 million upon the achievement of certain event-based milestones. In addition, with respect to ONGENTYS, in the event we fail to meet certain minimum sales requirements for a particular year in comparison to our annual sales forecast for such year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year. Further, upon our written request to BIAL 12 months prior to the estimated expiration of the term of a licensed product, we will negotiate the continuation of BIAL&#8217;s supply of such licensed product after the term. After the term, and if BIAL is no longer supplying such licensed product, BIAL would be entitled to receive a low double-digit royalty on our future quarterly net sales of such licensed product.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until a generic product with respect to such licensed product is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the agreement upon nine months&#8217; written notice to BIAL. BIAL may terminate the agreement in the event we fail to meet the minimum sales requirements for any two years, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party&#8217;s insolvency.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation, or MTPC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We out-licensed the rights to valbenazine in Japan and other select Asian markets to MTPC in 2015. In December 2020, we entered into a commercial supply agreement with MTPC, pursuant to which we agreed to supply MTPC with valbenazine drug product for commercial use in Japan and other select Asian markets. MTPC is responsible for all development, manufacturing and commercialization costs of valbenazine in such markets.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, MTPC launched DYSVAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in Japan for the treatment of tardive dyskinesia. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $20.0 million in the second quarter of 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC&#8217;s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in the second quarter of 2022. In addition, we will receive royalties at tiered percentage rates on MTPC net sales of DYSVAL. DYSVAL royalty revenue was not significant for the three and six months ended June&#160;30, 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with MTPC, we may be entitled to receive potential future payments of up to $30.0 million upon the achievement of certain sales-based milestones and are entitled to receive royalties at tiered percentage rates on future MTPC net sales of valbenazine for the longer of 10 years or the life of the related patent rights. MTPC may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Inc., or AbbVie.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, AbbVie launched ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix tablets) in the United States for the treatment of moderate to severe pain associated with endometriosis. In June 2020, AbbVie launched ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States for the treatment of heavy menstrual bleeding related to uterine fibroids in premenopausal women. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $5.2&#160;million and $9.4&#160;million, respectively, for the three and six months ended June&#160;30, 2022 and $5.9 million and $10.4 million, respectively, for the three and six months ended June&#160;30, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our license agreement with AbbVie, we may be entitled to receive potential future payments of up to $366.0 million upon the achievement of certain event-based milestones and are entitled to receive royalties at tiered percentage rates on future AbbVie net sales of elagolix for the longer of 10 years or the life of the related patent rights. AbbVie may terminate the agreement upon 180 days&#8217; written notice to us. In such event, all out-licensed product rights would revert to us.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979357478960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Debt Securities</a></td>
<td class="text">Debt Securities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">491.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our security portfolio consisted of 166 debt securities available-for-sale, including 164 such securities that were in an unrealized loss position but of high credit quality. Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recognized as of June&#160;30, 2022 or December&#160;31, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of June&#160;30, 2022, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale totaled $2.7 million and $2.2 million, respectively, as of June&#160;30, 2022 and December&#160;31, 2021. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during the six months ended June&#160;30, 2022 or 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979434644864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of investments, which were measured at fair value on a recurring basis.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,145.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">890.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,338.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">396.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain included in earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Unrealized gains and losses on restricted equity security investments were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) In the first quarter of 2022, our equity security investment in Voyager was transferred from Level 3 to Level 1 as the associated holding period restriction expired.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979357200192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979434912896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_RestrictedCashTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted Cash<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_RestrictedCashTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_RestrictedCashTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979357200192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases that have commenced have terms that expire beginning 2024 through 2031 and consist of office space and research and development laboratories, including our corporate headquarters. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our operating lease right-of-use, or ROU, assets or operating lease liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, pursuant to which we also secured a six-year option for the construction of a fifth building and an option to purchase the entire campus facility, which will consist of office space and research and development laboratories, in the future. Upon completion of construction, we expect to utilize the campus facility as our new corporate headquarters. This lease has not commenced for accounting purposes. Under the terms of the lease, on a building-by-building basis, base rent will be subject to a 10-month rent abatement period following the respective lease commencement date, which dates will be determined in the future based upon achievement of substantial completion of construction with respect to each such building in the condition suitable for the installation of our furniture, fixtures, and equipment, and on which date we will record a lease liability, corresponding right-of-use asset, and begin lease expense recognition with respect to each such building. After the rent abatement period, monthly base rent will be $6 per square foot, subject to annual escalations of 3% during the initial <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMTA5OTUxMTYzMDM2OQ_4e49d25c-03ed-44eb-9e93-c4a67b6332d1">13.6-year</span> lease term, which term we have the option to renew for two additional terms of five years each.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our operating leases, in lieu of a cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $7.8 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental operating lease information for operating leases that have commenced.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate non-cancelable future minimum lease payments under operating leases as of June&#160;30, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 (6 months remaining)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less current operating lease liabilities included in other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts presented in the table above exclude $17.2 million for 2024, $33.3 million for 2025, $41.9 million for 2026, and $479.7 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979354134432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text">Convertible Senior Notes<div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance in effect at the time of issuance, we were required to separately account for the liability and equity components of the 2024 Notes. The initial carrying value of the liability component of $368.3 million was calculated using a 7.50% assumed borrowing rate, which reflected the market interest rate for a similar non-convertible instrument at the date of issuance. The equity component of $149.2 million, which was treated as a discount on the liability component and amortized over the seven-year term of the 2024 Notes using the effective interest rate method, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and recorded as an increase to additional paid-in capital on the issuance date. In addition, we allocated transaction costs of $14.7 million related to the issuance of the 2024 Notes to the liability and equity components based on their relative values on the issuance date. Transaction costs attributable to the liability component were being amortized over the seven-year term of the 2024 Notes using the effective interest rate method, while transaction costs attributable to the equity component were recorded as a reduction to additional paid-in capital on the issuance date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $130.7 million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of 3.37%, which was the market rate for similar notes that have no conversion rights. The difference of $56.3 million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component and recorded as a reduction to additional paid-in capital. The carrying amount of the liability of $112.4 million at settlement was recognized as a reduction to the 2024 Notes and resulted in an $18.4 million loss on extinguishment, which we recognized in the fourth quarter of 2020.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjY2OA_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span> using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million, and reduced the accumulated deficit by $74.5 million.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment, which resulted in the recognition of a $70.0 million loss on extinguishment in the second quarter of 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of June&#160;30, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) While the 2024 Notes were classified as a long-term liability as of June&#160;30, 2022, the future convertibility and associated balance sheet classification will be monitored at each quarterly reporting date and determined based on the market prices of our common stock during the prescribed measurement period. In the event that we have the election to redeem the 2024 Notes or the holders of the 2024 Notes have the election to convert the 2024 Notes at any time during the prescribed measurement period, the 2024 Notes would be classified as a current obligation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the interest expense of the 2024 Notes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2024 Notes in cash upon conversion and to settle any conversion premium, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $1,000 principal amount and equivalent to an initial conversion price of approximately $75.92 per share, reflecting a conversion premium of approximately 42.5% above the closing price of $53.28 per share of our common stock on April&#160;26, 2017.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130% of the conversion price then in effect (equal to $98.70 as of June&#160;30, 2022) for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price (equal to $98.70 as of June&#160;30, 2022) on each applicable trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">during the&#160;five business-day period immediately after any&#160;five&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2017 Indenture) per&#160;$1,000&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="margin-bottom:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change (as defined in the 2017 Indenture) occurs prior to January&#160;15, 2024, we would, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2017 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979434644864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">(Loss) Earnings per Share</a></td>
<td class="text">(Loss) Earnings per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Loss) earnings per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) earnings per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979352405840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K, or the 2021 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2021, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjI0MA_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjgwMA_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span> removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzA0Mg_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span> prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#8217; equity to liabilities as it relates to the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzM2NQ_27a74808-cedc-4067-91c0-ce68f133d49f">ASU 2020-06</span> on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million and reduced the accumulated deficit by $74.5 million.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy consists of the following three levels:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979357189376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.644%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized <br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0 to 1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">491.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 to 3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of June&#160;30, 2022, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979357178960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Investments Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of investments, which were measured at fair value on a recurring basis.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,145.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">890.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,338.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">396.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain included in earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Unrealized gains and losses on restricted equity security investments were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) In the first quarter of 2022, our equity security investment in Voyager was transferred from Level 3 to Level 1 as the associated holding period restriction expired.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979357205712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979357262096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of reconciliation of cash cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979357283840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Description of Operating Lease</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents supplemental operating lease information for operating leases that have commenced.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except weighted average data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents approximate non-cancelable future minimum lease payments under operating leases as of June&#160;30, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 (6 months remaining)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less current operating lease liabilities included in other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts presented in the table above exclude $17.2 million for 2024, $33.3 million for 2025, $41.9 million for 2026, and $479.7 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979354167104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Notes Net of Discount and Deferred Financing Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of June&#160;30, 2022.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) While the 2024 Notes were classified as a long-term liability as of June&#160;30, 2022, the future convertibility and associated balance sheet classification will be monitored at each quarterly reporting date and determined based on the market prices of our common stock during the prescribed measurement period. In the event that we have the election to redeem the 2024 Notes or the holders of the 2024 Notes have the election to convert the 2024 Notes at any time during the prescribed measurement period, the 2024 Notes would be classified as a current obligation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unamortized Debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leveling</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Level 2</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the interest expense of the 2024 Notes.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979357234608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Loss) earnings per share was calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) earnings per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979352053424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 02, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">$ 335.1<span></span>
</td>
<td class="nump">$ 169.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(635.8)<span></span>
</td>
<td class="num">(564.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">42.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">106.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">74.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">$ 335.1<span></span>
</td>
<td class="nump">$ 169.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979347804320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">378.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688.8<span></span>
</td>
<td class="nump">525.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Heptares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">2,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Idorsia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Xenon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.9755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity securities, stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Xenon | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_SaleOfStockNumberOfSharesSoldInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Voyager</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 113.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.9625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Voyager | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_SaleOfStockNumberOfSharesSoldInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | BIAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | MTPC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | MTPC | Minimum | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PatentTerm', window );">Patent term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="nump">366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | AbbVie | Minimum | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PatentTerm', window );">Patent term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Royalty | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PatentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PatentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePaymentReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payment receipts under a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePaymentReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payments under a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_SaleOfStockNumberOfSharesSoldInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares sold by the collaboration partner per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_SaleOfStockNumberOfSharesSoldInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_UpfrontPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments made under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_UpfrontPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_HeptaresTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_HeptaresTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_IdorsiaPharmaceuticalsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_IdorsiaPharmaceuticalsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_XenonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_VoyagerTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_BIALPortelaCaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_BIALPortelaCaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbix_AbbVieIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbix_AbbVieIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979351506272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 491.3<span></span>
</td>
<td class="nump">$ 370.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(6.3)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">485.0<span></span>
</td>
<td class="nump">370.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">213.3<span></span>
</td>
<td class="nump">128.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">210.6<span></span>
</td>
<td class="nump">128.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">199.8<span></span>
</td>
<td class="nump">37.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(3.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">196.6<span></span>
</td>
<td class="nump">37.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">78.2<span></span>
</td>
<td class="nump">204.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">77.8<span></span>
</td>
<td class="nump">204.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">415.5<span></span>
</td>
<td class="nump">563.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(10.3)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">405.2<span></span>
</td>
<td class="nump">560.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember', window );">Long-term investments | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">266.8<span></span>
</td>
<td class="nump">358.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">261.2<span></span>
</td>
<td class="nump">357.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember', window );">Long-term investments | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">148.7<span></span>
</td>
<td class="nump">204.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(4.7)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 144.0<span></span>
</td>
<td class="nump">$ 203.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979352217216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions', window );">Number of debt securities available for sale | security</a></td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of debt securities available for sale in unrealized loss position | security</a></td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivables | $</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff', window );">Accrued interest receivables write-off | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale position number of positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267862-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979352185296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">$ 61.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Loss</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">61.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Unrealized Loss</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">403.8<span></span>
</td>
<td class="nump">$ 428.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Loss</a></td>
<td class="num">(7.5)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">60.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Loss</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">464.6<span></span>
</td>
<td class="nump">428.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Unrealized Loss</a></td>
<td class="num">(8.3)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">329.1<span></span>
</td>
<td class="nump">230.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Loss</a></td>
<td class="num">(7.4)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Loss</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">340.6<span></span>
</td>
<td class="nump">230.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Unrealized Loss</a></td>
<td class="num">$ (7.9)<span></span>
</td>
<td class="num">$ (1.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979348566896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">$ 1,145.1<span></span>
</td>
<td class="nump">$ 1,338.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">254.9<span></span>
</td>
<td class="nump">396.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">890.2<span></span>
</td>
<td class="nump">931.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">471.8<span></span>
</td>
<td class="nump">485.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">471.8<span></span>
</td>
<td class="nump">485.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">340.6<span></span>
</td>
<td class="nump">240.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">340.6<span></span>
</td>
<td class="nump">240.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">83.8<span></span>
</td>
<td class="nump">63.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">83.8<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">163.3<span></span>
</td>
<td class="nump">340.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">163.3<span></span>
</td>
<td class="nump">340.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">77.8<span></span>
</td>
<td class="nump">204.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">77.8<span></span>
</td>
<td class="nump">204.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979354160704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail) - Level 3 - Fair Value, Recurring - Equity securities&#8211;biotechnology industry - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at beginning of period</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 38.9<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="nump">$ 38.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Unrealized gain included in earnings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">20.8<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers out of Level 3</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at end of period</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 38.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 38.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979352040784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Summary of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">17.9<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 29.3<span></span>
</td>
<td class="nump">$ 30.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979347621824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 163.3<span></span>
</td>
<td class="nump">$ 340.8<span></span>
</td>
<td class="nump">$ 368.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash included in other assets</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 171.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979352315520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative Information (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 08, 2022 </div>
<div>USD ($) </div>
<div>renewalOption</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding', window );">New campus lease lessee option term for construction of fifth building</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_RentAbatementPeriod', window );">New campus rent abatement period</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot', window );">New campus lease monthly base rent per square foot</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_AnnualRentEscalationPercentage', window );">New campus lease annual rent escalation percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">New campus lease term</a></td>
<td class="text">13 years 7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NumberOfRenewalOptions', window );">New campus lease number of renewal options | renewalOption</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">New campus lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash in connection with operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_AnnualRentEscalationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Rent Escalation Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_AnnualRentEscalationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Monthly Base Rent Per Square Foot</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of term of lessee's option for the construction of a fifth building under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of renewal options under the terms of the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_RentAbatementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent Abatement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_RentAbatementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979348550000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 8.2<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 8.2<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979353845584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Liability, Payment, Due (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (6 months remaining)</a></td>
<td class="nump">$ 8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">17.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">15.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">70.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">146.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less accreted interest</a></td>
<td class="nump">29.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">116.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current operating lease liabilities included in other current liabilities</a></td>
<td class="nump">17.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">99.6<span></span>
</td>
<td class="nump">$ 105.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2024</a></td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2025</a></td>
<td class="nump">33.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for 2026</a></td>
<td class="nump">41.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive', window );">Non-cancelable future minimum lease payments under operating leases not yet commenced for thereafter</a></td>
<td class="nump">$ 479.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979348928784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 02, 2017 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">$ 335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(635,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(564,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(564,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">42,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid in Capital</a></td>
<td class="nump">106,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">74,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">381,200,000<span></span>
</td>
<td class="nump">$ 517,500,000<span></span>
</td>
<td class="nump">170,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_CarryingAmountOfLiabilityComponentUponIssuance', window );">Carrying amount of the liability component upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Convertible senior note assumed borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Convertible senior note carrying value of the equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Convertible senior notes term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Transaction cost related to issuance of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,200,000<span></span>
</td>
<td class="nump">210,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Aggregate repurchase price paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment', window );">Fair value of the liability component immediately before extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Equity component of repurchased convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_CarryingAmountOfLiabilityComponentAtSettlement', window );">Carrying amount of the liability component at settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">$ 335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible senior notes convertible in to shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0131711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible senior notes conversion price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtInstrumentConvertibleConversionPremium', window );">Convertible senior notes premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market price of common stock (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Convertible senior notes redemption rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024 | Conversion Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive common stock trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of common stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger', window );">Common stock price trigger (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold common stock trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024 | Conversion Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PrincipalAmountOnConversionRate', window );">Principal amount on conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold common stock trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice', window );">Minimum percentage of common stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024 | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_CarryingAmountOfLiabilityComponentAtSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the liability component at settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_CarryingAmountOfLiabilityComponentAtSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_CarryingAmountOfLiabilityComponentUponIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the liability component upon issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_CarryingAmountOfLiabilityComponentUponIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConvertibleConversionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConvertibleConversionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the liability component immediately before extinguishment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PrincipalAmountOnConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal amount on conversion rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PrincipalAmountOnConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConversionAxis=nbix_ConversionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979347651232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes - 2024 Notes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 02, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Net Carrying Amount</a></td>
<td class="nump">$ 169,000,000.0<span></span>
</td>
<td class="nump">$ 335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember', window );">2.25% Convertible senior notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">170,400,000<span></span>
</td>
<td class="nump">381,200,000<span></span>
</td>
<td class="nump">$ 517,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Unamortized Debt, Discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(43,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized Debt, Issuance Costs</a></td>
<td class="num">(1,400,000)<span></span>
</td>
<td class="num">(2,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Net Carrying Amount</a></td>
<td class="nump">169,000,000.0<span></span>
</td>
<td class="nump">335,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value, Amount</a></td>
<td class="nump">$ 224,800,000<span></span>
</td>
<td class="nump">$ 464,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979352175120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Interest Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtInstrumentCouponInterest', window );">Coupon interest</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 12.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentCouponInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Coupon Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentCouponInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139979347613872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings per Share - Schedule of Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income - basic</a></td>
<td class="num">$ (16.9)<span></span>
</td>
<td class="nump">$ 42.3<span></span>
</td>
<td class="num">$ (3.0)<span></span>
</td>
<td class="nump">$ 74.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net (loss) income - diluted</a></td>
<td class="num">$ (16.9)<span></span>
</td>
<td class="nump">$ 42.3<span></span>
</td>
<td class="num">$ (3.0)<span></span>
</td>
<td class="nump">$ 74.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">95.6<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
<td class="nump">94.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">95.6<span></span>
</td>
<td class="nump">97.7<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
<td class="nump">98.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">(Loss) earnings per share, basic (in USD per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">(Loss) earnings per share, diluted (in USD per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from diluted per share amounts because their effect would have been anti-dilutive (in shares)</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities', window );">2024 Notes (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>nbix-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nbix="http://www.neurocrine.com/20220630"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20220630.xsd" xlink:type="simple"/>
    <context id="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3b6bbcbb257d4f17876a212fbc193ac7_I20220728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="i19857cd19784459d879fae5b6542a369_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic0112165dc8043d29e138802b05038e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i556d51bdaf9b486095b8ed36cedbe915_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8626a338deed4dddbd32b530cea19a5c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i07d1811ee7e34faab1b65618d330ae8a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5f2cb608667e43f19507d5f97f5092e1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i46565cbc932a4ecc83bc6363809460fd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iec8947a06f7f4b8f9ad89f1a53e3024e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib3571830b1824c328e93c8aee0d0c12e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id9616929076a46a2b8a10b5cadb88003_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifea1c6e2bc7341889b0e9bdb1f1db6a9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8dcb1e428512458eaf6a0bc1b8414ebc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7db70dedd62742a6831d1f0c2ec694aa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id4a6b675fbfc45268b58ff5bf6fb855e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i824b16455d3342c7bf87a435697bab24_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie7e2792b074c4cb5b0a136e01c9e0804_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8338e74ebc694742b502151eabd9e41e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3d13a78bcd1f4c6882ee9fe8cbf5b711_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie6ae0c23a2454cc2abcf61a77e930c6c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iacf77ed46fbe4d5cb0a4c8117097d74d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0029346e11d24e2489268d48f5de1c60_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia7180cf1c41f49b6948e46307ec11e60_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib84184652a2e49aebdf6d92adfcbc04d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib1b0a1dff46e4f7a9e47f283288de125_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i70110cfad88d4060a5dbaa9f2cedc49f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if8b70242d24a48a6a99af94c82b13c0d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ied4ed2118815424ab62c252c7749f6de_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2f5736e265cf4768afa36a5cd7c9e9a3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia6292fa456fa4806a43afc6154943c3d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie39f82d525f6414195ec1a20af940a1d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7a894b024126486eab337fda4f4fb0f9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i607fe14f45874407b052191669ff7dcc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i644297e85df8490caa1319af010903f3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5e390addaf324fa492c8b98404f47c9b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i08908942de0f491f8951674a9b93614b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i49d6d0041b1b4429b9640e29170494e4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia726c285fe9348d98e1aa42d192576d6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i798f9a1494f44261a5cfc2579e2c5d6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbcf4054dfb74e3793b2c0599d057e19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2bb5b491d36940f6b9f1a57707a58f6f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9d9884a14e643e0b6e6704e1d74e903_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i787d806f66c443c8ac342b1496f0ee61_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i391c44c0626e492884c04b5900b62430_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if91a28c2ae1249938c18889676def742_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie030c4abde7f4cf784cc031f496e6485_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i465519c475194c1d9739d8c1fca3961d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i91b516301ebe44a6b87c40ee75c6677c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie20bd8d4ea894bff986d00fbffc83784_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2e14680288bd42149b5cdf6969e7f02b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8ef17498aa9d498c8992b5221561c777_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i46b42b5fd65e44418a23dcde417525dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72d820c9109a4f90b3f7b8e63c0993ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e67fafca0274dee95d180cc3fb1f41f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1739e70f0194d8fa9900c2c02abbe2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93d94c70d96d4cf8aa28362a0b2141c5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic92e784af6164e40ab1441eb9d508ae1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i570417ef7f454c59b464a0797bfa388a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9dd39c3aa14042ba9edda98ae8d9cb55_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifa023efd07b7418a8139d17baa936118_I20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="i8b377cc0ad4940e794a4a0f398f996ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b01af7da7264226a39cc415c4f4de88_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0378ba60bbf54c9c984afe9729769082_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i82ea1ca4da564dcb9abb0f23996feb31_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:HeptaresTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1d87729af3eb438a8f50b92d4f11b0ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38ba4b66e35b4a058bd00122f74f68a1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0b5f0284f514463fb5639c0b9dc36242_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29dde29babb8447aa6253d6d81080068_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icc12b8925fe24715a37c917e89b4a2d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i41dedb5b6dd648adafef4d12efc9d560_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3113317a93804d79b80f423ec6d08d4a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i423078e1d1174d878d489e6ef59f9d7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdca041dd4cd4227abc30499d4f8bebf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i62a271eec056493ab613a72c7a5b002b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if71d1cf4c4b84dcd8a6b38e623f46644_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i53b573b749c34f2dbfe2a3f74272c97c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i35309e0240cb45d68c83e6a9539b437e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i05ec7aad29694aba88b3325431ac3cca_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2cea7f1f684e4ceda425fdd38139bd65_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i31d5d364edff4ad4b48da1b643c16353_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i98646b31fd7d4d0583d03a62061c0725_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i6bde3727bced42719f1bdb0078bc223e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iee097ca4107145a4a7cafe11c7f7c028_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i26b03ed42a86426fa271e7a51e9a3975_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:BIALPortelaCaSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id08aaa35e1ac4e31a43d685f09135c6e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idf5acfc15e784512b7a82dc8e2d2fe95_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic20aa02fac274005a61e03b4bc0375b0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id6c1cfc608dd4f8f81032e9e441a7511_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7cfb08820e8842e1871b6c2dd2a4c189_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i26703103080243799d2bb6d6f1b72bd4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i721def435135454b974f4d03651a3930_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib5c1bb3894ae4915b5e4726823772c30_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3cfc8c33916a4939a12f81454e0c35ca_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbix:AbbVieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia1724975ad3a44d5aafd1acb6e95ee7f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3e3fa10d15714457a50f9425cd51126e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia968122986d748ccba38b5b654f41190_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibc36e662e8904155b5ef697ff21e9aec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20cfedabe3c94d5bad4df94bc450895e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3d2144d7b33a4ad9aadec72dd35693ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd5d17a30ac7439c9cd69e44e7d10155_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic173cd64901047748e412993eb622ad8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8752290fc66f4c8db3353da827e19de9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaf0e1c77adff4ec88d625c49c6294e39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7d162d0857b48afb064eef3b8599c86_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9bcedbc2244f433299e4bcb31bd4bd37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7df34d9c3e404caa9a985cda59b147ed_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3b67814da34d4da988b4bf57d0e478e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id4cdb346b995405d841286aaa096490d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i074a75852b8a4e13bae6f329be3373f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ecf9c7bbfe243a89adac1ac817f3336_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie091570b8c7e468aaa662efd674b1a48_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i38c4567a749e4031aed667e267ff71cf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i67109db4be9c4ba1bdead9f009154aed_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia2bfb40cca13406fa0b41700ae0ee8fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56225d1fd9af4788a6c4c2c401b49441_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib836ccb73c334b1e92c3bb0032674ed2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56223020056d47c38dbea1cc503a767f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3bf20361175e48e8a2b61d38d6483435_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3d34c798b0c047d18064663be75d6f59_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i578731c40e2a43fd9bd0b849e2773a25_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2e334b57cf1645dca4bb9f652d8b8ebd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i53bbe7b73503454da09d5f5c6dc24da1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a7d2babfc2941b297b24e9e5e8a7958_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3edac7da69b94cd794ccfbce890c2b19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie155cdd1531a43a589fe6b7ea1553a8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73e9ff90e3d945f48f05c03731be0dea_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i00d60ef478c64a6aa6e2b15688f36c19_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie71d87a7ca30406082e35c819e1436ed_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8110a30289e34b7b9625883f2787fc8a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id542276cdcda416ab9e520eb0c59e6b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e52574305944b99802e51d55304a886_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93a9c71abed34ec1b434462a578f36c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc6fd4b26ceb4e1b95da9a0661d58688_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id80f2f492d604d77ae916ea5296d3824_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibfb55cdc59344e51950ad5eb6569c231_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iac5f50efda0b428ea5e117442266f762_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0a9a8a35647d496daedc583782304e30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9487e38c52d9410798197fe77cd60f57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74a9046e38e0432d9b62315b9af06dad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d9e4bf673604e399b7bafea5de77c4a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib0d0694197d34f049fae415dfd7cef26_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9e3ff765407f4755bfb5dc08e8b68c7f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i37fab9ec8504467e986c6cfccf616c70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i123fc2a261774a52826809562d82f303_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84f8c5fe309e43cf85287198b3684b1f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f432d4ebd4d4bcd821e1de57052b96d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i36adfd64e3fc494ba2d120614d619968_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ied205516acc24818a8843666669b4299_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id43fcc32d6374531b9d90dc9c1ddd0c6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i013f9e5d35d54ee8bb4f7e21d12111c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1f28d0e9745496a9b27303558bbcf74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifcbeb7bb580346078bdfa5dea238778a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92d2e80d30204b05a36b4e40d614504c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59e9b7c8721845489d2a7f16466d93aa_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i908c9a1b5d0e454fb77ebdb1a35749ba_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i25d1241a853a41268cccdaac0eae9a28_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i05b6c8a59df04fb3945d4e66bc2c822d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia631a5398e544dd4908958402f41dc86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e1d5afb5a0c4854bd3eaac9022c5921_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7e2006bc26e4660a1ce0449ce12fef8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i621ed28665cd4c74accdf1592a8116ee_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibb7802d7f08044b48c8621fbe04086f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife94fc300dd145afad28237e20171bac_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i05896d4787104c06a015bb730c5b5e50_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd7bdc03323d43ba8e38762cd7fca030_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9ed7ddd2a42348d1a2f7fec8628844f9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icfbdc30b238f4e70816874e44b5711ea_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7e101b09704b41349a0ec8f0acd6d9fc_D20220208-20220208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2022-02-08</startDate>
            <endDate>2022-02-08</endDate>
        </period>
    </context>
    <context id="i6c2a25388e8a402297637fc25af2ac23_I20220208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2022-02-08</instant>
        </period>
    </context>
    <context id="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="id787ce82b3d34435b9e6f64183561da4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i24b6741f0df8412ca89fcbb38c28ed03_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a5baeaf4e9c48f8b60039ae0a01b8e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia90120fdd18140988db29b2003f29587_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id2e9c013eb7a4a48a31e064dfc261340_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i168ae0643eac4fb187856eb9bb504202_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="ibdc8838b1a0d4a7b843404626b18a02c_I20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="id38ba1f5324844d0866a8eac585463a2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if6357f4608a44780bb374e2677bba023_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbix:DebtInstrumentConversionAxis">nbix:ConversionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="i014deb2a111f43c7a8fdebb84cf4af4a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibe515815525d40479e6d960e227a7c66_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idcac76a70c464f9fa879fb1284e91eda_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ife67923fc29b44728cff990336550617_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i19b7065611c64ade9f1f759584b9c5f9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icef2199eebcc4873a2e393ef3bf1e3d0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2b11647fa1d44f21b454d711e8e45279_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i97101bf55ded451fb77e7a8e8dabab08_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8fb5e17e77a8471e993d6b327c5c67b4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i13a71ac92a8441239671f089b427fe9f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i142b169cb78e431b902b44d821c15b70_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i25c047985ee44b64a2fbeff282b6c067_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>nbix:security</measure>
    </unit>
    <unit id="renewaloption">
        <measure>nbix:renewalOption</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80L2ZyYWc6ZDg1N2EyZTBkYTg3NGE5ZGE1ZjJjMDRmYzA3ZDIxYmYvdGFibGU6MmUxNGUwOTY5NzU0NDFkZmE2ZmMwZTFiNWY1ZmJkYzcvdGFibGVyYW5nZToyZTE0ZTA5Njk3NTQ0MWRmYTZmYzBlMWI1ZjVmYmRjN18yLTEtMS0xLTc1MzQx_8e7502ed-58b5-4392-b757-7eac9cc6a181">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80L2ZyYWc6ZDg1N2EyZTBkYTg3NGE5ZGE1ZjJjMDRmYzA3ZDIxYmYvdGFibGU6MmUxNGUwOTY5NzU0NDFkZmE2ZmMwZTFiNWY1ZmJkYzcvdGFibGVyYW5nZToyZTE0ZTA5Njk3NTQ0MWRmYTZmYzBlMWI1ZjVmYmRjN18zLTEtMS0xLTc1MzQx_c4d3808f-e499-4471-aa32-8a3d0171c991">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80L2ZyYWc6ZDg1N2EyZTBkYTg3NGE5ZGE1ZjJjMDRmYzA3ZDIxYmYvdGFibGU6MmUxNGUwOTY5NzU0NDFkZmE2ZmMwZTFiNWY1ZmJkYzcvdGFibGVyYW5nZToyZTE0ZTA5Njk3NTQ0MWRmYTZmYzBlMWI1ZjVmYmRjN180LTEtMS0xLTc1MzQx_0683a52d-60b8-49c4-8995-eded2f2e4f0d">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80L2ZyYWc6ZDg1N2EyZTBkYTg3NGE5ZGE1ZjJjMDRmYzA3ZDIxYmYvdGFibGU6MmUxNGUwOTY5NzU0NDFkZmE2ZmMwZTFiNWY1ZmJkYzcvdGFibGVyYW5nZToyZTE0ZTA5Njk3NTQ0MWRmYTZmYzBlMWI1ZjVmYmRjN181LTEtMS0xLTc1MzQx_bc667bf7-2b70-494c-a472-f3c34ccfef79">0000914475</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80L2ZyYWc6ZDg1N2EyZTBkYTg3NGE5ZGE1ZjJjMDRmYzA3ZDIxYmYvdGFibGU6MmUxNGUwOTY5NzU0NDFkZmE2ZmMwZTFiNWY1ZmJkYzcvdGFibGVyYW5nZToyZTE0ZTA5Njk3NTQ0MWRmYTZmYzBlMWI1ZjVmYmRjN182LTEtMS0xLTc1MzQx_4d7777af-4478-4460-80ef-e98caafd782a">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="if91a28c2ae1249938c18889676def742_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjEtMC0xLTEtOTE5OTQ_1af9cee6-f810-4eaf-b311-f7383604b8af">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="if91a28c2ae1249938c18889676def742_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjI0MA_27a74808-cedc-4067-91c0-ce68f133d49f">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="if91a28c2ae1249938c18889676def742_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjgwMA_27a74808-cedc-4067-91c0-ce68f133d49f">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="if91a28c2ae1249938c18889676def742_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzA0Mg_27a74808-cedc-4067-91c0-ce68f133d49f">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="if91a28c2ae1249938c18889676def742_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzM2NQ_27a74808-cedc-4067-91c0-ce68f133d49f">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i6c2a25388e8a402297637fc25af2ac23_I20220208"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMTA5OTUxMTYzMDM2OQ_4e49d25c-03ed-44eb-9e93-c4a67b6332d1">P13Y7M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="if91a28c2ae1249938c18889676def742_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjY2OA_27a74808-cedc-4067-91c0-ce68f133d49f">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81NS9mcmFnOjE0YjE5MmQwNDJjNDRiYmFhZWUyYjU0MmU1Y2YyODAxL3RhYmxlOmExNjliMjU0YWFiNjRkMmFhMGNmMTE5MDczYzdjMGNiL3RhYmxlcmFuZ2U6YTE2OWIyNTRhYWI2NGQyYWEwY2YxMTkwNzNjN2MwY2JfMi0xLTEtMS03NTM0MQ_f64ee74c-7a3a-4141-a6b6-e3b0d5178ab8"
      unitRef="number">0.0131711</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDg0_76f24892-4daf-4886-bb7e-3307b04b8c5a">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDg1_6d3639bd-2536-4384-8ef0-6cf29c4336be">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yMjE_7550ed98-b31a-47d8-9f5a-f6cdfd30dabd">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDk5_7fc02ce0-4256-4cd9-985e-1f8be996809d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNTAw_2461ef57-6928-4271-925d-6cdea1421de5">0-22705</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDg5_fbbc18be-2728-44aa-887b-0142f5c4a7f5">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDk1_8323d1fd-3993-4bb2-bb16-5bb59c7fe3e8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDkw_2e46503a-17dd-4b29-9339-d9b5578bc4f5">12780 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDgw_382ce85f-1304-4d23-a42f-4d63fb81ab90">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDk2_3a7b1a8e-b10c-47f5-a2a4-38e6765deca2">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityTaxIdentificationNumber
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDgx_c4f15692-c440-485b-9b3f-1dae1b85011e">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDgy_ced37e4d-b690-4d12-9e3d-04c44e24cf22">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDk3_67d15662-0653-4a2d-b465-02bfbb7898e7">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDk0_a9168b81-1caa-4e9b-88cf-c90dfcafb829">617-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGFibGU6YzU3NmFhNzY4YjMwNGE3ZWI2NmVmMTdmYWM2NzlkZWYvdGFibGVyYW5nZTpjNTc2YWE3NjhiMzA0YTdlYjY2ZWYxN2ZhYzY3OWRlZl8xLTAtMS0xLTc1MzQx_1991798d-2f3d-4833-a53c-c73c5ac75f99">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGFibGU6YzU3NmFhNzY4YjMwNGE3ZWI2NmVmMTdmYWM2NzlkZWYvdGFibGVyYW5nZTpjNTc2YWE3NjhiMzA0YTdlYjY2ZWYxN2ZhYzY3OWRlZl8xLTItMS0xLTc1MzQx_ec435338-a227-4862-bf99-44db15366e7b">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGFibGU6YzU3NmFhNzY4YjMwNGE3ZWI2NmVmMTdmYWM2NzlkZWYvdGFibGVyYW5nZTpjNTc2YWE3NjhiMzA0YTdlYjY2ZWYxN2ZhYzY3OWRlZl8xLTQtMS0xLTc1MzQx_550a6e48-3e96-4fec-9e07-ab70c6bf9ad7">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDkx_283d1bad-c92c-4358-8db2-2c12876afa9b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDky_337cbbff-7341-4cb8-8cac-5907084143cd">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDg2_93e67756-55ca-4c95-b232-cdcb21419da2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDk4_80571c4f-70ad-4bbb-ac47-e3aec9b9b51e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDgz_5db77ca8-12e5-4ce3-b554-c70171498a9d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDg3_c877f51e-8b6d-4506-9297-e1426b838039">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i3b6bbcbb257d4f17876a212fbc193ac7_I20220728"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xL2ZyYWc6MWVmNzhiNDY3NjQ2NDc1MGE5ZjdmNTdjNzc3ZTJjMjQvdGV4dHJlZ2lvbjoxZWY3OGI0Njc2NDY0NzUwYTlmN2Y1N2M3NzdlMmMyNF8yNDY5_c8a8283a-5769-40f7-9c78-91b40b55191d"
      unitRef="shares">95639321</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMy0xLTEtMS03NTM0MQ_aa52d590-bab8-4f5b-89bd-483e6f9a5fe9"
      unitRef="usd">163300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMy0zLTEtMS03NTM0MQ_6a2df597-89ee-411c-b58d-bd19c8154cb7"
      unitRef="usd">340800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNC0xLTEtMS03NTM0MQ_d6ceef2d-7bbb-4c3f-bb51-307a7969671e"
      unitRef="usd">485000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNC0zLTEtMS03NTM0MQ_c1c7cd1c-74db-40c4-9341-4831e869e302"
      unitRef="usd">370500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNS0xLTEtMS03NTM0MQ_6f08b476-0061-45b1-a0e5-58b98197f0e8"
      unitRef="usd">279000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNS0zLTEtMS03NTM0MQ_00dd71d2-7ee9-4035-a5e8-0a4e82b6e00f"
      unitRef="usd">185500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNi0xLTEtMS03NTM0MQ_9f0a4415-7db9-4806-9e1c-ee914df6157e"
      unitRef="usd">29300000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNi0zLTEtMS03NTM0MQ_02820dcf-585a-4739-b187-d72f8bf5c0ba"
      unitRef="usd">30500000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNy0xLTEtMS03NTM0MQ_99566c4a-1c91-429d-a260-7dffe6d2f451"
      unitRef="usd">62700000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfNy0zLTEtMS03NTM0MQ_2471c16e-0f7e-4ac0-b9bd-3e79b431bbf9"
      unitRef="usd">45500000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfOC0xLTEtMS03NTM0MQ_8414e817-3128-48cb-ac42-207b412d52b0"
      unitRef="usd">1019300000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfOC0zLTEtMS03NTM0MQ_fc67671b-a42d-4fe6-aacd-e2c62ca8f56c"
      unitRef="usd">972800000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfOS0xLTEtMS03NTM0MQ_ce77c6f3-a17b-4dc2-a2f8-5397c29c45ec"
      unitRef="usd">328400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfOS0zLTEtMS03NTM0MQ_35ebd656-8cf2-4514-9493-1703e6472c0b"
      unitRef="usd">315100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTAtMS0xLTEtNzUzNDE_31027b22-00f2-4407-b200-80eea30b1d4b"
      unitRef="usd">405200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTAtMy0xLTEtNzUzNDE_a29b703b-20b0-4f51-90a2-5b514b737bad"
      unitRef="usd">560700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTEtMS0xLTEtNzUzNDE_4778b679-3b10-47e5-9a83-33390cf72628"
      unitRef="usd">92200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTEtMy0xLTEtNzUzNDE_e2a8e683-7102-41e7-b902-bc7ffa526cca"
      unitRef="usd">97200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTItMS0xLTEtNzUzNDE_40ba896f-adec-4a4e-baf6-033e51244675"
      unitRef="usd">83800000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTItMy0xLTEtNzUzNDE_7bff6b65-1d2b-4626-a462-e6611d3556fb"
      unitRef="usd">63700000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTMtMS0xLTEtNzUzNDE_67112eef-f63d-4154-823d-11bb14c7f860"
      unitRef="usd">66800000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTMtMy0xLTEtNzUzNDE_7783bb1e-827d-48eb-89cf-be503bc4b0ef"
      unitRef="usd">58600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTQtMS0xLTEtNzUzNDE_8a054dc6-c637-45f7-8db5-829c97151f43"
      unitRef="usd">10000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTQtMy0xLTEtNzUzNDE_0b8fee4d-f3b1-4d93-b7c6-b1f51e8010cb"
      unitRef="usd">4400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTUtMS0xLTEtNzUzNDE_b9b4a0bc-f85c-4d2f-931c-0bb0928bb717"
      unitRef="usd">2005700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTUtMy0xLTEtNzUzNDE_ae70dc25-ddde-4a5c-b269-955ecafb72d8"
      unitRef="usd">2072500000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTktMS0xLTEtNzUzNDE_a61c40d4-9d97-4c9b-b975-68d78d265258"
      unitRef="usd">265700000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMTktMy0xLTEtNzUzNDE_473d0ac2-fefa-433a-81a6-25ec5bae4f30"
      unitRef="usd">225800000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjEtMS0xLTEtNzUzNDE_03ce921c-7095-4b0e-82ab-357324bfa8bb"
      unitRef="usd">20000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjEtMy0xLTEtNzUzNDE_d0515cbd-b611-4221-8fad-b8a3cfbeab52"
      unitRef="usd">20000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjItMS0xLTEtNzUzNDE_de9cd336-e74f-4c0a-910c-56f62fc40824"
      unitRef="usd">285700000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjItMy0xLTEtNzUzNDE_6e275c41-e87e-4a38-8329-c09bb52e50ea"
      unitRef="usd">245800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjMtMS0xLTEtNzUzNDE_297d9798-df4d-45a6-be1d-3bce8ef2f0f8"
      unitRef="usd">169000000.0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjMtMy0xLTEtNzUzNDE_764a29ec-e901-436b-a1cf-4ee74d079ebf"
      unitRef="usd">335100000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjQtMS0xLTEtNzUzNDE_0674d889-b732-4806-aa2f-c77df4db6954"
      unitRef="usd">99600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjQtMy0xLTEtNzUzNDE_d3369e91-e1ee-4182-815d-4b0f6b5953e8"
      unitRef="usd">105300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjUtMS0xLTEtNzUzNDE_8afd6446-0c82-4fa4-a809-e566a2849942"
      unitRef="usd">28000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjUtMy0xLTEtNzUzNDE_d633f998-3ded-4be6-adb5-ed31637c24ba"
      unitRef="usd">12300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjYtMS0xLTEtNzUzNDE_7bf42929-26a4-4ca1-a7d3-e2e565e224d3"
      unitRef="usd">582300000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjYtMy0xLTEtNzUzNDE_6cbc7475-de20-48b7-9103-637b085ca664"
      unitRef="usd">698500000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV8yMQ_d40153aa-3069-4fd5-8810-816221d16229"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV8yMQ_dc40b07a-12d0-49ad-b679-08b48462e759"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV8zNQ_2bc08a6e-e754-4a3d-a20d-e027bfd4b87d"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV8zNQ_b5fab148-db25-4fe2-adfe-7319395e8131"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV81Nw_0a2d176d-e20f-4a11-b3bd-502483311a6d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV81Nw_22006747-71e1-4c31-b252-43295ae78a20"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV81Nw_2a9831a4-4ad6-4f0b-a76e-5bd52220c3bb"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjozNjA3MWUyNTA5ODc0YzgzYmYzMzVhZjZkOGI4MzYyMV81Nw_8cf27fb2-22a1-4efc-bf92-14709d441c4b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMS0xLTEtNzUzNDE_f17854e3-948d-49b2-9ced-7f08fe264f1e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMjktMy0xLTEtNzUzNDE_f6c3e0e3-b978-4a62-8303-1535ad74eca8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF8xOA_0bd4f136-be2c-4292-91ce-dcdadf1be607"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF8xOA_52d3a322-fc9b-4b9c-96bf-c45f29fadf54"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF8zMg_4455336a-ba41-4fc4-b6aa-46cd6497899b"
      unitRef="shares">220000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF8zMg_6fb726be-410f-4ce2-84f8-cdafd15ffc5f"
      unitRef="shares">220000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF84OQ_7950cb44-bda7-4e04-a03f-14cf7aac2596"
      unitRef="shares">95600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF84OQ_df9317f7-4303-467e-9494-51bcd2797271"
      unitRef="shares">95600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF8xMDI_e6977150-c809-48a4-8f7b-c683c670deda"
      unitRef="shares">94900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMC0xLTEtNzUzNDEvdGV4dHJlZ2lvbjo0ODZjOGU3MWUzNWY0MzE4ODMyMTFjNjBmN2VjYjJlMF8xMDI_f2f8b403-9e58-4cc0-9660-7f4b6f78f9af"
      unitRef="shares">94900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMS0xLTEtNzUzNDE_70bf3a04-fc55-4b72-9ac9-7f57fbaa8e1b"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzAtMy0xLTEtNzUzNDE_276af021-3577-4ddb-954c-7cd71f9a217c"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzEtMS0xLTEtNzUzNDE_20ef6b6a-6b0e-4c33-9887-50591aa1b403"
      unitRef="usd">1999800000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzEtMy0xLTEtNzUzNDE_308d61b2-6044-48bc-a83e-3a2e7fe06d2e"
      unitRef="usd">2011400000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzItMS0xLTEtNzUzNDE_570a877d-eb0e-42b0-8a21-338550ebdd52"
      unitRef="usd">-12200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzItMy0xLTEtNzUzNDE_6a7d1247-666f-4ad3-9705-507265c20c4f"
      unitRef="usd">-1700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzMtMS0xLTEtNzUzNDE_54d9f608-4b69-4a74-af8e-cb7453837b14"
      unitRef="usd">-564300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzMtMy0xLTEtNzUzNDE_d4d8012d-4ec0-4b3e-b4f1-26a4b9bd3afd"
      unitRef="usd">-635800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzQtMS0xLTEtNzUzNDE_d5f8021b-c697-4cc7-a85e-288417c1cc85"
      unitRef="usd">1423400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzQtMy0xLTEtNzUzNDE_b12a6b3a-7bfe-46dd-a92a-a8dba7cc4321"
      unitRef="usd">1374000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzUtMS0xLTEtNzUzNDE_bea6c4f7-2c75-4a7b-8952-bd6e48c091a4"
      unitRef="usd">2005700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xNi9mcmFnOjlkZWNmNGEwNGYzOTRhNTI4N2NlMTkxYjU0ZjQ2OGM1L3RhYmxlOmQzNTM2NGRiMTBiYjQ5NzlhNWQ0YmI5ODY4MTMwYTNhL3RhYmxlcmFuZ2U6ZDM1MzY0ZGIxMGJiNDk3OWE1ZDRiYjk4NjgxMzBhM2FfMzUtMy0xLTEtNzUzNDE_163d2e81-64c2-4722-bc02-263d25f9edc6"
      unitRef="usd">2072500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i556d51bdaf9b486095b8ed36cedbe915_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMy0xLTEtMS03NTM0MQ_80c9331a-ffd5-48a3-8995-cbb29a0d517f"
      unitRef="usd">352000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8626a338deed4dddbd32b530cea19a5c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMy0zLTEtMS03NTM0MQ_5c6e326f-5a8b-4a59-8d7e-cb2d92f95ec5"
      unitRef="usd">266800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07d1811ee7e34faab1b65618d330ae8a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMy01LTEtMS03NTM0MQ_7349ad35-7e2a-46c2-83d1-722ab624accf"
      unitRef="usd">657000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f2cb608667e43f19507d5f97f5092e1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMy03LTEtMS03NTM0MQ_bef67a90-0125-4d7f-abfb-03992321fff0"
      unitRef="usd">497800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46565cbc932a4ecc83bc6363809460fd_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNC0xLTEtMS03NTM0MQ_9acd858a-e489-493b-9ff0-444351e4dfc1"
      unitRef="usd">26200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec8947a06f7f4b8f9ad89f1a53e3024e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNC0zLTEtMS03NTM0MQ_0182a23e-7ada-48a8-a750-848d9e0709c3"
      unitRef="usd">22100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3571830b1824c328e93c8aee0d0c12e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNC01LTEtMS03NTM0MQ_067ea060-7f9c-4228-8f27-1b653b6e5d2f"
      unitRef="usd">31800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9616929076a46a2b8a10b5cadb88003_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNC03LTEtMS03NTM0MQ_54138892-1a3c-40ca-be56-1c7a1015a3b1"
      unitRef="usd">27700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNS0xLTEtMS03NTM0MQ_4bec69a3-ba2b-421d-a0eb-15e4b7e92c57"
      unitRef="usd">378200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNS0zLTEtMS03NTM0MQ_484c6e75-8835-40ac-8a7f-446fbdd0b6b4"
      unitRef="usd">288900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNS01LTEtMS03NTM0MQ_523b8dc5-5097-4d40-ae73-1fa0426887f0"
      unitRef="usd">688800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNS03LTEtMS03NTM0MQ_ba06f01c-52ec-42e7-bd9c-5a80cbb735d6"
      unitRef="usd">525500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNy0xLTEtMS03NTM0MQ_212d8ed3-5a3a-4bcf-872c-d21fd96db3e5"
      unitRef="usd">4800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNy0zLTEtMS03NTM0MQ_276e7eab-c78c-4d06-93e1-d0d78556805f"
      unitRef="usd">3100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNy01LTEtMS03NTM0MQ_93357615-e4b7-4f13-8d89-caae01c53177"
      unitRef="usd">9400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfNy03LTEtMS03NTM0MQ_125cc7ab-6cc2-4938-9ac8-a6de5440636f"
      unitRef="usd">6000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOC0xLTEtMS03NTM0MQ_bc286ac0-5ed4-4233-8929-b09b68faeb41"
      unitRef="usd">135900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOC0zLTEtMS03NTM0MQ_cbdc828b-bd1b-49c1-86a1-dd7fa9b0f061"
      unitRef="usd">74800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOC01LTEtMS03NTM0MQ_8ee46942-8e74-4ef4-9ad6-c8113bbbc4c9"
      unitRef="usd">238100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOC03LTEtMS03NTM0MQ_30950c21-f903-4b05-8730-7c038460b1dd"
      unitRef="usd">148000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOS0xLTEtMS03NTM0MQ_cd279414-de20-42a8-ab8d-cfccf96e3a7e"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOS0zLTEtMS03NTM0MQ_f4a79a9d-9219-49c9-8824-9178e62053ec"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOS01LTEtMS03NTM0MQ_265a98d8-d12b-4409-b83e-6a81c8481219"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfOS03LTEtMS03NTM0MQ_7634118a-2fa0-4efc-bd03-3c53c915b13a"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTAtMS0xLTEtNzUzNDE_3042b334-35ce-46e2-a864-ce193ac0dd31"
      unitRef="usd">182800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTAtMy0xLTEtNzUzNDE_c0e572e1-f8c1-4167-9200-ee469613ae26"
      unitRef="usd">143200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTAtNS0xLTEtNzUzNDE_e8de32b3-a104-450b-bd51-2fcc4a2d8e20"
      unitRef="usd">383500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTAtNy0xLTEtNzUzNDE_4fc8676b-e6e7-4b28-b00e-aad68118ce0f"
      unitRef="usd">272200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTEtMS0xLTEtNzUzNDE_c9bedd49-2272-4e40-8704-5b65c8b6c647"
      unitRef="usd">323500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTEtMy0xLTEtNzUzNDE_e6b6f107-4f16-479f-aaf7-2c4cf4989386"
      unitRef="usd">226100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTEtNS0xLTEtNzUzNDE_f5bf10d3-5b81-45cc-b9e1-eddcfea9cde4"
      unitRef="usd">631000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTEtNy0xLTEtNzUzNDE_630a7e91-5129-4939-8b63-6fd3421741ca"
      unitRef="usd">431200000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTItMS0xLTEtNzUzNDE_66192188-45e7-42a8-b6f1-6f71fb169545"
      unitRef="usd">54700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTItMy0xLTEtNzUzNDE_ec1072f1-dcf5-4a85-a94b-e92e4d7e980b"
      unitRef="usd">62800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTItNS0xLTEtNzUzNDE_335c68ca-d627-4558-af2b-f4f0d92ce282"
      unitRef="usd">57800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTItNy0xLTEtNzUzNDE_9e11bbaf-b769-4cd4-ab8a-76778cd4a431"
      unitRef="usd">94300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTQtMS0xLTEtNzUzNDE_573e7523-a1e5-4114-8ae2-999b1febbbf0"
      unitRef="usd">2200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTQtMy0xLTEtNzUzNDE_8148dc76-7a5e-4499-8d7c-9fb974e2fb72"
      unitRef="usd">6200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTQtNS0xLTEtNzUzNDE_09da6cd8-c9aa-4e5d-b676-848d69125d05"
      unitRef="usd">4800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTQtNy0xLTEtNzUzNDE_37fbdff2-4937-45d9-83e2-aa897e413e2c"
      unitRef="usd">12600000</us-gaap:InterestExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTUtMS0xLTEtNzUzNDE_c08eb35c-d086-4357-b521-057ac4b4495e"
      unitRef="usd">-7400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTUtMy0xLTEtNzUzNDE_47d0e1ea-2e5c-4aa1-b22c-0359d953036a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTUtNS0xLTEtNzUzNDE_90904d63-685e-4a51-ac48-4b7955beb552"
      unitRef="usd">12500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTUtNy0xLTEtNzUzNDE_5285c688-b851-4062-b9ba-80225e7f3aea"
      unitRef="usd">700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtMS0xLTEtOTg1MzM_fe6bbb55-ea94-4453-b7fe-cf4b1b1672b8"
      unitRef="usd">-70000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtMy0xLTEtOTg1MzU_bda8a225-09fa-40a9-aaf4-a494cd40d0c9"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtNS0xLTEtOTg1Mjk_8e86a543-6624-4aaf-a1ee-07a9b109751f"
      unitRef="usd">-70000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtNy0xLTEtOTg1MzE_0ddb218f-4847-4ef3-9fe4-62805e367198"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtMS0xLTEtNzUzNDE_a1c7261f-aad6-446b-ac39-3cb1962948ed"
      unitRef="usd">1600000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtMy0xLTEtNzUzNDE_fb433a00-685c-40f4-84c0-33a430dd6941"
      unitRef="usd">900000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtNS0xLTEtNzUzNDE_24960742-0a7f-4c5d-9c77-f98f28895c0e"
      unitRef="usd">2600000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTYtNy0xLTEtNzUzNDE_653afaca-b327-4553-a830-49f0823365b5"
      unitRef="usd">2300000</nbix:InvestmentIncomeAndOtherNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTctMS0xLTEtNzUzNDE_f978689b-122f-402e-aa29-998700c44943"
      unitRef="usd">-78000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTctMy0xLTEtNzUzNDE_b039c7aa-e52f-4587-8870-490adda4e0f0"
      unitRef="usd">-5300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTctNS0xLTEtNzUzNDE_7a1c5f89-0459-43eb-a7ee-5620a0b19c4b"
      unitRef="usd">-59700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTctNy0xLTEtNzUzNDE_f63c4c58-4ca9-4911-be63-b7e0b81fae6a"
      unitRef="usd">-9600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTgtMS0xLTEtNzUzNDE_907603bf-527a-40c2-806f-043fec33cbdb"
      unitRef="usd">-23300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTgtMy0xLTEtNzUzNDE_d0dd4d68-1fe5-40e5-a5ba-f0e035416ace"
      unitRef="usd">57500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTgtNS0xLTEtNzUzNDE_d492c677-0485-4c3e-a529-e7a2d5db900d"
      unitRef="usd">-1900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTgtNy0xLTEtNzUzNDE_aa56103d-a38d-4a82-8601-80efb6f9fcd4"
      unitRef="usd">84700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTktMS0xLTEtNzUzNDE_d939ef40-7395-45fb-8beb-e08368ac0edc"
      unitRef="usd">-6400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTktMy0xLTEtNzUzNDE_b241453d-3fb6-4831-89db-ad4c91159c69"
      unitRef="usd">15200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTktNS0xLTEtNzUzNDE_a13c7e3c-e488-4542-b073-ee7689b7c7db"
      unitRef="usd">1100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMTktNy0xLTEtNzUzNDE_457797f4-a2a5-4400-9867-d3cd34637949"
      unitRef="usd">10300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjAtMS0xLTEtNzUzNDE_ba708bf8-3dab-4529-b5c0-66dfa4cf3fd1"
      unitRef="usd">-16900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjAtMy0xLTEtNzUzNDE_1e709037-2027-4794-8760-7da17217e8d6"
      unitRef="usd">42300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjAtNS0xLTEtNzUzNDE_79ceed8d-ce8c-4a1a-9718-0b625190c765"
      unitRef="usd">-3000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjAtNy0xLTEtNzUzNDE_2036beb2-7889-40f6-9124-3cf05341df17"
      unitRef="usd">74400000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjEtMS0xLTEtNzUzNDE_08eeb90c-7785-435c-a8b2-a9ccd2e2cbf2"
      unitRef="usd">-2900000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjEtMy0xLTEtNzUzNDE_6c565926-ef8a-42e8-9f07-e4634e64498f"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjEtNS0xLTEtNzUzNDE_19c31d2c-542a-4ab1-bd79-c1406ad78e3d"
      unitRef="usd">-10500000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjEtNy0xLTEtNzUzNDE_c5305103-c42e-4be4-86ba-c01f9920dc8c"
      unitRef="usd">-1100000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjItMS0xLTEtNzUzNDE_f8092fac-bb7a-47c3-9924-e92807c93bf8"
      unitRef="usd">-19800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjItMy0xLTEtNzUzNDE_14d93d4e-45ec-4ae1-a561-daeaad632aec"
      unitRef="usd">42000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjItNS0xLTEtNzUzNDE_3b9161d4-9c61-4a3e-8f9b-6936638ad52a"
      unitRef="usd">-13500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjItNy0xLTEtNzUzNDE_627daee1-1ccc-4633-80a8-3ddd1341d324"
      unitRef="usd">73300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjQtMS0xLTEtNzUzNDE_6a392a63-a504-49ea-ab30-a39d100c99de"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjQtMy0xLTEtNzUzNDE_73dd20fb-a8e0-4878-844a-c2448888d457"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjQtNS0xLTEtNzUzNDE_a36d9aee-a715-4ff9-bdcb-ef6077e16d0a"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjQtNy0xLTEtNzUzNDE_02be3e07-27cf-428c-b841-165d5ddf0ee3"
      unitRef="usdPerShare">0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjUtMS0xLTEtNzUzNDE_d80880dd-06a9-4f5e-b938-1b462bcc747d"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjUtMy0xLTEtNzUzNDE_9b0ec50c-183f-483a-ab96-6dcac503781d"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjUtNS0xLTEtNzUzNDE_af97c21f-98db-4f01-bb75-ea0b4e9354d9"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjUtNy0xLTEtNzUzNDE_464905a6-5fc6-4417-ac2b-669bae950150"
      unitRef="usdPerShare">0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjctMS0xLTEtNzUzNDE_e9e8ca48-7e4d-4768-bc6e-66e76f59542f"
      unitRef="shares">95600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjctMy0xLTEtNzUzNDE_d0756227-ca08-4d5b-b76c-ed78c65f21a7"
      unitRef="shares">94600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjctNS0xLTEtNzUzNDE_0316df47-5703-4522-871d-3bd4d8b182ab"
      unitRef="shares">95400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjctNy0xLTEtNzUzNDE_6f68e306-8214-4a68-ab67-cdb4e671d4af"
      unitRef="shares">94400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjgtMS0xLTEtNzUzNDE_55a36e39-5d81-4ee7-977f-ff8dd8e73413"
      unitRef="shares">95600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjgtMy0xLTEtNzUzNDE_8055bdd2-0fda-44f2-ac19-cacf16ae07f1"
      unitRef="shares">97700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjgtNS0xLTEtNzUzNDE_750d3d92-d40f-4c82-9afd-b557c4ba13cb"
      unitRef="shares">95400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8xOS9mcmFnOjlkMmZhNTRlYjhjMTRhMjE5YWU0MTcwZDMzNWVjZGY2L3RhYmxlOjJkYWU5MmM2NzRkZTRhYjNhNWUxOWNmOGJjNzdmYWVkL3RhYmxlcmFuZ2U6MmRhZTkyYzY3NGRlNGFiM2E1ZTE5Y2Y4YmM3N2ZhZWRfMjgtNy0xLTEtNzUzNDE_854f4a9f-96d1-4fa8-8d0e-120606e7d68e"
      unitRef="shares">98000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="ifea1c6e2bc7341889b0e9bdb1f1db6a9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMy0xLTEtMS03NTM0MQ_c8701e32-6338-4521-b1f6-8a988e6cb2af"
      unitRef="shares">95500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifea1c6e2bc7341889b0e9bdb1f1db6a9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMy0zLTEtMS03NTM0MQ_fb7b7776-fbbf-4351-8671-dfcdb52bb07b"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8dcb1e428512458eaf6a0bc1b8414ebc_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMy01LTEtMS03NTM0MQ_6d57abbb-11bb-4ddb-b824-d1c169b4b865"
      unitRef="usd">1947700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7db70dedd62742a6831d1f0c2ec694aa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMy03LTEtMS03NTM0MQ_7d8ecf80-3de0-42d0-b0be-eb16c332fabf"
      unitRef="usd">-9300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4a6b675fbfc45268b58ff5bf6fb855e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMy05LTEtMS03NTM0MQ_43ec0b52-3e16-4dce-af4b-2ce18b523520"
      unitRef="usd">-547400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i824b16455d3342c7bf87a435697bab24_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMy0xMS0xLTEtNzUzNDE_576f9a2a-88ca-4dda-a251-83123f52d6fa"
      unitRef="usd">1391100000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie7e2792b074c4cb5b0a136e01c9e0804_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfNC05LTEtMS03NTM0MQ_5625aec8-18cc-4522-8c84-f32233a6d06a"
      unitRef="usd">-16900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfNC0xMS0xLTEtNzUzNDE_4f618c26-7e01-4552-9874-799856d8e5ac"
      unitRef="usd">-16900000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8338e74ebc694742b502151eabd9e41e_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfNS03LTEtMS03NTM0MQ_e99e1218-c389-4ada-9a9b-bd1b89391001"
      unitRef="usd">-2900000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfNS0xMS0xLTEtNzUzNDE_43bf6891-1651-4c66-bd56-8786fe752446"
      unitRef="usd">-2900000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3d13a78bcd1f4c6882ee9fe8cbf5b711_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfNy01LTEtMS03NTM0MQ_4dd57b38-473f-4da1-9260-9cae163f5c85"
      unitRef="usd">49500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfNy0xMS0xLTEtNzUzNDE_1e89120b-12ae-400a-9b4a-1d1adf1ce667"
      unitRef="usd">49500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie6ae0c23a2454cc2abcf61a77e930c6c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOC0xLTEtMS03NTM0MQ_6433280e-9fc2-430b-a3db-c9abd804402e"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3d13a78bcd1f4c6882ee9fe8cbf5b711_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOC01LTEtMS03NTM0MQ_bb28ce60-8c31-4a83-bbea-136768904591"
      unitRef="usd">2600000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOC0xMS0xLTEtNzUzNDE_8f596ba0-c266-4164-bbff-595d13200e96"
      unitRef="usd">2600000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="iacf77ed46fbe4d5cb0a4c8117097d74d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOS0xLTEtMS03NTM0MQ_2e01b54f-fe1a-4539-9e2b-c2176b9edd0b"
      unitRef="shares">95600000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iacf77ed46fbe4d5cb0a4c8117097d74d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOS0zLTEtMS03NTM0MQ_08ed9ba3-601d-48ba-b6dc-60ae6588b45d"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0029346e11d24e2489268d48f5de1c60_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOS01LTEtMS03NTM0MQ_5628fb47-f1ae-4a4b-8a4a-dc83f37ec970"
      unitRef="usd">1999800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia7180cf1c41f49b6948e46307ec11e60_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOS03LTEtMS03NTM0MQ_f1dcf8e4-dc5f-494c-93c2-5772f2cf2649"
      unitRef="usd">-12200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib84184652a2e49aebdf6d92adfcbc04d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOS05LTEtMS03NTM0MQ_eab979d9-3ae1-47b3-a9a4-d1b6207be457"
      unitRef="usd">-564300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfOS0xMS0xLTEtNzUzNDE_ad06f7c9-47b8-4913-b30f-9588586a31b1"
      unitRef="usd">1423400000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ib1b0a1dff46e4f7a9e47f283288de125_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTEtMS0xLTEtNzUzNDE_ca4234e9-1c99-4664-a49d-037a329b4cee"
      unitRef="shares">94500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib1b0a1dff46e4f7a9e47f283288de125_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTEtMy0xLTEtNzUzNDE_2b63b4eb-a077-441c-b314-60d6abb2776b"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70110cfad88d4060a5dbaa9f2cedc49f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTEtNS0xLTEtNzUzNDE_1800261f-e58a-4e18-a4d5-093996b6d521"
      unitRef="usd">1897800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if8b70242d24a48a6a99af94c82b13c0d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTEtNy0xLTEtNzUzNDE_4199bde9-9004-4e5e-84ad-2e785b10e1be"
      unitRef="usd">1000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied4ed2118815424ab62c252c7749f6de_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTEtOS0xLTEtNzUzNDE_12c701d9-299d-4d66-9acd-b3735b5fa748"
      unitRef="usd">-693300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f5736e265cf4768afa36a5cd7c9e9a3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTEtMTEtMS0xLTc1MzQx_26fc1e39-b143-4e1a-b5d8-1ac4c7c29ca8"
      unitRef="usd">1205600000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia6292fa456fa4806a43afc6154943c3d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTItOS0xLTEtNzUzNDE_f2dbbf05-9c62-42f9-aa7a-bedde6ad231d"
      unitRef="usd">42300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTItMTEtMS0xLTc1MzQx_514f4497-db98-4dea-98c0-fe812a5ed101"
      unitRef="usd">42300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie39f82d525f6414195ec1a20af940a1d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTMtNy0xLTEtNzUzNDE_50bd5fd0-2cd1-4206-850a-49cfa964d61b"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTMtMTEtMS0xLTc1MzQx_bc554810-43b7-4a22-9ea2-be1f4f76fc0f"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7a894b024126486eab337fda4f4fb0f9_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTQtNS0xLTEtNzUzNDE_4c04c178-7869-43d1-9643-37a340a0227d"
      unitRef="usd">28600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTQtMTEtMS0xLTc1MzQx_ee374560-fb0b-4635-9932-5abda6684365"
      unitRef="usd">28600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i607fe14f45874407b052191669ff7dcc_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTUtMS0xLTEtNzUzNDE_efc63c56-2666-4f4f-938e-ee72cbae43ec"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7a894b024126486eab337fda4f4fb0f9_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTUtNS0xLTEtNzUzNDE_643d5648-cc50-4a9d-94fa-16a5fb708b08"
      unitRef="usd">3000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTUtMTEtMS0xLTc1MzQx_17ed8c99-ea21-4315-954d-9a71bd1a635e"
      unitRef="usd">3000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i644297e85df8490caa1319af010903f3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTYtMS0xLTEtNzUzNDE_bc8e29dc-dec0-4edf-b4e8-6ebd1bff0c84"
      unitRef="shares">94600000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i644297e85df8490caa1319af010903f3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTYtMy0xLTEtNzUzNDE_3bba0b40-44ff-4773-80f3-318079fa6076"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e390addaf324fa492c8b98404f47c9b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTYtNS0xLTEtNzUzNDE_67bd89d4-cce7-473c-8b71-57a9a48854b1"
      unitRef="usd">1929400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i08908942de0f491f8951674a9b93614b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTYtNy0xLTEtNzUzNDE_4992e256-6956-4e63-8263-bb063a0073a6"
      unitRef="usd">700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49d6d0041b1b4429b9640e29170494e4_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTYtOS0xLTEtNzUzNDE_b91caf03-dbc5-4457-8746-f847b9abbc47"
      unitRef="usd">-651000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTYtMTEtMS0xLTc1MzQx_f97889a2-3305-456c-81f2-15f210c829cb"
      unitRef="usd">1279200000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i798f9a1494f44261a5cfc2579e2c5d6d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTgtMS0xLTEtNzUzNDE_d85b14a5-abe0-4631-9d65-203e2e92e5fe"
      unitRef="shares">94900000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i798f9a1494f44261a5cfc2579e2c5d6d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTgtMy0xLTEtNzUzNDE_bd7eae04-919a-42af-b741-abe8f5856444"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifbcf4054dfb74e3793b2c0599d057e19_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTgtNS0xLTEtNzUzNDE_8207c370-38b2-411c-88fd-5ea2928c2578"
      unitRef="usd">2011400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2bb5b491d36940f6b9f1a57707a58f6f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTgtNy0xLTEtNzUzNDE_e34aeb94-d0c8-4dbc-b546-dbd8fb55ef19"
      unitRef="usd">-1700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia9d9884a14e643e0b6e6704e1d74e903_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTgtOS0xLTEtNzUzNDE_62d7aae6-4189-4b86-ae58-36368dc40a30"
      unitRef="usd">-635800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTgtMTEtMS0xLTc1MzQx_5fda93ef-ab06-4eca-91ff-7f6cb3d82ea9"
      unitRef="usd">1374000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i787d806f66c443c8ac342b1496f0ee61_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTktOS0xLTEtNzUzNDE_2e5dc5d6-8f19-492d-8ab2-2f3a399e264e"
      unitRef="usd">-3000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMTktMTEtMS0xLTc1MzQx_d9af7043-021d-419f-a91b-abb297b081b9"
      unitRef="usd">-3000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i391c44c0626e492884c04b5900b62430_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjAtNy0xLTEtNzUzNDE_471b1f55-a864-434e-823d-8876883adab6"
      unitRef="usd">-10500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjAtMTEtMS0xLTc1MzQx_2c96cbea-bf01-40c4-b962-011ff671f4ae"
      unitRef="usd">-10500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ie030c4abde7f4cf784cc031f496e6485_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjAtNS0xLTEtOTIwMTk_950f0626-e6cf-4efa-8dd7-51079b3eb61c"
      unitRef="usd">-106800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i465519c475194c1d9739d8c1fca3961d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjAtOS0xLTEtOTIwMTM_f3956639-6f59-470c-8d80-0bbcc446730c"
      unitRef="usd">74500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i91b516301ebe44a6b87c40ee75c6677c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjAtMTEtMS0xLTkyMDA3_ebb49526-fd8f-4fd6-a071-be7b1cf77631"
      unitRef="usd">-32300000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie20bd8d4ea894bff986d00fbffc83784_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjEtNS0xLTEtNzUzNDE_5431fe42-ca4a-4720-9156-cdc1ddee4d83"
      unitRef="usd">86500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjEtMTEtMS0xLTc1MzQx_9fbb50be-8ed7-4a6e-b8cf-575c1028607d"
      unitRef="usd">86500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2e14680288bd42149b5cdf6969e7f02b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjItMS0xLTEtNzUzNDE_69b1c6c0-8d69-4783-ab01-975a83e97469"
      unitRef="shares">700000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie20bd8d4ea894bff986d00fbffc83784_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjItNS0xLTEtNzUzNDE_648a4e49-16b3-48d0-a18b-3f8c905c60ae"
      unitRef="usd">8700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjItMTEtMS0xLTc1MzQx_e5296301-2ee7-4201-9cd3-8a7094dfc5ca"
      unitRef="usd">8700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="iacf77ed46fbe4d5cb0a4c8117097d74d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjMtMS0xLTEtNzUzNDE_ec9aab4b-d996-46f9-8bc3-c3085a82a3ea"
      unitRef="shares">95600000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iacf77ed46fbe4d5cb0a4c8117097d74d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjMtMy0xLTEtNzUzNDE_e5f9720e-ccc3-49a1-abc6-3638322d5779"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0029346e11d24e2489268d48f5de1c60_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjMtNS0xLTEtNzUzNDE_96e40438-aaf9-44b0-b62a-2b5952107578"
      unitRef="usd">1999800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia7180cf1c41f49b6948e46307ec11e60_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjMtNy0xLTEtNzUzNDE_e219046d-cb0c-4bef-b07f-439a2b563c6c"
      unitRef="usd">-12200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib84184652a2e49aebdf6d92adfcbc04d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjMtOS0xLTEtNzUzNDE_43c5d6d8-7384-408f-9889-a5a306462fd1"
      unitRef="usd">-564300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjMtMTEtMS0xLTc1MzQx_a0797833-4b2d-47be-a988-4a4acbd8e670"
      unitRef="usd">1423400000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i8ef17498aa9d498c8992b5221561c777_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjUtMS0xLTEtNzUzNDE_22041d72-6ce9-4dff-be7d-e2ce682053d5"
      unitRef="shares">93500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8ef17498aa9d498c8992b5221561c777_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjUtMy0xLTEtNzUzNDE_8d1ff0bf-f329-4492-a23e-9eff12cccdb6"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i46b42b5fd65e44418a23dcde417525dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjUtNS0xLTEtNzUzNDE_cea05999-52c4-48d8-8453-b79dc8253d5b"
      unitRef="usd">1849700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72d820c9109a4f90b3f7b8e63c0993ee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjUtNy0xLTEtNzUzNDE_5ffb6c06-19c3-45b1-9bdb-f975fcff719e"
      unitRef="usd">1800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e67fafca0274dee95d180cc3fb1f41f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjUtOS0xLTEtNzUzNDE_c1b42d51-a296-4655-958f-259ae1dc95d1"
      unitRef="usd">-725400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1739e70f0194d8fa9900c2c02abbe2b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjUtMTEtMS0xLTc1MzQx_0d8a93ec-8c9e-40c8-8950-64e49410b1b6"
      unitRef="usd">1126200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i93d94c70d96d4cf8aa28362a0b2141c5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjYtOS0xLTEtNzUzNDE_4744b310-9705-4ae2-9bbf-d7b4762523cb"
      unitRef="usd">74400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjYtMTEtMS0xLTc1MzQx_b23c2705-489f-42e3-a51e-d7496173b5c4"
      unitRef="usd">74400000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic92e784af6164e40ab1441eb9d508ae1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjctNy0xLTEtNzUzNDE_059277ac-7771-4276-9fa4-41de1c746a92"
      unitRef="usd">-1100000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjctMTEtMS0xLTc1MzQx_52e38044-c65a-475c-a028-567adc1461d7"
      unitRef="usd">-1100000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i570417ef7f454c59b464a0797bfa388a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjgtNS0xLTEtNzUzNDE_7e69e5fd-1f01-4b62-ba93-15d692aab5bf"
      unitRef="usd">61500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjgtMTEtMS0xLTc1MzQx_f66036eb-d5bf-45cc-9584-8874e17a2e14"
      unitRef="usd">61500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9dd39c3aa14042ba9edda98ae8d9cb55_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjktMS0xLTEtNzUzNDE_8db22d4d-4d0f-469e-98d2-517b48d9e88f"
      unitRef="shares">1100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i570417ef7f454c59b464a0797bfa388a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjktNS0xLTEtNzUzNDE_d4dfa2a4-78f7-4bc0-8d8c-c958129b7f7e"
      unitRef="usd">18200000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMjktMTEtMS0xLTc1MzQx_825fa68b-b7b0-48ed-9707-01f83f5b5c71"
      unitRef="usd">18200000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i644297e85df8490caa1319af010903f3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMzAtMS0xLTEtNzUzNDE_3d7b96b0-5e5f-4648-9fc6-284f34810342"
      unitRef="shares">94600000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i644297e85df8490caa1319af010903f3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMzAtMy0xLTEtNzUzNDE_dbff8eea-fa4f-4832-8037-3431780666ae"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e390addaf324fa492c8b98404f47c9b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMzAtNS0xLTEtNzUzNDE_892bc170-a306-47cf-9051-24cb7ee40fba"
      unitRef="usd">1929400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i08908942de0f491f8951674a9b93614b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMzAtNy0xLTEtNzUzNDE_1290f186-5bdd-445a-b4e0-067be9e50155"
      unitRef="usd">700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49d6d0041b1b4429b9640e29170494e4_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMzAtOS0xLTEtNzUzNDE_3907e40d-a4bd-44aa-9662-8a7d231fa9d4"
      unitRef="usd">-651000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yMi9mcmFnOmUzMjAzZWFiMmJlMjQxZDFiZThmYjlkMmMwNjU1YjFjL3RhYmxlOjI3Nzg4ZTkyNTUzNzRkNjVhMjhmMTE3ZWMxZGE1ZDEwL3RhYmxlcmFuZ2U6Mjc3ODhlOTI1NTM3NGQ2NWEyOGYxMTdlYzFkYTVkMTBfMzAtMTEtMS0xLTc1MzQx_dea922f6-ab70-4716-939f-53c58fcfac11"
      unitRef="usd">1279200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMy0xLTEtMS03NTM0MQ_3fffa89f-8877-4386-a916-7383194c5c4d"
      unitRef="usd">-3000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMy0zLTEtMS03NTM0MQ_f5134777-9bd9-4f19-8ad3-5bf05baf27ba"
      unitRef="usd">74400000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNS0xLTEtMS03NTM0MQ_ad63f658-d91d-45da-a248-14552acd5aaf"
      unitRef="usd">86500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNS0zLTEtMS03NTM0MQ_2871bcb2-1b8c-445d-9d72-753e5aad3f52"
      unitRef="usd">61500000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNi0xLTEtMS0xMDQ1NTg_1f786860-fc02-4ad4-8dec-f27d52c6d1af"
      unitRef="usd">-70000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNi0zLTEtMS0xMDQ1NTg_eabfd3b6-39e1-4d45-a024-962cc5afea69"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:Depreciation
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNi0xLTEtMS03NTM0MQ_7335710a-ac7c-4c1d-988a-fb836459af05"
      unitRef="usd">7200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNi0zLTEtMS03NTM0MQ_1a606b40-8de2-48f8-ba09-4ebd80fe1694"
      unitRef="usd">5100000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNy0xLTEtMS03NTM0MQ_ffe26043-9bac-4dfd-b42d-1ced3a3d7525"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfNy0zLTEtMS03NTM0MQ_224e4d50-4c31-4785-8511-86f70f3b8e37"
      unitRef="usd">7900000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfOC0xLTEtMS03NTM0MQ_d22f44b3-4f4d-4394-8098-3e767b82458f"
      unitRef="usd">800000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfOC0zLTEtMS03NTM0MQ_d205ab7e-37e8-490b-8245-55f265dce93c"
      unitRef="usd">600000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfOS0xLTEtMS03NTM0MQ_142a7a90-c6dc-4492-9a0c-44ba161465f9"
      unitRef="usd">12500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfOS0zLTEtMS03NTM0MQ_ece2ffa5-2902-4472-9149-b2bcf3774cf2"
      unitRef="usd">700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTAtMS0xLTEtNzUzNDE_61c7e3bf-b41f-48e7-91e0-249ac4039d85"
      unitRef="usd">-3400000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTAtMy0xLTEtNzUzNDE_5c8b795b-c696-4bb7-9cb7-644dbd4435dc"
      unitRef="usd">3300000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTEtMS0xLTEtNzUzNDE_52760815-feb4-466b-9e52-659d65c06b05"
      unitRef="usd">2300000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTEtMy0xLTEtNzUzNDE_7d624464-4c19-4c3f-9b92-df3855008476"
      unitRef="usd">5600000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTMtMS0xLTEtNzUzNDE_50b88c69-53b7-41f8-ba78-e602e7e094f4"
      unitRef="usd">93500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTMtMy0xLTEtNzUzNDE_2fc5ce9d-71ab-4780-9915-6d195c2fd9bc"
      unitRef="usd">1400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTQtMS0xLTEtNzUzNDE_0197c211-45ee-4984-83d5-3aba65c9d03a"
      unitRef="usd">-1200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTQtMy0xLTEtNzUzNDE_94361334-de88-4006-bf55-d2907c776949"
      unitRef="usd">300000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTUtMS0xLTEtNzUzNDE_eb49f61a-4edb-406f-a6a2-5194d1c072c3"
      unitRef="usd">44200000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTUtMy0xLTEtNzUzNDE_342a2aaf-0024-4307-84dd-043327bed1ed"
      unitRef="usd">29000000.0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTYtMS0xLTEtNzUzNDE_a40e11b2-4c5d-414b-bfbd-b5ea4fc094ce"
      unitRef="usd">2200000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTYtMy0xLTEtNzUzNDE_e87e601c-55be-4a66-9bea-9fa67b4e2263"
      unitRef="usd">-5500000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTctMS0xLTEtNzUzNDE_c1869407-5782-477a-8cd4-d8276ae3c8f0"
      unitRef="usd">97600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMTctMy0xLTEtNzUzNDE_5302de94-8116-4a6f-a4c6-354f54c06cf7"
      unitRef="usd">190500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjAtMS0xLTEtNzUzNDE_d043b265-1825-4a53-afc1-8210fb61025b"
      unitRef="usd">253700000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjAtMy0xLTEtNzUzNDE_7ed543f7-0d91-4787-8f7e-0dae653359c9"
      unitRef="usd">383100000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjEtMS0xLTEtNzUzNDE_f6452634-aa21-46f0-9254-8de0a44df063"
      unitRef="usd">277600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjEtMy0xLTEtNzUzNDE_45cdb11d-7b5b-445e-bb3a-4819ddaf1aee"
      unitRef="usd">364200000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjItMS0xLTEtNzUzNDE_bf858b1e-a0ab-427f-aba2-ad5fbbae824d"
      unitRef="usd">7700000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjItMy0xLTEtNzUzNDE_9468f5aa-535f-4528-baa9-88d1c502fcfa"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjMtMS0xLTEtNzUzNDE_698ca243-f269-400d-b945-6f413e675435"
      unitRef="usd">16400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjMtMy0xLTEtNzUzNDE_ea8bc07f-5b65-49c1-bf38-420ab357a64f"
      unitRef="usd">8800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjQtMS0xLTEtNzUzNDE_f2c743b3-b435-4e0c-b6c1-abd9dcf3c2c4"
      unitRef="usd">-200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjQtMy0xLTEtNzUzNDE_bddcc996-a5e6-41d3-b7ae-2c26730db738"
      unitRef="usd">-27700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjctMS0xLTEtNzUzNDE_dade520d-6a93-437e-b88f-2cc570ce99d2"
      unitRef="usd">8700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjctMy0xLTEtNzUzNDE_e3c46585-cffa-4cc9-be55-2bd2a0557ba6"
      unitRef="usd">18200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjgtMS0xLTEtNzUzNDE_181fc01b-6bcb-4a75-8658-4b218b85fa51"
      unitRef="usd">279000000.0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjgtMy0xLTEtNzUzNDE_471bc282-cea9-4386-a102-60d65174b46a"
      unitRef="usd">100000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjktMS0xLTEtNzUzNDE_d3494ac6-a2b6-4397-881e-81ef947b0292"
      unitRef="usd">-270300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMjktMy0xLTEtNzUzNDE_3d30edef-8808-4305-b449-ea17c4ec988e"
      unitRef="usd">18100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzAtMS0xLTEtNzUzNDE_21847618-ff5c-45e2-8f86-e0b02b461d46"
      unitRef="usd">-172900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzAtMy0xLTEtNzUzNDE_ba162d56-ee42-4f70-832f-c9adf882e10c"
      unitRef="usd">180900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzEtMS0xLTEtNzUzNDE_658ecf59-616e-4f5f-bbe4-e7e9e57ecb94"
      unitRef="usd">344000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic1739e70f0194d8fa9900c2c02abbe2b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzEtMy0xLTEtNzUzNDE_b73f288e-f8c3-4b19-bf79-69e8a852a921"
      unitRef="usd">190300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzItMS0xLTEtNzUzNDE_78f694c5-9437-497e-ae0f-63498f572899"
      unitRef="usd">171100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzItMy0xLTEtNzUzNDE_6a8d0dfa-950d-4f1a-81e3-f3356b5f14cb"
      unitRef="usd">371200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzUtMS0xLTEtNzUzNDE_35e21228-7d22-4447-ae1e-a0a26ac93675"
      unitRef="usd">900000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzUtMy0xLTEtNzUzNDE_fbfdb97e-75f6-4bca-9e72-eefcd31d8226"
      unitRef="usd">2200000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzYtMS0xLTEtNzUzNDE_ca22a9a3-20f4-42ac-8377-5d131b9c0bfd"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzYtMy0xLTEtNzUzNDE_fe099079-d1ab-444e-9fd3-21b74a317a56"
      unitRef="usd">21600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzctMS0xLTEtNzUzNDE_3504b2df-bd2b-4461-8e41-d39b1f9b5daa"
      unitRef="usd">4600000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzctMy0xLTEtNzUzNDE_6ecce6be-664a-4e4f-b2e5-4391f48dfc2d"
      unitRef="usd">4300000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzgtMS0xLTEtNzUzNDE_7a44b803-8979-4e8b-823a-dde4aec11c4d"
      unitRef="usd">3100000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8yNS9mcmFnOjE1MTBlMmZhNDI5YTRiYWQ5N2UwNDhmZGY3MmZkZmEwL3RhYmxlOjhhM2E1ZTk2ZTA5NzRiNGNhODhiYTlmODQ3NzFhYjY2L3RhYmxlcmFuZ2U6OGEzYTVlOTZlMDk3NGI0Y2E4OGJhOWY4NDc3MWFiNjZfMzgtMy0xLTEtNzUzNDE_b56a36fc-e3dc-47bb-8c78-a4b6689a3e26"
      unitRef="usd">1600000</us-gaap:IncomeTaxesPaid>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzgxMQ_b8d153f7-59ab-4d3c-ad1e-c38ad12d7010">Organization and Significant Accounting Policies&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K, or the 2021 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2021, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjI0MA_27a74808-cedc-4067-91c0-ce68f133d49f"&gt;ASU 2020-06&lt;/span&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjgwMA_27a74808-cedc-4067-91c0-ce68f133d49f"&gt;ASU 2020-06&lt;/span&gt; removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzA0Mg_27a74808-cedc-4067-91c0-ce68f133d49f"&gt;ASU 2020-06&lt;/span&gt; prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#x2019; equity to liabilities as it relates to the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzM2NQ_27a74808-cedc-4067-91c0-ce68f133d49f"&gt;ASU 2020-06&lt;/span&gt; on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million and reduced the accumulated deficit by $74.5 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzgwOA_7f8b0293-4ba7-4131-9f3b-a35b6a3e754f">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K, or the 2021 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet as of December&#160;31, 2021, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzgxMA_6106a6ff-4bf2-4978-a4ce-82d7ff0829ee">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjI0MA_27a74808-cedc-4067-91c0-ce68f133d49f"&gt;ASU 2020-06&lt;/span&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2020-06,&#160;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity's own equity. Among other changes, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMjgwMA_27a74808-cedc-4067-91c0-ce68f133d49f"&gt;ASU 2020-06&lt;/span&gt; removed the separation models for convertible instruments with cash or beneficial conversion features. Instead, entities now account for convertible debt instruments wholly as debt, unless certain other conditions are met. The adoption of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzA0Mg_27a74808-cedc-4067-91c0-ce68f133d49f"&gt;ASU 2020-06&lt;/span&gt; prospectively reduces reported interest expense and increases (decreases) reported net income (loss), and resulted in a reclassification of certain conversion feature balance sheet amounts from stockholders&#x2019; equity to liabilities as it relates to the 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes. We adopted &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzM2NQ_27a74808-cedc-4067-91c0-ce68f133d49f"&gt;ASU 2020-06&lt;/span&gt; on January&#160;1, 2022, using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million and reduced the accumulated deficit by $74.5 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifa023efd07b7418a8139d17baa936118_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzI5Ng_49b07f2e-79cb-4242-95e1-120fe697f524"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzY3OQ_5b64e963-da74-4625-ade7-2825d656559e"
      unitRef="usd">42200000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzcxOQ_e0a152b1-ce79-4aca-bdab-2230fddb78e0"
      unitRef="usd">-9900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzc2MQ_c8dc538d-da09-44ab-aab9-bfe81ac74ef8"
      unitRef="usd">-106800000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zMS9mcmFnOmYwZTU3YWI4OTZiNzQ0NWNiNjA3NGFmZGRjZTY2NzdiL3RleHRyZWdpb246ZjBlNTdhYjg5NmI3NDQ1Y2I2MDc0YWZkZGNlNjY3N2JfMzgwMw_bd015d84-bb81-432d-a353-1f661e1a0e8a"
      unitRef="usd">74500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjAyMTE_e752bcab-44ea-410c-b238-87bf843aa4d8">Collaboration and License Agreements&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Heptares Therapeutics Limited, or Heptares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We entered into a collaboration and license agreement with Heptares, which became effective in December 2021, to develop and commercialize certain compounds containing sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists, which compounds we have the exclusive rights to develop, manufacture and commercialize worldwide, excluding in Japan, where Heptares retains the rights to develop, manufacture, and commercialize all compounds comprised of M1 receptor agonists, subject to certain exceptions. With respect to such rights retained by Heptares, we retain the rights to opt in to profit sharing arrangements, pursuant to which we and Heptares will equally share in the operating profits and losses for such compounds in Japan. Subject to specified conditions, we may elect to exercise such opt-in rights with respect to each such compound either before initiation of the first proof of concept Phase II clinical trial for such compound or following our receipt from Heptares of the top-line data from such clinical trial for such compound. We are responsible for all development, manufacturing and commercialization costs of any collaboration product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Heptares $100.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;amp;D in 2021. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2022, the FDA accepted our submission of an investigational new drug application, or IND, for NBI-1117568 for the treatment of schizophrenia, for which we anticipate initiating a Phase II study during the second half of 2022. Based upon this progress, a milestone of $30.0 million was expensed as R&amp;amp;D in the second quarter of 2022, which we expect to pay to Heptares in the third quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Heptares may be entitled to receive potential future payments of up to $2.6 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which the royalty term for such licensed product has expired in such country. On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a licensed product and terminate on the later of (i) the expiration of the last patent covering such licensed product in such country, (ii) a number of years from the first commercial sale of such licensed product in such country and (iii) the expiration of regulatory exclusivity for such licensed product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement in its entirety or with respect to one or more targets upon 180 days&#x2019; written notice to Heptares during the research collaboration term and upon 90 days&#x2019; written notice to Heptares following the expiration of the research collaboration term. Following the expiration of the research collaboration term, Heptares may terminate the agreement on a target-by-target basis in the event that we do not conduct any material development activities outside of Japan with respect to a certain compound or licensed product within the applicable target class for a continuous period of not less than 365 days and do not commence any such activities within 120 days of receiving written notice. Either party may terminate the agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited, or Takeda.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2020, we entered into an exclusive license agreement with Takeda, pursuant to which we acquired the exclusive rights to develop and commercialize certain early to mid-stage psychiatry compounds, including luvadaxistat, NBI-1065845, NBI-1065846 and four non-clinical stage compounds. Luvadaxistat and the 4 non-clinical stage compounds have each been designated as a royalty-bearing product. NBI-1065845 and NBI-1065846 are currently each designated as a profit-share product. We are responsible for all manufacturing, development and commercialization costs of any royalty-bearing product. With respect to NBI-1065845 and NBI-1065846, we and Takeda will equally share in the operating profits and losses. Takeda retains the rights to opt-out of the profit-sharing arrangements, pursuant to which Takeda would be entitled to receive potential future payments upon the achievement of certain event-based milestones with respect to such compounds and receive royalties on the future net sales of such compounds (in lieu of equally sharing in the operating profits and losses). Takeda may elect to exercise such opt-out right for such compound immediately following the completion of a second Phase II clinical trial for such compound, or, under certain circumstances related to the development and commercialization activities to be performed by us, before the initiation of a Phase III clinical trial for such compound.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Takeda $120.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&amp;amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Takeda may be entitled to receive potential future payments of up to $1.9 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any royalty-bearing product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any royalty-bearing product, the royalty term has expired in such country; and (ii) for any profit-share product, for so long as we continue to develop, manufacture, or commercialize such licensed product.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a licensed product-by-licensed product and country-by-country basis, royalty payments would commence on the first commercial sale of a royalty-bearing product and terminate on the later of (i) the expiration of the last patent covering such royalty-bearing product in such country, (ii) a number of years from the first commercial sale of such royalty-bearing product in such country and (iii) the expiration of regulatory exclusivity for such royalty-bearing product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement in its entirety or in one or more (but not all) of the United States, Japan, the European Union and the United Kingdom, or, collectively, the major markets, upon six months&#x2019; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. We may terminate the agreement in its entirety or in one or more (but not all) of the major markets upon 12 months&#x2019; written notice to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class for which first commercial sale occurs. Takeda may terminate the agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Idorsia Pharmaceuticals Ltd., or Idorsia.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2020, we entered into a collaboration and license agreement with Idorsia, pursuant to which we acquired the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker in clinical development for the treatment of a rare pediatric epilepsy and other potential indications, including essential tremor. We are responsible for all manufacturing, development and commercialization costs of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Idorsia $45.0 million upfront, which was expensed as IPR&amp;amp;D in 2020. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. Under the terms of the agreement, Idorsia may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement, in its entirety or with respect to a particular compound or development candidate, upon 90 days&#x2019; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Xenon Pharmaceuticals Inc., or Xenon. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we entered into a collaboration and license agreement with Xenon to identify, research and develop sodium channel inhibitors, including NBI-921352 and three preclinical candidates, which compounds we have the exclusive rights to develop and commercialize. We are responsible for all development and manufacturing costs of any collaboration product, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Xenon $50.0 million upfront, including a purchase of approximately 1.4 million shares of Xenon common stock (at $14.196 per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $14.1 million after considering Xenon&#x2019;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $36.2 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;amp;D in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the European Union&#x2019;s approval of our clinical trial application for NBI-921352 for the treatment of focal onset seizures in adults in September 2021, we paid Xenon a regulatory milestone of $10.0 million, including a purchase of approximately 0.3 million shares of Xenon common stock (at $19.9755 per share). The purchased shares were recorded at a fair value of $4.6 million after considering Xenon&#x2019;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $5.4 million of the milestone payment was expensed as R&amp;amp;D in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the FDA's acceptance of our amended KAYAK&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;study protocol in January 2022, we paid Xenon a regulatory milestone of $15.0 million, including a purchase of approximately 0.3 million shares of Xenon common stock (at $31.855 per share). The purchased shares were recorded at a fair value of $7.7 million after considering Xenon&#x2019;s stock price on the measurement date. The remaining $7.3 million of the milestone payment was expensed as R&amp;amp;D in the first quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Xenon may be entitled to receive potential future payments of up to $1.7 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product. Xenon retains the right to elect to co-develop one product in a major indication, pursuant to which Xenon would receive a mid-single digit percentage increase in royalties earned on the future net sales of such product in the United States and we and Xenon would equally share in the development costs of such product in the applicable indication, except where such development costs relate solely to the regulatory approval of such product outside the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular licensed product and country, the license obtained by us with respect to such product and country will become fully paid, royalty free, perpetual and irrevocable. We may terminate the agreement upon 90 days&#x2019; written notice to Xenon, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Voyager Therapeutics, Inc., or Voyager.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we entered into a collaboration and license agreement with Voyager, pursuant to which we acquired certain rights to develop and commercialize the NBIb-1817 for Parkinson&#x2019;s disease program, Friedreich&#x2019;s ataxia program and two undisclosed programs. We are responsible for all development costs of any collaboration product, subject to certain co-development and co-commercialization rights retained by Voyager. In February 2021, we notified Voyager of our termination of the NBIb-1817 for Parkinson&#x2019;s disease program, which became effective August 2, 2021. The termination did not apply to any program other than the NBIb-1817 for Parkinson&#x2019;s disease program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Voyager $165.0 million upfront, including a purchase of approximately 4.2 million shares of Voyager common stock (at $11.9625 per share). We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitute a business. The purchased shares were recorded at a fair value of $54.7 million after considering Voyager&#x2019;s stock price on the measurement date and certain transfer restrictions applicable to the shares. The remaining $113.1 million of the purchase price, which includes certain transaction-related costs, was expensed as IPR&amp;amp;D in 2019. In addition, we paid Voyager $5.0 million upfront, which was expensed as IPR&amp;amp;D in 2019, to acquire the rights outside the United States to the Friedreich&#x2019;s ataxia program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Voyager may be entitled to receive potential future payments of up to $1.3 billion upon the achievement of certain event-based milestones and would be entitled to receive royalties on the future net sales of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement. We may terminate the agreement upon 180 days&#x2019; written notice to Voyager prior to the first commercial sale of any collaboration product or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIAL &#x2013; Portela &amp;amp; Ca, S.A., or BIAL.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We acquired the United States and Canada rights to ONGENTYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(opicapone) from BIAL in 2017, and launched ONGENTYS in the United States in September 2020 as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations. We are responsible for all commercialization costs of ONGENTYS in the United States and Canada and rely on BIAL for the commercial supply of ONGENTYS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the license agreement, BIAL may be entitled to receive potential future payments of up to $75.0 million upon the achievement of certain event-based milestones. In addition, with respect to ONGENTYS, in the event we fail to meet certain minimum sales requirements for a particular year in comparison to our annual sales forecast for such year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year. Further, upon our written request to BIAL 12 months prior to the estimated expiration of the term of a licensed product, we will negotiate the continuation of BIAL&#x2019;s supply of such licensed product after the term. After the term, and if BIAL is no longer supplying such licensed product, BIAL would be entitled to receive a low double-digit royalty on our future quarterly net sales of such licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-licensed product and country-by-country basis until a generic product with respect to such licensed product is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the agreement upon nine months&#x2019; written notice to BIAL. BIAL may terminate the agreement in the event we fail to meet the minimum sales requirements for any two years, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party&#x2019;s insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mitsubishi Tanabe Pharma Corporation, or MTPC.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We out-licensed the rights to valbenazine in Japan and other select Asian markets to MTPC in 2015. In December 2020, we entered into a commercial supply agreement with MTPC, pursuant to which we agreed to supply MTPC with valbenazine drug product for commercial use in Japan and other select Asian markets. MTPC is responsible for all development, manufacturing and commercialization costs of valbenazine in such markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, MTPC launched DYSVAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (valbenazine) in Japan for the treatment of tardive dyskinesia. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $20.0 million in the second quarter of 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchange for a license of intellectual property. Under the royalty exception, the milestone would be recognized as revenue only when the later of (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales-based or usage-based royalty has been allocated has been satisfied (or partially satisfied). As the milestone related to a license of intellectual property and was contingent upon MTPC&#x2019;s first commercial sale of DYSVAL in Japan, the milestone was recognized as revenue in the second quarter of 2022. In addition, we will receive royalties at tiered percentage rates on MTPC net sales of DYSVAL. DYSVAL royalty revenue was not significant for the three and six months ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our license agreement with MTPC, we may be entitled to receive potential future payments of up to $30.0 million upon the achievement of certain sales-based milestones and are entitled to receive royalties at tiered percentage rates on future MTPC net sales of valbenazine for the longer of 10 years or the life of the related patent rights. MTPC may terminate the agreement upon 180 days&#x2019; written notice to us. In such event, all out-licensed product rights would revert to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AbbVie Inc., or AbbVie.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, AbbVie launched ORILISSA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(elagolix tablets) in the United States for the treatment of moderate to severe pain associated with endometriosis. In June 2020, AbbVie launched ORIAHNN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States for the treatment of heavy menstrual bleeding related to uterine fibroids in premenopausal women. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $5.2&#160;million and $9.4&#160;million, respectively, for the three and six months ended June&#160;30, 2022 and $5.9 million and $10.4 million, respectively, for the three and six months ended June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our license agreement with AbbVie, we may be entitled to receive potential future payments of up to $366.0 million upon the achievement of certain event-based milestones and are entitled to receive royalties at tiered percentage rates on future AbbVie net sales of elagolix for the longer of 10 years or the life of the related patent rights. AbbVie may terminate the agreement upon 180 days&#x2019; written notice to us. In such event, all out-licensed product rights would revert to us.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i2b01af7da7264226a39cc415c4f4de88_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTMxMQ_75a06ca2-3ff9-4235-bf3b-eb4c2ea4ded9"
      unitRef="usd">100000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0378ba60bbf54c9c984afe9729769082_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjE5OTAyMzI4NjgwOA_a8848962-6d29-41fa-a644-78cdd8132c98"
      unitRef="usd">30000000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:PotentialMilestonePayments
      contextRef="i82ea1ca4da564dcb9abb0f23996feb31_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTYyOQ_3eeb12c6-3399-44ff-a74c-f8ef177c66e3"
      unitRef="usd">2600000000</nbix:PotentialMilestonePayments>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i1d87729af3eb438a8f50b92d4f11b0ff_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfNTA4Mw_98594569-7448-491d-85a6-9f890c023682"
      unitRef="usd">120000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:PotentialMilestonePayments
      contextRef="i38ba4b66e35b4a058bd00122f74f68a1_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfNTM5OQ_60531135-e7e8-4f40-a08b-ece9c144b376"
      unitRef="usd">1900000000</nbix:PotentialMilestonePayments>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i0b5f0284f514463fb5639c0b9dc36242_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfODc5MQ_a0afd23a-4e96-482d-945c-263e7c89a676"
      unitRef="usd">45000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:PotentialMilestonePayments
      contextRef="i29dde29babb8447aa6253d6d81080068_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfOTA2Mg_3294d20a-e667-4b99-81e1-043866732f35"
      unitRef="usd">1700000000</nbix:PotentialMilestonePayments>
    <nbix:UpfrontPaymentsMade
      contextRef="icc12b8925fe24715a37c917e89b4a2d3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTAxMjI_b37132dd-4220-412e-9abf-24beae0fd548"
      unitRef="usd">50000000</nbix:UpfrontPaymentsMade>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction
      contextRef="i41dedb5b6dd648adafef4d12efc9d560_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTAxNzI_daf56185-d92a-4651-93f6-002d663e610d"
      unitRef="shares">1400000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="icc12b8925fe24715a37c917e89b4a2d3_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTAyMDg_7ab4770e-c355-480f-b7d5-9e52fe1f3098"
      unitRef="usdPerShare">14.196</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="icc12b8925fe24715a37c917e89b4a2d3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTAzOTU_b30282b0-35c6-4ed2-9906-23a6739a2bd4"
      unitRef="usd">14100000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i3113317a93804d79b80f423ec6d08d4a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTA1MzQ_bef44666-1d1f-48c7-95e5-6b2b62c21660"
      unitRef="usd">36200000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:MilestonePayment
      contextRef="i423078e1d1174d878d489e6ef59f9d7d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTA4NTA_52c5b868-5acb-4ade-adb8-5c16fdd7aaf6"
      unitRef="usd">10000000</nbix:MilestonePayment>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction
      contextRef="icdca041dd4cd4227abc30499d4f8bebf_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTA4OTI_e55cbc75-d058-40ff-8538-44dc7bff4ebf"
      unitRef="shares">300000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="i423078e1d1174d878d489e6ef59f9d7d_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTA5Mjg_ca2d466b-3db1-40cc-acd7-e27a71195903"
      unitRef="usdPerShare">19.9755</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="i423078e1d1174d878d489e6ef59f9d7d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTA5OTc_70e3e9dd-81c9-4101-8a36-7e4363978bf7"
      unitRef="usd">4600000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i62a271eec056493ab613a72c7a5b002b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTExMzY_d76af3fd-e49f-4721-8941-db35a3e3bf56"
      unitRef="usd">5400000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:MilestonePayment
      contextRef="if71d1cf4c4b84dcd8a6b38e623f46644_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTEzMjg_df6bc807-482c-4b47-98ac-dc9c44b16ec1"
      unitRef="usd">15000000</nbix:MilestonePayment>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction
      contextRef="i53b573b749c34f2dbfe2a3f74272c97c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTEzNzA_c95c0adf-0ae7-4418-be1d-f30686ba757a"
      unitRef="shares">300000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="if71d1cf4c4b84dcd8a6b38e623f46644_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTE0MDY_185f456f-02a3-4994-b36f-49984c1a7479"
      unitRef="usdPerShare">31.855</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="if71d1cf4c4b84dcd8a6b38e623f46644_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTE0NzU_3ebc9f39-216c-4cc3-be77-d919e9f1515a"
      unitRef="usd">7700000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i35309e0240cb45d68c83e6a9539b437e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTE1NTU_441e733d-ff06-420d-85e3-00411b1ae414"
      unitRef="usd">7300000</us-gaap:ResearchAndDevelopmentExpense>
    <nbix:PotentialMilestonePayments
      contextRef="i05ec7aad29694aba88b3325431ac3cca_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTE3MzU_a19a02d5-a15c-4868-b3fb-b6791e8d2abc"
      unitRef="usd">1700000000</nbix:PotentialMilestonePayments>
    <nbix:UpfrontPaymentsMade
      contextRef="i2cea7f1f684e4ceda425fdd38139bd65_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTM5MTk_17632eb7-8f0c-40cd-a933-b427f8169adf"
      unitRef="usd">165000000</nbix:UpfrontPaymentsMade>
    <nbix:SaleOfStockNumberOfSharesSoldInTransaction
      contextRef="i31d5d364edff4ad4b48da1b643c16353_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTM5Njk_31630462-2650-41c9-97b4-44741a613cc4"
      unitRef="shares">4200000</nbix:SaleOfStockNumberOfSharesSoldInTransaction>
    <us-gaap:SharePrice
      contextRef="i2cea7f1f684e4ceda425fdd38139bd65_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTQwMDc_44a31d5c-310d-45a2-adbb-47b56e17710f"
      unitRef="usdPerShare">11.9625</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="i2cea7f1f684e4ceda425fdd38139bd65_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTQxOTQ_aa9c97f0-2b31-41d9-91a3-e74d5a348ba3"
      unitRef="usd">54700000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i98646b31fd7d4d0583d03a62061c0725_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTQzMzU_3ae57c2f-67e9-4cca-bdf1-f7156599ea79"
      unitRef="usd">113100000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i6bde3727bced42719f1bdb0078bc223e_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTQ0NzE_0e9cba27-a70c-4d06-8830-c28a8768423e"
      unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nbix:PotentialMilestonePayments
      contextRef="iee097ca4107145a4a7cafe11c7f7c028_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTQ3MDg_5a1fc73b-0838-4966-a45d-3123eae8dd0f"
      unitRef="usd">1300000000</nbix:PotentialMilestonePayments>
    <nbix:PotentialMilestonePayments
      contextRef="i26b03ed42a86426fa271e7a51e9a3975_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTYwMTc_ee8ca2a4-e0ee-411a-ac62-716983c5468e"
      unitRef="usd">75000000</nbix:PotentialMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id08aaa35e1ac4e31a43d685f09135c6e_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjE5OTAyMzI4MjM1Nw_89e22f71-1bc9-42df-b248-9c627cd8555a"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nbix:PotentialMilestonePaymentReceipts
      contextRef="idf5acfc15e784512b7a82dc8e2d2fe95_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTg3NDE_20d64390-87b8-42f1-8048-674b5c4af6dc"
      unitRef="usd">30000000</nbix:PotentialMilestonePaymentReceipts>
    <nbix:PatentTerm
      contextRef="ic20aa02fac274005a61e03b4bc0375b0_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTg5MjY_757119b9-8572-4ac9-a271-d7ed573dded1">P10Y</nbix:PatentTerm>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6c1cfc608dd4f8f81032e9e441a7511_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjE5OTAyMzI3OTAzNg_b637f174-55eb-44c7-87cf-07f20fa0ff2a"
      unitRef="usd">5200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cfb08820e8842e1871b6c2dd2a4c189_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjE5OTAyMzI3OTA3MA_459529e2-b7c9-42f4-a343-3edf1f19cd80"
      unitRef="usd">9400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26703103080243799d2bb6d6f1b72bd4_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjE5OTAyMzI3OTA3Ng_06e62a24-862e-4b2b-81ac-3bd28b79f5fc"
      unitRef="usd">5900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i721def435135454b974f4d03651a3930_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjE5OTAyMzI3OTA1NQ_738f725f-0e68-4b6b-9e02-34e2819d7890"
      unitRef="usd">10400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nbix:PotentialMilestonePaymentReceipts
      contextRef="ib5c1bb3894ae4915b5e4726823772c30_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMTk4NDM_daad9dcf-afa4-458a-bf7f-0a3e21879304"
      unitRef="usd">366000000</nbix:PotentialMilestonePaymentReceipts>
    <nbix:PatentTerm
      contextRef="i3cfc8c33916a4939a12f81454e0c35ca_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNC9mcmFnOjA1MmU4OTVlOTkxMDRhNjU5NWVlOTA2ZmFlMzY2MjBhL3RleHRyZWdpb246MDUyZTg5NWU5OTEwNGE2NTk1ZWU5MDZmYWUzNjYyMGFfMjAwMjQ_1d7c5cea-dcd0-4fc1-ad2c-87221e26d618">P10Y</nbix:PatentTerm>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTc5NQ_38a65841-17ff-4c7a-82d1-b64daf593daf">Debt Securities&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;491.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;266.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;563.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, our security portfolio consisted of 166 debt securities available-for-sale, including 164 such securities that were in an unrealized loss position but of high credit quality. Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recognized as of June&#160;30, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of June&#160;30, 2022, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;403.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;464.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivables on debt securities available-for-sale totaled $2.7 million and $2.2 million, respectively, as of June&#160;30, 2022 and December&#160;31, 2021. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during the six months ended June&#160;30, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTc5Ng_3a9c254e-06a8-4c3b-917a-e8d379769a06">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss) and fair value of debt securities available-for-sale, aggregated by major security type and contractual maturity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Unrealized &lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0 to 1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;491.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;266.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1 to 3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;405.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;563.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia1724975ad3a44d5aafd1acb6e95ee7f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi0zLTEtMS03NTM0MQ_f59e749c-5e1e-4d1d-8db3-4cda978c1cdf"
      unitRef="usd">78200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia1724975ad3a44d5aafd1acb6e95ee7f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi01LTEtMS03NTM0MQ_69b715f4-06a8-4cf1-8ef5-91e9bf65477d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia1724975ad3a44d5aafd1acb6e95ee7f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi03LTEtMS03NTM0MQ_a78cf5fb-1efe-4811-9ae8-eb0ee0dcb587"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia1724975ad3a44d5aafd1acb6e95ee7f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi05LTEtMS03NTM0MQ_08d298fd-3286-419a-a3a4-dbfe15786526"
      unitRef="usd">77800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3e3fa10d15714457a50f9425cd51126e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi0xMS0xLTEtNzUzNDE_33987c00-a0be-42bc-9685-f9c60c78ca93"
      unitRef="usd">204800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3e3fa10d15714457a50f9425cd51126e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi0xMy0xLTEtNzUzNDE_d7775508-bb1c-4362-a5e8-780e342b5795"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3e3fa10d15714457a50f9425cd51126e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi0xNS0xLTEtNzUzNDE_bc2b57ee-3313-4a60-a990-e3cd53993bb5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e3fa10d15714457a50f9425cd51126e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMi0xNy0xLTEtNzUzNDE_68c00316-386f-4590-ac1b-f27b21a8c2fc"
      unitRef="usd">204800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia968122986d748ccba38b5b654f41190_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy0zLTEtMS03NTM0MQ_d89093d5-ae5e-4f17-96bd-8dca96ee62cf"
      unitRef="usd">213300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia968122986d748ccba38b5b654f41190_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy01LTEtMS03NTM0MQ_b8c79b5e-a5bb-4a20-b520-7656150be63e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia968122986d748ccba38b5b654f41190_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy03LTEtMS03NTM0MQ_5a79a771-217e-47b6-83db-6fb8436cd527"
      unitRef="usd">2700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia968122986d748ccba38b5b654f41190_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy05LTEtMS03NTM0MQ_00ce52ea-2bc7-4048-b037-89c159254fca"
      unitRef="usd">210600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibc36e662e8904155b5ef697ff21e9aec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy0xMS0xLTEtNzUzNDE_de28c5cf-d563-4398-88e0-799cbb4dcf98"
      unitRef="usd">128200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibc36e662e8904155b5ef697ff21e9aec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy0xMy0xLTEtNzUzNDE_4fd4e455-a1be-40ab-9fda-941980eaf9ea"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibc36e662e8904155b5ef697ff21e9aec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy0xNS0xLTEtNzUzNDE_fcff4a07-61c2-4c2c-929c-0f7bfd383496"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc36e662e8904155b5ef697ff21e9aec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfMy0xNy0xLTEtNzUzNDE_21c977bc-8db5-4de9-a9d4-c7975f71743f"
      unitRef="usd">128100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i20cfedabe3c94d5bad4df94bc450895e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC0zLTEtMS03NTM0MQ_fe7f8d3b-6093-4ba1-b087-42393006a4c8"
      unitRef="usd">199800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i20cfedabe3c94d5bad4df94bc450895e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC01LTEtMS03NTM0MQ_1947c669-1efd-401e-a16f-176a81548976"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i20cfedabe3c94d5bad4df94bc450895e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC03LTEtMS03NTM0MQ_7cbe383f-77f1-450a-bb4d-0de07ef33137"
      unitRef="usd">3200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20cfedabe3c94d5bad4df94bc450895e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC05LTEtMS03NTM0MQ_aa2248aa-3200-4901-b487-e07dbba5bf28"
      unitRef="usd">196600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3d2144d7b33a4ad9aadec72dd35693ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC0xMS0xLTEtNzUzNDE_26581310-5b2d-4d13-aa8e-6ef3e3b6d9f7"
      unitRef="usd">37600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3d2144d7b33a4ad9aadec72dd35693ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC0xMy0xLTEtNzUzNDE_422cb335-984b-44f1-a6fa-0ac05235003d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3d2144d7b33a4ad9aadec72dd35693ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC0xNS0xLTEtNzUzNDE_124a0d6f-d2ca-4b67-9eb6-f654fc2d2559"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d2144d7b33a4ad9aadec72dd35693ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNC0xNy0xLTEtNzUzNDE_032f2eae-be41-4c94-b85e-28592628b86a"
      unitRef="usd">37600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibd5d17a30ac7439c9cd69e44e7d10155_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS0zLTEtMS03NTM0MQ_76df2971-d5bb-4dc3-85a0-fdbda38ab63a"
      unitRef="usd">491300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibd5d17a30ac7439c9cd69e44e7d10155_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS01LTEtMS03NTM0MQ_945861ef-65d9-4860-883b-b2e2262f7bf9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibd5d17a30ac7439c9cd69e44e7d10155_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS03LTEtMS03NTM0MQ_c17ddd38-43be-402d-a82e-b44e65391a25"
      unitRef="usd">6300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd5d17a30ac7439c9cd69e44e7d10155_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS05LTEtMS03NTM0MQ_5fbc6f41-b1a1-46e3-822d-3032f206071c"
      unitRef="usd">485000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic173cd64901047748e412993eb622ad8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS0xMS0xLTEtNzUzNDE_2eb4a347-0f57-488e-8bca-9dd03f9f169d"
      unitRef="usd">370600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic173cd64901047748e412993eb622ad8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS0xMy0xLTEtNzUzNDE_3ed8ed00-f115-47ec-a1a6-60f459bbcfe9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic173cd64901047748e412993eb622ad8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS0xNS0xLTEtNzUzNDE_dc076b56-cc4f-4e1f-833f-f9e1ab769887"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic173cd64901047748e412993eb622ad8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNS0xNy0xLTEtNzUzNDE_64d47e16-e95a-4c93-ab09-84db309460eb"
      unitRef="usd">370500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8752290fc66f4c8db3353da827e19de9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy0zLTEtMS03NTM0MQ_86182ef0-ece6-41e5-951b-904ee29b9226"
      unitRef="usd">266800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8752290fc66f4c8db3353da827e19de9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy01LTEtMS03NTM0MQ_fd76b88a-aff1-4d08-8e94-67884e6b6b8c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8752290fc66f4c8db3353da827e19de9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy03LTEtMS03NTM0MQ_95543c29-9dfc-41fd-ab4d-e69b5e2238f0"
      unitRef="usd">5600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8752290fc66f4c8db3353da827e19de9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy05LTEtMS03NTM0MQ_7e255f62-8646-4886-91e4-2bd0a99ae030"
      unitRef="usd">261200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaf0e1c77adff4ec88d625c49c6294e39_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy0xMS0xLTEtNzUzNDE_8e7c8138-78f1-4fa5-bf95-5d12514a248f"
      unitRef="usd">358900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaf0e1c77adff4ec88d625c49c6294e39_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy0xMy0xLTEtNzUzNDE_05d39dd2-4c57-4211-a215-405ec340fc6a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaf0e1c77adff4ec88d625c49c6294e39_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy0xNS0xLTEtNzUzNDE_e7b88e33-cc1e-4f0b-baff-afc2a20a4a1a"
      unitRef="usd">1500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf0e1c77adff4ec88d625c49c6294e39_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfNy0xNy0xLTEtNzUzNDE_7862a7e1-1186-4668-9cc9-16f4ff53503a"
      unitRef="usd">357400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if7d162d0857b48afb064eef3b8599c86_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC0zLTEtMS03NTM0MQ_dd48b0d8-1871-48bd-98b3-3e338afc186d"
      unitRef="usd">148700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if7d162d0857b48afb064eef3b8599c86_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC01LTEtMS03NTM0MQ_5437333d-ebc1-411e-93f9-b4a8a4e56674"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if7d162d0857b48afb064eef3b8599c86_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC03LTEtMS03NTM0MQ_ba50d622-0661-48c3-97cb-dc0c888c5093"
      unitRef="usd">4700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if7d162d0857b48afb064eef3b8599c86_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC05LTEtMS03NTM0MQ_284f05a2-78cc-4bad-b8e1-4f26f808fcb6"
      unitRef="usd">144000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9bcedbc2244f433299e4bcb31bd4bd37_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC0xMS0xLTEtNzUzNDE_25428597-349b-44c0-894c-659066e3cbaf"
      unitRef="usd">204300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9bcedbc2244f433299e4bcb31bd4bd37_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC0xMy0xLTEtNzUzNDE_dc747cfc-ab5b-486d-b474-57fe554067de"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9bcedbc2244f433299e4bcb31bd4bd37_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC0xNS0xLTEtNzUzNDE_1db57b03-0f2b-45d0-858d-2cf6594a4249"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9bcedbc2244f433299e4bcb31bd4bd37_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOC0xNy0xLTEtNzUzNDE_2a688d35-fa49-4db9-af6a-12b3e001a75b"
      unitRef="usd">203300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7df34d9c3e404caa9a985cda59b147ed_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS0zLTEtMS03NTM0MQ_1c7352c0-0172-4441-952c-a18364f6264d"
      unitRef="usd">415500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7df34d9c3e404caa9a985cda59b147ed_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS01LTEtMS03NTM0MQ_feb38e9e-c1dd-4547-b47d-94d0f2f56cfd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7df34d9c3e404caa9a985cda59b147ed_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS03LTEtMS03NTM0MQ_2b9c99a5-eb50-423a-9faf-35195114a930"
      unitRef="usd">10300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7df34d9c3e404caa9a985cda59b147ed_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS05LTEtMS03NTM0MQ_db95220b-6da3-4639-8fe1-3b16fac6265b"
      unitRef="usd">405200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3b67814da34d4da988b4bf57d0e478e6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS0xMS0xLTEtNzUzNDE_d0fd0536-bd11-4eef-8eb3-502c0403aa5c"
      unitRef="usd">563200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3b67814da34d4da988b4bf57d0e478e6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS0xMy0xLTEtNzUzNDE_3df0d800-f502-4882-a8ad-36bed979eafc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3b67814da34d4da988b4bf57d0e478e6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS0xNS0xLTEtNzUzNDE_1b67a646-dff7-4683-b274-74c2d277ebd6"
      unitRef="usd">2500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b67814da34d4da988b4bf57d0e478e6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOmZlMjYzZmFlMDk1YjQ0MjVhNWU3N2RjMjM3OTlmNjliL3RhYmxlcmFuZ2U6ZmUyNjNmYWUwOTViNDQyNWE1ZTc3ZGMyMzc5OWY2OWJfOS0xNy0xLTEtNzUzNDE_8af42e20-cddd-4ba8-a214-6355d152bb2c"
      unitRef="usd">560700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMzIw_836bcec0-c7ea-461f-9940-0f45fc395773"
      unitRef="security">166</nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMzY5_35abdd10-5ecf-43e8-ba33-35d4da1ff858"
      unitRef="security">164</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTc5Mg_4c58f46a-93e5-4272-8905-49d7b45ecd79">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of June&#160;30, 2022, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;403.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;464.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents debt securities available-for-sale that were in an unrealized loss position as of December&#160;31, 2021, aggregated by major security type and length of time in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMi0xLTEtMS03NTM0MQ_e7bdd20c-4bb3-4de7-886e-50dc9fff1f28"
      unitRef="usd">61000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMi0zLTEtMS03NTM0MQ_2c5125ec-0bca-421b-920f-c58e48250918"
      unitRef="usd">400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMi01LTEtMS03NTM0MQ_fea69c13-46d3-4c99-b1f0-7d662ce9cfdc"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMi03LTEtMS03NTM0MQ_d031c557-4c40-4406-8d87-ff0297e73ead"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMi05LTEtMS03NTM0MQ_b49d9949-66cf-4914-8699-4a9317991186"
      unitRef="usd">61000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMi0xMS0xLTEtNzUzNDE_87eb26b0-9274-4547-9173-d5e83ea1e279"
      unitRef="usd">400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="id4cdb346b995405d841286aaa096490d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMy0xLTEtMS03NTM0MQ_c14dac74-a594-459e-96aa-0de79f1613af"
      unitRef="usd">403800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id4cdb346b995405d841286aaa096490d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMy0zLTEtMS03NTM0MQ_fd8c69e5-83e2-46fc-b915-36331d99362e"
      unitRef="usd">7500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="id4cdb346b995405d841286aaa096490d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMy01LTEtMS03NTM0MQ_2ae40d4f-7e1b-46c0-a021-5f9609750700"
      unitRef="usd">60800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="id4cdb346b995405d841286aaa096490d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMy03LTEtMS03NTM0MQ_20acce1f-567c-49c1-9a49-26ce280372f0"
      unitRef="usd">800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="id4cdb346b995405d841286aaa096490d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMy05LTEtMS03NTM0MQ_c60e3abf-9854-4ecb-9a9f-944f2c03d1d4"
      unitRef="usd">464600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="id4cdb346b995405d841286aaa096490d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfMy0xMS0xLTEtNzUzNDE_44a26858-fd7c-4ace-8b3a-eef2e1014885"
      unitRef="usd">8300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfNC0xLTEtMS03NTM0MQ_e95801ae-c19d-405e-ae71-69ab926e8cef"
      unitRef="usd">329100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfNC0zLTEtMS03NTM0MQ_a6108789-13f8-4761-ac5b-01e53590c8d2"
      unitRef="usd">7400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfNC01LTEtMS03NTM0MQ_eb2f2aef-4925-4c78-b5d6-a146a9bfbd06"
      unitRef="usd">11500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfNC03LTEtMS03NTM0MQ_9b59a1ac-eca5-4ae0-9f3c-171f6011dff3"
      unitRef="usd">500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfNC05LTEtMS03NTM0MQ_1eec3c96-06a2-42bd-a9b1-2bf1d3464b28"
      unitRef="usd">340600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjY0ZjA2ZDQxYzAxYTQyMTY5Mzg4MjlkYWRhZWI3Y2FjL3RhYmxlcmFuZ2U6NjRmMDZkNDFjMDFhNDIxNjkzODgyOWRhZGFlYjdjYWNfNC0xMS0xLTEtNzUzNDE_06cf6cfc-a150-475b-b4ec-7ad71320fc74"
      unitRef="usd">7900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMi0xLTEtMS03NTM0MQ_516a50d4-29f4-4f86-aee4-855307436820"
      unitRef="usd">428600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMi0zLTEtMS03NTM0MQ_d38bd67e-6d10-4fa6-8f61-bb9e98fd0770"
      unitRef="usd">1600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMi01LTEtMS03NTM0MQ_3b052b89-5c30-4143-a74a-57c5ad1ab5f7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMi03LTEtMS03NTM0MQ_d15abf91-ea47-4626-8b5f-b1a18921f06b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMi05LTEtMS03NTM0MQ_80c07f80-8fac-478e-b31a-aee4164c6f77"
      unitRef="usd">428600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMi0xMS0xLTEtNzUzNDE_e4359b47-561f-484c-aa9a-4fc8469a3e3d"
      unitRef="usd">1600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMy0xLTEtMS03NTM0MQ_9ce9730c-66e7-4400-bfda-7b51c45ed1a2"
      unitRef="usd">230500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMy0zLTEtMS03NTM0MQ_6b590329-81ce-45bd-9968-a1fe4ca0ff29"
      unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMy01LTEtMS03NTM0MQ_7d334113-2ffb-47b0-8f00-d3b29cffd8ee"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMy03LTEtMS03NTM0MQ_84ffe46c-32f2-4b56-a2b8-f54f7c878f82"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMy05LTEtMS03NTM0MQ_3858ca98-47a5-4e51-812f-d2dd1e433275"
      unitRef="usd">230500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RhYmxlOjFhMTRjYWM1NDVmNjQ3YzZhM2ZmNmFjOTdjMGI0OTk1L3RhYmxlcmFuZ2U6MWExNGNhYzU0NWY2NDdjNmEzZmY2YWM5N2MwYjQ5OTVfMy0xMS0xLTEtNzUzNDE_848b54f6-378b-4547-b60e-49f962017943"
      unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:InterestReceivableCurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTI2MA_6e1fd68f-015d-41ba-a033-fbb2b179d59b"
      unitRef="usd">2700000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTI2Nw_16cc8dec-10ce-4b99-9a42-9a05a64442fb"
      unitRef="usd">2200000</us-gaap:InterestReceivableCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTcwOA_1f07f627-7b35-4859-9989-5e834278ecae"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl8zNy9mcmFnOjBmM2U5OGNhMDgyYjQ0YzU4YWU0ZDYwNzFmZThmZDI3L3RleHRyZWdpb246MGYzZTk4Y2EwODJiNDRjNThhZTRkNjA3MWZlOGZkMjdfMTcwOA_fd897c09-cefd-486b-b90b-9ca8b5b62666"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RleHRyZWdpb246YzFiYTIxZTBiOTdmNDM0NzhhY2Q3MGYwZDY0NDgyY2JfMzA1OA_79f3a821-5f22-4250-956f-39825dedc2c5">Fair Value Measurements&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of investments, which were measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;471.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;471.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,145.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;890.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,338.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;396.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;931.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gain included in earnings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Unrealized gains and losses on restricted equity security investments were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) In the first quarter of 2022, our equity security investment in Voyager was transferred from Level 3 to Level 1 as the associated holding period restriction expired.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RleHRyZWdpb246YzFiYTIxZTBiOTdmNDM0NzhhY2Q3MGYwZDY0NDgyY2JfMzA1OQ_270ff8b9-620e-4d71-90bf-5ceeb098b2b7">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RleHRyZWdpb246YzFiYTIxZTBiOTdmNDM0NzhhY2Q3MGYwZDY0NDgyY2JfMzA1NQ_3a830e1a-5228-425b-9376-716b89148e9d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of investments, which were measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;471.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;471.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,145.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;890.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,338.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;396.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;931.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:Investments
      contextRef="i4ecf9c7bbfe243a89adac1ac817f3336_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC0xLTEtMS03NTM0MQ_66ed7db0-1d18-49d0-903d-f8a918dcf936"
      unitRef="usd">163300000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie091570b8c7e468aaa662efd674b1a48_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC0zLTEtMS03NTM0MQ_246bb5ba-eec7-42df-b884-6f257326d652"
      unitRef="usd">163300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i38c4567a749e4031aed667e267ff71cf_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC01LTEtMS03NTM0MQ_5dee0094-5860-4a17-85ed-cda18f893166"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i67109db4be9c4ba1bdead9f009154aed_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC03LTEtMS03NTM0MQ_268109b6-dcdd-4c56-a3a2-bee7ccbd12ae"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ia2bfb40cca13406fa0b41700ae0ee8fe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC05LTEtMS03NTM0MQ_9ec2aeaa-7a09-48b8-8704-a51a4f00197b"
      unitRef="usd">340800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i56225d1fd9af4788a6c4c2c401b49441_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC0xMS0xLTEtNzUzNDE_552f3f9f-7f59-446c-a37d-e8cd424e41b5"
      unitRef="usd">340800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib836ccb73c334b1e92c3bb0032674ed2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC0xMy0xLTEtNzUzNDE_d339c9a6-1769-445e-967d-66f3ca1543f0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i56223020056d47c38dbea1cc503a767f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNC0xNS0xLTEtNzUzNDE_0784bf18-52ab-47d4-88de-a83f1e95c7c0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i3bf20361175e48e8a2b61d38d6483435_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi0xLTEtMS03NTM0MQ_ffa4a497-7a51-4bf2-9018-4e972a0caaff"
      unitRef="usd">7800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3d34c798b0c047d18064663be75d6f59_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi0zLTEtMS03NTM0MQ_1d51238a-2bbc-4d96-baa2-3b31e1dd4fed"
      unitRef="usd">7800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i578731c40e2a43fd9bd0b849e2773a25_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi01LTEtMS03NTM0MQ_5b2e2862-57b6-4e8f-9e43-5ea6aa44f35d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2e334b57cf1645dca4bb9f652d8b8ebd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi03LTEtMS03NTM0MQ_a113385d-ff61-44a7-b6d8-14200c95a9b5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i53bbe7b73503454da09d5f5c6dc24da1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi05LTEtMS03NTM0MQ_bd19b22a-210b-42e5-a0b2-2484efc4da7b"
      unitRef="usd">3200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3a7d2babfc2941b297b24e9e5e8a7958_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi0xMS0xLTEtNzUzNDE_f8ce8e71-7c8f-4f77-b661-52c7b42bcb77"
      unitRef="usd">3200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3edac7da69b94cd794ccfbce890c2b19_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi0xMy0xLTEtNzUzNDE_20df762d-0f93-405a-b993-ed912499d6ac"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie155cdd1531a43a589fe6b7ea1553a8d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfNi0xNS0xLTEtNzUzNDE_2ea65b42-981c-4428-a505-ad9954b7a9cf"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i73e9ff90e3d945f48f05c03731be0dea_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC0xLTEtMS03NTM0MQ_3b209379-b264-4ac6-ac1e-017da9b6e542"
      unitRef="usd">77800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i00d60ef478c64a6aa6e2b15688f36c19_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC0zLTEtMS03NTM0MQ_30ad2a27-2275-4f1b-ab34-d423ee2a2b04"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie71d87a7ca30406082e35c819e1436ed_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC01LTEtMS03NTM0MQ_d7bad3f9-ceb6-4e4c-8a09-f9321228a88e"
      unitRef="usd">77800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8110a30289e34b7b9625883f2787fc8a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC03LTEtMS03NTM0MQ_cf4501bf-e837-4615-8b30-1325550d4c85"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="id542276cdcda416ab9e520eb0c59e6b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC05LTEtMS03NTM0MQ_0fb89af2-1a0a-4646-9c39-ac2116e1c417"
      unitRef="usd">204800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4e52574305944b99802e51d55304a886_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC0xMS0xLTEtNzUzNDE_bb524b47-ba30-4995-bb47-f79a6f5af44d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i93a9c71abed34ec1b434462a578f36c8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC0xMy0xLTEtNzUzNDE_5e03f842-7e81-4282-94ac-e3e6f89364a2"
      unitRef="usd">204800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifc6fd4b26ceb4e1b95da9a0661d58688_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOC0xNS0xLTEtNzUzNDE_d312f198-025a-4ef2-bb88-05903af5cc8d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="id4cdb346b995405d841286aaa096490d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS0xLTEtMS03NTM0MQ_00837eed-bbfb-4e11-9359-84440530f64a"
      unitRef="usd">471800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id80f2f492d604d77ae916ea5296d3824_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS0zLTEtMS03NTM0MQ_2a48c8b5-ae71-426b-ac14-9c0264bfc6c5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibfb55cdc59344e51950ad5eb6569c231_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS01LTEtMS03NTM0MQ_e0365fd2-0583-4b91-b609-afdbdb71f8a9"
      unitRef="usd">471800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iac5f50efda0b428ea5e117442266f762_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS03LTEtMS03NTM0MQ_f4a1c70d-7362-4839-b0db-24597718631a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i074a75852b8a4e13bae6f329be3373f7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS05LTEtMS03NTM0MQ_2b34324c-99fb-4b87-9b25-337d5b0307c2"
      unitRef="usd">485500000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0a9a8a35647d496daedc583782304e30_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS0xMS0xLTEtNzUzNDE_842bacea-0af1-4228-b856-b218a72140cd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9487e38c52d9410798197fe77cd60f57_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS0xMy0xLTEtNzUzNDE_8ac62db3-76df-470a-b1c7-764e8481617a"
      unitRef="usd">485500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i74a9046e38e0432d9b62315b9af06dad_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfOS0xNS0xLTEtNzUzNDE_c06bfbff-a0f5-406b-80fc-32a9e31799e5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ia962a94e2b0e4f53ada6ae2420a32e49_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtMS0xLTEtNzUzNDE_36bc928d-ad01-42b1-aba4-f9b4a3ff4ad2"
      unitRef="usd">340600000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6d9e4bf673604e399b7bafea5de77c4a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtMy0xLTEtNzUzNDE_4e84b370-7336-4391-8b60-a1853a07376d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib0d0694197d34f049fae415dfd7cef26_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtNS0xLTEtNzUzNDE_4172c6cf-fe7a-43d7-bf93-5b4054512b2d"
      unitRef="usd">340600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9e3ff765407f4755bfb5dc08e8b68c7f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtNy0xLTEtNzUzNDE_70b498a8-2d66-4971-b91a-1c22493116a6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i546d0ef2cc6f44b7b69497d56e3e8162_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtOS0xLTEtNzUzNDE_5d44b210-02ae-497f-bab0-3aab830a8e6d"
      unitRef="usd">240900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i37fab9ec8504467e986c6cfccf616c70_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtMTEtMS0xLTc1MzQx_8108ff14-bac2-433f-867b-319e21e93a66"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i123fc2a261774a52826809562d82f303_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtMTMtMS0xLTc1MzQx_4c951eda-e6fb-4542-9bad-78b305644db5"
      unitRef="usd">240900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i84f8c5fe309e43cf85287198b3684b1f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTAtMTUtMS0xLTc1MzQx_891d3c13-f7ee-44fe-9f4b-5fd0bb6060d7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i3f432d4ebd4d4bcd821e1de57052b96d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItMS0xLTEtNzUzNDE_ea27e64d-f99c-4811-8e75-e8bc2ee31b9c"
      unitRef="usd">83800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i36adfd64e3fc494ba2d120614d619968_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItMy0xLTEtNzUzNDE_251aa21c-9693-42b8-84e0-132681c94fdf"
      unitRef="usd">83800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ied205516acc24818a8843666669b4299_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItNS0xLTEtNzUzNDE_9aeb8775-96e1-42ae-80fa-4fd83d04e3b0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id43fcc32d6374531b9d90dc9c1ddd0c6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItNy0xLTEtNzUzNDE_9190b4ab-1808-4f94-82d1-ef78f43e4120"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i013f9e5d35d54ee8bb4f7e21d12111c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItOS0xLTEtNzUzNDE_0dc48d1c-7f95-4366-9da2-7c887b4e6874"
      unitRef="usd">63700000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib1f28d0e9745496a9b27303558bbcf74_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItMTEtMS0xLTc1MzQx_a332cdef-08ad-4129-bcaa-6959f5bc98ea"
      unitRef="usd">52700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifcbeb7bb580346078bdfa5dea238778a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItMTMtMS0xLTc1MzQx_3bea0510-0a09-4add-8aab-457705e850b5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i92d2e80d30204b05a36b4e40d614504c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTItMTUtMS0xLTc1MzQx_d1976267-05b0-4f83-b6e8-5e3e1cbd70e5"
      unitRef="usd">11000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtMS0xLTEtNzUzNDE_2b623c05-4915-4a74-97b3-834e6afd7742"
      unitRef="usd">1145100000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i59e9b7c8721845489d2a7f16466d93aa_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtMy0xLTEtNzUzNDE_428661c2-46e3-4060-9d81-a792549820a6"
      unitRef="usd">254900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i908c9a1b5d0e454fb77ebdb1a35749ba_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtNS0xLTEtNzUzNDE_46477c69-4b15-4374-a83b-6c17802ba290"
      unitRef="usd">890200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i25d1241a853a41268cccdaac0eae9a28_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtNy0xLTEtNzUzNDE_9a748e0f-a941-4698-be08-40011e6a92d8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtOS0xLTEtNzUzNDE_11c44f8f-2bac-4d51-9891-582b12db426d"
      unitRef="usd">1338900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i05b6c8a59df04fb3945d4e66bc2c822d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtMTEtMS0xLTc1MzQx_c3b00ebb-6a40-4272-8a85-de63cac67dab"
      unitRef="usd">396700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia631a5398e544dd4908958402f41dc86_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtMTMtMS0xLTc1MzQx_330618b5-42f0-4797-ba6a-0b9bbe8a9b24"
      unitRef="usd">931200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2e1d5afb5a0c4854bd3eaac9022c5921_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjEwZTU5NjM1YmNiODQ3YzJiMjQzOGExN2Y2OWM1NDM5L3RhYmxlcmFuZ2U6MTBlNTk2MzViY2I4NDdjMmIyNDM4YTE3ZjY5YzU0MzlfMTMtMTUtMS0xLTc1MzQx_80c23124-7dc7-4d8b-8e21-89fbf132377d"
      unitRef="usd">11000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RleHRyZWdpb246YzFiYTIxZTBiOTdmNDM0NzhhY2Q3MGYwZDY0NDgyY2JfMzA1Ng_be7e3869-8f35-424b-b791-267c07048a46">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of equity security investments which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gain included in earnings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Unrealized gains and losses on restricted equity security investments were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) and are included in other income (expense), net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) In the first quarter of 2022, our equity security investment in Voyager was transferred from Level 3 to Level 1 as the associated holding period restriction expired.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ia7e2006bc26e4660a1ce0449ce12fef8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfMi0xLTEtMS03NTM0MQ_b93ec4ae-49ce-4560-a508-01f2f37ee027"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i621ed28665cd4c74accdf1592a8116ee_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfMi0zLTEtMS03NTM0MQ_660eea09-64be-4139-a9d1-25cab9ea2e85"
      unitRef="usd">38900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i92d2e80d30204b05a36b4e40d614504c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfMi01LTEtMS03NTM0MQ_c47ac9f9-c04c-4a7d-9433-c5bae9a584a8"
      unitRef="usd">11000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="ibb7802d7f08044b48c8621fbe04086f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfMi03LTEtMS03NTM0MQ_b347f9b8-9185-4ebf-9ecc-bc1450e5bd10"
      unitRef="usd">38200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="ife94fc300dd145afad28237e20171bac_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNC0xLTEtMS03NTM0MQ_cedf3ce1-93d5-40b8-9a8f-67f5de3090c4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i05896d4787104c06a015bb730c5b5e50_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNC0zLTEtMS03NTM0MQ_36609465-9612-4efc-9fd2-003df9472a5d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="idd7bdc03323d43ba8e38762cd7fca030_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNC01LTEtMS03NTM0MQ_88c60dcb-fc85-4a14-bd1f-ac562f370973"
      unitRef="usd">20800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i9ed7ddd2a42348d1a2f7fec8628844f9_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNC03LTEtMS03NTM0MQ_4e9b160b-1f75-4155-b842-1e63049d0099"
      unitRef="usd">700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="ife94fc300dd145afad28237e20171bac_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNS0xLTEtMS03NTM0MQ_8dc19c0a-2dbf-41bc-b63c-9f716a75258a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i05896d4787104c06a015bb730c5b5e50_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNS0zLTEtMS03NTM0MQ_7f977e3d-8b28-480e-820c-c8a5645748cf"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="idd7bdc03323d43ba8e38762cd7fca030_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNS01LTEtMS03NTM0MQ_26b2d824-02fc-46d4-a33b-2a9c292d58e2"
      unitRef="usd">31800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="i9ed7ddd2a42348d1a2f7fec8628844f9_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNS03LTEtMS03NTM0MQ_6323e91a-d107-4bd1-ac86-4f75eafed5df"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="id43fcc32d6374531b9d90dc9c1ddd0c6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNi0xLTEtMS03NTM0MQ_1aee6414-f37e-4863-9241-875a11a3775d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="icfbdc30b238f4e70816874e44b5711ea_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNi0zLTEtMS03NTM0MQ_647dac38-cc20-442f-8935-6c7619371e0c"
      unitRef="usd">38900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="id43fcc32d6374531b9d90dc9c1ddd0c6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNi01LTEtMS03NTM0MQ_db465987-15b5-49f9-afb4-98e2d1fb52b8"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="icfbdc30b238f4e70816874e44b5711ea_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80MC9mcmFnOmMxYmEyMWUwYjk3ZjQzNDc4YWNkNzBmMGQ2NDQ4MmNiL3RhYmxlOjA4NGFhMzM3NWIxOTRmMTJhYjU5N2U5YzhhZWI3MzlhL3RhYmxlcmFuZ2U6MDg0YWEzMzc1YjE5NGYxMmFiNTk3ZTljOGFlYjczOWFfNi03LTEtMS03NTM0MQ_ba58a3ad-18a7-456c-b4e9-bc553a3b1983"
      unitRef="usd">38900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RleHRyZWdpb246ODAwZTY1YjI2YTljNDkzM2EzOWRjZDNiYmQ3YTY0MjZfNjI_ecf01704-c1a6-4c72-a40e-f892a1aec2ac">Inventories&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RleHRyZWdpb246ODAwZTY1YjI2YTljNDkzM2EzOWRjZDNiYmQ3YTY0MjZfNjA_b60773bb-ed63-4888-8455-b6887501732b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfMS0xLTEtMS03NTM0MQ_310c8e22-b37d-4c7c-890f-18a617684a82"
      unitRef="usd">8000000.0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfMS0zLTEtMS03NTM0MQ_4c2a781d-7de6-4bcf-a1d8-ec209128a39c"
      unitRef="usd">11200000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfMi0xLTEtMS03NTM0MQ_a824f259-256b-4f6d-a846-beabfa7bb2f4"
      unitRef="usd">3400000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfMi0zLTEtMS03NTM0MQ_36718f77-5201-4beb-94a6-553e5fe15461"
      unitRef="usd">3600000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfMy0xLTEtMS03NTM0MQ_de380db6-d6bd-4a79-bfcb-7dfe20fbfb36"
      unitRef="usd">17900000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfMy0zLTEtMS03NTM0MQ_997e9a2a-850a-427b-a63d-4c0e8acdf65b"
      unitRef="usd">15700000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfNC0xLTEtMS03NTM0MQ_8f535f5e-f8ce-4eef-9224-d014af9dc086"
      unitRef="usd">29300000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ic0112165dc8043d29e138802b05038e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80My9mcmFnOjgwMGU2NWIyNmE5YzQ5MzNhMzlkY2QzYmJkN2E2NDI2L3RhYmxlOjkwNmI0ZGIzODI5MzRkMWZiMDU2OThjYzNkM2VkMDI1L3RhYmxlcmFuZ2U6OTA2YjRkYjM4MjkzNGQxZmIwNTY5OGNjM2QzZWQwMjVfNC0zLTEtMS03NTM0MQ_46f583ed-7dbc-4e3b-815c-62cb399409c7"
      unitRef="usd">30500000</us-gaap:InventoryNet>
    <nbix:RestrictedCashTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RleHRyZWdpb246OWMyMjE3NWUyMzFjNDQ1YWFmM2I1OGRkZTJkMzkwOWJfMjE3_35ef6dec-d969-4718-959c-2730729b64f7">Cash, Cash Equivalents and Restricted Cash&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;368.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbix:RestrictedCashTextBlock>
    <nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RleHRyZWdpb246OWMyMjE3NWUyMzFjNDQ1YWFmM2I1OGRkZTJkMzkwOWJfMjE4_e025ca32-d579-47e3-90e5-da26133459b0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;368.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash included in other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RhYmxlOmUyZmFjNDY0ZGRiYzRlNTNiZTY3NjFiMGVlZjdiZmQ4L3RhYmxlcmFuZ2U6ZTJmYWM0NjRkZGJjNGU1M2JlNjc2MWIwZWVmN2JmZDhfMS0xLTEtMS03NTM0MQ_f3070120-cad2-4e84-9648-75de62af347c"
      unitRef="usd">163300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RhYmxlOmUyZmFjNDY0ZGRiYzRlNTNiZTY3NjFiMGVlZjdiZmQ4L3RhYmxlcmFuZ2U6ZTJmYWM0NjRkZGJjNGU1M2JlNjc2MWIwZWVmN2JmZDhfMS0zLTEtMS03NTM0MQ_55d4690f-3b71-4dcd-9dab-d7370e678766"
      unitRef="usd">368000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RhYmxlOmUyZmFjNDY0ZGRiYzRlNTNiZTY3NjFiMGVlZjdiZmQ4L3RhYmxlcmFuZ2U6ZTJmYWM0NjRkZGJjNGU1M2JlNjc2MWIwZWVmN2JmZDhfMi0xLTEtMS03NTM0MQ_00edca9c-29b0-4518-b2ac-53e511eed6a8"
      unitRef="usd">7800000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RhYmxlOmUyZmFjNDY0ZGRiYzRlNTNiZTY3NjFiMGVlZjdiZmQ4L3RhYmxlcmFuZ2U6ZTJmYWM0NjRkZGJjNGU1M2JlNjc2MWIwZWVmN2JmZDhfMi0zLTEtMS03NTM0MQ_17d3c80a-4655-479c-80ee-ea892950bbb4"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RhYmxlOmUyZmFjNDY0ZGRiYzRlNTNiZTY3NjFiMGVlZjdiZmQ4L3RhYmxlcmFuZ2U6ZTJmYWM0NjRkZGJjNGU1M2JlNjc2MWIwZWVmN2JmZDhfMy0xLTEtMS03NTM0MQ_e593b560-3a93-41d4-a46f-cc9329f58b85"
      unitRef="usd">171100000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80Ni9mcmFnOjljMjIxNzVlMjMxYzQ0NWFhZjNiNThkZGUyZDM5MDliL3RhYmxlOmUyZmFjNDY0ZGRiYzRlNTNiZTY3NjFiMGVlZjdiZmQ4L3RhYmxlcmFuZ2U6ZTJmYWM0NjRkZGJjNGU1M2JlNjc2MWIwZWVmN2JmZDhfMy0zLTEtMS03NTM0MQ_99ca9166-d2ef-48b5-90f8-2045f86fbad2"
      unitRef="usd">371200000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjQ2MA_e2569e01-1321-4045-afe3-e0666690bfe3">Leases&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases that have commenced have terms that expire beginning 2024 through 2031 and consist of office space and research and development laboratories, including our corporate headquarters. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our operating lease right-of-use, or ROU, assets or operating lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;8, 2022, we entered into a lease agreement for a four-building campus facility to be constructed in San Diego, California, pursuant to which we also secured a six-year option for the construction of a fifth building and an option to purchase the entire campus facility, which will consist of office space and research and development laboratories, in the future. Upon completion of construction, we expect to utilize the campus facility as our new corporate headquarters. This lease has not commenced for accounting purposes. Under the terms of the lease, on a building-by-building basis, base rent will be subject to a 10-month rent abatement period following the respective lease commencement date, which dates will be determined in the future based upon achievement of substantial completion of construction with respect to each such building in the condition suitable for the installation of our furniture, fixtures, and equipment, and on which date we will record a lease liability, corresponding right-of-use asset, and begin lease expense recognition with respect to each such building. After the rent abatement period, monthly base rent will be $6 per square foot, subject to annual escalations of 3% during the initial &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMTA5OTUxMTYzMDM2OQ_4e49d25c-03ed-44eb-9e93-c4a67b6332d1"&gt;13.6-year&lt;/span&gt; lease term, which term we have the option to renew for two additional terms of five years each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our operating leases, in lieu of a cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $7.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental operating lease information for operating leases that have commenced.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents approximate non-cancelable future minimum lease payments under operating leases as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022 (6 months remaining)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less current operating lease liabilities included in other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Amounts presented in the table above exclude $17.2 million for 2024, $33.3 million for 2025, $41.9 million for 2026, and $479.7 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding
      contextRef="i7e101b09704b41349a0ec8f0acd6d9fc_D20220208-20220208"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjQ3MQ_8a6c0871-723d-4546-b1e1-4175e5b91e02">P6Y</nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding>
    <nbix:RentAbatementPeriod
      contextRef="i7e101b09704b41349a0ec8f0acd6d9fc_D20220208-20220208"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjQ3Mg_14d38738-32ea-499c-9a6c-cd6a0deedf57">P10M</nbix:RentAbatementPeriod>
    <nbix:LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot
      contextRef="i6c2a25388e8a402297637fc25af2ac23_I20220208"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMTYyNg_44924e2c-9096-4e02-b2db-a67e472d08b3"
      unitRef="usd">6</nbix:LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot>
    <nbix:AnnualRentEscalationPercentage
      contextRef="i6c2a25388e8a402297637fc25af2ac23_I20220208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMTY3OQ_f933c3e5-f623-43a0-9d1b-33fdccc897aa"
      unitRef="number">0.03</nbix:AnnualRentEscalationPercentage>
    <nbix:NumberOfRenewalOptions
      contextRef="i6c2a25388e8a402297637fc25af2ac23_I20220208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjQ2NQ_a5d6f8f0-1c95-485d-9883-9352cb7e598c"
      unitRef="renewaloption">2</nbix:NumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i6c2a25388e8a402297637fc25af2ac23_I20220208"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMTc4Nw_2e8fda68-f677-4f70-ad05-1a3811214001">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMTk3Nw_74643fd7-495a-42ec-a68a-99e2fd5cf8ac"
      unitRef="usd">7800000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjQ2Mw_abe3d14a-626e-446f-af65-c644eaaa2ec0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental operating lease information for operating leases that have commenced.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except weighted average data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfMi0xLTEtMS03NTM0MQ_eb85acb2-8463-46e2-a055-881210dc2e63"
      unitRef="usd">8200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfMi0zLTEtMS03NTM0MQ_040de5a6-6c09-41d1-a38c-64ba7f6ca632"
      unitRef="usd">7300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfMy0xLTEtMS03NTM0MQ_f5554e88-c4b8-4297-99ff-83e197d049ae"
      unitRef="usd">8200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfMy0zLTEtMS03NTM0MQ_ae1d1c09-e1b0-4676-acec-09364c06e83b"
      unitRef="usd">5500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfNi0xLTEtMS03NTM0MQ_f98febb8-0a00-42df-be46-ed3468d61da3">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfNi0zLTEtMS03NTM0MQ_99beedd9-ae76-41fe-b79e-75572c3f0273">P9Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfNy0xLTEtMS03NTM0MQ_4d91a6c4-2241-4d6c-8f4d-cddbadc0b7a9"
      unitRef="number">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia726c285fe9348d98e1aa42d192576d6_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOjRmYzdhZTlmZjliODRmYmU4YWMyNTliODIxNTczZDMwL3RhYmxlcmFuZ2U6NGZjN2FlOWZmOWI4NGZiZThhYzI1OWI4MjE1NzNkMzBfNy0zLTEtMS03NTM0MQ_1a602a5c-bdd4-4bef-b442-44a44ebe8c61"
      unitRef="number">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjQ2Ng_4ab8d0ee-df79-472c-bda6-94949cdfde0d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents approximate non-cancelable future minimum lease payments under operating leases as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022 (6 months remaining)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less current operating lease liabilities included in other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Amounts presented in the table above exclude $17.2 million for 2024, $33.3 million for 2025, $41.9 million for 2026, and $479.7 million thereafter of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfMS0xLTEtMS03NTM0MQ_74e03082-ab35-47ba-b29c-27461de0285c"
      unitRef="usd">8700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfMi0xLTEtMS03NTM0MQ_a8e8f694-f1ea-47d0-b811-02127bc17b2e"
      unitRef="usd">17900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfMy0xLTEtMS03NTM0MQ_909f78cf-93bc-4f05-8163-62575f6a7a2a"
      unitRef="usd">17400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfNC0xLTEtMS03NTM0MQ_0486affc-155f-4227-b610-b4184259a553"
      unitRef="usd">15900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfNS0xLTEtMS03NTM0MQ_b36d910b-0cf8-4246-8b87-9fa83ddb6e14"
      unitRef="usd">15700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <nbix:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfNi0xLTEtMS03NTM0MQ_24708a90-64e7-4c11-9858-4c97ec7bc03d"
      unitRef="usd">70400000</nbix:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfNy0xLTEtMS03NTM0MQ_e668b092-2d86-409e-beec-ad6841c2fc76"
      unitRef="usd">146000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfOC0xLTEtMS03NTM0MQ_26e45bb3-27a4-4c6f-8ee2-b73cd5b13192"
      unitRef="usd">29300000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfOS0xLTEtMS03NTM0MQ_e1fa2c08-e8f3-4fc3-a6c1-38c51e0a76b7"
      unitRef="usd">116700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfMTAtMS0xLTEtNzUzNDE_e3b0da59-d1e4-4abe-8f86-aba19e7b2ceb"
      unitRef="usd">17100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RhYmxlOmRhMjQ5YTZhYmMwMTQ5NGY5Yzc0MjkzMjA4ODQyNmQzL3RhYmxlcmFuZ2U6ZGEyNDlhNmFiYzAxNDk0ZjljNzQyOTMyMDg4NDI2ZDNfMTEtMS0xLTEtNzUzNDE_1f02d5eb-575c-4966-884b-20ae132d3bd8"
      unitRef="usd">99600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjI5MQ_1279d6bd-391e-48ad-ab33-c17498bc95d6"
      unitRef="usd">17200000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjMwNA_301af7f2-1d80-4a67-97b7-13c0991b457d"
      unitRef="usd">33300000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjMxNw_92d1ea37-08d0-49eb-909c-eb8e7fe52902"
      unitRef="usd">41900000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive
      contextRef="i19857cd19784459d879fae5b6542a369_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl80OS9mcmFnOjk2ZmY3ODM1N2ZhYjQzMDRiY2I4NjIxNWI5N2Y1ZmM4L3RleHRyZWdpb246OTZmZjc4MzU3ZmFiNDMwNGJjYjg2MjE1Yjk3ZjVmYzhfMjMzNA_2a941cda-8114-4cf9-93ce-cd3e020e571f"
      unitRef="usd">479700000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNzY3MA_3908bcf3-1c5c-4690-9065-d084758f383c">Convertible Senior Notes&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;2, 2017, we completed a private placement of $517.5 million in aggregate principal amount of 2.25% fixed-rate convertible senior notes due May&#160;15, 2024, or the 2024 Notes, and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 of each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with authoritative guidance in effect at the time of issuance, we were required to separately account for the liability and equity components of the 2024 Notes. The initial carrying value of the liability component of $368.3 million was calculated using a 7.50% assumed borrowing rate, which reflected the market interest rate for a similar non-convertible instrument at the date of issuance. The equity component of $149.2 million, which was treated as a discount on the liability component and amortized over the seven-year term of the 2024 Notes using the effective interest rate method, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and recorded as an increase to additional paid-in capital on the issuance date. In addition, we allocated transaction costs of $14.7 million related to the issuance of the 2024 Notes to the liability and equity components based on their relative values on the issuance date. Transaction costs attributable to the liability component were being amortized over the seven-year term of the 2024 Notes using the effective interest rate method, while transaction costs attributable to the equity component were recorded as a reduction to additional paid-in capital on the issuance date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2020, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $186.9 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment. As a result, we attributed $130.7 million of the aggregate repurchase price to the liability component based on the fair value of the liability component immediately before extinguishment. The fair value of the liability component was calculated at settlement using a discounted cash flow analysis with a discount rate of 3.37%, which was the market rate for similar notes that have no conversion rights. The difference of $56.3 million between the fair value of the aggregate consideration remitted to certain holders of the 2024 Notes and the fair value of the liability component was attributed to the reacquisition of the equity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;component and recorded as a reduction to additional paid-in capital. The carrying amount of the liability of $112.4 million at settlement was recognized as a reduction to the 2024 Notes and resulted in an $18.4 million loss on extinguishment, which we recognized in the fourth quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we adopted &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjY2OA_27a74808-cedc-4067-91c0-ce68f133d49f"&gt;ASU 2020-06&lt;/span&gt; using the modified retrospective transition method, which allowed for a cumulative-effect adjustment in the period of adoption and did not require restatement of prior period amounts. Under this transition method, the cumulative effect of the accounting change increased the carrying amount of the 2024 Notes by $42.2 million, reduced deferred tax liabilities by $9.9 million, reduced additional paid-in capital by $106.8 million, and reduced the accumulated deficit by $74.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2022, we entered into separate, privately negotiated transactions with certain holders of the 2024 Notes to repurchase $210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $279.0 million in cash. We accounted for the partial repurchase of the 2024 Notes as a debt extinguishment, which resulted in the recognition of a $70.0 million loss on extinguishment in the second quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) While the 2024 Notes were classified as a long-term liability as of June&#160;30, 2022, the future convertibility and associated balance sheet classification will be monitored at each quarterly reporting date and determined based on the market prices of our common stock during the prescribed measurement period. In the event that we have the election to redeem the 2024 Notes or the holders of the 2024 Notes have the election to convert the 2024 Notes at any time during the prescribed measurement period, the 2024 Notes would be classified as a current obligation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;464.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the interest expense of the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2024 Notes in cash upon conversion and to settle any conversion premium, calculated based on the per share volume-weighted average price for each of the 30 consecutive trading days during the observation period (as more fully described in the 2017 Indenture), in either cash or shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $1,000 principal amount and equivalent to an initial conversion price of approximately $75.92 per share, reflecting a conversion premium of approximately 42.5% above the closing price of $53.28 per share of our common stock on April&#160;26, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130% of the conversion price then in effect (equal to $98.70 as of June&#160;30, 2022) for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt"&gt;during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price (equal to $98.70 as of June&#160;30, 2022) on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt"&gt;during the&#160;five business-day period immediately after any&#160;five&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2017 Indenture) per&#160;$1,000&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt"&gt;upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt"&gt;if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change (as defined in the 2017 Indenture) occurs prior to January&#160;15, 2024, we would, in certain circumstances, increase the conversion rate for a holder who elects to convert their notes in connection with the make-whole fundamental change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness. The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2017 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default, 100% of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifa023efd07b7418a8139d17baa936118_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNzY3MQ_3c757e7a-e0d9-4aac-8292-6c6d7b55f46a"
      unitRef="usd">517500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifa023efd07b7418a8139d17baa936118_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMTEy_49b07f2e-79cb-4242-95e1-120fe697f524"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <nbix:CarryingAmountOfLiabilityComponentUponIssuance
      contextRef="ifa023efd07b7418a8139d17baa936118_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTAy_35e78912-f48c-46e5-98ca-39c1bf3e73a9"
      unitRef="usd">368300000</nbix:CarryingAmountOfLiabilityComponentUponIssuance>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTI4_b8ecbd25-9aaf-4cb3-9e16-673e06d104f2"
      unitRef="number">0.0750</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="ifa023efd07b7418a8139d17baa936118_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNjg2_7bc88231-2a44-41b7-b55d-3003322c5612"
      unitRef="usd">149200000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentTerm
      contextRef="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNzY3Mg_2463b5a0-37a0-4e2c-b5a7-dd2d5f8c746f">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ifa023efd07b7418a8139d17baa936118_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMTA2Mw_92c1c59c-d10f-408e-afd3-ac094e5bd869"
      unitRef="usd">14700000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentTerm
      contextRef="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNzY3Mw_33cae26f-ce05-4f60-8941-df58249ca858">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="id787ce82b3d34435b9e6f64183561da4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMTYxMA_2c2d8041-ded8-4925-9618-75c29ef54e88"
      unitRef="usd">136200000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="i24b6741f0df8412ca89fcbb38c28ed03_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMTY4Nw_29b5aa64-2e86-4892-a1a6-99deb3a7d29b"
      unitRef="usd">186900000</us-gaap:RepaymentsOfDebt>
    <nbix:FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment
      contextRef="i24b6741f0df8412ca89fcbb38c28ed03_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMTgwMg_3d49c0e7-2317-4733-ba5b-54a15bad91ef"
      unitRef="usd">130700000</nbix:FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i5a5baeaf4e9c48f8b60039ae0a01b8e3_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjA4NQ_9aacf96a-0d63-4fa6-a322-a7560e1d2401"
      unitRef="number">0.0337</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i24b6741f0df8412ca89fcbb38c28ed03_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjE4Mw_e154100b-0f99-4e7e-8f72-1b169228a1cf"
      unitRef="usd">56300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <nbix:CarryingAmountOfLiabilityComponentAtSettlement
      contextRef="i24b6741f0df8412ca89fcbb38c28ed03_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjQ4Mw_7ca8ae60-7ed1-420c-92e7-6c8dc8667fba"
      unitRef="usd">112400000</nbix:CarryingAmountOfLiabilityComponentAtSettlement>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i24b6741f0df8412ca89fcbb38c28ed03_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjU1OQ_03a6bd55-672e-407f-87af-1407a3334a04"
      unitRef="usd">-18400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjk3NQ_5b64e963-da74-4625-ade7-2825d656559e"
      unitRef="usd">42200000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMzAxNQ_e0a152b1-ce79-4aca-bdab-2230fddb78e0"
      unitRef="usd">-9900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMzA1Nw_c8dc538d-da09-44ab-aab9-bfe81ac74ef8"
      unitRef="usd">-106800000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8b377cc0ad4940e794a4a0f398f996ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMzEwMA_bd015d84-bb81-432d-a353-1f661e1a0e8a"
      unitRef="usd">74500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ia90120fdd18140988db29b2003f29587_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjE5OTAyMzI2NTc1NA_c438646b-7888-4f0a-a8a0-1d1ecf4ad33c"
      unitRef="usd">210800000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="id2e9c013eb7a4a48a31e064dfc261340_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjE5OTAyMzI2NTc3Ng_02a54324-112b-4bc6-9699-905118be95d7"
      unitRef="usd">279000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id2e9c013eb7a4a48a31e064dfc261340_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfMjE5OTAyMzI2NTc5Ng_732b3a3d-cb9d-45d2-a340-cfecd2089360"
      unitRef="usd">-70000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNzY3NA_d177d57f-6b71-4b42-9c88-1801f48cef2d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"&gt;_________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) While the 2024 Notes were classified as a long-term liability as of June&#160;30, 2022, the future convertibility and associated balance sheet classification will be monitored at each quarterly reporting date and determined based on the market prices of our common stock during the prescribed measurement period. In the event that we have the election to redeem the 2024 Notes or the holders of the 2024 Notes have the election to convert the 2024 Notes at any time during the prescribed measurement period, the 2024 Notes would be classified as a current obligation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the 2024 Notes as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unamortized Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leveling&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;464.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the interest expense of the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Coupon interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia90120fdd18140988db29b2003f29587_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmE2ZjA0NmJhN2MwNzRkOWE5Yzk0OGZiZjE1OWIxNTBmL3RhYmxlcmFuZ2U6YTZmMDQ2YmE3YzA3NGQ5YTljOTQ4ZmJmMTU5YjE1MGZfMi0xLTEtMS03NTM0MQ_d52f68cb-7b33-4202-964f-9c6e37199949"
      unitRef="usd">170400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="ia90120fdd18140988db29b2003f29587_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmE2ZjA0NmJhN2MwNzRkOWE5Yzk0OGZiZjE1OWIxNTBmL3RhYmxlcmFuZ2U6YTZmMDQ2YmE3YzA3NGQ5YTljOTQ4ZmJmMTU5YjE1MGZfMi0zLTEtMS03NTM0MQ_cbfcce85-cc37-4630-ac03-0f6895606b35"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ia90120fdd18140988db29b2003f29587_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmE2ZjA0NmJhN2MwNzRkOWE5Yzk0OGZiZjE1OWIxNTBmL3RhYmxlcmFuZ2U6YTZmMDQ2YmE3YzA3NGQ5YTljOTQ4ZmJmMTU5YjE1MGZfMi01LTEtMS03NTM0MQ_0a701312-d4bb-464b-8b62-0c85f9be7a2c"
      unitRef="usd">1400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ia90120fdd18140988db29b2003f29587_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmE2ZjA0NmJhN2MwNzRkOWE5Yzk0OGZiZjE1OWIxNTBmL3RhYmxlcmFuZ2U6YTZmMDQ2YmE3YzA3NGQ5YTljOTQ4ZmJmMTU5YjE1MGZfMi03LTEtMS03NTM0MQ_fbfef37c-f5a7-4f47-b982-0e6afaf2e583"
      unitRef="usd">169000000.0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ia90120fdd18140988db29b2003f29587_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmE2ZjA0NmJhN2MwNzRkOWE5Yzk0OGZiZjE1OWIxNTBmL3RhYmxlcmFuZ2U6YTZmMDQ2YmE3YzA3NGQ5YTljOTQ4ZmJmMTU5YjE1MGZfMi05LTEtMS03NTM0MQ_89aeccdb-991e-4c0e-936e-59e252cc196a"
      unitRef="usd">224800000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i168ae0643eac4fb187856eb9bb504202_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmJjZWM0NjM2YWJhOTRmN2JhNjg0NmNkZDUxZjkzZmY2L3RhYmxlcmFuZ2U6YmNlYzQ2MzZhYmE5NGY3YmE2ODQ2Y2RkNTFmOTNmZjZfMi0xLTEtMS03NTM0MQ_47196eba-334a-4a5d-8130-184b0e8d3d7a"
      unitRef="usd">381200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="i168ae0643eac4fb187856eb9bb504202_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmJjZWM0NjM2YWJhOTRmN2JhNjg0NmNkZDUxZjkzZmY2L3RhYmxlcmFuZ2U6YmNlYzQ2MzZhYmE5NGY3YmE2ODQ2Y2RkNTFmOTNmZjZfMi0zLTEtMS03NTM0MQ_96760441-90fe-4dfb-ba15-1c7be9ba6fd3"
      unitRef="usd">43200000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i168ae0643eac4fb187856eb9bb504202_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmJjZWM0NjM2YWJhOTRmN2JhNjg0NmNkZDUxZjkzZmY2L3RhYmxlcmFuZ2U6YmNlYzQ2MzZhYmE5NGY3YmE2ODQ2Y2RkNTFmOTNmZjZfMi01LTEtMS03NTM0MQ_e47122fb-b750-4577-b9f0-396d532dc160"
      unitRef="usd">2900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i168ae0643eac4fb187856eb9bb504202_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmJjZWM0NjM2YWJhOTRmN2JhNjg0NmNkZDUxZjkzZmY2L3RhYmxlcmFuZ2U6YmNlYzQ2MzZhYmE5NGY3YmE2ODQ2Y2RkNTFmOTNmZjZfMi03LTEtMS03NTM0MQ_7ec45956-ba21-408f-800b-0018105e2512"
      unitRef="usd">335100000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i168ae0643eac4fb187856eb9bb504202_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOmJjZWM0NjM2YWJhOTRmN2JhNjg0NmNkZDUxZjkzZmY2L3RhYmxlcmFuZ2U6YmNlYzQ2MzZhYmE5NGY3YmE2ODQ2Y2RkNTFmOTNmZjZfMi05LTEtMS03NTM0MQ_cb349808-4b0a-4ec7-af50-3bc37093c302"
      unitRef="usd">464700000</us-gaap:DebtInstrumentFairValue>
    <nbix:DebtInstrumentCouponInterest
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMi0xLTEtMS03NTM0MQ_d254b29c-260c-4f20-bb6b-70f52b5e3cbb"
      unitRef="usd">1800000</nbix:DebtInstrumentCouponInterest>
    <nbix:DebtInstrumentCouponInterest
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMi0zLTEtMS03NTM0MQ_57ed719e-1a6f-4c07-9dfb-b8b1841dcd34"
      unitRef="usd">1900000</nbix:DebtInstrumentCouponInterest>
    <nbix:DebtInstrumentCouponInterest
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMi01LTEtMS03NTM0MQ_6779bb7d-a666-4c1e-8b00-38952719a73a"
      unitRef="usd">4000000.0</nbix:DebtInstrumentCouponInterest>
    <nbix:DebtInstrumentCouponInterest
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMi03LTEtMS03NTM0MQ_f7f7bb46-2476-48ed-aec7-c056d564314f"
      unitRef="usd">4100000</nbix:DebtInstrumentCouponInterest>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMy0xLTEtMS03NTM0MQ_1cb6fb41-901f-4a60-85fe-2be5ab773f3d"
      unitRef="usd">400000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMy0zLTEtMS03NTM0MQ_2808555a-163a-46cf-a382-5b90b3110863"
      unitRef="usd">4300000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMy01LTEtMS03NTM0MQ_9219777f-4bc7-43f4-bc5c-1aaf887211c3"
      unitRef="usd">800000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfMy03LTEtMS03NTM0MQ_8a14177b-ffcc-4e07-86cf-d44c77913428"
      unitRef="usd">8500000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpense
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfNC0xLTEtMS03NTM0MQ_ef529daa-6e1e-4771-8ba2-753f4e2c0609"
      unitRef="usd">2200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfNC0zLTEtMS03NTM0MQ_3c7f3a28-578e-4afc-802d-033ead7c28d5"
      unitRef="usd">6200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfNC01LTEtMS03NTM0MQ_b5f087e3-742c-4df1-a780-a7b5aee263f7"
      unitRef="usd">4800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RhYmxlOjU1YTI0YjIzMTk4ZTQyN2Y4ODMyZDJhZDM1Zjg4MzJjL3RhYmxlcmFuZ2U6NTVhMjRiMjMxOThlNDI3Zjg4MzJkMmFkMzVmODgzMmNfNC03LTEtMS03NTM0MQ_5462b0a7-03c8-4b1a-b46c-e56908970b84"
      unitRef="usd">12600000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDE0Ng_42ce3d9f-af74-41c7-ba0b-9de9e6b46388"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="ibdc8838b1a0d4a7b843404626b18a02c_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDQ0MA_1400a132-63f9-46ea-ab2d-5124e908a874"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ifa023efd07b7418a8139d17baa936118_I20170502"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDUyMw_80cac108-8c57-45b7-ad73-734dd749db92"
      unitRef="usdPerShare">75.92</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <nbix:DebtInstrumentConvertibleConversionPremium
      contextRef="ifa023efd07b7418a8139d17baa936118_I20170502"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDU4Ng_1ea7e9f8-fe9c-4d8d-8377-63846eeed4c2"
      unitRef="number">0.425</nbix:DebtInstrumentConvertibleConversionPremium>
    <us-gaap:SharePrice
      contextRef="ifa023efd07b7418a8139d17baa936118_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDYxNg_c0d11bb2-690d-4b0c-a803-af5748c3fcb9"
      unitRef="usdPerShare">53.28</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDc5NA_407bd8c4-cf67-49bf-952f-6d98efdd7354"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleStockPriceTrigger
      contextRef="id38ba1f5324844d0866a8eac585463a2_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDg0Ng_736b149c-e988-4088-859d-f1d232da1e25"
      unitRef="usdPerShare">98.70</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDg3Mg_38bdcb06-72d4-4582-845f-daa2f6f7986b"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNDkyOA_42ce3d9f-af74-41c7-ba0b-9de9e6b46388"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTM3Mg_38bdcb06-72d4-4582-845f-daa2f6f7986b"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTQzNg_42ce3d9f-af74-41c7-ba0b-9de9e6b46388"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i195d26bb3f264615956bcdecaefbe331_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTU1Nw_407bd8c4-cf67-49bf-952f-6d98efdd7354"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleStockPriceTrigger
      contextRef="id38ba1f5324844d0866a8eac585463a2_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTU5NA_736b149c-e988-4088-859d-f1d232da1e25"
      unitRef="usdPerShare">98.70</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="if6357f4608a44780bb374e2677bba023_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTY1MA_a2cbda75-5604-4b9e-b6d6-2c993f5a9ee0"
      unitRef="d">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="if6357f4608a44780bb374e2677bba023_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTY5NQ_a2cbda75-5604-4b9e-b6d6-2c993f5a9ee0"
      unitRef="d">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="ibdc8838b1a0d4a7b843404626b18a02c_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTgwOA_1400a132-63f9-46ea-ab2d-5124e908a874"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice
      contextRef="if6357f4608a44780bb374e2677bba023_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNTg5OQ_ce4fea78-8e1e-4333-9fd0-f9369f26ab0e"
      unitRef="number">0.98</nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNjYyMA_4c1e12d4-5345-42c0-a9cc-738b68418552"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="ib582ecb16ea04ab68609a08a1805d570_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81Mi9mcmFnOmEzYThhYmNiMDAwMjQwOTU5NzU2M2I3YzEzMjBlNDFkL3RleHRyZWdpb246YTNhOGFiY2IwMDAyNDA5NTk3NTYzYjdjMTMyMGU0MWRfNzU2Ng_4c1e12d4-5345-42c0-a9cc-738b68418552"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RleHRyZWdpb246ZmYwNTQ2MDVjZWMyNGNkNjk5NmEwOGM2ZTI0OTcwNTdfNzQ_e39ba332-8fed-4b27-9e27-46d95ec4dd51">(Loss) Earnings per Share&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Loss) earnings per share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Loss) earnings per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Loss) earnings per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares excluded from diluted per share amounts because their effect would have been anti-dilutive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RleHRyZWdpb246ZmYwNTQ2MDVjZWMyNGNkNjk5NmEwOGM2ZTI0OTcwNTdfNzU_78cce948-c88b-4eac-b024-e94f826499b7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Loss) earnings per share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Loss) earnings per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Loss) earnings per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares excluded from diluted per share amounts because their effect would have been anti-dilutive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi0xLTEtMS03NTM0MQ_325a0431-a79d-4848-9e4a-55308f1ed966"
      unitRef="usd">-16900000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi0xLTEtMS03NTM0MQ_afaf9ae8-cc8d-4df2-b3f6-7c81d911e711"
      unitRef="usd">-16900000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi0zLTEtMS03NTM0MQ_14991c04-bfc9-404d-9e6e-9e5e5b285bf7"
      unitRef="usd">42300000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi0zLTEtMS03NTM0MQ_d34085f6-c375-4274-bba1-4ea40d3cc143"
      unitRef="usd">42300000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi01LTEtMS03NTM0MQ_b1a626ba-a87d-43ed-9e49-4bc86af505b2"
      unitRef="usd">-3000000.0</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi01LTEtMS03NTM0MQ_ff6fabaf-2aa6-4d50-a450-015f9675901a"
      unitRef="usd">-3000000.0</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi03LTEtMS03NTM0MQ_195ba536-ca55-4d1f-af81-861a039b16d4"
      unitRef="usd">74400000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMi03LTEtMS03NTM0MQ_3e21993b-2373-4675-9849-f371cc8972c0"
      unitRef="usd">74400000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNC0xLTEtMS03NTM0MQ_66fc8131-6625-43c9-8f79-75d9260b50af"
      unitRef="shares">95600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNC0zLTEtMS03NTM0MQ_a2e3ae7a-f9e3-440d-8eac-e7c042b9caef"
      unitRef="shares">94600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNC01LTEtMS03NTM0MQ_01a177a7-7302-452b-86c3-672c53dd0963"
      unitRef="shares">95400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNC03LTEtMS03NTM0MQ_39fe30b8-c54f-4027-bb0e-4bcfb49a687c"
      unitRef="shares">94400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i014deb2a111f43c7a8fdebb84cf4af4a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNi0xLTEtMS03NTM0MQ_2381849a-45e5-4aa8-a138-a1ed64651302"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ibe515815525d40479e6d960e227a7c66_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNi0zLTEtMS03NTM0MQ_08e6e9d4-8ccf-463e-a537-09c18d1a5285"
      unitRef="shares">1800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="idcac76a70c464f9fa879fb1284e91eda_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNi01LTEtMS03NTM0MQ_bd30a19d-8c61-431b-9136-ff2d36fb29d2"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ife67923fc29b44728cff990336550617_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNi03LTEtMS03NTM0MQ_d37542a2-0853-440e-b9c7-5707026722cb"
      unitRef="shares">1900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i19b7065611c64ade9f1f759584b9c5f9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNy0xLTEtMS03NTM0MQ_8cc75ef4-ddfa-470b-9056-8ade853f85d8"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icef2199eebcc4873a2e393ef3bf1e3d0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNy0zLTEtMS03NTM0MQ_0b116be1-cda9-487a-9e0c-5439fdf513ee"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2b11647fa1d44f21b454d711e8e45279_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNy01LTEtMS03NTM0MQ_4ae18eb1-25ff-4d8a-9990-4a0b9524d5ef"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i97101bf55ded451fb77e7a8e8dabab08_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfNy03LTEtMS03NTM0MQ_0b389eca-3cce-4be8-8e97-4099e35690a5"
      unitRef="shares">400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="i8fb5e17e77a8471e993d6b327c5c67b4_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOC0xLTEtMS03NTM0MQ_fd8882a0-8e07-4fdc-9ace-69048c4d2e04"
      unitRef="shares">0</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="i13a71ac92a8441239671f089b427fe9f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOC0zLTEtMS03NTM0MQ_e2985c9f-eb22-49e5-90e5-48df50ba7f8e"
      unitRef="shares">1000000.0</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="i142b169cb78e431b902b44d821c15b70_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOC01LTEtMS03NTM0MQ_78ca160c-7f5e-45db-a7f3-854f546cffd9"
      unitRef="shares">0</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="i25c047985ee44b64a2fbeff282b6c067_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOC03LTEtMS03NTM0MQ_9b8c4caf-242a-4854-bd59-779e090807f5"
      unitRef="shares">1200000</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOS0xLTEtMS03NTM0MQ_31dbd372-b35c-43cf-b9a8-5341381d37c3"
      unitRef="shares">95600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOS0zLTEtMS03NTM0MQ_6d25a6d9-6955-4acb-add3-80e1a59f680a"
      unitRef="shares">97700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOS01LTEtMS03NTM0MQ_c2d048d9-9833-4d60-b9b1-e6358a308af8"
      unitRef="shares">95400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfOS03LTEtMS03NTM0MQ_1036de02-1b72-40c7-97af-3b6419178fd0"
      unitRef="shares">98000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTAtMS0xLTEtNzUzNDE_88ffe2b6-4707-48be-94f4-555712c34c99"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTAtMy0xLTEtNzUzNDE_aeedb4d4-008d-404b-9c57-78faf37645a1"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTAtNS0xLTEtNzUzNDE_e86e8ee0-abd3-46dd-af9d-4db371fdd9b8"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTAtNy0xLTEtNzUzNDE_5cafb1ba-beaf-4a20-ac24-07b1a314c4ea"
      unitRef="usdPerShare">0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTEtMS0xLTEtNzUzNDE_ca993863-9769-4ccd-9ae6-6c9869a6cdc6"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTEtMy0xLTEtNzUzNDE_dc0d217c-6f4d-4871-ab6c-535c03e0acf1"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTEtNS0xLTEtNzUzNDE_1528b57e-a976-4055-9462-91ab59e951d1"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTEtNy0xLTEtNzUzNDE_55db97db-5706-4e2c-a3e8-dabf1dfeddd5"
      unitRef="usdPerShare">0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTMtMS0xLTEtNzUzNDE_fd53e1b4-51f2-4b3c-a6ad-cdfdab9945a9"
      unitRef="shares">12500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i634225d5113842c385f7e02dbf25cbb8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTMtMy0xLTEtNzUzNDE_1ce7d154-f373-402a-a1d4-3a8647395238"
      unitRef="shares">4700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTMtNS0xLTEtNzUzNDE_668e1a35-d779-4dc6-b390-d9f39cef5222"
      unitRef="shares">12200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie70aed53c3234380976f1ee2ec29da3a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1YjI2MDMyNDA5ZjRiY2ZhODBlZmE5MGU2MzZhOGIyL3NlYzphNWIyNjAzMjQwOWY0YmNmYTgwZWZhOTBlNjM2YThiMl81OC9mcmFnOmZmMDU0NjA1Y2VjMjRjZDY5OTZhMDhjNmUyNDk3MDU3L3RhYmxlOjQ4NzU3NmM0NzhiZjQyZDM5MDllYzMyZTIzNTNlYmMzL3RhYmxlcmFuZ2U6NDg3NTc2YzQ3OGJmNDJkMzkwOWVjMzJlMjM1M2ViYzNfMTMtNy0xLTEtNzUzNDE_35ecb69c-b6dd-4360-951c-cac8860b8a3a"
      unitRef="shares">3700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M8Y ?^!,9!]!8PT7HY]Q(C3X@Z;I-I\,ZM&VMU7AP75Y6\K)C>(=! .KIV?Z
M?(#GR%UBSRLN25GOPB&CB'@<')^$1L,C*SDJ4Y>\-$44M2'_(_?,&=3J!_F8
M6*EQN1E/R$THEM**>@I'1$M+1'%3\Q:U:,%3)3=AXMNSC&MZ0ROH*7P2+8T2
MQ>W-6]"I3#6/R%_ANKJ3PA4O&74=*^DI+!,M/1/%K4Y>6X<P\ZT&PP7>770N
M?K2"G<(CT=(D4=S9?) ^9&RZD@EF(@Z(=&FOV>LZ]L2=PB+1TB-1W. \A!KL
MD5P0RM[-?R0SX6<*<FF%Q)4\&<<P+LVT]+^>D>^=<\>A9,T5V?#([O)QP;KH
MI8>BN/D!WQN$R9+,GN.YM T)UP<$)M?C/ZU<I[!)K+1)##<R^QR2T9._XLE2
M5)K# T*3X>QF:)U^XH%U"4M7Q(YR15ZFE)G ;&<M>2IA),FL2RX'%+]8%VH\
M/*HN9^F&V%%N:)S +'N[0F=FHGP/;N7$%:LX3^%]6.E]V%'>Q\S4P,:#&5A*
M9>V"#NA\X IJ^]#W!0B!3+"5M!*?P@*QT@*QHRS0+.911*ZS%&ZG]GJ+ZU1.
MO/&XNGRE\V%'.9]1+-32-,R?04&OP!S$:Y[84XL+5H.>POBPTO@PW+?L$[D2
MD$@,#Y>IQCN%_6&E_6&X<]GWM*_&]EF^L$WN,@UV-C%CJ)7X&QF;W7?8JG5R
M-;.;LAE<=KKNI<MHO[6Q,986B.'&91B+),A7PFXC;D?!!:J3=PJ#PTJ#PW!_
M4JSPW8:I<;%?!+BQ6[AH[VEPL<J]@U.8';<T.^Z!59LWC+M%VTK* W*?K(QX
M4%W&TNZXQ]D=P%2 .$X"\41^$]9^YH"4 W^7M-WN61=_\."ZG*7=<7%SLO=S
M+ZLKMOI^0*[9I*SI4BOH-_4[K1<;AF; R_=14^*;]<CMWF%QM=BK'>8[E*WR
M\>U&[T=NQLN41&(!H<YY#SH\M=T[W9YHN<ZW'^=2:QGGARO! Z', W!_(:7>
MGY@7%#O8@_\ 4$L#!!0    ( /J !%4:!BH;_ 4   L9   8    >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&ULM5EM;]LV$/XKA%<4&U#+(F7)=IH8:),-:X&B
M0;-NGVF)CHE*HDM23K-?OZ.DZ,6DF!;H\B&FY+OC<T?RGCOZ\D'(+^K F$;?
MBKQ45[.#UL>+Q4*E!U90%8@C*^&;O9 %U? H[Q?J*!G-:J4B7Y P3!8%Y>5L
M>UF_NY7;2U'IG)?L5B)5%065CV]9+AZN9GCV].(3OS]H\V*QO3S2>W;'].?C
MK82G16<EXP4K%1<EDFQ_-7N#+ZZC6J&6^)NS!S48(^/*3H@OYN%==C4+#2*6
MLU0;$Q0^3NR:Y;FQ!#B^MD9GW9Q&<3A^LOY'[3PXLZ.*78O\'Y[IP]5L/4,9
MV],JUY_$PY^L=2@V]E*1J_H_>FAEPQE**Z5%T2H#@H*7S2?]U@9BH("7$PJD
M52#?JQ"U"E'M:(.L=NN&:KJ]E.(!22,-ULR@CDVM#=[PTBSCG9;P+0<]O;T6
M90:+PC($(R5RGE$-#V]I3LN4H3MC6*$Y^GQW@WY]\1MZ@7B)/O \AS50EPL-
M$(RA1=I.][:9CDQ,][XJ Q2%KQ )"7&H7_O5;U@*ZKA6QV/U!3C>>4\Z[TEM
M+YKROI*2E1I1I<#-"Y<_C8&EVX Y9!?J2%-V-8-3I)@\L=GVY2\X"5^[O/M)
MQD:^1IVOD<_Z]IJJ Z)EAE(S8%\K?J(Y..]<Q<944ILRF>"TQ4D41)>+T] =
M6RI:AL&ZDQKA7'8XEUZ<-VRGD6)I);GF3"%ZHCRGNYS-(6G-%6!V 6YLQ@,H
MRW5\!K>160WAKL(@=L.-.[BQ%^Z;-!451!%R6LH@I#LWOMC"1U:;,WRQA0^O
MXRE\28<O\>)[5YY@D86$4+IP)=:<9&.MLRT43<9MU>%:>7%]U <F(<,-#Z +
MX,J:.R'!Z@R@+;2<#-RZ [CV OQ+:)I_!\"UO6HAMF-HBVU69.JL;#J,FV?.
MRIX!O@QI^LT#<6.O'UD'RS.$#BD<!]B-$(<]P83_PWENC8Z6-(P#<H;9(18G
MX6!_C$$/6!%[0=?ES%SLYY5BGL"V5D:K2FR0#JG50&J,L><N[*6+[>^0PO7C
M(+1.A,2:>QT-MEV+T):"=#\5Q9YQL)]R;B64FQ(P&MHQC'.$ E"_0B733JR1
MC2*QL=I2\3I()K#VK(/]M-/D(\]2VPR#PW-H-L,L!\=LC*PG&.QGF"81>9#9
MO %%?&PE2:<<Y*")/(E[AL')=U51.:<[GM=;T5E*82]3_6@M];.LC9WNZ0O[
M^:OC_2-]--FLWN,T364%Z7@0"6<@;+XBB6/!'&(DGN(,W!,;]C/;F'J?P[JV
M*Q=KWWMEQBA[:L-^;AOS[W,H;?(B:T=$'6++R8B2GN.(G^.@=SI!HN-F'RA6
M<B%1*;0;:FMJE$B2\U*0V+P619-D3'I>(WY>^PCYF&I>WJ.<0?/[7%B)@[DV
M0;P9_ITCMU4P)*-H OF@4_.S7;-I<U'>SS63Q;/(B;TESYF$V*R'R232GO6(
MG_6:C?L</A>+$:MJ=(@EF_54RB8]VY&E-V7?:9%^.8@\8U*]_&5-\.IU3=#Z
MT=T$>[GSA[O@GV1M['O/I\3/I[?RJ6I6)@JOT(LP"$,,B5PB:(DK]AK%08B*
MYI(#J0.5IFRM] &ZJ']9]AK.]M-;KI3)]R;WBTHK#0,X7,X0VAW@>1KUBHR=
M[;F9^-N_:U$4QHDI3PD)_;ZZ/7R2W,1!TFE3C=Y7)6N6ZNF2I];<+(/-4.P&
M>N5BQV0KZKS0:<-F]Y[A( VV@?,+C4/7,SQYAN&SC)NK1CC,1\JS.2]12H\<
M#K<3J$W6&+*C5;XZY$B(\5292'I6)WY6AX*D*JJ\OKX3#<.+ @[0P=RYGB#5
M"^7.1'9G.L=V$^,4FVH12,_RQ,_R0]09V_.4.UL#8A/W/$Z6=KYTR"71),-'
M/<-'?H9ODKJ:3)O.2S2;Q/&21%;C'3DJ@F@UL2&BGNLC/]=;/%0?Q1]T 5M7
M?,[>PBGGZ"T6@YMJ\S/!!RKO>:F@&MF#(C3N$ 39W+PW#UH<Z\OKG=!:%/7P
MP"B -P+P_5Y G=4^F/OP[O>/[7]02P,$%     @ ^H $508;+]H& P  =@H
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M.XV]:E.2FT0J]@=NV!S*U5;XTC]H8 4[X(<BMJ"#&CIX$S33.C\.'+S P3O
MAR*V@/LU</]-P/#"T(:(F(GE,>K^4>I#$5O4@YIZ<)!Z*M,4GN(W-O7@54U]
M+&H+?%B##T\ /[FCAR\*Z?N[Q3X<LT4]JJE'IU._KJ5+XT&#9A1T@E'SL\/?
MHNAU1KCQV;,''O[WRL2GYW-"QU?VIV35)CF2EMLX%-@3V1U12R8TXG0!'K@S
M@#U6Y2&GG!B9%>>$1VG@U%$,$S@84F4#X/Y"2K.9V*-'?=0,_P)02P,$%
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MLN7(R,4?7(A+<I<N^8Z1(?ET'Y"+-Y=$;*.,"1*GY'V<),KX+7E3?[P>2W!
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MPAPDS$7":)<#ZR$S,A!,T.;LI,U9JS;+^_VPF%1::[R=W/,QGE_.505?B^5
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M9OJS>/B%-0;-C+Y$9*KZCQX:V7"$DE)ID3># 4'.B_J7/C:.Z T />X!N!F
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M7RX.C>D8&OL9^B @APW0P)S"-BN/8]O[Y-0V'7?,C?W+W .L.VF* * U@3#
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MG9/T3OS/Q<05%@SE?_M$9HK'_11Q\WSKEC)1+_9@=SAEK]7>RV_^,3X=/=O
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M0!-IF11#<8F/Y;F/ 4C3*$ %/K122ZDC>WDT'HV&(W"V689CRB7(1P^B=0U
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M)7$Q2K _>$8[M!6P!@>K)7'102(#E@V//SJ*[:"]E-%";M)DQ3V.Y?V]!&"
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M\QAPX!Z!\&>%*-F. PB&K%B@RX<-/D-8IWTY?CH" URY;_[Q]'!\]DS<6%V
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M<PGK@;)8-3/8O*Z\F9(3JJC@S'7L51EN_WW'&N;X1M]%XS,#AYYZ-'$ E-3
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MO_!7).+%LVF:)*_$K[4-E(O*J0R>W:N-S/]""E.^+U1;@$A>]Y4@&PU%J!Q
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M-U5K# 25TO%?L6UY.# X'W_!8-H:3 /N&"B@_$%X<7UIS88LKX8WO@BI!FN
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M5BUYH=55IFM9"%F:UJ]/D_3LA5CH.Y6?6%J4];AQGIN*N<E;Q>Q,SMC:LY'
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M5#GJ_6(W@ [^1U5O6."E\<V-VYD Z#CY]@Y1A3$!SQ7]N.,127U!WS<SE9J
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M.[&DEQ*5=2![(:FDO6(W&-[>]0]02P,$%     @ ^H $5;S/M$GJ!@  ZA$
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M!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R%5%U/VS 4_2M7&9I
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M#?VSL0>Z]W0_L:KN?+14EES9#4MZ!E&[ -HOE++;B3M@>%C3OU!+ P04
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M0^TFT/A:*;MON 7:9]WB*U!+ P04    " #Z@ 15#W-NK4L$  !""@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6RM5FUOVS80_BL'=2@2()5M67&<
MU#:0. N682V")FT_#,- 26>+"$6Z)!4G^_6]HV3529R@P^8/YHMXSSWW2D[6
MQMZZ$M'#?:6TFT:E]ZN37L_E)5;"Q6:%FKXLC*V$IZ5=]MS*HBB"4*5Z2;\_
MZE5"ZF@V"7M7=C8QM5=2XY4%5U>5L ]GJ,QZ&@VBS<8GN2P];_1FDY58XC7Z
MSZLK2ZM>AU+("K631H/%Q30Z'9R<I7P^'/@B<>VVYL"69,;<\N*RF$9])H0*
M<\\(@H8[G*-2#$0TOK684:>2!;?G&_2+8#O9D@F'<Z.^RL*7TV@<08$+42O_
MR:Q_P]:>0\;+C7+A'];-V5$205X[;ZI6F!A44C>CN&_]L"4P[K\@D+0"2>#=
M* HLSX47LXDU:[!\FM!X$DP-TD1.:@[*M;?T59*<G\V-OD/K9:80KE%+8^&C
M\>A@[T;0GMN?]#RIX<.]O(4\:R"3%R!'\,%H7SKX51=8/);O$;V.8[+A>):\
M"OA[K6,8]@\@Z2?)*WC#SN9AP!N^@'>.F8=SZ7)E7&T1_CS-G+>4'W_M,K;!
M2G=C<<V<N)7(<1I143BT=QC-WKX9C/KO7V&:=DS3U]!GUTVI@%FT4?E(94H+
M)F]J[4'H LYQ@=9B 1=2"YU+O82Y<=[M,N95=;N-N2D1%D91]3*RYZR \%5[
M!V)3S<S*TTD*4=IR%8XW*7C8!2^&*RN)XDHH^*Q%92CS_D$V@2+"MLV%M0^L
MY[0*]NT-]N%"2 M?A*H1]J2F(E"*ZMGM__#"I7,U68Z-W1O9/_ .%6-M<?H%
M!D?].*7Q[9MQ,DC>TVQO$*?[_&5T'/=I3)(T'C?2D,#?+_T"MZ^E)'<\,7R-
ME%2Y$L[)A23K!/M)&;U\Y]%6H*3(I)+^89>'#@+8HO:<F/FF.-OCFK&<R:7P
M!)L)%8QNFO=&7RY"MUN3ER!#J(R6WG!V" \H\A*^U<(2#_5 /77% 2 /%008
MX MDBI061>AU!1 4$Z(0WY*2E94Y!M*FMD2O(GB@'I7?0E';D!]EDQVYE1F)
M5RBXQ*B+DS!::8H8+AM(\B]M^I)XK1%*<=?XL>O7WA#! K%ZZEYJ4;Q3&E6@
M=3L2;R=6Z\MG2<HU] ">+IJ?-N'@6<!-K0KV]M.@YS45)LF93,EE"$P,_[&>
MSC''*D,+PT'(F,'/U]3_6TC#\2!.N'S289QP_>PE\3&/P^%A/* Q':7Q45='
M_\YLJ2D/T5'*WM/SP^%S=[ C+>*CNP:NY?WCC<=V<H$%GVW-YJ9>489T"JD/
M4/7S_S';$#I"2O:<-HYMJHO8%.S>8KL/RXWS\N \;C-I/*1Q#./X$&Z,IPA1
M>PE>&X7_M%&5Q"/8=5OTMN[U"NTRO%X<!)7-%=_M=@^DT^9=\.-X\[KZ(.Q2
M:@<*%R3:CX\.([#-BZ59>+,*KX3,>'ISA&E)CSRT?("^+PQYO5VP@N[9./L.
M4$L#!!0    ( /J !%7_8.OY40,  'L'   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;'U5;6_;. S^*X1W&%*@]7O2)$L"-%L/=\-M*)KM]N&P#XI-
MQT)ERY/DIO?O1\FNYPYIOMBD)#Y\2(K4ZBC5@RX1#3Q5HM9KKS2F60:!SDJL
MF/9E@S7M%%)5S)"J#H%N%++<&54BB,-P%E2,U]YFY=;NU&8E6R-XC7<*=%M5
M3/V_12&/:R_RGA?N^:$T=B'8K!IVP!V:K\V=(BT84')>8:VYK$%AL?9NHN4V
MM>?=@7\Y'O5(!AO)7LH'J_R=K[W0$D*!F;$(C'Z/^!Z%L$!$XT>/Z0TNK>%8
M?D;_T\5.L>R9QO=2?..Y*=?>W(,<"]8*<R^/?V$?S]3B95)H]X5C=S:9>I"U
MVLBJ-R8&%:^[/WOJ\S RF(>O&,2]0>QX=XX<RP_,L,U*R2,H>YK0K.!"==9$
MCM>V*#NC:)>3G=E,_I%:7\ M4S6O#QH:5+ KF4*8?&%[@?IB%1CR8T\'68^Y
M[3#C5S!G\$G6IM1P6^>8O[0/B-] ,GXFN8W/ GYL:Q^2\!+B,([/X"5#T(G#
M2U[!&Z*]&Z+][V:OC:([\OU4O!U<>AK.]LU2-RS#M4>-H5$]HK=Y^R::A>_.
MD$T'LNDY],V.^C!O!8(L3I3I%-NS>*?9]M< Q_C:)>;(-&1,9*U@!G,@K9""
M6EDOX4NI$%_4&G;\Z>7"A-=T;86@#M27@$\9-F:$GM.=O7!EM9]H)'VF@301
MCA6O,UDA7-GVXQFP.H><B];2^0,FT<Q?7)"0QGYB]<0/K7J=^BE\<TV)^15[
M1$4SIO.J@::3-H1#L2YAZU 74W\&B]1^IF2YL.:W14'#PR;>^:/Q 1JS5G'#
MD>+?&9D]@&SL>-'P]LT\CN)W$/GSD;R >Z2+Q3/+5CN#Y\W0CT=R:L-.X;,T
M.,8*1W(,'_JP.[+7_G5/=D[G7BWA99\WRDWH1W.;''(W[?0PZ?3KQ3F 4;I'
M$,EO$+/N2FI;9M':ZA=*5H/QKZJS2K:UT;#'C+4:P93(%6"7[:-L10XE58SV
MD>9V;?C5D/\H]J>04N DQ)"0<*K%@M% K% =W-BG>VS==K-Q6!U>EIMNH/XZ
MWCU+GY@Z<"JOP(),*4H:Y*H;]9UB9./&ZUX:&M9.+.EU1&4/T'XAJ:2]8AT,
M[^WF)U!+ P04    " #Z@ 15VFE9?T0$   0%0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6S%F%MOVS84Q[\*H75#"R36S9;MS#:06!V6H=F"&MD>
MACTP$FUSI4B-I.-TV(??H:3*DB.K<$"@+[8NY_QYSH_BX66V%_*3VA*BT7/&
MN)H[6ZWS*]=5R99D6 U$3CB\60N980VW<N.J7!*<%DX9<P//B]P,4^XL9L6S
M>[F8B9UFE)-[B=0NR[#\?$.8V,\=W_GRX"/=;+5YX"YF.=Z0%=$/^;V$.[=6
M26E&N**"(TG6<^?:OXK]D7$H+'ZG9*\:U\BD\BC$)W-SF\X=ST1$&$FTD<#P
M]T26A#&C!''\4XDZ=9O&L7G]1?VG(GE(YA$KLA3L#YKJ[=R9."@E:[QC^J/8
M_TRJA(H $\%4\8OVE:WGH&2GM,@J9X@@H[S\Q\\5B(9#&)UP""J'X,C!'YYP
M""N'\-@A/.$PK!R&!9DRE8)#C#5>S*38(VFL0<U<%# +;TB?<M/O*RWA+04_
MO?A-;C"G_^*R$WB*5G3#Z9HFF&MTG21BQS7E&W0O&$TH4>@27:<I->:8H5M>
M?GG&^6U,-*9,O0.3AU6,WKYYA]X@RM$=90P,U,S5$+!IUDVJX&[*X((3P<4D
M&:#0OT"!%_@=[LM^]U]V'-R]PCWH<(_[W>_P9^0%QML?M[U=@%R3#FK202$7
MGI#[%<9 $Z@4'*X3 H-(*R0D6FXQWQ!#K&5&>4)S1M"?'T 0W6J2J;^Z4):M
M#[M;-^7C2N4X(7,'ZH,B\HDXBQ^^\R/OQRZP-L5B2V(MZF%-/>Q37S10KC1\
MWUBF"CWD*=9 ]/VS-A7L$>A^H$IW8GV]/'QUWJ47=>'M%3T7KR6Q%MYAC7?8
MF_]2\"<B=8%0$4[A,^9"D\ZQ7BI%A9*9CIX683@:P+A^:J(IK:8-*S^:MFWB
MWIA>F?&HSGCTM1[?93L&'9R:^06*HNY*MA09-]*XC"#;R5&V'6:C:#@(CQ+N
M#>F5"4=UPE%_%Y?IPNR,WJ_7,%U?H'LBJ4B16,-<(')3_2_@ZF^8K4PQ0_^A
MUPV+F]Y SBUA-L5B2V*M#AC7'3#^IA/'V"9UFV*Q);$6]4E-?6*MLDU>C.)A
M, B.AGIO<^>2L236(C.MR4Q[R<1D3:2$\J?Q,V(4/U(&Z\%N,M,79*:#HVJ^
M[&WM7#"6Q%I@?.^PF/;Z)X?#TCC'-#5#,L$YU9AU+GZ]%W1\+WHQ1_2W>2X@
M6VIM0HWMAF]C^JQ4FFC&P\'HF$QO6V>3L:36)G/8'OB]Z^ %5(S1]^A4V4'I
MKI@ZAYVTK*[]K:K%MM3:5 _+?S_\II.G;W,IO[2J%MM2:Z,_; W\_KW!+=<$
M=#629MF7$YD <[PAG1@M+>DKC#;5XDK-]QO%R!MX07 H1VU"AZV$W[^7.&>-
M44E];?M4F?7OG_K#.O?#<!NG3^:L\ [+#>4*,;(&>6\PAM9D>?Q6WFB1%P=2
MCT)KD1676X)3(HT!O%\+@%#=F#.N^A!T\3]02P,$%     @ ^H $5>@K@'*
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M^GPQ@(.7&U^3IY4H;GCSV3I^(G=$W*]OF;SRZBC+)",Y3V@.&'F\&%S"\ZL
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M*W^N2+PDK#"0SQ\I%2\7Q><=]><\\W\!4$L#!!0    ( /J !%7,>]-;%P,
M 'H*   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;*V6;6_:,!#'OXJ5
M55,KM4T(3QN#2$ ZK9,Z547=7DQ[89(#K"8VM1UHIWWXG9V0 H.T3/""V([O
M?W<_._9UET(^J!F )D]IPE7/F6D][[BNBF:04G4IYL#QS43(E&KLRJFKYA)H
M;(W2Q/4]K^6FE'$GZ-JQ6QET1:83QN%6$I6E*97/ TC$LN?4G-7 '9O.M!EP
M@^Z<3F$$^GY^*['GEBHQ2X$K)CB1,.DY_5HG;)OY=L)W!DNUUB8FD[$0#Z9S
M'?<<SP0$"43:*%!\+& (26*$,(S'0M,I71K#]?9*_;/-'7,94P5#D?Q@L9[U
MG \.B6%"LT3?B>47*/)I&KU(),K^DV4QUW-(E"DMTL(8(T@9SY_TJ>"P9E"O
M[3'P"P-_R\#W]QC4"X/Z6PT:A4'#DLE3L1Q"JFG0E6))I)F-:J9A85IK3)]Q
ML^PC+?$M0SL=A##69 11)IEFH,@%Z<<Q,TM"$W+-\WUE%N@T!$U9HLZZKD:_
MQMJ-"A^#W(>_QT>+W BN9XI<\1CB37L7XRV#]E=!#_Q*P:\9OR1U[YSXGN^3
M^U%(3D_.B,JS>-X1X/#M>K65W@Z9L%HFA AE:E4R&^G6RS6J6]WZ'MUKO@"E
M\5O3ZIS8!:,\)E>/&2:[OG8_^V.E)7Y)OW:M4>ZCL=N'.5TZ:DXCZ#EX?"B0
M"W""]^]J+>_3+I['% N/)+;!ME&R;52I!]^R= R2B D>%@A6O="D"]SN=)P
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M2#,!WT^$T*N.<5"6F\%?4$L#!!0    ( /J !%7UML]0=00  /(6   9
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M.&F-D$J;Z@Z@33ZLCC$GA4\J;:KS #[Y$5WC]A_\-'2&^4'=J$'*X6V_@;
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MKR$<#1/:RW>N2YK!U,';I4'MP$D_?@AB_\N0V_]$]LI[U'F/#K&G=[3"+\J
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MAT'C5;'%M8@[0G/$:'8.1?[]WT/'E>UK=A)PT;-H<XYF*+B1S#K@+EIP%\/
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MD\GH&UG'T7V\CF5\0EK.D;2F4Z.RK#$[*PM)"Z$T"J4Q*(VC:+JRW%99KGW
MWQK_=U&\('%*9M$FEM':J"WW>!8S&!G'_?:XG=6%I(50&H72&)3&431=7:VS
M[ECMTW.GDPUE7U9C?VA4%=0OA])"*(U":0Q*XRB:KJK6-7?LMKE[X0[_2DX-
MM\AB6TTV?:/2H&8YE!9 :2&41J$T!J5Q%$U78^OH.T/HE--!.L<S*"V TD(H
MC4)I#$KC*)HNP=;!=^P6_ET>I_-XH\9P[Y+2?S/*[MB ]B:.><IY;/,/G;'I
M>!P8J,YXX)L,67L?.JL!:LZ?WPV."JSOZM:?=^P&_?M4"L65)"\]U8W(YRKG
M1$MAW.5(VWK6T!QGOQIZ,7#=X:$FD&%#*(U":0Q*XRB:KJS6[G=^X/='>?Y<
M.O=1E4-*EU^NQ,YM>";S+-ED:7F(VZJ_)"Z*;93.S<J#.OH-32L[CB:F@DD
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M)S+;5+>9O,^DS)+JX4I$"Y&7'U#O/V3JJ-\\*0/L;L]Z_3]02P,$%     @
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #Z@ 15I5'12KH#  !M&@
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M%,2\@=+$-[V@K%,\WWP%T:9-70M[S\R<=1TQ)F6A8I=SF%[>+"@+%<\RA\%
M7@H;DN<:,([=D4(BC3')%V*)+?2(.6U6*]4^F&TF^DT:8U(6*A);Z!%S(D7W
MVGJ/78O[L-<>NVAB3,I"1?JW8D]72%V>CS$I"Q6)+41@\F%;;3QB4A8JDK\9
MVXHYUCZN-PO*0D5B"VVO-W%4E<L8D[)0T5IHL/F\4<%<:J@N\10.VTNARFO+
MPJ)[/7-P&&92\T:I<VR[TA,CJLW7DLV7GK>_ %!+ P04    " #Z@ 150+O#
M+8<!  "\%P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=C+;L(P
M$(7A5T%Y )R9X5H!JV[85KQ !.8B<E/LJO#VC6 !!W71#?)91;:5R;_Z%'GQ
MY<LBGIHZ'$]M&%RJL@[+[!AC^^%<V!Y]581AT_JZ/]DW757$?MD=7%MLS\7!
M.\WSB>N>9V2KQ?/,P>;:^O],;/;[T]9_-MOORM?QC\'NI^G.X>A]S :;HCOX
MN,S<I7QL!W=[R+"?G W6NV76K7>2N=1!"D&:/L@@R-('C2!HE#YH#$'C]$$3
M")JD#YI"T#1]T R"9NF#YA T3Q\D.<J8$R2]8$V@M2#70N"U(-A"(+8@V4)@
MMB#:0J"V(-M"X+8@W$(@MR#=0F"W(-Y"H+>BWDJ@MZ+>2J"WOOQL$^BMJ+<2
MZ*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z&VHMQ'H;:BW$>AMJ+<1
MZ&TOER4$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFWOU#O$:^G#H^>^
MQMO(=U(=^W?]X_.WY7T3<1[=<'9P6;_Z!5!+ P04    " #Z@ 15_WEJDI\!
M   =&   $P   %M#;VYT96YT7U1Y<&5S72YX;6S-F<UN@S 0A%\%<8V"8[M-
M?Y3DTO;:YM 7<&$)*( MVTF3MZ\A/U*K%"5*I<X%"[P[,WBE[P"3]ZTA%VWJ
MJG'3N/#>/#+FTH)JY1)MJ D[N;:U\N'6+IA1Z5(MB(G1:,Q2W7AJ_-"W&O%L
M\DRY6E4^>MF$QZ[4S32V5+DX>MH5ME[36!E3E:GR89^MF^R'RW#OD(3.KL85
MI7&#4!"SDP[MSN\&^[ZW-5E;9A3-E?6OJ@Y5;%,QY[<5N:1?XD1&G>=E2IE.
M5W5H29RQI#)7$/FZ2G:B@WYG'TZ8=E=^M7\GTV<8*N=6&Q<F9NERN\-(VNZA
M"4)D?=G_BD?'('WU^U$[[8RR,[W#\7YJN^SFX5BW7'_&WV=\U+\PAP#)(4%R
MW(#DN 7),0;)<0>2XQXDQP-(#CY""8)"5(Z"5(["5(X"58Y"58Z"58["58X"
M5HY"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5HE"5HE"5HE"5HE"
M5HE"5HE"5HE"5HE"5HE"5OF?9/W0>OG7'ZS;-:E5V1S\6?=78/8%4$L! A0#
M%     @ ^H $50=!36*!    L0   !               ( !     &1O8U!R
M;W!S+V%P<"YX;6Q02P$"% ,4    " #Z@ 15H7)21.\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #Z@ 15
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( /J !%7CMMXIU04  ,T>   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #Z@ 15
M&@8J&_P%   +&0  &               @($9#@  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ ^H $508;+]H& P  =@H  !@
M     ("!2Q0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M /J !%6.PN[>O@<  !HJ   8              " @8<7  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " #Z@ 15Y8G$@]$)  "0;   &
M            @(%['P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ ^H $58?THQ$ !P  UQX  !@              ("!@BD  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( /J !%5"^8<-M 4  #4.
M   8              " @;@P  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " #Z@ 15HN!LL 06  !#6P  &               @(&B-@
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ^H $5622P9PQ
M!@  @!$  !@              ("!W$P  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( /J !%4?2KULL04  *,.   9              "
M@4-3  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ ^H $
M5>^X-.EN @  7 4  !D              ("!*UD  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " #Z@ 158,EU[JD"  !R!@  &0
M        @('06P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( /J !%57?"-]UP8  ,@0   9              " @;!>  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ^H $56DNEU'%#   RB<
M !D              ("!OF4  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " #Z@ 15PCQF>T,#  "'!P  &0              @(&Z<@
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( /J !%6\S[1)
MZ@8  .H1   9              " @31V  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ ^H $5<>0=V?F!   %PX  !D
M ("!57T  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #Z
M@ 15&"7V"_0$   )#0  &0              @(%R@@  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( /J !%6'.OLM>P(  &0%   9
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M970R,RYX;6Q02P$"% ,4    " #Z@ 15VFE9?T0$   0%0  &0
M    @(%YF0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M /J !%7H*X!R@ T  (7)   9              " @?2=  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ ^H $57I;N$SM!0  VB,  !D
M             ("!JZL  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " #Z@ 15S'O36Q<#  !Z"@  &0              @('/L0  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( /J !%7UML]0=00
M /(6   9              " @1VU  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ ^H $56IPA&"'"   D58  !D              ("!
MR;D  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #Z@ 15
MCHVC@L #  "Z"P  &0              @(&'P@  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( /J !%6JZ$_5C@(  -D&   9
M      " @7[&  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ ^H $5?@$$@.] @  90@  !D              ("!0\D  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #Z@ 15E4[3XX<#  #:#@
M&0              @($WS   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( /J !%45V&S2] (  $,(   9              " @?7/  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ ^H $5=1\??CF
M P  E!$  !D              ("!(-,  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " #Z@ 15-]1T+$0+  "J=0  &0
M@($]UP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( /J
M!%7#\XT\0P,  &4-   9              " @;CB  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ ^H $54XFXXP4 P  M D  !D
M         ("!,N8  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    " #Z@ 15&(U4.%L%  ! '@  &0              @(%]Z0  >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( /J !%6*/,]<90,  /D6
M   -              "  0_O  !X;"]S='EL97,N>&UL4$L! A0#%     @
M^H $59>*NQS     $P(   L              ( !G_(  %]R96QS+RYR96QS
M4$L! A0#%     @ ^H $5:51T4JZ P  ;1H   \              ( !B/,
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /J !%5 N\,MAP$  +P7   :
M              "  6_W  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( /J !%7_>6J2GP$  !T8   3              "  2[Y  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     O "\ P P  /[Z      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>199</ContextCount>
  <ElementCount>232</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecurities</Role>
      <ShortName>Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Cash, Cash Equivalents and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Convertible Senior Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotes</Role>
      <ShortName>Convertible Senior Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - (Loss) Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LossEarningsperShare</Role>
      <ShortName>(Loss) Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesTables</Role>
      <ShortName>Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/DebtSecurities</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/FairValueMeasurements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/Inventories</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/Leases</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - Convertible Senior Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesTables</Role>
      <ShortName>Convertible Senior Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/ConvertibleSeniorNotes</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2332307 - Disclosure - (Loss) Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LossEarningsperShareTables</Role>
      <ShortName>(Loss) Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/LossEarningsperShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails</Role>
      <ShortName>Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Debt Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Debt Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails</Role>
      <ShortName>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Inventories - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails</Role>
      <ShortName>Inventories - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Leases - Narrative Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesNarrativeInformationDetails</Role>
      <ShortName>Leases - Narrative Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Leases - Supplemental Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesSupplementalInformationDetails</Role>
      <ShortName>Leases - Supplemental Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Leases - Liability, Payment, Due (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails</Role>
      <ShortName>Leases - Liability, Payment, Due (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Convertible Senior Notes - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails</Role>
      <ShortName>Convertible Senior Notes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Convertible Senior Notes - 2024 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails</Role>
      <ShortName>Convertible Senior Notes - 2024 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Convertible Senior Notes - Interest Expense (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails</Role>
      <ShortName>Convertible Senior Notes - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nbix-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - (Loss) Earnings per Share - Schedule of Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails</Role>
      <ShortName>(Loss) Earnings per Share - Schedule of Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nbix-20220630.htm">nbix-20220630.htm</File>
    <File>nbix-20220630.xsd</File>
    <File>nbix-20220630_cal.xml</File>
    <File>nbix-20220630_def.xml</File>
    <File>nbix-20220630_lab.xml</File>
    <File>nbix-20220630_pre.xml</File>
    <File>q2-2022xexhibit101.htm</File>
    <File>q2-2022xexhibit102.htm</File>
    <File>q2-2022xexhibit103.htm</File>
    <File>q2-2022xexhibit311.htm</File>
    <File>q2-2022xexhibit312.htm</File>
    <File>q2-2022xexhibit32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nbix-20220630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="643">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbix-20220630.htm": {
   "axisCustom": 1,
   "axisStandard": 16,
   "contextCount": 199,
   "dts": {
    "calculationLink": {
     "local": [
      "nbix-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nbix-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nbix-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nbix-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 353,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 8,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 13
   },
   "keyCustom": 28,
   "keyStandard": 204,
   "memberCustom": 15,
   "memberStandard": 24,
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.neurocrine.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Fair Value Measurements",
     "role": "http://www.neurocrine.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Inventories",
     "role": "http://www.neurocrine.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:RestrictedCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Cash, Cash Equivalents and Restricted Cash",
     "role": "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash",
     "shortName": "Cash, Cash Equivalents and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:RestrictedCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - Leases",
     "role": "http://www.neurocrine.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Convertible Senior Notes",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotes",
     "shortName": "Convertible Senior Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - (Loss) Earnings per Share",
     "role": "http://www.neurocrine.com/role/LossEarningsperShare",
     "shortName": "(Loss) Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "role": "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Debt Securities (Tables)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesTables",
     "shortName": "Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Inventories (Tables)",
     "role": "http://www.neurocrine.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)",
     "role": "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Leases (Tables)",
     "role": "http://www.neurocrine.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - Convertible Senior Notes (Tables)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables",
     "shortName": "Convertible Senior Notes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332307 - Disclosure - (Loss) Earnings per Share (Tables)",
     "role": "http://www.neurocrine.com/role/LossEarningsperShareTables",
     "shortName": "(Loss) Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "ic0112165dc8043d29e138802b05038e8_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Organization and Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Collaboration and License Agreements - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i2b01af7da7264226a39cc415c4f4de88_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "ibd5d17a30ac7439c9cd69e44e7d10155_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
     "shortName": "Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "ibd5d17a30ac7439c9cd69e44e7d10155_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Debt Securities - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails",
     "shortName": "Debt Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Details)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails",
     "shortName": "Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "ief0b4f5901fb4fd6a36bbaccb164c7c7_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "ia7e2006bc26e4660a1ce0449ce12fef8_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail",
     "shortName": "Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "ia7e2006bc26e4660a1ce0449ce12fef8_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Inventories - Summary of Inventories (Details)",
     "role": "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails",
     "shortName": "Inventories - Summary of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "ia726c285fe9348d98e1aa42d192576d6_I20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i7e101b09704b41349a0ec8f0acd6d9fc_D20220208-20220208",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Leases - Narrative Information (Details)",
     "role": "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails",
     "shortName": "Leases - Narrative Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i7e101b09704b41349a0ec8f0acd6d9fc_D20220208-20220208",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:LesseeOperatingLeaseOptionTermToConstructFifthBuilding",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Leases - Supplemental Information (Details)",
     "role": "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails",
     "shortName": "Leases - Supplemental Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Leases - Liability, Payment, Due (Details)",
     "role": "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails",
     "shortName": "Leases - Liability, Payment, Due (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Convertible Senior Notes - Additional Information (Details)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
     "shortName": "Convertible Senior Notes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "ifa023efd07b7418a8139d17baa936118_I20170502",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbix:CarryingAmountOfLiabilityComponentUponIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i19857cd19784459d879fae5b6542a369_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Convertible Senior Notes - 2024 Notes (Details)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
     "shortName": "Convertible Senior Notes - 2024 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "ia90120fdd18140988db29b2003f29587_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtInstrumentCouponInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Convertible Senior Notes - Interest Expense (Details)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails",
     "shortName": "Convertible Senior Notes - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtInstrumentCouponInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - (Loss) Earnings per Share - Schedule of Net Income Per Share (Details)",
     "role": "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails",
     "shortName": "(Loss) Earnings per Share - Schedule of Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i0a799c95299d4b3998a53e6e0ad2649a_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i8ef17498aa9d498c8992b5221561c777_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i8ef17498aa9d498c8992b5221561c777_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Significant Accounting Policies",
     "role": "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies",
     "shortName": "Organization and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.neurocrine.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Debt Securities",
     "role": "http://www.neurocrine.com/role/DebtSecurities",
     "shortName": "Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20220630.htm",
      "contextRef": "i189ee7bb3f6f413c8f10c21b7f9dc46b_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 40,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nbix_A225ConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Convertible Senior Notes.",
        "label": "2.25% Convertible Senior Notes [Member]",
        "verboseLabel": "2024 Notes"
       }
      }
     },
     "localname": "A225ConvertibleSeniorNotesMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_AbbVieIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AbbVie Inc.",
        "label": "AbbVie Inc. [Member]",
        "terseLabel": "AbbVie"
       }
      }
     },
     "localname": "AbbVieIncMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_AnnualRentEscalationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Rent Escalation Percentage",
        "label": "Annual Rent Escalation Percentage",
        "terseLabel": "New campus lease annual rent escalation percentage"
       }
      }
     },
     "localname": "AnnualRentEscalationPercentage",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_BIALPortelaCaSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIAL \u2013 Portela &amp; Ca, S.A.",
        "label": "BIAL \u2013 Portela &amp; Ca, S.A. [Member]",
        "terseLabel": "BIAL"
       }
      }
     },
     "localname": "BIALPortelaCaSAMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_CarryingAmountOfLiabilityComponentAtSettlement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the liability component at settlement.",
        "label": "Carrying Amount Of Liability Component At Settlement",
        "terseLabel": "Carrying amount of the liability component at settlement"
       }
      }
     },
     "localname": "CarryingAmountOfLiabilityComponentAtSettlement",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_CarryingAmountOfLiabilityComponentUponIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the liability component upon issuance.",
        "label": "Carrying Amount Of Liability Component Upon Issuance",
        "terseLabel": "Carrying amount of the liability component upon issuance"
       }
      }
     },
     "localname": "CarryingAmountOfLiabilityComponentUponIssuance",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_CashAndMoneyMarketFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Cash And Money Market Fund [Member]",
        "terseLabel": "Cash and money market funds"
       }
      }
     },
     "localname": "CashAndMoneyMarketFundMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration revenues"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_ConversionPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period One",
        "label": "Conversion Period One [Member]",
        "terseLabel": "Conversion Period One"
       }
      }
     },
     "localname": "ConversionPeriodOneMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_ConversionPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period Two",
        "label": "Conversion Period Two [Member]",
        "terseLabel": "Conversion Period Two"
       }
      }
     },
     "localname": "ConversionPeriodTwoMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_DebtInstrumentConversionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion",
        "label": "Debt Instrument, Conversion [Axis]",
        "terseLabel": "Debt Instrument, Conversion [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentConversionAxis",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbix_DebtInstrumentConversionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Conversion",
        "label": "Debt Instrument, Conversion [Domain]",
        "terseLabel": "Debt Instrument, Conversion [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentConversionDomain",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_DebtInstrumentConvertibleConversionPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.",
        "label": "Debt Instrument Convertible Conversion Premium",
        "terseLabel": "Convertible senior notes premium"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPremium",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_DebtInstrumentCouponInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Coupon Interest",
        "label": "Debt Instrument, Coupon Interest",
        "terseLabel": "Coupon interest"
       }
      }
     },
     "localname": "DebtInstrumentCouponInterest",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities available for sale position number of positions.",
        "label": "Debt Securities Available For Sale Position Number Of Positions",
        "terseLabel": "Number of debt securities available for sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSalePositionNumberOfPositions",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the liability component immediately before extinguishment.",
        "label": "Fair Value Of Liability Component Immediately Before Extinguishment",
        "terseLabel": "Fair value of the liability component immediately before extinguishment"
       }
      }
     },
     "localname": "FairValueOfLiabilityComponentImmediatelyBeforeExtinguishment",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_HeptaresTherapeuticsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Heptares Therapeutics Limited",
        "label": "Heptares Therapeutics Limited [Member]",
        "terseLabel": "Heptares"
       }
      }
     },
     "localname": "HeptaresTherapeuticsLimitedMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_IdorsiaPharmaceuticalsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Idorsia Pharmaceuticals Ltd.",
        "label": "Idorsia Pharmaceuticals Ltd. [Member]",
        "terseLabel": "Idorsia"
       }
      }
     },
     "localname": "IdorsiaPharmaceuticalsLtdMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Dilutive Effect Of Conversion Of Debt Securities",
        "terseLabel": "2024 Notes (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbix_InvestmentIncomeAndOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment income and other net.",
        "label": "Investment Income And Other Net",
        "terseLabel": "Investment income and other, net"
       }
      }
     },
     "localname": "InvestmentIncomeAndOtherNet",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due After Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Monthly Base Rent Per Square Foot",
        "label": "Lessee Operating Lease Monthly Base Rent Per Square Foot",
        "terseLabel": "New campus lease monthly base rent per square foot"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_LesseeOperatingLeaseOptionTermToConstructFifthBuilding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of term of lessee's option for the construction of a fifth building under operating lease.",
        "label": "Lessee Operating Lease Option Term To Construct Fifth Building",
        "terseLabel": "New campus lease lessee option term for construction of fifth building"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionTermToConstructFifthBuilding",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.",
        "label": "Long Term Investments [Member]",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.",
        "label": "Minimum Percentage Of Trading Price To Last Reported Sale Price",
        "terseLabel": "Minimum percentage of common stock price trigger"
       }
      }
     },
     "localname": "MinimumPercentageOfTradingPriceToLastReportedSalePrice",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_MitsubishiTanabePharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mitsubishi Tanabe Pharma Corporation",
        "label": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "terseLabel": "MTPC"
       }
      }
     },
     "localname": "MitsubishiTanabePharmaCorporationMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Five",
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for thereafter"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Four",
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for 2026"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Three",
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for 2025"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced, Year Two",
        "terseLabel": "Non-cancelable future minimum lease payments under operating leases not yet commenced for 2024"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of renewal options under the terms of the lease.",
        "label": "Number Of Renewal Options",
        "terseLabel": "New campus lease number of renewal options"
       }
      }
     },
     "localname": "NumberOfRenewalOptions",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_PatentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Patent term",
        "terseLabel": "Patent term"
       }
      }
     },
     "localname": "PatentTerm",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_PotentialMilestonePaymentReceipts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential milestone payment receipts under a collaborative arrangement.",
        "label": "Potential Milestone Payment Receipts",
        "terseLabel": "Potential milestone payment receipts"
       }
      }
     },
     "localname": "PotentialMilestonePaymentReceipts",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential milestone payments under a collaborative arrangement.",
        "label": "Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "PotentialMilestonePayments",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PrincipalAmountOnConversionRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal amount on conversion rate.",
        "label": "Principal Amount On Conversion Rate",
        "terseLabel": "Principal amount on conversion rate"
       }
      }
     },
     "localname": "PrincipalAmountOnConversionRate",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_RentAbatementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent Abatement Period",
        "label": "Rent Abatement Period",
        "terseLabel": "New campus rent abatement period"
       }
      }
     },
     "localname": "RentAbatementPeriod",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_RestrictedCashTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash [Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashTextBlock",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_SaleOfStockNumberOfSharesSoldInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares sold by the collaboration partner per stock transaction.",
        "label": "Sale of Stock, Number of Shares Sold in Transaction",
        "terseLabel": "Sale of stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesSoldInTransaction",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbix_SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2.25% Convertible Senior Notes Due in May 2024.",
        "label": "Senior Convertible Notes Two Point Two Five Percent Due In May Two Thousand Twenty Four [Member]",
        "terseLabel": "2.25% Convertible senior notes due 2024"
       }
      }
     },
     "localname": "SeniorConvertibleNotesTwoPointTwoFivePercentDueInMayTwoThousandTwentyFourMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of reconciliation of cash cash equivalents and restricted cash.",
        "label": "Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceutical Company Limited",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_UpfrontPaymentsMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments made under a collaboration agreement.",
        "label": "Upfront Payments Made",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPaymentsMade",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_VoyagerTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voyager therapeutics.",
        "label": "Voyager Therapeutics [Member]",
        "terseLabel": "Voyager"
       }
      }
     },
     "localname": "VoyagerTherapeuticsMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_XenonPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xenon Pharmaceuticals Inc.",
        "label": "Xenon Pharmaceuticals Inc. [Member]",
        "terseLabel": "Xenon"
       }
      }
     },
     "localname": "XenonPharmaceuticalsIncMember",
     "nsuri": "http://www.neurocrine.com/20220630",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r46",
      "r48",
      "r99",
      "r100",
      "r247",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r106",
      "r114",
      "r120",
      "r197",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r343",
      "r346",
      "r348",
      "r349",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r106",
      "r114",
      "r120",
      "r197",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r343",
      "r346",
      "r348",
      "r349",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r106",
      "r114",
      "r120",
      "r197",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r343",
      "r346",
      "r348",
      "r349",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r246",
      "r281",
      "r303",
      "r304",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r448",
      "r493",
      "r495",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r160",
      "r228",
      "r229",
      "r292",
      "r293",
      "r450",
      "r492",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r160",
      "r228",
      "r229",
      "r292",
      "r293",
      "r450",
      "r492",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r246",
      "r281",
      "r294",
      "r303",
      "r304",
      "r308",
      "r309",
      "r310",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r448",
      "r493",
      "r495",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r246",
      "r281",
      "r294",
      "r303",
      "r304",
      "r308",
      "r309",
      "r310",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r448",
      "r493",
      "r495",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r47",
      "r48",
      "r99",
      "r100",
      "r247",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r107",
      "r108",
      "r109",
      "r110",
      "r166",
      "r167",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r327",
      "r328",
      "r329",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r383",
      "r384",
      "r392",
      "r393",
      "r394",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r163",
      "r164"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r52",
      "r53",
      "r54",
      "r481",
      "r503",
      "r507"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r51",
      "r54",
      "r60",
      "r61",
      "r62",
      "r103",
      "r104",
      "r105",
      "r336",
      "r414",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "negatedLabel": "Additional paid in capital",
        "negatedTerseLabel": "Additional Paid in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r311",
      "r312",
      "r313",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r107",
      "r108",
      "r109",
      "r110",
      "r120",
      "r166",
      "r167",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r311",
      "r312",
      "r313",
      "r320",
      "r321",
      "r322",
      "r323",
      "r327",
      "r328",
      "r329",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r383",
      "r384",
      "r392",
      "r393",
      "r394",
      "r395",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r452",
      "r453",
      "r454",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments",
        "terseLabel": "Equity component of repurchased convertible senior notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r305",
      "r314",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r73",
      "r87",
      "r266",
      "r386"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r68",
      "r87",
      "r266",
      "r388"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r87",
      "r266",
      "r275",
      "r276",
      "r388"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Shares excluded from diluted per share amounts because their effect would have been anti-dilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r14",
      "r97",
      "r149",
      "r152",
      "r158",
      "r193",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r334",
      "r337",
      "r367",
      "r415",
      "r417",
      "r459",
      "r479"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r36",
      "r97",
      "r193",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r334",
      "r337",
      "r367",
      "r415",
      "r417"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of assets on recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r171",
      "r205"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r168",
      "r172",
      "r205",
      "r463"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r170",
      "r205"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r12",
      "r170",
      "r205"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r102",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Non-cash capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r11",
      "r89"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r82",
      "r89",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r82",
      "r376"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r330",
      "r331",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r103",
      "r104",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r417"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 220.0 million shares authorized; issued and outstanding shares 95.6 million at June\u00a030, 2022 and 94.9 million at December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59",
      "r66",
      "r466",
      "r487"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible senior notes",
        "verboseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r295",
      "r302",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r70",
      "r450"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r260",
      "r267",
      "r268",
      "r270",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r17",
      "r18",
      "r96",
      "r101",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r273",
      "r274",
      "r275",
      "r276",
      "r390",
      "r460",
      "r461",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Convertible senior note carrying value of the equity component"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r245",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Convertible senior notes conversion price (in USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r42",
      "r245",
      "r285",
      "r286",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Convertible senior notes convertible in to shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.",
        "label": "Debt Instrument, Convertible, Stock Price Trigger",
        "terseLabel": "Common stock price trigger (in USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage of common stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "verboseLabel": "Threshold common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r243",
      "r273",
      "r274",
      "r387",
      "r390",
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r258",
      "r273",
      "r274",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair Value, Amount"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r41",
      "r263",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Convertible senior note assumed borrowing rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43",
      "r96",
      "r101",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r273",
      "r274",
      "r275",
      "r276",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Convertible senior notes redemption rate"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Aggregate principal amount repurchased"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r96",
      "r101",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r273",
      "r274",
      "r275",
      "r276",
      "r285",
      "r287",
      "r288",
      "r289",
      "r386",
      "r387",
      "r390",
      "r391",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Convertible senior notes term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r256",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "negatedTerseLabel": "Unamortized Debt, Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest Writeoff",
        "terseLabel": "Accrued interest receivables write-off"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestWriteoff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r184",
      "r212",
      "r215"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Longer, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r184",
      "r212"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "12 Months or Longer, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r184",
      "r212",
      "r215"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less Than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r184",
      "r212"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less Than 12 Months, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r180",
      "r208",
      "r215"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Total, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r181",
      "r209"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "auth_ref": [
      "r207",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r179",
      "r211",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r182",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of debt securities available for sale in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Transaction cost related to issuance of convertible senior notes"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r256",
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized Debt, Issuance Costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "negatedTerseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r87",
      "r224"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "(Loss) earnings per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r67",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r121",
      "r124",
      "r134",
      "r135",
      "r136",
      "r140",
      "r141",
      "r349",
      "r350",
      "r467",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in USD per share)",
        "verboseLabel": "(Loss) earnings per share, basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r67",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r124",
      "r134",
      "r135",
      "r136",
      "r140",
      "r141",
      "r349",
      "r350",
      "r467",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in USD per share)",
        "verboseLabel": "(Loss) earnings per share, diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "(Loss) Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r60",
      "r61",
      "r62",
      "r103",
      "r104",
      "r105",
      "r108",
      "r117",
      "r119",
      "r143",
      "r197",
      "r284",
      "r290",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r348",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r414",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "terseLabel": "Fair value of equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "terseLabel": "Equity securities, stock price"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r16",
      "r364"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r192",
      "r489"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Change in fair value of equity security investments",
        "terseLabel": "Unrealized (loss) gain on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r187",
      "r478",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities\u2013biotechnology industry"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r352",
      "r353",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Investments Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r357",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r258",
      "r273",
      "r274",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r353",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r352",
      "r353",
      "r355",
      "r356",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r258",
      "r295",
      "r296",
      "r301",
      "r302",
      "r353",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r258",
      "r273",
      "r274",
      "r295",
      "r296",
      "r301",
      "r302",
      "r353",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r258",
      "r273",
      "r274",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r353",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "verboseLabel": "Unrealized gain included in earnings"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "negatedTerseLabel": "Transfers out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r258",
      "r273",
      "r274",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r363",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r189",
      "r190",
      "r191",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r211",
      "r213",
      "r214",
      "r215",
      "r269",
      "r283",
      "r339",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r218",
      "r220",
      "r222",
      "r223",
      "r451",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r218",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r87",
      "r277",
      "r278"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of convertible senior notes",
        "negatedTerseLabel": "Loss on extinguishment of convertible senior notes",
        "terseLabel": "Loss on extinguishment of convertible senior notes"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r64",
      "r149",
      "r151",
      "r154",
      "r157",
      "r159",
      "r456",
      "r464",
      "r469",
      "r490"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "(Loss) income before (benefit from) provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r118",
      "r119",
      "r148",
      "r319",
      "r324",
      "r325",
      "r491"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "(Benefit from) provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r84",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r136",
      "r306"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r63",
      "r147",
      "r385",
      "r388",
      "r468"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      },
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Total interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r80",
      "r83",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivables"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r216"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r7",
      "r34",
      "r417"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r30",
      "r216"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r29",
      "r216"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r187",
      "r457",
      "r473",
      "r524",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Description of Operating Lease"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (6 months remaining)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less accreted interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "New campus lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "New campus lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r97",
      "r153",
      "r193",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r335",
      "r337",
      "r338",
      "r367",
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r97",
      "r193",
      "r367",
      "r417",
      "r462",
      "r483"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r40",
      "r97",
      "r193",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r335",
      "r337",
      "r338",
      "r367",
      "r415",
      "r416",
      "r417"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r82",
      "r85",
      "r88"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r55",
      "r57",
      "r62",
      "r65",
      "r88",
      "r97",
      "r107",
      "r112",
      "r113",
      "r114",
      "r115",
      "r118",
      "r119",
      "r132",
      "r149",
      "r151",
      "r154",
      "r157",
      "r159",
      "r193",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r350",
      "r367",
      "r465",
      "r486"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income (loss)",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r121",
      "r122",
      "r133",
      "r136",
      "r149",
      "r151",
      "r154",
      "r157",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net (loss) income - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r123",
      "r128",
      "r129",
      "r130",
      "r131",
      "r133",
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net (loss) income - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r114",
      "r120",
      "r140",
      "r166",
      "r167",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r311",
      "r312",
      "r313",
      "r320",
      "r321",
      "r322",
      "r323",
      "r327",
      "r328",
      "r329",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r383",
      "r384",
      "r392",
      "r393",
      "r394",
      "r395",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r452",
      "r453",
      "r454",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r149",
      "r151",
      "r154",
      "r157",
      "r159"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r400",
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less current operating lease liabilities included in other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Noncurrent operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r398",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r404",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r403",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesSupplementalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r35",
      "r417"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r49",
      "r50",
      "r52"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on debt securities available-for-sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r49",
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on debt securities available-for-sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r417"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r74",
      "r76",
      "r169"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of debt securities available-for-sale"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r81",
      "r188"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "negatedTerseLabel": "Purchases of equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19",
      "r417"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuances of common stock under benefit plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r74",
      "r75",
      "r169"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Sales and maturities of debt securities available-for-sale"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r225",
      "r417",
      "r474",
      "r484"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedTerseLabel": "Repurchase of convertible senior notes"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Aggregate repurchase price paid in cash"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r316",
      "r449",
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r11",
      "r89",
      "r94",
      "r458",
      "r480"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r89",
      "r94",
      "r525"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash in connection with operating leases",
        "verboseLabel": "Restricted cash included in other assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.neurocrine.com/role/LeasesNarrativeInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r290",
      "r417",
      "r482",
      "r502",
      "r507"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r103",
      "r104",
      "r105",
      "r108",
      "r117",
      "r119",
      "r197",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r348",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r145",
      "r146",
      "r150",
      "r155",
      "r156",
      "r160",
      "r161",
      "r162",
      "r291",
      "r292",
      "r450"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r402",
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets acquired through operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r175",
      "r176",
      "r183",
      "r184",
      "r185",
      "r186",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r43",
      "r101",
      "r273",
      "r275",
      "r285",
      "r287",
      "r288",
      "r289",
      "r386",
      "r387",
      "r391",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Notes Net of Discount and Deferred Financing Costs"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in USD per share)",
        "verboseLabel": "Market price of common stock (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r520",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r45",
      "r60",
      "r61",
      "r62",
      "r103",
      "r104",
      "r105",
      "r108",
      "r117",
      "r119",
      "r143",
      "r197",
      "r284",
      "r290",
      "r311",
      "r312",
      "r313",
      "r322",
      "r323",
      "r348",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r414",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r143",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r284",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances of common stock under stock plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r290",
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances of common stock under stock plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r25",
      "r26",
      "r97",
      "r165",
      "r193",
      "r367",
      "r417"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r189",
      "r190",
      "r191",
      "r269",
      "r283",
      "r339",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r107",
      "r108",
      "r109",
      "r110",
      "r120",
      "r166",
      "r167",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r311",
      "r312",
      "r313",
      "r320",
      "r321",
      "r322",
      "r323",
      "r327",
      "r328",
      "r329",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r383",
      "r384",
      "r392",
      "r393",
      "r394",
      "r395",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r452",
      "r453",
      "r454",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetails",
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r295",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Securities of government-sponsored entities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetails",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetails",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r123",
      "r136"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r121",
      "r136"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.neurocrine.com/role/LossEarningsperShareScheduleofNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267862-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r529": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r530": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r531": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r532": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r533": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r534": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r535": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r536": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r537": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r538": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r539": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r540": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r541": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r542": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0000914475-22-000044-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-22-000044-xbrl.zip
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M,(UU0I$;@SA7!%G+*-*6!4P4\<: @;,19F;?=W#^7J@L_" +XUL6QE(S*VA
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M%IBBR8NE6HB^U;'MP3^7U$U(K$<WW.H.AOVB9PZ\^$OL#S,01B_SB.%.'IP
M+.6,'WZ)9PR/QJ6+;^"](SA?Y_UI8_VOHT9V[\[FX?['#^=[1V#:#F1U=.]\
M>WWM[#*SZVR<-8[:K3I\OP<98>-H!S+ S</ZFT;.[ 00^<7>!<#C3:-U,[/;
M:V[0[7R?3?C\XQ:%S Y2_8U3N :X_^?3QD7CJ$'K\![(OS7*ZB"E!\C5<?W]
MIR1YC(I[I"RSB!-.D)5.HL@<#H(H;9U>6L7+F#"BR&52/X'%:O'!E3&7?DRQ
M'[L^#NX8*LJ#8BN#8F@*8%,K!LE6AN?'8+Y!JW/<SN-4Q6>'_0)I5T>%EL\&
M 4[QZOHY1M?_>M'Q/0QZ)_WB73$>NC*&Z@@@C^EIFIPH%EV)DW>MD-^G5NS7
MBAN*=XZKO=[ZO]<[Q6[^>'7RT?6S'Q<=T9-W@Z'M#W./5M$[CN#F,)G\[NMW
ME[<9KAPJ41Y3N_[-Y/WD(J^N-=2=[<:<=,X[1X4*/ $RE+24T.0\,<QZ-0[/
MBNH2--=HX',X;@&%J+X\T?B;A[5 9KWB\0>'%F!U^60=D!@G_;@Z-D#QY>04
MD^\F[_,Y[D:BT4+Y0(S2G L3M#+)1N&DX-0R:<8M6@X 7F_1JYAZ9(N>%/Y\
MO<G& _PK'W;7?[@U/09Q0:0(7F/. C61@);$U$&P8: IB]8<Z8]2M29!A")&
M?KXUW\7^;@;BY>.%UA>XK:N'%L'=#GO]1S;\K=_G#]=CM]=I=>\Z[4/=X]HI
M7EV_^^_970@)@<H%FXSC67<(IV-@$O22BX:(,9_S9^3S\6/'@RQ>1F\#7.SL
MN-WRK>%(;]5"JY/%;9[Z-.@/5][U>^'$#[?[N['_I>7CVED+Z&:BA\;?3J3:
MG6>\;*K+"S\BKO!GCRM:4FD9TR'&P$,(+C#J!,,^6F*L\*,$8F(_4MGO?ON1
MA]N/3,U^6 6B"0%-%1E/UCH" 4P2'1C#%E+Y&>BI>;7?3'2=2-0[B;64*G*6
MB!%@49&,2@(;&LG8_TCE?P_QOX?:;WK^Q\';A'?>,&IY]%XSYR633&/#)4YA
MKN-?3@%77O?:;>MZ_6(VXD[\$KLG<1$C8?3:<&6Q3"IQIY.Q09M$K&"18<KC
M7$?"65ER)C'1,:&(9M@13;EG5$?#O+8QXH ]H7&N8^(,??+YHV,PDDA##5;2
M<FFITY9@)[P-#I)+S.8Z.L[0)Y\_3F*KC/%&4&,"=\P8G8E51FP#E=S8&<3)
MN8A*DG%*!:38A&E./=,BJ8AI<(F"['!Z!E%I+F) 5)#^!,& _AG/:DS)!%D2
MC9Z:8)F= 7/,A9\FR/N]C-1YQ3C1VC@<C0N.)!*<M)->4?;T_7@_2K239&-W
M"(^>?[/QGY,\\[C7.>YUX>W@>DX"GW=ZW=UASW^>/M]>[ZYEC^Y@O-Y5$[PC
MD5,M".5"1YNDQ<X3ISGAT?F%,<U:"*T<#FW[G6V%K>YK>]P:VO:<F$D%IW"(
M(4BJ.+52,Q)(PAZH1QIN[>*8R?N3SDD[KP[='A[&?CZN'P_SV;[$K:[O=9Y
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M=<[:VYWW%XUFG3;>[+3JS3];>T?O1>.B#==_#]?<$MOK>[S>K)_N-1N'D]_
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M[#3HWT=[1W^UZYOZ;'OM$W8!0C/+B^"I1WD"&S+$1Q1\L"$1%R56CQK F]I
M< 6BTH-(T, LHQ2E7(B;.^.1D2XAST6BP!TAY4633SYZ-[U%_9>(J\98Y@2&
M%_6#3Q"L!&/2(F<Y)/C)<^2DM8A+'R2':&;,#W<73:^@2X6I><24S/M<29?7
MEN:!$A]!&_.D$83'%(A(R8N4"WS?517SAT;N[NXIFAQ9$M#>VV=>H;8TJ.7;
M[S\I([!W'/@O6(5XQ!Q9S!(BW"=EK:?"R-(PX5V]YA6>2H6GD PC*@&4<K\
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MU@#=64"O('VE ?J! #WM\%LBU X%6#)EB::,Q8-(&J(M=!U"B!C=SJZ0ME7
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MOZPI(QI?W*3?;%?ES%>/&1V[N?4MT^]+5MN?9R)CRD@R2M0\72I>,^<(UI,
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M7 'F[""D&("R9L80UXGY2D5L"5,K&@LU%GH8&;1@ +G)H-5PSY0,8B*0)&9
MF)@!A8T0+'+@NBC8E#(CDI5[S&RY5QM9OD+ />^?75Y06B1/=\,X\[8K[#1G
M=CJ =?U\-?Z<BS]?SC;1MLQ:EA(P76<Q9D40G+3  VH18C1HTL(AK.[5V30>
M6A\>ZF (J['/%[+/E'IS@5%4+ *W,M?6X#6 [C3H%'WYO3263]@'N]2_M%'0
MUE%0IX-8C8R^C(QFPEC9F6*@#,ZF4*10,4P(1@%Y%I"<5)C<PF&LQD.-AS8J
MC-78YPO99[J5>W&/F?(:5(X:$+D!'T4 K5WPY!3CBDT"6;I#4F@+\K!^F?Q
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M%AR!G?8>61\4BKER$R%&&,P &,R&46))38!9]>KA%9V['ARMHO-PQ+2W[P]
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M 9PI43$&1TK"$G&*<Y*AR!#&G!!';.2$9VJZXH3Y%@WH_"+A#YAIOCIHOU]
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M-M).<H*^K<^VVROYK0;#G++O?!U>YV@)W^UURT3W\S,_-3$>'C!K/(5#%V%
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MM60%<LD() *A@G!+N4YKFTSH#=."40M&+1BU9J;'0J[YK%PB,!-"+O67+Y_
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M*Y%.DB#G3#0Z!:P4X"!9@H+WEU>U!< 6 %O!KRVU]%V!<#Z(G3F<=]H@X1D
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MI91KF[N#!51?A/DK<:DDM#V%S1C'C""I$RHXS4@RZG[I'!=S<B?V,VXN.1,
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M[V<*;OX8JP37Q'$._Q]S6?[<OR24$#/%@20*U]FFH*E0&V;>L?ZX"<PV%NQ
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M+:#ZS%$<@4;C,6'1*<!=KBTC$4L>DJ>2,(Y'J>+\6JIX%<6Q9&)BC:-#3*T
MW.4(A)U#W'F)C#0&&2P(T2X:$100DS)SV@L\143'52[+E3NOW(TIW#3CO1C[
MU.17.?@>D3 %$*9BU#'+ O+.!,1%H* :<(Q\BCY0K V3N.C)<PM=SG?VC4EH
MOD#>F"EU\(CU+K[X8]!K6[&DC2L!V7_+I2] Q 6B5! J(>D4Z(4N)U][$'9$
M8Y+3)&.B,Z4L'J'(X((*7A&MT\W^O,(96,0MCXKO953K#]OM[(2="WKPX]_#
M3BRSP!E>GT>#Q9_RMI?;P44-1WC!ECWMQW?C#W^$9O^T9<_?-3O%,(N+_KBN
M".>"A5/U&XL]W_+PU=[H!B[W1T<E?4=/'AW>* Y-U:0<'<NYBN3&PWCCYF.W
MWI9L:"X?=-O;CPG.J\%6@ZT&FP=K%KKMJ-3W5$A+KB*U=E/Y[W%A69S+RDX\
M8_+47O=LNDS_+<7!R^B4IRG@K.^JCU5 Y7_'EE012%):M3>V(KC'U)B7.1U?
M.U>97UF]6<94W)M*%FWP_.AA3XO-62,.:N-8E.<+T5ILK"6!7\:^+74$8N/.
MDG0PACD!=+E"'J(;>E;)R9':^09%D>0[NFB_?N;,*0FU(B?A&EO^ K(_:^N!
MRY<N;O@N;\PT_0+3\!O8@B-KL?_[D@#JNHX^6V?]MHX7JT<HVZ.T@ 4FY^XW
M?CO3-BY\5"MRYI=+66]O-A?6I2H2G.RI]2,+O*-Y /^:N_1<.5@>K9/;JVZT
M\X;ZZ#S.]N;DGN;+=NB/VN>\IP<G6[C1_ONX0>MGC8O/WW>_O1?[%]_Q[L>#
MYL')>[+[;>=G8^_/]G3[G/V]@W9]^Q/=;[^'>V^QQL?<AJ=ULKOWB1^T_V[7
MX=G[<'W]XT&J-V>:.09!D]3>(97;5G!8#&0D3\AX&9DBQAB>*ZDH/"?D=T6;
M.3X0=Z?%UH/?XRWC6 5BBX/8A/=F; +\-R?=#=LS\9!EM=N+V.M6>'<_O+N8
MPCOO$M"P%LA[IA"')<M%HQC"@()&2"P=$VN ;)H2^L=C(UX%=Q7</=5+__8L
M>#=;W*[ M@K#[H-A9 K#L%68,$)1X,X!AG&'M),48:]%,BXJ2SWH;',TMAD'
M7 5=%72M/'0] W+=DLE48==]L(M-85=R*2:F/$JYBBU/7"%G-&!7E#;91*/0
M#+!+SHN&K+2O"L(J"'NHQVQ4(*T"L/L!F)@",&UL]#XX9(J.KQY'9)B,2)A(
M!?6>F-R[B%(^)S?@%0/8?>ZQ\KL_B_%TL?M3H[.;/U5G[F?KS/VMK'A\/0BX
MJ&3L6[;?+^L'%)D0K2Z\2%%A>:*N]PW1PF6^_JCIY67[CJM:X'#GKB^3QYQM
M%9O2_>.8&UR.'NK+JD9GS5:KYG(E X#_;J^L)EBT>AJ%R+?.<PY'=@IVCLI.
M($7]@8GJ^Y/%$$?EY8K\H&+DW6&OZ*G9S7/?]=]KH>@"4^:(]&+?]YH.+F]?
MU?P;E2TH2N47U;9^Y!^+RG1GL2Q.5_R<NYR,*L' L&-L3\_Q*!/EY@RYN?<:
MS>5,U':NA71>MH=:]!769U:].VR%/-O3*S_2Y&M=!Q!2+,R\:/ 7&.:^'7W1
M0VQ$O&5)$E*%NK^&L.%JL-5@7]I@JU#W*M3]586ZK]ZT7(MFKPBE"KNNPJZK
ML.LJ[/K%S&85=EV%75=AUU78];(WD8C4-A=<8=%ZGAS12@L9G7%.X!SDNVCU
MM5<>=OWWR<&W.B[N]^UON/?G=H/^?=PX.<*-=N/[P?;7GP<GWR\.VOMT9A>I
MG<?ZJ1C[/KQ'X^,^@W_I;MY9HI^_-_8^M'?W&NV#D[EAUUP1 ^MA4:ZIC+@5
M 6G","*:.QQU8$'9M4VFR9RBGU78=;43_G)WPN\3A_@X*'9'W'4%;/<!MNGX
M:B.5Q)P39'"*B(?DD+-$(.*5B\99F0);V^1L#JY5P8D5GE5XMAB>O>:XZB?#
MKNFXZ@A:&:49L93 B N58Q,31LS((!@-GN2">'1.F>T*NBKH>GG0]0S(]=KC
MJI\,NZ;CJE7T7!@A0=NB!'&L$])%VT!,-,$B4D$H&)1,;)"W%)9805@%88_L
M$GM=<=5/!F#3<=7>,6YR@RCNL$4\>H5L C6,.<\4-LPS# #&)9_3:/H5 U@5
M5WU+7/54X/(H3/F9PH_O%[S9+!I2]',Q]M/8F5>P_47';7*^H36M8N"JP3[:
M8/5]H@O?6A34WG$OQEH=SCONU]YW0@Q%=%A.;:@QO/Z&X\.^-'\N."\+DLZ;
M" ^[S^[A:J]_SN=9U@O_2LC-2YPX4@42/@)%O<$(KAE:6E+T5F&IJ=7VT_S5
M'9X6'9U* ^"1O#:5Q^KE>ZRP5<9X(Z@Q@3MFC+:"11FQ#51R8Q?NX=9Q\-#K
M?JN2"G=&1/@ZG%<G7\G^W@Z&\5W4][[S@[U/YPVZSW=AK ?;?Q\?;-?)P<D1
MKU_\?3+MO&KL_7-<AW>IG]1_[NX=PWUWV.C<[_7VA^_UBW_:N]M'%_5V8VX5
M32JXH\8C*K%'/%&,G,O] W$2U(G(O'.Y(M.;*@E0(5F%9",DDXQ3*H(@A&E.
M/=,BJ8AI<(D*8 U=(!D9(QFID.S)D&PZ?DNH&!0Q$1$K4RYOHI I@KBT(YJ3
MX /C&<EF8R J)*N0[/4CV8-:4E9(]@1(-AW-)94RSJF K)02D(Q$I!W&B&G0
MJ 'BK&)V;9-7=>8J)'N32!85MC$(YAEEG&ELE$PD1AH]-<$R.]+)2*63/362
MS=3,5 DD#I>(<@5(IB-@6HZ/\%C(("1GA*>,9"\CLNO>KKY4_/<277U;99Z)
M'?=0+[JOAU'.25':JSG.IO:W9E/3^TW/7'Q^R5BU-$_8.(AK<F5V4QE'#[-7
M1-)O=2[S@OH5=-T'NLYG'&/$.YE<D0Y$P)RT$B.P_2.B+@KKE&*)A;7-)327
MN04D'DO5FGKDC;LW;YUYE^;\J9CW<9EWVA=$-=9""(N(9!9QZ1.R3%,DG,&.
M$8*US+E\&ZQBWE?+O$OS=U3,^[C,.^W^,)08I10(70>F F>)(^>%1\3:I+6B
MA'B6)>\O;TE5S+NRS+LT$[]BWL=EWFF+7UO"B5(.I>0]XA$KI+/X#9Q[I0P!
MC4JO;>H-L4+,^P8*,.UU![;U0&_**/">P>R&[C"'\1<>E<KA^HLS\UJP>NDN
MCK'W]7V98%)!\CT@N?'7C"<C)I&%ID4RYKX?2A&DG:5("5"M(O588I.+ RRY
M7M,O,<?+V&RJD+%"QB?U'U7(^$O(..TF8EXE9JE&0FE 1IL\TK \"#,6;5">
MZB#6-F6%C!4R5LBXVLZY"AE_"1FG?7!.)*Q59$B!W,K%\ BR2F/XXX2-D4J6
M5':@+SDLO$+&"AG?.#(NW?-9(>,O(>.T@U-P21VV"I1$GTN^$(L<EQY%(0W6
M1F&G<Y@YW9"O !KG%"\9O51CV 9.\+=T860S71B?J;S)3N>ROUS15FX]-P@L
M$DMCR,F,W:)\R8=FKS^H?1F>GK:*YGRV5=LI>D/FSHFC<T A45>_KM=.A[T<
M!#7(Q\^.F_XXW[G9Z\4?70]S=EYV#(2GP/%^' Q&#1Y/QPV2:K8H23ZG+5ZS
M4_.V?UPK$B[+7H/]#!PY\NKJ9KG5X,3!T[(6\#I<VO+#UJBKXT3;Q5.8@?ZQ
MA1?ZT6W! H[F+;<7A'O8HUAV9*RE;J]L[C@:V(WP-:/6&1&HS&H=E5R27-;-
M>0 G&Y.+C)$,7D1A@2D:?Y@$KYW&A]MK5DT4X<MU(OJY:2/\UH]^.&C^B'L]
MFTE^VY[WR27.X9>)<ZWXOY_/#[Z%4T>YW-]KP/,_P+AVSN#:8IR-O>^ 2?L7
M^R?AI+Y7/X=QXOJWSZFQ_1XWC@Y!;XLLF(1L4AQQXA5R%CMD0C11 F0QK=<V
MV6P,>5[1\836!N6,U@),Z61#RZX#9OQ1A@>672QKO]E^K=WMY6ZC+2#]<-GQ
MLMF9PSR_K^??8Q..]$I2[XYH<VX_T-F20C>"SC,646H"7S2!K2=XLI=;H:91
MC]$K!E\?X46S7^L/W0F@1&9K&TZ&_4'1&A0FI]]MC]J:]HO)/>UU?S0#3&B^
MW8V3VJ\1MD$4(1.S>:VS:@:!_W</A<0%KS73(.APX*#_:\XX!B$H'=$64Y^K
MS]W*RD64]653N+(+PV[GK\LY^@Q3M)9?JFT'\+R?@W>=81N%[@"-;O>&6?D3
MKF\=$J X2QA%8'49Q&6TR#H:D""41U ZK%99Y5@' I_EYAEADT5(_+]A\P=,
M:2FZ;&<>Y9:B *C'G@+E_82%&$3@ZUM)Y[^Q]R53W10)): 3%E/ RBD.5*,)
M,X$H9ZUADA ]GX3HPK+@BI;^FP?]EK'_ZWG][%!C;SW!&FDO%.+"*62# F.>
M\1 4-\$9NK:IQ(:9]6Q>*0GKM5Y,1<MC 'T[1]&8)8X;:0,X&M2OI9 %NS5[
M8RY-%*.]) I$WQY5<- (2+0JFJ11BB;[='1 FBD%J*(!4V(,W.<ZE71.;,:_
M:M9U1UVP?:O;SQ1QB0]/APAS],/BY@77OV&FW_\)R^MQ(,0YD!(&AUR+U".K
M,<NU2!77GB7OS-JF8!MTUFDW81G,:\8.'[9@N5NE 4OE>J%WK+Y.]BUWFC\?
M]WW/:E.A:=I6*VN;I[8WU_0J?VE9, ?+EO:@<O5M:VP<954LQ%0TM9^OA<V=
MPV.XS,78R2WB6S'?_'Y@^1RF%3!OKL $AN%N^I+?HF"TO5[SZ"B/[^WBJ1>-
MK4,.X!6TY\@G"5+6N(2,H G)8#1 &PA<D=6R.2;6O\9D-Z-NP8^=PC!**=L$
MOX&B!EH9Z&@/ =D 6KLE23#*-><!:RFM!KM>: 'FGZ5W;+(LKG_=3!MO#XN/
MLO&M&%A''*1L-%KGFO:@B@D34"*!,AHLB52L;1J]H>9H[+:PV7)AQQ)O&<YX
M2^GO!8+=#1^KX)29\,2\95I@]:-#8,+@'99(T<!!&=<4:2X2"M;2)),R6KI<
M5VZ6$*XY7WX[.XZ%LP1HH-,=3'II?A][9K(_<*7)HO+539/(]_/=K>7ZZH"P
MSL<^N=@I"*C;62]S=CN^-<R_K!?29X*^:LUV.X9F:<6YF+(?+Y\2LOOJTK4]
M\D!E^AOI_EFU:I_FL2RJ#3[?/L#_ @&"L)VC\F4EL13%@^E#=E!PU0 &DD5T
M=N1U+\V@8@K<$,RAV.^/G>R7WZ>G%:QF'XL)K]OS$MJ)**"=K\/%<,805,C2
M4WA5CMTW>W[8[@]RKG7_W>(J]WC_!^7MX7=$/]NT_]:\+-/[](^_/@MZ0Z@\
M#Q-PF7&G$VRO!HH6:/H]4.\[H5R-T5G](1#_]&G9TWJ'G3#/")@4X*/=P%6&
MZTJ* T3OU7])BI?+?']1/H;P;GH!A%+)]6FB^73Q*WMPY9+?N!%W*=:O$&A2
MEH\;=<R5/3. U^S7CGK1#@K)8SMW4%OEFUAUROM*&F>_XILH"> F!T7ED7AY
M!)&=58_DD8!E+P)%[.EIJ^F+'C\32/3'=74UWS>30[,S+"('KBFP(Z5-\*RZ
M=OO-?,*[7FS9#']7;7UR,-W$52-]%U]=8EV_VQH.;KYDIKS\2"_>+/IIW*A@
MWW394ZO31$Q-ZL3?X]Y5+X.CB!S ^G>0/3#8=[9UEK6X?U\W&L!B&-U<47CZ
M])3=/#'EWZGU+!G+&$,Y*$6..<N9B58P38S'UFI*0(5:>S%VR^H8+F)#3]@M
M ,SWU F39$(E+K&VG"N-050K'JE4RKF\$_?HQL-$= ?,A\\1'F?=7NC'SAL&
MYGU2WSJTU+M@E4!"8M 1G0&^E4$BZHUA25@3([!, A"<Q>6QJV'2Y3.I]16L
MG\W<BEQ> [F(QJ=?(9<;C8I)\ODM:WWM:/O#7A$&._K]][PI5?H!)SV'"^^(
MPEW*QU>19R^$VH[.=G\M\JQ<[P5BG2^CC>?8L+.46#L#:FME_^I#K=7EH5M!
M7_5FI]D>MB?MT1&6E?9']S]@GW\>.0B_ #5=CU9Y@Q;JD=C]=.@C3]$J,$.*
MJ@2,,612P"@9)DVBTCH<LT%R\^;Y::\;AOZ2HN[EB"WBZ*_;MT6D[MB>*9R^
M-ULR+T6!71T-EFW@(@ZH2&@H(LB]'_9ZL5,N4/\4^"LU8T[%Z\$2YK4H0Y_7
MKW:M:A;PH'=4.DYMN<0Y!+$,Y^D/7=XER6&L6?7)/Y8+;_O]..C_ ><LOD6U
M0HOX8X76L-P^:::\&>CS%,^!\JLMP74 XD&S]<O;9?FTJ[L6>Y*K'WNVVRFH
MM-# _[9@(?=F]OP6F)V^/XYAV,HI1#=LUMZZJWC\BUN>JS_-.P4M%ANG1UT
MA00?[2A_RX."<+2(>KH^F83A84ILL\BZ"H5+J7_7//9R.'T/1M'/UX,(&O;@
MT?UX6\1ALS<]Y9,7EH+KTM5Z/_W&"4VC=P2T-<RMDUIB8T'9(1J+(!3^5>OM
M\R4K%IK,I.(SI6M_+@(O8WC#RL[)_CD8^;F'!\D;AX)Q@3CU&%GC/5)@W4C-
MB1:"@AX]1XN>T';N5*2!4ER<(*.P7CMM 5%:[WO#G.0'2L^P<VJ;X:J)^Z"[
M#J"3F[E?"PV9PT83Y%D@,/!/+4N'$NE!)H!TMM\C.@-FF7N#10)GLU+0OPJT
MN $X@>//NL-6*'+(+OEU,E"BT!IZ,0]VGII7[,./N!K,VFZ9J%G,X 0H-HOM
MV5$V9K?3B27WG34'I15\Z^O.0N?SY:5-(DT.\0:EZ"AV8@\&.RR\ 3D3MNM:
MS:/"CUN85J!+V\[W6C]VFF6Z69$NG*GNU)ZWQYE#5UI6LY-[!,30&9EF@[RQ
M&'^">.KW04P!P'9[0%]%4NH-=YM.D1ME*L$H;[@@/_?J!29'L%&;>N_0'6^U
M%\22!5PJBX#: IJ[8%W:(M/%=T'OM#GIKEOXSFJ93P#HRID99]*.!I%;(S1S
M3%0G]$O.N>R+D.>EV.6_-C.C3,"KLWJ3C)4UX?PVP%0P9G<.(F7\)I.,,GZ-
M?LT/P9X!67P^3A0L>C4D.VP-2CJ%P9^.!-OT]%[IU<5RE:G&(V::N=MZ)81>
MKA""^^5HA*4*(>#-V^1*MS,MG<Z: !9VF,FU*#A0!!KZG.,:AK&X!S!5WD'<
M6&37L%A *QR5F%&.3>+.)ZLQ4*O!43)IM:.'0J\M9+(_<IT">E=KZ0*IS<:8
MQT;%%990,NDZ"[VWO0[P>W^\.[\'-_^SU?7?GYDA=O\:,\1!N[[]%<-U9)_^
M<U(_^7QRL+TO=O<.CNO;QR>-]E=X_G<&Y[!IACAH[Y\U]C[!&/\Y.?@&X_S8
M^-XX^2X:[?=GNQ_K]&!O!^_N>3@G $-\.HS,.,L813K%G"Y%%3(1_G 9C(B>
MAR!(B6E >#%L90>QT9XQ:P,5FG ;E4[<>*."(4)Y'=5:+0+&G.;=8F ,,-[_
MT^WW?Z^-I[W(LBHF?J:*QC6*G[^M>M>S-Q^9>+Z,3-'=-$U&?]I^TQ=%M//&
M>]C+3/QV2>OKH=+>1\,U\EH[Q*/UR $.(O@MZ5P2U[@94GD^!7%$I'&22,M4
MP.QIGR@E8ONCL.0Y8<B;_U,4B;D*RRBJTL KM.QI/[X;?_@C-/NG+7O^KMDI
M!E)<],=U/!:G,T5IBMB+\O!5C,(&+N,41H6[1T\>'=XH#DV5V"F/<;ZA-;WQ
M,-X@-QZ[[;:$;&@N'W3;VX\)SJO!OJS!ZH5N>T?9^3M[1)B94^<4ARMCE9ZF
M%IJ^2\TI2]$?]V*LU>&\XW[M/9@TH8@ORM%E-8;7;^PD]_IGYDOSYX+SLB#I
M/&NQP,MW+F[XKCF A_D%9N$W,#_A.:W2\QI_^G@ZF!!*P0[L[PL0R8V%T>;4
M1EMMLL@*V;)>^$:6>:431Y8!)Z]T;BJB6@I1O8'N,8TXJ/W6*LR$9J=PV:!<
M6!",S.RV":79M[1>O=,D\:J+WB[P^BM=V?:WIVT4TX?WA4_3O@D@T)V",+,M
MN_7#-EN%#Z+[5Q'S4R2#C+9P1SZ*E:F"^T#_Q*@*[B?>N/C*&NTZ;EP<-P].
M/IT?;-=%?;L%XZB?'^SM7#3V8$SM^L5,%=SM(];8\W3_XA/;_?AWN[']]_?Z
MQ7<8+SS[XN]6_:1.ZO2?YOY%T=A[NJ<,H\)BSG)5<!,0!Y,'F<@M$H)AG4@,
M1LJG;B+TR[11^+$JRO@URK#))F.C1M[KD"O'4Y2]CDAY38(A)"I"UC:)W# S
MVPPS/\SH^4L#U9=1*[Z2C2]:-CYGIZ *]1X5]:8["1%N#/&8(Y>\01SS /)0
M1O@CHG!4"Y?42R&(2D5:"DD$QC&LFD2>J;S=KH XG"5Y/XCC_\_>FS>Y;67G
MPU\%Y9^32"F2YK[8>5W5UC+N&2V.)(\S^2=U 5R0&($ !TNWZ$__GN5>X ($
M*;)74(U4RJ/N)H&[G'UYCCMRG,%X1'";NT/([W9RP+>K#9^R*CPC/7B*CW@'
M@Z%:'_%Q!.#.#*F!P%X]T17S&7@"(XDZ<;S L>[SJ? F?5",#STTK/41FT 9
M'ER@L(77'0HQ!1]QTN^*,?RG/YAXB^ELLN@/Q'<_CWJ[E6CWZ"*V&K'5B WT
M#.]\'E@KZ^Y5UE7GA0T6$UM,1N &B FX >X T<#F@^Y\.A#]T<(>3-WQN1!$
M:QC="4F,Y'"P6(SL[G T&W7'H/"ZBSD81MYH-G"<^6(V=/K?_3P;]\8/[AG>
MW=2X:D9T.#Z@#CWZOW-*B?ZA)J=U]>0T/6TI2[$%B;;QU-+$I"_V%A4,3]MK
MK?%R/HJ<R>'NDUQET:VI\(*)\!UUXKSWJ"H[>5^08JO)3Q7;[U[L9+:F4\^9
M#T:#[G0Z!$T^<A;=N3=;=&<3=S&<]NU)7WC?_;R8W-GDSP8Y)"T7WV-HON7B
M>^3B:EA>#.5(R)GH>@L)QM>X[W81@;0K9TY_/+07"%H+7#QNN?C;YN(["":V
M7/Q@7%R-(/8'8C";B5EW-NH/N^/)T :'VAEUI^ [34:NVU],1Z2+=UVHEHN_
M(2Z^\V!(R\7WR,4[@9"%)T=]>]YU)F.O.^X/9UW;[DO,$'DV^$/3^<PA7=PD
M+GX*T8U7/'Z.T"T"Q@HM<"GN):Y!5S'KS2;-/IB// ^3@">2-M1Q(-0Q&+O2
M'HK!8."!JSP3<P]^MN=CQQL+^/^30QV7B.?#"#LJ,$VOO4C3V+>SE$/6NAU=
MNK\Q0,M%'",8#_ZS#"O\H^=_D6[W3QE'K10_18KO5OP.1_/!'*0UF&%RTAT+
M,>\*<(WA/]*=CJ>3 9AHWX' G@\'PY\:),A;<^S.N=Z6D\%D/IA,AA-WW!_/
M%G+J+J9].1R"K>Y,IR>'1NZ"ZUON/H6[J_&2_EQ.Y<(==^>. S;:="2[8C*:
M=?L+9S!W!V(RG$^^^WG0VP7J;3G[&^)LUQ'.;"IF?6<\'7L+3\QG"\\>#.=C
MN0 Y+TX.E[3ZO"D<OU.WYX[Z8K!P@>.G@^YX-+"[B\%HVO6\H3N:>C9XUJT^
M?QI<[\GI;#$<><YP88_'L^'<\;S%HC\:32>3_G0P.SF\TNKSA^;N:LS%'<TF
MXZ$8=OOS">4_9-=>.+/N9-:?]8?3V7#HV*C/=]OS&A9R.<3B]1&7,XDQ?%!X
MHSC% ,,--PHSU)S MRB@!@M[UI].IH.!,QT+5RZ\@3>;+";S,1#UQ%NT888S
M%5S;G3 #^!^SB?3&7=?U1'<\PSFJ_<FT.X=K!U'FS2?N_,[,D@,"Y+[,DLHK
M;V26/!&N=Z2'%912VHXSGL]&F--?C*0WLKV!'+G]-LS0>.[>"3/8@\'4EH.N
MXXI%%RY5=!>R[W0GX]'"<[W)8"3E=S_W>\.6L[]ESAXB&8QGGABXXS$PN3V>
MC-W98"#G<CP9SA9MF.%L.;X:9A@+.9A+&RYRXGG=L3L'C@??LCL6?7LQ&8[=
M"19BM?K\"7#]8@8,;7N3B2O=\63@V;.9G(FYG+O"%G9_WH89&L_=U3!#WQ[-
M%](1W9'C8$&'Q$%_BUEWW >[;329+OIB@OK\UI4==\C93ZN4H1C-T-8Q[!=-
M<\^>R &((Y!'X]E +A8C=VJ/AC-GXDQG]OCH  /-"CU*+KU4)3=<A//>*^;5
MOO=P",K'O!*G-4WN0'B]W^WT\-SY?#X4?1!9?1!9GNMT%P+$&$BM\=P9NT/9
M'[<9D"?!_X.1F V$LQ@"^X\'P]%B.AMX_?G"'@]GGEQX1X<:[H?_6SX_A<^K
M00<Y7,PGSL+K2GLX[(X7<M)=]+&&:>YZD[XM9MY<8BYDWW#KEL>_#1X?#^W!
M=.'8L[G$=/>B/[3'X) .!\Y@8O.LLJ."#JV.;R[O5\,/L[DC@(>=[LR;@(,R
M<>TN\/NH.Y^,O<EXZGB>NVAU_)/@_^'$P5K%^43*\=B>CL70LV'?P_G0GCK]
MZ?%5#JV.?WP^KP8B%C98[ YB38V' C3[9-RUW<FB.YLM9'_1G_>!_U''WSJQ
MT+QZAR9''U[6#PTX)2IZ"Q"L,Q=8#X4CH2YII_FME4FGR*2/N^CY ]=V1S-$
M1I\XB"3A=>V%F.-@UL%H/H _.:.[09(XB57.*"/R='G_H= G6MZ_&]ZOQARF
M[G BINZB.UT@'IQPP.]P7? [^G(@)@MO.N\+X/U9;];R?LO[CX-9T?+^W?!^
M->;@#-W^> Z\OYB/1MVQ.^V#WK<'73D=3>9BU)\+;WXWJ!4M[W]KO/]02!<M
M[]\-[^_@P/9'4Q<,M2Z(ZV%WW'=FW<5,>-V1/1T/%H/9W'/[P/OSVR<;'H3W
M58A"KR*?*$Z<?=<QRB.>8>QV!%MRHPS'D9>V>YO'MTL\UR4^@5C:LS<TFE.*
M.(05)\6PY Y/Z;Q-+=4WAB%?M\-&&PD'9Z?\)F/2TW<;'ASN'9/Q2E&8?F\9
M!*O?&@9?1P/_=(%& 04$X7U_OGOYZO_F<\^30WN*/4VS[GANR^YB[(V[D\ED
M-A@ZH[&S6&"IY& 78N'XZ1?-*X!NI=#Y2*$;"*%;QBF'K>RY%]FS+<L>(:5K
MC]UQM]_'::W]L=U=.)-9%]P1X8UFT_%$#*A,>]*@.NU6 #TY 703,^B6T=+6
M#+I?4?2N8@;)^53.I>QWA>WB5!37[0H/AXN[]F@V\%QW8<]1%/5WYV6V9E"#
M6/4;ED(W$$*W#-NV9M#]R)Z*&31QA&</;-&UI?"Z8S$$*>0,P2J:V0,Q&HR=
ML10H>V:W1L5I7KM:DV7)@<B66U] =NM:UJ8=P<GS$<]'G#8ZME6===>*UF-$
MZZN=Z)8C%HO1?#KJ@N9;=,>.XW870DZ[4V<QGR[$U'&=Z:VC6\VKKV_ET/G(
MH09&MUKI<T/I4S'L7*?O#@<SISOUQB[""@W O9PZW<EHXO1'H#4<C^-;NT[E
MV;?XM"+H?$10H^-;K3"ZF3"J1K@&D^'<GLQD5X MU!WW)Y/N8CP==A<#84\6
M<C$9N(-;1[A:.=3*H6\JPM5*GQM*GVJ,:^+:BYEK(](S2!\Y=+IB).==5]C>
MP/6DZ[J$R#1KTN#+.RDS/+;^N'W&M_6,N\3S&O1K=!+][(>N#-,?NRA@&R3)
MN8#;DE^<('.E:WEQM-9!TR*.:HDU'$":6+9T1)9(*X6'Q);D^6_741:XUDI<
M2?B[#"T1IGY73X1K4<,>L$'W DY>'WR!#?!*7>YKN-L7T7J3I2(E"(&J#KV@
M6VY+^$]2H6]W8ID>F#ER8(^[DX$W[,+%@@J="B!NUP,MNEB,)V+QW<^#8>_6
MU3+-L^);]K[''MR6O1^%O2L6\L"1,W<P&7>]T6R$XVA%%W&HNR,QGXYG(Q#G
MH_EW/X]OWYG;<G>3N?O.NVQ;[GX,[JY&WZ;3N1R(T:3KSF:+[MAUIEVPS/I=
M=^&-%H[T)L/AD)1WDY" 6O9N?B-MR]Z/PMX5Y3V:2,>>+IRNC96CX]&TWUU,
M!D[7$<Y\/NW;<[C:[WX>-4IY4X#B!X*$@_]U_:N?]>+>96M@!8=_1O+UPXSH
MY^?_@H]5PF&3,;#))DI\_,"/L0P$DN)/U[Z;KC2+&-_B-?S8+[XB["3"P,#>
MKQC;<B3P4JP8_>?_LN,??LZ/CG9PQ-?N3#Y05.:@@!CB5@;3\A+-_^)RB>'$
MQ!Y.^Z/AN+_PQK;CB7E?>F+1E]/15,SMX?]-!]_I+ZWRB.1&+&77CJ7XW!4>
M[/!'$5R+;?+=#Z6#6/NA7M%L"$NNGO/^T]PYT[6(E_ T=8E3$O-W>Z;#RIG.
M:L_T,I5KYIQASWHK0L&#$P@P<_938KWT$R=+$-'0$J%K780BV"9^8D6>]=H/
M1>CX(K!>1*%+)$B?^2"3+$CI(^\W,B9Z3_82U_T?1$Y<],0?_11(V3F"W#ZM
MI.5%01!=@X"XS[.Q$LD:#R6$\.$77A1?B]CM!E'T&5^>@-;A@18=ZWKE.RO+
M#Z^BX$I:L9]\3NC16>B D(*OH]KJ6>^SV +)F,$28O52A^* KN]Y,K;6\,08
M%AAL.::8KJ)$4FC0\3<"HXM^B&'$1!Y8C27@_]7S<4]7(O:C#-8/;XYB6*P?
MHOK$+_'S$YGBXU+<@/6;B%/K\K)C%40XN(!]N+ \>+/EB T="Q[XL/_3!]BJ
M]9J?W*/?#7ZR\))\E$G^VO+R0S=7"$>3KN!6[O4"5W2T-MR'%'1R<)7_A!NA
M[UW[L%_<T-X%ACB_ 3\2RS3" Z*/;Z6(+1EBV/>E="0">_ IC08="XT:M3E\
M:T!7=H][U(2'T69%ITPC$1#:11@BH7V0&[A;"Q[S.HK7UJ#?_=N)F\&'_7<&
M="%C(,S=Y_UW_KQT%4MIK6$EJT0]]ZV(G57IH</>D7)G]&@"^#V8%E>^O'[$
MA1ZG?2]2>%(61TX,?[)^\:/$\27('* ,O+5-%F^0PX&T$G^] 4%K 2D#8?H2
MQ%22H=!!.8#WMY$1?(#Y8@D<DUJAE"X\R,Y /,!R(V)\D&*OZ;;QIL%T%RZ^
M[%IR*D-L-O!L)AEP%?Z5H2!(<,$H$")X)"Q6K1&7(MPK@?]<2Q=$7"A)RO*G
M@FB)QET'Z4CM#XEQDVR=E2]PBBM(S800*Y1D!=,1*#/AE;#\8V[X'9P6^-='
MY.\$EA^Y]*B7<;:T+EPP(/PD98Z"8XNMUR\O.KB3.+J";Z5X%BP5B,Q!Z((%
M:+G;Y#,NV!<=E)GP[R0*<P:'E4F12%[\6L)JP1Y,_I-U @K&$ 6/'4>^JWXK
M+'QLG/@>GA^R&*@Y/T)^![4BD]1?T@J!HU$DB0THE$*(;4!6@9; /^*ANK#[
M!"X WFPY0#5XD'R=^#S0)#[MYSJ* Q?L)6D%_A72 3WO!J>O^:09-L*S_R19
M'P3"COA:>6,7MOUW7UJ7H=.C>^:?GS>>R?^ ^Q&@MU9 &)?O_O+AU?_^[\6]
MG/BT-SEB037N$"+&=$?T[:I3!ER #T"X]\%L_-,]4\K!<[2>78G EJ'X$_[T
M7)E2%>$ OWPKMJ"F!C.TH]A B),4A4(WEPDN2HY<Z6D!@;RU*QZ(;_+[>__N
M+Z_>??K'Q_;^;G)_T0:6MHD.W=Y'N4G)D$%3HT^V<%B^/!"/71 )Q;7A10;R
M*G*CC?C!$;'MX[_P886D1/F1B_G_R 6\);^ ,8;J#,7G.@(SV/*"#$U\I2PU
MPX)832U8@0M_M!(1P&ICN0$YC2O G6#!* A_!ZQ]\ /^&<5^ND6*0E6:1BD)
M\,H3'M.0.N[*4"UOP'(,I1:W!BM\N'QS^?'CV8JR^]9ZAW4<K'<)!L(7BT)<
M:;*?(RZR908"#$3:O%YFK2,7'0HRR!(P#,&9V( G ;R31.")X-.(_DNV3$6L
M?;B\^/7=N_8J;W.58&RA'>KZ4: <4/ \5W[HQA&:7X[$*T4''"Q;R1>04X'^
M[7XR^&L&#R&96$L$*RFNMF"'A[ $=!N!J"3%"+0;"\11M5Q)1-) #I"7&8@D
ML"CAAY[U!]K?CD1%&$=;$6#TPP*/ OXWYA(IC%F"5VS%M#P0QTHZH(QCZ0AK
MTKL[5L[=:Z#J:#GWUD^3S/:3E6]] M??EM9O*Q&O!3CTX(T9?L;;3[^]Z!0\
M]/(?'_]^\>9<6:A9AMU?!2[#H/KAL>;:C8@7;[),NGR9S8]T_)(EN._$^A5^
M&> ?$NMX;M.9FBZ6;/XXF&\J=9OXF\:$CBDZ.7U$0JV<UAC9ZKN?+RDN&4HC
M+(GD!#8F.QY.M%X#R5& $JBK(*YZ.J=8C*)?C"K +D"KH +9\"1F?,#WPWZO
MCW\*2!9Q$/%:H$GJ1&"&_HE?Q9^N9$@A'+90X8^@<_[%H4!\SBG1O$<GES,E
MCOTGWZ&_@6\#MH&#;@_'W4#YK'T.+L,'B3S*\:,0UDL>+$7KG$(A7;Y[V2$Y
M^>Z7R^Y@,)A-IGM,QL19^7]&FU4L0PR X6<4$9GI"G@SZ!-X/I@1 K4@.$R7
MEW"NF;NUW"SF%$2^O94(O)RJ+)H>;F4;=-4P50">SQ+#6IT242,QCPQB)BI&
MIRQ,F(8__+M8;WYZ>9B&.\7J\;O@7X&U _R"__,KG"R5>ZLGP&+BE@D>D@D^
MD??K2AM(KP!-Q^!S+(E(["U(M$&_-\^I .[M^\&LWQOGORF2AL@CX'IGL4,$
MB3R"H8$O/F;?@JTUF?P;F0;U;STL"RGUQ=\42R#7)7*!\;)-[#M,M,/9HD*U
MX'-QEDHD*S+NS1 V)Y1(.*>:LZWO9R;E!U%"Q@@0$RPT P.4N+45WH\HO'/?
M6TMK+02%DH)P#RALY\/9H#_&NP()IR/YX%F!7'5]2D6":X;V)0@GSA" ,[Z)
M_#!-M*2,E'A"XE.A(U>D0B>2=U[=(9L6)6L*!T%F@QO1FS:!( X"IG DMK=D
M,:8<BFQ#GE)PP4 (HHW6"H=W\IA>W)%U%^N-<#C'^E8X<=1]!3P3K7U'9[CQ
MD-'5TU9S$\S[O59P_1Y?O/_[Y<ON8&'])8ALN)O?0-)(V&+S8XE_<([;1XL4
MJ',=@2A4MHE/%T=2&W[*M[A1>\-K0ZEOJVLS2R#P]SD]IUA\D718QW?1H=]:
ML.X,2R>R6&+Q1))1BC/F^$N">6('Y7ITY7,N##4 R$4*ZT;*KLA7M :;0B\6
M7ES4'CBE9']<)/NCHJ !N(@*4?*B$OHL,+ K-Y*D,&XTQ/(VK/>06(Q"V=VZ
MP@_,N8HD0\/&EO0K\5F&J$I%EJXB+K2D<_;)= 2[;HEO5\'J#=54P/KTUEB\
M27CWDI*[\">T,['X1!0E'_"4*^$'PO9)1M$19F"\)HF7@<HLY6(I D3-<NB*
M7X&-BY?'Z6<0)VA=\OAF^JQ2D?65-SNA3%JK/A]^26+N9I=B\">];#@5V"3'
M3'./G^^-'*:$A2Y]16<=5. ^R2LJ:H4H/V29!0)N;*LSVAWX'98'P7M5>0Y5
MYUB#BYY5*L#9R\-M->.1U8RS_=6,C2E,;)(Z^8!E3.*'WS_'6'N$-4L>?#%M
MOC8!X^RUM&,PA[?*/..M<+P%A(<*GL!)P"? A1;:HU9[94D?A<L(9<A21IL(
M/LQJ)(O7D<]!?*6R*#VHGZ9JZ7.S?DD.>!HM96%G85E&2(5]@BO6$E0<D;+T
M>*T=+G6A[F*0>"2NDRQ!96")("!##@O"ROJ-7G_%\AT==R-VRDF=[$JXXHN/
MY7"X1G4N^">]]<;'X_%JW$SI$=*2)0O!460*JB^]QN[KW3VB7EUA3'0+J@2T
MG0L?QTQ;KLBJ.K[T7$//:UVM4KDGB/U=A7^_RN_8DZGH1B;S&^_R]LJM*>Y#
M?1FJCI]]HHHY/(./_A?K+==(OJ(:20S>JA+)/I=(TN>P /,,-LTFS\Y"FZ*A
MWH';_)NJFOA(QAK8N/P/]>O>;L;CY_]B9L\-(1J,135EFT3^J/_QD^LG(&2W
M/_HAO9B^]%/Y:FIR9V3M\)\+JZ#79\M @6JH-ZL_]^A/E?X9_MMXW)O/AWO_
MW.\-]O[MT&,'@]Y\/+W18P__;3(>MXL]K\7.CWKL5R!A&@&-/3^JZ;&^:RW?
MT^*8/;$;\SB[VA&$?;:)4 &9BH=<#\H<@M[9N]W=*]S; GNF)U-5R/O/Y9YH
M_.[5Y7$;?W8O(?/YZ9J:5@/FH\IE))6B[$/]VOM&L>+BSXH*T>X[@@F/VO Q
M>%_?TL$-[D)Z?:-GTQ+5G1#572+>S9H-PKJ_9OW43OZCZ>';!*<]?ON-!@$9
MC1>]Z<V@'$X1"$T&4FX)^5L@Y.%TW)NWA-P2\KD3\G0R[ U;0FX)^=P)>;P8
M]\8-)>23+?X# P@;;O'KMN2O6_Q'P=T=.U^U<>0X/)D8FS?U]EN_H7Y[0XV^
MH=--[/:&'MB??TPI]P1&ZWZJAVNXH8%3E,I9;I1A58+>P%X+Z.G8O[<^G&8S
MZN1T=7>WYW,>3F#+(D^618;3Z2U#>BV+M"SR3;/(=#)KM4C+(BV+' I#SLY4
MB]3@W!_LXE:_P=4\7GL&#FT0L=F/X-!OJ.8: ?4B-[$"D:2$4,RMA7[([?[8
MDG( 5 \[Z=W8O^)>1OTEEYH1%9P?[%;$JA,/>^IC5[7L(QR?$_L;A:T<2R_
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M(EGM)T(MT'/E0 C/1+<G:K,\4I.1D886LHSAL6N4_NK5L, 4* 7_R'2#N/[
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M+&UMHCCU0"A$'0NN";X0P%E'GI? 5=A;XX7YY%F\I$T<8>:4Q\8:\V"+CX=
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M<O[Z?C*8]29F/<+A"HAA;SCY-Z#3+]+MQD2S>^LAL%8R7]1@@JL:CLE/0@[
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M2M#A?W,<!I(VJG??* WE(JN /*$*PAV#XA&,N2J+HLHJ3,6AJ'7@3I.\EJB
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M4#(PB-+T\[6.3LR1)\:[%&?GG.C5C3E61*0&.!M$G=]P_G M:S."I4;?+='
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M/0WY4CETU9]7G<NMBIVH-C$+C?=H5E&;8I=)=6&4)O$@F&ZY_*68*4P;I08
MP[)6O1U%E@,]LIYU27$]AN_35)V#1078."Q4>%?"BJ.M5&O",,X&M[;FUQ4
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M;$&Q@-8-(2[#-^/\]$:(M_6Q.(8 S1<%O/XT).R0%#"#SG$HIYS6Z'U'@Y>
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MH_F+7S!10>7.ZHY;?-'9FTM6DO%I$KM<N;_\VN^]_TW SC\>'#W>._SE;R2
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M:(W?&OOB]9L?LL'K:]UNH8XV^S.G?M%6++]2,<%OP5T0S]W<@9#N"+XB\92
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MJHW!1H35XOGONBTTO\DY_6#V%G%11W,GXX4^OX]L'3D[3]U_P1:GQWI<P/D
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MXZI(RFJ1&,KAT07&<-.OE<V2AKGPZ'NSX[EHGI%R_>6H8'KER1C6W4#1BCS
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M6(6U212&Y-"H$/J1V?\$-L':L((=N=FC6'!7TKB9OA<_D(2OD9/-K$2$3+J
M3%[%OV<+,5]2J&<18F+UF?1"--^@#D>L:K&97Q5M+/MN20]P?BTS<M;E1MR-
MJJ.J%?%^*A4EU;!-&@*E,_B_DJ4C1>Y>Y*6G,G1W(NGPJ77#OSGR8_WP-^3]
M [2W<GD+913X^S ,Q+#(-?&BY1C=CT!!8&;_3ZT:3B)T[A2^]%HQ^, _G=;]
M8Q&>?/LT*XB]EVC!15 BZ(&-3CA\(<&3^"M%+GJYSHB-OE5,&3(TC196([F;
MO\JYF<&<,X&ECQV94UET[0-^/5FP[,0V[ES<EO/Q6@@S#L5TT4%W56[?Z'NW
M ))M0*U_J3+C(1/8R&:V(#F8K1@X+>5:@DCC_)_W^XGRCJ(C<I^8+SC>C"[7
MU*6@)T6[&S[E$KR_P3M(9VZ(+8E8(HJU_<L6+:/(_9"K*=/&'#M2D\GZT7NN
M^RXA(;;/.5(:N/[)8QRBZ%156ONY;XJ6V#6U,^A&8\&8&DK4;BRB;SS*%I1/
M&6BV#^-ILPN'<N-T=J:$0[%[4_H=!AO+N/JQQ@[@8G!H4Z@/Y=!ES4L<4= C
M"XES;6&!7$MA3":,N=DKA)(!6D= O6C6$6+LNY^B2&?'O]DK4-,<[A_L<S;"
M.U+@ C1H;!J-8S)+"YRQ)[2J@="F&&O%Y+RRU^6X.%%C\\*/+D_R.^J,F1>E
M',;'W!+*]T5>"K&,-S,E7^GXY-C'0?X.%/YJVXP_@T.^.6^EML&S=]K4WNVK
MM+?"_T8V(3$<-I1?R=0\2AJL(X9_]5,ON0#!W\&^;==.2%-==8[\3,A^:42U
M;/*>$:_Y*0)';RVX=\?;:%?- R5?2NML;@+T]. YM9#$[66\-[K\HQRX2THB
MBH$(WY3"DU0"ZI3\53X%9O6-&&XJ%&'72,51H=D2?OO!ARL<BU;B_:;[ASD>
M-:K$WPQ1K'^_'=;E5C6'_014O2 V%[2V.Z2__!*9U5QYHZE1YF1C4(4O&M-+
M$.M@R8#8@UZ .0L@OJ".#$I&$.F$Z44KH?\0(;]U0;6.[XNMHN7(V!0A-A8T
M]G"VI;7-'"9FA^Q(LC[/4M+C3OT5.J9[%,BI]V#5K[SE..5]G1S-LU5/N27B
M.*\6XF"](OKNO%C,GI-)>(?OT8%"$TGKX/!H[^!/6% '1WO[?U*KDXNR4G)Y
M1NB3Z=2U"22I9""Q-#.-T7%Z[!;*;2X4'_UUY_6"(QE_Z/-AK$O#QQ4J\V-\
MMQLN#&0\\Y+"<- >UR+[(IDN&(OSO"19IZ*B#!7^T7;>E<8_5\3.2]]$F8#)
MDW>+X187 VB8M0"06@7)Q[=QQGF)&' _(E>N]?$T>V\=\!ZX<W[4BXMBT5/L
M<7E><P*]:LA+1!8\7)=S6 N.M>KFS$?6S-&S.S%N=^[7>9A[YP.W0J;5>PUH
M8L#^#;,4.+!/-U.8:*J6EO4E>G,X0"9_<TE%B'")(+Q'"R=H#)E54L 51GDY
M1V&'E8L.CH["":-QZ)JN1=420KI(V\CI)FG),.'^IR[MG3[MKX:U'-X/6,O.
M;GRZ \';IJ%,0],Q1\3SN+G/\C6C0/I(D(L\A7:/6,<"KF=%X#8"KT2;\:WW
M*==UX9^O7CX@YI9P28IPEY9I0W(Z:;L:]RV)\U&+>:/?>Z^3NKASE 8BGXN!
M . %UM08M1"MM9@<7G)U<LJ6U'VWEL1+N.VI"P<D>U!3([<[Y#[7(8?DO(:U
M84G 2PV+*WJZ;[F!4O)A[YE4?9S"Y.2KK/,=_/[6C0_E@"7#^>!$&7G>]!VK
M>;U3INZ7HEW(-@5E*V*V ')UN=%R,6O%9(K-8V9!*NY(GWX@E7:H\1 @BE*3
MR@=.3@\Y0G!<E(%JR9"@\_"I>U$8:P0PP^6?C] -NG"F1Y:2C[SF#;3*.'(Y
MXG>;?QP@8OP>)$ZA&;%D'>X?'DS45-[W:\JTSDZ E/";<E6T%$WD%NPE]>P%
ME&<3?((?327>HO0GP!%($T<12_(XNQ96H"%QTE/I7J#O8,GO/XL>*1EZ2H3B
M#P?/D+!NW-I1!$LQ\HF?^P8MS#^>]P(%I!L+X&S%_JVL';VU*@11#O?NKPSI
M.\YXPVB-Y:I9:WIFOWCK1P;;;?87^A]E1<OMZI(6#9H[*39CLD4"4:)%!M+@
M/,;>6O<-Y<>YIR9T88Q2\#'8,$TD-#M)$PC[)*=^E5>S[]UITQ.FX."1K% N
MVREOU=K%%OKC_HP\%_TD^&A&+P;\!.4WFA[5U'&:E/;6F:OFA;)_713N4FZK
MS2?BG@2]JD1?%10Z/(+ -8Z*)^1M)'RV@TH;;4\>P1 ,+=R*:RL*'OG9::G@
M,B\N&+G)L:!,'5W<S2[KYD-2+LF"X> 7!"Z3B'ZHA3EB>4[SQGMCC>&QPX-N
MK0*-IS8\NI1G8'RF$*7)#DVI37[VXX-5YZ^A&YMMAK%W0Q:]3HQ,Z0W]C'LT
M!%%MOJ2$)28E/L1AB-'DG6*Y8D@>D9Y5: 3TY>Z\W7B#U(!%DX"ZR[7FE.&Z
MOZ2#\T6]ICWBPW6!/V">\E:Q"$KYI-?156<Y[E _$7ZBX&JO\PT7[[BO1914
M_8CW:V2R_\1^^)J*W-X-]!.^H=D$TV+.DFJ8FWYQYCI:&H BQ.KG06I%_!+Q
MOSQBJ)=021&>R^^+(< &E=?P;#%E/Z+@>EDMFYS-"%7"7Z8ZPW^O3UNNYDX?
M/+I+#O>)R<]]G+MU)Y$,H;CKAC9AVR-UAR"'T(&O<F\'8=SVXS:#9W5T(-*M
M5_'H40=3"9A-K&*FNTHP;'[_=/D'5^WY0X6,G1Z/!EW !VO.,-DPR3&%:.<8
M(T T7_P6!W_B^?!/ZY^4)_SH3V$;%V .-9..?>@?";.E.Y"-^_&*RA5^@G_,
M?4RQ\8_ZCB0%EV8E'$XGQE2J6M6F)U=F2ZT@C(G@%6K7P'G=@F=0=4Z)V6O6
MD25EX ;<X-:24)G%1 ]G,>_F*$7E/-;L< (QHI/^:WKC8%P)+N$8->W7,0W=
M/8!_&:Y)-2)!>&\"SQ8LC.#;8QPI/:I\!"JYU7!6V5=Q#2AI&!,0X73XV_FF
MI1.G&I=7@,Z8*TKMY&\OW_K%IA#W(?KBD=H? 5(0%9'IQPU%0'J0OLPSA74N
M72/"B4K-Y3T:;SF0/_DKXRG>@> 4/'R(A/S3AO=#.Z]*<\)O^V?//8'ZB0+"
MX"S.+FF@;??^+_GJ6_FJ5)1HZS$Q'NI+L@K;^#22-.XNZQDE#EFLN5'ISM2.
M&C=P<<&DN\>E=%M?N'#K5_7"E5Q>/W[[JHVJIZ_\LNL>,#O*R_!J^K7WF]9;
M4WSMU<NW[P$]>TT-G81[\]/TE,T8AZRMR:W[R8806/1B)-? SW#RZGT6G&<Q
M6>3U\3^9#0O -5W2]=4#>MRQB:/NA8PX3OF\2-T8-#4)M,HV=6RY:N*CP#GS
M/X;UG2+?[H&=\&M4B:@"(I(_X2@02-SW=MZ0PNY& +3EAD&*6]-$0HW(C4A$
ML"<CVXC$1%!CO1*]X4/.]V1WPMW/$9H&XL)PG BL-SUZ(2K:: B1N&$*_+P:
M[L<=3=C TT<>VOFYBR,!4_%)(O+)&)),@YYNJ(M^ZKI+=A,CAC+%%4BZ->K9
M<N $U]H<:VH]4@!FK()K-V1@+YK(6_AY/7PH[A#=Y;WWH7AK'QQE0II-;_!C
MTZ_60P^>@.\][(U.RR!23'IX1E,?1H"3'-QZ)S76@);5*RL0(WF"D*0.4-L!
M>:;VC!' +W0L^6=B9R(Q.\!N!-+2RHP$!H=-M/ BG,,F(R$6:H*G?5'R6O->
M,46L E'C8!/JO!$W &?C)*_R11XXT# CQK+:X4\3$\^)HKM3N*TD<NG.?^O]
M0DK-[-_^]CY3DXI7-@S#WD+6X ]M\R58,D]YM5C^!0:YF! $CSXP VGM@^:Z
M)/.VKM%I(FX E09FS[VC7F!++7PT/8==:<(9)I?=2#FCDQ)ZTP:W6\''SCK,
M;91+/MT0$I,]6YY6.I@Y.*>%02Z.?=O)5_1;K63DNX362<4&Q9-+YT\"%%&&
M5]-DR++X"'OC4N7DL/NWO>K('C I<-P2H66$O:-@R?WI[MUWJLAT13G[N[\"
M<CY81M\.$.,O=>_O'QYDVT/TN%-&V:U,TXK^J%S52."<* <#!S&=#2Y>^!U8
MKS992#F2=^/=MJ[P;V5AGGFQXG$?GQ1X!\)3U17W@.&9@PT8/6!M-_'33%[6
M;PAK 4Z2/H*WM&YI%KU/C7/%O];?B,L7J*"W7)&3GK&.3MA6*>)+%_=W,&Q-
MY))NJ>&<B'5RM$DZ[NB*$%4;/Z>9)3WCE)R1E1+(Q61O3W"-\3GVO!5)CC4*
MB5.>7B7PCTF+:"(2\SN^=K*.PK,5D52&U:6&&-]!9FC0K\4'M7UF>O7T#(:O
M2&VK3/0'\\'^/=KY:;%?90WIO4)UE:=I!X;XM6"(H_L!AOA"PR,5_"M*Y70>
MRMG%2W)\DJ*!4C",ZC)?HJ-3+A_@L6<XY:1%$6YGSEF2HEIJQHGS+&NR1'2>
MK>LY 9ZY(PMW@^O9#E/ E^<.>[#&/RLQ"^3_%'[<**O($'Z;"]!<=# FE.L\
M[D+T[A3CI-L>&6/I;C?DR.N\'1H'Z2;0RR:,X,:'#_U5TXUO2C$T\MRM:2JX
M*T-]\M37#KT:5!,(M?8LZ%1HPY#Z!'JG/"9!N&H30J0!^WP29$3;B1QL0NZ?
M)>_M/U[WJ"18)Q2>&]O2V$6*L>C+#ZK/0QW_=SZ2_6G4H,=-.<8QX_>\HC01
M4F34QR=)^J0,,FQ>1M37%&=U0QP'H5834(4TDMR^F"R23%JV$O&3^K*ZS)O%
M9%^="_W#%.32::V4-LQX 6@0UA$.X]@@C*S'F&PDWC:MSZ5Y:GI"ZUM-9K^9
MX3Y)5:<;@E/L:N&":FZ\\0-"$SB#NASHE@2#DMPD9&PY^!#A*^XSW>8=8SM)
M ZH$QEJ4:K:M#GX<;=/NY7ZG#BZ--'&S^@'*,OY3/84#'39WRVE&?CGOT0?B
M&LN=Y!=YZ%8:=G?'$M$J_SDT_8-.1(H'<DN:-+3!4X!!3ZA9C8GF%&O-PL30
MBM2LW-UO#/QI2#EB>:+I+?QF&:ST@?<;SX?(!F1%9$S'FC3&2MN:V ?-'J4,
M*S@,_7VE'!429<-<T] 5#R(1-WA>\79Q*@ZXUGGA,T/5',LL,.+42[Y#[$#&
M17F)#ZGC<^*O" TV0;LIGGU<@$_IH[UO09Q9*N[&$ JXHMP.F<C\6=XQ+<]H
M\6A(?SD6M(WD"&PQ)+?W283<=XJX@&UHS A*KC_=O$O-:G(GM*B016D2T,(9
MRC3_@U^RWA_P;N-74E-,FB"_WM:GS^HZE>1\(AF=V!QT=O*"CQP#1F-8S,E4
M>[R@$+(DUT,P)/XI0Z%ME) UXT#$%JH*DQ+$LS8,,ES8&\1\(?19D):AMAN\
M"O8!Z\9<.E[[7!<'1:C?/?YF!1,*5" @Z:,F0I8J)9 32>^"2/H\V/G6#I%W
MEBL0CV M]^3VE<KF!*^P#Z*_O*R-&,)=6,O7DLN'-1 ?G'$.<4F(T8S3/)CU
M5+@*C%'7K@)[C"E%<2S^9L-^9_G.TF\?I]2M_*M%WN7L0<PWDIB!*.9&_FY<
MR,3Y!L=*E)L*'DEP)KP7N +\PAO@WD7-JP2Q%.O-5NE+G2#1MH.M.R]."?7D
M7W9!@1P0@LNI'6A&)A(W8FBDCA%!G8GJ=,:4.\5I+VQM&OUH'(,?8G@B9I=R
M??1Q5AV% !8,5;0_X_*HY6.);V"RHJ/!X)+;= TF,4YQU6&W;[&4JD#"$%I9
M?^ED3Y@[O*(9@BQ$@?/Z0:@6^[=ONZ#FY0*K@+[[W?>OWJN)5&3 KC?^EE62
MU=P=^VWRX#^+^0=BIT-UAW MG-=7&]!.[P)O?5NUO0'[CV" "$PY<Z+G,A^,
M+;+*O)#1C")52HHQ<2 UILC5N%5?B8'??GZ+M*JP7WXH*"W!'9)"9M$X"G/E
M!/ _^7V%_'JH G%UE& 3[+;FMG../RD.H^J\9@)"Q=59'VBACF(&YYJT?)";
MXLPOXSQD4&77RA&U(C983LOE5P118RR,#:!V?2Z?:;?,_;)@%V'>D!-&"V1\
MP*<(P_2[W^/C)_QQYHDA'!+^]JJNN(CP5GW"V0_L-F+E"'E)N#,> U\,/F0@
M7[&]GTPI)]N3EO/49HY;%OHD<O92XB 7-D/XT_)'Q[O,OEY,L&0Z&JALRG(/
M;>H\7E2I)'^I+\4S7>7,J"I_AP>FR#D0OV8Q1F2*FKG#&!AF)$U6^]=SF^W/
MM]LMM[Q;I #V,J#*WU("V,C6D0R#=^_T5]@&!!1X^?;X.%WM[=1RCVWR6Y>S
M5&*QHMKY.?50@-=2G?2-M;%:_U9;&Y?C8#&FNK_F"L*8NEM9M[BR9'5LI=5Z
M:>08?XR$@F2$N/1/S#QD:[7Q3+X7C##%T2&)6R1*V)&J&'TGLC0-)YLU^MS:
M1+A0&]"+BCHD6;D8IT;9?C<HV4_$:UD@JP*4)[)CX6.HDOE+^+@4Q1@;1:++
M)88]*A 3^B>T1=<!.:1/C?S.D.65L"9GO82@4B^@0#:+46RH&DE<QO4_/8^(
M/8!;!0MD4D(+2IB]'4/ KRZ*/[P?1?&=$?PUSNC;@ )^JZF@]SVE<RMA(%3Z
M(13WVV!;1MR14@E:.,'L!2@LEX<19)3>,A '@&",TEB&^"\O\J+$ADXQ!MFH
M@^SDO"@7C4%-C=T%A;1S^E3DX:6]AJTM^BFHKBPL;RP@?O+JO34D"?1SE"V#
MB5K*$'#&#,$8?3CV#WSE?8:B4MH=[EI8U&(<8<=:</JO*?'4-?S3NEYX^XH?
MV&TY+XA7F6WJU]FX]I=DVV=?:; 7<=Z:XY$+5E3N%,@S".:(3!MVE\1&DKX6
M$5J/_ WI] _^2$V_:U.(3TF#KACV^I(>@L#%7&L.;51077,T$N>NQ)EM1C>>
M/\4*XKD=!0BTE_RR(]#<3G7O]MGM<K_9*0,.-S>;E;4"5)05=UJ@6A<I)\N)
M4OW!!\TCX=OCP#B*W-*2V[ _47(]W*1Y+5@5VX>OX1=575[$CF2NDW+..Z1:
MV@@'P&*KZNI! CJ(^B]:?AJ@;5#81T<LEI_@A&@($,,J5FH Z(F\U:$T%#5#
MMFCA!0OHWXO"H49+1[""A 1W#/#4-AD"C5[D53?\&/Y!F?&^/,L-N?1$[+OU
M?::Q7[+;KS.J,;D^8553@QH_.N7CIBL!HB"+HE/,A$6V7O$F";$QUY C7S$3
M% >.+'%%+4]QFX!XN"?-J$:5>5_YB#)T+.,QGH5ML) --'XNGL&SB&T>TS;S
M;O"#SFD6AK&-KRVX9PP'06=FM.D4USRU6Y^9LM9H9_/J&/CS:6$JLG;;E1#@
M7T4S[U=<@D"U@E4->;<O"K .(2\,12VI5:6"\>AFP-+PGFB%1!$K"3CIR/ K
M6@+ [AS8IY5(3 "V%G:#$,3?_4+F"V&R!V8!:S7H@$S6I[2Z'0V+.;4'E4J1
MXB%KZ<:"%WNSG\Y)D$>%S1M%8E\# 8A&$@"-M8\;7#-57TL>.\*[0Y/U8L)$
M:N6-URT;&+5LTZ"R$?^_:+5P28P;.J4JQ[  [3@=CG)L'%/]"OML6I2CA*74
MY+A&@M)\Q'PB4\IOP:/JERZ?9G&:AA7B*108XPV&>D=!:#(/!4!3]5M'\ECO
M8ZTC_Y)B::D'MVX6J9"\%#R[S9I9$L),RI2!*[ [CTP.0]$%[9#+Q"7U!I+<
MB,1C3,[6*SIV,KM08G$^"C9EZ?S.8]F_=5U7VO1<(*POFBM&BU$=*?X!"*84
M6+(D$AQ)?I.^E ^-@O&.ZJV\>%E,Z92:.G#("-)J"$!$[V!<.9P95W^HCPJ#
M"8E&-HDYL"84N=$LS9<.>BX,UB3@2U9:=* PAS'$9WX*!3@:]IP/ODAJ3S&\
ML1-XP!=@XKUH$:X$!QH,&GL;G'HSU/"X$.34J*N39?)D?9JU0F1R#5$N=*SK
M>\;)*,5]6:AX_"5<G!:&DDA%@L+"$HZC.5@&ANH.@'6R67+.7B$C8S!SHK%]
M]Q$!J5HDX14Y4$C$]&8U<]88:"L9N:XMA%M@0E<$&=RR^$!CI*NGQSFL3A$M
M/>^Y<K9@.>27X0/65<KK3CL]K4%8Y^I.."*?B [\24!J+&$=BRT$6YU9;7 Y
M9#=1+ZP-P''9X]*7I^)YV>S-Z[^^>/WC_WD?C&,ZH48A07QGX,_;V80F.5?5
MQ1>NE\L'97[J2G6#*0M^]Y?YL02.&RN>Y0?-7?E>>'&R)(GB!$'C9^'S8*HH
M6DM:D8=A9C@_LO+SV.RF&GCQ'%.-1_Y:B%>_?W[\('0"\-TFA7RD'[57V7AL
MCT1CA^]K8P26B@M7ETC6>%%V)0C!UU[,A7*)I0NJ?.=H5!%,/;]6E.B NKL=
M,!I#5:;5QNUXC$W<6<7ZY$^D?!-BW3!<\_.Z8 5;CM@"NPSRC3K&HZ\9]=^0
MA/VY7YSQR=R1%NRBCJ"]@(SC;,2JKX($'P8V9BAJ)3Z#366-V9&:7S(LXA_&
M4=-,3N@<HNH3#DIJ!J81@2O'Y!I&CSD^!$1GH7+A#[GN?-FSQT)?716MOQQ\
M1AMNZA*->LGH]VRA'L@AT=1*G:4KE;J+9G';Z46#GP<_5#;A8K"=J)#5M6$7
MC9RTQ!\+AC.I[XT!)-Y\\%Z E!^K]DPED48N4=KBM;SA@IV4;=2E,Q:KC8^N
M-AS75S/.>,_+($&(X6@,)1P]4(ASII^'#F6F*):S(\"IV=MVFB.V+SQ@69AR
MF:^$#@RZB.FEH^!C6#Y4UF<Q<SX1@2DF=G1!U?H+@[=!VRG(A?1_"E$"!QEF
M'+;$ QB-T+N(C-]$O!/0/;U(U 14^B!,RV>WG&7>ZE%,GW)^X<ZZ?/5%]63;
MONA(!ZNG&,*?*GELXBHINO9'$)T<I^X\+Y>ZG2RHB2$"W/@D[LXB+-FP4A4S
M*2P.:8-/LL\2>]I7P4IQ^5X[!88&QF9SL*(I\1"P:'#!*%&*@&26$_31IF:"
MK0G9>S*AM,( KI)4\Y5Q5)O0]_$Y@"##X*"'#[XKZ/_:@OZC>U#0_W)>-!UC
MU5D-'AFE;4+INJY(45=VH.19AT&]<2VG4N?<<(KM(AD2V57A5(N;RG3*4<V6
M8W%MSI/>N="SJ0G(S&BE>A,@7,_\%)I-N(]AY)\EO9:X<!&7U8+43:Q5E\.Q
M\WZEDQGREK* B%$PA%0,:@J'-@<96>[14'HN /;(TV66V'"1:]M3D*]M^G6H
M<0^R@FHKT?:AZ#'OB2 M+L5)/0AH^\W/'>=:I=,GL!DE@#%*#^G-XDQ+N7Y6
MUBV<NMA25XN_?B?6PDVZ91,*A1C*(%]XY9)@!('E94W@=?4IE2_"]Y#.C*FM
M08.J2/="9H\+K(!.B)\;]R"6&50VLQG4*@/0+>,P)0NES7B>(@@!93JX<:HE
MEQ.UBXP8?9!W=73=QANC>?+J8A$JUQ&_L[YW7#E"/BI,C6GE#=6,+8T96MG!
MZ_1L5M:0]%%2.I7X-M=D#J;D)9)GE3;PT%2K/4VLYNZ<87/DQA#D1?U;R#>=
MM[KUQKE [*'ZF=W$CF-*""G0('WMSC8:5!3MM@%5OD74+;G268"5%4DD3>/S
M7[EWF9:U-OVN2_?1=+Q?O4CU;6OE XU-K=Z^+VAT<+I<GGN#A,7%Z>(X2E3T
M7W%6@(8)9 M4XZ%LQ0?'1D=WA-5>NNA+:HN1+E0<]T3F0%^C[AHJP1"_9,\M
M<:&$*X:)DM1^&=>K2S21=%T^_T!@CEIHX;T!<4*@%/Y&P*_-@_DY"E#ZV^A4
MSC>GKGD@?]B;O1M=?L8@:S_$'-);9A5_'"+5*CN&0*A^9FJ$4A?  W5")XP3
M,HNK1'99DG)7GDQD*H?/@3JB1(EK=/SH(&+ O:O':IT!UA""6_E27U&P*HU*
ML1%XX=WR>O:5.626MGQ7+$<N1M)?W\9>2^Z8E[M_O3=[S_4*[EA%A2B9A(2I
MAK-URP9DV*%^?T'$JE*ABU$ZV352 PQQND)B"DG448'7WC!$Y,CJF/.9<TD<
MZV\T&:::Z_[$+FMBH2"-(;=D#0LRNBI;..8!X%6*+0CI&#F5U41\\L&AH,-?
M\,7E8%SPQ#0J!(C9TC?]VYZVAS>+;+]D6"W$D41,@Y4^R=D2(:B]@(HHB\'9
M4B* [%C@@!.1*^((SFXZVVPZA>:)!1-D,S1%^X&<-G#F#,\@%E2 L^CMLW]T
M'S,(X:^<QH:0H TE)4Z-.5KY]\ -2]7,*V*WHC.Y:/TJ1\E]S3),VE4@L\4-
M8^M"?MAJUR:G^NN,&AT:'W.UA-_-V5DZ<[71N/$NAK]M=\VE]6.!KO)=W[;"
M<?2/#\1XY13R6KHDW\UH$'@(N.$R+TH@R%*B'\F1D&51&Q'# %& SHM&.4X_
M>/MF,"/P^83@%   ^.OD(,5+++>Z4]:?G?34LL1-,[SI<4? E[.>UE[2 A,.
M?MH(<E28]'04<>2#0]B,P3?/?$<D$Q1E"/SCE,721>0:H>*L#Q[\FGC9MEZ?
MD[**F1:3)8*-!U3$<3;<44PT_X"EJ8LHP1:2I&I#;RLFV8ZB%ETC,Q-;;8-[
M _KZ'FS;ECTJ !+SKDTH31Q 73;?'7AGZ:_ 2R95B 1=T7H#-E>(:KRH-[DD
MW(4^T7,D1J0&T+$P5\);!1R\$ALX<<$4NTWI[6)J$:K32KEW%.R(R,-%#%Q0
M#TNO!X=H\-U0*46"$31V6CR243&9 C#28D$+RX_R2/AXU!\%TF=.=ROC6UH>
MNYQ96&..WR!&1R\5:)2MSQC<1$?#.?U**:N3*F?AH[H*V-3Y_5:0?H9PTJN_
MAU9X\)T!/FDV'N]N&'^>+#-Z_$2!KQ<Y0^J73$,&5/3J.8!P-Z;J^I(4\UJ_
M99>1&IM+M_!C92M+<8EP-^@J!X,>&>DY2VN-_,\%T/&7/(IT98WS(G*-YM ;
M;!*S(>-/NS@,IEZX#4HH9E("E:!;V<VI4$U]<DLX&2X<Z01KW;,QA9 TY5T7
MT6*]A<M%0 )ST>&O^.<],*),V/05*_$8Q'^_)H(IB<D;5VZ^3O**H[5/%VA<
MFD+ 5"0+:/BU;,(2:<X2!1?$:$ZE!NRO!+O+)"B6:G\*_OA5&F@&L\P)1DE7
M&]!?[L_*3J,=))KIDU\_NQD&[YNZB3"\9R.&4?&)D(0/F2^[Y+XR4%#KM_C[
M1YRG_=2\S"FOA@2K_Q#A(59\L VSJ<^(5UDPCG!J26AZC,9[9M".5.Y'+;?E
M"Z1)8 F"34K*/)?TN@FWXE)?(J;QR1E\9LMN@CND9VB3L#ZZCLM!:IGW;T!N
ME*[C:%L+'<2M4/IPGIRG-"<]"JOC(<BYYA&2*IS$>>H]&"=1LG]"TANTC)"Z
M1B&3$S7JAYK2NO_ULHM)M:FT)/.^7.WNZDMQ+X6M@R9=(G@X?Z!O[C[VZPU&
ME-."%GS.R1.K*P69J8 FP8'A[3#Q('/MGS(O*JM"5/>G=,@1YED:*J.(X<0%
M=5W$1\DQP$L2<Q:,K)XKRD>J7TZAQ- R0C7$X+!-'62JL23NX>T3MJL2W[!*
M_/@>5(GO4HF2O03*#T2!3.Y DW:+NED3DSE@>QP5!(+4$:))$/(7PDO"K5%;
MX:U"(J=Z%9!<X&4:X1-T7-P'E]N8>X1,%756 I47:Y^9.EPS5G5AHL(MPS?P
M9 -2)A1BIZ>%<'VCD1[@B+?-*)M-YH&!B<NI[N3R50F<CWE0K?>9)L&HH6'Z
M!.5JA.\I2Y KA?-V;W:B3,(9QP+V48(4&\,KDY&9A-EBM>%$X/2-9F)>]'3
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MBX2?14I'[H2&-RB<]XUH)2[CMYZ$>M?5U?KDREVMHF#;52\@=^5O7K#@Y%6
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M3^"Y1_P_"!:7/!2YAMB^H,T6C(Y@5,FC073BSEG-,]^4%+1K=&?"&8P'\5S
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MQR%-!QF-X8HK8#P5,@!DAN E+=($(0PWF0R$QJM:QG!S35?4?3&^6-WY#O+
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M,C(&*DH!03H#69/%* )&F4MK_W$C9$^%5SWHX39;5 N#JA[M%TL?1&8=ALR
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M1!3,TRN;I2%Q^0J09]!9"RSHN-2M[> U4)X(>W83<0_[%YVHU\(T:#.2#<5
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M4@AM#'G(N4BR*K( K[4%*X.U)DOI4^L6=-NC?)9$:Z6U'FH9;L==?-0U-AV
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M(T(OHFZ]%;S.W7@R7$(Y>3.]P%:T02E0T1X8&=""$9RH,]V2<(EVR.+T9G4
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M,->5I4__$H:G\Q9TW;@VU-QA),(QP&XR6.$8%G)#_DOC&3"*S(VP)5E4GJO
MK;;..LVT%V0;#8YA :T:NRQ__M63WUQV#BFNWB$[#MF4F@C(,P06(FBKO4*A
M>!"MHY5; =RYAOZ6C-?J]^<PH2/1)UL*0P8LFNHG%0,^.P'.<0RY."%\;"R0
M;3'N_SCICU.W2NO[U%<?0P'OQIO28L@A;1>W=X^?ZV:!M1E42B9F;S7XZ RH
MC'0P1Y/ ":N9,*6@U/LEW6; GS$3>]!L'RU$'KB(>GA=+<(4Q[73$J(H=7
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M"ADEM#Z8@A!\'6E09Z6&G#.0KRYLRDXXU3K/J>D"VC42(5G0_XE4'"2R8NJ
MK S>!@O28A16V"B7FP$T[!AR@$CWX9BTOJ7(=EKHHQGI7!:7HOEE.*GA2)+$
MP!9+RZOC2Q%S3?VF@ZF@ E0AD4%<3#'-N]JN _.<R=)&0WV,?6H@HD7@M%C%
ML2@)(D<%*A<%SB.] \7;S$JL\VN.<%?>Z]7(\1#R,'H_EAN4.VKN?9$\:<7
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M$]'OX0S/.Q%M@JNG=G?K,!VF==VN.KN3 CL*?)^$"!B%LIZ(;FKV+7H%CF,
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M)^N#QCJ"HB9N<@2O,8(P2>:HBI*N-+9MMP+XV.V9_K720S?/:ME?$?S""-\
M4U]#BU;@.4S I$<U+D]Z::6#/D8+K<)F)&-:F@A<N03*H(!H@P*30Y+.E,AT
MZ]O=_?'BGIC)@6FQC>A[H,/:-AFD,,;,Q:6 QFPB=T!P#"A.<.=S_X(M.J(J
M7MJ]-2NY#NP 8WYVUN&F?4H>K("&=LG:4I+)A4&/UM,[D#ED0:^",II#3*A
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M%U&Z@VJY=?AN(_AS45Z6X%Y,?J\AT,7(Y@^89N/YQ,V!5R61)#7D8 09I\I
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MHV.@HZ5E8&)@8+Q*$5IZ9A:FJ\S_UO\^Y-_;_[V+<K]*1TMW]?^SD-L K'0
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MO9""*9KCN?\( Z>PXHH(YI]I_\.R_W>&A?__LNQ_,^Q_MVL6<)6:BA(\:E8
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M<\92BM#WH.4X$-UU)[QV+_<):2R>#$B8TL,'0%6K<93>1C.$48Z2OEW#."C
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MHUMW)E\<R%08$BH-^*[HFZ1.EUY2N1%.=ZL!B+NU2<A:XH1/MX).OJF>=_;
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M\E_G?_M\428$-<]I+YCLOX;/-CPG6YW/B^/<[ME^B4I:Z^"K!XL/?+CPNF#
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MQE5L/6Z&:;'(@_(\'&?KW#"Q_NQ=RWOHR$S) 3@<MY6]91. U^*5?O2#(G<
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M::R-(.6&%!VU$EC_G@J1:%Y0Y?W[2P@<MXM%C#[#6.W3KQYRRFQ\_XIBH87
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M&%4#H *Y#PI\ O"7@CXL>)/'&EZ2MKXH\71PQ:M>B>1C=K$H6,%&8HN  /E
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M0M !1110 4444 %%%% !1110 4444 %%%% !1110!__94$L#!!0    ( /J
M!%4*H2SN;Z<  (*P!@ 5    ;F)I>"TR,#(R,#8S,%]L86(N>&ULW+UKD]PX
M=C;XW;\".W[7TQU1Z"9(D 1G;+]1NHVUH9844K7GG>W8R,!514]69IED5JO\
MZQ<@F?=,)L $6;0_M%JJ(G'.>4 \N)W+/__O[P]S\"2+,E\N_N4/Z*?@#T N
M^%+DBV__\H=?[]Y!\H?__:__\ ___']!^']>??D WBSYZD$N*O"ZD+22 OR>
M5_?@KT*6?P>J6#Z ORZ+O^=/%,)_K5]ZO7Q\+O)O]Q4(@S \_&WQIX#C4(B
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M]L'LV&:1D#BAB$.91'IMH('7RP(<Z-UK&..4(\:Y<@HR\J'5U)BGC<F3K17
M?!>;".A-\CQ 'YHBV$QRNBJEB6'.BW74\^_+U5R >_HD]>_E E -%-R$1O<^
M3?/S%=AQW^A].S!-[MJSDY, O-WKYQV;C*?FVBJ3*Z8YW;L!C64>XZA\ NTK
MU,J+3N-&8_F$\2A@RVOC?6.ZZB"QM]\?Y4+DU<H<=BZX<=X0KU;5QV7U-UG5
M5V@L80E/LP &RIPX"!Q!BF,"<9Q2'DA!XLCI>-)6\-2(_.-R >M(G3:,5%/Z
MU@+7:!U+["WO-09 =.B+CA;#79W!6FF@=YDF@0]XUIM0OY>>KE!Y"ZJQ%#MR
M_(P;&,>A,H[ON]<X>+UZJ!/'K)-V?*YCXSZI6[%\-.1X^STO9^;04YHST0R;
M8/>4(LA43*%$/ X3181D5C>LM@*GQDQ;G=O4275F3:VV67.L%0>_&=4M/<>M
MH>\FJ"$ '9J8?&#I5&C!!: K*C!8B1FM-(.+T;LU&YS>N[(:^VU9RLK4>-GQ
M;FUWY.+3XHM9MQ5Z6:8?T$N#8OU/XPQ6?L@7\GTE'\I9QE(5J0Q#%%$3P8<H
M9(*%4(0L)2BF69 X.:1ZU6YJ1+8M3J[W1;5]=0SNCH7K2T\]'$U43&M5_=2N
MF;6W90E^,Y:"VE1+XAOF([!;QKU8UPY,J2_2J_WKT?M$WW?=>B^ZO4Q]>Y^P
M'BY$AQ'2W]EGNZ??^ V_6Q9?Z5S^JJ72N<D!96YZ/B_+.G'+QY4)IOJDUO\N
M9SP-0Q'(&%)9U_-2"!(>II!$(N-2[\?C@+OZ!%VMU=2FBT;!.J/D01Y(NG''
M-^[$I3;1A(ZO-F8"<\D+'EO#W+V.KN]@NREA]&X;>"HXR.!ZLXV;@+JCH#'J
M!FS- L8NL#;D!FP[?&.<7Y\G;UA[=(VZ7J?1/:B\P7C*T<I?X^,1O.;S1,6F
MAC:/)858&#>:A&3&;2N+,$\ES3(7MZT^2DS-N^MN6:>3VRX/A^?A 6GW?PK+
MOBRA3H _IT^7/MGQ2C(TN8^J9W-;M5S(1=6ZPP2<ASRF%*810A GC$(F8PY)
M$*F,$Q)EW"G!\4DI4UN--DJ"C99N;'8:2#NZNAJ>@?GH$)D!G(DZ(?!$)J=E
MC,H6G68>TD'WPV[C7<A\=OL@%\+X(KV;TV\S'&:)8)S!(,Y,:;F40DHB4W5)
M"(3"+ KM*I(<M3RU<;U1#ACM[$;U,5S=(_DJ$ 8>O9;V6P_9L[:>&*9Z2__3
MM^73S_J=9H3JOVP'YG%+HPS&LP:L!^#Y!WI'@)CXZ,_%\BD74KQZ_K64XOWB
M_>))EJ8.VRVO\J>F,$FH$A2C,#(9 F.(HY3 C* 4ABSC>E0BH7_K&!YB*7IJ
MNXLZHES-E[^7C2M6OE89T(W.SN[]MMU@-V\/ ^[ =& " VILUVH#]@Q^,)IK
MB'\$&^7![668^\0(."+F+X# 5O#8T06.@)P(/7!MP4?QVM?+LIHQ2@6B+(0!
M9^:4&PM(42J@HE&:9 FE:9#T+T]K1$QM,;$MD3HW*@*N=;RF[&P-HQW;7 ?.
MP*QR5#KV=1<P5]:%W;5]D,JOM8 7K.VZ:V!W]=:])WU$M[_3_=LZAF=9H'<%
M)(0*JQ1BK-<BQ+@^,(*C."5(9C3L']>^%32U,?ZYR!<\?Z3S2[[=;G#:'UU>
M"](8QY.[@>Q&2^]^\)> &"1X?4?,"X:M'QO;';!^XGD_H8>[Q:#;G+-IC%!*
ML=Z6A"9F*&49S$2@_Z!4I:$,H@0[>9-?%CDU>C@*L+O9+XM^75#B"<CMB,,O
MD -3R"4,+R=*OCI<\3P^ X4MGA#XHN&+YP&X%,;8\6;?Y'EFLV+:-Q&2C4]X
M1'"81!'$,C&ASM3XSL0(DBR.4AZ97.M.BX]C$5/CE:V&/6*;3R!H1QO7X3(P
M31Q XLUM^[+QWK+H'0D8.9'>.0./<^F=?;)GB'+MRK?Q[#.<,5\:&ID)P6(4
MA2E4'&40,R+U8@(CR%',%2>9TDL,I[#C<Y*F-L)K3XDGHZ-Q@:*-*VV=X7[M
M(&MR^SJ>:I['V8X O* W]!5&K>.NJPG8ZNDQ]/82%+[":<_*&3=$]I*Y1V&O
M%U_HG7GSL9#W<E'F3[+)H_)15I_4'?T^PP'.!*<,,A$AB!'E,(M,,DX<D(AC
M$B99Y'(ATB%K<C<@NZI>D]>H"U\[DO"$VL TL0_87O:C&V#N/33K:HUO!D^%
M9 &7OR2=9R6-G:CSDLDGDG5>?*5G71*IF4KNGY26=_)[]6INZOTF5$J>! 32
M+,(04^.<KTQ:WU2&+.89CF.G:XMN<5-;A33J.58DZ0;4CD3\P30PCS2*WH"#
M2XT2_&:T!;6Z/NN36.'BJT9)M[!QZY18&7Y4J\3NK3Z5WIKJD+\L%_+Y%UK\
M75;O5OJ?S2F<2=@OTHS#4)D@]9ADD.JU">0XC#.>B(0D5A$]%R5-C2]J9P$3
MRO=@M 4/M;I :7V=2KYU8=O-'UX1&WH)8L#2>H):4=!H"HRJO6J_=8'F4OW-
M$WACU7^K2Q#Q9[,WOC=?'BW![W(^-_\7\L'\1,@Z^$O_/*_N];9Y\7>]DRZ
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MSIA>54H4)Q#3*(8X4@&D21)!(GC(!$J#++.*]K&4-[4%9)NP84_GG;0-K>;
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M>]?7<NX3R\.8 9$>^M#E\-)^@WJK/MCHWZ:RO>M"_<H;?7OH!KGKMQ#_@EX
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M[!;I[5 6"04E9F$LA$1"OVK!;B=;GQIW;?0#CXV"#H'[1\AU4\_5> R]D=E
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MERJ*!$R$R""F%$$F(@E)1(F*0T%B[I06NZ\B4R,F_25&CH5Y^W:!'2V- >S
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M)"19BDP]X!!FH5[#$1XE*$PY%;AG)I1#45/CM9V,'6M5>X<O= !LN>_T MO
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ME7S6KW^L8PU^(6=N\-U@SQUON2D^A>X,O:.^M\K$D'LO@7'3%!)J';UK[[Z
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M3"!F:0$SGF8)(0@G*+6]/7FID:F%(:V=H#&T.9]\9S:(M*WV]RDO0MI/';Z
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M3&T*-DX ROE*FE&O^U*:?0)'Y;)!W6&W8Q <Y,!S:&/_W7'BYQW8.7$'NFZ
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MU+U,=\_7\^_>\W?/PN1M?^[P[2/OQ9UU[73?[?S'_.C_&O$P/LM5A),BUU%
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M]2;W)Z-^!#XU1]1F(C/2#_6 ?2N57)EMG??S)5WR>F535JY,:=$?=GSH%^7
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MGBV^G6TE4PIXN="NE^9 52]"Z;[ IJ\406L\>_, K[]EO&0_:X\.,OKLGQI
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M>HDIM9HE&:0\)BB+"4_M*CCT-S,U9JMOW4!FS 2\8^?V1JMC>O5Y:.WHZG;
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MTEC0(A<**H(41!1ED&":0R(SD7"2,$JI:SG!XT:F1@V[>GE[0T%CJ7L]P1-
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M&&_NP-9T-]9SZ0P[PO.-[:MD^-R! X!;R\$OK>U_\5R"9P!FGAC.I>51R6T
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M_=/__F_;?]'_,Y)^__N__?]02P,$%     @ ^H $51T3Z@0U8P  NUX$ !4
M  !N8FEX+3(P,C(P-C,P7W!R92YX;6SDO5F76TEN+OKN7U&W[^M%5\R#E^VS
M5"JIK755)1U)[;;O"U<,B!1/,TDUR525_.LO@CF/XA";.[)L5TN9S-3>&+Y
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MC.BXQ^)$^YP4CP(TUL1\)B:#B!JL#U$*JWC!YKGM[<GK!G8'(>*1H];6ZND
M>1MO\ $VN V6JV3 )E;(]#L2%[<DO:R-5=KIQ%K;LD=(&7>?' A1+<3> 7H>
MX "+T&ALAI*\!A43!Q)3 1V"*XFA=T^V\+39!,?-;P^$F0.%W8';_G(Q_XK+
M]91L:$W/WP@_*5#Q6?, +-<K Q)GX(SB]=8I'XF1S&SK0.Y18KHQ.,-Y3FT4
MT8$!NIVFOY3=MQL,I5A,XE( DW5<4RP*HJ7PEGD7D5,XPY^<BGCX"<D#1'5C
MGH9#6%O%]("T.SOV34ZLX;GP0CZ>H4V[EE?%X#TD6BV9<R\$:UU%\#@UXY[
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MX/MZ)EI&8[CB"ABOMZD;F2%X2>R8((3A)J?FEX_<I:$3EW1/G=ZKKSU P/T
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MT,84P%PD>4Y9@-?:@I7!6I.E]*EU@>7N5(X[XZ,#D+;28 \8O9=5\U$3"R4
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MFK$;OE_164H9"PAD%/PQIR XH^H"Q^"L5X*W+L_?D<1Q*P '@\KVD#Q8;QW
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M@G(9D94R&$"W(;"30[Z&"'D,A,W5U1,6-T5*JXW$^(7!YRD:&;@&3"F!2LQ
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MD\A6$CRGWOL"'"!EW,Y>PV8IG<;OYF#S*B3<M>9)1DMIC0<O'/F$S-4)ZR:
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M(8!4NC8^"1ZB<1QLKN=]9H8<Z4X*JOL[N\'H*@+S0W*[ ;7U_A-Q=(/_"1'
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M&=>LZ04'^_JC'\:WZST]M4LWMSTG^4K//&U K?(4O8/K%A^Q,&DA16E(^MR
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M\B\*9%.X@_;%2K[B#9I$6_=#3;^"K^'KR Z!.Q+OV3&,)D_Q7B9GK(;W;,-
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M\;U@<F%R+_F.MW\>6D9TI<<*XRH$AC,9OEFWF>JV!(./H(G&N)7YYJ/[$NY
M5L!0V9ZLJB)FZ$PBK"=\E9'V95-FMLGF0XI)LMQ5W3)+VI8?WX6?7O^_;(YF
M?WD<S?W=PZ</5&Y)[@<LA6LZ(2>8W5FTOWGM5"<;6:I=,_5  FA*VF9EG[JG
M3XJ>;%@N^N_.0W7EG818 /.^/BJ,E([X/V%LT$:H"]&!5!#6.:S0ET@KD[!I
MQ;]]0[YK9;Y,#!XF\PN&0C'CWY1@=NEJV@GK&9_&7USC>K+Q.]**\8]D>U36
M;VI%RX.ITXC%,K=>S>P@@*>:>K9ZC<H=%.<+@C"$^2<>/(WZD%0@#6[:JS ?
MIE"I9I>GVV=?F^#IT?)HMX=R_$DC/O8)ERHN+;"G@ ^3S@!7"\T5.W!38^G'
M!Z;GY;B2I%Z[ "<D4J.BX>C&O^\S+&@7D4%5H%O-'8UB,2PRD1'. 9@<1(+"
M;!,DH+!R?RI-C+5!:!Y/".R:@7JKR!(ADQFM[:H58F&,3%<@A(,MTS-L)43$
M#J\TAA<L)(ER7*']U?&"Z'I((<:YM>RNOE9R5@='XA[/K6^7TEV_5$Q%_P0_
M%$PI<!*N= 4BS1IEJYUZO\8P _SB>/>9+;LMVL^Z\6Z.EH;\$Y6BJ^"=\>PC
M\^Q.@ 969:0EFWJEQK1[:"'SY43G*HB$T*90X=B(DDAUYR:RC6I*[AK0PR7(
M3]76\^8HNMM33C(=FPZJA#1G7%H\U*C&2P&PR'F-O6OPHW??*Y<.=D(6M((5
M/>C!'X?XQU.>X/'N<8BK,&G(KN*!SD6G<D/XJG>9=XA$]_JOS3WS=%7NF3^=
MZOR>@60G3$7B3$YFXLOU #,6!H\:V'%<W5%WL8^$\63\R4 CTU.&%A>YTUF!
M>>M:?1"SJ[ 9#+,9].,*[+Q,E=X'82@<!;6"UY_X5V&F[E>:I. ;&6AK _D_
M_R]$_)]')V_>O/WSY/+T_#HZN3R+?KFZN/SU/'I]?GG^R\7-FC 7'*U.,< _
M5:R^^VKCN3#XL4*)3\=HJ,S ;M[)(G)]?3>% 5D8BJH UP6)?K0Z2/37<D-^
MQ\?\C MHYYKD:$/3JH6<D"P7*JN*674G^.FA5ADY0DB(@::S-4O2VL,JRA,H
MZ(>_-&7Q>4JEM+FZ90M%$)T,Z?/QT7W885P9&VGLR%#$90IBERJ)+*JD&$^'
MN[HF.6=^3&$^K1&DQM_$&636[$=EZ0 =LIC9 ; ZN5+$X0$O!V\?@0SLSE24
MDV&&CM"DLJO(Z-$[!3_%6;L51;IFLUAM9 ZZ2%0P:Y_K/6\R>VU@T?]LQ?\P
MA[&#RLR;A;?;,::[J00[ ']S8)C\+5I>/4J;D<=?8KXFV1%T^W? BHR2(H/9
M2_;*GQ$];Y/8WB2VOZ["+'4ZZL--KEO'V01>Y"3#^:T(',_1 1$BCT"7HWSV
M:5P4(RK"VAMPX!5K,E1M0?30<[4DLR%Q&I0+6"R!5EFI)FSY%*NR-6CL*YEX
MTLD]BCDQ(9G!,5<0*6^C*4:8MDBFB^\ZE(6%S&/<*(]3C)2B((-DXX,)2:,_
MH!NK,<,2-Z6XB&[8?C3V%_N4=^;;Y_)M!]^:TA+S]G#.$X/QA-_T6"@HUPWZ
M&]8$M#3!'6A+&,OC_[CV:BX95:E@23^D(S@^W0<#H\F'E(>??MR7/E+7J(7G
MK887MY0W)@P3@SNWH2P2KJ>),FBSK:T!C@O0:ZD)#I1%K&$M=7<]5@>J5$83
M704/?8</];@G'H-FM(R)E#I,$+]5XV#1@/!C'#8[7TXBC3:!<  )>L*>D>JA
M]9L!H/#< AW-GQY6==%KPB6U&T.6 5)QCXGJ!+G&L! *S(([_)Q7U7 &1@HQ
MUQ[NFU>'9S4,[-./L!C+E2O,F^D]G/-N85X;CV=EBAI>&XJ;SJ.U\8.,"':E
MTQ^("!A+'R0.<;VA4 XD76]9N(C/9J<8[(R+^+VNNV\]3.ELS5 4\W0#)2,%
MB\1T.<(N9CVY&2R)@Z;,I7]#X"Y\O#XDK6!TOJMM\M90Z_=5:Y7<;?%H-6BN
M*OVI]]*\AXL3MB0Z5G\]A;H4L?-OE'1:F]CYZ=O+7R[.SB]O+D[>7-S\]WK<
MI4]7)TC^#A1]F6I2?1<YX3XW,7/1[J4&3[BB3!_1EZN2D;\4[,:H8%C-P:!?
MT=2)SA#:[4"O%I_0$60G2CC$Q\W8#7KB17['!)[>?;XFMN?3U8FV7^D:S N\
M_-Z1B51_ST13F+$WMA-A&\FPZF$N')'I#?P5,^1C6T['YM9X.*DP/"Q69CT1
M X'(:\EV8[%!($Z?&17"\(GDJL 6P@ (.J[I?.IM1SU#\$JL=W+ 5SN*,+[<
M:5V"Y/<<&XP/PYT:10]5A,'IT:'!OW+$VKRQ3<V)L2GX!0R/+-F9ZL#U5Y")
M?*SBD%9[,BU\-;QNI-Y3KP@8KB*,[SC5M*TPWJ01O!(%MT?(#=SFK91)K8U.
M6AE_^+*(_F Y>$=D$J=%/J"D#(8R-I=Z>*E3])1D+1=";$HT(?H]*ZIV10\>
M=P1$%DP4T]<@SWSF8W^14T_D^AJS2>0""1L6:P;\!((*.9U55B'W+5-O8/KM
MDP5H*?R?XXW_\U'^S\WYU>\7EVO$%GJ\.K[/KYQF7JA:C*)OU&2X6S.>S,!Y
M[^\>S$0=^_VHR,1P7:E4A5T)VMGVRZ)&B\P27P=,1[WYL(V.#E22LO/:O\'
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MG#6UH:8O9;%4-;65<O2"0D)96TOFQ\K=ZYG$+&3<8MQM0&T2_7/<3?SD9&=
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M*->6<+0+-T)"=_%4WX/D>1WK.QVA#?G4!DOT]67VHRJ.5)K8CFC24Z@S#%V
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MZAL=BP"1N)7C3W0%PMPWR5LP*YO2:QIY9T*/;<2Q%]T@#+#%O5OSF #PB!3
M![JGK1SB9%::YFAI0AJ?GJ8)J-$WJ9K/ORY&2Q/H$O-R[L'HL,>N\'%+<1(6
M$US[<MF95MN!66F2(^S'(6D2/T6#HGJ;WK%B3JG+VJ$I*U+)'3N+LQ7[N@A4
MOC0"]9BJ(ILH6#SJGYOR7(3(1WN:J_G'.3B[<PF13$W;QY'T1%M?CJ1G>Z58
M>A;KS"Q/*8VXHQNBGN^-J&?! K!$$O"4@LASNXJK:AANUPDCH@VUP]*1]K1
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M*G@)4I?0\VD70LO"=V_E[O:P/=1*T%2,\D6>BZKCN&9'X;()YE!/URVQ^.5
M6H>!GXS@2U\96__ 'N1Q\#V_/!?I747OV)3O\[U?C9ZZR,'2S\' O\*(>8.*
M*R$=N?_B^3$5%:@1]CQ,PA[&\"%7/VM0DECJRYG4%#-,.9'V]*A?;=C06'\@
MY&6M/D3I"',)I)_-\(Y>O'CAU&BBVVX5?O5&?6C5[Y)2-74A#M#K%TI<(6,>
MO(OK@J1TZ*<?#X]>A;^A'WG/8$RTR8EF6/:%?$E@U7G 9O-JKV6O1*:Y^GG&
MQ_N:KZU@?=PDJ21[TOGB7M2,V:I+/)X1<H**6G%-A_<F25YKZN!,T^R9.(YZ
MSQ8R/BR.*5U.X&('*! 4G4'*X2N1R"WS,S*PFPR&8.>2_V70MMZ,MB2]/6Z\
MVH\AR#'.S7LG:S\D.D22[I[//6LE[S\L[U$OHD@H3VD'3Q8!9>TJ@.Q2X3E<
M"&B4Q%8-Y%.P#U7;0"W.9,;&H<$]?;+=/'<1?Z<\ED88=Z>>"8"X=/2FQ+KB
M$PE2Y5!S?HM4,R8Z[57'6>]-E;=+48R!:XMW@"H4!ZLR-U98EY]^/'KVRALS
M[ZN;FI=ELW@%E>=<YQ^P!KNM0-NMO1>H/.Q &<'HV JQ;&^DZR&;RN[EY $Y
M42,DM$(N@-;3&<*"/AA"=?@!L$ &EVG^#?8BGCBU/M?R$MW*Q^+]7 CBA!@A
M8.-3*HFJX/S"#S(/7641N%/WE$$G<>%%AZ"&$A!18:Y]JG^YQQD1>:!^3RTL
M"+[)ED&I;DLU'LH0NV6]UXFKPV#7&&=3:G#%K4]D/0-X'GH1*56VV2;'OCP;
M&9^^/EJ3FS<X*?2@9 P2P2EATDN*IE];7-OT Q]8K<F\U9H"/AMUXYBIF Z4
M%H8,M&XMVP[ON'<9^V*-Y'2),D '7O0.%V>L:84PEHMDC"4="@(+BL7 (,5R
M%.G\5MU.EQ^A:K\%18Q8? 6F2NU@)'[AF)?G(P5AJV3]FE96&XFNXC+MAP%Q
M-&VW^AC^WCK91GHAWXZDDRBTM2T4IB$)P,HFOGCJCYXY2.N,R9,Y7!([IJK,
M]Y20IN)BP'\-!-$%>GHFIXI+1^A(60X3Y^CT*:H4SH8*PGDA>)-6 >PLF#>&
M<S@\0YEHD*WBUJ R.F>^2;EM4FY?.^76*5N@#T;JO<0QM5?'X/4+L&'Y%CV(
M6'@@$P1XY?J8BAUSS EXMV;KT7V)IWZ<'O ;&!ALL#^V$QC3;0%F[$#A$%KO
M+#Y%]83OL#8MHL9!C?13=FW0: >C&%S%"E5J,Q;@K[5(X/>3HEDY//\L8LC]
MI8E)/D ,^3LHO]OEH(,E\G:\D6UHBKF3I<38D5D+O5O;K\1"!_*FG R,>'8L
MO,[0]<-R]K$F*=QN+U1I34$*'SQN GJ5S@8[/O%$7EBRTX??B/=N]UN=3TBX
M]4G(T KZ)&_3UK?PB-XP9R#?ZR'<Z[?#]A0H/D!^ ZRA#,;4_7U.F9<C^!>1
MMW3]#*WQMW9MM,#*]&(]+8HR29>"%AKL7[X=9K.[N%//<)**K=5,&O=P6$G2
MZ73NL1*DZMF4,\,<RQ)-6 XTH4-7&D1P:$'WVL)I@[.Q630*Y<!URJTOZ(W!
MTXTO/2TNP5C;Q)LE4\>()C !30/=,3&RSN\6@P$R/]J 5#T9,_S$A0&MDFTI
MP!F38#;-I* AN2_SX,(1^1'&N<_D)DQA>4][1]=&%QRNBBXXX3BX$3R;&ME[
M<?(=4P:W2S3AQ&.>Z]:8[ZQ;RHFU3NJ@)L2V+R%<0#9QZ2BB#NA@;FW=B:0.
MO$";ORU!I,&D/1STC1%,+'ZWC43A/"21J9SG! OQ% RL+R^%CP%5GDF(^6/P
M6/&N.VAHK8%FBPO1A\@\P1^2!2-/GE$C9G*,;8(1?R"["RW#6S2M== KR2TG
MV]$(E6<+4,_/UN(Z;BD*9;UNA[*XZ"G-X;1P#;:G^ ?165HIZKHW"3@L#=AA
M!D?TH= 1S^)1G/4]0V,L],66W*V&>_76EGW.+$6U-SEV@LIT23>Y"";8'NFH
M&1D!G4Y^P?IP:A1^+I6KDBRE'"AS&#FY-L:_R7]B<O5_MXE[?.MXV]1/&H1.
MY_+BS(A(,B]\*NO?50G?V']J0:HJ ^<=1!?A6SY_-!7AM'LCX[I1QM4L-+Z@
M'?KV@I42@E?;PC[@H &RRBYS.%-,]W?Q@.T<<+34C/L&T5\-M2@)-5<];"J/
M27-"*=KV$,U)'Q9EO4,(XD0/-!@;MOJ/,,&=?-@RGGT<S]'<\6!\EC(4W+Y'
MBT&6?BG!\Q79+ %L<Q9R4<J,(Q[NGFNB98C&3>H2_<LLI9/JT8N1(VUE^U&#
M _N-N>G-(0A*\FD7!=2P\,VT&%8)'-#1YVO)HO2.P\KF6;7+'/7KN,519MU9
M*2+,DB/+A?2HTQ_@7+C'J=FF%Q<]C=!TH WBODO>!H4&14!QPTV85 *CJ[2
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M>B'7[EBO.JW,,IWL55_+CV"26@J.G@=LT2?](IG ?X;U*/O[_P=02P,$%
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MCM!_>%_XZ?"NZ">U[R(]>"?N:;CWWZW[($KZ0L1!PV9&%XWB_>\QVW]@F:#
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M@>XQI1#EPGJF^<K +;C8;2T+>Q*,IY)&#OQ *4Z"QR$4(C$5]6.1F\RTX<G
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M7._0DF*W23LVJOC=C2I&UCQL7.%6__#:5QP$5=ETM)9F'WX0?H8P@[,?Y70
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M&L[7!NQGA/CTF#LIA$9J;JB_L[03$\5@/ DD?\.2/=!OR\H.J"@;S1EWOT+
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M%^4PA+?"ZQ3+2J1C"O,^RY1ZTZ]*>]_([GN)O:7+JLCB^8#:P?(D4.@T-BQ
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MA>5F!_%X"X8<8UJY6YE)D8(<#%M_/KSBR+"ZV?&(!^PBH\QXSI/-9-1RZVH
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M4O=\12(L$Z<^P$H.X1@4HN.$J_L^(7>-^4F8CK6(%&MF4ZV]^UR.*S'U!N!
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MTE3$UR""^WG/OZ<GR4$49-7U=$3]Q819J#U)G]0Q.*U9FD(&_4L8!)XPJ%7
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M'!2&064)HQ:\_T#,N_.,@2O@_3QAFG>CA63=@,7Z_[=W;;MM&T'T5P04+63
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M(H+"Q'LN0,O80M !'4>JFR8Y0!43K6T?R2H1P+8&5SA0)OA?1BCR&/&'3-N
M8**9F64Y;F7B%+F'PK1,1^MG^D-MCS2L1IA4@Z5X-JC!T.VMY,=PO(#PCDI!
M45J)LJ3-0V ] N^O0QHDRKLYM$W*?$4"U0?5MU%$S*HZIK^R1+B(/1+L(3.8
MJAHUV% U(V4JG+>:2&*R.B!JAM]&;KQWU2>GPS3*W!XX+;,J49T0XT(CVN-&
M5S(Y&0/8PCTB58+Z C1.J))V@>^ZDK8'2>_#J;G31.JJNM!R51DRI'^5\'D]
M3L/.2L>*UHC'"/EPR/P[IE6T'^!';Q#Z$?FW+<BUR*_DT0JP>@[T6K[FWLA'
M^#J2+/']5PYCKXWE3A.MTN?+"Q3;%W"^ME9"-"AS2US,8)$YN1>O["4TA7Q4
MQ.$ZT1RE7S6T.'K.&I)I"%QYL$#2_-WB:Q_D\9,F0AK5^O]#X1@%_BR+HXM/
M=KE:JYDX"6'&FAHX:L[V8AGR8&%2@@%P3P0BB\CK%7>*4!"*X0$G1 CLF]CI
M,N[28X"^M95;! >A#Q*_U02-K5KB_WY1\O[?9?UQDO[-];N?C/;WN_^,7 CP
M8[%>YK_]"U!+ P04    " #Z@ 158DQ7(?8L   F0@$ %@   '$R+3(P,C)X
M97AH:6)I=#$P,RYH=&WM?>F3&\>1[_?W5_1*S]Z9B"8Y& X/D5I%T*3D5<1*
M5HC4*O;3BT)W85!BHPOJ8T#XK]\\ZNP#,^23I6I[_,'B (VN*S,KCU]F?OEO
M;_[V^MW__/!UMNUV5?;#3W_YKV]?9Y\]>/3HY\>O'SUZ\^Y-]I_OOONO[.KA
MQ2I[UXBZ59W2M:@>/?KZ^\^RS[9=MW_QZ-'A<'AX>/Q0-]>/WOWX"%]U]:C2
MNI4/RZ[\[*LO\1/X?RG*K_[/E__VX$'V1A?]3M9=5C12=++,^E;5U]G/I6S?
M9P\>F*=>Z_VQ4=?;+KN\N+S,?M;->W4C^/M.=97\RK[GRT?\]Y>/:) OU[H\
M?O5EJ6XR5?['9^K9NGRZ>KQ9K9X53ZZ^>"K%Q<65?';QI+B\$,6F6/^_%4SR
M$3S.OVF[8R7_X[.=JA]L)8[_XMGEOGMY4&6W?;&ZN/C39]%SG?S0/1"5NJY?
MT&SAVXV&M9FO"UWIYL7G%_2_E_C-@XW8J>KXXM_?J9ULL^_E(?M1[T3][WD+
M._R@E8W:\(.M^KM\L<+!Z<^#F0V\IU*UM+/C*7W]8:O6JLM6%P\??_D(G[=K
M&JTLF'$!NR>;WWS*5W>:\O>R;W31P.?97Y1N"R7K0K9Y]FU=/(R7$!Z+:*[A
M9-:ZZ_2.-^=W6,_#)W=:T>7%ZGGV]6Y?Z:.4V=M.%^^S'_JFV(I69C]4HIY=
MUC]^#7<CHU>EWB-'KH]9MX5ST:(I,[W)WJA&%IUNVC]__N3YR^P;N6YZT1RS
MIWF&BTY_7?M]HV_\PNALMKHJI5W2=^*875XM93D@]DI8C:C+[$?9=B(XL]=Z
MMY=U*U!4XQ\[U752VD4",68K6N;EY1V9[/+J=V&RW_(@5\\_:H4X]A^TGI43
M=;__Z"_WHBSAYGU0R4WWXO(9;L)?92T;4<%6?O$29=<>[_'TM_%,G/\^^WAU
M^SY>/KR@C7BW9:&?(<4J4&XRD>TDC(*T>]@JX,2O@:'4NI+NTFA1V%HN%O61
M.+R032=4G<$K@/^(UW^4%?WWM883:HC7VVP'E+^6V;6ZD37\,--[^*[K:]4!
MK^AL;V^B=BL:'@G% T@)8J*'6>9G+!L0&VTT$WC#->B ':P"=XE?X&ZW'W$W
M6GQH8DT]"*L&9W3J;EP"E:W3H;+5P\=/+)69(\J1L)C"#!7AON9P7/(]'4TC
MB8[P&YC"C2KX$-L>2=&>5HY/MK+H&TG4-_.C&M;D3Q@?1!)C2L]4C9<$T&&;
M;73# P!-M4BE\)C\ !0-Y/I![?I=)C?P3,=/TBA] 6-,<@+2Y!3I+X!V+A,3
M]*]*L'!4V_$.+F #4Q7QK",?5%5EPNRI;!SW&:G*#Z& +F4EKX& W<-\ "''
M(HL(K[IEP!?N#V!/T5H^ X8 X0V*.;[@\JPXA]$6<)")2M'@(+?B1M)Q[/5!
M-B!!^_4OL,UP,#G)H8/JMD8F5@H.QES >I/39_+#OD$)1L?4FJ_<\9*:NH!C
M4ND<T]7#IU_0,6G@GPZ5DUJ""D5J3IEM]6&DB- QHC*$*HNQE.A HR.1 BZF
MOVTV,,7Z.CMCI:R6\'RM._PY,!G<8X6HSI<@(55"1P:<]=0=F=%;LTVC=UD'
M8Z*(H__RED^JL_8(I54H4<$0#1R'VN/+# ,N17=4"9W.ZOG#B\?F= K8ZZ[I
M6=E3:-J#\.K\980?#[@KM_H>NA[6E6JW\ FZ)(S">*/?RZSI*Z,8-O*ZK\RA
M6B5O_O8+;\S<'C)JC(6""="#JK6"&6_40C?HG,I022SE!OZ99WJGVI9>W* R
M"B/CM5P7QY!JZ.U@DXFZ)O.$EL2C=>B>5AV\3^Y:D BHD**_"UX'PEV6"K^'
MIW?BO?1;M>FKZHCZ+%[)-XNPF]5-2D3II'PKNPXX7H $@,/KT.73M&AS BT!
M7:"T/D6@2]CY=#;>J[/:L+'?6V8K$M4S>N?J<A&[G93P]73>MWO<<)2*I-;@
MQ?;/N/L);?\3HYD85V=US*U/@FX8=E;@]>+=&K*!>VO'7XD"U$LXC3O<#G!@
M.VT.= UW)5^O\(^/<F[8612BP3%ZOIOQ53C*5@1W-6A+G8FIBO:?P>%VDY36
M=.FU)H&!,D,KC2YDV3=&VP%;\<&^0B<<'D$C8_H0&+_8-XKX7!M':Z#6(D\'
M*@IZ]+R7[;#5]$8@1IACG=6"X_$M41X_5B*%M.B$PW?\5"LDAK<8(3IQ*X:!
M[KWF,/^+!FD1U)C9T+>ACPO_$[%N==5W\S\)PDB_]&VG-D=#65]]N6Z^F@I<
M\_]O&_N&O;B6#]9 Y.\?B UPTPM1'<2Q_>RW#-Y/3&:6.Y[%P;$[KBI)9BN2
MX3302)[%;IG(==;J'7G%4#TT@O03O6E@;'R[&?X8S L[5#GX=6ZEMGF9\Q:1
M+0&J:FWN9?00W3*QW'N8*-("5I=&SH:/VA8DQC ,3Z*>/%-K*>MXBM&L<"Y%
MU3LMF8; I]P&TJ) 4!5N(7@)36SE33C!8-VP1:+OMKJ! RZCZ_.,+;X-+ ?A
M''9RO 22;/!;I[>C 8;7WWY?J4*@D>^\,0XE1'M,^T,,3Y?<8,49!1G\<LZ=
MRRY'[Y"\05L1PQHHKT%0HY#"JS4G/T]@(';^X*:==^1^-8$V8< 28Z]&>&XC
M#W 04#%[R/$YF$31@RE;=V!$3KB2_=1>!\=&[\Q#53%'"YRUC6#K)WC&G"R8
M^S=*]VWE.0PG_?-6XJ;C;W"3_)M @0B([\Z,EP>OB)VL&U![JY!*K8</Y_IK
M#TNQI[#70":L+5E%JS@R8^#.B@8IT.[MO(=A 8I/F8XLMC[R5W :]FR$81_G
M+PI45>-0*FQ0NHSY <_G6FM@&X'T3*1@O*W>S8XDK& MZR.1-<<.C>N=O8)$
M-'FV5C7).3,PB+T6A18^#,^9F.,"#OQQ8N'!MY,8@>RM/Z$E<5."H<-@)YTM
MOX*)9JQVX]6ML]=BKSI0+/_.,NQ5B>HE7HHM2U-Q?=WPC5[WNS4*Z\T,NL,+
M28QJM&V/L%N"9037B^%$^:&@$ B*X"T\U. 5OX4; IGL[(N+BQSVZ]P,E!L7
MOIF :DT,?X<S.%/G\&<CI][S.'X/3Q"N ,DV$F*\C&D[=79K4;R_;C2\]8$Y
MQ@W][^7O<Z@@#>NZAUOK.RGIL$"H$?J3E@8VZ^2D?Z^YM>K#Q(8__>?;<(_P
M^R.V>0F2+\%8.QI<<*?'+GOO_FQ)ST4W%RB(>-)D[5C[@M0'C+.P )P1=BC%
M+-S-RCG2_0>#,FKC&M7QM2Q00Q8W0E5DB&"D"@6E #-F("J7</!I&O,M'0]M
M*^[QU VT#D\U,#+70!%];:XN.!LP!XM?>]60M]2??6C\FO<TTM-" )(FDY=M
M!;T'$H.S>R^[!9SM56*ZXE\)%CI&@S*(V!KT"]C8%/7$V'<P=C4P)A?XP6(O
M;83]>N94;L/H>CB,\8K@O^$UNB;_P0X]5#Z. (_JLCTG@ROX[1O42>'IZ(,V
M:V4%NN[ L?4PR[Z.<#A6#(!4)J%-L1=G^V$\6-BO\-9P5F>IC!':#ET-&*B)
M7._!VV 'CMZUTDB2*>1X@D5;U?SJ\C%<I6=/SGW@ACSLZ':!M_AMM'BC23R2
M\WBT DZNX6]P*C"K&U7):W)(XHE/K@OE83VU386)%O'&.N<;6N?>3N,PDH\.
M8<QA G<1N[U:"8_AAME1VVEX5$[B68Z/D86QS,[ #-#]]3:8;>"5&?K:K(MP
ML!IZMG39@W!TC6JME].-"V2GT7-U '7AG%]/5)J5/<^+[)7H)PYJ9*$;UJHQ
MOQR:1MT!)G $/D>D_=GELW-@B[K;MO .D&0UO[(;#((LD#L@6MNOVXYTB_$>
M&!*/(KUM]B2S>_C<7'+M0D FB2JAV0\V[%9WY-4DV09,79.P&^B*&%:# R/%
M(M9;<OB[0KSGEAW1^!]+@!GZIPH2?JBX:F3K4E9P<$WDN4=MA/.7T&8F1B*Q
MQQKJ'F44NE/9>8O\ 0.A=W8H9X8S<_:H&.N^0* BJ\CMZMSWP%% DF>:K@(I
MFDK)YL&T4 ,BW&2EVA!_=J.9D+!S F(P MP8CN><9F]V [5[=%]C&(0N*0/'
M6DN*CLPM9 M_S*PDPZ#ZW#)^XU7<!UGO@ZS+L\NFPC*E:HM&TC6-H3-RZ7-2
MD+_36LU*D.([[!NA&DPR!3LJ^V]1]72Y";;#1D:ZL;TVJ@%F?]>(DB_)(_\&
M\XL&:J:'W<.(;@H@"TGXLMP& ? KNHF,+/F4"<5*+*O3P8#D>*B-:S.<",<I
M'8I+[7:R1&43HWE&KX''1\L-9#2);7\GM5FHYBK._!OI+& B UV0>$+P:=UH
M$)\<6:5-=#_PNLFIG:?Q)C9_ 7K&D\3L8K:R5*6ZXP)V+T7C=W@;VPQ7<Y'K
MFM6BV>Q9W>2Q-<@P$IN.@#Q2@#E2DAY.>H3/IEJ?YZ-WBRF 'MJO8!;LNSF,
MYA-Z5XC&"X.>87I#L+:Q8H=2+I\44NP+=6]'59:<IA8\3U^,]X;^G%B0V[,"
MQ^<]SWTB)UHGJNYUWUKS:-_(0K+'K0\M0!*@H_TW)C:;C##%6F=H1WF@AWVB
MM.^'F0>#\G)VK!)Z<0_3NR;KMN&KH#MH,,W.LR-HL83S@<,NV93.!S.RKA,2
MT+4>G--O=491FNV?/W]^N7KV$FP]T&6 >YICN*X0Z7'+8>']Y^T6-DQAW1?G
MV5;W#1U1=I#R/4-%W(,;C)*C/\,8KO@8W""R+D5#6Y;9XR93)BL:!3NKQ!0[
M6;C&$$43.$]"M\D29&&"%NN[>9(E<]%@) Y;G5M/!_$P4H$<^(YR<_=ST(.1
MPD.7(!$_T;+(2N/.*]F+MY>%VBA96@'C=1)RFA1:U045/'!T7 KRM?/W03KX
MZ1G B/P+712]!<F108(8IT(B#8_,06L!1RH;OV8J^A,#R]!1R)8H:E:!CRQX
M&\B2MW.QI-C#!U\WHD"^ 7NE8$#P*/*%ICPLO";US4J6R440[@IT<K6&)W#:
M"B29Y*L''[U/+/WDQ%*FT4X.B'3H*?#^77LSX ]1EE]>O(S$/7VV>NDTZL&;
M-@:)M^<**VT8M8HP5E9P#MP:TZ^E@,L2"" A"K!YJH&?V&QY8&EUA!K=&[S.
M;"29+"PD(4SE&&A!"%DD=S[+QO"2IP2@3:P[<>P,?K6(XTSG/%UFZPD-3VVB
M*^A.5R$Y'D1P]06T0HA?=DX&QQF24!ZXAIWN[VZP,1AB0OPO06M*S[?U_2EE
M?A0IG;J<U2:/73FD*N"3$V* $W[,'3'0^#-]J%L#@# (?Y0.I(@#,6'!'%#(
M_W3N@JR&ACK="8I3KBDB=*,I(,MH:7CTQGFU,)I9"7PQ21-V:8UL/K/,:3OV
M&XPCFRO)1>*\&5N<L^7$J=U1>/3JK(QCHT'@@DI7\9UFM5(SNT,-++A5>SLK
MNU?L$^.'@NO8;26QM-UY$[G&T$@0HAD=#'+E/JXL$$1#_80HAAH-MP362Q$O
M'EH*L*>#6/KSB%[R:<$[</B,-&=T *E)78CJ6%US"@-'B)#^Z4\3>(]U[3",
M/Y4M.9FR.<-),':I&83&^7U,3L/5.1] XX 9OD;;#/O.C$C!P:*@,@Y8H8UB
M]LPY'+)N;<R:Y(T#A9:ZJ@185F?_]_()@T-AR$FG.2V!9W7F3'Z'&*4[D+-K
M)N0@H2UP,OE(E_*1RONXV7W<;!YK:T5V2'J6)55C*0II.X8<G=,M3PZ2V+VE
M(D,OH-KP$@FRJI9P"<AT+@&C?\%A@+G:S K/TR4M<Q-7//+!.$S%&+Z6WZ5:
MD,<P#>"\6?:][E RN8.G\!@H8=?:1OPFC D58]Y(71\G:R,NH3H26HG*\L(2
M@X=\(3$LW&B@=H.;\NK\[,V$<C41/P@6O !Z?9I8O&X2ONJ5 '2\+&!74XSC
M_:T>8 ,Y(D*?C9@Y1RT(<?>D((0<1KF$0X33J-+;*+,@4*OZ/2L=&.>Y+6/*
M_(B ZE(%BJ0UU^"R)Q<U?VC+F;)*E8F=[NO..FVMD MQKRX 9EY.T38/,F3C
M$+0(67O[<$4&XF8FE@3W6DWR[8Q&W:AZF$.N!@=Q'H8*C$N#=H=<6>TT).+,
MAH8(5L5^TR@LY"YIKO<EC%SJ<5_\R,8EY@:A]YA:YH/ @G7@TR/VP&MM)L"1
MKVG/RQ(8-NE@$^VVJ_-&P,BSU?D8"<X ;T--(=,ZC_K0>+,,&W+[!*(F@@B2
M6V":7>W#/M=C(KP?^5B70!OIN=2^'=>YB&7[I)2.-2CV"QP)1.4EYT?EL$8I
M/>2X"\"\(4E%1YY;,.QO/Z:N8_\AB<K3$XEF\HFYO/&<@ 4B -F)\8&5_OSY
MU;.7P,E8!? ?/9./VQZNRQ*G.+M+?'XZ/K%LK^NH:.2<\ ER [W8T7U56JB_
M\_3.[0[C 5VE2K%NI4'UXT^9Y@4SB[-@<KP3&XUN&I&=K6G3M+F:@UUS%SN(
ML7[76_NH[AJUY@(FY[C1NHA"A3-[XS,;K:0D1D4AB4D=HD'G-F;8$>[<%L7T
MSM(]AK)-D1:ZNG_M%=X*B]")$W2/4K*-I4H?U9TY/)OJ&'+,7,UCU"$])!9)
M O\B/KZ'"'PR1  SJ$BG]Y S^HUQJ3H5_;E1T6?AQR=X=$K=9C-4-TLXM82.
MS<;U?\=C"ZI81=?< @3DL]1<,6%!1.: GT'3+!MQL,V)WGF0S (V.$6OS*NY
MB!MEZ9+SQ:;?@P5_Q,0",.U+6]G)F/RNX<Q.O$>9%>DGJ I2BBT7[:"0$V>_
MF0HW@5,X#[VA'%": QI2M)!3'0@O2RJ+@U['.?XFKW7X-%V6U@XA[F4I0;P=
MKH"*GVF7^8DKMIH@_R(*<HZRFJ?4N7@ >VT7<+\K5W)PK?7[]U+N:=O BNUY
MXB;4&=@=@QH*88VL4E+P2Y8>:W3-16^S34^>E]@K;["$AZTI"F.E624.%I-M
MRL8,#GDTE$#H "B^Z/BA$X@*JX<@^2ZH-W,?^KL/_8U%9\#T$>&SV7EM<Z1B
MDN32_PS6&:E4MQ+DJ2$#P' IL8,M%KT,"F[J[.^RT>>F\P!_'R3L1M,<3<3(
M$L[EFI^5\KD,)O5!U6TG17E*#H]%^-3RJ*-!_%N;=@XOX*R+(_JJMSALL97H
M*6^4;EAL+4WQ2='Y^F;D1)TZJ$)R=L[$8=L61:@NF9(A(0NLC_.7, QT<(K6
M7>Y5^SN<DMHA<@SS!8 4<;$3.=LNJ=(.P]Z>G]!A0WSLA\]'EYV[08? [&%2
M*->>"&![/B_3%F"P$^<"(5@H%/=/>H!OL-_CO/O0(\.5B?IVZ)QQA:QLV7=8
MYZO)Y81;CL<U*O-!>068*$4%*MB]%<Q&^DS#B;BW1S[-1< Y%#5:MM4C7#X6
MUQ!&RC')I4.M:CPXUKF G^,3;O0ER(7T'.]WB9_@43O*F:JN-9V?;-*WP[,W
M04GTT*N68FVZOAYT\=P80!I><GSA;JA:L/W@+"CH2F5<==L]"-+<XK+W)OSH
MB W$#2B>=)&2TQ[)W4% _(3F\ ^Q>)KC<BS/ =(-/0._%9,O@+@3=(=..C,-
MQ*4#2F^!J,D8P>!"3*ELM:R/)F/-7%- .V3@8,H4$AO9GI8 "%R$V<% ^8S1
M[$877,Y#K<%B HU,88JFC>0CN4;96&%'E@L@/7N%3TK[2FTD%^J>\^":R 6M
MES"N%I(<O&X)=)8>(.TGKM3C!4GD8XA4KI&28"]AO0:1XV"W>U1\#.]GU'(]
M5/#3/Z3GB;G^OIZ/VBU@-U/T\UGT5:2#YY\0;?0U1] WY"LVW1Z9S1WR2MX]
M]#X2S+Z,7>QM#\RD+IX0Q]5F_8B$_ 25F^.SH .8F;C2>J90]EZ/VQ!.)__/
M6/!43'8P]@*(.4'C>"3 3WA). 3O';OSA-W(G4"\&R7YS? $O<5[E.X 1^!V
M4-1R!%]/&@%/)BI:%'B?0TO+#U#+VTHH(>W&)O8PX1]!"C.3L=2^E57I2@Z=
MV@2;.'>'+? V2"T_='.VB:N@-V&"LF7<LF%,-9D9)#F/\S8EC#YTL<?,%"<0
MML?;8/7>."BG?0#NY*>V>\+4MP"6F;B"/X;?ENBP-0_&_T7;Q;6P;B,QA/4=
MMKKZ?8@MW&Y3TOL3MGV8-KU(:RP]5\/W8W") 7E%U1HY9D2.:\._)X+D7%,C
MO%'IY-R5.HQC-5B[A,MD$MK.%V?%)K"^L0\AAMF=$ %))5ID8(9UV#;V5=$Y
MQ8%>KTC6[P05M3%E@)7'B0J3O&H4C(TL,6IVGZ1V'ZDZ%:DB4LQ=>T9*.28O
M6NLIT7](#HJ R,*>.GA[F-H[ ZW]%,*O8>Q7JPV'$//H)J)Z;GAF*WE9JL=&
M:+=Y(QBC&*?:QC6-AU>BC4)7XDA0RTY5M\T_\!CR)7T'OI]@[-'R@C(Y<U,U
MSB8[W:BH5H75LE:7KES6B16'%<T09#FHS351-'H<H3%!2D,#HX%,5@G/<V!5
MV8@FVDY</_</IAE*]4-Q>C=GZJ0R-G!.+]+I^D5B?I;7<+G6#,V.4" ?LY4L
MMU6-]6Q>,-[N#Q&\(T]_BQ7O,#*^IEX!Q&%<5-O>Y -9;8O&(Q<@D>J&@$O$
M0P9+<$W-!DU3FE] GK>E,KCNFU!S8;GE.COZ?I&AYLTU1Z:*5)"&Q*:CK*IY
MX#W0/:E,1DZPGHQ31L8C[P-'83A_;0,+M5W#[$XI=%K8J\?L%!D*OBLEBDNT
M06 JSNJS/Q]VO[ZU\83Y'NX]T/9];QU:JJC&!L=4+7.J;C"WRD*WW83?EK:^
M4O+&]NK$;T"&F8 ISGLC5(6UC4^=C,V6@&<&9Q3/>IAZ,%6<8@'R:G61CL!:
M$2PB"+[ MO[%QV46L)LI^H4'\ V3C\K7O8EQD+#*;1F3..Y&*MJ:/Z?@OXN.
M4>0KC)MA+CRQ8ECS:MYI9CDMU@V<FG3*53*P(B<"VR5JX0:7PD5->!ZSXZ**
M-&K9$ ;B1D"8VW=R."EL_PLZXK694AF3>K"5""&Q&4E1--+/WKQHUU-5,S8B
MN(6.;?,W /(L@'L2=$2/.H@@8>6VJ_4P%0SK=*ER+I@\<6DYG,TG<$IG,85@
M=G::RH0%W9"Y"!@]0$J0:P(4D30LK]8G7N&*3 -5:45 E#,S[OM:'RI97LN!
M9GD>+9-\LE@HL467HV\VD-M>[[3\D$,_=OU3<J+=ZQ[S[TJYEZ2VMMQ+CATU
M6+NY0:$!2Q\]&3Z(S(W+K$<8=G)]6NN554K;O;B-3CDJ1;X 'ERM$M,'@FZX
MK'2])L%']G]()YPN8LO*2&QX4+<<\5N"'I:BYO"M"8?>F#9I8KY3\:CM>]"&
MK3J:[F<:CH8BL/P9_=AW0\(74&7#,ZSGQ"WO1R%D[V%KQSVJ(]>P!>H\AIUE
MVG#--^)1;GF[]WL-PLVQ3R^L)^7QE_C3R7HSIAG(W2?$3>A,[5$[.]M3S(Y0
MJ9URW:'($-8UU38*0^'OXH,B)#B\!1&]8>-INN&Z=E"G^$Y]V6&0!3!<BLK&
MF.&FY%G.%15(06QN%'DJ\.:F[&'\(^R]AV5<\!SWHK'M]/"2IHL)J*[?474;
MTWA!GBRNB=5 L*P#]K13'>(K6R X+/=B"JL%"1*"/^.*A>008<JE@NG800 =
M- P(%<KIVU1Y<*NK$HN)&?UJ<@NXX-N)R>8>4+KY_]RJ/^X^_.RK/[3!>*DE
M&S<?3R?NI_/$<NL!LHXU\ D;%>\^1'<?HCM!N;=CV_IV@(V8K3?$R:H8S%E=
MG(/)WV+%JQ9[7;0^)6I64,VW)3=W[&1]Z5--QL@#S)7-S:\6H-ZN+E,S*T#-
M*5ES?=NW6+/1! #>C;LR+*49?((FA%<V2=_ 30_ '[[NJDU@<C6#M[[*7!Q_
M(!?%#:/F0='\3WT =:EQH=^9YERK%>R.L>LY&V[6E&GS4 TQ[C11C=.D;%Z,
ML*04T@LGOW'IV:FWJ39*@1FD8<-O*].3.VA5O0@[-D&U.B;"EMB=H]].PD[1
M),.&;VE.-\R^VJHJ>)MJ[7 <;F?AK<AK[+L]+N%8TT.OH8.<':W(LKZW.H@"
MT%&[BEF&D3@NE<,:QY0L>4*%M<=K,UMKS^6Y.5)[84RT\?&)> 9M8A%H%67/
M"L?UUL=_IY<;"8>VGROT@*94('F,#Q+$VV&K=S.ZA0R+MG.AO%# 8I "T1]'
M7U ?,4SYI$0B,^L:(^,U_BTJ&UFGO?;V8.ZP'.2C"-SA<5/XF69RS@<3OMUC
MK @?LD?'\@TLK5=<"M* $'T,/9+_)[L G&>WS-R=7#@AARYP4P@+YYGIH!38
ML4#PH-=7)3>M,+@?-ETG#L:$[\D05S6#'L2-YI2Y3GQPAY2S&]N!'*@'!IX0
MUR+ .B25%,VP8B-?T*<8PV[&-)39DJ-MUN"O1C58"9!XW\@)I!:G>H>!>,M0
MC$D*^\V%E'B">L;R]8^Q2O[\^>KIQ<OQ_P_+D@-QH=%Q;3T@M'JC;'CPF 83
M1WH8+%KF#6SNR!.+,"T6B&CP!-WG7;57CB*9@"+Y0@;.309U\\;;] &1%7W3
M$%B&B9[0;S\]?/O0MIL(O*XF'AJ;8HI%6NN@208['A=2CJ-O1/QTXVKCKB1%
M:P=4+][+P&=$KAM'ER!D"M.)!\9"3[1L*E>S:& D<F$DG*);0;1= 13E()2K
M>.2]IR;'.0HVF\BU<Y92%2#\BZ96]E1S)V8+N^L^#>N ASI,$(C,5=<&(:J3
MZM?;H(*M:UN_9WBN)X/OT>G9K<&2HB0T;KM1T7D$5(%UF%AI7BL0D^3;QD*;
MC2O(CU=>:PMK^K+[N#=,CR-I03N'.1#X<GN_^T!Y<)D9 <%L-Y 2@6/^)CQN
M ^-UPI^6$IS:7$WLZ;BG-UZ\2W_8437 !Z/J:H)8=JX\4(R"5^2T%'"K[[>1
MXF%=K0;)7W7<3HJ5D,E.6(-^.4&)"EXH=VGP+3/1=(-C%)4_N+A0\ A$.SE0
M])LY@?TQSJP_TMGQ.#%GQ]<.6VW3:3[6I9$2!-1KU]S-+X".&QAUO-YI.VX,
M83;)+4BO'L1.@X4HB A;$\4K8AB$+6;O+'Z+U#$>Q=6E!88;&R,J9%5&1BDF
M>Z&&B.@+1BXXWP%SCW-S7)Z)\SPT-XRN>3ZH6K< )KI*C(F^ QDN0;&I);8G
M_\&9+4NPWA/T#/Z -RAV+',ZAT4'SS?J.%T3&>\Z$VHZ5?]P_KSN0T?_4J&C
MY3@P7XWK=;DTIJ"3.1*Y\3/K#7D X',J9T+*.7.!B;X2NL \/.C6E\]Q8 "Y
MF2F+,+@[IY!YMU0^O[6D/VJ?C<1^'[X8 %91'94YM=%\6U:(4CNZ\R6(Z_2<
MK4[OPA-VJKUI?QD(7DSD\Y6_V"=1=-QZ;<JE,:CFX'+K"""+#JG*:D3"$K[H
M^L:@;:<(+!@>WA_S2$&=8,/W'\ &:[6T$-R@YH]1):VA,^P#0EY2@X4PB^"1
MI[IY3G>]0W=A/,A=?A>-[(?=.<C0PHI')5BD[-W(+=T-S [C\O:&@"U#AO]^
M:^'6;^#T#BBOK-,4))]N? <DPF6'OM--I0J6S?0^:L"\@#-</4E,57^#3='4
M1T-_4S%R7[4,3PED)7MU-[JJ]($DKU]AV(/;^H)M;!O%'GEE$*=9L$M5PBN6
MTB D0;L%^?7RXN4_>%[TQA=TB,4=-BJ*'_V1D$':G=5+TR[@&[EN>@SX/,VS
MRXO5<^L34>V$D^,@O)<C<E8L@$X3M!G2I-.ZQE)%WTEJ%)$.H9)P54W;P=_<
MPR+6QKSY$CK\*&0RT70:556B\S=@TA2=;MAJ:2FN= _W^#0+)$EZ)@&5%AES
M> BU3T=\GU[YX=XH2%N>SH(8TZ%)M&4-M(",'M7:CH2Y!\Q0QHM)<M)%T4_X
MI P%3WJC0H_"H!CY$%<R#;EQ%AJC2@JI]F1-QYDJ<4)U9AMF[&1SC0A4?%A7
MJC3F?2-U<RUJ<S;X=Q&=%GZBZB+T"-#MDE&I<KA.<O<OM 0XB-]%: OLSY&#
MK0CC9[6N&TP7XZP6;-SAW\/O;?>5ZG!4,%U;&7]8J5][FCG:%NYWA=ZM V@;
M^^YRCQ4)/C.?J-IEU. (35^PM\8>M,T!H;:2!/<USU",/TQQ$H8<T'ZA&B;&
M(GKK"D+!Z-_ [&JL$)*]\OB*MPA! "'8&EDX^=5K75+]5EK;.[U71?9L]9R<
MA@;;A8 1AA\ULM/G[,.*<#ILDC624NQRB\+!W34;1K1/GW14Q#+(YQMX>^(Z
MZ)(L-=2'YV'*2Q#CZ14&3U.*ZS(AHPW)\EL$5&(=SA]1,O<&A DTN_KB^5/B
M31-7SK,@Y:^.<.Q#J&8 BK2 S#_J&*:W80D<M4F'HZX>7CQ.F*5V5%0\(;[B
M@E8T*>0D6XL7T8L(_]A)S/H>H+PLD-O7ZG)0E!*LR6LQ=)90;*/ Z)BO<FK!
M(9=@U2V!QJ_3H?&DG7ZA-IP.F;,61#-C#7-YUN<V'0),V_KD(TV']KZ7?:.+
M!EO2_47IME!8F F,DV_KXB$VUW,!N<#J6@)!)M1PV_9)3Y0@ X1Z.F3)(?YQ
M9V67OV2[?(+";;IO?D2'$8,CC] )A=T(SBI &)S)\O# &C'PC0S;%OH^H5/3
M4S5BBZ(F:MSR8G/WF;O2.C6WOYHHXX?J#E6@J, H+E']B9LS^^8QKO& 264H
MC4\AWBG7XG1P&/>@P'M0X"D)_$M*$CAINVNB!D9:DAC=M/UN9URNE,F&B6&5
M#/V/!IL&7\&P[*YK#!8K> K37]G+A]:<M>2,PNO!&NS=7@KF(D%E0Q V_%^V
M#I/SGI>JM?<)$1ZV,FVXQ!)<EB;A YMC"E^W;<)!,%F.TU"M#V*0![J5H\KQ
MKC+<6QA7E4H@@U#RW!*(.R'J!MONJ:?N;/:4;9NG&E[7'5'EH4ZG9U]<_.G<
MGDV8>3D;95C.(:5S2JOGYKH5TW$^8D 3U KO#R_]&0H2,I I&4TY+ZXJ76"2
M<B:J;I9P5#<IG92]+7[+DYH]):K^3=].IS2$+!D6\-IC?-G%#S]JJB99&..)
M7$G"1F))QM^HINN=^O%1+R9KSI0Q-G%FQ.I)4UW#1CIW<5'2G./,5G!AG\8E
M>%/>)T.R:;OW+( H'?5=F"A)%"19 LE5Z9!<T@Z\.'$['<(CWYF;6^G*Z</]
M0+BCTA1CF0(X&UJ-H:\H5!D1[1QDIA2.?:5JYSHY3(-1,9\$2^X8 .L2N&*7
M#%<X+2]-KK!-<&W-JG08 PC5%=+"]B](?>VX-A.8D:@_=%NK3%B&.6O/32[5
MR%E+I6QHY=S :=P!./8EQXQ$O."F)JIV=FZWC#.:^E*J@=;)<%?::DZ*3'4T
ME?QB>!42NRJX@H]5SG)B.[@LS-YR-J@L[1N1NO<]&"VM')9(.UN?GUV=>Q]!
M*8<(U[D<U+#N*JSX!MLAH$.I.C)HT4\.1Q=!<NI&DB%A&K[P3]O<PQ\+T6,C
M O<&D]D>E#&";3!+M0<WM]2@C-("V%6GPZY)HUY.U6U,B(6S/2IQ=!51H:MV
M5,@ BU92&4@F<4:CMZYUMBV_%?.UA6W[7B28'&K''F*F*4LT+H3,?'^Z.F)Z
MS+%/ASG2OLLL,O]5D5 *""7%>Z=T.$G&%#^^BC'%KMHK)L#37R&8&!2]75^9
M9GN^0>H"R/C7>S*^$QE_@\4)OQ/->]"]_UM4?3JZ&=&IB?F6KE/[#<XQ"+9X
M)W 0A1.M<37?1X(_W6OU[<0>PT6'58^Y<3T>C*O="1_Q=>DSELCO74X_NR.*
MXR,=D2#KK^3KGV@20E5!<EL&R;G#YZ*P)EFHTE22%L-_K>DJYI5CKHO49K_V
MVJR-/@^7PA.FI*6HAJ__RM43O::DHK;+;G1%O7PVM!%!29YP1>>V,HWU8$5=
MP(@)&HG=W*2I!=QJ4$AD5 @5VS9@0V9JU+ $:D^(W&UH^*<A/3DG1TQ-C)QK
M)(<69PEKQ#JG3[FS#9C&S&#KX,R1L7EQA7%K'_"B<8+&&$C/2-ZVOCUP<7O*
M6KO'XMUC\1*%!WP[:@;,WGABFG:2^^8N&LM;)Q \UUJ7V,V>O9)<&-\G_,3-
M9%K;K%C ;.J:<X>[035]9QY>?/%J:<9ADPPU))UE:CWER>C21B\QU?1&08YV
MHOIC[A6:$,K>;74[+C N>J!,N!H8B$YE!;@@.<,VJ-/%)D)N>F<2%_ W!=BY
MA);I<5HJ5XT]+(Y.3&O*SE;4[V,4.$B:*EP_B13(8QCX9+G',A1.;[Y,?'K"
MJ4U'.#TV2F7B=)A4X%^PSFI+-XT),I0!W#EIAPK $DBS2X<TD\YI,%&W9(CR
M7Q8'+VQ_,Q/RQ((_-B)ZQ^*YMITK 21%;2J]N?8)3^V+0A_U$GBY3X>7D_8L
M![F%R? S@6B&VB_1.&*[F,QG&RLMH97'63H@\;1CVVG%L F+>"JEGA",)QLI
M+D%T'I(ASM47*6OH[F#3TM!#^QUU]=9F?H>:^;3^3IJ$FFN_'O6&HEQ]^[@%
M7[0GNM785Q2B:;!Y'Q87G*C-0T[")=FS'Y+AEL1%>>Q*2H=?A.E.29HN#&/+
M-<C2*L<!X^212PM(D#7F00$*;BKGNEEP(>5W)KKX1AR#%*N@Z 3]"OE*LEZ#
M =GX6ZQ($3 QUJ,PK1)O==PM@)..]YST<9Q$PCDA1JH-9H\0XW:2,]>!;789
MM^U<CI+T]Y2(-=T8RX3+(26"/=H8Q!Z(E,H$!3G'_"A(5/-,:]/[CY//#>K7
MFES16A]L20+Y:P]C5!'$QI3UQ6B-":J@UC9"J;;9U>75F3SG;KR;\]Q6@E8W
MLCKF2PM0BG3:F*R>IBSJ Y!HR@!6CUM]'.)6ET"*ZW0ZE:RN'CY]GBXI.NF7
M#!GFPZ+XH03.LS-U;@J.>W<W4"F;K*0E4\WXC=J$142>S!01,;7J#0QQ*ZCZ
M@<8N[7@AW&CN7:\/DE)TR+PF@,DO7*;6O'%MFU&483,*,GK#:9ZIQ@MXGC1=
M)[F-U:.A8LO8VXI+=-\4E6AM;_G66N3#UY,M3GTPT5[ [>6_HE6LL1J]:'G3
M<,RMV.^EC1"82N[XO*R+XSF%'\*Y\0*K(Q>.LG_EV=\.]2B!EP'N"#CD5"_1
M=&!DM5NUS[G///P"<9.<CUCXF(9IE@#3@,]5/5&P8DOY5SQ\.!7*-L%J^]G9
M3%D'LQF4L&6S'[DT!((.-UCP![?9D(4K, B/$/V<)# PY+Z92,YRM?/Q]##O
M"T@XC]4*!X6R+1R-L(!M#306.DW_C<]^,VEF3G*K08ONN5.SA0+ML6,32SBU
MIL&8$"=Z4]*!99><JX.AZ@*G&%7$R.E,4"=BRR D.I<N3DE^TE2*M$P%3TK3
MQ-4<(F'-Z?=C63!8ZA(NHR*=+D.K9P\?IWL9!;Z49&XCDP)Q]&[1$(*.>=T.
MA4Y_V*?F&@"#^# H_C.7\YI3C1W,"[5BT7:"^?Y_WGYM_B7:4OR:_;72:Y!+
M;_DF^BY \L</3'QC6FQ8$.:P TCK6H"@T-=P)S 2B<]DP85#'ZUU>83_;+M=
M]=7_ E!+ P04    " #Z@ 15,\'#[!@(  #$)P  %@   '$R+3(P,C)X97AH
M:6)I=#,Q,2YH=&WM6FUS&CD2_GZ_0DOJLG'5\ Z)C8FK""87:G/VGD,NNY^N
M-#,:4%F,9D<:,/?K]VG-\&+ &U+>;(CO4A7,2*U6M_I1/RTQW1\NK_NC7W\>
ML(F=*O;SQS?OAWU6*E>KGYK]:O5R=,G>C?[YGK4JM3H;I3PVTDH=<U6M#JY*
MK#2Q-NE4J_/YO#)O5G0ZKHYNJJ2J555:&U$);5BZZ%(+/@4/+_[6_:%<9I<Z
MR*8BMBQ(!;<B9)F1\9A]"H6Y9>5R(=77R2*5XXEEC5JCP3[I]%;.>-YOI57B
M8JFG6\V?NU4W2=?7X>*B&\H9D^'KDCQK\EK0.FOXO"5:41U/[=II4P@_%,VS
M9KWUGSJ,K$(\'V/L0HG7I:F,RQ-!\W=>-1)[/I>AG73JM=K?2_?DK+BS9:[D
M..XX:]$;:?A6= =:Z;3SK.;^G5-/.>)3J1:='T=R*@R[$G-VHZ<\_M$S6.&R
M$:F,<D$C_RLP(R9WC_/"&NA1,A9+Z^H-,FEP-Y&^M*Q9K]2[59)?^K3K&4_'
M<,[J!&.A?,.# *LITF_D0G]P,QJ^'?9[H^'U%;M^R_KOAH.W;/#+H/]Q-/SW
M $WH'=P J#<?/O:N1O?]W!^3;^K1Z)I]&/2=.\U:@UP:O1NP#[V;-[VKP8?R
M]2_O![^R7G]$/8U:K?&@0ULA^^KNM/:Z,_383V(F8]:OL'_H%/H\UI]($;'!
MG0@R*V>"74>1#$3*=(19LU0'*=2P-U*;0(HX$,9CPSBH> Q"5D8+9B?</G_6
M/CT_U/GSA(<A\D59B0B6G2X1+.,0L>Z4J>4;+5"]LG3BKY]]:UEJE38MPY!-
M.**2(FQBCDQK)]*PWS*>8E.H!=H3G5JF8_86\63U6OE?GXL<8G7V%&+5.+I8
MO>$&$4(LI@MV&^NY$N%8>'G(BD"%&B;$&LR)&3AV(H\7+(MMF@EX "YUM(H(
M<C;%4RJY8A$/T(0=.04]6)W+[0C$ A$V/%V0R)3?"LR[H=.@+80QF%(Y3L8<
M)!#(%!P,,0((+ FQ]><3&4R8R>AC/7XN4E$H(0>FTBB0-?'^7-H)'#2)")R!
MI#>!:3J$FS,,"YF_V%R&IP+!YO<#0<$B&2/(A)=U4#W@#^+H3C?Z91P1.5"I
MB.^!RD+H!' V(N@!=)(24(*X$V0)RDJM,5G P6Q-#=B'K@;U2")3$  0-=#B
MIC/.GH";"8N4GILE2E,QEL:B@+6,4V-N-ZST-L!FEL;L6/M4\-8Z.KR-[@7G
M^;/31OW5N2D0550(E")T4550V(:,I\(!! &7OA(42": 2E]),R%Q$ILB/5**
MI.=0FD!IDV$<)<Y4JQPI"5A.A&@V[ 6 $0H@+8_^X"Z8\'@L6 \YZ293D,#!
MH5QOOQ G;FB]'>9/^:.D*C/.$4KZ&26N#>#F0");#IXHNC=1='+B.4>W\0P1
MHOA'E%#-ET>$47YR1!AMM&@=+H7!20+A<I3V>2QYQ+8!S\SA0XCV? %<%#/E
M1*JS% J0G6;2N)P'*1$[/50UK[/E9L9-A>(.: 63KK'B%=F8.B4R)VPQ6LG0
M'<%-YAL92IY*<D#F?.\X("9-F2$.=OO2.,)V&1)G?!B$P[<;E*"JE$&F."5V
MN.6,6',Y1N25P69!@V^^($'D7HP7X2-R[5'AV#\:')]57K[:A?'!"6L'S8>G
MNH-!C8TPDR%AE1L=<\KIW #G5%42@'D:+L$$>$ON2R7M@MA]W[2TM1SN'*3R
M77%/=*,J==1Q5SB49&D"2!M7C02!3D-G@*M/QR)&D:& ;/2(A+8,B:#VSM&+
MK2439.^G@M_@:/"[RL.#&5>92U8471%%*!#E#'$Q>PJ]52UQ0/+-'_?7?@ZO
M&(C$:?(*T]>9?=B"0^B!KZ0%E<_1YT\\S%\6YFX+BGPE8(^#&TWP!" 7'@WD
M5BDS#^8N*.C87=1MKF<O\KX@41*;ZR#(4@K]!G7NT3K5QJ*=[C6ARP105-SG
ML!</#(F 8:2P+>G"<)R6A+LQH,N$.%O9=9);->%F56=0\G.8%Z%C!;<>1<9>
M,"5OA2JN#[;DO4<OT2-Q?E3'L/83.8:YF\5PN46\=8ZBE+D)TW6Z(J!]0>6Q
M4\*N3.,H8ZU.S8KL70-43J?26B'^@!!\C7*"^D,)^YR2%P S\J^A_(Z_5$PO
M=Z#X+9,PW^VV+ [<+</)_P];7XWD>PKU&>I%":31^9:.RN[^619$O3KTS 6_
M)>;-ZS7'O:[2='>=RQNA+P)<<3[)KQ?VY#4>8J 1J[3V(#B+^A1#@#"4D5Y.
M_P;<;[(I\(%5<LX4=++W[NPI4?OQG89Z8/ H1=;P$'7A$AUPXVZF"X!Y.0'*
M>*;53! +QGQ<7+"G16X4TT3IA4#O?*+SA,COP1=P^U-*A,H."/[LI6P<%,CG
MS^HO:P>E/D<L7>L.<T6OCZT@TC)L53PQHK/\<@X2211?=&3L9G2#S@M=OK96
M3TG=^8R8""5,\=.N W?>O?YUOE++?Z&W*?Z'RYF+[HKKJMIPMZ_=J+1/VP]V
MURKU!_O^2&VK76G4#U-;=2;G9F-E3,+CUZ5F:3F@0'&GD=RQ^OU?[0G8.XNC
MD])7P<EGMYQ;_TLZISF:9+ULG!F; Z?EN9<YMEY0*%;F\4[G8/CK<UPMWQHM
M;&GWN?TS^=:N^5K1_C9>[[BVWZ-B\SNR2F FW3RRI7W?4YRW8ON_'=7O*7 /
MO*JR&\"J(Z ]]+;Y/EBB\[?A.OF%^TP\^(98P6"U]1#N _Z9W1V2+\Q%UR<K
M[N7(S<_\_3;WIMW%[U!+ P04    " #Z@ 15O(##2QH(  #3)P  %@   '$R
M+3(P,C)X97AH:6)I=#,Q,BYH=&WM6FUOVS87_;Y?P;E8UP#RBQR[31TW@.LX
MJ($NV5(/W3X-E$A91"A1(RD[WJ_?O:3\DMA9761=W3S/@+FQ>$G>RWMXSB6M
M_O?G5\/)[S^/2&HS27[^]>W[\9#4ZLWFQ^-ALWD^.2?O)C^])YU&*R0337,C
MK% YE<WFZ+)&:JFU1:_9G,_GC?EQ0^EI<W+=Q*$Z3:F4X0UF6>VLCT_@DU-V
M]EW_^WJ=G*NXS'AN2:PYM9R1THA\2CXR;FY(O5Y9#56QT&*:6M)NM=ODH](W
M8D9]NQ56\K/E./VF_]YONDGZD6*+LSX3,R+8FYJ(D^3DI-4)VY1%G23L4-KI
MML+7)R=)DM 6>_5'"$XVP=SW,78A^9M:)O)ZRG'^WJMV84_G@MFT%[9:/]3N
MV%E^:^M4BFG><]Y":Z(@MJHY5E+IWK.6^^\46^H)S81<]'Z<B(P;<LGGY%IE
M-/\Q,+#"=<.U2+RA$7]QF!$F=U_GE3<PCA0Y7WH7MM&ET6TJ(F')<=AH]YMH
MOXQI.S*JIQ"<507TA<$W(HAA-;G^2B$,1]>3\<5X.)B,KR[)U049OAN/+LC%
M^')P.1P/WL,C:!U= U"O/_PZN)S<C7-W3KYJ1),K\F$T=.$<M]H8TN3=B'P8
M7+\=7(X^U*]^>S_ZG0R&$VQIMUKM!P.ZE[(O'DYG9SCC@/Q$K4UAM&&##"*N
M<V[314"&J> )N1 YS6-!);E*$A%S350"4Y=:Q1K&(F^%,K'@><Q-0,9YW @(
M&%F1+(A-J7W^K'MRNN\*G!:4,2"-NN0)N'>RA+'(&22\5\<G7VF5PL8RB/]^
M]GO+TFIT<1G&)*4S3C2?"3X'NK6I,.3/DFK8&7(!SPNE+5$YN5 Z(V&K_LNG
M,@>Y>OT4<M4^N%R]I08R!+G(%N0F5W/)V90'/F55HI@"%W(%\@DS4)$3FB](
MF5M=<H@ !-5I*V20D@R^:=R1"8WA$>S(##3"*F^W99!SR+"A>H$F&;WA,._&
MF :>,7 &II1.F&$.-(B%!B$&,P0(>,)@Z\]3$:?$E/BQ[C_GFE>#8 "9,!(4
M&\5_+FP* 9J"Q\Y!'+< UQ2#,&?0C9%HL;D,3P6"Q]\.!#E)5A2_3FH ^ -S
M:-8;[2)/@$PHUHOP=RQ+!F,"<#8R& #H!!)0 7E'R"*4I5QCLH*#N3<UP)ZY
M0C1 BU*" 0!1 5K<=,;Y$U.3DD2JN5FB5/.I,!:J6$LH/O1^@Y?!!MC,TIDM
M;Y\*WCH'A[?)G>0\?W;2#E^=F@I1586 %*&JJ@+3-B94<P<02+B(),=$$@ZH
MC*0P*9JC60;TB!2)WYDPL52FA'Y(G%I)CY0"5(XS>&S("P &XX TG_W1;9S2
M?,K) #CINI1@$1[3>MA]P8]<U[#+_#?_56"IF7N$XO@$B6L#N!Y(Z,O>$R5W
M)DJ.C@(7Z'T\@PE*_"-*J..7!X11>G1 &&UW<!W.N8'C!*3+2=JGL12@VL:T
M-/MW0=F+.."BFLD+J2HU# #L-!/&<1Y8\=R-@U7SFBTW&5=S21W0*B5=8R6H
MV!@;!3 G^&*4%,R=PTT9&<$$U0(#$%[OG0;D.%)I4(/=OC1.L!U#PD$?'((3
MN.M40%4IXE)2)'8(RSFQUG+HX2N#S8(&_HHX&@+W0G_.'L&U!X7CZ&!P_+KQ
M\M4VC/<FK"TT[T]U>X,:-L),,,0J-2JGR.G4 ,ZQJD0 4\V68 )X"QH)*>P"
MU7W7M+BU'.X<I/RNN&.Z494ZZ;BM BI*70"DC:M&XEAIYAQP]>F4YU!D2$ V
MM/ "MPR:0.WMT0M;2Q3 WD\%O_'!X'?%PZ,9E:4C*\PN3Q(H$,4,\F)V%'JK
M6F(/\O5?=]=^#J_0$8C3^ HS4J5]V(-]Y(&NK#F6S\FG3SPD6A;F;@MROQ+@
MCX,;3O $(,<.!G(KRO3)W 8%'KNKNLVU[$3>9Q EJKF*XU)CZC>D<\>HF3(6
MGN/E)HQE8ABHNL\A+Q[HD@"&@<+N65>.PVF)NQL#O$S(RY5?1]ZKE)I5G8'D
MYS#/F5,%MQX58R^(%#=<5M<']^R#1R_1(W%^4,>P[A,YAKF;1;;<(L&:HY R
M-V&ZIBL$VF=4'ELE[,HU"F6L5=JLQ-X]@"&S3%C+^3\(0J2@G,!V)L _-\@+
M #/PKT%^AW^QF%[N0/YG*<!]M]O*/':W#$?_/VQ],9$?2*C/H%X4@#0\W^)1
MV=T_BTJH5X>>.:<WJ+R^7G/:ZRI-=]>YO!'Z+,!5YQ-_O;"#URB#CH:O:.U!
M<%;U*70!A$$9&7CY-Z#]ILP '[!*+IA*3G;>G3TE:3^\T]  %#S1P!H!9)T[
MH@/<N)OI"F"!%T"1SY2<<53!G$ZK"W9=<2//"JD6'%KGJ?*$2._ %^#VKY0(
MC2T0_-M+V=XKD<^?A2];>U&?$Y:^=8>YJC6"K<!U'7R5M#"\M_SC%$2DD'31
M$[F;T74ZK<:*E+4JP^%.9ZA$4,)4O^\Z</OF]4_TC9;_F=YJ^)\M9ZZ:&ZZI
M:=EV6[?=Z)YT'VQN-<('V_YIV$ZWT0[W&[;I7/9NP\J8@N9O:L>U98<*Q;UV
M<4O"NS_=(["W%D<5M2^"DT]N.;?^YWA.<S))!N6T--8#IQ.X-SKNO:50K<SC
M@_9@^.\YKN6W1@>VM/O<^5OYO:WSI5+^=4+?"FUW1!4#.,4JP$V\?B1+_[ZE
M9.]*\/]V:K^E[#WPTLIV IM.BG8(W>;K887R+\?U_-7[C#_XPEBE9:UU%QK!
M'BCM=A>_,&?]"+VXPY:;G_YU-_?BW=G?4$L#!!0    ( /J !%5 @BFG0 4
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M:7@M,C R,C V,S N>'-D4$L! A0#%     @ ^H $50B%D"TS&@  (?H  !4
M             ( !AB," &YB:7@M,C R,C V,S!?8V%L+GAM;%!+ 0(4 Q0
M   ( /J !%71GO5%1SP  -61 @ 5              "  >P] @!N8FEX+3(P
M,C(P-C,P7V1E9BYX;6Q02P$"% ,4    " #Z@ 156&SYHSY&  #21P  %
M            @ %F>@( ;F)I>"TR,#(R,#8S,%]G,2YJ<&=02P$"% ,4
M" #Z@ 15"J$L[F^G  ""L 8 %0              @ '6P ( ;F)I>"TR,#(R
M,#8S,%]L86(N>&UL4$L! A0#%     @ ^H $51T3Z@0U8P  NUX$ !4
M         ( !>&@# &YB:7@M,C R,C V,S!?<')E+GAM;%!+ 0(4 Q0    (
M /J !%4Y=0#"^$D  )<D @ 6              "  >#+ P!Q,BTR,#(R>&5X
M:&EB:70Q,#$N:'1M4$L! A0#%     @ ^H $561YG@6P@P  (@8$ !8
M         ( !#!8$ '$R+3(P,C)X97AH:6)I=#$P,BYH=&U02P$"% ,4
M" #Z@ 158DQ7(?8L   F0@$ %@              @ 'PF00 <3(M,C R,GAE
M>&AI8FET,3 S+FAT;5!+ 0(4 Q0    ( /J !%4SP</L& @  ,0G   6
M          "  1K'! !Q,BTR,#(R>&5X:&EB:70S,3$N:'1M4$L! A0#%
M  @ ^H $5;R PTL:"   TR<  !8              ( !9L\$ '$R+3(P,C)X
M97AH:6)I=#,Q,BYH=&U02P$"% ,4    " #Z@ 150((IIT %   D)@  %0
M            @ &TUP0 <3(M,C R,GAE>&AI8FET,S(N:'1M4$L%!@     -
-  T 8P,  "?=!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
